<SEC-DOCUMENT>0001558370-22-004823.txt : 20220331
<SEC-HEADER>0001558370-22-004823.hdr.sgml : 20220331
<ACCEPTANCE-DATETIME>20220331071215
ACCESSION NUMBER:		0001558370-22-004823
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220331
DATE AS OF CHANGE:		20220331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		22789107

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>plx-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/31/2022 11:03:52 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 69db353d-9397-4d84-ad58-ae880b85eaf4 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:plx="http://www.protalix.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" xs:nil="true" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_LSkWDFyqpka1mNlo29Sx5A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" xs:nil="true" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_7f4UabzM3UKj1WoiR34YVA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_J0D8mXPoJkuP-g2JgHsH8Q">14838213</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_eu5z54v0BEi7IfWYizgaRQ">29148047</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_ZUuOi-suMEe05uLU3Qjq7Q">44140233</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityCentralIndexKey" id="Tc_3JVbmKYYYk6-829uppPjZg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:CurrentFiscalYearEndDate" id="Tc_KDt1cM7Bk0uPZzDGwYlHww_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:DocumentFiscalYearFocus" id="Tc_ftSG9cLFR0KVJ03LttbkyQ_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:DocumentFiscalPeriodFocus" id="Tc_8lLMZqIe60CqzbGcCwJHTw_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:AmendmentFlag" id="Tc_oLvPhaoiQkGOFbgFgauQXQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_HDYzV-AxhEO6ZtjFVfzV3A">45556647</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_W9fROlZvR0eDAlWsPj0McQ">34765280</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_chTUbKX-yU63liJhoI2MnA">1.23</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_pwzKxLMzFUqTpVS-7SVM7w">0.22</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_cL1EAZPir0ybRR3Iq6YGOw">0.62</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_12_9_2019_To_12_9_2019_4z22q3wSv0-NR5YhbAeSLw" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_bjDxAD1NEUOlk5FvFvWGtA">0.1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2019_To_12_31_2021_G69dnyWX7ESLQI7Zi6Aa7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GEPYGazCFU-lvckKnH9W0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-07</xbrli:startDate><xbrli:endDate>2021-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_v_mup5ayK0SZBeWgSy-6vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bCxAc5Cnfkm0EGvQetJhcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_9_2019_To_12_9_2019_4z22q3wSv0-NR5YhbAeSLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-09</xbrli:startDate><xbrli:endDate>2019-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_thD8r8M9pUScQANMOAi9Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kE8UTOIMfEGWg0hfCpFG2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ihvuMLoedUaKvUb3gZrBQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7sdZSqR5Akypy6gOZtXx-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EacWiMG0w0qlanSOpKQOQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MdPzxWvoIUiF79gdrm8reg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DMrVGdM36kS0syIA8uAVkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTJek5F4gEy9ScXTU5y5Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gHL5-QCaE0WNugpzgg9seQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSoqlLM0bEOf23D1EiiZ3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sleyo-TN7ECJ8-DDksi1cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_OHALbnwmZ0uHOEuQaP-GQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.60Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_3VKeoZyiuU-sD80UufftoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.10Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_cydItAIWhU2ynTqxcgAr8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_gNOcdY9dyE2xyodPldHVZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_mFoKIxmKnkitg7IY-C7heA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.70Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_lgDg9pDF2EWhgu2sSt2k9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_WDm67mnYvkO--UxyQkYsvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_wdkJLL3g1kqo4k9Y_B1iWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_JX7wlQ8FiU22etWN6WQRxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_mKYQ0uHMPk-JKlPiT881XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.60Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.10Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.70Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_M8ski3P7vkqI4q67BPAWeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-22</xbrli:startDate><xbrli:endDate>2020-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_JcT2p0tnbUqhmhTyDLIICw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_t32kanKUi0m7HxcXWb8NzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_c9-osb3oE0SkR9YTIYdxYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ssa4_sAGw0q1WnIXrqo2yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__onSW-uv_0Sf9fAA3WmGWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E0uJdNzPMUWVe1_NyQJfUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_H9sLbSYtM0qsnN-27mpO9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_xaWyKyysfE-N-Odg4q5ilQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_UATsTNG3GEyx6u5IsMGjaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GBgSGz6h9E-afGEP8417zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_VZS1TwgN7EWajbs4tfYp1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_3pw1DQ5CWkST8Aba5KMVVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_tr53Np7eY0-Ae6xS_WOJOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_T30NLjS9gUG6T5IRwHFs3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_M2UVRoW7sUyno7XdY9wpow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_OZABD-Gv0UisMJYQyGNklQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_ZsU_oN8S5kKt5laU31Nl6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_8B8k4Z958U29kvLCfB2P5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0sZc2uezPU2o1oMeQcRe9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_DKnjcKFjmUa1np2ibVNGnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_EbYkt392okObFSFj3u7OvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_HmzXf1hdDkK4__n1knviHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ePa1ql7mhEGcbcjaQMVPmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IDSvFh3OYUGGC0HZKS46ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-29</xbrli:startDate><xbrli:endDate>2021-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_0yT3uJM1BkaHr4dUCEjvtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToNonExecutiveDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_DhX0f2VRfE65d2xBozNi3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToNonExecutiveDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_Pn1OJZqDxUCu6sqgk4Nceg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToNonExecutiveDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zzCp5Zo2W0mA_IzpPeDB8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_liu81wlz_0GnnLU4yo84rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lj6QlQZTj0urSG1zMHyXZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_NVfyMY4qKEy_rMZnOFmZmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DSmWGfJ_nUqGx4cINjjxwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_lOmaI6ivKUCWZWzYSmOiTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_sXO4gqAD5E6e4X8EJdE_Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vAaunvUCaUm5Awsb6iJhXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_3tCMe8rWHUGVmPE1Vg1qcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_Nn22_559OUKyhCIEmepH8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HY-SW4N2TkyfFq3zDY1uuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_XEZ5o0zCB0Gtu8ErPOcE8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2020_To_3_18_2020_KfspxYy3cU2Kf_nxZFH28w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-18</xbrli:startDate><xbrli:endDate>2020-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_AUvvcJwK8kKDjzt8c3S49g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_D8rI_9bthkCH_hajh1im5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2017_To_7_24_2017_IHtLKtFOd0GdflSpPhFd5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2016_To_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rR_AcPv6HUeGQ6sr7l3x6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_4EDJzmaOZEiGDZsFWmKybw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_NaIif8seUUurDs8ggqZ2pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_DhHNkI_3EEiZeB01aqdpKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_Dv3dYp7Sn0usVBmj85F-iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_DVyyV14ssk6w6xsrUpAbPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_bOenO2dw9kqQgW48F-LuVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_JS88tOJOkUqlKtjBD7IPxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_k1N1AROJukiPb2LgQrs-Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_34oM70dfJ0WMj9Nuj8F7aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S4pb21hY0kuERZAIbjSSPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4zMtLtp0p0ed5O4m0g8GzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0E0KOb1OA0OHpvtP9-VXOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_KBRPKEthI0WlOxB3RgGCwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_NrgbIl6Vs0-zjQEgcvzrEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_5BNg8lS-ikul3R9lhuigJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_KCPpKqI-Okqwtns-9IWsAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_x038hBkxEEOMoMUfzZexDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_A2agnc-nXUWF5xH0NH47Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_QJLt9peuMUKwXJpzAoU8Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_W5Xtd1I87UWgu75FfSxL9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-h9AO0_j0Kk-RifcpTNhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xZes_pQ3jU-LW3EVr3FH_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_DCDOuQ7vOEmwiHAqrutTiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_oDSWqTAF3kmOozORnpamaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_we61rqymjEKVRph1U_HyOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wVjVKlFU-kmp2kWFh3RuVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_5QixDFM82UiwwWLbZe1sTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eHDaBvSg7EqtccoqK2mu0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_31zyHW8jdkSb7SBDmFiccg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_b7Ak3fDnlkmmGkfD-wjobA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Dql2hzl-NkS8Ek6wKzfhtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6zDHzo_aTEew3DryvNkYTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_bFAp9JROpkOcrhLPvQRlPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_GmiPA7ea602B3Bzo6qlgCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_24_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BD69mggkuU62grMnuucETQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_7_2016_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_-Ae00XL6BEyY4dAoZ4k0DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDueTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cFbsJrjci0yg4ImOcaQUEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_wwXeRF1bvke94qCksDkYng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_FourPointFivePercentageConvertibleNotesMember_m95eebdJ1ECA3BKmoDsZlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2016_To_12_7_2016_MCerakGL40qMS2YHRbNFsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_CflCHQ20lEaDx_EcPWhJ-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:KirinHoldingsCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_8sWurxglp0KmGkrtptMYNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_sNb9nRVA7UyHg24tmVfidA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_pRbaNlihhk-Mb6yk0UeU_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_kaobUQfqT0ORdmCuBmiC7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lDW5LBY3rUuDb7f7KXNKnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_rKMXQYZpckOR3T6wCl0-lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_GvWEuJLKREuv90OClpZMKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_phM4VtIB9kyKjfXahRtTSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nz1R62d_CUWRP0hHMNoUuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cDyFN34pu0WU-HKDRkiujg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_avlksYPTbEKq7Od9FRAY9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jz0yWSUNLUeUy5fbrRm0BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qzxX_tCY20S2bKMHuz5WJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cm4dDuAzykmSlgO-pcMmBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_FiocruzMember_zNisG5sSw0exkK1iIkuF0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_ChiesiMember_9OarDvgYGEWjO_OZkl86jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-TK4_F-2eE-xNEY8Kn76Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_dXz0lHVvlkiQrMZ4_xG4Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Wn4pMZFBa0ulpQZlimXCwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_uVGroeg7jUGkxDgm63pXFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WwsBRNfRtkKswONdYE8A3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-18</xbrli:startDate><xbrli:endDate>2020-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-25</xbrli:startDate><xbrli:endDate>2021-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-11</xbrli:startDate><xbrli:endDate>2020-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-05</xbrli:startDate><xbrli:endDate>2020-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-07</xbrli:startDate><xbrli:endDate>2020-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-07</xbrli:startDate><xbrli:endDate>2020-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iKUFwyX_yU2n3k92ORA_uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.57Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NoExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.57Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_sXjLs1UWbk-sYqhuiYE3qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NoExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_14Iut1EZ1UWck-v0gKCugw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_N12CUuFMQkiGURk7lpa5rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_7pabyZcaV0G2hX0lA_wo6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_z5fjaYB3Vk6_8J6_3XOy1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_mmHdbT-en0uuXTv2hCvVNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VF0OGmePw0eTywhYkjcUPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_RzJRTxQNVUyCZrS9EnncRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_Pgw8cC8LGkmkSDN1ikOZrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rSbtuiUSrEKogWgpJVQOAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_2cmmFTV-8k-KecBEkLzBtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_dh4fOPoiskqOmGCaGTu_CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2022_To_3_22_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_Ak-XTuYc0UeiX460wPg5iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-22</xbrli:startDate><xbrli:endDate>2022-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_2_2022_To_2_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_TdEixVwmTkix-fdRgGxOWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_12_2022_To_1_12_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ph-iL0zoGk631_yyBbBhuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-12</xbrli:startDate><xbrli:endDate>2022-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OutsideOfIsraelMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_eeNvck2ATEWfgpCZeTLqVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OutsideOfIsraelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__0_D2FCWxk2p5kjrroefXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_Wf6RC2H560WbAcJnDFtApw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_BNmP4P54wkaBDpMrzeAVfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_dm10EvNOd0iKnY1gsz2csw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_-QuyUNmrLkKtu3HAPB64rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_TGSo8Z2q4UakwLgn9fGO-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_BR_WFR8ra7qdUO5CmDbCylH2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MskvE4NE_0SV-ZzLosD1-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_b_41YkbhLEmgakzPAuDz4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_TMhvyqD6DkCvNMBhkKseug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HHTyRmsve0-CvhM6s-xekA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_OfZWjQmIWECye0yv_boCTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__EIHv6aGREKNgPGju82ldg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_9zcjXo47CkaRE7ICQLJ5lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Wv2Wn8JO-UidVlRirC-2eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-20</xbrli:startDate><xbrli:endDate>2020-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kDIPT7eBJUiHYr1xa6GU6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ng8kcf3PY0-KI0QEryv2Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2020_To_3_16_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_e7awM79XzUyuSOlCW0jrbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:KirinHoldingsCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_1SnkfDBBdEa_ScKv2fZZOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_gflWc2-vqEuhHmJU56LALg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2009_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_VnPnDdgZPUGYN2qTVnlGFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_TPIzg0z-10Sb7x1kinz4UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_-UYZW6POc02nrytjPuH6oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r5Iht_Jc2k2j2OA7nlHKlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_uD3PPat1MEmGE12PwGBQuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ASM4sF594k-MTqGZBVQyyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_15_2022_yzNKajpAX0W9kN1xa7645w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_MK3JtZwR6kijibu1mfvLvg"><xbrli:measure>plx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ"><xbrli:measure>plx:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_director_yAcLdDF3PE-23pSbigEjyQ"><xbrli:measure>plx:director</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_BN18wiEo1UyImbahotyXDw"><xbrli:measure>plx:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;">gbEnterF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9fafcf7e_fb3d_4bfb_b4f8_ae45e3baa95e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:DocumentType" id="Narr_Je-Ta-rqJEqh-LzV7yjAoQ"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><a id="_d3cfb9af_6096_4d8c_be73_3670c88bd207"></a><a id="Tc_CUOjDrnpcEqQzK6o9zhJ3g_1_2"></a><a id="Tc_Cgalr8lcMEafZK61luFk1g_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.11%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:DocumentAnnualReport" id="Tc_X6B0iZoMdk-wCAZ02qG92w_1_1"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:DocumentPeriodEndDate" id="Narr_ADwibvLoIUu55kjfWXUfCg"><b style="font-size:7pt;font-weight:bold;">December&#160;31, 2021</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_363c4b72_8c99_4fe4_8cf1_fef7ba3a7dcb"></a><a id="Tc_FjTBKocfakKi0wfxsTqZsA_1_2"></a><a id="Tc_mM8FA1lHyk2S3m70_v296A_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.11%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:DocumentTransitionReport" id="Tc_giS2bj23eECFiLBqnLpbIA_1_1"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;"> </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityFileNumber" id="Narr_Ifq7ZhM-BkyD00Pz6MaP-Q"><b style="font-size:7pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityRegistrantName" id="Narr_-KeWy2rzQEafHi0aGachYg"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a6c241f7_1ec8_4187_a30c_8be39e61aefa"></a><a id="Tc_hrvp6vC0GEKBooNpdU1agw_2_0"></a><a id="Tc_z1rmyCXP7EWmv3ycTHIWZg_2_1"></a><a id="Tc_araceiaKrU-d5PpJmBiMpw_4_0"></a><a id="Tc_ZRq3BEnZ2E2daVQGErZe5g_6_0"></a><a id="Tc_8xyDtBRgTUm4jhW3FYDJJw_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.51%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityIncorporationStateCountryCode" id="Tc_K1Brb5_2-USIDwcS_411kQ_1_0"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityTaxIdentificationNumber" id="Tc_LjQGN-T8MUmF4Wss8L_bDA_1_1"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization</b></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:middle;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityAddressAddressLine1" id="Narr_Vi3EgQAiSkW9P1n-BqgYYw"><b style="font-size:7pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityAddressAddressLine2" id="Narr_ns7dkf5D7Ea7EwC76c6EaA"><b style="font-size:7pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityAddressCityOrTown" id="Narr_FNiHkg9nC0K87Fjq9s4xBQ"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityAddressStateOrProvince" id="Narr_oH_I17b98ESJZBAY0ObukQ"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityAddressPostalZipCode" id="Tc_aDt-PFM2l0m9JaYQ42PfMA_4_1"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:CityAreaCode" id="Narr_KtsP71zfl0a6kvmbETUOSQ"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:LocalPhoneNumber" id="Narr_OXGqzrGDnEOUFy1sb8xUiw"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_6ead232e_1582_40d9_b92c_15f6a55d95c5"></a><a id="Tc_rwXkTBrxikC8PIjrgOCOCQ_0_0"></a><a id="Tc_Ea2b9p38CUqh-JFefZB3Qg_0_2"></a><a id="Tc_bUhdcd2YcEa_h44mDx9sdA_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:29.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:top;width:2.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.34%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:1.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:29.49%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:29.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:Security12bTitle" id="Tc_urzUdxxcBEmIqxhanELQ4w_1_0"><span style="font-size:7pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.34%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:TradingSymbol" id="Tc_oFbQGFXp7EGDg3wOzGvw1Q_1_2"><span style="font-size:7pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.49%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:SecurityExchangeName" id="Tc_qT_rfT99Gki_xObOFtoMCQ_1_4"><span style="font-size:7pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_VQV7YfyptU2GOdHU1KZjGw"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityVoluntaryFilers" id="Narr_0lsuwYUn_0KlbsR-ZfgmTQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityCurrentReportingStatus" id="Narr_N5UiswvEWEOzze3pfxXu5A"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityInteractiveDataCurrent" id="Narr_1Xb9YmkSsE2789SjXwLAYg"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &quot;large accelerated filer,&quot; &quot;accelerated filer,&quot; &quot;smaller reporting company,&quot; and &quot;emerging growth company&quot; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_69b1fb3e_fd77_4713_8a3b_720977774d44"></a><a id="Tc_49FiL6KEm0qbXvxymQJPyA_1_0"></a><a id="Tc_iVyAVT12_0a-XFBwM35cRg_1_1"></a><a id="Tc_IZuimPGM0Um_tXt4ZOVJcw_1_2"></a><a id="Tc_3WUYbdyhOUKl7TEtv6_0gA_1_3"></a><a id="Tc_nvD569GCt0aWGI27-BOePw_2_1"></a><a id="Tc_hrv5k8e340SbN36tOEeQOg_2_2"></a><a id="Tc_LkXtROu3aU-TBqxpPIen1g_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityFilerCategory" id="Tc_1lYiD2_lHUibzfaubk4Fdg_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntitySmallBusiness" id="Tc_tEM5fq2i0kSkDwPSm4eM3Q_2_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityEmergingGrowthCompany" id="Tc_WIF5hDJWJkSZYvmLsQG_cw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:IcfrAuditorAttestationFlag" id="Narr_XqmqycE_k0S2E4NFh6OgYg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:EntityShellCompany" id="Narr_xecEuZ9BDk65SgKESS7OLQ"><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The aggregate market value of the voting common stock held by non-affiliates of the Registrant as of June&#160;30, 2021 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_ASM4sF594k-MTqGZBVQyyg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_3yEwLZ0FkEKQojoNx-UkZw">85.1</ix:nonFraction>&#160;million, based on the closing price for shares of the Registrant&#8217;s common stock reported by the NYSE American for such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt;">On March&#160;15, 2022, approximately <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_15_2022_yzNKajpAX0W9kN1xa7645w" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_TMb31ldOk0-4POSBNJchEg">46,316,129</ix:nonFraction> shares of the Registrant&#8217;s common stock, par value $0.001 per share, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 2pt 0pt;"><span style="white-space:pre-wrap;"> Portions of the registrant&#8217;s proxy statement related to its 2022 Annual Stockholders&#8217; Meeting to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K. Except as expressly incorporated by reference, the registrant&#8217;s proxy statement shall not be deemed to be part of this report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:36pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a9f31411_e068_4025_9bb1_c1046c655253"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FORM&#160;10-K</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_803173"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a><b style="font-weight:bold;"> </b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARYSTATEMENTREGARDINGFORWARDLOOKI"><span style="font-style:normal;font-weight:normal;">Cautionary Statement Regarding Forward-Looking Statements and Risk Factors Summary</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_626044"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_626044"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_907582"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_907582"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_932888"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_932888"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_147620"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_147620"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_453527"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_466791"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Reserved]</p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_730194"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_730194"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_882944"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_882944"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_463758"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_376320"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_376320"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV_377623"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_450405"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_450405"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_579077"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_270f69fc_d7d6_4575_b525_d6b2851f28bf"></a><a id="PARTI_803173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Except where the context otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or &#8220;the Company,&#8221; refer to the business of Protalix BioTherapeutics,&#160;Inc. and its consolidated subsidiaries, and &#8220;Protalix&#8221; or &#8220;Protalix&#160;Ltd.&#8221; refers to the business of Protalix&#160;Ltd., our wholly-owned subsidiary and sole operating unit.</i></p><a id="S1_002"></a><a id="CAUTIONARYSTATEMENTREGARDINGFORWARDLOOKI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<br />AND RISK FACTORS SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The statements set forth under the captions &#8220;Business,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors,&#8221; and other statements included elsewhere in this Annual Report on Form&#160;10-K, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words or phrases of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing and progress of the preparation of an updated Biologics License Application, or BLA, for PRX-102 addressing the Complete Response Letter, or CRL;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of final approval by the U.S. Food and Drug Administration, or the FDA, and the European Medicines Agency, or the EMA, of a resubmitted Biologics License Application, or BLA, and of a Marketing Authorization Application, or an MAA, respectively, for PRX-102, and, if approved, whether the use of PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, the European Medicines Agency, or EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business;</div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug product to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Funda&#231;&#227;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These and other risks and uncertainties are detailed under the heading &#8220;Risk Factors&#8221; in this Annual Report and are described from time to time in the reports we file with the U.S.&#160;Securities and Exchange Commission, or the Commission.</p><a id="_1358243f_6df8_4cc7_96f9_31a917ea756e"></a><a id="Item1Business_89253"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1.</b></span>Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our strategic focus is to develop tailored complex recombinant therapeutic proteins primarily produced through ProCellEx while genetically engineering and/or chemically modifying the proteins pre- and/or post-production. We </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:144.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">intend such engineering and modifications to provide added clinical benefits by improving the biologic characteristics (e.g., glycosylation, half-life, immunogenicity) of the therapeutic protein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our proprietary ProCellEx platform is being used to manufacture our approved and marketed product, Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, for the treatment of Gaucher disease. We are also developing, via ProCellEx, a pipeline of products. Our clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease is in advanced clinical stages. In addition, we are developing uricase, or PRX-115, for the treatment of refractory gout, PRX-119, a long action DNase I for the treatment of NETs-related diseases, and a number of other product candidates in early and preclinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20211231x10k001.jpg" alt="Graphic" style="display:inline-block;height:144.54pt;width:488.1pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our ProCellEx Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacturing of recombinant proteins, which are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255.66pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><img src="plx-20211231x10k002.jpg" alt="Graphic" style="display:inline-block;height:255.66pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allowing for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Business Highlights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso for the treatment of Gaucher Disease is currently approved and marketed in 23 countries including the United States, Australia, Canada, Israel, Brazil, Russia and Turkey. In June&#160;2012, the European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion regarding the benefit of Elelyso but did not immediately grant marketing authorization because of the ten-year market exclusivity granted to Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Takeda Shire) in August&#160;2010 for the same condition, which was later extended for an additional two&#160;years. Elelyso is marketed globally, excluding Brazil, through an exclusive licensing agreement with Pfizer. We maintain the distribution rights to Elelyso in Brazil, where it is currently marketed as BioManguinhos alfataliglicerase, through the Supply and Technology Transfer Agreement we entered into on June&#160;18, 2013, with Fiocruz, an arm of the Brazilian MoH, or the Brazil Agreement. In 2021, we generated $6.4&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Pegunigalsidase alfa (PRX<span style="font-style:normal;">-</span>102)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pegunigalsidase alfa, or PRX-102, our lead product candidate, is a late-stage clinical asset in development for the treatment of Fabry disease. We expect PRX-102 to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time and, as a result, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> accumulates, primarily in the blood vessel walls. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;7, 2022, an MAA for PRX-102 was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting on October&#160;8, 2021, we and Chiesi discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA originally submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway. The BLA was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of our manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act, or the FFDCA, in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup>(agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021 to discuss the FDA&#8217;s requirements for a BLA resubmission. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the clinical data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements (ex-U.S. and U.S.) with Chiesi for PRX-102; on October&#160;19, 2017, Protalix&#160;Ltd., our wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi, or the Chiesi Ex-US Agreement, pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102 and on July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi, or the Chiesi US Agreement, with respect to the commercialization of PRX-102 in the United States.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Alidornase alfa (PRX-110)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Alidornase alfa is our plant cell-expressed recombinant human DNase I product candidate, administered via inhalation, chemically modified to resist inhibition by actin, thus enabling enzymatic activity in the presence of actin. In vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA compared to the unmodified DNase I. We completed a phase&#160;IIa clinical trial of PRX-110 in Cystic Fibrosis patients in 2018, and PRX-110 was shown to be generally well-tolerated with no serious adverse events reported. Efficacy results demonstrated clinically meaningful lung function improvement following treatment with PRX-110.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">PRX-115</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated Uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of refractory gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. An estimated approximately 2% of the gout population is considered to have chronic refractory disease. The uricase enzyme converts uric acid to allantoin, which is easily eliminated through urine. However the uricase enzyme does not exist naturally in humans. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of refractory gout which we are designing to have an improved half-life, reduced immunogenicity and potentially longer-term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">PRX-119</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase I treatment reduce NETs toxicity. Our proprietary modified DNase I may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2021 and Recent Company Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Recent Developments</i></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On March&#160;18, 2022, we, together with Chiesi, announced final results from our phase&#160;III <i style="font-style:italic;">BRIGHT </i>clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BRIGHT</i> study, designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 treatment, 2&#160;mg/kg every four&#160;weeks, in up to 30&#160;patients with Fabry disease previously treated with a commercially available enzyme replacement therapy, or ERT (agalsidase alfa &#8211; Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or agalsidase beta &#8211; Fabrazyme).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;24, 2022, we, together with Chiesi, announced that the PRX-102 MAA was submitted to the EMA following the October&#160;8, 2021 meeting we, together with Chiesi, held with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102, and that the submission was subsequently validated by the EMA. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">2021 Developments</i></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;15, 2021, we, together with Chiesi, announced the final dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study for the proposed treatment of Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;11, 2021, we, together with Chiesi, provided a regulatory update regarding PRX-102 which included an announcement of the receipt of the official Type A (End-of-Review) meeting minutes from FDA regarding the CRL confirming a potential pathway for resubmission of a BLA for PRX-102.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;25, 2021, we exchanged an aggregate of $54.65&#160;million principal amount of our outstanding 2021 Notes, representing a substantial majority of our then outstanding 2021 Notes, with institutional note holders for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;2, 2021, we <span style="letter-spacing:-0.15pt;">announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On July&#160;2, 2021, we entered into the Sales Agreement with H.C.&#160;Wainwright &amp; Co., LLC, as our sales agent, or the Agent, pursuant to which we may sell from time to time up to $20.0&#160;million worth of shares of our common stock in at-the-market transactions through the Agent. Upon execution of the Sales Agreement, we terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement we entered into on October&#160;1, 2020 with BofA Securities.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;2, 2021, we, together Chiesi, announced topline results from an interim analysis of the phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial. The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments (PRX-102 and Fabrazyme) was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set. At the time of this analysis, two patients had discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. No deaths were registered. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million milestone payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We also agreed to negotiate certain manufacturing related matters. We received the payment in June&#160;2021.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On April&#160;28, 2021, we, together with Chiesi, announced the receipt from the FDA of a CRL in response to the PRX-102 BLA.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.5pt 10pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;23, 2021, we, together with Chiesi, announced positive topline results from our <i style="font-style:italic;">BRIGHT </i>study.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 10pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;18, 2021, we announced the closing of a public offering of our common stock raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;11, 2021, we announced an exclusive worldwide license agreement with SarcoMed USA Inc., or SarcoMed, for PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. The agreement expired during 2021.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our Marketed Product</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product for the treatment of Gaucher disease, is the first plant cell derived recombinant protein therapeutic approved by major regulatory authorities, including the FDA and the EMA. Elelyso is approved in 23 markets for infusion as an ERT for the long-term treatment of adult and pediatric patients with a confirmed diagnosis of type&#160;1 Gaucher disease. We have licensed to Pfizer the global rights for Elelyso, excluding Brazil. In Brazil, we maintain the distribution rights to taliglucerase alfa, marketed as BioManguinhos alfataliglicerase, through the Brazil Agreement. In 2021, we generated $6.4&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people. The global market for Gaucher disease is forecasted to be approximately $1.5&#160;billion and $1.6&#160;billion in 2021 and 2022, respectively (Global Data) and to grow at a CAGR of approximately 8.6% from 2020-2027 (Global Data).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Sanofi Genzyme&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and VPRIV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Clinical Development Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:10pt;margin:0pt;"><span style="font-weight:bold;">Pegunigalsidase alfa (PRX-102)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease is forecasted to be approximately $1.9&#160;billion and $2.1&#160;billion in 2021 and 2022, respectively (Global Data) and to grow at a CAGR of approximately 10% from 2020-2027 (Global Data).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Fabry disease is generally treated with an ERT, Fabrazyme or Replagal. In ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients, which also impacts social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated women. This represents a 20- and 10-year reduction, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On February&#160;7, 2022, the PRX-102 MAA was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential treatment for Fabry disease. The submission is supported by the 12&#8211;month interim data analysis generated from our phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102, which was released in June 2021. Data generated from the completed phase&#160;III <i style="font-style:italic;">BRIDGE</i> clinical trial, the phase&#160;1/2 clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the filing. In addition, the MAA includes data from the completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial of patients treated with the 2&#160;mg/kg every 4&#160;weeks dosage.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The initial BLA submitted on May&#160;27, 2020 included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data from our phase III <i style="font-style:italic;">BRIDGE</i> switch-over study and safety data from our on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme, a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021 to discuss the FDA&#8217;s requirements for a BLA resubmission. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the clinical data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. We intend to continue to work collaboratively with the FDA resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given the changed regulatory landscape in the United States, the planned data package for the PRX-102<span style="direction:rtl;"> </span>BLA resubmission will include the final two-year analyses of the <i style="font-style:italic;">BALANCE </i>study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our clinical development program is designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to currently marketed Fabry disease enzymes, Fabrazyme and Replagal. In preclinical studies, PRX-102 showed enhanced activity in Fabry disease target organs, reduction of the accumulated substrate, significantly longer half-life due to higher enzyme stability, and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of antibodies. Providing a meaningful improvement in the health and quality of life for Fabry patients being treated with PRX-102 represents a significant potential market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102. In the phase&#160;III clinical program, we are studying two potential dosing regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:244.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients that completed the <i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Currently, 126 subjects that participated in the our PRX-102 clinical program have opted, with the advice of the treating physician, to continue PRX-102 treatment in one of our long-term extension studies; 10 subjects that completed an extension study from the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial, 18 subjects that completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects that completed the <i style="font-style:italic;">BALANCE</i> study; and 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study. Of the 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study that are enrolled in a long-term extension study, 27 of them are being treated with 2&#160;mg/kg of PRX-102 every 4 weeks and two are being treated with 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="plx-20211231x10k003.jpg" alt="Graphic" style="display:inline-block;height:243.9pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:474.04pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;">Phase III BALANCE Study</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BALANCE</i> s<span style="background:#ffffff;">tudy is a 24</span>-<span style="background:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background:#ffffff;">102 in Fabry patients with impaired renal function. A total of 78 patients were enrolled in the trial which was </span>designed to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme) on renal function in Fabry patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. The last patient in the study received the final dose in October 2021. <span style="background:#ffffff;">Patients previously treated with </span>Fabrazyme <span style="background:#ffffff;">for approximately one year and on a stable dose for at least six months were screened and then randomized on a 2:1 ratio to 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background:#ffffff;">mg/kg of PRX-102 or 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background:#ffffff;">mg/kg of </span>Fabrazyme<span style="background:#ffffff;">. Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &#8805;</span>&#160;<span style="background:#ffffff;">1</span>&#160;<span style="background:#ffffff;">g/g by spot urine sample. The study was designed such that no more than 50% of the patients enrolled in the study would be female. Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of estimated Glomerular Filtration Rate, or eGFR, slope between Fabrazyme and PRX-102. eGFR is considered a reliable and accepted test to measure kidney function and stage of kidney disease. Additional parameters being evaluated include: </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events and pharmacokinetic and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2021, we, together with Chiesi, announced topline results from an interim analysis of the <i style="font-style:italic;">BALANCE </i>study. The primary endpoint of the interim analysis is the comparison of mean annualized changes (slope) of the eGFR<sub style="font-size:7.5pt;vertical-align:sub;">(CKD-EPI)</sub> after completion of at least 12 months of treatment between the two treatment arms (Fabrazyme and PRX-102). The interim efficacy analysis was conducted on two pre-defined analysis sets: Intention to Treat (ITT), consisting of all randomized patients who received at least one dose (77 patients), considered as the primary analysis for this interim review; and the Per Protocol (PP), consisting of all patients who completed at least 12 months of treatment with no major protocol violations (74 patients). The patient population (ITT analysis set) of the study is comprised of 47 males (61%) and 30 females (39%) with a mean age of 44.3 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set. At the time of this analysis, two patients discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. No deaths were registered. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102. We expect top-line results from the BALANCE study to be released in the second quarter of 2022 and final results to be released in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;">Phase&#160;III BRIDGE Study</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with Replagal (agalsidase alfa; marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc)) for at least two years and on a stable dose for at least six months. The trial was completed in December 2019. Patients were screened and evaluated over three months while continuing Replagal treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE </i>study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.<span style="font-size:12pt;"> </span>In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">et</span>. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">al</span>., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of treatment <span style="letter-spacing:-2.9pt;"> </span>emergent adverse events were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate treatment emergent adverse events were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent antidrug antibodies over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.14;margin:0pt 5.2pt 10pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> study, which were first announced in February 2020, were used to support the PRX-102 BLA filing with the FDA, and we anticipate that the final analysis will be used to support the planned MAA submission to the EMA and the BLA resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;">Phase&#160;III BRIGHT Study<i style="direction:rtl;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIGHT</i> study was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four&#160;weeks for 52 weeks (a total of 14 infusions). The trial, which was completed in June 2020, enrolled 30&#160;adult patients (24&#160;males and 6&#160;females) with mean (SD) age of 40.5&#160;(11.3)&#160;years, ranging from 19 to 58&#160;years previously treated with a commercially available ERT (Fabrazyme or Replagal), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every 2 weeks to 2&#160;mg/kg of PRX-102 every 4 weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without anti-drug antibodies, or ADAs, at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30&#160;patients received at least one dose of pegunigalsidase alfa, and 29&#160;patients completed the one-year study. Of these 29&#160;patients, 28 received the intended regimen of 2&#160;mg/kg every 4&#160;weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg pegunigalsidase alfa every two weeks per protocol at the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Overall, 33 of 183 total treatment-emergent adverse events (TEAEs) reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs lead to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36&#160;nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05)&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every 2&#160;weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every 4&#160;weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (NCT03614234) of the 2&#160;mg/kg PRX-102 every 4&#160;weeks dose.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete two of the trials and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 18pt;">Phase I/II Study</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, currently the only commercially available DNase therapy), even more so in the presence of actin. In February 2021, we entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment<span style="direction:rtl;"> </span>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. The license agreement expired during the three months ended September&#160;30, 2021. We are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We completed a phase&#160;I clinical trial of PRX-110 with 18 healthy volunteers, in whom alidornase alfa was found to be well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In July&#160;2016, we commenced a phase IIa clinical trial of PRX-110 for the treatment of Cystic Fibrosis, and we released the final results of the study in April&#160;2017. Sixteen patients were enrolled in the study, all of whom completed the study. The phase&#160;IIa clinical trial was a 28-day switchover study to evaluate the safety and efficacy of PRX-110 in Cystic Fibrosis patients previously treated with Pulmozyme (dornase alfa). Participation in the trial was preceded by a two-week washout period from Pulmozyme before treatment with PRX-110 via inhalation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Primary efficacy results from the phase&#160;IIa study demonstrated clinically meaningful lung function improvement following treatment with PRX-110, as demonstrated by a mean absolute improvement in the&#160;percent predicted forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline. Moreover, a mean absolute increase in ppFEV1 of 2.8 points was also observed in patients participating in the study when compared to measurements taken from patients at initiation, before the switch from Pulmozyme to PRX-110.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of refractory gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. Refractory gout patients are those whom, despite treatment with existing ULTs, have high flare frequency, consistent tophi, and the inability to maintain therapeutic goals of urate levels. An estimated approximately 2% of the gout population is considered to have chronic refractory disease and are in need of other therapeutic options. One option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for treatment of chronic gout refractory to conventional therapy (no longer approved in the European Union) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of refractory gout which we are designing to have an improved half-life, reduced immunogenicity and potentially longer term efficacy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have a robust patent portfolio, which is a key element of our overall strategy. We work to continually enhance, strengthen, and protect our intellectual property and now hold a broad portfolio of more than 80 patents globally, including Europe, the United States, Israel and additional countries worldwide. Our patents are designed to protect our proprietary technology, proprietary products and product candidates, and their methods of use. Additionally, we have more than 30 pending patent applications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During 2021, we received a patent in Brazil for each of the patent family named &#8220;Production of High Mannose Proteins in Plant Culture&#8221; and the patent family named &#8220;Large Scale Disposable Bioreactor,&#8221; adding to the more than 10 previously granted patents in each of those families. We received a second United States patent for the patent family named &#8220;Stabilized Alpha-galactosidase and uses thereof,&#8221; adding to the more than 10 previously granted patents in such family. We received a patent in each of the United States, Australia, South Africa for the patent family named &#8220;Modified DNase and uses thereof.&#8221; Finally, we received a patent in each of Israel and Japan for the patent family named &#8220;Use of Plant Cells Expressing a TNF Alpha Polypeptide Inhibitor in Therapy,&#8221; adding to the four previously granted patents in such family.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our competitive position and future success depend in part on our ability, and that of our licensees, to obtain and leverage the intellectual property covering our product candidates, know-how, methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property and to operate without infringing on the intellectual property of third parties. We seek to protect our competitive position by filing United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology and improvements to existing technology. Our patent strategy includes obtaining patents on methods of production, compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership opportunities to develop and maintain our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our outstanding 2024 Notes are guaranteed by our subsidiaries and secured by perfected liens on all of our material assets, primarily consisting of our intellectual property assets, including a stock pledge of our foreign subsidiaries in favor of the holders of outstanding 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, our patent portfolio consisted of several patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and system and product candidates, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:25.3pt;"><td style="vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Name/Int. App. No.</b></p></td><td style="vertical-align:bottom;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Pending Jurisdictions</b></p></td><td style="vertical-align:bottom;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Granted Jurisdictions</b></p></td><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominal Expiry</b></p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Production of High Mannose Proteins in Plant Culture/PCT/ Il2004 000181</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Japan, Israel, Canada, Russian Federation, Mexico, India, Australia, South Africa, Republic of Korea, Singapore, Europe, Hong Kong, Ukraine, China, USA, Brazil</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2024(1)</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell/Tissue Culturing Device, System and Method/PCT/Il2005/ 000228</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2025</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">System and Method for Production of Antibodies in Plant Cell Culture/PCT/Il2005/001075</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Israel</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2025</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Large Scale Disposable Bioreactor/PCT/Il2008/000614</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A </p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Australia, Canada, China, Europe, Hong Kong, India, Israel, Republic of Korea, Russian Federation, Singapore, South Africa, USA, Brazil</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2028(2)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Stabilized Alpha-galactosidase and uses thereof/PCT/Il2011/ 000209</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">Brazil</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Canada, South Africa, Russian Federation, Singapore, Israel, India, New Zealand, Republic of Korea, Australia, China, Japan, USA, Europe, Hong Kong, India</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2031</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Nucleic Acid Construct for Expression of Alpha-galactosidase in Plants and Plant Cells/PCT/ Il2011/000719</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">Brazil</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">India, China, Republic of Korea, Japan, Israel, Europe, Hong Kong, USA</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2024(2)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Therapeutic Regimen For The Treatment of Fabry Using Stabilized Alpha-galactosidase/ PCT/Il2018/050018</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">USA, Europe, Brazil, Japan, Canada, Australia, Chile, Israel, South Africa, Republic of Korea, China, New Zealand, Russian Federation, Mexico, Hong Kong</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Dry Powder Formulations of DNase 1/PCT/Il2013/050094</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2033</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">DNase I Polypeptides, Polynucleotides Encoding Same, Methods of Producing DNase I and uses thereof in Therapy/PCT/ Il2013/050097</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">Brazil</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Europe, Israel</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2033</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Inhalable Liquid Formulations of DNase I/PCT/Il2013/050096</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2033</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modified DNase and uses thereof/ PCT/Il2016/050003</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">Europe, Canada, China, New Zealand, Israel, Mexico, Hong Kong</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Australia, South Africa</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2036</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Use of Plant Cells Expressing a TNF Alpha Polypeptide Inhibitor in Therapy/PCT/IL2014/050231</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, Japan, USA, Europe, Australia, Canada</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2034</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chimeric Polypeptides, Polynucleotides Encoding Same, Cells Expressing Same and Methods of Producing Same</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">2035</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Removal of Constructs from Transformed Cells /PCT/IL2019/051266</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Long-Acting DNase/PCT/IL2021/051207</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Dicer-Like Knock-Out Plant Cells/ PCT/IL2021/051194</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Modified Uricase and Uses Thereof/PCT/IL2021/051305</p></td><td style="vertical-align:top;width:27.3%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#9dc3e6;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">N/A</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent granted in Australia expires in 2029.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent granted in the United States expires in 2032.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are aware of U.S. patents, and corresponding international counterparts of such patents, owned by third parties that contain claims covering methods of producing glucocerebrosidase. We do not believe that, if any claim of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to infringe any valid claim under such patents. However, there can be no assurance that a court would find in our favor or that, if we choose or are required to seek a license to any one or more of such patents, a license would be available to us on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In April&#160;2005, Protalix&#160;Ltd. entered into a license agreement with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize Icon&#8217;s technology to express certain proteins in our ProCellEx protein expression system. We are also entitled to a non-exclusive worldwide license to make and have made other proteins expressed by using Icon&#8217;s technology in our technology. As consideration for the license, we are obligated to make royalty payments equal to varying low, single-digit&#160;percentages of net sales of products by us, our affiliates, or any sublicensees under the agreement. In addition, we are obligated to make milestone payments equal to $350,000, in the aggregate, for each product developed under the license, upon the achievement of certain milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our license agreement with Icon remains in effect until the earlier of the expiration of the last patent under the agreement or, if all of the patents under the agreement expire, 20&#160;years after the first commercial sale of any product under the agreement. Icon may terminate the agreement upon written notice to us that we are in material breach of our obligations under the agreement and we are unable to remedy such material breach within 30&#160;days after we receive such notice. Further, Icon may terminate the agreement in connection with certain events relating to a wind up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to conduct operations for a certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to reach certain milestones within a designated period of time. Notwithstanding the termination date of the agreement, our obligation to pay royalties to Icon under the agreement may expire prior to the termination of the agreement, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many specialized biotechnology companies have formed collaborations with large, established companies to support research, development and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&#8217; financial, marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies on their own through collaborations with pharmaceutical and biotechnology companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to Gaucher disease, we face competition from two ERTs, Sanofi Genzyme&#8217;s Cerezyme and Takeda&#8217;s (Shire) Vpriv. In addition, Actelion markets a small molecule drug for the treatment of mild to moderate Type&#160;1 Gaucher disease (Zavesca or miglustat), an oral treatment approved by the FDA only for patients for whom ERT is not a therapeutic option. In addition, Sanofi Genzyme markets a small molecule oral drug, Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, approved for Gaucher patients with certain CYP2D6 metabolizer status.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to Fabry disease, we face competition from Sanofi Genzyme (Fabrazyme), Takeda Shire (Replagal) and Amicus (Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>). In addition, we are aware of other late clinical stage, early clinical stage and experimental drugs which are being developed for the treatment of Fabry disease by other companies. For example, eleva GmbH (formerly, Greenovation Biotech GmbH), or eleva, is developing an ERT for Fabry disease which has completed a phase&#160;I clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to refractory gout, we face competition from Horizon Therapeutics Public Limited Company (Krsytexxa), which is indicated for treatment of chronic gout in adult patients refractory to conventional therapy. In addition, we are aware of other clinical stage, early clinical stage and experimental refractory or chronic gout treatments. For example, we are aware of a product candidate that is the subject of a phase&#160;III clinical trial for chronic refractory gout and another product candidate that is the subject of a phase&#160;II clinical trial for hyperuricemia in gout patients with advanced CKD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also face potential competition to our ProCellEx system from companies that are developing other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed proteins. A number of companies have developed or are developing alternative expression technologies. Examples include Crucell N.V. (acquired by Johnson&#160;&amp;&#160;Johnson) has an expression system based on human-cell technology, Dyadic International Inc.&#8217;s expression system based on a fungus, Pfenex Inc.&#8217;s (acquired by Ligand Pharmaceuticals Incorporated) bacteria-based expression system, and others. Companies developing alternate plant-based technologies include iBio,&#160;Inc., Medicago,&#160;Inc., and eleva. Unlike ProCellEx, these alternate technologies are not cell-based. These companies base their product development on transgenic plants or whole plants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Agreements and Partnerships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso &#8211; Pfizer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets, excluding Brazil, pursuant to an Amended and Restated Exclusive License and Supply Agreement, or the Amended Pfizer Agreement, which we entered into with Pfizer in October&#160;2015 to amend and restate our initial Exclusive License and Supply Agreement with Pfizer, or the Pfizer Agreement. Pursuant to the Amended Pfizer Agreement, Pfizer retains 100% of revenue and reimburses 100% of direct costs. For the first 10-year period after the execution of the Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, subject to certain terms and conditions, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods, subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period. Any failure to comply with our supply commitments may subject us to substantial financial penalties. The Amended Pfizer Agreement includes customary provisions regarding cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements. We maintain distribution rights to taliglucerase alfa in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso, marketed as BioManguinhos alfataliglicerase in Brazil, is commercialized in Brazil through the Brazil Agreement with Fiocruz, which became effective in January&#160;2014. Gaucher patients in Brazil are entitled to receive ERT paid for by the Brazilian MoH. The Brazilian MoH clinical treatment guidelines state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is currently estimated to be used by approximately 25% of Gaucher patients in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Brazil Agreement provides for a staged technology transfer which is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">produce a sustainable, high-quality, and cost-effective supply of BioManguinhos alfataliglicerase. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement. Accordingly, we and Fiocruz discuss on a continuous basis, potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">PRX-102 &#8211; Chiesi Farmaceutici</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45 million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We Company received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We use our current manufacturing facility in Carmiel, Israel, which has approximately 14,700&#160;sq/ft of clean rooms built according to industry standards, to manufacture drug substance for Elelyso, pegunigalsidase alfa and other recombinant proteins for commercial use and phase III clinical trials. We maintain an approximately 3,400&#160;sq/ft pilot plant for protein development and to manufacture supplies for clinical trials (phase&#160;I and phase&#160;II). Elelyso, pegunigalsidase alfa and our other drug product candidates must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory authorities. We are currently producing PRX-102 drug substance for our phase&#160;III and other clinical trials, as well as the manufacture of the Elelyso we need in the near future, including the Elelyso to be purchased by Pfizer under the Amended Pfizer Agreement. In addition, we intend to use our manufacturing space to produce all of the drug substance needed in connection with the clinical trials for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In 2017, the FDA approved the supplemental New Drug Application, sNDA, we submitted to allow us to convert our manufacturing facility from a single dedicated product facility to a multi-product facility. This conversion allows us to realize potentially significant operational savings. Our facility&#8217;s current capacity can serve all of our current and expected commercial and clinical needs, and we believe it will be sufficient to serve our production needs for the anticipated commercialization of pegunigalsidase alfa.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our manufacturing facilities have undergone successful inspections by the FDA, the Irish Medicines Board (under the EMA&#8217;s centralized marketing authorization procedure), ANVISA, the Israeli Ministry of Health, the Turkish Ministry of Health, the Australian TGA and Health Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our current facility in Israel has been granted &#8220;Approved Enterprise&#8221; status, and we have elected to participate in the alternative benefits program. Our facility is located in a top priority location, or &#8220;Zone A,&#8221; location, and, therefore, our income from the Approved Enterprise will be tax exempt in Israel for a 10-year period, commencing with the&#160;year in which we first generate taxable income from the relevant Approved Enterprise and after we use our net operating loss carryforwards, or NOLs. We expect to be entitled to similar tax benefits for a number of&#160;years thereafter. To remain eligible for these tax benefits, we must continue to meet certain conditions, and if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs. In addition, our technology is subject to certain restrictions with respect to the transfer of technology and manufacturing rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Raw Materials and Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that the raw materials that we require throughout the manufacturing process of Elelyso and our other current and potential drug product candidates are widely available from numerous suppliers and are generally considered to be generic industrial biological supplies. We rely on a single, approved supplier for certain materials relating to the current expression of our proprietary biotherapeutic proteins through ProCellEx. We have identified additional suppliers for most of the materials required for the production of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Development and regulatory approval of our pharmaceutical products are dependent upon our ability to procure active ingredients and certain packaging materials from sources approved by the FDA and other regulatory authorities. The FDA and other regulatory approval processes require manufacturers to specify their proposed suppliers of active ingredients and certain packaging materials in their applications. From time to time, we intend to continue to identify alternative approved suppliers to ensure the continued supply of necessary raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Government Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. Biologics are subject to regulation by the FDA under the FDCA, the Public Health Service Act, and related regulations and other federal, state and local laws and regulations. Biological products include a wide variety of products including vaccines, blood and blood components, gene therapies, tissue and proteins. Unlike most prescription products made through chemical processes, biological products generally are made from human and/or animal materials. To be lawfully marketed in interstate commerce, a biologic product must be the subject of a BLA issued by the FDA on the basis of a demonstration that the product is safe, pure and potent, and that the facility in which the product is manufactured meets standards to assure that it continues to be safe, pure and potent. The FDA has developed and is continuously updating the requirements with respect to cell and gene therapy products and has issued documents concerning the regulation of cellular and tissue-based products. Manufacturers of cell and tissue-based products must comply with the FDA&#8217;s current good tissue practices, or cGTP, which are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of such products. The primary intent of the cGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The process of obtaining regulatory approvals and ensuring compliance with appropriate federal, state and local statutes and regulations in the United States, and foreign statutes and regulations, requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, product detention, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The process required by the FDA before a biological product or drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled clinical trials according to Good Clinical Practices, or GCP, to establish the safety and efficacy of the proposed biological product or drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a BLA for a new biological product or a new drug application, or NDA, for a new drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA or NDA.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include the requirement that all subjects participating in the clinical trial provide their informed consent regarding the trial. Further, an institutional review board, or IRB, must review and approve the plan for any clinical trial before it commences at any institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject, or his or her legal representative, and must monitor the clinical trial until completed. Once an IND is in effect, each new clinical protocol and any amendments to the protocol must be submitted to the FDA for review, and to the IRBs for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase I.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted in patients having the specific disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:1pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase II.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Phase II clinical trials involve investigations in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and the optimal dosage and schedule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase III.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Phase III clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for regulatory approval and product labeling.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Post-approval studies, also called Phase&#160;IV trials, may be conducted after initial marketing approvals. These studies are used to obtain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected side effects. Phase&#160;I, Phase&#160;II and Phase&#160;III testing may not be completed successfully within any specified period, if at all. The FDA or the trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the study subjects or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the applicable product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the product candidate, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA or BLA, requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees which may be waived under certain limited circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The testing and approval processes require substantial time and effort, and may not result in an approval on a timely basis, if at all. The FDA may refuse to approve a BLA or NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Generally, it takes one to three&#160;years to obtain approval. If questions arise during the FDA review process, approval may take a significantly longer period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase&#160;IV testing which involves clinical trials designed to further assess a drug&#8217;s or biologic&#8217;s safety and effectiveness after BLA or NDA approval and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Orphan Drug Act of 1983, the FDA may grant orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 persons in the United States but that sales in the United States are not expected to recover the costs of developing and marketing a treatment drug. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. Among the benefits of orphan drug designation are possible funding and tax savings to support clinical trials and for other financial incentives and a waiver of the marketing application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same treatment for the same indication for seven&#160;years, except in limited circumstances, such as (i)&#160;the drug&#8217;s orphan designation is revoked; (ii)&#160;its marketing approval is withdrawn; (iii)&#160;the orphan exclusivity holder consents to the approval of another applicant&#8217;s product; (iv)&#160;the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v)&#160;a showing of clinical superiority to the product with orphan exclusivity by a competitor product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan drug status in the European Union has similar but not identical benefits in the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December&#160;2017, the European Commission granted Orphan Drug Designation to PRX-102 for the treatment of Fabry disease. In addition, On July&#160;21, 2020, the FDA granted Orphan Drug Designation for alidornase alfa for the treatment of sarcoidosis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidate, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between (a)&#160;the effective date of an IND and the submission date of a BLA or an NDA plus (b)&#160;the time between the submission date of a BLA or an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the extension must be requested prior to expiration of the patent. The U.S. Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We anticipate that we will apply for restorations of the patent term for certain of patents covering our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Fast Track Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA has a fast track program that is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the purpose being to make important new drugs available to patients earlier. A drug candidate that receives Fast Track designation from the FDA is eligible for some or all of the following: more frequent meetings with the FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to support drug approval; more frequent written communication from the FDA about such things as the design of the proposed clinical trials; eligibility for the FDA&#8217;s Accelerated Approval and Priority Review, if relevant criteria are met; and eligibility for Rolling Review, which allows a drug company to submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the BLA or NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. We used the Rolling Review option for our taliglucerase alfa NDA, which we completed in April&#160;2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2018, the FDA granted Fast Track designation to PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Accelerated Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Section&#160;901 of the U.S.&#160;Food and Drug Administration Safety Innovations Act amends the FDCA to allow the FDA to base Accelerated Approval for drugs for serious conditions that fill an unmet medical need on whether the drug has an effect on a surrogate or an intermediate clinical endpoint. A surrogate endpoint used for Accelerated Approval is a marker; that is, a laboratory measurement, radiographic image, physical sign or other measure, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a measure of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. The FDA bases its decision on whether to accept the proposed surrogate or intermediate clinical endpoint on the scientific support for that endpoint. Studies that demonstrate a drug&#8217;s effect on a surrogate or intermediate clinical endpoint must be &#8220;adequate and well controlled&#8221; as required by the FDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Accelerated Approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Under subpart H of the Accelerated Approval pathway, the FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. The Accelerated Approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;IV or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any drugs for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse effects with the product, reporting of changes in distributed products which would require field alert reports (FARs), drugs and biological product deviation reports (BPDRs) providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. In September&#160;2007, the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority, including the authority to require post marketing studies and clinical trials (PMRs and PMCs), labeling changes based on new safety information, and compliance with risk evaluations and mitigation strategies (REMS), approved by the FDA. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers of drugs and biologics must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Drug and biologic manufacturers and other entities involved in the manufacturing and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, GTP applicable to biologics, and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA may withdraw a product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Discovery of previously unknown problems with a product subsequent to its approval may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, warning letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, the FDA regulations and policies are often revised or reinterpreted by the agency in ways that may significantly affect our business and our development efforts. It is impossible to predict whether further legislative or FDA regulation or policy changes will be enacted or implemented and what the impact of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Foreign Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements, labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from FDA requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pharmaceutical products may not be imported into, or manufactured or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals in Israel is quality, safety and efficacy of the pharmaceutical product and the Israeli Ministry of Health requires pharmaceutical companies to conform to international </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">developments and standards. Regulatory requirements are constantly changing in accordance with scientific advances as well as social and ethical values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The relevant legislation of the European Union requires that medicinal products, including generic versions of previously approved products, and new strengths, dosage forms and formulations, of previously approved products, shall have a marketing authorization before they are placed on the market in the European Union. Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order to obtain an authorization, an application must be made to the competent authority of the member state concerned or in a centralized procedure to the EMA. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical, biological or microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials. All of these tests must have been conducted in accordance with relevant EU regulations and must allow the reviewer to evaluate the quality, safety and efficacy of the medicinal product. Orphan drug designation in the European Union is granted to medicinal products intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious conditions that affect not more than five in 10,000 people in the European Union. Orphan drug designation is generally given to medicinal products that treat conditions for which no current therapy exists or are expected to bring a significant benefit to patients over existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Third Party Payor Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement status of any approved therapy carries uncertainty and risk. In both the United States and foreign markets, our ability to commercialize our product and product candidates successfully, and to attract commercialization partners, depends in significant part on the availability of adequate financial coverage and reimbursement from third party payors, including, in the United States, governmental payors such as Medicare, Medicaid and the Veterans Affairs Health programs, and private health insurers. Medicare is a federally funded program managed by the Centers for Medicare and Medicaid Services, or CMS, through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations that govern its individual program. Each payor has its own process and standards for determining whether it will cover and reimburse a procedure or particular product. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. The competitive position of some of our products will depend, in part, upon the extent of coverage and adequate reimbursement for such products and for the procedures in which such products are used. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by the government and other payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Possible legislation at the federal and state levels in the United States focused on cost containment and price transparency may impact our ability to sell our product and product candidates for maximum profitably. It appears likely that the pressure on pharmaceutical pricing will continue, especially under the Medicare program, which may also increase our regulatory burdens and operating costs. Moreover, additional changes could be made to governmental healthcare programs that could significantly impact the success of our product and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some third party payors also require pre-approval of coverage for new or innovative devices, biologics or drug therapies before they will reimburse healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules&#160;and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs and biologics, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S.&#160;Department of Health and Human Services (e.g., the Office of Inspector General), the U.S.&#160;Department of Justice and individual U.S.&#160;Attorney General offices within the Department of Justice, and state and local governments. These regulations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the Health Care Reform Law requires manufacturers of drugs, devices, biologics, and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which among other things, strictly regulates drug and biologic product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Compliance with Environmental, Health and Safety Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to FDA regulations, we are also subject to evolving federal, state and local environmental, health and safety laws and regulations. In the past, compliance with environmental, health and safety laws and regulations has not had a material effect on our capital expenditures. Compliance with environmental, health and safety laws and regulations in the future may require additional capital expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Israeli Government Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a brief summary of the current principal Israeli tax laws applicable to us and Protalix&#160;Ltd., and of the Israeli Government programs from which Protalix&#160;Ltd. benefits. Some parts of this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore, the views expressed in the discussion may not be accepted by the tax authorities in question. This summary is based on laws and regulations in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">effect as of the date hereof, and should not be construed as legal or professional tax advice and does not cover all possible tax considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">General Corporate Tax Structure in Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The income of Protalix&#160;Ltd., other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at regular rates. Pursuant to the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget&#160;Year), 2016, the corporate tax rate in 2018 and thereafter is 23%. Capital gains on the sale of assets are subject to capital gains tax according to the corporate tax rate in effect in the&#160;year which the assets are sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Law for the Encouragement of Capital Investments, 1959</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Law for the Encouragement of Capital Investments, 1959, as amended, or the Investment Law, provides certain incentives for capital investments in a production facility (or other eligible assets). Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an &#8220;Approved Enterprise,&#8221; is entitled to benefits. These benefits may include cash grants from the Israeli government and tax benefits, based upon, among other things, the location within Israel of the facility in which the investment is made and specific elections made by the grantee. In order to qualify for these incentives, an Approved Enterprise is required to comply with the requirements of the Investment Law, and Letter of approval received by Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. will continue to enjoy the tax benefits under the pre-revision provisions of the Investment Law. If any new benefits are granted to Protalix&#160;Ltd. in the future, Protalix&#160;Ltd. will be subject to the provisions of the amended Investment Law with respect to these new benefits. Therefore, the following discussion is a summary of the Investment Law prior to its amendment as well as the relevant changes contained in the new legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Investment Law prior to its amendment, a company that wished to receive benefits had to receive approval from the Authority for the Investment and Development of the Industry and Economy, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset, e.g., the equipment to be purchased and utilized pursuant to the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">An Approved Enterprise may elect to forego any entitlement to the grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under which the undistributed income (after deductions and offsets) from the Approved Enterprise is exempt from corporate tax for a defined period of time. Under the alternative package of benefits, a company&#8217;s undistributed income derived from an Approved Enterprise will be exempt from corporate tax for a period of between two and 10&#160;years from the first&#160;year of taxable income, depending upon the geographic location within Israel of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible for the reduced tax rates otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits period (up to an aggregate benefits period of either seven or 10&#160;years, depending on the location of the company or its definition as a foreign investors&#8217; company). If a company has more than one Approved Enterprise program or if only a portion of its capital investments are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise and are contingent upon meeting the criteria set out in the certificate of approval. Income derived from activity that is not integral to the activity of the Approved Enterprises (including capital gain) does not enjoy these tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A company that has an Approved Enterprise program is eligible for further tax benefits, as an alternative to exemption, if it qualifies as a foreign investors&#8217; company. A foreign investors&#8217; company eligible for benefits is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and appointment of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents. A company that qualifies as a foreign investors&#8217; company and has an Approved Enterprise program is eligible for tax benefits for a 10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 23%, depending on the amount of the company&#8217;s shares held by non-Israeli shareholders.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a company that has an Approved Enterprise program is a wholly-owned subsidiary of another company, the&#160;percentage of foreign investments is determined based on the&#160;percentage of foreign investment in the parent company. The tax rates and related levels of foreign investments with respect to a foreign investor&#8217;s company that has an Approved Enterprise program are set forth in the following table:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of Foreign Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate&#160;of&#160;Reduced&#160;Tax</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Over 25% but less than 49%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">23%</p></td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">49% or more but less than 74%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">20%</p></td></tr><tr><td style="vertical-align:bottom;width:81.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">74% or more but less than 90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15%</p></td></tr><tr><td style="vertical-align:bottom;width:81.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">90% or more</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our original facility in Israel has been granted &#8220;Approved Enterprise&#8221; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved Enterprise program, the facility is located in a Zone A area and, therefore, the undistributed income from that Approved Enterprise will be tax exempt in Israel for a period of 10&#160;years, commencing with the&#160;year in which taxable income is first generated from the relevant Approved Enterprise. The current benefits program may not continue to be available and Protalix&#160;Ltd. may not continue to qualify for its benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A company that has elected to participate in the alternative benefits program and that subsequently pays a dividend out of the income derived from the portion of its facilities that have been granted Approved Enterprise status during the tax exemption period will be subject to corporate tax in respect of the amount of dividend distributed at the rate that would have been applicable had the company not elected the alternative benefits program (generally 10% to 23%, depending on the extent to which non-Israeli shareholders hold such company&#8217;s shares). If the dividend is distributed within 12&#160;years after the end of the benefits period (or, in the case of a foreign investor&#8217;s company, without time limitation), the dividend recipient is taxed at the reduced withholding tax rate of 20% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty. After this period, the withholding tax rate is 25% to 30%, or at the lower rate under an applicable tax treaty. In the case of a company with a foreign investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding tax on dividends does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted into foreign currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Investment Law also provides that an Approved Enterprise is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This benefit is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The benefits available to an Approved Enterprise are conditioned upon terms stipulated in the Investment Law and its regulations and the criteria set forth in the applicable certificate of approval. If Protalix&#160;Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix&#160;Ltd. may be required to refund the benefits received, linked to the Israeli consumer price index with interest. We believe that Protalix&#160;Ltd. currently operates in compliance with all applicable conditions and criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Amendment No.&#160;60 to the Investment Law introduced a tax benefits regime referred to as &#8220;Benefitted Enterprises.&#8221; Under the Investment Law, the approval of the Investment Center is required only for Benefitted Enterprises that receive cash grants. Benefitted Enterprises that do not receive benefits in the form of governmental cash grants, but only tax benefits, are no longer required to obtain this approval. Instead, these Benefitted Enterprises are required to make certain investments as specified in the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The amended Investment Law specifies certain conditions for a Benefitted Enterprise to be entitled to benefits. These conditions include, inter alia, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Benefitted Enterprise&#8217;s revenues from any single country or a separate customs territory may not exceed 75% of the Benefitted Enterprise&#8217;s total revenues; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 25% of the Benefitted Enterprise&#8217;s revenues during the benefits period must be derived from sales into a single country or a separate customs territory with a population of at least 14 million people (starting from January 1, 2012, 1.4% must be added for each year).</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that Protalix&#160;Ltd. will comply with the above conditions in the future or that Protalix&#160;Ltd. will be entitled to any additional benefits under the Investment Law. In addition, it is possible that Protalix&#160;Ltd. may not be able to operate in a manner that maximizes utilization of the potential benefits available under the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the future there may be changes in the law, subject to the preservation of benefits, which may affect the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits available under the Investment Law could impact our tax expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Amendment of the Law for the Encouragement of Capital Investments, 1959</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In recent&#160;years, several amendments have been made to the Investments Law which have enabled new alternative benefit tracks, subject to certain conditions. The Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Investments Law. On December&#160;29, 2016, Amendment 73 to the Investments Law, or the Investments Law Amendment, was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise.&#8221; To date, we have elected not to have the Investments Law Amendment apply to our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Encouragement of Industrial Research, Development and Technology Innovation Law, 1984</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, Protalix&#160;Ltd. has received grants from the Office of the Chief Scientist of the Israeli Department of Labor, or the OCS under the Israeli Law for the Encouragement of Industrial Research, Development and Technology Innovation, 1984, and related regulations, or the Research Law. On January&#160;1, 2016, the Israeli government established the National Authority for Technological Innovation, or NATI, which replaced many of the functions of the OCS. For purposes of clarity, references to NATI will include the OCS. NATI grants are made available to finance of a portion of Protalix&#160;Ltd.&#8217;s research and development expenditures in Israel. As of December&#160;31, 2021, NATI approved grants in respect of Protalix&#160;Ltd.&#8217;s continuing operations totaling approximately $53.2&#160;million (before interest, as described below), measured from inception. Protalix&#160;Ltd. is required to repay up to 100% of grants actually received (plus interest at the LIBOR rate applied to the grants received on or after January&#160;1, 1999) to NATI through payments of royalties at a rate of 3% to 6% of the revenues generated from NATI-funded project, depending on the period in which revenues were generated. As of December&#160;31, 2021, Protalix Ltd. either paid or accrued royalties payable of $14.6&#160;million, and Protalix&#160;Ltd.&#8217;s contingent liability to NATI with respect to grants received was approximately $38.6&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Research Law, recipients of grants from NATI are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants outside of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Research Law and the regulations promulgated thereunder, NATI Council may allow the transfer outside of Israel of know-how derived from an approved program and the related manufacturing rights in limited circumstances which are currently as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a sale of know-how itself to a non-affiliated third party, provided that upon such sale the owner of the know-how pays to NATI an amount, in cash, as set forth in the Research Law (and the regulations promulgated thereunder). In addition, the amendment provides that if the purchaser of the know-how gives the selling Israeli company the right to exploit the know-how by way of an exclusive, irrevocable and unlimited license, the research committee may approve such transfer in special cases without requiring a cash payment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a sale of a company which is the owner of know-how, pursuant to which the company ceases to be an Israeli company, provided that upon such sale, the owner of the know-how makes a cash payment to NATI as set forth in the Research Law (and the regulations promulgated thereunder).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of an exchange of know-how such that in exchange for the transfer of know-how outside of Israel, the recipient of the know-how transfers other know-how to the company in Israel in a manner in which NATI is convinced that the Israeli economy realizes a greater, overall benefit from the exchange of know-how.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Research Committee may, in special cases, approve the transfer of manufacture or of manufacturing rights of a product developed within the framework of the approved program or which results therefrom, outside of Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The State of Israel does not own intellectual property rights in technology developed with NATI funding and there is no restriction on the export of products manufactured using technology developed with NATI funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described above. For a description of such restrictions, please see &#8220;Risk Factors&#8212;Risks Relating to Our Operations in Israel.&#8221; NATI approval is not required for the export of any products resulting from the research or development or for the licensing of any technology in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Law for the Encouragement of Industry (Taxes), 1969</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that Protalix&#160;Ltd. currently qualifies as an &#8220;Industrial Company&#8221; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law. The Industry Encouragement Law defines &#8220;Industrial Company&#8221; as a company resident in Israel and incorporated in Israel, that derives 90% or more of its income in any tax&#160;year (other than specified kinds of passive income such as capital gains, interest and dividends) from an &#8220;Industrial Enterprise&#8221; operating in Israel (including Judea&#160;&amp; Samaria territories and the Gaza strip), that it owns. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose major activity in a given tax&#160;year is industrial production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following corporate tax benefits, among others, are available to Industrial Companies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amortization of the cost of purchased know-how and patents over an eight-year period for tax purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerated depreciation rates on equipment and buildings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under specified conditions, an election to file consolidated tax returns with other related Israeli Industrial Companies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to a public offering are deductible in equal amounts over three&#160;years.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix&#160;Ltd. may fail to qualify or may not continue to qualify as an &#8220;Industrial Company&#8221; or that the benefits described above will not be available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Tax Benefits for Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under specified conditions, Israeli tax laws allow a tax deduction by a company for research and development expenditures, including capital expenditures, for the&#160;year in which such expenditures are incurred. These expenditures </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">must relate to scientific research and development projects and must be approved by NATI. Furthermore, the research and development projects must be for the promotion of the company and carried out by or on behalf of the company seeking such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects. Research and development expenses which were not approved shall be deductible over a period of three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, we had 206 employees of whom 202 are full time employees and 20 have a Ph.D. or an M.D. in their respective scientific fields. We believe that our relations with these employees are good. We believe that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli Ministry of Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements, or Expansion Orders, that apply to types of industries or employees including ours. These agreements affect matters such as cost of living adjustments to salaries, length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees are not represented by a labor union or represented under a collective bargaining agreement. See &#8220;Risk Factors&#8212;We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Company Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We were originally incorporated in the State of Florida in April&#160;1992, and reincorporated in the State of Delaware in March&#160;2016. Protalix&#160;Ltd., our wholly-owned subsidiary and sole operating unit, is an Israeli company and was originally incorporated in Israel in 1993.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is our registered trademark. Each of the other trademarks, trade names or service marks appearing in this Annual Report on Form&#160;10-K belongs to its respective holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our main corporate website address is </span><span style="background:#ffffff;">http://www.protalix.com</span><span style="background:#ffffff;">. </span>We make available on our website, free of charge, our Commission filings, including our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file these documents with, or furnish them to, the Commission. <span style="background:#ffffff;">The </span>Commission<span style="background:#ffffff;"> maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the </span>Commission<span style="background:#ffffff;"> at </span><span style="background:#ffffff;">www.sec.gov</span><span style="background:#ffffff;">. </span>Additionally, from time to time, we provide notifications of material news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is not intended to be incorporated by reference into this report or in any other report or document we file and any references to these websites are intended to be inactive textual references only. Interested persons may sign up on our website to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are also listed on the Tel Aviv Stock Exchange, or the TASE, and, accordingly, we submit copies of all our filings with the Commission to the Israeli Securities Authority and the TASE. Such copies can be retrieved electronically through the TASE&#8217;s internet messaging system (www.maya.tase.co.il) and through the MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our website also includes printable versions of our Code of Business Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors. Each of these documents is also available in print, free of charge, to any stockholder who requests a copy by addressing a request to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Protalix BioTherapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;University Plaza, Suite&#160;100</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">Hackensack, NJ  07601</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Attn: Mr.&#160;Eyal Rubin, Sr.&#160;Vice President and Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f8709e50_3076_45ed_befe_35d0e1f780f7"></a><a id="Item1ARiskFactors_654735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks described below together with the other information included in this Annual Report on Form&#160;10-K. Our business, financial condition or results of operations could be adversely affected by any of these risks. If any of these risks occur, the value of our common stock could decline. For a summary of the risk factors included in this Item 1A and for further details on our forward-looking statements, see &#8220;Forward-Looking Statements and Summary of Risk Factors&#8221; on page 1.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the COVID-19 Pandemic</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease, may adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December 2019, a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. The virus has spread globally. To date, our clinical trials have not been adversely affected by COVID-19, although certain practices we have adopted in our offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The spread of an infectious disease, including COVID-19, may result in the inability of our suppliers to deliver components or raw materials on a timely basis. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread of an infectious disease, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. While the extent of the impact of the current COVID-19 pandemic on our business and financial results depends on future developments that are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others, a continued and prolonged public health crisis such as the COVID-19 pandemic may adversely affect <span style="background:#ffffff;">our business, results of operations and financial </span>condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Travel restrictions related to the COVID-19 pandemic have delayed FDA and other regulatory authority inspections of our facilities required for marketing approvals and there is no certainty with respect to the timing of such inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">We are subject to inspection by the FDA and comparable foreign regulatory authorities to determine our compliance with applicable regulatory requirements, as are our suppliers, contract manufacturers, and contract testing laboratories. The FDA had advised us that it requires an inspection of our manufacturing facility and the facility of a third party in Europe that performs fill and finish processes for PRX-102 as part of the FDA&#8217;s review of the BLA application, after resubmission. Due to the FDA&#8217;s travel restrictions resulting from the pandemic, the FDA was unable to conduct the required inspection during the review cycle for the initial BLA. Also, with respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug and Cosmetic Act in lieu of a pre-licensing meeting. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions and is actively working to define an approach for scheduling outstanding inspections. We cannot predict when such inspections will take place. Once such inspections are able to be conducted, if the facilities are not in substantial compliance with cGMP, there may be adverse consequences to the approval process. Delays in the approval process or our inability to obtain approval for any reason for any drug candidate may have a material adverse effect upon our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Clinical Trials and Regulatory Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To commercialize our drug candidates worldwide, we need FDA Approval, EMA approval and approvals from other foreign regulators to commercialize our drug candidates elsewhere, as applicable. In order to obtain FDA approval of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">any of our drug candidates, we must submit to the FDA a BLA or an NDA demonstrating that the drug candidate is safe and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. In the European Union, we must submit an MAA to the EMA. Satisfaction of the regulatory requirements of the FDA, EMA and other foreign regulatory authorities typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires substantial resources for research, development and testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings or other comparable authorities for such clinical trials. Further, even if favorable testing data is generated by the clinical trials of a drug candidate, the applicable regulatory authority may not accept or approve a marketing application we file for the drug candidate or may require us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also cannot assure you that the results of our ongoing <i style="font-style:italic;">BALANCE</i> study will demonstrate that our product candidates are safe and effective for their intended uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Failure to obtain approval of the FDA, EMA or comparable foreign authorities of any of our drug candidates in a timely manner, if at all, will severely undermine our business, financial condition and results of operation by reducing our potential marketable products and our ability to generate corresponding product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">In light of our receipt of a CRL from the FDA regarding our BLA for PRX-102, the U.S. regulatory requirements and timing for PRX-102 approval are uncertain; we are substantially dependent on receipt of regulatory approvals for PRX-102, our most advanced product candidate.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The CRL issued by the FDA in response to the PRX-102 BLA did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. However, in the CRL, the FDA noted that agalsidase beta (Fabrazyme), a therapy used to treat Fabry patients, was recently converted to full approval which must be addressed in the context of any potential resubmission seeking accelerated approval of PRX-102. Although the FDA, at the Type A meeting held on September&#160;9, 2021, in principle, agreed that the data package proposed for the BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease thereby confirming a potential pathway for resubmission of a BLA for PRX-102, we can not guarantee when, or if, we will be successful in receiving regulatory approval for PRX-102. The regulatory requirements and timing for approval are uncertain at this time. If we do not obtain approval for PRX-102 or are delayed in obtaining such approval, it would have a material and adverse effect on our operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA may request additional data or impose other conditions in connection with a resubmission or approval. We cannot assure you that the FDA will eventually approve PRX-102 on a resubmission. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we may incur significant additional expenditures in order to obtain or maintain FDA approval. Any approval of the resubmitted BLA may also be subject to post-marketing commitments or requirements, and we may need to develop and/or improve certain antibody or additional assays as post-marketing requirements or commitments. Even if we comply with all the requests of regulatory authorities, the FDA and other authorities may ultimately reject the BLA or any other marketing application that we file for a product candidate in the future, if any, or we might not obtain regulatory clearance in a timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Fast Track designation for pegunigalsidase alfa for the treatment of Fabry disease may not lead to a faster development or regulatory review or approval process or increase the likelihood that pegunigalsidase alfa will receive regulatory approval for the treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA has granted Fast Track designation to pegunigalsidase alfa for the treatment of Fabry disease. As noted above, there can be no assurance that pegunigalsidase alfa will receive regulatory approval for the treatment of Fabry disease and following the receipt of the CRL timing for resubmission and the regulatory review process is uncertain. Despite the designation, we may not experience a faster development process, review or approval compared to applications considered for approval under conventional FDA procedures. In addition, the FDA is entitled to withdraw the Fast Track </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">designation of a drug candidate at any time. Any failure to realize the benefits of Fast Track designation may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are subject to extensive governmental regulation including the requirements of the FDA and other comparable regulatory authorities before our drug candidates may be marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Both before and after marketing approval of our drug candidates, if at all, we, our drug candidates, our suppliers, our contract manufacturers and our contract testing laboratories are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. Failure to comply with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of the following actions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines and other monetary penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the FDA&#8217;s or other foreign regulatory authorities&#8217; approving, or the refusal of any regulatory authority to approve, any drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recall or seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of manufacturing or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecutions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval, to us, our drug candidates, our suppliers, contract manufacturers, and contract testing laboratories. These include requirements related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quality control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">export;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and there can be no assurance that the FDA, or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations in response to these inspections which may require significant resources and may have a material adverse effect upon our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory reviews of such drug candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Delays in obtaining regulatory approvals with respect to any drug candidate will materially and adversely affect our prospects, business, results of operations and financial condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in obtaining regulatory approvals with respect to any drug candidate may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay commercialization of, and our ability to derive product revenues from, such drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay any regulatory-related milestone payments payable under outstanding collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to perform costly procedures with respect to such drug candidate; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in the approval process for any drug candidate will have a material adverse effect upon our prospects, business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Preliminary and initial results from a clinical trial do not necessarily predict final results, and failure can occur at any stage of the trial. We may encounter problems that cause us to abandon or repeat preclinical studies or clinical trials. The clinical trial process is also time-consuming. Failure or delay in the commencement or completion of our clinical trials may be caused by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment, particularly with respect to trials of rare diseases such as Fabry disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination of dosing issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of effectiveness during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement by applicable regulatory bodies over our trial protocols, the interpretation of data from preclinical studies or clinical trials or conduct and control of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination that the patient population participating in a clinical trial may not be sufficiently broad or representative to assess efficacy and safety for our target population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of sufficient funding to finance the clinical trials.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure or delay in commencement or completion of any clinical trials of pegunigalsidase alfa or our other product candidates will have a material adverse effect on our business, results of operations and financial condition. In addition, we or the FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether, which will significantly impair our ability to generate product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of our clinical trials with respect to any drug candidate might not support our claims of safety or efficacy, the results of our clinical trials may fail to conclusively show superiority over other commercially available treatments for the same or similar indications, the effects of our drug candidates may not be the desired effects or may include undesirable side effects or the drug candidates may have other unexpected characteristics. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. The clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses. In addition, our clinical trials, may involve specific and small patient populations. Results of early clinical trials conducted on a small patient population may not be indicative of future results. Adverse or inconclusive results may cause us to abandon a drug candidate and may delay development of other drug candidates. Any delay in, or termination of, our clinical trials will delay the filing of BLAs and NDAs with the FDA, or other filings with other foreign regulatory authorities, and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interim, topline or preliminary data from clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may publicly disclose interim, topline or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, any interim, topline or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different than the preliminary data we previously publish. As a result, any topline data should be viewed with caution until final data are available. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data becomes available. Further, regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses, or may interpret or ascribe different weight to the data, which may impact the value of the clinical trial and may affect the particular clinical program and the approvability or commercialization of the particular product candidate and our business in general. If regulatory authorities disagree with the conclusions we reach, we may not be able to obtain approval for and commercialize our product candidates, which will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may find it difficult to enroll patients in our clinical trials, or patients may discontinue their participation in our clinical trials, which could cause significant delays in the completion of such trials or may negatively impact the results of these studies and extend the timeline for completion of our development programs or cause us to abandon one or more clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Some of the diseases or disorders that our drug candidates are intended to treat are relatively rare and we expect only a subset of the patients with these diseases to be eligible for our clinical trials. Our clinical trials generally mandate that a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">patient cannot be involved in another clinical trial for the same indication. Therefore, subjects that participate in ongoing clinical trials for products that are competitive with our drug candidates are not available for our clinical trials. An inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, patients that enroll in our clinical trials may discontinue their participation at any time during the study as a result of a number of factors, including withdrawing their consent, experiencing adverse clinical events, which may or may not be judged related to our drug candidates under evaluation, or due to planned or actual pregnancies. The discontinuation of patients in any one of our studies may delay the completion of the study or cause the results from the study not to be positive or to not support a filing for regulatory approval of the applicable drug candidate. Any failure to enroll a sufficient number of patients in our clinical trials in a timely manner, if at all, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Because our clinical trials depend upon third-party researchers, the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent, beyond our control, which could impair our clinical development programs and our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend upon independent investigators and collaborators, such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators may not assign as great a priority to our clinical development programs or pursue them as diligently as we would if we were undertaking such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs, or if their performance is substandard, the approval of anticipated NDAs, BLAs and other marketing applications, and our introduction of new drugs, if any, may be delayed which could impair our clinical development programs and would have a material adverse effect on our business, results of operations and financial condition. Our collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators also assist our competitors, our competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors may affect our ability or the time we require to obtain necessary regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have only limited experience in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover, some of the drug candidates that are likely to result from our development programs may be based on new technologies that have not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may be less well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in connection with obtaining regulatory approvals of any products that we develop, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Orphan drug designation may not ensure that we will enjoy market exclusivity in any jurisdiction. If any of our other competitors are able to obtain orphan drug exclusivity for any products that are competitive with our products, we may be precluded from selling or obtaining approval of our competing products by the applicable regulatory authorities for a significant period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the United States, the European Union and other countries, a drug may be designated as having orphan drug status, subject to certain conditions. There can be no assurance that a drug candidate that receives orphan drug designation will receive orphan drug marketing exclusivity and more than one drug can have orphan designation for the same indication. In addition, the orphan drug designation granted to pegunigalsidase alfa by the EMA does not affect Fabry disease treatments that preexist the approval of pegunigalsidase alfa, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time to time, we may apply to the FDA or any comparable foreign regulatory authority for orphan drug designation for any one or more of our drug candidates. Other than pegunigalsidase alfa which was granted orphan drug designation by the EMA, none of our drug candidates have been designated as an orphan drug and there is no guarantee that the FDA or any other regulatory authority will grant such designation in the future. In addition, neither orphan drug designation nor orphan drug exclusivity prevents competitors from developing or marketing different drugs for the relevant indication. Even if we obtain orphan drug exclusivity for one or more indications for one of our drug candidates, we may not be able to maintain the exclusivity. For example, if a competitive product that is the same drug or biologic as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">one of our drug candidates is shown to be clinically superior to the drug candidate, any orphan drug exclusivity granted to the drug candidate will not block the approval of the competitive product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If any drug receives orphan drug exclusivity in any jurisdiction for the same indication of any of our drug candidates, we may be prevented from attaining a similar designation with respect to our drug candidate or from marketing the drug candidate in the jurisdiction during the applicable exclusivity period, which will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited operating history which may limit the ability of investors to make an informed investment decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Taliglucerase alfa is our only commercial product. The successful commercialization of our other drug candidates will require us to perform a variety of functions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing to perform preclinical development and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participating in regulatory approval processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting sales and marketing activities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical trials and clinical trials of our principal drug candidates. These operations provide a limited basis for investors to assess our ability to commercialize our drug candidates and whether to invest in our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We currently depend heavily on the success of pegunigalsidase alfa. Any failure to commercialize pegunigalsidase alfa, or the experience of significant delays in doing so, will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are investing a significant portion of our efforts and financial resources in the development of pegunigalsidase alfa and our ability to generate significant product revenues in the future, will depend heavily on the successful development and commercialization of pegunigalsidase alfa. The successful commercialization of pegunigalsidase alfa will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s efforts under the Chiesi Agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining marketing approvals from the FDA, EMA and other foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the successful inspection of our facilities by the FDA and other foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s development of successful sales and marketing organizations for pegunigalsidase alfa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage or reimbursement to patients from healthcare payors for pegunigalsidase alfa, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety and efficacy profile of pegunigalsidase alfa following approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks described in these Risk Factors.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to commercialize pegunigalsidase alfa or the experience of significant delays in doing so will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any failure by us to supply drug substance to Pfizer may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Amended Pfizer Agreement, we have agreed, for the first 10-year period after the execution of the agreement, to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. As part of that obligation, we agreed to substantial financial penalties if we fail to comply with the supply commitments, or are delayed in doing so. The amounts of the penalties depend on when any such failure occurs and for how long it persists, if at all, and other considerations. Any failure to comply with the supply commitments under the Amended Pfizer Agreement may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our strategy, in certain cases, is to enter into collaboration agreements with third parties to leverage our ProCellEx system to develop product candidates. Failure to enter into such agreements, or non-compliance by us or our collaborators with such agreements, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our strategy, in certain cases, is to enter into arrangements with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates. Under these arrangements, we may grant to our partners rights to license and commercialize pharmaceutical products developed under the applicable agreements, as we have done with Elelyso and pegunigalsidase alfa. Our partners may control key decisions relating to the development of the products and we may depend on our partners&#8217; expertise and dedication of sufficient resources to develop and commercialize our product candidates. The rights of our partners limit our flexibility in considering alternatives for the commercialization of our product candidates. If we or any of our current or future partners breach or terminate the agreements that make up such arrangements, our partners otherwise fail to conduct their obligations under such arrangements in a timely manner, there is a dispute about their obligations or if either party terminates the applicable agreement or elects not to continue the arrangement, we may not enjoy the benefits of the agreements or receive a sufficient amount of royalty or milestone payments from them, if any, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to develop and commercialize our product candidates, our business will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our strategy is to develop and commercialize a portfolio of new products in addition to taliglucerase alfa. We seek to do so through our internal research programs and strategic collaborations for the development of new products. Research programs to identify new product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may not be accepted by patients, the medical community or third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our product candidates obsolete;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research methodology used may not be successful in identifying potential product candidates; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to develop or commercialize any of our other product candidates may have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The manufacture of our products is an exacting and complex process, and any manufacturing problems encountered by us or certain of our suppliers may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar requirements that the FDA or foreign regulators establish. We or certain of our materials suppliers may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing. To date, our current facility has passed audits by the FDA and a number of other regulatory authorities but remains subject to audit by other foreign regulatory authorities. There can be no assurance that we will be able to comply with FDA or foreign regulatory manufacturing requirements for our current facility or any facility we may establish in the future, and the failure to so comply will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties for final processing of taliglucerase alfa, pegunigalsidase alfa and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of taliglucerase alfa and our other product candidates or result in higher product costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no experience in the final filling and freeze drying steps of the drug manufacturing process. We rely on third parties in the United States and Europe to perform fill and finish activities for taliglucerase alfa and pegunigalsidase alfa, and have engaged other parties for our other product candidates. We may be unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA and other regulatory authorities, as applicable, must approve any manufacturer and/or replacement manufacturer, including us, and we or any such third party manufacturer might be unable to formulate and manufacture our drug products in the volume and of the quality required to meet our clinical and commercial needs. If we engage any contract manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical or commercial needs. In addition, contract manufacturers are subject to the rules&#160;and regulations of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find that they are not in compliance with applicable regulations. Each of these risks, if realized, could delay our clinical trials, the approval, if any, of our potential drug candidates by the FDA and other regulatory authorities, or the commercialization of our drug candidates or could result in higher product costs or otherwise deprive us of potential product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Developments by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Our drug candidates will have to compete with existing therapies and therapies under development by our competitors. Our commercial opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective or safer than our drug products. Other companies have drug candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to develop drug products. Some of these potential competing drugs are further advanced in development than our drug candidates and may be commercialized earlier. See Business&#160;&#8211; Competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Most of our competitors, either alone or together with their collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater financial resources than we do, as well as significantly greater experience in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and human clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining marketing approvals from the FDA and other regulatory authorities;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching, marketing and selling drugs.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These organizations also compete with us to attract qualified personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated costs on our business or adversely affect the market for our drug products which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we in-license drug candidates, we may delay or otherwise adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to our own internally developed drug candidates, we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential to take advantage of our development know-how and technology. In-licensing additional drug candidates may significantly increase our capital requirements, and place a strain on the time of our existing personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may have a material adverse impact on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to manage future growth successfully there could be a material adverse impact on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability on the part of our management to manage growth could delay the execution of our business plans or disrupt our operations. If we are unable to manage our growth effectively, we may not use our resources in an efficient manner, which may delay the development of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If we are presented with appropriate opportunities, we may acquire or make investments in complementary companies, products or technologies. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology with our products, diversion of our management&#8217;s attention from other business concerns, the potential loss of key employees or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating to acquired intangible assets. Any failure to successfully integrate other companies, products or technologies that we may acquire may have a material adverse effect on our business and results of operations. Furthermore, we may have to incur debt or issue equity securities to pay for any additional future acquisitions or investments, the issuance of which could be dilutive to our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are highly dependent upon the principal members of our management team, especially our President and Chief Executive Officer, Dror Bashan, as well as the Chairman of our Board of Directors, Zeev Bronfeld, our other directors, consultants and collaborating scientists. Many of these people have been involved with us for many years and have played integral roles in our progress, and we believe that they will continue to provide value to us. A loss of any of these personnel may have a material adverse effect on aspects of our business, clinical development and regulatory programs. We have employment agreements with Mr.&#160;Bashan and our other executive officers that may be terminated by us or the applicable officer at any time with varying notice periods of 60 to 180&#160;days. The loss of any of these persons&#8217; services </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">may adversely affect our ability to develop and market our products and obtain necessary regulatory approvals. Further, we do not maintain key-man life insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also depend in part on the continued service of our key scientific personnel and our ability to identify, hire and retain additional personnel. We experience intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our collaborations with outside scientists and consultants may be subject to restriction and change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We work with medical experts, biologists, chemists and other scientists at academic and other institutions, and consultants who assist us in our research, development, regulatory and commercial efforts, including the members of our scientific advisory board. These scientists and consultants have provided, and we expect that they will continue to provide, valuable advice regarding our programs. These scientists and consultants are not our employees, may have other commitments that would limit their future availability to us and typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, we will be unable to prevent them from establishing competing businesses or developing competing products. For example, if a key scientist acting as a principal investigator in any of our clinical trials identifies a potential product or compound that is more scientifically interesting to his or her professional or academic interests, his or her availability to remain involved in our clinical trials could be restricted or eliminated, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Under current U.S. and Israeli law, we may not be able to enforce employees&#8217; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into non-competition agreements with substantially all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. Under current U.S. and Israeli law, we may be unable to enforce these agreements against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former employees gained while working for us. If we cannot enforce our employees&#8217; non-compete agreements, we may be unable to prevent our competitors from benefiting from the expertise of our former employees, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. While our assessment of our internal control over financial reporting resulted in our conclusion that as of December 31, 2021, our internal control over financial reporting was effective, we cannot predict the outcome of our testing or any subsequent testing by our auditor in future periods. Any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information and affect our reputation, which could have an adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our management is required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as long as we are a non accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could identify deficiencies in internal controls over financial reporting that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Despite the implementation of security measures, our internal computer systems and those of our present and future contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We have a cybersecurity insurance policy to protect us from such risks. However, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability despite our insurance policy, and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Securities class action litigation is often brought against a company following a period of volatility or decline in the market price of its securities. As with pharmaceutical companies generally, our company has experienced significant stock price volatility in recent years. If we become subject to such litigation, we will face substantial costs and a diversion of management&#8217;s attention and resources, which could have a material adverse effect on our business, results of operation and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If product liability claims are brought against us, it may result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The clinical testing, marketing and use of our products and product candidates exposes us to product liability claims if the use or misuse of those products or product candidates cause injury or disease, or results in adverse effects. Use of our products or product candidates, whether in clinical trials or post approval, could result in product liability claims. We presently carry clinical trial liability insurance with coverages of up to $10.0&#160;million per occurrence and $10.0&#160;million in the aggregate, an amount we consider reasonable and customary. However, this insurance coverage includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential claims. We may need to obtain additional clinical trial liability coverage prior to initiating additional clinical trials. We expect to obtain product liability insurance coverage before commercialization of our product candidates; however, such insurance is expensive and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate insurance in the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage or one that is meritless and/or unsuccessful, may adversely affect our cash available for other purposes, such as research and development, which may have a material adverse effect on our business, results of operations and financial condition. Product liability claims, even if without merit, may result in reduced demand for our products, if approved, or result in adverse market reactions, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increasing healthcare expenditures have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would result in changes in the U.S.&#160;healthcare system are continuously introduced or proposed in the U.S.&#160;Congress and in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">some state legislatures within the United States, including reductions in the pricing of prescription products and changes in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products. Legislation and regulations that reduce reimbursement for our product candidates could adversely impact how much or under what circumstances healthcare providers will prescribe or administer our product candidates, if approved. This could materially and adversely impact our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our products, if approved. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales, upon approval, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Governments outside the United States tend to impose strict price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In some countries, particularly European Union member states, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time (six to 12&#160;months or longer) after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries with respect to any product candidate that achieves regulatory approval, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Any unavailability or limitation on the reimbursement of our products upon approval, if at all, or the determination of unsatisfactory reimbursement prices, may have a material adverse effect on our business, results of operations and financial condition. Further, if we achieve regulatory approval of any product, we must successfully negotiate product pricing for such product in individual countries. As a result, the pricing of our product candidates, if approved, in different countries may vary widely, thus creating the potential for third-party trade in our products in an attempt to exploit price differences between countries. This third-party trade of our products could undermine our sales in markets with higher prices which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our ability to utilize net operating loss carryforwards may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our NOL carryforwards as of December&#160;31, 2021, are equal to approximately $247.9&#160;million, of which approximately $36.1&#160;million may be restricted under Section&#160;382 of the Internal Revenue Code, or the IRC. IRC Section&#160;382 applies whenever a corporation with NOLs experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post-change&#160;year that may be offset by a pre-change NOL may not exceed the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income and prudent and feasible tax planning strategies. We reassess our valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly. Any ownership change (including as a result of conversion of our outstanding convertible notes into shares of our common stock), or any other limitation on our utilization of NOLs, could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our corporate structure may create U.S. federal income tax inefficiencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. is our wholly-owned subsidiary and thus a controlled foreign corporation of our company for U.S. federal income tax purposes. This organizational structure may create inefficiencies, as certain types of income and investments of Protalix&#160;Ltd. that otherwise would not be currently taxable under general U.S. federal income tax principles may become taxable. These inefficiencies may require us to use more of our NOLs than we otherwise might and may result in a tax liability without a corresponding distribution from our subsidiary which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a holding company with no operations of our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are a holding company with no operations of our own. Accordingly, our ability to conduct our operations, service any debt that we may incur in the future and pay dividends, if any, is dependent upon the earnings from the business conducted by Protalix&#160;Ltd. The distribution of those earnings or advances or other distributions of funds by our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of Protalix&#160;Ltd. and are subject to various business considerations and U.S. and Israeli law. If Protalix&#160;Ltd. is unable to make sufficient distributions or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash resources necessary to conduct our corporate operations or service our debt which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to our Financial Condition and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Servicing our debt and settling conversion requests may require a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt. Furthermore, restrictive covenants governing our indebtedness may restrict our ability to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We currently have outstanding $28.75&#160;million aggregate principal amount of our 2024 Notes which are secured with a perfected lien on all of our assets. Under the terms of the indenture governing the 2024 Notes, or the 2024 Indenture, we are required to maintain a minimum cash balance of at least $7.5&#160;million. Our ability to make payments with respect to the 2024 Notes and to satisfy any other debt obligations depends on our future operating performance and our ability to generate significant cash flow in the future, which will be affected by prevailing economic conditions and financial, business, competitive, legislative and regulatory factors as well as other factors affecting our company and industry, many of which are beyond our control. If, when required, we are unable to comply with the terms of the 2024 Notes, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. In addition, certain terms of the 2024 regarding the security interest or future indebtedness may restrict us from adopting any of these alternatives. We may be unable to obtain amendments and waivers of such restrictions. If there is a default of such notes, the note holders could, among other things, elect to declare all amounts owed immediately due and payable, which could cause all or a large portion of our available cash flow to be used to pay such amounts and thereby reduce the amount of cash available to pursue our business plans or force us into bankruptcy or liquidation, or, with respect to our indebtedness that is secured, result in the foreclosure on the assets that secure the debt, which would force us to relinquish rights to assets that we may believe are critical to our business. Any default on our debt will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our significant level of indebtedness could adversely affect our business, results of operations and financial condition and prevent us from fulfilling our obligations under our convertible notes and our other indebtedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our 2024 Notes represent a significant amount of indebtedness with substantial debt service requirements. We may also incur additional indebtedness to meet future financing needs. Our substantial indebtedness could have material adverse effects on our business, results of operations and financial condition. For example, it could:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make it more difficult for us to satisfy our financial obligations, including with respect to the convertible notes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">result in an event of default under our outstanding convertible notes if we fail to comply with the financial and other restrictive covenants contained in agreements governing any future indebtedness, which event of default could result in all of our debt becoming immediately due and payable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase our vulnerability to general adverse economic, industry and competitive conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the availability of our cash flow to fund working capital, capital expenditures, acquisitions and other general corporate purposes because we will be required to dedicate a substantial portion of our cash flow from operations to the payment of principal and interest on our indebtedness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit our flexibility in planning for, or reacting to, and increasing our vulnerability to changes in our business, the industry in which we operate and the general economy;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent us from raising funds necessary to purchase convertible notes surrendered to us by holders upon a fundamental change (as described in the 2024 Indenture governing the notes), which failure would result in an event of default with respect to the convertible notes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">place us at a competitive disadvantage compared to our competitors that have less indebtedness or are less highly leveraged and that, therefore, may be able to take advantage of opportunities that our debt levels or leverage prevent us from exploiting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit our ability to obtain additional financing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Each of these factors may have a material and adverse effect on our business, results of operations and financial condition and our ability to meet our payment obligations under the convertible notes and our other indebtedness. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times-BoldItalic';font-weight:bold;">We are required to comply with a number of covenants under the 2024 Indenture governing our outstanding convertible notes that could hinder our growth. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times-Roman';">The 2024 Indenture contains a number of restrictive affirmative and negative covenants, which limit our ability to incur additional debt; exceed certain limits; pay dividends or distributions; or merge, consolidate or dispose of substantially all of our assets, including all of our intellectual property assets and other material assets securing such convertible notes. A breach of these covenants could result in default, and if such default is not cured or waived, </span>the holders of the indebtedness could, among other things, elect to declare all amounts owed immediately due and payable, which could cause all or a large portion of our available cash flow to be used to pay such amounts and thereby reduce the amount of cash available to pursue our business plans or force us into bankruptcy or liquidation, or, result in the foreclosure on the assets that secure the debt, including all of our intellectual property assets, which would force us to relinquish rights to such assets that we may believe are critical to our business.<span style="font-family:'Times-Roman';"> We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. Any default on our debt will have a material adverse effect </span>on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any conversion of our outstanding convertible notes into common stock will dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The conversion of some or all of our convertible notes into shares of our common stock will dilute the ownership interests of our existing stockholders. Any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of our outstanding convertible notes may encourage short selling by market participants because the conversion of convertible notes could depress the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The fundamental change purchase feature of our outstanding convertible notes may delay or prevent an otherwise beneficial attempt to take over our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The terms of our outstanding convertible notes require us to offer to purchase the notes for cash in the event of a fundamental change. A non-stock takeover of our company may trigger the requirement that we purchase the notes. This feature may have the effect of delaying or preventing a takeover of our company that would otherwise be beneficial to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may fail to meet the continued market capitalization-based listing requirement or other continued listing requirements of The NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of the listed companies. The trading price of our common stock has been volatile and has been subject to wide price fluctuations in response to various factors, many of which are beyond our control. The volatility of our stock price has from time to time in recent periods affected our market capitalization. Adverse fluctuations in the price per share of our common stock or our market capitalization may result in our failure to meet the continued listing requirements of The NYSE American, which would require us to take steps to gain compliance with alternate listing standards or take remedial steps to bring us into compliance. A failure to maintain or regain compliance with applicable listing standards could adversely </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">affect the liquidity of our common stock and could result in an event of default under the 2024 Indenture, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We currently have no significant product revenues and need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which will have a dilutive effect on our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not generated significant revenues from product sales and only minimal revenues from research and development services and other fees, other than the milestone and other payments we have received in connection with our agreements with Pfizer and Chiesi. For the years ended December&#160;31, 2021, 2020 and 2019, we had net losses from continuing operations of $27.6&#160;million, $6.5&#160;million and $18.3&#160;million, respectively, primarily as a result of expenses incurred through a combination of research and development activities and expenses supporting those activities, which includes share-based compensation expense. Drug development and commercialization is very capital intensive. We fund all of our operations and capital expenditures from the revenues we generate from licensing fees and grants, the net proceeds of equity and debt offerings and other sources. In addition, changes may occur that could consume our existing capital at a faster rate than projected, including, among others, the cost and timing of regulatory approvals, changes in the progress of our research and development efforts and the costs of protecting our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will need to finance our future cash needs through corporate collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. If we are unable to secure additional financing in the future on acceptable terms, or at all, we may be unable to commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates from the FDA and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product licensing, reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business and results of operations. Furthermore, any additional source of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are not currently profitable and delays in achieving profitability, if at all, will have a material adverse effect on our business and results of operations and could negatively impact the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may incur losses for the foreseeable future. We expect to continue to incur significant operating expenditures, and we anticipate that our expenses will increase in the foreseeable future as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to undertake preclinical development and clinical trials for our current and new drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for our drug candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to in-license additional technologies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also may continue to experience negative cash flow for the foreseeable future as we fund our operating losses and capital expenditures. As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the foreseeable future, if at all. Delays in achieving profitability, or subsequent failures to maintain profitability, will have a material adverse effect on our business and results of operations and could negatively impact the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Commercialization of Drug Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">There has been continued non-compliance with the terms and conditions of the Brazil Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We do not control and may not be able to effectively influence Fiocruz&#8217;s ability to distribute BioManguinhos alfataliglicerase in Brazil. Any failure by Fiocruz to comply with the purchase requirements of the Brazil Agreement, or any other material breach by Fiocruz of the agreement, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We face the risk of lower than anticipated purchases of BioManguinhos alfataliglicerase by the Brazilian MoH. In addition, we may fail to supply the intended amounts on time, if at all. We also cannot accurately predict the amount of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenues we will generate under the Brazil Agreement in future periods, if any. Any failure by the Brazilian MoH to purchase BioManguinhos alfataliglicerase, by us to supply BioManguinhos alfataliglicerase for purchase or by Fiocruz to distribute BioManguinhos alfataliglicerase in Brazil, or the experience of significant delays in any of the foregoing, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in selling, marketing or distributing products and limited internal capability to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We currently have very limited sales, marketing or distribution capabilities and no experience in building a sales force and distribution capabilities. Under our arrangements with Pfizer and Chiesi, we have out-licensed the marketing rights to Elelyso, pegunigalsidase alfa and alidornase alfa via inhalation, except that we retained the marketing rights to BioManguinhos alfataliglicerase in Brazil. We have not licensed the marketing or commercialization rights to any of our other product candidates to any party. The commercialization of a drug product requires that we commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities. Factors that may inhibit our efforts to commercialize our products directly and without strategic partners include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to an adequate numbers of physicians or to pursuance them to prescribe our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;&#160;and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may not be successful in recruiting or retaining the sales and marketing personnel necessary to sell BioManguinhos alfataliglicerase or any of our products upon approval, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may enter into distribution arrangements and marketing alliances for certain products and any failure to successfully identify and implement these arrangements on favorable terms, if at all, may impair our ability to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may need to establish a sales force to market one or more of our product candidates, if approved. We do not anticipate having the resources in the foreseeable future to develop global sales and marketing capabilities for all of the products we are developing. We may elect to pursue arrangements regarding the sales and marketing and distribution of one or more of our product candidates, and our future revenues may depend, in part, on our ability to enter into and maintain arrangements with other companies having sales, marketing and distribution capabilities and the ability of such companies to successfully market and sell any such products. Any failure to enter into such arrangements and marketing alliances on favorable terms, if at all, could delay or impair our ability to commercialize our product candidates and could increase our costs of commercialization. Any use of distribution arrangements and marketing alliances to commercialize our product candidates will subject us to a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to relinquish important rights to our products or product candidates;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to control the amount and timing of resources that our distributors or collaborators may devote to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our distributors or collaborators may experience financial difficulties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our distributors or collaborators may not devote sufficient time to the marketing and sales of our products; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may need to enter into additional co-promotion arrangements with third parties where our own sales force is neither well situated nor large enough to achieve maximum penetration in the market. We may not be successful in entering into any co-promotion arrangements, and the terms of any co-promotion arrangements we enter into may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If physicians, patients, third party payors and others in the medical community do not accept and use taliglucerase alfa, or any of our other product candidates, if approved, our ability to generate revenue from product sales will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Physicians and patients, and other healthcare providers, may not accept and use any of our products or any product candidates, if approved for marketing. Future acceptance and use of any of our products or any product candidates, if approved, will depend upon a number of factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceptions by physicians, patients, third party payors and others in the medical community about the safety and effectiveness of taliglucerase alfa or our other drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects, including any limitations or warnings contained in our products&#8217; approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pharmacological benefits of taliglucerase alfa or our other drug candidates relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of education, marketing and distribution efforts by us and our licensees and distributors, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning taliglucerase alfa or our other drug candidates or competing products and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coverage and reimbursement of our products by third party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price for our products and competing products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A lack of market acceptance of BioManguinhos alfataliglicerase in Brazil, or globally for any of our other products candidates, if approved, would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If the market opportunities for other product candidates, and for BioManguinhos alfataliglicerase in Brazil, are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, our development efforts have focused mainly on relatively rare disorders with small patient populations, in particular Gaucher disease and Fabry disease. Currently, most reported estimates of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed, the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in the broader world population. If the market opportunities for our current product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement may not be available for one or more of our product candidates, if approved, in all territories, which could diminish our sales or affect our ability to sell any such products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Market acceptance and sales of any one or more of our product candidates, if approved, will depend on coverage and reimbursement policies in the countries in which they are approved for sale. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Obtaining reimbursement approval for an approved product from governments and other third party payors is a time consuming and costly process that requires our collaborators or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness data for the use of our products, if and when approved, to every payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of approved products, if any, to such payors&#8217; satisfaction. Such studies might require our collaborators or us to commit a significant amount of management time and financial and other resources. Even if a payor determines that an approved product is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or other regulatory authorities. In addition, full reimbursement may not be available for high priced products. Moreover, eligibility for coverage does not imply that any approved product will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs. Limited reimbursement amounts may reduce the demand for, or the price of, our product candidates. If coverage and reimbursement are not available or are available only to limited levels, the sales of our products, if approved, may be diminished or we may not be able to sell such products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All marketing activities associated with drug products that are approved for sale in the United States, if any, will be, directly or indirectly through our customers, subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical products in the United States, including, without limitation, the federal Anti-Kickback Law, the federal False Claims Act and HIPAA. These laws may adversely impact, among other things, our proposed sales, marketing and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership interests and providing anything at less than its fair market value. Despite a series of narrow safe harbors, the federal Anti-Kickback Law prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Law include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Law, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe harbors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. Violations of the federal False Claims Act and the analogous state laws may result in substantial financial penalties, some as much as three times the actual damages sustained by the government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HIPAA created several new federal crimes, including health care fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are unable to predict whether we could be subject to actions under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that taliglucerase alfa or any of our product candidates, if approved for marketing, will be sold in a foreign country, we and our future collaborators may be subject to similar foreign laws and regulations. If we or any of our future collaborators are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring or our operations, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The intellectual property and assets owned by our subsidiaries are subject to security agreements that secure our payment and other obligations under our convertible notes, and our subsidiaries have guaranteed all of those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the issuance of our 2024 Notes, we entered into new security agreements pursuant to which our subsidiaries provided first priority security interests in all of their assets, which consist of all of our intellectual property and other material assets. The security agreements secure certain payment, indemnification and other obligations under the 2024 Notes. If we were to default on certain of our obligations, or in certain other circumstances generally related to a bankruptcy or insolvency, holders of our outstanding 2024 Notes&#160;could seek to foreclose on the collateral under the security agreements to obtain satisfaction of our obligations, and our business could be materially and adversely impacted, which would in turn have a material adverse effect on our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, in connection with the issuance of the 2024 Notes, our subsidiaries guaranteed all of our obligations under the 2024 Indenture. If we were to default on our obligations under the 2024 Indenture, the holders could require our subsidiaries to satisfy all of those obligations under the guarantees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business, competitive position and results of operations would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, we had more than 30 pending patent applications. However, the filing of a patent application does not mean that we will be issued a patent, or that any patent eventually issued will be as broad as requested in the patent application or sufficient to protect our technology. Any modification required to a current patent application may delay the approval of such patent application which would have a material adverse effect on our business, results of operations and financial condition. In addition, there are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications to not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of originality of the technology. Our competitive position and future revenues will depend in part on our ability and the ability of our licensors and collaborators to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent applications for process patents, as well as composition of matter patents, for taliglucerase alfa and our product candidates. However, we cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents, including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate litigation or administrative proceedings, which may be costly, whether we win or lose.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, we held, or had license rights to, more than 80 patents. If patent rights covering our products or technologies are not sufficiently broad, they may not provide us with sufficient proprietary protection or competitive advantages against competitors with similar products and technologies. Furthermore, if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents or circumvent the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from or to third parties may not provide any protection against our competitors and those who infringe upon our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the life of our patents is limited. The patents we hold, and the patents that may be issued in the future based on patent applications from the patent families, relating to our ProCellEx protein expression system are expected to expire by 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our policy is to enter agreements relating to the non-disclosure of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors and others. Despite the protective measures we employ, we still face the risk that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these agreements may be breached;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these agreements may not provide adequate remedies for the applicable type of breach; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our trade secrets or proprietary know-how will otherwise become known.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any breach of our confidentiality agreements or our failure to effectively enforce such agreements may have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have not received to date any claims of infringement by any third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position. If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial costs and we may have to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain licenses, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign our products or processes to avoid infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of our drug candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of management resources; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay damages.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any costs incurred in connection with such events or the inability to sell our products may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we cannot meet requirements under our license agreements, we could lose the rights to our products, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend on licensing agreements with third parties to maintain the intellectual property rights to certain of our product candidates. Our license agreements require us to make payments and satisfy performance obligations in order to maintain our rights under these agreements. All of these agreements last either throughout the life of the patents that are the subject of the agreements, or with respect to other licensed technology, for a number of&#160;years after the first commercial sale of the relevant product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Relating to our Operations in Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Potential political, economic and military instability in the State of Israel, where the majority of our senior management and our research and development facilities are located, may adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our executive office and operations are located in the State of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business. Since the State of Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic or financial condition of Israel, could affect adversely our operations and product development. Although Israel has entered into various agreements with Egypt, Jordan and the Palestinian Authority, Israel periodically experiences an increase in unrest and terrorist activity. The establishment in 2006 of a government in the Gaza Strip by representatives of the Hamas militant group has created additional unrest and uncertainty in the region. Our facilities in northern Israel are in range of rockets that were fired from Lebanon into Israel during a 2006 war with the Hizbollah in Lebanon, and suffered minimal damages during one of the rocket attacks. Our insurance policies do not cover us for the damages incurred in connection with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be enough to cover potential damages. If our facilities are damaged as a result of hostile action, our operations may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There is currently a civil war in Syria, also bordering Israel, and Israel has been hit by rockets and mortars originating from Syria. The ultimate effect of these developments on the political and security situation in the Middle East and on Israel&#8217;s position within the region is not clear at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our operations may be disrupted by the obligations of our personnel to perform military service which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Many of our male employees in Israel, including members of senior management, are obligated to perform up to one&#160;month (in some cases more) of annual military reserve duty until they reach the age of 45 and, in the event of a military conflict, could be called to active duty. Our operations could be disrupted by the absence of a significant number of our employees related to military service or the absence for extended periods of military service of one or more of our key employees. A disruption may have a material adverse effect on our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Because a certain portion of our expenses is incurred in New Israeli Shekels, our results of operations may be seriously harmed by currency fluctuations and inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We report our financial statements in U.S.&#160;dollars, our functional currency. Although most of our expenses are incurred in U.S.&#160;dollars, we pay a portion of our expenses in New Israeli Shekels, or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation of the NIS in relation to the U.S.&#160;dollar or if the timing of these devaluations lags behind inflation in Israel. In that event, the U.S.&#160;dollar cost of our operations in Israel will increase and our U.S.&#160;dollar-measured results of operations will be adversely affected. To the extent that the value of the NIS increases against the U.S.&#160;dollar, our expenses on a dollar cost basis increase. Our operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The tax benefits available to us require that we meet several conditions and may be terminated or reduced in the future, which would increase our taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are able to take advantage of tax exemptions and reductions resulting from the &#8220;Approved Enterprise&#8221; status of our facilities in Israel. To remain eligible for these tax benefits, we must continue to meet certain conditions, including making specified investments in property and equipment, and financing at least 30% of such investments with share capital. If we fail to meet these conditions in the future, the tax benefits would be canceled and we may be required to refund any tax benefits we already have enjoyed. These tax benefits are subject to investment policy by the Investment Center and may not be continued in the future at their current levels or at any level. In recent&#160;years the Israeli government has reduced the benefits available and has indicated that it may further reduce or eliminate some of these benefits in the future. The termination or reduction of these tax benefits or our inability to qualify for additional &#8220;Approved Enterprise&#8221; approvals may increase our tax expenses in the future, which would reduce our expected profits and adversely affect our business and results of operations. Additionally, if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received together with interest and penalties which could have a material adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the past, our research and development efforts have been financed, in part, through grants that we have received from NATI. We, therefore, must comply with the requirements of the Research Law. Under the Research Law we are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. We may not receive the required approvals for any proposed transfer of manufacturing activities. Even if we do receive approval to manufacture products developed with government grants outside of Israel, we may be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate. This restriction may impair our ability to outsource manufacturing or engage in similar arrangements for those products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These restrictions may impair our ability to sell our technology assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain period of time even after we have repaid the full amount of royalties payable for the grants. If we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together with interest and penalties, and may become subject to criminal charges, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Investors may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers and most of our directors or asserting U.S. securities laws claims in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Most of our directors and all of our executive officers are residents of Israel, and accordingly, most of their assets and our assets are located outside the United States. Service of process upon our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us, some of our directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that investors may find it difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws against us, our officers and our directors. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Israeli courts might not enforce judgments rendered outside Israel which may make it difficult to collect on judgments rendered against us. Subject to certain time limitations, an Israeli court may declare a foreign civil judgment enforceable only if it finds that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the judgment may no longer be appealed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the obligation imposed by the judgment is enforceable according to the rules&#160;relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the judgment is executory in the state in which it was given.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Even if these conditions are satisfied, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel. An Israeli court also will not declare a foreign judgment enforceable if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the judgment was obtained by fraud;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there is a finding of lack of due process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the judgment was rendered by a court not competent to render it according to the laws of private international law in Israel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the judgment is at variance with another judgment that was given in the same matter between the same parties and that is still valid; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at the time the action was brought in the foreign court, a suit in the same matter and between the same parties was pending before a court or tribunal in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Investing in our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The market price of our common stock may fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market price of our common stock has experienced significant volatility as a result of the recent announcement relating to the receipt of the CRL from the FDA regarding the BLA for PRX-102. The securities of life sciences companies often experience significant volatility in connection with clinical trial and regulatory announcements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate that the market price of our common stock is likely to continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and any delays in anticipated marketing approvals for pegunigalsidase alfa;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our studies of pegunigalsidase alfa and the progress and results of the studies of our other product candidates;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sale of shares of our common stock under our ATM program, or market expectations that such sales are to be executed;</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases of BioManguinhos alfataliglicerase in Brazil; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning intellectual property rights and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the announcement of new products or product enhancements by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our and our competitors&#8217; results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in earnings estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments in the biotechnology industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market conditions and other factors, including factors unrelated to our operating performance.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility of our common stock may be worse when the trading volume of our common stock is low. We have not paid, and do not expect to pay, any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations. As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold at a profit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales of our common stock could reduce our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If our stockholders sell substantial amounts of our common stock, including shares of our common stock issuable upon conversion of our outstanding convertible notes or warrants, or if we sell a substantial amount of our common stock under our ATM program, the market price of our common stock could decrease significantly. The perception in the public market that our existing stockholders might sell shares of common stock could also depress the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A substantial majority of our outstanding shares of our common stock are freely tradable without restriction or further registration under the federal securities laws. In addition, we may sell additional shares of our common stock in the future to raise capital. A substantial number of shares of our common stock are reserved for issuance upon the exercise of stock options, upon conversion of our outstanding convertible notes and upon the exercise of our outstanding warrants. At December&#160;31, 2021, there were outstanding options to purchase common stock issued covering approximately 2.3&#160;million shares of our common stock with a weighted average exercise price of approximately $4.42 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">per share. Also at December&#160;31, 2021, there were approximately 1.8&#160;million shares of common stock available for future for issuance in connection with future grants of incentives under our amended 2006 stock incentive plan, approximately 21.5&#160;million shares of common stock reserved for issuance upon conversion of our outstanding 2024 Notes and approximately 14.6&#160;million shares of common stock reserved for issuance upon the exercise of our outstanding warrants. The issuance and sale of substantial amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities analysts stop publishing research or reports about us or our business or if they downgrade our common stock, the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If any analyst who covers us downgrades our stock or lowers its future stock price targets or estimates of our operating results, the market price for our common stock could decline rapidly. Furthermore, if any analyst ceases to cover us, we could lose visibility in the market, which in turn could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our common stock is listed to trade on more than one stock exchange, and this may result in price variations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is listed for trade on both the NYSE American and the TASE. Dual-listing may result in price variations between the exchanges due to a number of factors. First, our common stock is traded in U.S.&#160;dollars on the NYSE American and in NIS on the TASE. In addition, the exchanges are open for trade at different times of the day and on different&#160;days. For example, the TASE opens generally during Israeli business hours, Sunday through Thursday, while the NYSE American opens generally during U.S.&#160;business hours, Monday through Friday. The two exchanges also have differing vacation schedules. Differences in the trading schedules, as well as volatility in the exchange rate of the two currencies, among other factors, may result different trading prices for our common stock on the two exchanges. Other external influences may have different effects on the trading price of our common stock on the two exchanges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses, divert management&#8217;s attention from operating our business which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The laws, rules, regulations and standards including the rules&#160;promulgated by the national securities exchanges, including the NYSE American, to which we are subject are changed and/or amended from time to time. New or changed laws, rules, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, rules, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Members of our Board of Directors and our executive officers, could face an increased risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and executive officers, which could have a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set by regulatory authorities or governing bodies which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The issuance of preferred stock or additional shares of common stock could adversely affect the rights of our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our Board of Directors is authorized to issue up to 100,000,000 shares of preferred stock without any further action on the part of our stockholders. Our Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we have no shares of preferred stock outstanding.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">Our Board of Directors may, at any time, authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without any further action on the part of our stockholders may impede a takeover of our company and may prevent a transaction that is favorable to our stockholders.</p><a id="_0b28c5d8_a8f4_4b03_af8e_d60cbac7f2a0"></a><a id="Item1BUnresolvedStaffComments_626044"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_70f05d30_b943_4608_8ab8_573b1ff22e54"></a><a id="Item2Properties_907582"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain a United States corporate office in Hackensack, New Jersey. Our headquarters, including manufacturing facility, executive offices and others, are located in Carmiel, Israel. The facilities currently contain approximately 14,700&#160;sq/ft of manufacturing space and 3,400&#160;sq/ft for a pilot plant, 11,700&#160;sq/ft for offsite warehouse space and approximately 39,100&#160;sq/ft of laboratories, front warehouse and office space, and are leased at a rate of approximately $81,000 per&#160;month. In addition, we are entitled to use an additional 14,500&#160;sq/ft in the same facility, which we intend to utilize in connection with an anticipated expansion of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business, and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. Our original lease for the facility was in effect until 2016 and we have exercised two of three options to extend the term, each for an additional five-year period. The lease is currently in effect until 2026 and we retain an additional option to extend the term for another five-year period thereafter. Upon the exercise of each option to extend the term of the lease includes a 10% increase to the then current base rent.</p><a id="_3ffde9d0_b196_4907_887d_21b400773987"></a><a id="Item3LegalProceedings_932888"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_349c69b3_ac69_458c_98d9_daeca4ed7fff"></a><a id="Item4MineSafetyDisclosures_147620"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a90fcf85_d9fb_47c3_952f_e86d40e6b998"></a><a id="PARTII_453527"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our common stock is traded on the NYSE American under the symbol &#8220;PLX.&#8221; Our common stock is also listed on the TASE under the symbol &#8220;PLX.&#8221; As of March&#160;15, 2022, there were approximately 61 holders of record of our common stock. A substantially greater number of holders of our common stock are &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Equity Compensation Plan Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table provides information as of December&#160;31, 2021 with respect to the shares of our common stock that may be issued under our existing equity compensation plan.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">C</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities&#160;Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Available&#160;for&#160;Future&#160;Issuance</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">to&#160;be&#160;Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Under&#160;Equity&#160;Compensation&#160;Plans</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Upon&#160;Exercise&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Excluding&#160;Securities&#160;Reflected&#160;in</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Column&#160;A)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Compensation Plans Approved by Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,259,020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.42</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,786,256</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Compensation Plans Not Approved by Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,259,020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.42</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,786,256</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_09ce3da0_e521_4ded_ba4a_39944916cced"></a><a id="Item6SelectedFinancialData_466791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;[Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d548316f_f3c3_4cd1_a0d0_0f4dbc087a25"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) is intended to help the reader understand our results of operations and financial condition. The MD&amp;A is provided as a supplement to, and should be together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read &#8220;Risk Factors&#8221; in Item&#160;1A of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins primarily based on our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system. We developed our first commercial drug product, Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, using our ProCellEx system and we are now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of complex recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications, including applying the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of our outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pegunigalsidase alfa (PRX-102), our proprietary plant cell culture expressed enzyme in development for the treatment of Fabry disease, is our most advanced product candidate. Our PRX-102 phase&#160;III clinical program of PRX-102 for the treatment of Fabry disease includes three separate studies: the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021. The studies were designed to evaluate the potential superiority of PRX-102 over current therapies, demonstrate the potential for improved efficacy and better quality of life for patients with Fabry disease and demonstrate the safety of our drug/therapy. We are also evaluating the potential of a once-monthly treatment regimen with a higher dose of PRX-102. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;7, 2022, an MAA for PRX-102 was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On April&#160;28, 2021, we, together with our development and commercialization partner for PRX-102, Chiesi, announced the receipt of a CRL from the FDA regarding the PRX-102 BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme (agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. We intend to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our partnership with Chiesi is based on two agreements. On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into Chiesi Ex-US Agreement and on July&#160;23, 2018, Protalix Ltd. and Chiesi entered into the Chiesi US Agreement. Under each of the Chiesi Agreements, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, the Chiesi Ex-US Agreement provided for additional payments to Protalix Ltd. of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per&#160;year, and up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. The Chiesi US Agreement provided for additional payments to Protalix Ltd. of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per&#160;year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. is required to manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi is required to purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;1, 2012, the FDA approved for sale our first commercial product, taliglucerase alfa for injection, an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries. Taliglucerase alfa is marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries, and under the name Elelyso in other territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer, as provided in the Pfizer Agreement. In October&#160;2015, we entered into the Amended Pfizer Agreement which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, we sold to Pfizer our share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0&#160;million. Under the Amended Pfizer Agreement, Pfizer has an exclusive license to commercialize Elelyso worldwide other than Brazil; we maintain full rights to BioManguinhos alfataliglicerase in Brazil. We will continue to manufacture drug substance for Pfizer, subject to certain terms and conditions. Under the Amended Pfizer Agreement, Pfizer is responsible </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">for 100% of expenses, and entitled to all revenues globally for Elelyso, excluding Brazil, where we are responsible for all expenses and retain all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On June&#160;18, 2013, we entered into the Brazil Agreement with Fiocruz, an arm of the Brazilian MoH, for BioManguinhos alfataliglicerase. As Fiocruz has not satisfied certain purchase commitments under the agreement, we and Fiocruz continuously discuss potential steps to maximize sales of BioManguinhos alfataliglicerase to the Brazilian MoH. We are continuing to supply BioManguinhos alfataliglicerase to Fiocruz, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil. We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, we will determine what we believe to be the course of action that is in our best interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to PRX-102, our product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1)</span>alidornase alfa, or PRX-110, a proprietary plant cell recombinant human DNase, which has successfully completed a phase&#160;II efficacy and safety study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2)</span></span>PRX-115, our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3)</span></span>PRX-119, our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer, and the rights to commercialize pegunigalsidase alfa worldwide to Chiesi. Otherwise, we hold the worldwide commercialization rights to our other proprietary development candidates. In addition, we continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Critical Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in note&#160;1 to our consolidated financial statements appearing at the end of this Annual Report on Form&#160;10-K. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Revenues</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our primary sources of revenues include our sales of BioManguinhos alfataliglicerase in Brazil, of drug substance to Pfizer under our Amended Pfizer Agreement and of drug product to Chiesi under the Chiesi Agreements. We recognize </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenue from the Amended Pfizer Agreement at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also generate revenues from the Chiesi agreements. According to Accounting Standards Codification 606, Revenue from Contracts with Customers, and all the related amendments, or ASC 606, a performance obligation is a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the&#160;research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The future manufacturing is contingent on regulatory approvals of the drug and we deem these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The transaction price of the Chiesi Agreements was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which we would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. We estimate variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, we use significant judgment to determine the probability of a significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. We used significant judgment when we determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect our research and development expense to remain our primary expense in the near future as we continue to develop our product candidates. Research and development expense consists of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal costs associated with research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments made to third party contract research organizations, investigative/clinical sites and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing development costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities relating to the advancement of product candidates through preclinical studies and clinical trials; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, as well as laboratory and other supplies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table identifies our current major research and development projects:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Project</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expected Near Term Milestones</b></p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-102&#160;&#8211; pegunigalsidase alfa</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies complete; extension studies ongoing </p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Top-line results from <i style="font-style:italic;">BALANCE</i> study to be released in the second quarter of 2022 and final results to be released in the second half of 2022; resubmission of PRX-102 BLA in second half of 2022</p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-110&#160;&#8211; alidornase alfa</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preclinical</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-115&#160;&#8211; Uricase</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preclinical</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.28%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-119&#160;&#8211; Long Acting DNase I</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.28%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preclinical</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate incurring increasing costs in connection with the continued development of all of the product candidates in our pipeline. Our internal resources, employees and infrastructure are not tied to any individual research project and are typically deployed across all of our projects. We currently do not record and maintain research and development costs per project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The costs and expenses of our projects are partially funded by grants we have received from NATI. Each grant is deducted from the related research and development expenses as the costs are incurred. For additional information regarding the grant process, see &#8220;Business&#8212;Israeli Government Programs&#8212; Encouragement of Industrial Research, Development and Technology Innovation, 1984&#8221; in Item&#160;1 of this Annual Report. There can be no assurance that we will continue to receive grants from NATI in amounts sufficient for our operations, if at all. In addition, under the two Chiesi Agreements, Protalix&#160;Ltd. was entitled to payments of up to $45.0&#160;million in the aggregate to cover development costs for pegunigalsidase alfa, capped at $17.5&#160;million per&#160;year. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At this time, due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our preclinical product development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. The current focus of our product development efforts are on pegunigalsidase alfa. Our future research and development expenses for pegunigalsidase alfa and the other product candidates will depend on the clinical success of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. See &#8220;Risk Factors&#8212;If we are unable to develop and commercialize our product candidates, our business will be adversely affected&#8221; and &#8220;&#8212;We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect our research and development expenses to continue to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development programs for our product candidates, particularly with respect to the development of pegunigalsidase alfa. The lengthy process of completing clinical trials and seeking regulatory approvals for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expense to increase and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">any net cash inflows from our projects. See &#8220;Risk Factors&#8212;Clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs which may have a material adverse effect on our business, results of operations and financial condition.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We measure share-based compensation cost for all share-based awards at the fair value on the grant date and recognition of share-based compensation over the related service period. The fair value of stock options is determined based on the number of shares granted and the price of our ordinary shares, and calculated based on the Black-Scholes valuation model. For grants made to employees we recognize the fair value of the grant as expense over the service period using the accelerated method while for grants made to consultants and other non-employees we recognize the expenses using the straight-line accounting method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The guidance requires companies to estimate the expected term of the option rather than simply using the contractual term of an option. Because of lack of sufficient data on past option exercises by employees, the expected term of the options could not be based on historic exercise patterns. Accordingly, we adopted the simplified method, according to which companies may calculate the expected term as the average between the vesting date and the expiration date, assuming the option was granted as a &#8220;plain vanilla&#8221; option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In performing the valuation, we assumed an expected 0% dividend yield in the previous&#160;years and in the next&#160;years. We do not have a dividend policy and given the lack of profitability, dividends are not expected in the foreseeable future, if at all. The guidance stipulates a number of factors that should be considered when estimating the expected volatility, including the implied volatility of traded options, historical volatility and the period that the shares of the company are being publicly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The risk-free interest rate used in the valuation of the options is based on the implied yield of U.S.&#160;federal reserve zero&#8211;coupon government bonds. The remaining term of the bonds used for each valuation was equal to the expected term of the grant. This methodology has been applied to all grants valued by us. The guidance requires the use of a risk&#8211;free interest rate based on the implied yield currently available on zero&#8211;coupon government issues of the country in whose currency the exercise price is expressed, with a remaining term equal to the expected life of the option being valued. This requirement has been applied for all grants valued as part of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Convertible Notes </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board, or the FASB, Accounting Standards Codification, or ASC, 815 requiring that we determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The 2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital. <span style="background:#ffffff;">The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at our option, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On August&#160;25, 2021, we completed the Exchanges of a substantial majority of the 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021. The Exchanges are described in greater detail in Note 10 to the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. We allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, we recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component and a reduction of stockholders&#8217; equity of $12.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2021, none of the 2021 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Year ended December&#160;31, 2021 Compared to the&#160;Year Ended December&#160;31, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenues from Selling Goods</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues of $<span style="direction:rtl;">16.7</span>&#160;million for the year ended December 31, 2021, an increase of $<span style="direction:rtl;">0.5</span>&#160;million, or <span style="direction:rtl;">3</span>%, compared to revenues of $<span style="direction:rtl;">16.2</span>&#160;million for the year ended December 31, 2020. An increase of $2.1&#160;million in sales of drug substance to Pfizer was partially offset by a $1.6&#160;million decrease in sales of drug to Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenues from License and R&amp;D services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $21.6&#160;million for the year ended December&#160;31, 2021, a decrease of $25.1&#160;million, or 54%, compared to revenues of $46.7&#160;million for the year ended December&#160;31, 2020. Revenues from license and R&amp;D services represent mainly the revenues we recognized in connection with the Chiesi Agreements. The decrease is primarily due to lower costs incurred in the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $16.3&#160;million for the year ended December&#160;31, 2021, an increase of $5.4&#160;million, or 50%, compared to cost of goods sold of $10.9&#160;million for the year ended December&#160;31, 2020. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of certain one-time manufacturing costs incurred while preparing for the then anticipated FDA approval of the PRX-102 BLA and higher manufacturing costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses, net were $29.7&#160;million for the year ended December&#160;31, 2021, a decrease of $8.5&#160;million, or 22% from $38.2&#160;million for the year ended December&#160;31, 2020. The decrease is primarily due to the completion of the three phase III clinical trials of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Selling, General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $12.7&#160;million for the year ended December&#160;31, 2021, an increase of $1.6&#160;million, or 14%, from $11.1&#160;million for the year ended December&#160;31, 2020. <span style="background:#ffffff;">The increase resulted primarily from an increase in corporate costs of $1.7&#160;million related mainly to insurance.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Financial Expenses and Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Financial expense, net was $7.1&#160;million for the year ended December 31, 2021, a decrease of $2.1&#160;million, or 23%, compared to financial expenses of $9.2&#160;million for the year ended December 31, 2020. Financial expenses are comprised primarily of interest expense on our outstanding convertible notes equal to $3.6&#160;million and $4.3&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. The decrease resulted primarily from the exchange of our 2021 notes; $0.7&#160;million decrease in interest expenses, $0.8&#160;million decrease in amortization of debt discount, and $1.3&#160;million decrease in related expenses offset by a $0.8&#160;million loss on extinguishment related to the Exchanges.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Year ended December&#160;31, 2020 Compared to the&#160;Year Ended December&#160;31, 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">For a discussion of the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, see Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At December 31, 2021, we had $39.0&#160;million in cash and cash equivalents. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;25, 2021, we completed Exchanges with institutional note holders of a substantial majority of the then outstanding 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate of the 2024 Notes is 563.2216 shares of our common stock per $1,000 principal amount of 2024 Notes, which is equivalent to an initial conversion price of approximately $1.7755 per share of common stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the 2024 Indenture which was entered into between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operations was $10.3&#160;million for the&#160;year ended December&#160;31, 2021. The net loss for the&#160;year ended December&#160;31, 2021 of $27.6&#160;million was further increased by a $4.9&#160;million increase in inventories and by a $1.0&#160;million increase in accounts receivable and other assets, which was partially offset by a $13.2&#160;million increase in contracts liability and an increase of $2.4&#160;million in accounts payable and accruals, by $2.7&#160;million amortization of debt issuance costs and debt discount, by a $2.4&#160;million in share-based compensation and $1.1&#160;million in depreciation. Net cash provided by investing activities for the&#160;year ended December&#160;31, 2021 was $18.9&#160;million and consisted primarily of a net decrease in bank deposits. Net cash provided by financing activities for the year ended December&#160;31, 2021 was $12.1&#160;million, net proceeds of $37.6&#160;million from the issuance of common stock and of $8.6&#160;million from the issuance of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">common stock under the sales agreement were offset by payments of $30.0 million for convertible notes redemption and transactions costs, and $4.1&#160;million net payment to satisfy an outstanding promissory note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2024 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;background:#ffffff;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2021, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. In addition, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v)&#160; payment of interest on our outstanding 2024 Notes. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. On July&#160;2, 2021, we entered into the Sales Agreement in connection with a new ATM program pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. On the same date, we terminated our former ATM program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Contractual obligations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our contractual obligations include obligations under our convertible notes, operating lease obligations, purchase obligations, a certain clinical contract and the liability for employee rights upon retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our convertible senior notes had an aggregate outstanding principal balance of $28.75&#160;million at December&#160;31, 2021. The notes will mature on September&#160;1, 2024 unless earlier purchased, converted, exchanged or redeemed, and interest is payable on the note semi-annually at a rate of 7.50% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We lease certain assets under operating leases, which expire through 2026, with an option to extend the lease on our main facility to 2031. The leases relate primarily to office, laboratory and manufacturing space and vehicles used by our employees. Our aggregate future minimum commitments under these facility and vehicles leases over the next five fiscal years is approximately $5.1&#160;million as of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, we are subject to open purchase orders issued to certain suppliers and other vendors mainly in connection with our research and development and manufacturing activities that were outstanding as of December&#160;31, 2021 for approximately $5.1&#160;million over the next five fiscal years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have a contractual obligation of approximately $853,000 as of December&#160;31, 2021 payable over the fiscal year ended December&#160;31, 2022. In addition, we enter into contracts in the normal course of business with CROs, CMOs and other third parties for clinical trials, preclinical and other research studies and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2021, we have a contractual obligation of approximately $2.5&#160;million for employee rights upon retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are also party to certain research and license agreements. If all of the contingencies with respect to milestone payments under our research and license agreements are met, as of December&#160;31, 2021, the aggregate milestone payments payable would be approximately $8.4&#160;million, and would be payable, if at all, as our projects progress over the course of a number of&#160;years. The royalty payments payable by our company in connection with sales of each of our product candidates, if any, shall not exceed low, single-digit percentages of net sales of the relevant product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Effects of Currency Fluctuations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the&#160;years ended December&#160;31, 2020 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain recently issued accounting pronouncements are discussed in note 1r of the financial statements included in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><a id="_d48eee2a_bd0b_4da2_88aa_044d9a23d0b8"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Currency Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and approximately 65% of our expenses and capital expenditures, including the repayment of our 2021 Notes, are incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 31% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Average rate for period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.565</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.442</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.230</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.456</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.110</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><a id="_9de7b5b2_46ae_493b_99f8_6b9f9eea7277"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">See the Index to Consolidated Financial Statements on Page&#160;F-1 attached hereto.</p><a id="_0da0df3e_0281_4782_9bd8_15df9ae9063c"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_e7e8eebc_68b1_4476_baf2_f53935470d91"></a><a id="Item9AControlsandProcedures_730194"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form&#160;10-K. The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Form&#160;10-K, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The evaluation of our disclosure controls and procedures included a review of the controls&#8217; objectives and design, our implementation of the controls and their effect on the information generated for use in this Annual Report on Form&#160;10-K. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures can be reported in our periodic reports on Form&#160;10-Q and Form&#160;10-K. The overall goals of these various evaluation activities are to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls and procedures as dynamic systems that change as conditions warrant.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form&#160;10-K, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information related to our company and our consolidated subsidiaries are made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of management and our directors; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Management assessed our internal control over financial reporting as of December&#160;31, 2021, the end of our fiscal&#160;year. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies and our overall control environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on our assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal&#160;year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&#8217;s assessment with the Audit Committee of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Inherent Limitations on Effectiveness of Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Attestation Report of Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Changes in internal controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_9c2052a8_da6e_421c_9bcf_7e91332a3c42"></a><a id="Item9BOtherInformation_882944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March&#160;31, 2022, Einat Brill Almon, Ph.D., having reached retirement age, retired from her position as our Sr. Vice President &amp; Chief Development Officer. Dr. Almon will continue her service to our company on a consultancy basis, taking a facilitating role in the continued progress of our clinical development program, as well as assisting in the identification of her replacement.</p><a id="_132ee225_d96e_42b8_824e_ebef67dc0850"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="_9e6357e0_f050_41ad_9dc1_f424fb4b3ca5"></a><a id="PARTIII_463758"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information in our 2022 Proxy Statement regarding directors and executive officers appearing under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management &#8212; Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance&#8221; and &#8220;Election of Directors&#8221; is incorporated by reference in this section.</p><a id="_699c26cf_a93c_4072_b0d8_fa9f5dd351a9"></a><a id="Item11ExecutiveCompensation_376320"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information appearing in our&#160;2022 Proxy Statement under the headings &#8220;Director Compensation,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Report of the Compensation Committee,&#8221; and &#8220;Executive Compensation&#8221; is incorporated by reference in this section.</p><a id="_542abfaf_75f1_46b0_bb15_62b0d5633776"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2022 Proxy Statement under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_b9505013_91d4_4c2e_8e23_4ef82e32febe"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2022 Proxy Statement under the headings &#8220;Election of Directors&#8212;Corporate Governance&#8221; and &#8220;&#8212;Certain Relationships and Related Transactions&#8221; is incorporated by reference in this section.</p><a id="_679b73f2_96a0_4062_92d5_7039922880ee"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our independent registered public accounting firm is</span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), A member of PricewaterhouseCoopers International Limited, </span></a>Tel Aviv, Israel, PCAOB ID. No. 1309.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2022 Proxy Statement under the heading &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9cb47f12_cb5a_40d9_b965_791d723fc9bb"></a><a id="PARTIV_377623"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">The following documents are filed as part of this Annual Report on Form&#160;10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">1.<i style="font-style:italic;"> Financial Statements.</i> The following Consolidated Financial Statements of Protalix BioTherapeutics,&#160;Inc. are included in Item&#160;8 of this Annual Report on Form&#160;10-K:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB name: Kesselman &amp; Kesselman C.P.A.s and PCAOB ID: 1309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_216383"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the years ended December 31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Capital Deficiency for the years ended December 31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended December 31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">2. <i style="font-style:italic;">Financial Statement Schedule.</i> Financial statement schedules have been omitted since they are either not required, are not applicable or the required information is shown in the consolidated financial statements or related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">3. <i style="font-style:italic;">Exhibits.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:7.83%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.13%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:7.83%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.71%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.03%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.62%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:13.53%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.13%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465921088982/tm2121219d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At the Market Offering Agreement, dated July&#160;2, 2021, between the Company and H.C.&#160;Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;2, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Def 14A</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appen. A</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Def 14A</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appen. A</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;20, 2019</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416086642/v432711_ex3-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between Protalix&#160;Ltd. and Angel Science Park (99)&#160;Ltd., dated as of October&#160;28, 2003 as amended on April&#160;18, 2005</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January&#160;8, 2007</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unprotected Lease Agreement</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2008</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Agreement between Protalix&#160;Ltd. and Comercio e Servi&#231;os Ltda. dated June&#160;17, 2013</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Technology Transfer and Supply Agreement made as of June&#160;18, 2013 by and between Protalix&#160;Ltd. and Funda&#231;&#227;o Oswaldo Cruz</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:42.4pt;"><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License and Supply Agreement by and between Pfizer&#160;Inc. and Protalix&#160;Ltd., dated October&#160;12, 2015</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;11, 2015</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/tv486893_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License and Supply Agreement dated as of October&#160;17, 2017, made by and between Protalix&#160;Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;6, 2018</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive U.S. License and Supply Agreement dated as of July&#160;23, 2018, made by and between Protalix&#160;Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;7, 2018</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420419027423/tv522023_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement made effective as of May&#160;20, 2019, by and between Protalix&#160;Ltd. and Mr.&#160;Dror Bashan</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;21, 2019</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement made effective as of July&#160;28, 2019, by and between Protalix&#160;Ltd. and Mr.&#160;Eyal Rubin</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;29, 2019</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920070904/tm2022015d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement with Yael Hayon, Ph.D. dated June&#160;7, 2020</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June&#160;8, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13&#8224;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920070904/tm2022015d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement with Einat Brill Almon, Ph.D., dated June&#160;7, 2020</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June&#160;8, 2020</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021011566/plx-20210812xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Agreement, dated as of August&#160;12, 2021 among Protalix BioTherapeutics, Inc. and the holders named therein</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;12, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated U.S. Security Agreement dated of August&#160;24, 2021 among Protalix BioTherapeutics, Inc., the guarantors party thereto, Wilmington Savings Fund Society, FSB, as collateral agent and The Bank of New York Mellon Trust Company, N.A., as Notes Trustee</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Security Agreement/Debenture, made on August&#160;24, 2021 between Protalix Ltd. and Altshuler Shaham Trusts Ltd., as security trustee</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095012310017277/y03091exv21w1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;26, 2010</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), A member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20211231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL INSTANCE DOCUMENT - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL SHEMA FILE</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL CALCULATION FILE</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL DEFINITION FILE</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL LABEL FILE</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL PRESENTATION FILE</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">&#8224;&#8224;&#160;&#160;&#160;Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment under Rule&#160;24b-2 of the Exchange Act.</p><a id="_6511c496_3850_4af8_b39f_e90c778c2acd"></a><a id="Item16Form10KSummary_450405"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;16.&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3675ec5f_7bc1_4c03_ac02_dffbb745a3cf"></a><a id="SIGNATURES_579077"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, as of March&#160;31, 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:middle;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dror Bashan and Eyal Rubin, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:44.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:21.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:44.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:middle;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer) and Director</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer, Treasurer and</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Secretary (Principal Financial</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">and Accounting Officer)</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Zeev Bronfeld</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Zeev Bronfeld</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Amos Bar Shalev</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Amos Bar Shalev</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pol F. Boudes</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pol F. Boudes, M.D.</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Granot</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">David Granot</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Gwen A. Melincoff</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Gwen A. Melincoff</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d729adcb_0b66_4acb_b7d6_22c522940fe7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">TABLE OF CONTENTS</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:7.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><b style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></a><b style="font-weight:bold;"> (PCAOB name: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:AuditorName" id="Narr_UmRgZISEUUKSFUnVf2bCdQ"><b style="font-weight:bold;">Kesselman &amp; Kesselman C.P.A.s</b></ix:nonNumeric><b style="font-weight:bold;"> and PCAOB ID: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:AuditorFirmId" id="Narr_wN2B3X94uEWZ2XSQUQOG8g"><b style="font-weight:bold;">1309</b></ix:nonNumeric><b style="font-weight:bold;">)</b></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</b></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_216383"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2020 and 2021</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Capital Deficiency for the&#160;years ended December&#160;31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:61.8pt;"><a id="_92a32b50_7c08_41fa_9d46_f59884dd09ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;"><img src="plx-20211231x10k005.jpg" alt="Graphic" style="display:inline-block;height:61.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:86.4pt;" /></span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">To the Board of Directors and Stockholders of Protalix Biotherapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">We have audited the accompanying consolidated balance sheets of Protalix BioTherapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, and the related consolidated statements of operations, changes in capital deficiency and cash flows for each of the three years in the period ended December&#160;31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2021 in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 8pt 0pt;"><span style="font-family:'Georgia';">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 8pt 0pt;"><span style="font-family:'Georgia';margin-right:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:61.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 10pt 0pt;"><img src="plx-20211231x10k005.jpg" alt="Graphic" style="display:inline-block;height:61.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:86.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt -9pt 8pt 0pt;"><span style="font-family:'Georgia';">alter in any way our opinion on the consolidated financial</span> <span style="font-family:'Georgia';">statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Georgia';font-style:italic;">Revenue Recognition - Estimated Costs to Complete License and Research and Development (&quot;R&amp;D&quot;) Services Performance Obligation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">As discussed in</span><i style="font-family:'Georgia';font-style:italic;"> </i><span style="font-family:'Georgia';">Notes 2(b) and 8 to the consolidated financial statements, $21.6&#160;million of the Company&#8217;s total revenues for the year ended December 31, 2021 was generated from&#160;license and R&amp;D services. For the Company&#8217;s license and R&amp;D services, control transfers over time; accordingly, management recognizes revenue based on the extent of progress in each period towards completion of the performance obligation. The selection of the measure of progress towards completion requires management judgment and is based on the nature of the products or services to be provided. As disclosed by management, the Company uses the cost-to-cost method to measure progress for its contracts because management believes that measure best depicts the transfer of control to the customer, which occurs as the Company incurs costs on the contracts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">Under the cost-to-cost method, the extent of progress towards completion is based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation, which includes both the actual costs already incurred and the estimated costs to complete. Revenues are recognized proportionately as costs are incurred. Due to the nature of the work required to be performed on the performance obligation, management&#8217;s estimation of costs at completion is complex and requires significant judgment. Management has disclosed that there are many factors that can affect the accuracy of cost estimates, including, but not limited to, the availability and costs of labor and materials resources, and productivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">The principal considerations for our determination that performing procedures relating to revenue recognition &#8211; estimated costs to complete license and R&amp;D services performance obligation is a critical audit matter are the significant judgment by management when developing the estimated costs to complete the performance obligation. This in turn led to significant auditor judgment, subjectivity and effort in performing procedures to evaluate management&#39;s estimate of the costs to complete the performance obligation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Georgia';">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, evaluating and testing management&#8217;s process for determining the estimate of costs at completion, which included evaluating the reasonableness of significant assumptions, including the estimated expected labor costs used by management and considering the factors that can affect the accuracy of those estimates. Evaluating the reasonableness of significant assumptions used involved assessing management&#8217;s ability to reasonably estimate costs to complete the performance obligation by (i) performing a comparison of the originally estimated costs and actual costs incurred; (ii) evaluating the timely identification of circumstances that may warrant a modification to the estimated costs to complete, including actual costs in excess of estimates; and (iii) testing management&#8217;s process for evaluating the Company&#8217;s ability to properly execute the work plan and design phases consistent with customer expectations for completing the performance obligation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Kesselman &amp; Kesselman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certified Public Accountants (Isr.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">A member of PricewaterhouseCoopers International Limited</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="dei:AuditorLocation" id="Narr_vYtPTRjavkCoRgjginrkvw">Tel Aviv, Israel</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March&#160;31, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2000.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c190ac5c_225d_48bc_8ed3_602b2a8f60a4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDBALANCESHEETS_216383"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><a id="_bce056b9_e47a_4043_bece_09f9fd587143"></a><a id="Tc_tEtz2qt1aU21Nbez1nsmJA_1_2"></a><a id="Tc_g5L26j6zGkq8s5NA6RhW2w_2_2"></a><a id="Tc_ZBU-ZP3urUuV0CIShnSzrg_2_5"></a><a id="Tc_y3L7PySJqUSWM2zJH8M6LA_3_0"></a><a id="Tc_hyrTsfYRh0SY35a_7peucw_5_0"></a><a id="Tc_332U0iMX10OhN4Dwwzpr1Q_6_0"></a><a id="Tc_3Y81xoouokSEZaorQoYZww_6_2"></a><a id="Tc_8WrJmMMu4EWLi9lActsJzQ_6_5"></a><a id="Tc_i5WPvoidq0aOWC28YyRsKQ_7_0"></a><a id="Tc_1kYn2qtLR0aamUyG9loJdQ_8_0"></a><a id="Tc_p7yn6kKx70m-yi8YLR0Rng_9_0"></a><a id="Tc_sdkSopMhSEmzyXyoV6IRQg_10_0"></a><a id="Tc_HrKZCI0HAkevpwIX6kHKow_11_0"></a><a id="Tc_efoFU-DbH0W4OytEjz4t0Q_11_2"></a><a id="Tc_djCUUbYo8Emcmlq1e3YiTw_11_5"></a><a id="Tc_bEHU5p9Z20GMLjGq86ZrOw_13_0"></a><a id="Tc_peYZcynYN0SS0vmVnQ7-1Q_14_0"></a><a id="Tc_WnK-HsrPJESIo3DNG-qC3Q_14_2"></a><a id="Tc_2AwpYewonUKhQ-vJz7yVtg_14_5"></a><a id="Tc_-sDmj2hI_USlQqG2Bo56zQ_15_0"></a><a id="Tc_7YUjWWzkxEO0tfLYb_ftcA_16_0"></a><a id="Tc_RV5vUy8ya0StpHW5AqGc8Q_17_0"></a><a id="Tc_Jd1VJLB0ekui7eZxPEVOvw_17_2"></a><a id="Tc_DX_RJG_Vm06-no8U8KaYJw_17_5"></a><a id="Tc_75wRuHEx-0W5udpyk_J47Q_19_0"></a><a id="Tc_5uA-Wbu5bEunsfHZjp7oGw_21_0"></a><a id="Tc_xmAdi_JqhUuEQtJkbVYMqQ_22_0"></a><a id="Tc_DP07gtCMTkuJWP8RapwpKA_23_0"></a><a id="Tc_500m43FJXkuQVyvY9vp0tg_23_2"></a><a id="Tc_mfVqAyA6bE2oINwMp8J7wg_23_5"></a><a id="Tc_fyzTDR1tQEWnZFqUEyXjyg_24_0"></a><a id="Tc_K7iG4zrHxk69QizdOC3Oxw_25_0"></a><a id="Tc_NVEqMiYFxU2r83p3dIjFow_26_0"></a><a id="Tc_IZO9Jynk30eizaz9RZ8vKw_27_0"></a><a id="Tc_F6Qe4_oquUetQLXygK1bow_28_0"></a><a id="Tc_Q8JuJdChw0ixxs20LG_F3w_29_0"></a><a id="Tc_-q3rll_SBUWYJCXJ7AxlAA_29_2"></a><a id="Tc_3n9sx9G_hUmh2Krn_yrh1g_29_5"></a><a id="Tc_Iuny8sB-PEiwfHpchPkWEg_31_0"></a><a id="Tc_Ms3j5zDz7UKeWKIznG3RMQ_32_0"></a><a id="Tc_IjIHZ-I4j0u4zpuiiwtuEw_32_5"></a><a id="Tc_cWIbfpS6HEGRyI-DNuu1UQ_33_0"></a><a id="Tc_dUBGn1bNTEKBAdyOTWHR1g_33_2"></a><a id="Tc_KCK-1DfMgkqHTZLH2OS0Sw_34_0"></a><a id="Tc_Y2QrPiE4lk-C-HatdSg_hw_35_0"></a><a id="Tc_dcZvGwKiy0K8N34kCG-OdA_36_0"></a><a id="Tc_e0uUQz1Xc0SxNXYX83Q-jg_37_0"></a><a id="Tc_gbO1-zov1ECKyknRIBTexA_37_2"></a><a id="Tc_7v4HlPMN4k6DK464yoXkuw_37_5"></a><a id="Tc_D175qlBZvEaHi7KmwLFEKQ_38_0"></a><a id="Tc_8LEKOiRZYUqXkaAHrnm-Cw_38_2"></a><a id="Tc_yjQmKhf9T0yjOXQkhD9-2g_38_5"></a><a id="Tc_g2vlahTs7kmnP9PHbQfg5w_40_0"></a><a id="Tc_cSLLn9c9bkqlbQiyObDP2Q_42_0"></a><a id="Tc_R5pSsG25Cka5phYuUXxsvg_43_0"></a><a id="Tc_aEdYNnWvHU6oZp53EQ9OzA_44_0"></a><a id="Tc_FGQ45Vr52kGySmFadyQ8og_45_0"></a><a id="Tc_1lVdTjGJhEGCuOlA3SHZJA_46_0"></a><a id="Tc_15dGoirxwEuja7oTyPlgFw_47_0"></a><a id="Tc_2xNUMLfG80ONDmZACAqNHg_47_2"></a><a id="Tc_rfkxRgWCHEiAR95C1TyNiA_47_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_lHTd_h0L9UuEQA2xlkTbzA_6_3">18,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_fs0Vr966xUm83PlEcDjs_w_6_6">38,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_FtyWNVK880qkvbwJKZgE9Q_7_3">20,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_2dc-NdMi2UGmBr6OORge6Q_8_3">2,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_QalFYplO50CLb9WvGxVTmw_8_6">3,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_bZ_RfM5hAkyEPeUNMM0kyA_9_3">2,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_H-GakV-9u0ut-tD8VEbIrw_9_6">1,285</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_q7VoK_ujo0SqHWbmIpvEEw_10_3">13,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_W1Vd6LhIPk6MuCXQXfwk5Q_10_6">17,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_vUCQ8CsIJEyarNJjGAIoDw_11_3">55,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_TlQdTiQHDEy2AdX7S_k5_g_11_6">61,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_kOYw7UfB0ECE0GNonrpozw_14_3">1,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_zPuqY_HiK0iowWipJ0C73g_14_6">2,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_NSJ78e3PlEem63K3ZAotjA_15_3">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_D5BGy3tiukKTi4h6QDuYGA_15_6">4,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_WFj4zHMYQUONMJry5mhG9A_16_3">5,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_eX-_bGZBEkymYI4lLo5FoQ_16_6">4,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Fo6tlLiAZ0uVccqJmzPOTQ_17_3">67,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_fapeKX1xM0CihGJDkT1hKw_17_6">73,665</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_Zv5PgywO90GxrVmayvcmOQ_23_3">7,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_vE0wEdbrYkqNnEVvJ1sP6Q_23_6">6,986</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_6KgfeaPBU02bTXhJsQQYKw_24_3">13,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_WrTjfxZchkmSO6-9ztgrmQ_24_6">16,433</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_PLvqQRbxaE-utGuLiLMW_g_25_3">1,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc__V78BnOhLEqlY9wDFjd1Xg_25_6">1,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_ZrneXdG_TECZQRgxAds2Hw_26_3">5,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_9NIIstHdyUSpcgzQhr0z9Q_26_6">8,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_hhPvrAms5k-6IjkTuCBLGw_27_3">54,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_c66ni3HnTUSzR8jwPuBbiQ_28_3">4,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_TzK54gf8aEWLatevB-bocQ_29_3">86,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_h5HQCIqz0UCnh-luo1eVoA_29_6">33,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_WPr1FgFSRk-E0qYPZTDTog_32_6">27,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_MSMKVPbIxESyUqYMdgXgFQ_33_3">1,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_BeM3AHnVG0m9b_t9gYYEOg_33_6">11,790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_aFc3R9sRIUKqxxJnxTB3Pw_34_3">2,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_Q6eIVf8SbEWRozGgM_nHRA_34_6">2,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_aJMTyfbkK0isFze6KYeikQ_35_3">4,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_kWqUfAN7f0a3iYfwn72krw_35_6">4,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_XjP4DFX4gE-dHPGHwblnLw_36_3">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_S3pYcwGXQ06gyWr81RGvFg_37_3">8,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_rvVv4C-cS0yu7Q716_oYQA_37_6">46,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_EdG_O9A59kSmhdUlEGgQqQ_38_3">94,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_NkZRw9rM1EacjCNbYd7PcA_38_6">79,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ih3d1Tzl8UuGokGhY7REpg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_iPbBLVQ-NUaNjvb6M_rG5A">0.001</ix:nonFraction></ix:nonFraction> par value: Authorized - as of December 31, 2020 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ls2WT_jFpEiSKWkaahuhUQ"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_VvSfXW_EVkmzYGnIxp_8UA">120,000,000</ix:nonFraction></ix:nonFraction> shares; <span style="-sec-ix-hidden:Hidden_HDYzV-AxhEO6ZtjFVfzV3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_W9fROlZvR0eDAlWsPj0McQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> - as of December 31, 2020 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_GLsrN9afxk25hT8URHIPUA">34,765,280</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_arGEFsEIJUKNvskziM_1CQ">45,556,647</ix:nonFraction> shares, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_q4EZs_8My0usxo6fhh4YUQ_43_3">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_h-CyuOAJa0y1uKnSBrXtNA_43_6">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_xkgT-VZTfUSafyFzrqf7DA_44_3">320,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_vG3rGlQFxEWt4aKjMHog2w_44_6">368,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_Bu04g0JhcUyM3rEhWYpdkg_45_3">347,352</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_d8yrbXWubUqCAf8BdgH-WQ_45_6">374,934</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FlQrwd2lSUSaDFI13uaMew_46_3">27,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Wn7C7bjIJ02TuUbJmP6tkQ_46_6">6,036</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_-gg0HC5h5kqLEZ4sJ-wY6Q_47_3">67,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_mDeGQBX9yUi15NAtRF1wHg_47_6">73,665</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f627b018_9512_4177_bbfe_afe04702208b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands, except share and per share amounts)</p><a id="_d91fdb32_c624_4904_87bf_07693d72df8d"></a><a id="Tc_mKJL5LzBEUmppBOzzMzs7g_1_2"></a><a id="Tc_24RunEEyRUWEBXDRf6HnuQ_2_2"></a><a id="Tc_CsmgCqngGk-do7ZdZVaopQ_2_5"></a><a id="Tc_pWltAgrYWUqAWhzDJD3Xfg_2_8"></a><a id="Tc_KFizPY34FUW9pTrZTvgcTg_3_0"></a><a id="Tc_s5L_rkQjoEmtjGyAz7roCQ_3_2"></a><a id="Tc_DAr_1qylfUiBHwC-CX3hjA_3_5"></a><a id="Tc_66C9Bqq4GEWPPwNbIt9lYA_3_8"></a><a id="Tc_O5XCpB-Vu0Wd5nUm32yIzg_4_0"></a><a id="Tc_JmgN2Wgj7k2up1NrZH8CYg_5_0"></a><a id="Tc_s8JHtyhdL0ec9wj-0RJG0Q_6_0"></a><a id="Tc_PbQ6rY2ONEymGwSDbc9xeg_7_0"></a><a id="Tc_G-HE3CN1TUagDiMGwNJRfw_8_0"></a><a id="Tc_v8oXvxLm0UGeLZWHg04ZMA_9_0"></a><a id="Tc_NOLxNX-Oek2lYKsz5oJw3g_10_0"></a><a id="Tc_jtqh6YSKwE2E94zVarbH-g_11_0"></a><a id="Tc__cpdrkRia0SW0EAtvBGo-g_12_0"></a><a id="Tc_rpd1mo5NlE6ZdLrJVCCwrQ_13_0"></a><a id="Tc_1Y2IIFDpkk-5zPS-2DQiQA_13_2"></a><a id="Tc_nq8NT_4v7kmX3DkCBDwKBw_13_5"></a><a id="Tc_tWJoiddheEuTcs9I5dplGQ_13_8"></a><a id="Tc_ewjgyYR5PEStkFlt7zdLDQ_14_0"></a><a id="Tc_MgJzTafvBkWIyz-rYwbyVg_15_0"></a><a id="Tc_dCk0aZcljU2Pc1Vb2lXfiA_16_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_HmzXf1hdDkK4__n1knviHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_CNLDTdsctkmqTIl6qX--KQ_3_3">15,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_8B8k4Z958U29kvLCfB2P5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_lPL_aKntz0-1SwvH75tRMw_3_6">16,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_tr53Np7eY0-Ae6xS_WOJOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_DCZneEAkhECDYGlbiJos_A_3_9">16,749</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ePa1ql7mhEGcbcjaQMVPmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_dS5MD4oJoEefdJgqYGgqEg_4_3">38,827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0sZc2uezPU2o1oMeQcRe9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_PK4OBbGfAk-teQEPO8bvDQ_4_6">46,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_T30NLjS9gUG6T5IRwHFs3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rEKeZvYSZEug2vHX3oXahg_4_9">21,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-8TMrpXMI0aRUmakd4By5A_5_3">54,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5EyVYd1qMUKnFiFAeefUIw_5_6">62,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_crJB78x9_UmTuuBHJJR8QQ_5_9">38,350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_O7rtbiCQwkO89oUJO7inmQ_6_3">10,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_QMYlEzCsIUWIfNrngkoa3Q_6_6">10,873</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_5Qrcbe3B6kaeN2PkRosmOg_6_9">16,349</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES, NET</b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_uOJbe48u8EyGRtAMJMlmDg_7_3">44,616</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_R5d-asVWgUuj55PQ7146rQ_7_6">38,167</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Q87-43YILkmTA1nsbF8vDg_7_9">29,734</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_MeHfLXFdA0SGN3GwfOE8Nw_8_3">9,899</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_YwTzi7TC6kqatRxHCyrDqQ_8_6">11,148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_7eIKLDCKJkSOyq2bVkHQIA_8_9">12,729</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_LOf3Jic1PEKR0SAOD3d1Yw_9_3">10,717</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_H0kXZtNpVkS2Wn56TfcO0g_9_6">2,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_gW_wAE6khkW9W_mVri4aSA_9_9">20,462</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_CsabvlmmwUCm6JH59NQh7A_10_3">7,966</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_4F2_KNYO9UW5yzAUZ0UhsA_10_6">9,671</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_2aqEdJE6MEiOyWZFASNlAQ_10_9">7,521</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_gYoFJcvsZ06AuJ6bZ1QcTg_11_3">407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_7tlJzDFxXESbtqFg2FTz1A_11_6">438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_Ae1ZuH6zBEOwS9Qms7pWIA_11_9">401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES &#8211; NET</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_lve_VlgtEEWAbsl_QxKuLg_12_3">7,559</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_ueSxQNdCOkOk6xc0PXhuqA_12_6">9,233</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_MCzpGTZT60ay1MCgbh9NsA_12_9">7,120</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE YEAR</b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_5nR1mx869UeGv8CYaUXxLg_13_3">18,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zcwuPkx63E-zj8rKMU_1YA_13_6">6,523</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ENRizmTiDUG9HaGtuJo7vA_13_9">27,582</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_chTUbKX-yU63liJhoI2MnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_nFpDznTQiU2PNzLrqaqRMw_14_3">1.23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pwzKxLMzFUqTpVS-7SVM7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_CmxexE88_0Gn3ejAHf8Ttw_14_6">0.22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_cL1EAZPir0ybRR3Iq6YGOw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_YxIOQJo6SkW79t8K3AHTig_14_9">0.62</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_KPz2Klsca0qLxApA7B9LxQ_16_3">14,838,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_w0Li3jkwSEuitwme7XoABQ_16_6">29,148,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_yTShvGNZLkOl6-33yFEWpg_16_9">44,140,233</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_725ffd28_bfa7_4af0_a641_db95e55e1169"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands)</p><a id="_8855922c_9f36_478f_8bf1_33e13ceb6cc0"></a><a id="Tc_5Ab8KebHfUKa-m0GanI8qw_1_7"></a><a id="Tc_zfolKylX1UWoSnqZ1CXMMw_2_2"></a><a id="Tc_7WDYQeL9T06ZfqKNQsi0GA_2_4"></a><a id="Tc_yaTGFO9910ekrRxa1PXZPQ_2_7"></a><a id="Tc_JUylKUq76E-fzHm3Ylls1g_2_10"></a><a id="Tc_DsKChCmv0kG3uKu7CUhcjQ_3_2"></a><a id="Tc_-Y_6EYm6pkujdPkVpWbdaw_3_4"></a><a id="Tc_0_Yfnm5yy0q004g9xUy72Q_3_7"></a><a id="Tc_vrzjI5aRvUmJiN5YIrd-tQ_3_10"></a><a id="Tc_ZceHOIlNREiaMH-K9g7zSQ_3_13"></a><a id="Tc_XTIi5252pEGn6FbuLMxC_Q_4_2"></a><a id="Tc_LL6S4_6Lt06p-bWQ3wU6qA_5_2"></a><a id="Tc_6EysqTH1c0u1teWDwQ-Dbg_5_4"></a><a id="Tc_ZQlGRxtI0EWpykAXmQkA_w_6_0"></a><a id="Tc_Sr8RWV4V6kCYNwo9ovLDnw_6_4"></a><a id="Tc_gz6IOfx4xEO6t5AomwyAYA_6_7"></a><a id="Tc_ChOikg8wA0KDwuJXyTFQNw_6_10"></a><a id="Tc_dYGP-F8_906cTSipIDvsNg_6_13"></a><a id="Tc_oF623Z-UF0KvIuIQ8HyeKw_7_0"></a><a id="Tc_zQxyblu1AUCnUveqwDLNuw_8_0"></a><a id="Tc_cy-N_tIDvEGIqr2apAymmw_9_0"></a><a id="Tc_J0pgH9y3eUmPpU_OJSSauA_10_0"></a><a id="Tc_Iy_Q3cKo9EGyZ-VSN7sL_A_10_4"></a><a id="Tc_0sXKti-gLUiiTAIJQA-vqQ_10_7"></a><a id="Tc_b7NF1cCjBUuGTtmJwtR8Vg_10_10"></a><a id="Tc_z10UPCPUdUa5K59Miatvqg_10_13"></a><a id="Tc_AaM8aCTuX066Yn9aCnbe5w_11_0"></a><a id="Tc_mPEexfuRH0OSjuPU_4oAuw_12_0"></a><a id="Tc_K9I8gzhA1ESm2I7s86y58w_13_0"></a><a id="Tc_yCXeCQ1ep0uHKH-ue6sPKg_14_0"></a><a id="Tc_NxZdGG5zpkK_--DsHmBnPQ_15_0"></a><a id="Tc_-ZRogSCAs0-YeSfGTDsing_16_0"></a><a id="Tc_FTVqr3bMs0-RxQ01OmBXdA_16_5"></a><a id="Tc_reULgIIEukOJ66KW0Lg9OQ_17_0"></a><a id="Tc_bXEQ-tU_dEaUa7_BfWDymQ_18_0"></a><a id="Tc_2gdGcQpSgkOamxbYJdNofg_18_4"></a><a id="Tc_DT82Mr8j9E6Q2e7E2ZZWYw_18_7"></a><a id="Tc_ungj84FMd0aWxiocVAVxig_18_10"></a><a id="Tc_w6gtjxS3wUOb4vRTNhbOgA_18_13"></a><a id="Tc_JWOGddEH6E2ob6gAO4nTDQ_19_0"></a><a id="Tc_A8Fiv4P1bk2Imex0tZ6o4Q_20_0"></a><a id="Tc_bitQ6exrFkWqgJUkLWVv3Q_21_0"></a><a id="Tc_U2qSbqHJpUS-UbTBDvwNAQ_22_0"></a><a id="Tc_dJPTcwEdeE6Gq_kEkFDH_g_23_0"></a><a id="Tc_f-Rsaji1kkS5eLzI73XNzQ_24_0"></a><a id="Tc_qlJiIhbo5EqE6N4BBpVQRQ_24_5"></a><a id="Tc_Jar57XfPJUWHw6TfvQHTWg_24_8"></a><a id="Tc_pOtU8Rgx7EuyS5iedI9dbg_24_14"></a><a id="Tc_AXicWW7hn0WrJOOZbdU9uA_25_0"></a><a id="Tc_gnlMo0L380ibjYfdMX0iQw_26_0"></a><a id="Tc_QTx9HVtl1EqLk0a2aZ9ryw_27_0"></a><a id="Tc_eECFTO2mCkm_zkE-B2s8sA_28_0"></a><a id="Tc_6NR2Bp3xfEeSwhOy1aWt0g_28_4"></a><a id="Tc_7fYZ9SLVO02OeAu3ziBnDA_28_7"></a><a id="Tc_IZm2aDPDkUG0U6cl58PqBg_28_10"></a><a id="Tc_3XdcO0nwjE-XOTaBxfMzfA_28_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid&#8211;In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January&#160;1, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_E2XrxPIKmUK6tbEnjtWUmQ_6_2">14,838,213</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NelsAh7rlE-pOOZZycwB9A_6_5">15</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTJek5F4gEy9ScXTU5y5Nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UD2QWBqCSEu-oiqUkKIrgA_6_8">269,657</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DMrVGdM36kS0syIA8uAVkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zA3z0GepAEe9Pvj1iXIE0w_6_11">322,553</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2018_rKMXQYZpckOR3T6wCl0-lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_E2DFIoHBVEqdgW2wLxm9Qw_6_14">52,881</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2019:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cm4dDuAzykmSlgO-pcMmBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_4gWmiVDbtUCSKJRfhw0NYg_8_8">835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_mABPGJs5hEmUFm-EW8mPEA_8_14">835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0E0KOb1OA0OHpvtP9-VXOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WGTeup2xrkuKipZYbbpfqg_9_11">18,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ccD1ReQ1hUST5HzYSbORug_9_14">18,276</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sleyo-TN7ECJ8-DDksi1cA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_lYSEf-XPTUOf31pYlplRyA_10_2">14,838,213</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sleyo-TN7ECJ8-DDksi1cA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8JURES_KTEmBJIgEe-P2dA_10_5">15</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MdPzxWvoIUiF79gdrm8reg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_w6KYX7DIpUefchAs0f7-CQ_10_8">270,492</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EacWiMG0w0qlanSOpKQOQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KYO5o90gvkms2mPTqPe9cQ_10_11">340,829</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7zIYud7HukiWhxcpqLHvUw_10_14">70,322</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="INF" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" scale="0" id="Tc_1IduWJxxiEGzpEIEq84oQw_12_2">17,604,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_kuFUk20cGEu-BrH4R-5U8g_12_5">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_gIPHOV7eZ0CMb9-liYupPA_12_8">41,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_w6b3KiE7A0e9rFcB3Tet5A_12_14">41,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_e2pdLAcABkaUKV8NoONpUg_13_2">1,428,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_8t3ObCSbEkKTGhgurTDT4Q_13_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_CQP0XW9WoUiRceAY-k8CzQ_13_8">4,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_ckLgr_-6CkCu34mmoKyXfA_13_14">4,867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_tXdcyieYSk2Hk_d4CwwtUg_14_8">2,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Buc8LQQhNEiJSZ6bkh6lkA_14_14">2,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_WLJ9Mlg7LUWCmRK3IoWp-Q_15_2">694,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_G_KZlwsNME-Ck0DssJp51g_15_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_GzfLE2WeRkm0aGNbEIDd8w_15_8">861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_flzzBGEas06JAtFWZUruog_15_14">862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_3yeeyoqgGk228uSlFR_4dQ_16_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_AQC-48FkeUOufLZHtIEqdw_16_8">472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_uuVKQZp8SUC7x3i4_jBuOQ_16_14">472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4zMtLtp0p0ed5O4m0g8GzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4EO8y_fpN0aSfD3Koc9r_w_17_11">6,523</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6uJjjeSxZUGhjmj2OJJ7KA_17_14">6,523</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSoqlLM0bEOf23D1EiiZ3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_lH-uwEL0rkKsDy5N_voD1A_18_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSoqlLM0bEOf23D1EiiZ3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_K8XToHHy606fvYkKem0iJQ_18_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7sdZSqR5Akypy6gOZtXx-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_C7ILbroVj02DbtV-m4HVFA_18_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ihvuMLoedUaKvUb3gZrBQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_E3FMllUL6kiDBCq7TAbGPA_18_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kjA2PchGwk213tRNG5ENcA_18_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_pbMBetID7kK4sALv_oqwww_20_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_6bWhX8ymhEC8srJLbbzvgg_20_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_r65ZZC9GBEKgV6PQg8bAzw_20_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_NPop2PCLqkuiqXCABA0TrA_20_14">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_e9-hivyNWUqS1E0_oQY-2w_21_2">1,867,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_RDJCJlw7bUuLvdD7PXR_cA_21_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_FYRaW6PbsE6dd26SW693ew_21_8">8,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_b3eHF2ZkhEeZYjtyE4Vgow_21_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_-8oD6dv_PUSy3v9b_mYdAA_22_8">1,405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_U10t2AEIFkSQxSFSiwPQ4A_22_14">1,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_WCHYUfFKUEGNdlclSu73pA_23_8">970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_YR2wBFxOaU--frvnUMGXVg_23_14">970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_SbwgxAVjWEa4IPTxriKv2A_24_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reacquisition of equity component of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_G8hIU5gUOEOanVnSVgqOPg_25_8">12,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_u60gB_tcaEmJxXvLjsUYjA_25_14">12,019</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity component of convertible notes, net of transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_KHAYE8QUt0-5YUqvz9iGzQ_26_8">12,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_NgwGpW-fQkubp_mOvSAElQ_26_14">12,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S4pb21hY0kuERZAIbjSSPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_azpIEUfl00y3uZKWCmlm1A_27_11">27,582</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CL8XmJkik0y3_CILuMyJNA_27_14">27,582</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gHL5-QCaE0WNugpzgg9seQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_7lluMipghkqGX22fLeEaSw_28_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gHL5-QCaE0WNugpzgg9seQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_M7nGZ0yzyE-8zbJ6LsRIJQ_28_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kE8UTOIMfEGWg0hfCpFG2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_DSk0Ni9QKUS-LwyWJHXkXA_28_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_thD8r8M9pUScQANMOAi9Vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uGMsAS3Wh06HuwhnMPouXg_28_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mT93EvVFQEq9vszypeBzfg_28_14">6,036</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a430c62c_46d2_4eb1_8351_16509f57979b"></a><a id="_f039d4ba_6379_4a08_90ba_4461bd382d48"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Represents an amount less than $1.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5dab3b4a_48a9_4cc1_96ac_8bbf29ddd680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(U.S. dollars in thousands)</p><a id="_15df2cb2_a76a_406b_bdeb_65c569f49b2b"></a><a id="Tc_HBHuvqooN0OJGm2bv__Tqw_1_2"></a><a id="Tc_6b5_nK5BiUCVpY70PVXP1g_2_2"></a><a id="Tc_b0vnzoM1KUyUCwy2vm62xw_2_5"></a><a id="Tc_fKbvXyvRLEGmRcStdqtssQ_2_8"></a><a id="Tc_kxeVPQ2qvkiQczp5FzP9WA_3_0"></a><a id="Tc_270M0ufb5Umnl7FCXNg8Ag_4_0"></a><a id="Tc_BBe1MGYvzkedPDXKjieD4A_4_2"></a><a id="Tc_gwEEIb02zU-p3Qx470TlUg_4_5"></a><a id="Tc_QyrEjvdTAkuUqQ-lbSC4oA_4_8"></a><a id="Tc_rRHGpAI38EOY3o7gmKHixA_5_0"></a><a id="Tc_p4NxKOT-NEaMefUSVUOTow_6_0"></a><a id="Tc_E7TDWH8_Ek6YUuhfKjUdkQ_7_0"></a><a id="Tc_9r-my0irjUyVTE8NWGDnuw_8_0"></a><a id="Tc_o5BWIEGITEWqOnXk3hUrlA_9_0"></a><a id="Tc_b5jVgcBk0kGVigNNqQq_cg_10_0"></a><a id="Tc_jYwqfRMZL0iZ0CSV_nAZmw_11_0"></a><a id="Tc_OWDQ-kFLYESwD05OOaKiFQ_12_0"></a><a id="Tc_tItUevvgm0KUi8KzCBUVuA_13_0"></a><a id="Tc_P0dQyUARnk64YGZeSyo9ww_14_0"></a><a id="Tc_3yhLxR1Hi02lM4cnnoYamA_15_0"></a><a id="Tc_o3jOf1PBTUyu_zjozUnzHA_16_0"></a><a id="Tc_BkpE27kRd0WhXhykZ97h0g_17_0"></a><a id="Tc_xuMxYH9NZEyP4k1altBIkg_18_0"></a><a id="Tc_W6pqheWh_0-iOp1Rf995SA_19_0"></a><a id="Tc_HUuZJWlXEEuhHOp-OJjyZg_20_0"></a><a id="Tc_tNuJYSkygkm8P3AdQeTxzg_21_0"></a><a id="Tc_yiLe6dwa4E2LZxyu7GIK0w_21_2"></a><a id="Tc_mhRdPrhdqEuOFUUzW9whlA_21_5"></a><a id="Tc_4SzzVouzX0-yM4nK9I6NVw_21_8"></a><a id="Tc_wwQZiqyl2UymfnmQBViN3g_23_0"></a><a id="Tc_Nk91mR9Wgkesldi60gQKYg_24_0"></a><a id="Tc__10oayenT02zXVMpjGh-zg_24_5"></a><a id="Tc_iYf088d77UGE5W2eYZmzrg_24_8"></a><a id="Tc_r_rA9W3kKEOP28kiB9eLrQ_25_0"></a><a id="Tc_shqGehS7v06KcgpeGbWtzA_26_0"></a><a id="Tc_Ic4BQ3P6W0OTlijVpM1beQ_26_2"></a><a id="Tc_-ydN1dQn20SfvmpCjj2n7g_27_0"></a><a id="Tc_zzq6BiQWc0aIEEiwlZyn3w_28_0"></a><a id="Tc_lKz34fNyW0yWXIOWJuoGfw_29_0"></a><a id="Tc_2jAg73MIoUyoeC7Y_NqOJg_30_0"></a><a id="Tc_XZXSrkPn-EatIS0By34LQw_30_2"></a><a id="Tc_APdwVSrB1UKt1HXGe7FbQA_30_5"></a><a id="Tc_X5Shzu_WjUKw8TjevMYOeQ_30_8"></a><a id="Tc_UJgwLQlE-02-qPDxnk4JLw_32_0"></a><a id="Tc_vNovdurGe0muagTdmzm_LA_33_0"></a><a id="Tc_xcDzgMxklUiYipWm0-9Xrg_33_8"></a><a id="Tc_Bur0KsDG20mWnkA6cRBQKQ_34_0"></a><a id="Tc_Tg4zgXQ4JEKfMUanF04SHg_34_5"></a><a id="Tc_0vSdQFaHMkyz4KKGWEXLiA_35_0"></a><a id="Tc_Fmbu5hzV006yUeLKhHZ0Yw_36_0"></a><a id="Tc_mwcQWCg0mUaJ_GHSmnZB7A_37_0"></a><a id="Tc_SEZVaosCLEOQXrMCwxK_MQ_38_0"></a><a id="Tc_Y1aUEYmVuUuK9tr4Dem2vQ_38_2"></a><a id="Tc_oDBfp6IAk0KZ5SFB5v89gA_38_5"></a><a id="Tc_CQegpHRANk-bfsVsCe63xg_38_8"></a><a id="Tc_a9LxAFihl0CW0OBZvxQBRw_39_0"></a><a id="Tc_6-8PBJ_u6Uy9QyfHRySxHw_39_2"></a><a id="Tc_romeYbuCJUWmnfMcglP8WQ_39_5"></a><a id="Tc_Gd3qINHJ1kOoko6wjTBW6g_39_8"></a><a id="Tc_VAjUsnv19Eyk-fzsboKGmA_40_0"></a><a id="Tc_GuM8o0xZaUOdI0zglzm0_g_41_0"></a><a id="Tc_Lg5aIEksKk-W7tJfQx48Cg_42_0"></a><a id="Tc_w6zmhNvR00CAxlt16HLG8w_42_2"></a><a id="Tc_-VjUcEKCjUKNQ7oUfBIc4g_42_5"></a><a id="Tc_4t5VKPTrEE-XtVPJ1XmVnA_42_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JoJMWJZzb0aF0z1EsOoaPQ_4_3">18,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_r3Ba0MQoU0CPcEQvTBr3UQ_4_6">6,523</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GJbBMzlXf0WQnc6ZpcaXbg_4_9">27,582</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_MQwj52IDd0GZerSYDBSFDw_6_3">835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_YSWRmdUkzUaIHazYaFxI8w_6_6">3,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_FmZGYlmbMU6xFn2Ff_PfXg_6_9">2,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_z7r2wHgVwEWySeLuNTXRLg_7_3">1,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_zyfjHwfThkSuFT5tJx-SGg_7_6">1,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_UmzfDPyYr0WvYzZWyygDTA_7_9">1,118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_egEh7xJ5zkKkXUdZgUzH4w_8_3">378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_JMM9nuSfq02Jk7myAHrfsQ_8_6">171</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_L_DN_PSaRE-6xc42QBsLhQ_8_9">417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_izEZFw0yyEGAxjPozKeF8g_9_3">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_HXvdRjjhTk6WZAyKhKnwtQ_9_6">494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_kkpkD05jWk6v4pLRyazYCA_9_9">133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_D2IzcZZjwkCaH3tP_wQK_Q_10_3">58</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_Y4YMSHVdS0CF9U0svDkg3Q_10_6">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_z7iNACRsekaK_qaMeIPgCA_10_9">100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_NF3JhAIL6kSJYmLNldY4zw_11_9">51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on extinguishment of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_3J-uzJtGPUWt4GnlL9y1TA_12_9">831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_I9DoL8azGU2fd3tesc5BcA_13_3">2,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_vTIy3LWmRU6nLaR4AHVZ3w_13_6">3,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_4lEdN9xmvU6Kj5EV-CwmNw_13_9">2,673</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_gM77IFiUH0Gh9yE9KoIWAQ_15_3">9,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_9sfVhnaP9k2IzVuZDQnrqw_15_6">26,205</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_hP7lSV4Kc0ejIMmNdGZ1Aw_15_9">13,230</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_nALmxKUjzUuW0YR9fanzVQ_16_3">188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_Z21c-U-thE2V3OKyWeI9YQ_16_6">2,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_OsAf5459jUqdJ9fdzmRCrw_16_9">1,032</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_P2MZUjd430-QwiEnHB9oMQ_17_3">110</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_Pvh2jFjJ9E6N9ggcQfpdNQ_17_6">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_flxwT9BDp0aiQ9Pj3-D7ZQ_17_9">241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_lHCaBbuNUEKNi_p90y119g_18_3">414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_DHJFNLNQQUSn1-8kHui28A_18_6">4,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_hlENV_esnUe8u1dZLsZswg_18_9">4,872</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_HzGR8LKBCEmMbI3mpQUNQw_19_3">2,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_hI8MZQY3kUKrhgbQRlndcQ_19_6">2,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_-c2iPopT6keQlPjFhd0aQw_19_9">2,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_Q03VDyitW0yD2KHEY_zH4A_20_3">482</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_VZatXFbv6UG2i6fsXR4j5g_20_6">458</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_4JlQsZLGYkWZDR4hzJXjGQ_20_9">51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_pf2DiBrv6EydBbBsuTMTwg_21_3">19,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_RWZAQtfyjU6038PIaYCaYw_21_6">26,106</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_WMAL-5SdjUK55GLTcLXdXQ_21_9">10,285</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_cHnfhsSpwEyyrNI3oXioKw_24_6">20,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_LLJdejhGMEGTUNhcbq5ejA_24_9">37,835</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_b5pZhNktpkuk3kFb0_wzqA_25_9">57,835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_bM8sE3u-s0iN_gdqeaGFmg_26_3">627</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_eD3c8unPfkGtbnt5XTf9lg_26_6">655</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_BiOFjBEfkkuYUej_x6RSSQ_26_9">1,459</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_mtcOejmI9EmBKCcrZI6YHQ_27_9">53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease (increase) in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseOfRestrictedInvestments" scale="3" id="Tc_7mNmPHsl2E6CAVvTn8ZmxQ_28_3">259</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseOfRestrictedInvestments" sign="-" scale="3" id="Tc_YgCEG3cc_kiyFG7U4njQ7w_28_6">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseOfRestrictedInvestments" sign="-" scale="3" id="Tc_w-33H4bmukqiUlIRQldhUw_28_9">436</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_0gW0gfJzpE6YkIHmUtyx6g_29_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_65RYeEMylUunXgyKGzZfcg_29_6">319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_HEdF5fbwgE2pmCoD4jj-1g_29_9">109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_uB6SNRaMHka-eD1Ygj-xnA_30_3">883</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_s121caE7EEuWD8n7PwHrpw_30_6">19,952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_8ys1DQa6l0utAKTIrD8xnw_30_9">18,921</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for convertible notes redemption and transactions costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_bC1GUatfN0SJEQlwa46bvg_33_9">30,036</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_pWF97yOQJUC8RgmQU4-k2Q_34_6">215</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_XGJeSr4yY0KhXmYW76MCBw_34_9">4,086</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" id="Tc_4NLZA4wd60G0gqgUTmSkiQ_35_6">41,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet" scale="3" id="Tc_8sDs6555cEW4u8LX9Ut3kg_35_9">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Xby_shRC1kqhifmdDjbbSQ_36_6">4,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_3mKlZaAXI0uQIvfv64s2Nw_36_9">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_b2yiufwdQ0-r2ti0LEzpWA_37_6">472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_MgZeRCip3E-IqVSt9oCqKg_38_6">46,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_42upKbTNXkKqeRV7EILq2g_38_9">12,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_t9zH-jXG90K78ZJ_KDV22w_39_3">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_7vWgKsXCr0qIpXXXXUjIdA_39_6">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_5c_f2etqskCQmrogXeFbGg_39_9">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_bQ1RnnO_UUm8n-H1SWMhew_40_3">20,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_ZK_GVb4Ew0C7b7_6CrfvrQ_40_6">473</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_MUDTd0magkOxyv4h7x_yXg_40_9">20,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2018_rKMXQYZpckOR3T6wCl0-lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_W5otX0futkeI9bEA23QtKA_41_3">37,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_61sRQMPQF0WUhPtK40FU8w_41_6">17,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YqThTE3xTEOrbi6402GRPw_41_9">18,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_G_B6_vfWvk6lFtQMM7qGXg_42_3">17,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__CqDRAQ8-0aY6sqv9uL8Vg_42_6">18,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_nilYxhox9E2MOBn5CIvWow_42_9">38,985</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS </b>(CONTINUED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands)</p><a id="_ceb6d648_2733_42c0_a9c0_4f88182ebfa7"></a><a id="Tc_JHgAkaRcIUCLRuZVEDQdSA_1_2"></a><a id="Tc_p2wkm8Vv6U6frPG_8Nxzvg_2_2"></a><a id="Tc_Kzo7DYreTkmovzesGrY6GQ_2_5"></a><a id="Tc_p5J2QwKd2EWIbzbtvMVSaA_2_8"></a><a id="Tc_e5U2nV3TkkKKWAD-uXdu1A_3_0"></a><a id="Tc_owYcak6O4EOUT5kYOFOhCw_4_0"></a><a id="Tc_w-dC_qwmqEiNiG2rKw1bLg_4_2"></a><a id="Tc_tepWZbCV8Uuk1fgmN-4Qhw_4_5"></a><a id="Tc_fXxDj3Cxfkep7XttIvBC2g_4_8"></a><a id="Tc_06urlr_xf0axO3mwTBOODw_5_0"></a><a id="Tc_4irOAxIGx0OXq-pl0RcKOQ_5_2"></a><a id="Tc_IRB_tcA7C0Ki59b8pZhdkg_5_5"></a><a id="Tc_W9NEpO-bgkmwsM1LvHjjWQ_5_8"></a><a id="Tc_N1Ebl295ckKsujr0uG3Vag_7_0"></a><a id="Tc_EGfMB5XqpkurmjCoITqKIg_8_0"></a><a id="Tc__ru0-Rj-S0CYStSXyndEIg_8_2"></a><a id="Tc_4fM8-OUJwEKkRhYf6DE0Lg_8_5"></a><a id="Tc_RFoA1kLsT0OsDZlPkFU-_w_8_8"></a><a id="Tc_ImAUr9erU06--rPqJT7TrQ_9_0"></a><a id="Tc__QwuwqohNUmgdFljphW7bg_9_2"></a><a id="Tc_1kssy9mLL0mpTf1SYqF75A_9_5"></a><a id="Tc_uPuKjrCi8kyhbkL0_5dedg_9_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_CNtLcqeRcU6r-bW_7D6dPQ_4_3">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_19VFk6ExY0q21K6pevDd3g_4_6">317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_xVSPpniMkE6vlx7CFBVslg_4_9">94</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_YhQ17pd_a0Kl2CqPY4vCcg_5_3">388</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_FR22VVYbbU-ZynPzKJwtJQ_5_6">632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_HCoLDvNATECI-cypY9ac2w_5_9">309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_9OkCNIJr7EKYhtLENcX40g_8_3">4,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_1bj560mrtUO_Gjdw01jFYg_8_6">4,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_nszHcCOmGEyEzF5ehUHxMA_8_9">3,410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_820dPfYwEEOJ5dzVTaFJaw_9_3">407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_m1ix4FGc20KwcE5YnZh87Q_9_6">438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_xCWhL-5UQ0C7XNsr7J7EhA_9_9">379</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">As to extinguishment of convertible notes see Note 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_30336"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_1IC0GYRu10Ct3zHWo6lgfg" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_Rn_sD7qWH0uev5yzJTPhwA" continuedAt="Tb_Rn_sD7qWH0uev5yzJTPhwA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_tmadFwBwtEapw0Ht3eLdiQ">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_t99o9vD1Tk2cAZ4D3ibP2g">54.65</ix:nonFraction>&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_7pFGW1zRm02Xpop7-T3taw">28.75</ix:nonFraction>&#160;million principal amount of newly issued <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_b6lNSxVe7Uu0M1ENL8VJLw">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_Q4UJshBSEE6g9XE3w8sk4Q">25.90</ix:nonFraction>&#160;million in cash, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" scale="6" id="Narr_Ho2tGzEmj0yu43Xp02uUZA">1.1</ix:nonFraction>&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="INF" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_LhFxHVx56UuxHeT8hKCpzw">563.2216</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BWA4wyMFXkKaZLvGmQYa1Q">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), for each $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_uJUo4ISfEkC5vROwdl--qQ">1,000</ix:nonFraction> principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_SAjrT2E60kiZjhXqKg6dKw">1.7755</ix:nonFraction> per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfPremiumToClosingPriceOfStock" scale="-2" id="Narr_cuAm7IfIT0GEMZTp8_-8KA">32.5</ix:nonFraction>% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021. See also note 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont1" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont2"><ix:continuation id="Tb_Rn_sD7qWH0uev5yzJTPhwA_cont1" continuedAt="Tb_Rn_sD7qWH0uev5yzJTPhwA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme (agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#8217;s exclusive worldwide license agreement with SarcoMed USA Inc. with respect to PRX-110 for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its Common Stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rSbtuiUSrEKogWgpJVQOAA" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_uvX0oKF5iEGgHAa9IDnTtw">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;BofA Agreement&#8221;) it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont2" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont3"><ix:continuation id="Tb_Rn_sD7qWH0uev5yzJTPhwA_cont2" continuedAt="Tb_Rn_sD7qWH0uev5yzJTPhwA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_AUvvcJwK8kKDjzt8c3S49g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_frBP5N8g60-tlTN5T-eZsA">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_AUvvcJwK8kKDjzt8c3S49g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_INhXJHPTYkuk-TrWRxUKJw">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company closed a public offering of its Common Stock, raising gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_wcQqNw44XkOA2fgt_B00eA">40.2</ix:nonFraction>&#160;million at a price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_2ccvQgTHhk6j-x6yQ8wwJA">4.60</ix:nonFraction> per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;18, 2020, the Company completed a private placement of its Common Stock and warrants. In connection with the offering, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rQ0pbYqhgUKp9mrOGNLfvw">17,604,423</ix:nonFraction> unregistered shares of Common Stock at a purchase price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw" decimals="3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues" scale="0" id="Narr_1LQGCM2Z5k22UwhTntll8g">2.485</ix:nonFraction> and warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Cr5NjNn2-0GMpiZ-kkd_lw">17,604,423</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_eCfWiOSe20OnVfHEY1Fbww">2.36</ix:nonFraction> per share. The warrants were exercisable commencing <ix:nonNumeric contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw" format="ixt-sec:durwordsen" name="plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" id="Narr_1mJ1kiFPU0eaRuyfv6k5Dg"><span style="white-space:pre-wrap;">six months</span></ix:nonNumeric><span style="white-space:pre-wrap;"> following their issuance for a period of </span><ix:nonNumeric contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_FoyqDHUUjEuDRGbv8RP3_A"><span style="white-space:pre-wrap;">five years</span></ix:nonNumeric><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms. The net proceeds generated from the private placement were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_3_18_2020_To_3_18_2020_KfspxYy3cU2Kf_nxZFH28w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_beiTChTrH0udTM0CM9Mu1Q">41.3</ix:nonFraction>&#160;million, after deducting advisory fees and other estimated offering expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_dXz0lHVvlkiQrMZ4_xG4Cw" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_iPXwlF_w50-pxGiPcI-ORw">25.0</ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_Pg2zKzLP10KlTzFhQk5fkQ">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_DoZB7M6abkiuuNAAWTvB7w">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_LwkeyaHSLE-DJtMw52XZEg">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_RxG780a2CU2qDaCOJ6TPAA">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_b_41YkbhLEmgakzPAuDz4Q" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_jShP7PkbckuM2MFSVHB8aQ">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HHTyRmsve0-CvhM6s-xekA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_pyP7dvqcmEuN8kkcV7p4yA">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MskvE4NE_0SV-ZzLosD1-w" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_L0zGCEKooUm2Q8pfzkyTvA">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_TMhvyqD6DkCvNMBhkKseug" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_q9aMI6QT30-FSGljWqUUUQ">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r5Iht_Jc2k2j2OA7nlHKlA" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_mftACwTCf0-f-mIZ_7-YTQ">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_TPIzg0z-10Sb7x1kinz4UQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_THWbxSo63E2z6lQK7K9Xng">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont3" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont4"><ix:continuation id="Tb_Rn_sD7qWH0uev5yzJTPhwA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_gflWc2-vqEuhHmJU56LALg" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_hi0hWLqNfkG5pRm9jzxuww">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#39;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that its cash and cash equivalents as of December&#160;31, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_h5yQ0uAy3kq3Tc6C6O2bkQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:UseOfEstimates" id="Tb_F4YKuqgve0qILmWvY1p5cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The severity, magnitude and duration, as well as the economic consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_9o0IPY2-lkO_lHRcYhAfnA" continuedAt="Tb_9o0IPY2-lkO_lHRcYhAfnA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d187cc1b_a46b_4d94_9d6c_400758cd4370"></a><a id="Tc_-W1QUQcF6UOIi0AmYhIECA_1_2"></a><a id="Tc_e-hCiFdNekKv0o1a7D94qA_2_0"></a><a id="Tc_oVUovAPUOU-_hmi-QfsDng_3_0"></a><a id="Tc_-A1_dgjYPU6SRnK5q0Jyhw_3_2"></a><a id="Tc_8Q6GoBbrdUyZ_Q9MOKZBYw_4_0"></a><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont4" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont5"><ix:continuation id="Tb_9o0IPY2-lkO_lHRcYhAfnA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_eqfj0xPmUUi-idd_9R6bPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_1ry2Cmyx3U2l_W3sYA3iwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;">No write-off activity and recoveries for the periods presented were recognized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_gwquuY0Q9USjnl5i1QW54w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_3rK26UpnEkiLpAbqUXcZlA" continuedAt="Tb_3rK26UpnEkiLpAbqUXcZlA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="plx:ScheduleOfUsefulLifeTableTextBlock" id="Tb_5msa4YZByEC8RgDXKHd2vQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_NVfyMY4qKEy_rMZnOFmZmQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_cZEKwEBiqEGMj7sG4lof7A_2_2"> 5</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zzCp5Zo2W0mA_IzpPeDB8A" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_soSvnlepn0GxL8dTSvwwQA">10</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_liu81wlz_0GnnLU4yo84rw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_lFd0QHXRSUODf1j0QKdRKw">15</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lj6QlQZTj0urSG1zMHyXZg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_8FvRFPr680-4yb2KEAwsEg_4_2"> 3</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont5" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont6"><ix:continuation id="Tb_3rK26UpnEkiLpAbqUXcZlA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_tDrCieaNqUeg1s9qN-seKg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_IisAOFUj7ki8hADCU97iSw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used statutory tax rates of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_uVGroeg7jUGkxDgm63pXFQ" decimals="2" format="ixt:numdotdecimal" name="plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" scale="-2" id="Narr_2h5pBFpXAkas0TShzXGw3w">21</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Wn4pMZFBa0ulpQZlimXCwA" decimals="2" format="ixt:numdotdecimal" name="plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" scale="-2" id="Narr_9QZmOQ0ALUCGQApHY1Sxiw">23</ix:nonFraction>%. See also Note 12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_REzyQBWAnkGomdnSbViAkw" continuedAt="Tb_REzyQBWAnkGomdnSbViAkw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_1Ng5w2e0IEKgemPuDzLHfQ">two</ix:nonFraction> performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont6" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont7"><ix:continuation id="Tb_REzyQBWAnkGomdnSbViAkw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_6lru2stIUki0EXrKbkR5EA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#8220;NATI&#8221;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_BYjWl7sIyUSmL_MoP89OVA" continuedAt="Tb_BYjWl7sIyUSmL_MoP89OVA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont7" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont8"><ix:continuation id="Tb_BYjWl7sIyUSmL_MoP89OVA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December 31, 2021, the accounts receivables balance was composed of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_FiocruzMember_zNisG5sSw0exkK1iIkuF0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_XF9WDLPIf0CVKcN6Qn1ePQ">2.2</ix:nonFraction>&#160;million from Fiocruz and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_ChiesiMember_9OarDvgYGEWjO_OZkl86jg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_84-eo74moU6QKHsPvMd_rg">1.2</ix:nonFraction>&#160;million from Chiesi.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_XFF3K7wvhUG4OuHuqa-YKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock units, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for the </span>restricted stock units<span style="background:#ffffff;"> based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Options granted to consultants and other service providers are recognized over the related service period using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_1FzmkDe4yU6DdQoxRqT-eA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_GgDtdoH2q0uQV45A8KEwUg">7,838,120</ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_FiaNTOYHv0eZqDey9HVMHQ">22,850,682</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_pQslM_rm90Scz-iX__Fm8g">28,502,017</ix:nonFraction> shares of Common Stock underlying outstanding options, warrants and convertible notes for the fiscal&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, because the effect would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:DebtPolicyTextBlock" id="Tb_RslFju-R30aRwCU4UJAWSw" continuedAt="Tb_RslFju-R30aRwCU4UJAWSw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The 2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital. <span style="background:#ffffff;">The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont8" continuedAt="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont9"><ix:continuation id="Tb_RslFju-R30aRwCU4UJAWSw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="Narr_2OC-Tsvu7ketqcqBETAjJw">28.75</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2021, <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ConvertibleDebt" scale="0" id="Narr_owgQmdlGWEaLikIRz5XAkA">none</ix:nonFraction> of the 2021 Notes&#160;were outstanding.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_qeKccOpY602TWq1n4ZYWHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company adopted ASC&#160;842 on January 1, 2019, using a modified retrospective transition approach, with certain practical expedients, and as a result did not adjust prior periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the package of transition practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The lease standard also provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Additionally, following the adoption of ASC&#160;842 and in subsequent measurements, the Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_tSxv5o0VIUOV6A3EDwU_Vg" continuedAt="Tb_tSxv5o0VIUOV6A3EDwU_Vg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;Recently issued accounting pronouncements, not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1IC0GYRu10Ct3zHWo6lgfg_cont9"><ix:continuation id="Tb_tSxv5o0VIUOV6A3EDwU_Vg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In March 2020, the FASB issued ASU 2020-04, &#8220;Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; In addition, in January 2021, the FASB issued ASU 2021-01, &#8220;Reference Rate Reform (Topic 848) - Scope.&#8221; The amendments in these ASUs apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Together, these ASUs provide optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December&#160;31, 2022, except for hedging relationships existing as of December&#160;31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. These ASUs were effective upon issuance and may be applied prospectively to contract modifications and hedging relationships entered into or evaluated through December&#160;31, 2022. <span style="background:#ffffff;">The adoption of this standard is not expected to have material impact on the Company&#39;s consolidated financial statements.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_18vJHMf3l0WVQrbOQ4OzqA" continuedAt="Tb_18vJHMf3l0WVQrbOQ4OzqA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><b style="font-weight:bold;">a.</b>&#160;&#160;&#160;&#160;On November&#160;30, 2009, Protalix&#160;Ltd. and Pfizer entered into the Pfizer Agreement (as amended in June&#160;2013) pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except for Israel and Brazil. Under the Pfizer Agreement Protalix was entitled to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_11_30_2009_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_VnPnDdgZPUGYN2qTVnlGFA" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementProfitSharePercentage" scale="-2" id="Narr_Gz5CCPn5BUmtBRKjH5Ea_w">40</ix:nonFraction>% of the results (profits or losses) earned on Pfizer&#8217;s sales of taliglucerase alfa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Protalix Ltd. also agreed to provide Pfizer with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Promissory note&#160;&#8211; as of the date of the amendment, the Company owed Pfizer $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_wwXeRF1bvke94qCksDkYng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_rfWo0D5n_kiEh15QepY15A">4.3</ix:nonFraction>&#160;million as a result of the accumulated losses incurred by the Collaboration Operation. Following the new agreements, the Company committed to pay Pfizer the principal sum of the debt at the earlier of (a)&#160;November&#160;12, 2020 and (b)&#160;the date upon which it becomes due pursuant to any event of default, as defined. In September 2020, the Company amended the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_34oM70dfJ0WMj9Nuj8F7aA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="Narr_k0khXKBF3k6SXljosHCe0w">4.3</ix:nonFraction>&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a)&#160;January&#160;31, 2022 and (b)&#160;the date that the Company receives any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also provides that the Company shall make a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_XEZ5o0zCB0Gtu8ErPOcE8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" sign="-" scale="0" id="Narr_gLVttn19YkWDYNmC_fJLUw">430,000</ix:nonFraction>&#160;to Pfizer. The payment was creditable against the principal amount of the note, in whole or in part, if the Company satisfied the note in full on or prior to September&#160;30, 2021, depending on the date the note is satisfied. As of December&#160;31, 2020, the promissory note was classified to current liabilities. <span style="background:#ffffff;">On March&#160;29, 2021, the Company paid approximately </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IDSvFh3OYUGGC0HZKS46ww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="Narr_CLYl5voQx06frWXwltT8GA">4.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million to Pfizer satisfying the promissory note in full.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><b style="font-weight:bold;">b.</b>&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#8211; the drug) for the treatment of Fabry disease. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_18vJHMf3l0WVQrbOQ4OzqA_cont1" continuedAt="Tb_18vJHMf3l0WVQrbOQ4OzqA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the terms of the Chiesi Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Protalix&#160;Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_t3cZ3DfePUO3n_BPuEH9dg">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_quAg_unXBEyOkFYOkGfgFw">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_dv86yCv72kKxSnHO7AoexA">10.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_wIVZDrjO_kG2uh3Kaugzlg">320.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_9zcjXo47CkaRE7ICQLJ5lA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_VZguZPhZFU6OlYIYiwcU2w">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Wv2Wn8JO-UidVlRirC-2eA" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_G5B4EUN0HECmSsG1ZE2IGA">35</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix Ltd. will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Chiesi does not have sublicensing rights (except for certain territories).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In July 2018, Protalix Ltd. entered into the Chiesi U.S.&#160;Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi U.S.&#160;Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-TK4_F-2eE-xNEY8Kn76Sw" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_wnpRq0quZkKXmvm8FydKBA"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_gde-AQW6JEK6LG4oAXLXqg">25.0</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_Y_hjwT2CY0Grvbia1mdf0g">20.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_wR-rDXqyJki6uoeU7PfLhw">7.5</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_GPpkKY3Shk-nDZ0Ra23eyw">760.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement, which has been reduced to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_uD3PPat1MEmGE12PwGBQuQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_UZHGu5whJE6ooeaFJyIJcQ">735.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_OfZWjQmIWECye0yv_boCTg" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_HBkOJbTpAUeUqSPu8esU6A">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__EIHv6aGREKNgPGju82ldg" decimals="2" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_I74NyBH5NkKv2aAIodNUBQ">40</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Chiesi does not have sublicensing rights.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_18vJHMf3l0WVQrbOQ4OzqA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">As of December&#160;31, 2021, the Company has received, or is entitled to receive, the following payments from Chiesi:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront payments equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_VS-LUMsDV0yexHAxGQA2gQ">50.0</ix:nonFraction>&#160;million, in the aggregate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentInConsiderationForDevelopmentServicesPerformed" scale="6" id="Narr_-1ri4GLZ0EOnLpQp-kAycg">45.0</ix:nonFraction>&#160;million in consideration for development services performed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentsInConnectionWithPerformanceOfAdditionalStudies" scale="6" id="Narr_j7v0Z0sdrUevGpb9M5hwVA">33.6</ix:nonFraction>&#160;million in connection with the performance of extension studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">Payment equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_LNbEjlJnCU2reGz3EwLElw">10.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;million in lieu of certain milestone payments.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">During 2019, 2020 and 2021, the Company recognized revenues of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_sNb9nRVA7UyHg24tmVfidA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_1YvRUG-YbkK_elVjz_Wv6Q">4.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_8sWurxglp0KmGkrtptMYNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_WFlyjZlPrE2TNxY0S1UjJg">3.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_NSZLBDmXjEe-fcGdxiHsSQ">0.6</ix:nonFraction>&#160;million, respectively, related to the then $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_kaobUQfqT0ORdmCuBmiC7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_vSedQP0gMUSP_XE7zBoAcA"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_pRbaNlihhk-Mb6yk0UeU_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_j5OLIQp7jUiH2JcL0glYPg">10.0</ix:nonFraction></ix:nonFraction>&#160;million future milestone payment. The Company assessed the likelihood of achieving the milestone using the most likely amount method and evaluated for the constraint by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. <span style="background:#ffffff;">The&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_-UYZW6POc02nrytjPuH6oQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_wD_ZD5Rvk0SfJNKDF3TNzw">10.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million payment was received in June 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><b style="font-weight:bold;">c.</b>&#160;&#160;&#160;&#160;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil. Approximately <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_BR_WFR8ra7qdUO5CmDbCylH2Q" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" scale="-2" id="Narr_XvUgQbDFz02B5vrRyyhrQw">25</ix:nonFraction>% of adult Gaucher patients in Brazil are currently treated with BioManguinhos alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><b style="font-size:10pt;font-weight:bold;">d.</b><span style="font-size:10pt;">&#160;&#160;&#160;&#160;On March&#160;16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) to evaluate the production of a novel complex protein utilizing ProCellEx</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;">, the Company&#8217;s proprietary plant cell-based protein expression system. Under the agreement, Kirin was obligated to bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provided Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_3_16_2020_To_3_16_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_e7awM79XzUyuSOlCW0jrbw" decimals="-5" format="ixt:numdotdecimal" name="plx:NonRefundableFutureServicePayment" scale="6" id="Narr_KuctlX-OGEabn557fCbMRA">1.0</ix:nonFraction></span><span style="font-size:10pt;">&#160;million. </span><span style="font-size:10pt;background:#ffffff;">During the year ended December&#160;31, 2021, the Company</span><span style="color:#212529;font-size:10pt;"> completed its obligations under the agreement and the agreement expired, including the</span><span style="font-size:10pt;"> o</span><span style="color:#212529;font-size:10pt;background:#ffffff;">ption to provide additional services. Following the expiration of the option, the Company recognized as revenue the&#160;</span><span style="color:#212529;font-size:10pt;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_CflCHQ20lEaDx_EcPWhJ-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_L9IKhETzU0uLUFnWCnlOlQ">1.0</ix:nonFraction></span><span style="color:#212529;font-size:10pt;background:#ffffff;">&#160;million received in March 2020</span><span style="font-size:10pt;">.</span></p></ix:continuation><a id="_aaea0655_06ef_42a8_afdd_2523c5905b3f"></a><a id="Tc_JGiXomLaUEOlH-oVh_IKGQ_1_2"></a><a id="Tc_hKz779FYR0qv5SuphA8SBw_2_0"></a><a id="Tc_HlEdyEwBBUijTyoaUBXVIA_2_2"></a><a id="Tc_vQIvqaS670uQOCuiwH9aJA_2_5"></a><a id="Tc_H_BrqThBUEGHktpZgIbGDA_3_0"></a><a id="Tc_qBzbN_h5hk641Jhbu3_C6w_3_2"></a><a id="Tc_eQ1Pk7Cv7UuH_zEAhCWhJQ_3_5"></a><a id="Tc_dShx36qmnUelzstq3B7m5A_4_0"></a><a id="Tc_56MbMbx-T0Sc8FytZSHbSg_5_0"></a><a id="Tc_6vkBYWU5yUy0eU2kOUR1Bg_6_2"></a><a id="Tc_W3CNeiny_0Ko7yKkFb6XhQ_6_5"></a><a id="Tc_R5AXrbzz5Ui5U33IgUz8_Q_7_0"></a><a id="Tc_osu-GRPNKUmAQduiOkYiiA_8_2"></a><a id="Tc_ziHnnueIMEq4LeH9U1V0wQ_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_tBY-3Twyd02Zc_VbP2JZjg" continuedAt="Tb_tBY-3Twyd02Zc_VbP2JZjg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;</b>Composition of property and equipment grouped by major classifications is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_bMooHRtMCkWiN_nTYOcuaA" continuedAt="Tb_bMooHRtMCkWiN_nTYOcuaA_cont1" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_3tCMe8rWHUGVmPE1Vg1qcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_XQaCZR3-K0uLYmvCLCCuQg_3_3">17,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_lOmaI6ivKUCWZWzYSmOiTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_baxcm1TgxU2xUb9nmvWNlQ_3_6">18,237</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_Nn22_559OUKyhCIEmepH8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_IjcdV8JJgkiQLDsXhsiJhw_4_3">2,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_sXO4gqAD5E6e4X8EJdE_Aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_NxZ45d_B1EG1BbOnz1flHQ_4_6">2,718</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vAaunvUCaUm5Awsb6iJhXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HFmSRIDI3EicmypgSGYnQw_5_3">16,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DSmWGfJ_nUqGx4cINjjxwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_jU0Oy0NyjkOCEOaT6b2lRg_5_6">16,759</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-2SMTRj-FUmekzZYLQzf9w_6_3">36,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_jRnkxWrBSUaR3yKx41A87w_6_6">37,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_d-t99FbFp0GURax2hUEMiQ_7_3">31,923</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc__xbpGtggIUCwkG6E-5J_QQ_7_6">32,752</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qyt3p5tfu0u4-wTYyLOGlw_8_3">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_a55jhC2QJ0SpkMbdfaSLFw_8_6">4,962</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tBY-3Twyd02Zc_VbP2JZjg_cont1"><ix:continuation id="Tb_bMooHRtMCkWiN_nTYOcuaA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>Depreciation in respect of property and equipment totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_dL9J8pv0GUulqxECopDm0g">1.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_POwyAZVQRkafP8ZywDbzDA">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_5hI8bCQCeEO0xLayLo3MAA">1.1</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p></ix:continuation><a id="Tc_maVKnsTlTkaO0KozVk-Hug_1_2"></a><a id="Tc_7ArDNl0g_UCs3jhSzIaFJw_2_0"></a><a id="Tc_PKH1mFfS3USkdQCnIH6Umw_2_2"></a><a id="Tc_fVdrJrS6Ukajlg-ZxBfypA_2_5"></a><a id="Tc_zBsGRWz1tUihHgkyGdQTNw_3_0"></a><a id="Tc_B7LOxXrSLUmim_crTLEQoA_3_2"></a><a id="Tc_eIct1EmnfUiiwq6_Gmth-g_3_5"></a><a id="Tc_fM253vpRoU67jmKrkJk0lw_4_0"></a><a id="Tc_O-CBdU8WJ0KpwtBvqGG6EA_5_0"></a><a id="Tc_1BVjc85QukG2_786ST5EBg_6_0"></a><a id="Tc_f4ZzLAytn0ST--Pg4-NYAw_6_2"></a><a id="Tc_Mm6Cmcl9YEupkKyg_CorNg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_7Jb8hyqBr0eFyCdIWDIePw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;- INVENTORIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2020 and 2021 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_bmur8O0Ra0Kei2uOTCZPvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_54by2RkZA0uBxqj_lhDNEA_3_3">3,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_1sa-HniJb0mqP8_FUr2tdQ_3_6">3,166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_wbogQDui80GlmdSQARynMw_4_3">2,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_AvLT81pTJUa-YrDgaP0QGA_4_6">3,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_hrxI4U0xoEm01pU3BwbQDA_5_3">6,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_NSy5I8WwEEiH7b3bNCaafA_5_6">11,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_yKNa-xsPdE-XLM55hXb-Vg_6_3">13,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_3sJ-zUmgkUigfc1v66FsGg_6_6">17,954</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>During the&#160;years ended December&#160;31, 2019, 2020 and 2021, the Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_6eSBb1jMnkCuAwdjumhp_w">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_9OD9fRRZVkePOhyU8OfiEg">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_Bh3L-zARp0S8ULe4revcnw">0.4</ix:nonFraction>&#160;million, respectively, for write-down of inventory under cost of goods sold.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_n8KYcBBBxEeGuygynznDUQ" continuedAt="Tb_n8KYcBBBxEeGuygynznDUQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#8217;s salary for each&#160;year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2019, 2020 and 2021, the Company deposited approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="0" format="ixt:numdotdecimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_yWhh_4PNk0KT3li3Ei1RMA">143,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="0" format="ixt:numdotdecimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_kHnj3TK2TUeYY2kOa6WZ2A">121,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="0" format="ixt:numdotdecimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_QKwsl7M1iUa2rqHgaasAYQ">108,000</ix:nonFraction>, respectively, with insurance companies in connection with its severance payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The amounts of severance pay expenses were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_9DnJIaDuJEelfunB5mXQiw">784,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_8NEJD6zr4UeCPvhp95PF7g">885,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_Zq8Xm0IRGU2FvN1aYbD5lw">990,000</ix:nonFraction> for each of the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_A3AqXrghlE2r528QiP8HyA">642,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_0_XWbmV05UCW2MjiswGTRg">747,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_MQUgiSV5Gk60KLTU1RxQKg">857,000</ix:nonFraction> in the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, were in respect of the Contribution Plans. Gain on amounts funded in respect of employee rights upon retirement totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_J8LsaQh9yUSEDF-NI2c34w">58,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_Y4rKmYikP0uJnypX2j7IuQ">28,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_gA2ESE-07E-MD6NaqnoCKg">100,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_n8KYcBBBxEeGuygynznDUQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company expects to contribute approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_A2agnc-nXUWF5xH0NH47Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Narr_jxxpLr6xj0KU1shRbEMZPw">984,000</ix:nonFraction> in the&#160;year ending December&#160;31, 2022 to insurance companies in connection with its severance liabilities for its operations for that&#160;year, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_QJLt9peuMUKwXJpzAoU8Lg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Narr_4lB-18Z2cE-nimWlGs4D3w">868,000</ix:nonFraction> of which will be contributed to one or more Contribution Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the five-year period following December&#160;31, 2021, the Company expects to pay future benefits to <ix:nonFraction unitRef="Unit_Standard_employee_BN18wiEo1UyImbahotyXDw" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" scale="0" id="Narr_2Vqy6qcWpkGQbU31RIugwA">four</ix:nonFraction> employees upon each such employee&#8217;s normal retirement age. The Company anticipates that the benefits payable will be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="0" format="ixt:numdotdecimal" name="plx:BenefitsPayableDuringNextFiveYears" scale="0" id="Narr_C5Tf_ouceUaKW0grcgvCNQ">72,000</ix:nonFraction>.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:CommitmentsDisclosureTextBlock" id="Tb_15GEU8Xgd0m79do9zZnfFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;6&#160;- COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Royalty Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is obligated to pay royalties to NATI on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of the applicable funding arrangements, royalties of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_2cmmFTV-8k-KecBEkLzBtw" decimals="2" format="ixt:numdotdecimal" name="plx:RoyaltiesOnSaleOfProducts" scale="-2" id="Narr_aLfY-gOkQ0SGYzK_mCYsRA">3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_dh4fOPoiskqOmGCaGTu_CQ" decimals="2" format="ixt:numdotdecimal" name="plx:RoyaltiesOnSaleOfProducts" scale="-2" id="Narr_sgAPOSpikk6lhY2dWUbRVg">6</ix:nonFraction>% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_BNmP4P54wkaBDpMrzeAVfA" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfRoyaltiesToGrantReceived" scale="-2" id="Narr_1J0b3rTFW0qMKy33eCKwdQ"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_Wf6RC2H560WbAcJnDFtApw" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfRoyaltiesToGrantReceived" scale="-2" id="Narr_gaAonHM6NU6EkQ8KRMvLwA"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__0_D2FCWxk2p5kjrroefXw" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfRoyaltiesToGrantReceived" scale="-2" id="Narr_vQ0ew9sm1E6JA4WGQMXqcw">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>%<span style="white-space:pre-wrap;"> of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OutsideOfIsraelMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_eeNvck2ATEWfgpCZeTLqVw" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfRoyaltiesToGrantReceived" scale="-2" id="Narr_4Ddyi4rsb0ai88QUGYkyGw">300</ix:nonFraction>% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_UATsTNG3GEyx6u5IsMGjaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_MBAjH5KvJEC8J3K0juvi3w">1.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_xaWyKyysfE-N-Odg4q5ilQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_hapZyCqtSEuydII1JbxErQ">911,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_H9sLbSYtM0qsnN-27mpO9Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_q_KYxXj350ymoGlRKtWUaA">1.2</ix:nonFraction>&#160;million during the years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">At December&#160;31, 2020 and 2021, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_Wf6RC2H560WbAcJnDFtApw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_zmC81LMeFkq-fAS8_tOr_w">39.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__0_D2FCWxk2p5kjrroefXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_lUST-BAEbEWz-C6IkFyHhg">38.6</ix:nonFraction>&#160;million, respectively (without interest, assuming 100% of the funds are payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Subcontracting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2021, total commitments under said agreements were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_1SnkfDBBdEa_ScKv2fZZOg" decimals="-5" format="ixt:numdotdecimal" name="plx:CommitmentAmount" scale="6" id="Narr_gWIfQnaE9kWBkm6kGI_ejQ">0.9</ix:nonFraction>&#160;million.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb__LjrRUfmYkOnlB5nF45OEA" continuedAt="Tb__LjrRUfmYkOnlB5nF45OEA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 7 - OPERATING LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="Narr_GzPNcmTbskGHXrbj_NpWwg">option to extend</ix:nonNumeric> certain of such agreements on <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="INF" format="ixt-sec:numwordsen" name="plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions" scale="0" id="Narr_S4B1ooTj0EGMaWqIiK-9gg">one</ix:nonFraction> additional occasion for an additional <ix:nonNumeric contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_ZE_w1OGdIUOyZuZwzo3yBA">five-year</ix:nonNumeric> period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_-QuyUNmrLkKtu3HAPB64rQ" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_eTOeRJDvvkuD06zWBUrj0A">7.5</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_TGSo8Z2q4UakwLgn9fGO-g" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_N8cEUsaMS0-y2TT1uH5OuA">10</ix:nonFraction>% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2021, the Company provided bank guarantees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_A0R9-9cxk0iW3IPJ1mvJsA">496,000</ix:nonFraction>, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8946ca28_4ca3_40ce_8e86_26661032a679"></a><a id="Tc_LMLcu-VyPk63hwQnarJ6VA_1_2"></a><a id="Tc_a4AN6SHvPkikpyoIYysSMw_2_0"></a><a id="Tc_lDVoUjHQfUK6e-0TKRDdPA_2_2"></a><a id="Tc_DXrIiq8IfEaEjE9i3mAT5Q_2_5"></a><a id="Tc_s4kdh8XJqUeR0-unRYlkGQ_2_8"></a><a id="Tc_0hB74k6uZ0Kiq3HyLr3XcA_3_0"></a><a id="Tc_6Z3PqUODK06coM9agiES6g_3_2"></a><a id="Tc_giuln91JNESZzDLB1wN1vQ_3_5"></a><a id="Tc_h7-wzGZ4KkSJO-CHOJmASg_3_8"></a><a id="Tc_RhJC9mc7n0CNBSb3tepH1w_4_0"></a><a id="Tc_N0hM9OuMU0e5D9onQjA7jA_5_0"></a><a id="Tc_tIqXQK_f_kWdw2hxjrO3SA_6_0"></a><a id="Tc_U0Y6T3mYJUy08-L-LggJmg_6_4"></a><a id="Tc_XQZCrauETUSPtu2S6Wx4QA_6_7"></a><a id="Tc_AkC6RA83JUykQKmMn0tfOQ_6_10"></a><a id="_b58a8809_660d_4181_8b1f_66ae75a25a5e"></a><a id="Tc_jKsQ26TF502_O7H6_zw06w_1_0"></a><a id="Tc_eVNEEfo3OUeTvUEHMAbkIQ_1_2"></a><a id="Tc_gUHb4ZojKU6j0nem83sA5g_2_0"></a><a id="Tc_6--U88N_00yDz9q_aFtpHA_2_2"></a><a id="Tc_aM5_CpRBU0C0B9uhsC-ZIA_3_0"></a><a id="Tc_qqDalIMmkk61Z2R3SyQOVA_3_2"></a><a id="Tc_2S3Z1RFqoUatY2OCq2Nz4Q_4_0"></a><a id="Tc_3VFkHxGMrkKE2TU7VZ547g_4_2"></a><a id="Tc_k8yNlq1VukGoOfOtN987ng_5_0"></a><a id="Tc_hLntxcbG80Shm6dyXP6H3Q_5_2"></a><a id="Tc_mkwoxMag5E6X2xRr_K6I1Q_6_0"></a><a id="Tc_VDGDm_GZEEqTzA5Oh8h0kA_6_2"></a><a id="Tc_bdFk93VSX0q0Wfir7kshPg_7_0"></a><a id="Tc_Xw7zC7BnuUmExzVGCuJCjg_7_2"></a><a id="Tc_A0Lud5IlPkKHrqhMpkhovQ_8_0"></a><a id="Tc_lI2DviiWzE2J3WP4bbDfTw_8_2"></a><a id="Tc_bq0281qlxUiDNfUuvXoKrg_9_0"></a><a id="Tc_Uatir8ao8kWaHyhfNcI4hA_9_2"></a><a id="Tc_BM_OpjJiX06ZIfGqVsF4og_10_0"></a><a id="Tc_fkKCL57xOE6QT76x6Tyt3g_10_2"></a><ix:continuation id="Tb__LjrRUfmYkOnlB5nF45OEA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company entered into several <ix:nonNumeric contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_KBRPKEthI0WlOxB3RgGCwg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_IcNxbgG-hUGosTupk_Bn6g">three-year</ix:nonNumeric> leases for vehicles which are regularly amended as new vehicles are leased.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:LeaseCostTableTextBlock" id="Tb_bwXIokJoAEOmGjojuMMcdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2019, 2020 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_oFtQlIlgSEiSQLcw0ZJWdA_3_3">1,219</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_WkGKeXHpeEus-Aj4mus4Tg_3_6">1,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_z6G2GvZ_eE6EVZH9BXvUuA_3_9">1,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_EQviyuIYx0yFvngBaI6XCQ_4_3">1,329</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_RlJbNq6g7kCkdmWmFJPsLA_4_6">1,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_gkeLl2EDn0OU9hAKzUQa4w_4_9">1,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_EVl31LdplUGbM6mbWPrW4A_5_3"> 10.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_tw45Doct1Ea4IMVuK2IIyw_5_6"> 9.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_8dP48qTZpk63j_PKQZqPcg_5_9"> 8.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_3V2-GXsHeEO98BecluLJmg_6_3">12.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_0H0UEcXUCEWmUT3_AVY91g_6_6">12.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_rEoXoD5gE0muXS6042Kyqw_6_9">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_O3O7zCCMP0SMN4LQpeQ7UA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_ferQiJuzXUqMkLP05woaeQ_2_3">1,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_51aa7BdbvkSRi-AzadK4TQ_3_3">1,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_OVLyGq3pMEu4yJ6_dVznbw_4_3">872</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_JalRO_D44UaoFxc44pbw4g_5_3">853</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_w_bXYCEuEUGPjxF06N5rHw_6_3">848</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_mZZBgw74XUW2ieMGMwWJqw_7_3">4,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_vvN30INWzUaT6k5rom_3XA_8_3">9,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_qH8FRIUrNk-xm03Mv-W6xQ_9_3">3,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Present value of  operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_-NaYWczdkUmuXgSRbQetWg_10_3">5,583</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_7ad1ee60_934f_4593_93cf_de1bbaae52b4"></a><a id="Tc_AIZJO0H37UKJ261MeF5uUQ_1_2"></a><a id="Tc_M2zMVexcKEiuIlN9Ul-DAg_2_0"></a><a id="Tc_lEkjl6naCUiuBoVcHD8nwA_2_2"></a><a id="Tc_CcsDGmMyx0egu1Uvk0Ln6Q_2_5"></a><a id="Tc_HKan_hnjr0aJ8Or9U9wXXg_2_8"></a><a id="Tc_qZboWPXUvUekRintEL0kcg_3_0"></a><a id="Tc_IMvbIakiRkKx1ntN5xDfZg_3_2"></a><a id="Tc_vwd086P98k-RK2OhTiZocA_3_5"></a><a id="Tc_omg1bpdVnka4xBUvTbsp2w_3_8"></a><a id="Tc_y3NQ48-PJkaLhqJiPLk15w_4_0"></a><a id="Tc_1y5EG3Q3uUyWniaCSAqvQw_4_2"></a><a id="Tc_l1dy6pI_DkGhKZQTT8jTXw_4_5"></a><a id="Tc_HRjg9sTDEUqH3xkVGt6ZMw_4_8"></a><a id="Tc_Ne5OQ0fKvU2O8cfYU82xsA_5_0"></a><a id="Tc_QkqH7AxkW0WknCIdnLMKOQ_5_3"></a><a id="Tc_AoiaUYXDhkSPRPaRPOloIA_5_5"></a><a id="Tc_uLSMewSMcU6wURuf4tVYag_5_8"></a><a id="Tc_WO8UYjUuuEupr-7Wri49Zw_6_0"></a><a id="Tc__q0RfCr1bUmrUdO-UFX6DQ_6_2"></a><a id="Tc_OzGDNVnveEWyvxd0mi-k5g_6_5"></a><a id="Tc_BE5_fUv49k2NPZ7m90wyEA_6_8"></a><a id="Tc_Aftj1COhcEmXsrVYT-1wxg_7_0"></a><a id="Tc_w-QJCxDFkUiRFDRkrejx-Q_7_2"></a><a id="Tc_NWn1jxKxt0CbYemkyesbrA_7_5"></a><a id="Tc_jwhXcW41UUePJWYohKIISQ_7_8"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="plx:RevenueDisclosureTextBlock" id="Tb_bB-DZX1nSUu-RPn0DF9iTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 8 - REVENUE</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_6XHq4pb4E06pNsyHNjj6MQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_DKnjcKFjmUa1np2ibVNGnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_WAxozEyon02rZe-cauE7Ww_3_3">6,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_M2UVRoW7sUyno7XdY9wpow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ONtFQUYm00GzEEcrsRMwhw_3_6">8,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GBgSGz6h9E-afGEP8417zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_zUHPMnyzeEeVlmrSq5unIA_3_9">10,160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_EbYkt392okObFSFj3u7OvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Irw2YwlLDkeMCtZXaieivA_4_3">9,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_ZsU_oN8S5kKt5laU31Nl6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3gHIBQ0DU0-zxSNH5lFLNQ_4_6">8,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_3pw1DQ5CWkST8Aba5KMVVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Jfs4NeFlhEWAStIQ0BKNhg_4_9">6,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_OZABD-Gv0UisMJYQyGNklQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6Cwo294NsU6SXCjhPCtcKA_5_6">131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_VZS1TwgN7EWajbs4tfYp1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vilV6cFHgEaWa_sAqfUS6A_5_9">189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_HmzXf1hdDkK4__n1knviHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bmKY_X0AdkujCP-ACiU03A_6_3">15,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_8B8k4Z958U29kvLCfB2P5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_a4molZDSAECVkQciiPIDAA_6_6">16,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_tr53Np7eY0-Ae6xS_WOJOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc__nWjiPYzCkSTdnSv0woQYw_6_9">16,749</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ePa1ql7mhEGcbcjaQMVPmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_e64DcXCuDEG5VfEiB_ryFQ_7_3">38,827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0sZc2uezPU2o1oMeQcRe9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_UnpBeEMpEkajAEEulotLrg_7_6">46,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_T30NLjS9gUG6T5IRwHFs3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9rxtUsVsKEWaYM6xbU3uMg_7_9">21,601</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the year ended December&#160;31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_KyuNtueviUGlU8z74VbRMg" continuedAt="Tb_KyuNtueviUGlU8z74VbRMg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;9&#160;- SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Rights of the Company&#8217;s Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s Common Stock is listed on the NYSE American and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_MK3JtZwR6kijibu1mfvLvg" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="INF" format="ixt-sec:numwordsen" name="plx:CommonStockNumberOfVotingRights" scale="0" id="Narr_rXKj9Qi8Rk-kLcblA-c0uA">one</ix:nonFraction> vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Reverse stock split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;9, 2019, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to, among other things, effect a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_bjDxAD1NEUOlk5FvFvWGtA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-ten</span></span>. The ratio was determined by the Company&#8217;s Board of Directors on December&#160;5, 2019 and the reverse stock split became effective at midnight December&#160;19, 2019. All share and per share amounts included in the consolidated financial statements have been adjusted retrospectively to reflect the effect of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Stock based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_JcT2p0tnbUqhmhTyDLIICw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_I42gjmTyt0-IkW9RhaBcSQ">5,725,171</ix:nonFraction> shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;<span style="white-space:pre-wrap;">102 and 102A of the Israeli Income Tax Ordinance. Each option grant made to an Israeli citizen  is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Israeli Income Tax Ordinance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_3wIocETWo0W_f9BIySjLlQ">1,786,256</ix:nonFraction> shares of Common Stock remain available for grant under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For purposes of determining the fair value of the options and restricted stock unit granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the three years ended December&#160;31, 2021, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4d5076e5_c0e6_4ce8_889c_f3c7eee17cdc"></a><a id="Tc_AEuP0zeykE-CGedWm47E7Q_1_2"></a><a id="Tc_Ix4b13Y7W0WfTgaPKOzomA_1_9"></a><a id="Tc__nfaNz1HpEapquZmx5qqmw_2_2"></a><a id="Tc_NTgXNcsQOk2bIP5790dkKw_2_4"></a><a id="Tc_v4ldK2FHe0KIsFRb0BUPXw_2_7"></a><a id="Tc_r0L9vNrpPk-FoZA7xudBqQ_2_9"></a><a id="Tc_75yJVL2D40GPNJqbzQX73A_2_12"></a><a id="Tc_Kj4mAzp3CUuH-lKli_ufIQ_3_0"></a><a id="Tc_oyiPMlz-vUSZRLuPLjHEwQ_3_2"></a><a id="Tc_BnRfbIlb4kW2OlXxZTfGog_3_4"></a><a id="Tc_4dsuLcsJlUaSk9JJ5mV1Rw_3_7"></a><a id="Tc_WCdKDkCSpEWC8ersu_qkJw_3_9"></a><a id="Tc_5d0x3Nxu6ESffDK05WnDWQ_3_12"></a><a id="Tc_2nP6Q_SoN0qnL2sCIdBhzw_4_0"></a><a id="Tc_yp34xbPZBkqfoA6i_SlCmA_4_4"></a><a id="Tc_D7i6mEpUOkeQzmcWFyHeNw_4_9"></a><a id="Tc_eaaUkM8wOkS2UrwadV9c-Q_5_0"></a><a id="Tc_hbq3TmLGr0um3P8sPh1idw_5_4"></a><a id="Tc_yVSAspaOEkmMDxmydqeJww_5_9"></a><a id="Tc_emJ6oDlcikucowHu_A6IOA_6_0"></a><a id="Tc_M2oohwuAWEukCmH9A9dlHA_6_4"></a><a id="Tc_ekZpVcRY5UWGtBvg6pJCSA_6_9"></a><a id="Tc_PjZXPI9bBUu-GP46Ct38Mw_7_0"></a><a id="Tc_X0hs8uzd0UWKH7xuz3n03g_7_4"></a><a id="Tc_CeWph6hCxkulGCPfePLfpw_7_9"></a><a id="Tc_Y66i2NPCg0GUdAWzBZVeRw_8_0"></a><a id="Tc_Cppk0Q5-R0qZItJSCwsBPQ_8_4"></a><a id="Tc_9oYjZKNa8US1R8w82CtPMQ_8_9"></a><a id="Tc_E8JSlJA-30-3sCsNd5iOcQ_9_0"></a><a id="Tc_CV1DRPDs30K87LV5mVxAYw_9_4"></a><a id="Tc_UHsVd0Br_0mezNxfSLtfbw_9_5"></a><a id="Tc_egP_A2ahEUeKgS4OC_BLrA_9_9"></a><a id="Tc_Xrop2Z7BRke_i7UqKUZqXg_10_0"></a><a id="Tc_9NpRmhKy70GWwfyW58j--A_10_4"></a><a id="Tc_EX5wmRJ6BU-rlV3rifFIFg_10_9"></a><a id="Tc_RGl-QTS4-U6-cJ4-Xw1KlQ_11_0"></a><a id="Tc_bKDz76oWL0yiYxXKDvmX-Q_11_4"></a><a id="Tc_bnoXBcOluESOeytjp9xnag_11_9"></a><ix:continuation id="Tb_KyuNtueviUGlU8z74VbRMg_cont1" continuedAt="Tb_KyuNtueviUGlU8z74VbRMg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options and restricted stock units granted to employees:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;">a)&#160;&#160;&#160;&#160;Below is a table summarizing all of the options and restricted stock grants to employees during the three years ended December&#160;31, 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" id="Tb_bWfhJoDwEU2hRstj_AZZqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">No. of options or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">restricted stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vesting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;grant (U.S.&#160;dollars</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year of grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">period</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_6rHcn90F30ei0Nk7bjxL-w_4_2">160,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_mWdh69YR_ES6XctO5KXbog_4_5">4.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_oUVEL-s7KU6DDyXUy3EVpg_4_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_RzJRTxQNVUyCZrS9EnncRA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_kwGkMV8h-0qB1Jj4TxnZhw_4_10">449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_H3yxy9l5OU6z_PZpby0xpg_4_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_D4D0sIib-EKSWhmr1U863w_5_2">80,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_y8ac_YRWHkCOWAHvdOZDiA_5_5">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_7jHujwWrUkS0AYlWf9I6cQ_5_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_Pgw8cC8LGkmkSDN1ikOZrg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_2CZb-Tz7w0K3S6SgAsSN5A_5_10">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_kHOOnSEzqkeKFKkgm48dew_5_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_KmdDdkF6ZU2RDeeEmnsaGg_6_2">196,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_-6P3alzTbEC-_BbJo7Oo2Q_6_5">3.59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_cQoPWedz70-zSoHfraK6fw_6_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_z5fjaYB3Vk6_8J6_3XOy1w" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_5Fb9Faai00iGrbgb8-VxEw_6_10">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_J_-BcGr3qk-IxcqDBc4v8g_6_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_PND5IfSzS06QeHne_fjBMQ_7_2">760,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_aZ8Ie5gjn0GeeoxJLXw6NQ_7_5">3.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_OD_nkzjFiEmz4agncRg2Rg_7_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_N12CUuFMQkiGURk7lpa5rA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_TotbdKmqTUyacupCXVU7RA_7_10">1,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_eJzd8g6keEWDZLfEovuDfg_7_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_nCAXi_iTN0uIN73fmF6GUw_8_2">129,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_AtTd458vXEmvZPYIFw_9Kw_8_5">3.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_mwGfFpO_j0mqDoR4lt4cUg_8_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_14Iut1EZ1UWck-v0gKCugw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_Zlt02sIlBUqLg5FVLsGGdA_8_10">329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_sYcYK8GcTkuGQDS9Kevk8w_8_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_4AtJzRR5aUivny6jFmZmKg_9_2">694,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_gCX34f_tF06J_ZP_GWGldA_9_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_sXjLs1UWbk-sYqhuiYE3qg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_H-xFCB3qjUWkR89sRTUjfw_9_10">2,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_sxgadNSvTUeRGfClRwAWJw_9_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_AkmHGE8H90Ge-cyGOifbpA_10_2">122,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_OfBL_9s1cUynUV3EiHNWrw_10_5">3.59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_g95KoZpfWUa9MgSnetZL6A_10_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_7pabyZcaV0G2hX0lA_wo6Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_Jla91kOhL0is1QQ5ruEMFw_10_10">299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc_sq4YVOqJYUWqp6AJJGzwSQ_10_12">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_KHN4zj8-hkuyHLNxI57BRA_11_2">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_mrsjbvfKOk2a_bWHWM41lg_11_5">1.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Tc_y4w4nuheIUSVZjJ8h2qVIQ_11_7">4 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="3" id="Tc_58r6NNh2HUerBGb-Ns-7ug_11_10">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" format="ixt-sec:durwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="Tc__CTXWMkvakeJyUc39efNqA_11_12">10 years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December&#160;31, 2021 (a portion of such grants appear in the table above):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In June 2019, the Company granted to its Chief Executive Officer <ix:nonNumeric contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_UiloDaQIwUGsUD3bPKB88A">10</ix:nonNumeric>-year options to purchase, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_XjE9FP5VCkSEsbzdiNsZ3w">160,000</ix:nonFraction> shares of Common Stock under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_f5S2EclrhESlhwpzU7z_JQ">4.69</ix:nonFraction> per share, vest over a <ix:nonNumeric contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_oskFULVPKEmtgNuZNA3qOw">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_074Ux0ChHk-ViFEcoUiZ5w">16</ix:nonFraction> equal quarterly increments. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_usqDohRTvEGNiiLQo4s6FQ">449,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_H3iws1NHT0CVxlREm745_A">4.69</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_Si8fEi_w20-kY0guW7LdNA">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_F86Wmy0GFUWs7z2VfJN-4A">65.3</ix:nonFraction>%; risk-free interest rates of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_TM3qH91fykaoduLnbSOU8Q">1.8</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_FmDRiYLVtU6IFSRlnOI9UA">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In September 2019, the Company granted to its Chief Financial Officer <ix:nonNumeric contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_SZfzdpkQ5U6MlNpdP2Y4kA">10</ix:nonNumeric>-year options to purchase, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_O5X5Tq-hwE2yzWa8ooDWoA">80,000</ix:nonFraction> shares of Common Stock under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_5qVCbuO9AEWYJ1672Ytvlw">2.00</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_shp8G6Y4wUChh0G12mubog">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_sgonKGGfHUaxR3pmYGWoAg">16</ix:nonFraction> equal quarterly increments. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_5Stm_GCkDEm7f81TdoYqUw">97,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_K3D4OPcc-E2XByylhFX79A">2.00</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_DzPpMWwCKEiZa_rlQ0V0yw">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_DUECFB-l3kmFrR0DicVkEA">66.48</ix:nonFraction>%; risk-free interest rates of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_WMZlRZEIyE-IFhiadnkFnA">1.695</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_TpXeZOvhVUuV84AwV5Rtzw">six years</ix:nonNumeric>. In addition, contingent upon certain conditions, the chief financial officer is entitled to a grant of restricted stock units with an aggregate value of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iKUFwyX_yU2n3k92ORA_uw" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" scale="0" id="Narr_bnZpCFo9OUqAcPiib2Edyw">100,000</ix:nonFraction>, on an annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On August&#160;11, 2020, the Company granted the following:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_S3_j-9Z9DE6wK3rshPVF8g">447,927</ix:nonFraction> shares of restricted Common Stock to its President and Chief Executive Officer under the Plan. The restricted shares vest over a <ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_haFVA-Ua9E-Qe6lbf8IIaA">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_a75hRMCGBkeJx1cTubxLxw">16</ix:nonFraction> equal quarterly increments and <span style="background:#ffffff;">are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control</span>, and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VF0OGmePw0eTywhYkjcUPg" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_K6UilgE8nk6qfpUGggL0fA">1.6</ix:nonFraction>&#160;million.</p></td></tr></table></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KyuNtueviUGlU8z74VbRMg_cont2" continuedAt="Tb_KyuNtueviUGlU8z74VbRMg_cont3"><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_H2ruHNJkEUWXFyEcwEgTJg">246,146</ix:nonFraction> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. Of the shares, <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_M8ski3P7vkqI4q67BPAWeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Narr_W9skiDb76EyMaTHZk0a6-g">27,855</ix:nonFraction> shares vested on September&#160;22, 2020. The remaining <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_mmHdbT-en0uuXTv2hCvVNg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_6bbH23qJX0-GYUqW3H6j6A">218,291</ix:nonFraction> of the shares vest in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_qI4Ltgwg6Eaqs8giG6of8A">16</ix:nonFraction>&#160;equal, quarterly increments over a <ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Lowr2D3vrkieYm8_o99tJg">four-year</ix:nonNumeric> period, commencing upon the date of grant and are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_mmHdbT-en0uuXTv2hCvVNg" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_22elLf9MEUWGNXUJa2Cw0A">900,000</ix:nonFraction>.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_0FaEZyviJkiWt93G_aqDzw">10</ix:nonNumeric>-year&#160;options to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_EGZrrW2_IE62pmcdTi0kUw">122,656</ix:nonFraction>&#160;shares of Common Stock to the Company&#8217;s Sr. Vice President, Operations under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_ZeAZOugfak63oI2bZEDzlw">3.59</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ptrLFeber0KAw-499JHMXg">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_LSFDZX0CxUWqDHgEriV94w">16</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President, Operations are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President, Operations to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_OwEwPCiTUUihphonbnPW2Q">300,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_LTPEK7_BSEi6GamhWJmUKA">3.59</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_o8g1T8bhekWO0iQz05zn0g">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_zerdtOs7d0irjnsrkkE1Kg">80.51</ix:nonFraction>%; risk-free interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_mQB1c5YsbkqupgVT9cVwnw">0.365</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_uRfvxtxI30-d4f2drIQ5Eg">six years</ix:nonNumeric>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On July&#160;5, 2020, the Company granted <ix:nonNumeric contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_zgNrTlj1L0Ckr6vSVBFaLQ">10</ix:nonNumeric>-year options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_MDEQVquA-0SfnX2hL8qPbQ">129,771</ix:nonFraction> shares of Common Stock to the Company&#8217;s Vice President, Research and Development under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_XBvUE1X8pk-qKuRM_IdTyw">3.73</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_sXd7WFJdTkyMBh1g2HCR3g">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_cO8YK6-AWEm9CdBXbtuIyA">16</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to the Vice President, Research and Development is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_-xC1CQGDH06ZkFThryPnbQ">329,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_ipQ6xw8uuUqeXeYQz__Mig">3.73</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_H06_XTPshUq3fF2bl1kwMw">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_JA9-UqnyQUiw4xbvLIyhsw">80.60</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_hB_5Zd3g4U6VOl8PJjWPNA">0.395</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_-X3BHHJVw0S5NvjIKWWvug">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On June 7, 2020, the Company granted the following:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_qvoaDj-PyEiN4Lziey2_jg">10</ix:nonNumeric>-year options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_0wpAH6pzwE6Ncn6JC7dW1w">196,995</ix:nonFraction> shares of Common Stock to the Company&#8217;s Sr. Vice President and Chief Development Officer under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_tuBYbPdbkECWNKPFieIrRw">3.59</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_gBWbgjSsnU-nLjY-_wzT5A">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_WfpGw9e2bEeyNt8u0o3kGA">16</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President and Chief Development Officer are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President and Chief Development Officer to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_wAaeelLeoUadU-c0CVfdnA">500,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_vzn-CF3R3kqbxhim-7a-pA">3.59</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_aESJSA7kzE2yJoyCCUISSw">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_coHONNTkkkalY7D8Yt3rSw">80.43</ix:nonFraction>%; risk-free interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_wsCpLEQOSEutS45T8G1tSg">0.59</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_gDuAofSa-E2yHq5bAChkQQ">six years</ix:nonNumeric>.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_0LstWmKk7EWQ5k4UeceZnw">10</ix:nonNumeric>-year options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_KA9_TTHARECtZf-jHUSoCg">760,311</ix:nonFraction> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Plan. The options granted have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_Mwi7Ak2WuE2oobRzpvpbPg">3.66</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_XiukU4qhIEqj5F0OPbsGhQ">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_dop5At0R5UeoAmRhdBC16A">16</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes </p></td></tr></table></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KyuNtueviUGlU8z74VbRMg_cont3" continuedAt="Tb_KyuNtueviUGlU8z74VbRMg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 108pt;">option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_mXHhvVuyXEClu4l6lNKgtA">1.9</ix:nonFraction>&#160;million based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_c4DyGKhd3kOgatIZlrty_A">3.66</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_vynQRq_z4EGlHYwaF1BcJw">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_DBPl3KjFpEqBTA3lijcP_Q">80.49</ix:nonFraction>%; risk-free interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_GDRhWk_Fu0yw68n9Tdzxzg">0.45</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_ggtrmyVrCU6PnxyMvyn4Ww">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On July&#160;25, 2021, the Company granted to a new employee, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_9l3sMQOxukmqvT_u04Og8g">10</ix:nonNumeric>-year options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_YJE75F9iuUOghE5DUFtL4A">50,000</ix:nonFraction> shares of Common Stock under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_DZ2uCbwFBEOFF6DXhvS3lg">1.57</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_kR7R8EpuBEKuSuP4MfnJXA">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_1FzjC4ANa0ir9Xr3FGaGAw">16</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_eZizp4cm6UWC__X503NjsQ">55,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_ovLelHT60UyCXd-pArrR3A">1.57</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_EezNP9eiiUmtVwIfA0fOmw">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_PSVtKQKQik-LlFEKKwRa0Q">84.30</ix:nonFraction>%; risk-free interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_uRAIuGZpMkqMtv81jU77Ug">0.88</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_8R7zH43jyEuQM0R8gr6szw">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b)&#160;&#160;&#160;&#160;The total unrecognized compensation cost of employee stock options at December&#160;31, 2021 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_sg4luUzTw061uzoDzAKSrQ">1.7</ix:nonFraction>&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_t7ogRQCo-EaZfrjUBfVQ3Q">0.9</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">During the three years ended December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2019_To_12_31_2021_G69dnyWX7ESLQI7Zi6Aa7Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_e37CWWL2BEy1wZ0_f0SgVg">no</ix:nonFraction> exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options granted to directors:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On February&#160;3, 2020, the Company granted <ix:nonNumeric contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_vdNjIkTywUK9dlRSNNVA8Q">10</ix:nonNumeric>-year options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_lJQqQZmGSEW2j-a_E_hPjA">240,000</ix:nonFraction> shares of Common Stock to the Chairman of the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_1AIaMeXtREaoAhMO5RYtEw">3.70</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_wtCs4p3w40-ap-2rmOwNxw">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_MQRrXr9L0ESXagwMGVfRuw">16</ix:nonFraction> equal quarterly increments. Vesting of the options granted to the Chairman of the Board is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_ozOeNu766km-9VgmWNJdmQ">593,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_n2_gNNuj6UuoNcRfi2mkeg">3.70</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_MWEojIkBE0asaHcvZGbLjQ">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_X5e6ZYrk4E6xiJkII1mmBg">76.91</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_2oeOWO1GiE-w6Wa3TQkacA">1.4</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_l4L5WleICkeAw5HC5K0uag">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On January&#160;20, 2020, the Company granted <ix:nonNumeric contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_Ic111ZbgVUuvnA5Z43Q14g">10</ix:nonNumeric>-year options to purchase a total of <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_6aRdO3voVkek1sE17bV95g">200,000</ix:nonFraction> shares of Common Stock to <ix:nonFraction unitRef="Unit_Standard_director_yAcLdDF3PE-23pSbigEjyQ" contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfDirectors" scale="0" id="Narr_B-0Yv-guiUqrraUxj2ikUQ">five</ix:nonFraction> of the Company&#8217;s independent directors under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_m_1tQ8fNOUiXb44bQLEeCA">3.55</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_VUvUmuXfzkmt0-cfqHmgmg">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg" contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_NKVSuZI8N0esQgkAqVXgpw">16</ix:nonFraction> equal quarterly increments. Vesting of the options granted to the directors is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_CTD3nhvfL0qQEv83Fm2tYg">475,000</ix:nonFraction> based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_S7zEiHpJb0a_ZvRX4uwvIw">3.55</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_pMYxLEc5Xka8wZ4FoR03Fg">0</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_fCmcXUBpAUC64xS52IKUkw">76.62</ix:nonFraction>%; risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_EQ1IyjuSo0yrgZoRxAnUsg">1.685</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr__0kI80O5_kCoeyFG6IWToQ">six years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">3.&#160;&#160;&#160;&#160;A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the&#160;year ended December&#160;31, 2021, and the effect of share-based compensation on the statement of operations for the&#160;years ended December&#160;31, 2019, 2020 and 2021, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b9d3babc_8f5a_46a1_9926_f04ce0a24d59"></a><a id="Tc_Br4IRpCPlkW38wsYXkxidw_1_2"></a><a id="Tc_N6QTBDQd0ka423wAD10CRw_2_4"></a><a id="Tc_7jL-3sdh_k6XPXfb2FodaQ_3_2"></a><a id="Tc_HLnf54ARRU2yTyuSxUHIig_3_4"></a><a id="Tc_9jT3jCyhWkSRcfUPwHb-Tg_4_2"></a><a id="Tc_RskPUxkCyUSancYT8ECkgw_4_4"></a><a id="Tc_y-hECGj2r0KY9NN1BYlV7w_5_2"></a><a id="Tc_GNLFPp6eK0WZvtMI9vq9iw_5_4"></a><a id="Tc_MNoajusGNEuhy2kooSWR2Q_6_0"></a><a id="Tc_fCcozl7fpUeNXvFK2KjZuQ_6_4"></a><a id="Tc_SnzvF4Z-tUOQ4LPKZT24VA_7_0"></a><a id="Tc_J9h6h1Sti0-V1Nv8mkzz3w_8_0"></a><a id="Tc_4N864z5RKkaOcA2_9XgN7w_9_0"></a><a id="Tc_WHTMZCJbAE2OhbJpQh-aLA_10_0"></a><a id="Tc_7CvxCFg_IECYif45lgCCWw_10_4"></a><a id="Tc_X-4nNayHr0W4mI9uVSi7Wg_11_0"></a><a id="Tc_p55Xjo1-akarKrOcdJvvuQ_11_4"></a><a id="_c9a0d936_23be_4d46_94b0_b360b26e53aa"></a><a id="Tc_NQOCUoPt4U-f5jFw5-Tn0A_1_2"></a><a id="Tc_TNzmugnFpkybseFIrtXb0g_2_2"></a><a id="Tc_qP4tBubv4UKJuSiAVNjCDA_3_0"></a><a id="Tc_Uihc13Jpd0OfIoonx1H30A_4_0"></a><a id="Tc_EloLPb-2cEya0ezgjtn2TQ_5_0"></a><a id="Tc_DBRajwMn-EutRRmFoGPx_g_6_0"></a><a id="_534d90bb_f835_4a05_9aa6_6d8fe6a4c0f0"></a><a id="_75006a0e_e4af_4364_99a6_2f30b45fe15e"></a><a id="Tc_VlfjI8F9SUuzdHSJUxfqBQ_1_2"></a><a id="Tc_q2CXFxaIxUexdHRqWfvY0w_2_4"></a><a id="Tc_gQQC97JuUk-tT6DTzJVj1w_3_2"></a><a id="Tc_NXieiVTLCEy8aviWz47Aew_3_4"></a><a id="Tc_aKCSq4Rd8UKotyEjLAIuYg_4_2"></a><a id="Tc_i449r6FS4EeqLAh9KxueeQ_4_4"></a><a id="Tc_qi1bgHNWB0ealwAu5318Pg_5_2"></a><a id="Tc_0b3cA8vR2Ump1EqixGAB2Q_5_4"></a><a id="Tc_6tP7HbB5_EORBXdAiG2H0g_6_0"></a><a id="Tc_RCkDyPdF0UiYw6kGE0iwWg_6_4"></a><a id="Tc_8rDTXD20SE6iH24kJ7XcOw_7_0"></a><a id="Tc_H2xHeh_u7kCsO6qhKfRC6g_8_0"></a><a id="Tc_AAeO2LkMUkWEQWhGuju0jg_9_0"></a><a id="Tc_ENBlKM2AKUOP0DJzffkHNA_10_0"></a><a id="Tc_8o23Z3cAgUygi2GTs6hmEA_10_4"></a><ix:continuation id="Tb_KyuNtueviUGlU8z74VbRMg_cont4" continuedAt="Tb_KyuNtueviUGlU8z74VbRMg_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;">a)&#160;&#160;&#160;&#160;Options granted to employees:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_iqAsZEGu-kah8XJEHVfbaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_jjzSYAqs50yz-gvCo7Kh8w_6_2">2,087,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_bEQ2b36DBkadQmra7vTKuA_6_5">5.66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_75Y_qY4n9Uaiplk0PJs_ow_8_2">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_PIKXNP7_xkmszQWHUf4uWQ_8_5">1.57</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited and expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_ITo57doiK0ODe97SEsxipw_9_2">318,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ClmAfvCkI0ycnQerojkMPQ_9_5">11.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_gSLMx8M3yk-2L3ZhchgvuQ_10_2">1,819,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_YSXc0x6y90CNAyvRWEFfRA_10_5">4.61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_aLRwKoBuK0y8KONhonjc7Q_11_2">961,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_cEsLgyZMeEi9f_BMAKbhkA_11_5">5.47</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Restricted stock granted to employees:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Tb__jN6omTbcESElxyTFnuXzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Restricted Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ssa4_sAGw0q1WnIXrqo2yw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_up1WZGns-0u-dGGoKQAfTg_3_2">624,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_t32kanKUi0m7HxcXWb8NzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_e3amVD7uBEy2XHOoPftVfw_5_2">166,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_c9-osb3oE0SkR9YTIYdxYQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_TVLO_SZ9Z0ytoKQwKaeVAg_6_2">458,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;">c)&#160;&#160;&#160;&#160;Options granted to consultants, directors, and other service providers:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" id="Tb_ys89yMcK1Eexu2lpm6lbrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_pOElBCAhPkyrVCdfrhdzdA_6_2">464,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_umddOfbkQUeauZn0n9KL8Q_6_5">3.74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WwsBRNfRtkKswONdYE8A3A" decimals="0" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesStockExpired" scale="0" id="Tc_ZKFuLiaSr0mRbWcKXe6AWg_8_2">24,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WwsBRNfRtkKswONdYE8A3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_2uX5dcmTX02_78NJgBYhnQ_8_5">5.60</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_893YOA7NtUK0y5fcj3yMmw_9_2">440,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_v2BMMTcWo0GsN_sOsYw_IQ_9_5">3.63</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_3hYbDgy-cUaYCqTzhOCYWQ_10_2">192,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_9ccWoUx8fUWfswxv1HjoHw_10_5">3.63</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_52a7e9b1_2099_4a9b_bd9a_70294445641a"></a><a id="Tc_pv-ISb4C-0SegJKCfvLRZQ_1_2"></a><a id="Tc_ocG0NwuujEK9Tk3pPvEfvg_2_2"></a><a id="Tc_ml5FT25WfU-NSo4LAQLbXA_2_6"></a><a id="Tc_NFa1TnphIUWSy8TzqkmE0Q_3_2"></a><a id="Tc_4v0cUyeF-Uy66jQtIyXv3Q_3_4"></a><a id="Tc_StK5Ha9fk0-5GogNCHVY6w_3_8"></a><a id="Tc__ZDm_3cCHUuZOyyAwraAgA_4_2"></a><a id="Tc_Szq-m5eod0ahrIbCSfXfxg_4_4"></a><a id="Tc_Gng235r_gk6igxn7rjmnkQ_4_8"></a><a id="Tc_fkYgM7miQEWIZ_w13qKTBw_5_2"></a><a id="Tc_V8q_Jmm6EEeko5n2DRGyXw_5_4"></a><a id="Tc_h639KLc_c0GAVRMzsSwZxg_5_6"></a><a id="Tc_Qo-DnZ71Q0-mCfzbI22HAQ_5_8"></a><a id="Tc_OCNRdrVY5ES5WdmiCtKOLA_6_0"></a><a id="Tc_abjs62JdMkuiGYNEebvGqA_6_2"></a><a id="Tc_aBfvsucNNEOADvu9PaBP7g_6_4"></a><a id="Tc_KCqa7b8PhUe2KqgQpDsCOg_6_6"></a><a id="Tc_qoojMcTg4ky2LXvEayv9Qg_6_8"></a><a id="Tc_kwkC_KPIx0qTQCzh2cUcHQ_7_0"></a><a id="Tc_fVb98jCDKUOXugpqrBy30g_7_2"></a><a id="Tc_rDuMgzHWoUeMzEpsxrtuqQ_7_4"></a><a id="Tc_4fZi3dBX6UeyB9SNtt0QLg_7_6"></a><a id="Tc_X-7i6leWV0OAOB2jyVhqHg_7_8"></a><a id="_8903c0f2_2235_4602_bbc5_3639744a2e79"></a><a id="Tc_SwwULHzthkGA4KeRVb3zPw_1_2"></a><a id="Tc_4T_Wpg2uBE6QWvXzonLLBw_2_0"></a><a id="Tc_csQLwb0150SzsaYfo0MczQ_2_2"></a><a id="Tc_pTiRvNq2EkOq1DuDTlY7Lg_2_5"></a><a id="Tc_kZWxz0q9G0OyjaWUzDdIRw_2_8"></a><a id="Tc_j0vTqlnQgk6utN73YfAXXg_3_0"></a><a id="Tc_KAvtpCc9W0Ci_zgirQyHwQ_3_8"></a><a id="Tc_jEQs3q8iak2m7_lLFICeIg_4_0"></a><a id="Tc_sp7J7ipENk2ybfTVK-0vag_4_2"></a><a id="Tc_S0NrAnpnik-NdsNuFrlg5A_4_5"></a><a id="Tc_VZ7nmpamjESF04w5CUQkjQ_5_0"></a><a id="Tc_MHXBLW3bfEC3S1X8JtOzwA_6_2"></a><a id="Tc_vYPAucCkR0GJeOWRlk6PEg_6_5"></a><a id="Tc_DXlJekD4FUm43BJqVo_tVg_6_8"></a><ix:continuation id="Tb_KyuNtueviUGlU8z74VbRMg_cont5" continuedAt="Tb_KyuNtueviUGlU8z74VbRMg_cont6"><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The following tables summarize information concerning outstanding and exercisable options as of December 31, 2021:</p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_qAQCmSzXEESyw__cLUqSIg" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_k5WMhl97TUSfz8rrM7OTRw_8_0">1.57</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_LBAMnE6--EKPrnn3iJRzbA_8_2">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_vgln8Qm_cUy86I_Caw65HA_8_4"> 9.57</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_gcNj7KT-fEOQ-oodpDGQjw_8_6">3,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_JDkHV8vRI0mKVdV87-T6lw_8_8"> 9.57</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_-pokF3EU2ESp7wDxrQqsow_9_0">2.00</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_JX7wlQ8FiU22etWN6WQRxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_h-k4cljLUEucgFwxJihGFg_9_2">80,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_ooVYtTigTkuAdFLBKRisGg_9_4"> 7.73</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_JX7wlQ8FiU22etWN6WQRxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_K6WcJwefaUWrwOulTEmuXA_9_6">45,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_j0lfuiLLC0OiKEbtEr4-pw_9_8"> 7.73</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_FGFTsiqq_kyGOAZX8Juyew_10_0">3.55</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_wdkJLL3g1kqo4k9Y_B1iWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_GCWMkO9q4UmLe8RPFattbA_10_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_zUOfpnl19UC73vZxzS28vw_10_4"> 8.06</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_wdkJLL3g1kqo4k9Y_B1iWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_bfUvYa_JSUytf9IXbrE3Qw_10_6">87,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc__rzsa_Jjvk2CJLf1Ql630A_10_8"> 8.06</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_DOCjWHZc3kC6HCBtmAVF2g_11_0">3.59</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_WDm67mnYvkO--UxyQkYsvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_uH08YvZ7V0irQzp-AKow0Q_11_2">319,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_SPUnYiheyUWvWy_8D8oNyw_11_4"> 8.51</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_WDm67mnYvkO--UxyQkYsvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_kvahYLI0tkmLuj6hzdgCNQ_11_6">112,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_R_B2nm6x9ESSV10Lql3fyA_11_8"> 8.50</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_4_bsr4PaUk2keWYLF8I5ug_12_0">3.66</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_lgDg9pDF2EWhgu2sSt2k9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_McXvn1aRk0Gvg0Nq83qIGQ_12_2">641,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_OKzjn1ViRUOJTUGUlB6LMw_12_4"> 7.71</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_lgDg9pDF2EWhgu2sSt2k9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_IRG3bsMP8kq85X2ilcUeLg_12_6">280,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_u8CBuvG0a06ViD6J_GMxbw_12_8"> 6.74</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_tn419ZeIsk2e9bKLTgptqw_13_0">3.70</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_mFoKIxmKnkitg7IY-C7heA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_QRExSVbi6Eepjeg1PajV9w_13_2">240,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc__5CjuVIMzEyWfvUv5YFCCw_13_4"> 8.10</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_mFoKIxmKnkitg7IY-C7heA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_znynEJUJKEmuvBk7T0kgXA_13_6">105,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_B4lA5vgi-UuPKtTgz6Q_lg_13_8"> 8.10</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_QU4Ae7ocu06-ckMOh8y8mw_14_0">3.73</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_gNOcdY9dyE2xyodPldHVZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_5AZ2paNlpkygE8dG5FetUg_14_2">129,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_x736wCHlEU-wfHpZVeXjnA_14_4"> 8.52</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_gNOcdY9dyE2xyodPldHVZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_cPOsmFdNKUKduKQmyi72mw_14_6">40,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_HVwMVqxeh0WxN69JPsp0QA_14_8"> 8.52</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_rXxEBBikYUqU9I3n128Kqw_15_0">4.69</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_cydItAIWhU2ynTqxcgAr8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_emoBOut1UUqbpMU8EL9l-A_15_2">160,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_V7a0mAiOp0OviupVMk2C1w_15_4"> 7.50</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_cydItAIWhU2ynTqxcgAr8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_aLVXX6q7X0u85UOSjfAjOg_15_6">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_Y05QHdkTpEiz3PUXgd72CQ_15_8"> 7.50</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_Qp38axCs40y_yKuA-hNHiQ_16_0">5.10</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_3VKeoZyiuU-sD80UufftoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_38WSzBjOREKOjYiCvLSFsw_16_2">215,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_TbBgiD_5fUKneSqJ6YaHCg_16_4"> 5.69</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_3VKeoZyiuU-sD80UufftoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_vz-apX5qAUu1IssHkA4AFg_16_6">181,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_mDSwN69hDkKtF-S4ni01iQ_16_8"> 5.50</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_Yh8qP0zgSEy5KVFIT02wag_17_0">5.60</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_OHALbnwmZ0uHOEuQaP-GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_I3OByk-OgkCSA4NcW3r0Ig_17_2">130,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_fGyMySPaIEGB-m2RQwLMGw_17_4"> 6.71</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_OHALbnwmZ0uHOEuQaP-GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_aD6PhrdSM06pM3cvKfsi3Q_17_6">105,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_weW2vbGezEiLafxHYuqyFQ_17_8"> 6.71</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_tcDLHYlbskWe11VE0rb0cA_18_0">17.20</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_mKYQ0uHMPk-JKlPiT881XA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_bphH7ZUdA0yDYAcRqgA07w_18_2">92,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_SDZjRmGJnEGmL5vSvP3uUw_18_4"> 2.93</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_mKYQ0uHMPk-JKlPiT881XA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_jbiu7ioaX0K6ITxKgE4Dhw_18_6">92,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_WYfdXxieJ0SWNAd_I0zyug_18_8"> 2.93</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_5dEa9Rhwl0KQ-pkDJXb49Q_19_2">2,259,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_68qHB9ifLkW0pqqLDatKQw_19_6">1,154,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*<span style="color:#231f20;"> As of December</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">31, 2021, all outstanding, exercisable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:0.05pt;"> had exercise prices that exceed the fair market value of the Common Stock as of such date</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">e)&#160;&#160;&#160;&#160;The following table illustrates the effect of share-based compensation on the statement of operations:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_Jghlsk7m_kWWsAGdQosSPQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nz1R62d_CUWRP0hHMNoUuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HGttPDZwekKgHWlDCB2Dow_3_9">269</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qzxX_tCY20S2bKMHuz5WJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fKLSPvJK2Uu0M41zEXMiQA_4_3">513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_avlksYPTbEKq7Od9FRAY9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_JtjvYxRnMky_O5yUtK75aA_4_6">1,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_phM4VtIB9kyKjfXahRtTSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ikl3SVjyakCQ-QE3Soa7sQ_4_9">648</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jz0yWSUNLUeUy5fbrRm0BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_inWC__1wKUq_1BYQ3BoS_w_5_3">322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cDyFN34pu0WU-HKDRkiujg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_3DZoxIsKGUCrb3AaGzAsXg_5_6">2,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_GvWEuJLKREuv90OClpZMKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_809i0R1EeUC839ZivGjoFA_5_9">1,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_a-vpf8_rLU2lZcHEq_R4nA_6_3">835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4idwpjpMQkefJncoFQuRfw_6_6">3,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wCm_BtoaEkOil7x38u_-og_6_9">2,375</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Private and 144A Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;18, 2020, the Company completed a private placement to certain existing and new institutional and other accredited investors (the &#8220;Purchasers&#8221;) in reliance on the exemption from registration set forth in Section&#160;4(2) of the Securities Act. The Company sold approximately <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_wEGqAMTqckmlktDDR_5caQ">17.6</ix:nonFraction>&#160;million unregistered shares of Common Stock to the Purchasers at a price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_XiCcAP8uxkGyCsytx4PQPA">2.485</ix:nonFraction>. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_G3h8otX0l0Wz2b80oNeSBw">43.7</ix:nonFraction>&#160;million in the Private Placement. Each share of Common Stock issued was accompanied by a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_H13Et8U1X0eYW0gE2I3pqA">one</ix:nonFraction> share of Common Stock at an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ifo_e8zga0ex-aiQJjoGSw">2.36</ix:nonFraction>. <span style="background:#ffffff;">During the year ended December&#160;31, 2020</span>, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HY-SW4N2TkyfFq3zDY1uuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_jdyhJB0TCk6G1dplksVY4A">200,000</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued in the transaction and generated proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HY-SW4N2TkyfFq3zDY1uuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_V4zrSBXHkkOZD6tgymAL2g">472,000</ix:nonFraction> from such exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June 7, 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GEPYGazCFU-lvckKnH9W0w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_youvm_f-Akawv7gCtIEegA">173,816</ix:nonFraction> shares of Common Stock in connection with the cashless exercise of a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lDW5LBY3rUuDb7f7KXNKnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_ajSZhVLJc0uVfS3IAoTATg">2,816,901</ix:nonFraction> shares of Common Stock issued in the transaction. The Company did not generate any proceeds from the cashless exercise.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KyuNtueviUGlU8z74VbRMg_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">On July&#160;2, 2021, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rSbtuiUSrEKogWgpJVQOAA" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr__rvf9tOvt06KhDUUNtHqYw">20.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_dm10EvNOd0iKnY1gsz2csw" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfCommissionOnSaleOfShares" scale="-2" id="Narr_ICJixSsZMUS7FpkcdQ_ZSA">3.0</ix:nonFraction>% of the aggregate gross proceeds from the ATM Shares sold. As of December&#160;31, 2021, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bCxAc5Cnfkm0EGvQetJhcA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_mOyfq4fRaEWIJE2hOsu4HA">no</ix:nonFraction> ATM Shares under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December 31, 2021, but prior to the termination of the BofA Agreement, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_D8rI_9bthkCH_hajh1im5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_gd_VCq_g0UmouueKXXx4_w">1,867,552</ix:nonFraction> shares of Common Stock under the BofA Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_D8rI_9bthkCH_hajh1im5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_JdhD97OAsU29J5yBSpR0bQ">8.8</ix:nonFraction>&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_mnMMnw1MBkCAOsBsUJSzcg">8,749,999</ix:nonFraction> shares of Common Stock in an underwritten public offering at a price to the public of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4FCUUv8AMkiNo-WOe5ng6g">4.60</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_jZj9p2ws3Ey9JsaRS-BfDA">40.2</ix:nonFraction>&#160;million before deducting the underwriting discount and estimated expenses of the offering. The above included the exercise of the underwriters&#8217; over-allotment option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_v_mup5ayK0SZBeWgSy-6vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wSp7K3FF90mcyNYfvT9KuQ">1,141,304</ix:nonFraction> shares of Common Stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_k4imgXBc-EuQmN5vT0V28g" continuedAt="Tb_k4imgXBc-EuQmN5vT0V28g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 10&#160;&#160;- CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;25, 2021, the Company completed the Exchanges of a substantial majority of the Company&#8217;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_OohPHfrxTEGi5zhqBBzPVw">54.65</ix:nonFraction>&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_KdXh27-UA0Wvm4J41NiNBw">28.75</ix:nonFraction>&#160;million principal amount of newly issued 2024 Notes, $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_FMHnCm5WPkaPYvj65xmTuA">25.90</ix:nonFraction>&#160;million in cash, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" scale="6" id="Narr_QDLGRFppdUGt5-XkzpQmaw">1.1</ix:nonFraction>&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="INF" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_uPo6j2cTVUqLekCiMI_CFQ">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_XxNKP-d0xEOLE2rB6REFTw">1,000</ix:nonFraction> principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_JkjAFx1On0S5Ovm9LlR8Fg">1.7755</ix:nonFraction> per share of the Common Stock), subject to adjustment in certain circumstances, which is based on a <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfPremiumToClosingPriceOfStock" scale="-2" id="Narr_dzsQqfDc20qdLHv_K5uCcQ">32.5</ix:nonFraction>% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_A-q8OJeB_E21kiVdxn1QyA">7.5</ix:nonFraction>% Convertible Notes Due 2021&#160;(&#8220;2021 Notes&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;1, 2016, the Company entered into a note purchase agreement with institutional investors, which held part of the 2018 Notes&#160;(the &#8220;2016 Purchasers&#8221;), relating to the sale by the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cFbsJrjci0yg4ImOcaQUEg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_vaJF5A0Jc020JcTocqlYVA">22.5</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cFbsJrjci0yg4ImOcaQUEg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_YB1lezT85k6OPGcyivXbxA">7.50</ix:nonFraction>% Senior Secured Convertible Notes&#160;due 2021 in a private placement pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. Concurrently with the consummation of the private placement of the 2021 Notes, the Company entered into a privately negotiated exchange agreement (the &#8220;2016 Exchange Agreement&#8221;) with certain existing note holders identified therein to exchange $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_FourPointFivePercentageConvertibleNotesMember_m95eebdJ1ECA3BKmoDsZlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_tpFUzgSTN0mdUIRmchM2FQ">54.1</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2018 Notes&#160;for (i)&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_7_2016_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_-Ae00XL6BEyY4dAoZ4k0DA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_bh_oWmp3MEmVugwpwjx-Bg">40.186</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes, (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_12_1_2016_To_12_7_2016_MCerakGL40qMS2YHRbNFsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_p47NjPAUqEGUAbnrYefatw">2,384,673</ix:nonFraction> shares of Common Stock and (iii)&#160;cash, equal to the accrued and unpaid interest on the 2018 Notes&#160;and any fractional shares. The closing date of the purchase agreement and the 2016 Exchange Agreement was December&#160;7, 2016. The issuance of the 2021 Notes&#160;and shares in the exchange and the private placement were made in reliance on the exemption from the registration requirements of the Securities Act pursuant to Section&#160;4(a)(2)&#160;thereof. The net proceeds from the private placement were $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_12_1_2016_To_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rR_AcPv6HUeGQ6sr7l3x6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="Narr_JqQgLJtAKkSB8IeL0efcrw">19.7</ix:nonFraction>&#160;million, after deducting the placement agent&#8217;s fees and the Company&#8217;s estimated offering expenses. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_21a6b451_5a65_46e8_99fb_c2e160d27adb"></a><a id="Tc_NIwYyEoAS06xlcM_rCRz8w_1_2"></a><a id="Tc_te8PoaZffEuEs1P_9svI2g_2_0"></a><a id="Tc_bG1Z6vQDz0WjcY-DiDgGwA_2_2"></a><a id="Tc_z-j-IJYOZEmlMh_ULYJ-SQ_2_5"></a><a id="Tc_LnCmZau0jkKgXBltuPqxsQ_2_8"></a><a id="Tc_hwH-WHFtyEyTzb5WV1uTpg_3_0"></a><a id="Tc_8m2x3zIex0y1CK4UdjpQrA_3_2"></a><a id="Tc_ZFXInR5mCUKJmtL-zg492g_3_5"></a><a id="Tc_rBi4eOWLh0ujiRV1FrMTrw_3_8"></a><a id="Tc_ByyG-5-ZvU2N0UjIxhxggA_4_0"></a><a id="Tc_-dsxAA3Uk0OTetL08p5MyA_5_0"></a><a id="Tc_HxBl8ySYk06P4QJ_zuHo4g_6_0"></a><a id="Tc_D19ZNWujbUmTpFgKrCwYRg_7_0"></a><a id="Tc_VhdfhR-P2EW8BgkVZ3mz3g_7_2"></a><a id="Tc_UfqlINuCRUigJyN_XlLkYQ_7_5"></a><a id="Tc_Bh-C4Nbee0CGuAbE9HrjhA_7_8"></a><ix:continuation id="Tb_k4imgXBc-EuQmN5vT0V28g_cont1" continuedAt="Tb_k4imgXBc-EuQmN5vT0V28g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In connection with the completion of the exchange and the private placement, the Company entered into the <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of December&#160;7, 2016, with the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a> (the &#8220;2016 Indenture&#8221;). The 2021 Notes&#160;accrued interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Lll7ybmUtEagcyuAnAYIQA">7.50</ix:nonFraction>% per&#160;year. A portion of the interest payable was allowed to be made in shares of Common Stock at the Company&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;24, 2017, the Company entered into another note purchase agreement with certain institutional investors relating to the private issuance and sale by the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_7_24_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BD69mggkuU62grMnuucETQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_oihLqo-XCECRRR3Fc8gbag">10.0</ix:nonFraction>&#160;million in aggregate principal amount of its 2021 Notes. The 2021 Notes&#160;were issued pursuant to the 2016 Indenture. The net proceeds from this purchase agreement were $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_7_1_2017_To_7_24_2017_IHtLKtFOd0GdflSpPhFd5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="Narr__OhhNbaTdEactbHeN_HzXQ">9.5</ix:nonFraction>&#160;million, after deducting the Company&#8217;s offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On November&#160;15, 2021, all the then outstanding 2021 Notes&#160;matured and were paid in full, and the 2016 Indenture expired.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_zJZ3ltB1mUmBuIBZE78vag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2021 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. Dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_B0jzXSlicUy5MgU0kNCepg_3_3">4,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_J1PIzuGTH0isBVLgLgPG9Q_3_6">4,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_WwPSrBpdi0emnNZ-7woXFg_3_9">2,855</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt discount amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_l34giQQYaEOLlWSmCU2cxg_4_3">2,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_IKD7Ia8AFk-Y4sXizJ3C0A_4_6">3,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_cQg4CM2wG0maObmmd7pqsA_4_9">2,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_civzKhzdtk24CTJ-XLhA3A_5_9">831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestExpenseDebtOther" scale="3" id="Tc_GwmpInnpVUC4heDrWBUYow_6_6">1,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_dT9mloroNUmfDXBpuMaX2g_7_3">7,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_Wl7IVhpUVE69ptOjbz6RDw_7_6">9,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_rx6KeUbDBkqbmkIHs26D4g_7_9">6,261</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_9DguQz6KHkaBgxBaj_Zg6Q">7.5</ix:nonFraction>% Convertible Notes Due 2024&#160;(&#8220;2024 Notes&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#8220;2021 Indenture&#8221;). Interest on the Notes will be paid semi-annually at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_bNJTLn6Mkk21sNeI_5o5Jg">7.50</ix:nonFraction>% per annum. The Notes will mature <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_0yrJo5MtlUqjI2rFYVFcqQ">three years</ix:nonNumeric> after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_BF3PX0Az50iEvKVPidQfVA">0.8</ix:nonFraction>&#160;million due to derecognition of the liability component and a reduction of stockholders&#8217; equity of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w" decimals="-5" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="6" id="Narr_4qEIZsDvOkWDqUBvMQZpkw">12.2</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature net of transaction costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="-5" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="6" id="Narr_4zV0zdO0J0mvLJud8kwQyQ">12.0</ix:nonFraction>&#160;million was recognized in the Company&#8217;s additional paid in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transaction costs in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" scale="0" id="Narr_1tfwp77x4U-_JpRqLVGRCA">869,000</ix:nonFraction> were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Holders may convert their 2024 Notes&#160;at any time. The initial conversion rate for the 2024 Notes&#160;is <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="INF" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_gec6krHFQUO4U6Bx5qU5NA">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_D0gDbWN210616U7ZsZ7KcA">1,000</ix:nonFraction> principal amount of 2024 Notes&#160;(equivalent to an initial </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_k4imgXBc-EuQmN5vT0V28g_cont2" continuedAt="Tb_k4imgXBc-EuQmN5vT0V28g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_jQCcGMpgfk2Po61czS296Q">1.7755</ix:nonFraction> per share of the Common Stock). Upon conversion, the Company may settle the 2024 Notes&#160;by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#8217;s election.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">To date, there has been no conversion of 2024&#160;Notes. As of December&#160;31, 2021, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="Narr_4GUGZZL79UaNiPUAR0cQXA">28.75</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" name="us-gaap:DebtInstrumentRedemptionDescription" id="Narr_3Cu074K_OECbw85HGVK1sQ">Prior to the maturity date, the Company may redeem in cash</ix:nonNumeric>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</span></span>any or all of the 2024 Notes&#160;if, on or after March&#160;31, 2023, the last reported sale price of the Common Stock for at least <ix:nonFraction unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="Narr_UxAma4MqH0-5nZszDwG12Q">20</ix:nonFraction> trading&#160;days (whether or not consecutive) during the period of <ix:nonFraction unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="Narr_flJDMJ6ZCUyFIn8laPd-yg">30</ix:nonFraction> consecutive trading&#160;days exceeds <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="2" format="ixt:numdotdecimal" name="plx:ThresholdPercentageOfConversionPrice" scale="-2" id="Narr_M-L_N90EdEO9NzXIePwZIw">130</ix:nonFraction>% of the conversion price on each applicable trading day, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</span></span>all of the 2024 Notes&#160;then outstanding if the aggregate principal amount of the 2024 Notes&#160;then outstanding is less than <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="2" format="ixt:numdotdecimal" name="plx:DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" scale="-2" id="Narr_XXBcOq0qV0GGZ4Mcri6c9w">15</ix:nonFraction>% of the aggregate principal amount of the notes issued on August&#160;25, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">To date, there has been <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="-3" format="ixt-sec:numwordsen" name="plx:DebtInstrumentRedemption" scale="3" id="Narr_WSkqyHWJ_Eq8gJsOIon6vA">no</ix:nonFraction> redemption of 2024&#160;Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes&#160;are guaranteed by the Restricted Subsidiaries (as defined in the 2024 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#8220;Collateral&#8221;), including, but not limited to, (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="2" format="ixt:numdotdecimal" name="plx:PercentageOfOutstandingCapitalStock" scale="-2" id="Narr_SljyX0gRPkyTacm8-Dod8w">100</ix:nonFraction>% of the capital stock of the Guarantors (as defined in the 2024 Indenture) and each Restricted Subsidiary of the Company that is held by the Company or any Restricted Subsidiary, (ii)&#160;intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii)&#160;all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv)&#160;all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2024 Indenture, and (v)&#160;all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both Wilmington Savings Fund Society, FSB, as collateral agent in the United States, and with Altshuler Shaham Trusts&#160;Ltd., as security trustee in Israel. The 2024 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#8217;s assets that constitute collateral securing the 2024 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Upon (i)&#160;the occurrence of a fundamental change (as defined in the 2024 Indenture) or (ii)&#160;if the Company calls the 2024 Notes&#160;for redemption as described below (either event, a &#8220;make-whole fundamental change&#8221;) and a holder elects to convert its 2024 Notes&#160;in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#8220;Additional Shares&#8221;). In no event will the conversion rate exceed the maximum conversion rate, which is <ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="INF" format="ixt:numdotdecimal" name="plx:MaximumDebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_YDvyJFHijE-zVIsvyF6DLg">746.2686</ix:nonFraction> shares per $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" scale="0" id="Narr_kr9JF9rzE0Cn0A7bEreJkA">1,000</ix:nonFraction> principal amount of 2024 Notes, which amount is inclusive of repayment of the principal of the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2024 Notes, or any portion of the principal amount thereof, that is equal to $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" scale="0" id="Narr_vJbNB4P6LEW4i62-5ANqKA">1,000</ix:nonFraction> or an integral multiple of $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" scale="0" id="Narr_HJ-IzcDlK0mBt0yFbjaE7w">1,000</ix:nonFraction> in excess thereof, on a date of the Company&#8217;s choosing that is not less than <ix:nonFraction unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kDIPT7eBJUiHYr1xa6GU6A" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" scale="0" id="Narr_ZnJzUG6JsUqdckJcQzgbew">20</ix:nonFraction> calendar&#160;days nor more than <ix:nonFraction unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ng8kcf3PY0-KI0QEryv2Yw" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" scale="0" id="Narr_4nrLx8mhB0-nYXFBi0X72g">35</ix:nonFraction> calendar&#160;days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2024&#160;Note is equal to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="Narr_QMKgka-eIEa9goSx3Iy-WQ">100</ix:nonFraction>% of the principal amount of such 2024 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. Under the terms of the 2024 Indenture, the Company is required to <span style="color:#222222;background:#ffffff;">meet certain covenants including the requirement to </span>maintain a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_vZg9ZqjxjU2Yq_6jx15n-A">7.5</ix:nonFraction>&#160;million. Failure to meet covenants can be considered an event of default and, accordingly, may </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_PV-TTJKCiUeEW--HjAyxFw_1_2"></a><a id="Tc_GHKEclxdykeK-yo_qKMlow_1_5"></a><a id="Tc_O9HLqsnw0ka8HmR0O-Nojw_2_0"></a><a id="Tc_VyIPDwq1S0aX-SLBLJxylg_3_0"></a><a id="Tc_yv-W5mPNtkqyqNglP4GV_w_4_0"></a><a id="Tc_RG1TJNWtqEGSCMzYsvW7xQ_4_3"></a><a id="Tc_Dgcd62ysVkaZ-6_byYA8DQ_4_6"></a><a id="Tc_Gx-jbK6PY0KFI0YPoWx9MQ_5_0"></a><a id="Tc_lj-AVaFjVk2w5GfgT1ZfpA_5_3"></a><a id="Tc_0V8E3imsgkynK6Oo7_uKRg_5_6"></a><a id="Tc_gnXPKlsSdUKp9fu9IbYM5w_6_0"></a><a id="Tc_72egvq35E0G8S5kQ8fOp4A_6_3"></a><a id="Tc_QNd45_4-fEWCciCQh08U3g_6_6"></a><a id="_28195651_5b53_456c_b394_edd9614bd437"></a><a id="Tc_Ly1ueSC9rkGOaW5UbxMyAg_2_0"></a><a id="Tc_kmO8jn6t8k6Y8orM15Ngzw_2_2"></a><a id="Tc_XSH83AePvk-L7KznfF4PFg_3_0"></a><a id="Tc_nh17SsH3hUekBmUz9keTow_3_2"></a><a id="Tc_uehC5a4TLkuvSeoTdbiWwQ_4_0"></a><a id="Tc_iksfap14QUeWRUkkgCsbBQ_5_0"></a><a id="Tc_Fl6V2ZfdgE61oqr9DW_XKA_5_2"></a><ix:continuation id="Tb_k4imgXBc-EuQmN5vT0V28g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2021, the Company was in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_NrgbIl6Vs0-zjQEgcvzrEg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Group_Jl9SNnnh-kGZ9CMWO7pTbw" continuedAt="Group_Jl9SNnnh-kGZ9CMWO7pTbw_2" escape="true">The following parameters were used:</ix:nonNumeric></p><ix:continuation id="Group_Jl9SNnnh-kGZ9CMWO7pTbw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_b7Ak3fDnlkmmGkfD-wjobA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_WfgHdROk10aJbXXh80Zv_A_2_2">1.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_we61rqymjEKVRph1U_HyOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_AN1k3pVqmUeHx1ce6iOtfw_2_5">1.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_bFAp9JROpkOcrhLPvQRlPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_5WElPmDEEUyJyPVrjAM5BQ_3_2">0.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eHDaBvSg7EqtccoqK2mu0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_z3PgCsyOD0um4Tv4KWREBg_3_5">3.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Dql2hzl-NkS8Ek6wKzfhtw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_ktjn6yy6NEWEU5NDo7gITA_4_2">0.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wVjVKlFU-kmp2kWFh3RuVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_eF2iGW8e70mmR1EO-x7cEQ_4_5">0.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6zDHzo_aTEew3DryvNkYTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_soNWH8oGMUChAfQGdj0l5g_5_2">78.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_5QixDFM82UiwwWLbZe1sTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_0rYoj7Hn1Eax17lfvG9QGg_5_5">91.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_GmiPA7ea602B3Bzo6qlgCQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Giv82oIPqkGjS7O0C_JMBw_6_2">7.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_31zyHW8jdkSb7SBDmFiccg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_em1eq9xg3keQCVSxj1vdaw_6_5">7.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_fA253TZhg0GisGMyPR7uIQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_zbx593BAukK1vfiEZkvwEQ_3_3">767</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_msEPorMooUGUTdY0kjuDmA_4_3">97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_GwCvXvwieUeFJ9cJ3PpysA_5_3">864</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk32092902"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_UkLNvfeftUOXKegDAnOPfQ" continuedAt="Tb_UkLNvfeftUOXKegDAnOPfQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;11&#160;- FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_cFYxNH_tvk6sCgkIjrS83Q">28.75</ix:nonFraction>&#160;million 2024 Notes as of December&#160;31, 2021 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_XwKfsbmeH0y77kwwIqU5Mg">33.3</ix:nonFraction>&#160;million based on a level 3 measurement.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ddd06362_5021_4fde_8812_536599c72313"></a><a id="Tc_beYnDY6CV0KekRtBLx6L5A_1_5"></a><a id="Tc_3u7024AkQUWkFKMEpQjJiw_2_0"></a><a id="Tc_mR8PcAIgQUS20f8sEiSmpQ_3_0"></a><a id="Tc_wOPjKx5GHUeXBh1jnN_NhQ_4_0"></a><a id="Tc_NFAgiqED006KLn0da7s9Fw_4_6"></a><a id="Tc_1MhxN4KsIUqeVNZONGNKVg_5_0"></a><a id="Tc_CogLefw2kUWtKxJ3yyn8jg_5_6"></a><a id="Tc_2NXdZ__hBEacU_0VIbZbSg_6_0"></a><a id="Tc_h_UWaKOJEUCndDsRNNqW-A_6_6"></a><ix:continuation id="Tb_UkLNvfeftUOXKegDAnOPfQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The Company prepared the valuation of the fair value of the 2024 Notes&#160;(a Level 3 valuation) as of December&#160;31, 2021. The value of these notes were estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_Lp3UKmDNekywkAJWOLUvVw" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_W5Xtd1I87UWgu75FfSxL9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_uxuACzHuQEy4Y587g8a3yA_2_5">0.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_DCDOuQ7vOEmwiHAqrutTiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_tMkEfG3a8kKmDNB2QoRMtg_3_5">2.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-h9AO0_j0Kk-RifcpTNhg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_knt5QKDAGkS2ftcXP9tEfA_4_5">0.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xZes_pQ3jU-LW3EVr3FH_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_EdWeavVuO0a6_anr76muYw_5_5">92.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_oDSWqTAF3kmOozORnpamaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_uReVaoxuBEWY4JQlUepg3A_6_5">10.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_GWmf273WPEa2zQlRY98b5g" continuedAt="Tb_GWmf273WPEa2zQlRY98b5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;12&#160;- TAXES ON INCOME</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at the rate of up to <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_TGSo8Z2q4UakwLgn9fGO-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_8xlD3qfaCkWA3GyzhNd7gQ">21</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was enacted into law. The new legislation represents fundamental and dramatic modifications to the U.S. tax system. The Act contained several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the Act included, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of net operating loss (&#8220;NOL&#8221;) deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The Act also repealed the corporate alternative minimum tax for tax&#160;years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the Act included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Modification of interest expense limitation rules under the Act provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 30% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">U.S.&#160;GAAP requires that the impact of tax legislation be recognized in the period in which the law was enacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that all future profits of its subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company as a &#8220;foreign-investment company&#8221; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GWmf273WPEa2zQlRY98b5g_cont1" continuedAt="Tb_GWmf273WPEa2zQlRY98b5g_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tax rates</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The corporate tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_x038hBkxEEOMoMUfzZexDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_k6oOWb32oEG68fkHOo-STw"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_KCPpKqI-Okqwtns-9IWsAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_ZJROFITExEqM9CgXhMJgvA"><ix:nonFraction unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_5BNg8lS-ikul3R9lhuigJA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_ZMnZNw-B2UyTD1F2kTIfxQ">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%<span style="white-space:pre-wrap;"> for 2019 and thereafter.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">a.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reduced tax rates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Accelerated depreciation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">c.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Conditions for entitlement to the benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GWmf273WPEa2zQlRY98b5g_cont2" continuedAt="Tb_GWmf273WPEa2zQlRY98b5g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">d.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021 and 2020, the Company had aggregate NOL carry-forwards equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_04kQF6uaakmkdWi9KI-VZQ">247.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_UwNewVS5DUKeuv6DRYEQvQ">231.4</ix:nonFraction>&#160;million, respectively, that are available to reduce future taxable income as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company&#8217;s carry-forward NOLs, equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_NaIif8seUUurDs8ggqZ2pg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_AmM4mDn8S0uKj5CE3EQWaQ">36.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_Dv3dYp7Sn0usVBmj85F-iw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_oSZHO0gTi064ghHn7TlobQ">30.9</ix:nonFraction>&#160;million as of December&#160;31, 2021 and 2020, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Protalix&#160;Ltd.</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">At December&#160;31, 2021 and 2020, the Israeli Subsidiary had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_4EDJzmaOZEiGDZsFWmKybw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_YYjFEI8BPUu3aWQxL7Qnqw">211.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_DhHNkI_3EEiZeB01aqdpKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_bziS4guqYE-9VH9J2IeScg">200.5</ix:nonFraction>&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a2aba8b0_2c4a_494a_b74c_05d76e2dad70"></a><a id="Tc_dYHo8oYDLEGcpbvnEfwmRQ_1_2"></a><a id="Tc_LC_1JMMxFkqVoW9udIK6wA_2_0"></a><a id="Tc_xkVpqFFsmUqD-QxkqBkh6g_2_2"></a><a id="Tc_CO6STG-f_EGzBRJFQTNb_A_2_5"></a><a id="Tc_lrlFahwyxEuWETNeo3Lg3A_3_0"></a><a id="Tc_A30lAf9A70CWMQGeGb1uTw_4_0"></a><a id="Tc_kGWi_5jG_UqBqrWHd1fVnQ_4_2"></a><a id="Tc_C2B4a8FPJUect1tADvO7hg_4_5"></a><a id="Tc_WAeY9Yv180uG8VossucENQ_5_0"></a><a id="Tc_BlR4fI_paEGfnzN_uwO9YQ_6_0"></a><a id="Tc_Uj4mA3PQxkyWUPmdneSeyw_7_0"></a><ix:continuation id="Tb_GWmf273WPEa2zQlRY98b5g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Deferred income taxes:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_OGmwp4CvJUWku6-N44_7eQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2020 and 2021 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_2XvJ3hTJ506dkKV9_0mYGw_4_3">9,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_BNFSd2UpK0OTI0DYGya1Zg_4_6">7,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsOtherTimingDifferences" scale="3" id="Tc_EdCdTATy6kyHHl0e__SPdw_5_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="plx:DeferredTaxAssetsOtherTimingDifferences" sign="-" scale="3" id="Tc_jCpGVLKUZk-9GTRGBDfXvA_5_6">1,989</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_O2tY3YDxj02GqDkeHi1tXw_6_3">54,122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_dmY2hxunw0WalA39Puz_sw_6_6">56,292</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_3N8AExcgP0yrGiFy1umxyQ_7_3">63,760</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_9ODJtQzYNEW-Bl2_d0zoqw_7_6">61,520</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_5soDWZH7JkSTLCe0fgOEjA_8_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_mgzRWnr8M0K4jIe8i4UbMw_8_6">-</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Tax assessments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In accordance with the Income Tax Ordinance, as of December&#160;31, 2021, all of Protalix&#160;Ltd.&#8217;s tax assessments through tax&#160;year 2016 are considered final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="plx:ScheduleOfOpenTaxYearsTableTextBlock" id="Tb_XWcft6K9SU6BZCm3DNtqjQ" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_DVyyV14ssk6w6xsrUpAbPw" name="us-gaap:OpenTaxYear" id="Narr_HAY5pAfAeEGVCP6sy68nxg">2017</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_JS88tOJOkUqlKtjBD7IPxQ" name="us-gaap:OpenTaxYear" id="Narr_rPSAomW_4023SMnXUaTfgg">2021</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_bOenO2dw9kqQgW48F-LuVQ" name="us-gaap:OpenTaxYear" id="Narr_aS7cwun5yUOpMXd8uaS12g">2017</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_k1N1AROJukiPb2LgQrs-Bg" name="us-gaap:OpenTaxYear" id="Narr_y60Fa1xY3US03Atq_gH4yg">2021</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_73f960ad_5752_420d_8783_ad8d2e519d13"></a><a id="Tc_fnRuX3eyoUagTi4aLDjOmw_1_2"></a><a id="Tc_vRaI9hhaOk6fAhJB8im7hA_2_0"></a><a id="Tc_gK7wmNbVhkiiv07ibq8KSQ_2_2"></a><a id="Tc_0fuMfmca1Uug5lnHaxCKsA_2_5"></a><a id="Tc_fxKZnYRZWkaV7KrT5A5BYw_3_0"></a><a id="Tc_bNslUikqYUCrGLoUPDSKCA_4_0"></a><a id="Tc_kH7NCoQiqESJlA02fRsE2w_4_2"></a><a id="Tc_FvMt6F40LkOnEPEiAbt4YA_4_5"></a><a id="Tc_bV0UG4eP_UmuuiGKA2GKHQ_5_0"></a><a id="Tc_1qdPm-SICkejuaMMMeWRkg_6_0"></a><a id="Tc_ldyILd59EUyW1bMMJyzqbA_7_0"></a><a id="Tc_Es9W1Qj2QkmmuXoju7ybaQ_8_2"></a><a id="Tc_Xx9pzGGmFUaDnILjRNQQug_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_qYP1J938B0C5kD9EQZTl7Q" continuedAt="Tb_qYP1J938B0C5kD9EQZTl7Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;13&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 54pt;">Balance sheets:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_rLdk9RBG9EqQYKEoEWzxMQ" continuedAt="Tb_rLdk9RBG9EqQYKEoEWzxMQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsInstitutionsCurrent" scale="3" id="Tc_KTe69hs9XkuCeLve-EFBMQ_4_3">771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsInstitutionsCurrent" scale="3" id="Tc_5tyXvrCqQEWvsxrVqYikHA_4_6">311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_7TJusOWogEStun4t5gnwoA_5_3">436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_AFsQmauf_EmdcesnCxiiBA_6_3">841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_TaFd6prfpEeD01JWszX7zQ_6_6">905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsSundryCurrent" scale="3" id="Tc_6vJ4J0ECcE-07_zBVOdstA_7_3">48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="plx:OtherAssetsSundryCurrent" scale="3" id="Tc_X9rNsjDNn0i3EMGN1jkCMQ_7_6">69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_-KA7XQ5f2U214gWSHH_cCA_8_3">2,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_4002VRRT5kWH2W_z9ZyOKA_8_6">1,285</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6a48e2ae_f89a_48d3_981e_fd922cca3af8"></a><a id="Tc_yLBvY3Zkg028vdfKz4Oxsg_1_2"></a><a id="Tc_bQ468Va6a0iktQvnU-sr1g_2_0"></a><a id="Tc_KS2904Du9EmnKQawlQlKAA_2_2"></a><a id="Tc_zXRcXVn9Z0SIVOtqYFsPCQ_2_5"></a><a id="Tc_gdpMyjPUf0m1AioiTxVqzw_3_0"></a><a id="Tc_cyBls4Q4uEW6Wr7LzXaxLQ_4_0"></a><a id="Tc_CtKZMaoCWkeDGkrIwdeDqQ_4_2"></a><a id="Tc_bkFER0uf20yUFqWCrMIEDA_4_5"></a><a id="Tc_jnT0GGqTzk6lufMMOR6BQg_5_0"></a><a id="Tc_G_lu5HMQhEaWlnEG5qragA_6_0"></a><a id="Tc_7AzyU5-EREOq-Jg0soPMJw_7_0"></a><a id="Tc_3YU4evyxOkmdLS5JSvdb8w_8_0"></a><a id="Tc_AiPdz2mOGU6o_QEtb3hsnw_9_0"></a><a id="Tc_Aq3PTpPdtUK1kO13uHB1Dw_10_2"></a><a id="Tc_-BUXXmLkp0-bi4_jjCOGyA_10_5"></a><ix:continuation id="Tb_qYP1J938B0C5kD9EQZTl7Q_cont1"><ix:continuation id="Tb_rLdk9RBG9EqQYKEoEWzxMQ_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_GzcnRQD4ZkGH_R-usx5IQg_4_3">1,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_DBqed8rkK0ux9CMiwxDg6g_4_6">1,562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_Lv_mqZY2ZUapDI09lZqQjQ_5_3">555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_ok4US0y9e0eMS4RV_I1flQ_5_6">767</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_AgVU-ZVGdUWGxRgqKR_a-w_6_3">1,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_BZmMKjUrfEemdp8UMyM-ow_6_6">1,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_iYYaJVuFQE29AI2OxsT_5w_7_3">9,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_NxtxQiFJgk2ygGC8vv_SgA_7_6">11,981</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_hwqxjrGZMkC-pXPrfIO-ww_8_3">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_YqoKDhhq2E6fJWzFnhCHOQ_8_6">522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_l_AmYt60qE69Fcn3J5sRig_9_3">317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_Sx8vCFDFhk6cEdMP9wxQow_9_6">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_o9TetTO6-E2a0IA2ducRKg_10_3">13,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_xVnuoCfqGUmgryBKfghnMQ_10_6">16,433</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_vtdBKHCYX0qEiHDl_BCYMw_1_2"></a><a id="Tc_494e_Deb9EefAXQnA1q4Sg_2_0"></a><a id="Tc_Yqc4KffiHkiPVdEhQTX_rw_2_2"></a><a id="Tc_3UpXsbInH0-4ArQ_TUEMfg_2_5"></a><a id="Tc_wKkOq8Z8zUmfW_y-bhZJEA_2_8"></a><a id="Tc_ZfpMUAZeSU--_Ir2TAKcXg_3_0"></a><a id="Tc_th3gn50HyUitMJpSOlYUXg_3_2"></a><a id="Tc_9idMjHCBU0Gs1liqswAf3Q_3_5"></a><a id="Tc_DwgeT7J5fk2lnK-6aLQlWw_3_8"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_-iSse8eS6kK-pcTWxqZQyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;14&#160;- RELATED PARTY TRANSACTIONS</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_c-zb-R98IEiBXeXlC1Jo0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_Pn1OJZqDxUCu6sqgk4Nceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_w8jX-zlzjkG8uqtVKes-cQ_3_3">444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_DhX0f2VRfE65d2xBozNi3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_YmBJWnXe2Ea9-kbqZjIjgQ_3_6">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_0yT3uJM1BkaHr4dUCEjvtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_9vhnTXrDgkaBnLPNx3mwIw_3_9">475</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_krEMap1cdkS-2w4puawLiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;15&#160;- SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On February&#160;25, 2022, the Company granted (i) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E0uJdNzPMUWVe1_NyQJfUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_rFQETHemEEuuhxSw9Jjr0w">637,531</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock to its President and Chief Executive Officer and (ii) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__onSW-uv_0Sf9fAA3WmGWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_2fFped45Nk2zUVIGD78kZA">121,951</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer, both under the Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January&#160;12, 2022 and February&#160;2, 2022, the Company collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_1_12_2022_To_1_12_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ph-iL0zoGk631_yyBbBhuQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_l42cHFod3US2Zk2M6j24KA"><ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_2_2_2022_To_2_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_TdEixVwmTkix-fdRgGxOWw" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_pGAdCyKyD0-nFRUMPloNsg">1.2</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On March 22, 2022, the Company collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA" contextRef="Duration_3_22_2022_To_3_22_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_Ak-XTuYc0UeiX460wPg5iA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_SPrtF6YMLUG_SvCxJL1VZQ">2.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales of alfataliglicerase to Fiocruz.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>plx-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/31/2022 11:05:09 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="plx-20211231xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:93.95pt;width:111.05pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 24pt 0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM<sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;"> </sup></p><p style="font-family:'Georgia';font-size:10pt;line-height:12pt;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-230604 and 333-237736) and on Form S-8 (No. 333-148983, No. 333-182677, No. 333-203960, No. 333-225526 and No. 333 239101) of Protalix BioTherapeutics, Inc. of our report dated March 31, 2022 relating to the financial statements, which appears in this Form 10-K.</p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:85.31%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="background-color:#ffff00;">X</font>, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:18.25pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tel-Aviv, Israel</b></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March 31, 2022</p></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Kesselman&#160;&amp;&#160;Kesselman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certified Public Accountants (lsr.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">A member firm of PricewaterhouseCoopers</b></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">International Limited</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:18.25pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>plx-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/31/2022 11:05:11 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<b style="font-weight:bold;">) </b>for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;31, 2022</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>plx-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/31/2022 11:05:14 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<b style="font-weight:bold;">) </b>for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;31, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President, Chief Financial Officer, Treasurer &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>plx-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/31/2022 11:05:16 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt -0.05pt;">This Certificate is being furnished to the Securities and Exchange Commission as an exhibit to the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;31, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>plx-20211231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/31/2022 11:05:19 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Sr. Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt -0.05pt;">This Certificate is being furnished to the Securities and Exchange Commission as an exhibit to the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;31, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20211231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20211231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D ]D# 2(  A$! Q$!_\0
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MX6-J?_/M;_K7&T4 =E_PL;4_^?:W_6C_ (6-J?\ S[6_ZUQM% '9?\+&U/\
MY]K?]:/^%C:G_P ^UO\ K7&T4 =E_P +&U/_ )]K?]:/^%C:G_S[6_ZUQM%
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M+:R>*&-)6P64'/'-=]7CGA#_ )&JQ_WS_(U['0 4444 %%%% !1110 4444
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M_P!*JD8)%>JSAFU/2GE4F9'GC9F*E@-A(!V\#UQ7E;??/UH EN?]8G_7-/\
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M W, .IXJ6T_X_(?]\?SJ./\ UB?44(#:?PGJ::I;:>1$9;B,R(P8[<#U./\
M.:R+JW>TNI;>3&^)BK8/&17ILMW&LTTS$>?;31VT?^[*(R?_ &:C1HO+GNY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#R#QI_R-5W_P !_D*Y^N@\:?\ (U7?_ ?Y"N?H **** "BBB@
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MQX<_Z"0_[]2?_$T<LNP?7,-_S\C]Z+O_  C>B_\ 0-M_^^:/^$;T7_H&V_\
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M1?\ H&V__?-4O^$X\.?]!(?]^I/_ (FC_A./#G_02'_?J3_XFCEEV#ZYAO\
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M;_\ ?-:>Y?4?G1N'J* ,HZ'IEH\<UO90Q2K(N'08(Y%:U0W!!C7!_P"6B?\
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M9(\\$Y/XYKH/^%;ZW_SULO\ OXW_ ,32?\*XUO\ YZV?_?QO_B:.: _JF/\
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M]ZT_[^-_\31SQ[A_9N+_ .?;.8HKIO\ A!-9];7_ +^-_P#$TG_""ZSZVO\
MW\/_ ,31SQ[A_9N+_P"?;.:HKI/^$'UGUM?^_C?_ !-)_P (1K'_ $Z_]_#_
M /$T>TCW#^S<7_S[9SE%=%_PA.L?].O_ '\/_P 32?\ "%ZQ_P!.W_?P_P#Q
M-'M(]P_LW%_\^V<]16\O@[5W!(%MP2/]8>W_  &E_P"$-UCTMO\ OX?_ (FC
MVD>X?V9B_P#GVS HK>_X0[5_2V_[^'_XFC_A#]7]+;_OX?\ XFCVD>X?V9B_
M^?;,&BMW_A#]7]+;_OX?_B:/^$/U?^[;?]_#_P#$T>TCW#^S,7_S[9A45N_\
M(AJ_]VW_ ._A_P#B:3_A$=7_ +MO_P!_#_\ $T>TCW'_ &9B_P#GVS#HK<_X
M1#5_[MO_ -_#_P#$TO\ PB&K_P!VV_[^'_XFCVD>X?V9B_\ GVS"HK=_X1#5
M_P"[;?\ ?P__ !-'_"(:O_=MO^_A_P#B:/:1[B_LS%_\^V85%;O_  B&K_W;
M;_OX?_B:/^$/U?TMO^_A_P#B:/:1[A_9F+_Y]LPJ*WO^$/U?TMO^_A_^)H_X
M0[5_2V_[^'_XFCVD>X?V9B_^?;,&BM__ (0W6/2V_P"_A_\ B:3_ (0_5Q($
MQ;9()_UA[8_V?>CVD>X?V9B_^?;,&BN@_P"$,UCTMO\ OX?_ (FE_P"$*UCT
MMO\ OX?_ (FCVD>X?V;B_P#GVSGJ*Z+_ (0G6?\ IU_[^'_XFE'@C6?^G7_O
MX?\ XFCVD>X?V;B_^?;.<HKI/^$&UD][7_OXW_Q-+_P@FLGO:_\ ?QO_ (FC
MGCW#^S<7_P ^V<U173_\(%K/K:?]_&_^)I1X!UH_Q6G_ '\;_P")HYX]P_LW
M%_\ /MG+T5U/_"O]:/\ %:?]_&_^)IW_  KW6O[]I_W\;_XFCGCW#^S<7_S[
M9RE%=9_PKS6O[]G_ -_&_P#B:7_A76M_\]+/_OXW_P 31SQ[A_9N+_Y]LY*B
MNN_X5SK?_/2S_P"_C?\ Q-+_ ,*XUO\ YZ6?_?QO_B:.>/</[-Q?_/MG(45U
M_P#PK?6_^>MG_P!_&_\ B:7_ (5OK?\ SULO^_C?_$T<\>X?V;B_^?;./HKK
M9?AUK443R-+9[44L<2-T'_ :?_PK;6_^>ME_W\;_ .)HYX]P_LW%_P#/MG'T
M5V'_  K;6_\ GK9?]_&_^)I?^%:ZW_SULO\ OXW_ ,31SQ[A_9N+_P"?;..H
MKL?^%:ZW_P ];+_OXW_Q-'_"M=;_ .>ME_W\;_XFCGCW#^S<7_S[9QU%=C_P
MK76_^>ME_P!_&_\ B:/^%:ZW_P ];+_OXW_Q-'/'N']FXO\ Y]LXZBNQ_P"%
M:ZW_ ,];+_OXW_Q-'_"M=;_YZV7_ '\;_P")HYX]P_LW%_\ /MG'45V/_"M=
M;_YZV7_?QO\ XFC_ (5KK?\ SULO^_C?_$T<\>X?V;B_^?;..HKL?^%:ZW_S
MULO^_C?_ !-'_"M=;_YZV7_?QO\ XFCGCW#^S<7_ ,^V<=178_\ "M=;_P">
MME_W\;_XFC_A6NM_\];+_OXW_P 31SQ[A_9N+_Y]LXZBNQ_X5KK?_/6R_P"_
MC?\ Q-'_  K76_\ GK9?]_&_^)HYX]P_LW%_\^V<=177R?#G6HXV=I;/"@DX
MD;_XFG?\*UUO_GK9?]_&_P#B:.>/</[-Q?\ S[9QU%=C_P *UUO_ )ZV7_?Q
MO_B:/^%:ZW_SULO^_C?_ !-'/'N']FXO_GVSCJ*['_A6NM_\];+_ +^-_P#$
MT?\ "M=;_P">ME_W\;_XFCGCW#^S<7_S[9QU%=C_ ,*UUO\ YZV7_?QO_B:/
M^%:ZW_SULO\ OXW_ ,31SQ[A_9N+_P"?;..HKL?^%:ZW_P ];+_OXW_Q-'_"
MM=;_ .>ME_W\;_XFCGCW#^S<7_S[9QU=!X.M/M.NI(1\L"E_QZ#^=:/_  K7
M6_\ GK9?]_&_^)KI/#7A"\T:";SW@::5ARC$C:.G;W-3.:MHSJP.6U_;Q=2#
M26IKAJD#4\:=<#NGYFGBPG'=/SKF/K$F,#4X&GBQF'=/SIPLY1W7\Z"K,:#3
M@:<+67U7\Z<+:3U7\Z!V8T&ES3OL[^H_.E$#^HH'9D;]%_WT_P#0A5VJDD;(
MJDX^^G_H0JW292* _P!9-_UT-.J#S7$LP$$A_>'D%?\ &G><_P#S[2_FO^-
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MOS3_ .*H\^3_ )])OS3_ .*H FQ2XJ#SY/\ GTF_-/\ XJCSY/\ GTF_-/\
MXJ@!+W_CPN?^N3?R-6*I7DTALK@&UE ,;<DIQQ_O5-Y\G_/I-^:?_%4 3T5!
MY\G_ #Z3?FG_ ,51Y\G_ #Z3?FG_ ,50!/14'GR?\^DWYI_\51Y\G_/I-^:?
M_%4 3T5!Y\G_ #Z3?FG_ ,51Y\G_ #Z3?FG_ ,50!/14'GR?\^DWYI_\51Y\
MG_/I-^:?_%4 3T5!Y\G_ #Z3?FG_ ,51Y\G_ #Z3?FG_ ,50!/14'GR?\^DW
MYI_\51Y\G_/I-^:?_%4 3T5!Y\G_ #Z3?FG_ ,51Y\G_ #Z3?FG_ ,50!/14
M'GR?\^DWYI_\51Y\G_/I-^:?_%4 +=_\><W^XW\JFJG=3R&TF!M9A\AY)3CC
M_>J7SY/^?2;\T_\ BJ )Z*@\^3_GTF_-/_BJ//D_Y])OS3_XJ@">BH//D_Y]
M)OS3_P"*H\^3_GTF_-/_ (J@">BH//D_Y])OS3_XJCSY/^?2;\T_^*H GHJ#
MSY/^?2;\T_\ BJ//D_Y])OS3_P"*H GHJ#SY/^?2;\T_^*H\^3_GTF_-/_BJ
M )Z*@\^3_GTF_-/_ (JCSY/^?2;\T_\ BJ )Z*@\^3_GTF_-/_BJ//D_Y])O
MS3_XJ@">BH//D_Y])OS3_P"*H\^3_GTF_-/_ (J@">BH//D_Y])OS3_XJCSY
M/^?2;\T_^*H 6Y_U:?\ 71/_ $(5-5.>:0J@-M*H\Q.25_O#WJY0!0'^LF_Z
MZ&G4T?ZR;_KH:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 267^J?_ *Z&K-<M<^)&TZ[FMA;APKYW%L=:
MB_X3-_\ GS7_ +ZH ZZBN1_X3-_^?-?^^J/^$S?_ )\U_P"^J .NHKD?^$S?
M_GS7_OJC_A,W_P"?-?\ OJ@#KJ*Y'_A,W_Y\U_[ZH_X3-_\ GS7_ +ZH ZZB
MN1_X3-_^?-?^^J/^$S?_ )\U_P"^J .NHKD?^$S?_GS7_OJC_A,W_P"?-?\
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M!S],U$I/GV[(1]A"/]HY^7.6SN]^F/TH YW:<9P<4$$#)!Q6^\I9I(2^8A8
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M:4&@"0&G U&#2@T") :<#48-*#0!*#3@:B!IP-,"4&E!J,&E!H =(?\ 5_\
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M7-=#]@M?^>*T?8;7_GBM '/YI<UO_8;;_GBM'V&V_P">*T 8.:<#6Y]BMO\
MGBM+]BMO^>2T 8>:4&MO[';_ //):/L=O_SR6@#&!I0:V/LEO_SR6E^R0?\
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MH FVBDVBHOLW_3:;_ONC[-_TVF_[[H EV#THV"HOLW_3:;_ONC[-_P!-IO\
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MSPA_7_&CE8>UB=517*_\)1=?\\(?U_QI?^$HNO\ GA#^O^-'*Q^UB=34+?\
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M,.=&G169_:4G]Q*7^T9/[BT68<Z-*BL[^T)/[BT?VA)_<6BP<R-&BL_[>_\
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M]GDB>0#8=V<^A'TJK1_KYF7//1V_K3_@F]=:WIUG)''/=*K2 ,N 2,'H20,
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M$VGS&!&1Q[U$NO3'PW+J3Q1QRJY148G .[:,U=L;6:'5=2FD3$<SH8SD<@*
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MGOY@\D[B^V[4DV;$!.&)Z[?;I2:B)O,O$TAMLRW[M((V ^4CY2?]GK[4<_\
M7W#]EY_UK_D<M-93P1P.Z'$Z[TQW&<?TJ(12%BHC8D=1CI751R3/:6^)2TYL
M72 [\_O _('OMI[W$EOHEWNE*WRVL0E(;YL^8< GUVXH<A>S3.0*,"05.1R1
MCI5JVTVZNHC+$B",';ODD5%SZ98C)K8N[A&T'[?N!NKM%M7]?DY8_B GZU!'
M$U]I%BEM"+AK=W\Z#=@G)X/'..V?:G<GD1D7-M-:3M!/&8Y%ZJ:BKLI84C4K
MIBQR70>$7"EQ)L7;\P!)/ /!J1;.UGO[62TCB:UBGN/,;C '.,_TI<Q7LNQQ
MLUO+;[/-C9-Z!USW4]#4=;GB25YVT^3.Z,V<8# #&X#D5AU29G)6=@HHHIDA
M1110!=TN7R[P*3PXQ6]7-6B&2ZB5>NX'\JZ2H9K#86EIM+2-![=1]!24-U'T
M%)0-[BTM-I:!#J6FYHH =2TVEH&+FEIM+2 =FEIN:6@!:7--S2T#'44VES0
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M^%'VF/\ N3?]^6_PJQ10!7^TQ_W)O^_+?X4?:8_[DW_?EO\ "K%% $'VF/\
MN3?]^6_PH^U1_P!R;_ORW^%3T4 0?:H_[DW_ 'Y;_"C[5'_<F_[\M_A4]% $
M'VJ/^Y-_WY;_  H^U1_W)O\ ORW^%3T4 4KRY1K&X 27F-AS$P[?2IOM4?\
M<F_[\M_A1>_\>%S_ -<F_D:GH @^U)_<F_[\M_A1]J3^Y-_WY;_"IZ* (/M2
M?W)O^_+?X4?:D_N3?]^6_P *GHH @^U)_<F_[\M_A1]J3^Y-_P!^6_PJ>B@"
M#[4G]R;_ +\M_A1]J3^Y-_WY;_"IZ* (/M2?W)O^_+?X4?:D_N3?]^6_PJ>B
M@"#[4G]R;_ORW^%'VI/[DW_?EO\ "IZ* (/M2?W)O^_+?X4?:D_N3?\ ?EO\
M*GHH @^U)_<F_P"_+?X4?:D_N3?]^6_PJ>B@"G=7*&TF&R;E#UB;T^E2_:D_
MN3?]^6_PI;O_ (\YO]QOY5-0!!]J3^Y-_P!^6_PH^U)_<F_[\M_A4]% $'VI
M/[DW_?EO\*/M2?W)O^_+?X5/10!!]J3^Y-_WY;_"C[4G]R;_ +\M_A4]% $'
MVI/[DW_?EO\ "C[4G]R;_ORW^%3T4 0?:D_N3?\ ?EO\*/M2?W)O^_+?X5/1
M0!!]J3^Y-_WY;_"C[4G]R;_ORW^%3T4 0?:D_N3?]^6_PH^U)_<F_P"_+?X5
M/10!!]J3^Y-_WY;_  H^U)_<F_[\M_A4]% $'VI/[DW_ 'Y;_"C[4G]R;_OR
MW^%3T4 4Y[E&5 %E_P!8G6)A_$/:KE0W/^K3_KHG_H0J:@"@/]9-_P!=#42W
M<;7SV@#>8B!R<<8)Q4H_UDW_ %T-8T]Y#8^()9)RZHT"@%4+<Y]A515R9RLK
MFRSJI 9@">F3UH,B*<%U!]S7-ZBT$UU-+/%-*LL"_9"J'AN?R.<5'-9-+'>O
M=1EYX[6+!]&P<_C5JFK:LAU'>R1U#.BG#,H/N:4LJH7)^4#.?:N4U'R=]W]J
MC=YC;(8" 3CCGZ5K7KR+X>1(@3)+&D:_4@"DX6L"J7;+6GZG!J4;O"LBA#@A
MP ?KUJ6>[@MK=YW<;$Z[>:Y[R=1LII872(&XMBB>1N(W(.,Y[XIIBLIM)N4M
M;282+"ID+*0NX'WZMUJG35[K8E5)6L]SHTND>5DPP"J&WG&TY]#4H=6SA@<=
M<'I7-7"(\-]]GC(A:UB" *1W-+<VWV8:C';HR1F"-B%[\_-^.*7(A^T9TBNC
M?=93]#5:XU"&WDD1E=C'$96V@<#_ !K+T?[,=7G-I&R0F!, J1W/8TZ[!-SK
M (RQMEVCVP?ZTN1)V*4VU<VXW$D:R#(# $9JG9ZM;WK3K$LF8>NX#YASR.?:
MJ8UBW;3'2 R-,D/"F-ASP.X]352S@O=-OK)KE(/*=/()BW$^H+9]Z:AO<EU-
MK?,Z"VN([JV2>/.QQD9ZBL^/7K=V7=;W,<3/L$SQC9G..H/K2Z"#_9A/\)ED
M*_3<:RH[A9=&.FQI(UT\I&W8<#Y\YSTZ4*"NT#F[)FVNJV[7%U!\_F6R[G&!
MR,9XYJQ#<Q36\4P.U9%#*&(!YKF[NUG6;4KN!298G (Q]]"@##^M5]05Y+6V
MC,3!EM%*-Y;,2?0=A]:?LT[6_K07M9*]UW_,[ NH8*6 )Z GK2[U#;=PW'MG
MFN2U!/\ 28Y=LCS&./:CQDANGW6!X]\T2V\[ZXYDDFCF,RF,+!O^7C^+(P/6
MA4EW!U7V.GFND@G@B8,6F8JN.@(&>:GK.OU)U'32 2!*V?;Y36C636B-4]6@
MHHHI%!1110 4444 9C>)-/TZ:6VN#)YBN2=J9'-'_"9:3_>F_P"_=<=XA_Y#
MMS_O#^59FUMN[!VGC..*ZXT(N*9PSQ$U)I'HG_"9:3_>F_[]T?\ "9:3_>F_
M[]UYZL4C'"QL3C. .U+Y$V<>5)GTVFJ]A 7UFH>@_P#"9:3_ 'IO^_='_"9:
M3_>F_P"_=>>/&\>-Z,N>FX8I%5G;:JECZ 9H]A 7UF9Z)_PF6D_WIO\ OW1_
MPF6D_P!Z;_OW7GCQR1XWHRY]1BD +' !)/84>P@'UF9Z)_PF6D_WIO\ OW1_
MPF6D_P!Z;_OW7G5&".M'U> ?69GHO_"9:3_>F_[]T?\ "9:3_>F_[]UYU3MC
M;]FT[NF,<T?5X!]9F>A_\)EI/]Z;_OW1_P )EI/]Z;_OW7GK12)C?&RYZ9&*
M:002""".QH]A /K-0]$_X3+2?[TW_?NC_A,M)_O3?]^Z\ZHH^KP#ZS,]%_X3
M+2?[TW_?NC_A,M)_O3?]^Z\ZHH^KP#ZS,]%_X3+2?[TW_?NK-KXFTR[#%)7&
MWJ&0UYC5[2I=EWM)X<8_&D\/$:Q,[GI']M6'_/8_]\'_  H_MFP_Y['_ +X/
M^%<I2U/L(FGMY'2P:O9(C!ICR['[I[D^U2_VS8_\]C_WP?\ "N4%.H5&(W7D
M=3_;-C_SV/\ WP?\*/[9L?\ GL?^^#_A7+44>PB'MY'4_P!L6/\ SV/_ 'P?
M\*7^V+'_ )['_O@_X5RPHH]C$/;R.I_MBQ_Y['_O@_X4?VQ8_P#/8_\ ?!_P
MKEJ6CV,0]O(ZC^V+'_GL?^^#_A1_:]E_SV/_ 'R?\*Y<4X4O8Q#VTCIO[7LO
M^>I_[Y/^%+_:]E_SU/\ WR?\*YD44>QB/VTCIO[6LO\ GJ?^^3_A1_:UE_SU
M/_?)_P *YH4HH]C$/;2.D_M:R_YZG_OD_P"%']JV?_/4_P#?)_PKFZ6E[&(>
MVD=)_:MG_P ]3_WR?\*B;4K0W4;>8<!&!^4^J_X5@BD/WQ]#_2ATHC]K(Z3^
MU+3_ )ZG_ODTO]IVG_/7_P =-<Z*6CV40]K(Z'^T[3_GK_XZ:/[2M/\ GK_X
MZ:Y^EI>R0_:LW_[2M/\ GI_XZ:7^T;7_ )Z?^.FL"G"CV:#VC-W^T;7_ )Z?
M^.FC^T+7_GI_XZ:PQ2T>S0>T9N?VA;?\]/\ QTT?;[;_ )Z?^.FL2EI>S0_:
M,VOM]M_ST_\ '32_;K?_ )Z?^.FL6G4O9H/:,V/MUO\ W_T-'VVW_O\ Z&L@
M4X4<B'SLUOML']_]#1]L@_O_ *&LH4M'(@YV7KRZA:QN 'Y,; <'TJ?[7#_?
M_0UCS_\ 'M+_ +A_E4HI<B'SLT_M4/\ ?_0T?:H?[_Z&LX4"CD0<[-'[3%_>
M_0TOVF+^]^AK/I:7*A\S+_VB+^]^E'VB+^]^E4:6CE0<S+WVB/\ O?I1Y\?]
M[]*I4M'*@YF7/.C_ +WZ4>='_>_2J@I:7*.Y;\Y/7]*/-3U_2JM**+!<L^:G
MK^E'F)ZU7I:+!<L>8OK1YB^M0"BBP[BW3K]DFY_@/\JFWKZU4N?^/67_ '#_
M "J84K!<EWKZT;U]:BI:+!<EW#UHW#UJ,4"BP7)-P]:,BF4M #LBC(IM% #\
MBC(IM% #LBBFTM(8M%)10 M%)0* %HHHH AN?]6G_71/_0A4U0W/^K3_ *Z)
M_P"A"IJ * _UDW_70TZFC_63?]=#67?7\Z7-S'"P5;>V,C<9RQZ?RII7$W8U
MJ*YVQU.Y>YA3[=%=K+$6<)&%,1 SSBHK+5KN1+64ZA%/)(X5[81 , 3UR*OV
M3,_;1-JYTFSO)_.FC)?&#AB P]\=:N    # '2L.XO[Z+43IRMF65PT4NT86
M/OD>HQ6S,[Q0,Z1F5P.$'!8TFG97*BXW=D245B0ZC?-HLMP8A)<B1UP, )C/
M)]ABF2ZC=M!8*D\<+S0>:\KKD$@ X HY&+VB-ZHYX8[B%X95W(XP1ZUF6VJ2
M32:<[ ".Z1@0.SCO_.M>DXN.Y49*2T*MGI]M8[O(0@MU+,6/YFIO(C^T>?C]
MYMV9SVZU)12;;U&DDK(*1E#*5/0C%+12&,AA2"%(HQA$& *?110 4444 %%%
M% !1110 4444 %%%% !1110!YWXA_P"0[<_[P_E5VT$<_A^WLY<#SYI!&Y_A
M< 8_ ]/QJEXA_P"0[<_[P_E5$W,IMHX"W[N-BZC'0G&?Y5WI7@CS)2Y:C9T3
M#R1=+-)+"5L80QC7+*>.V1_.LF"XQJEMY%W<R*9%!,@V'KTP&/%,;6+QYI)9
M&21I$"/O0$$#I5=KMVFCE"1(T9RNQ O/X4XQ:W%*2>QM21PW=]>K*5GN!<LJ
M0RS%/ER?NGIG.*IZ.ACUDH<QLJR [OX?E/7%5DU*X2223]VS._F$M&#AO4>E
M0QW<T5PTZO\ O6W98C.<]?YT*+2L-S3=_,VDMS+8PVTMT+D75PH21=Q$8&<\
ML <G/2I+2TMTO[::(11NMQLV),)-RX/)Y.#Q^M84-Y/!"T4;X1F#].C#H1Z5
M,=5NS+'(&12C;QM0 %O4^II.+Z#4XZ7-&/3;9[=@Z*LAMS,"SG?GKPHXV_7F
MI[BT@N,SF&("&TAQ&9"BL6'<D]N:R%U:[6/8&3[GEEM@R5],TT:I=#;EE($8
MB(9 0RCH#ZXHY9"4XVV-":RL[(?: @G1WC54$F0F1D\CKCH*>W_(Z$CC]_Q^
M59JZK=B1W+JV_!(9 0,=,#MBHS?W!U#[<6'G[M^[:,9^E/E?4'.-M/ZW-"Q=
MKN*_CN9&=%4.I8D[6W@#!_$U-)86K3W,44:S3K,ZF-YBK@#H5]?QS65)J$\B
M;!Y:+N#$1H%R1TSCK3QJMUO:3,9=F+[S&,@GJ0>U+E?0%.-K,T'TJVBA\IS&
MK_9_-\TS#=NQG&W/3MTIS:7:?9)]RB-XH4DSO)DY(SE1P!SQWZ5E_P!I77D>
M5O&-NS=M&[;Z9ZXIYU>[,;IN3]XH1SL&6 QC)_"CEEW!2AV-%=*M[FZB6%(_
MLQ<_OHYLY 4G# ]#Q["HQ9Z?O@DF:&(-O4QK-O3(&5RP)(![U0.J71*E61"K
M;_D0+D^IQUH.I7!=&_=@(" @C&WGKQTI\L@YH]@U&W-O<*/($2L@8!9-ZM[@
M^E58V*2*PZ@@BI+BZENF4R$?*NU548"CT IUC#YUY&IZ Y/X52T6I#LWH=$I
MR >F:=24M2:B"G4T4ZDMAO<****8"BB@44@"EI*6@ %.%-%.%(8HHH%% "BE
M%(*44#"EI*6D HI#]\?0_P!*44A^^/H?Z4F-#Q2T@I:!BTM)2T +3A3:<*0Q
M12T@I:0Q:6DI: %IU-IU(8HIPIHIPI#%%+2"EH&,G_X]I?\ </\ *I144_\
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M>D/YG_"C^P+K_GI#^9_PKHZ*/;2#V,3G?[ NO^>D/YG_  H_L"Z_YZ0_F?\
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MF7\E_P *** #[*?^?F7\E_PH^RG_ )^9?R7_  HHH /LI_Y^9?R7_"C[*?\
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M !-)_:FH_P#/Z_\ WPG_ ,3110 G]JZC_P _K_\ ?"?_ !-']JZC_P _K_\
M?"?_ !-%% "?VKJ7_/Z__?M/_B:3^UM2_P"?U_\ OVG_ ,3110 ?VMJ7_/Z_
M_?M/_B:/[6U+_G]?_OVG_P 3110 O]K:E_S^O_W[3_XFC^U=1_Y_7_[]I_\
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M;1O=2E6!4C:G0_\  :D!G_Y^I?\ OE/_ (FBB@!?W_\ S]2_]\I_\33L3?\
M/U+_ -\I_P#$T44 +MF_Y^I?R3_XFEV2_P#/U+^2?_$T44 +LE_Y^I?R3_XF
MCRY?^?J7\D_^)HHH 7RY?^?J7\D_^)H\N7_GZE_)/_B:** #RY?^?J7\D_\
MB:/+E_Y^I?R3_P")HHH /+E_Y^I?R3_XFCRY?^?J7\D_^)HHH /+E_Y^I?R3
M_P")H\N7_GZE_)/_ (FBB@ \N7_GZE_)/_B:/+E_Y^I?R3_XFBB@!'@>1&1K
MF4JPP>%_^)I?+E_Y^I?R3_XFBB@ \N7_ )^I?R3_ .)H\N7_ )^I?R3_ .)H
MHH /+E_Y^I?R3_XFCRY?^?J7\D_^)HHH /+E_P"?J7\D_P#B:/+E_P"?J7\D
M_P#B:** #RY?^?J7\D_^)H\N7_GZE_)/_B:** #RY?\ GZE_)/\ XFCRY?\
MGZE_)/\ XFBB@ \N7_GZE_)/_B:/+E_Y^I?R3_XFBB@ \N7_ )^I?R3_ .)H
M\N7_ )^I?R3_ .)HHH /+E_Y^I?R3_XFCRY?^?J7\D_^)HHH /+E_P"?J7\D
F_P#B:/+E_P"?J7\D_P#B:** $,#OC=<2D!@<87L<^E6J** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20211231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20211231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (  \L# 2(  A$! Q$!_\0
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MPW::#X8OFMI9W,NS=YI!Q@]L 5AI8^%/[/61M6NUN]F=@7@-Z?<_K7:>,_\
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MY'\J75/^1P\/_P#7,4V6>7PGXDOKN>WEET^]P_F1C.UO\DUC&_+'E^+ET_\
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M25QC_"I+3QQ%9V26M]97*7L:A-@7AB.*ATNRNWTW6]8O(S$]W$^R,C!QC/\
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MK&ZMB03G(Z'RFX_2AKNV88;<1Z&-O\*LT4#L5EN[9!A<K](F']*7[;!_>?\
M[]M_A5BB@"JUU:O]X%OK$Q_I2B\ME&!N ]!&W^%6:* L5//L_P"Y_P"03_A2
MBYM5!"@C/7$1_P *M44[L5D5//L_[G_D$_X4OVFT*A=O [>4?\*M4478614\
M^S_N?^03_A3_ +;;D8RW_?MO\*L44K@DD5//L_[G_D$_X4OVFTQC;QZ>4?\
M"K5%.["R*WVNVW!N<CH?*;_"D:ZMFQN!./6)O\*M44AV*K7-JYRP)/O$?\*0
M7%F#D)@_]<C_ (5;HIW8K(K-=VSC#9;ZQ,?Z4+=VRC"[@/:-O\*LT4AV*QO+
M=A@EB/0QM_A0+RW48!8#T$;?X59HH K_ &V#U?\ []M_A31<V@.0I!]1$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5[+_ %#?]=9/_0VJQ5>R
M_P!0W_763_T-J !/^0C-_P!<D_F]6*KI_P A&;_KDG\WJQ0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !112;AZT +12;AZT9% "T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 44R26.%=TLB(OJS 5']NM/\ GZ@_[^"@">BH/MMI_P _4/\
MW\%21S139\J5'QUVL#0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KV7^H;_K
MK)_Z&U6*KV7^H;_KK)_Z&U  G_(1F_ZY)_-ZL573_D(S?]<D_F]6* "BBB@
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MN*U'CPU-U^X:[71/^0'8_P#7%?Y55?H+!=?D7Z***YSN"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"GJO_(+N/\ =JO ?^)0_N#UJQJO.EW'^[5,'&D,
M,^M7'8PJ.TOD95HNUY%R#@8R*W-$_P"0:O\ OM_.L*QZ2'VQ_P#6K<T/_D&+
M_OM_.M*NQAA?B-*BBBL#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH HS?\A6#_ '/\:R-88C4N/0?A6O-_R%(?]S_&L;59"U_MXQD&MJ>Z]#CK
M_"_4KW1SJNF?]=A_(UU]<?=?\A;2_P#KM_0UV%34W-</\(4445F;A1110 44
M44 %%%% !1110 4444 %5[+_ %#?]=9/_0VJQ5>R_P!0W_763_T-J !/^0C-
M_P!<D_F]6*KI_P A&;_KDG\WJQ0 4444 %9^M:@NEZ1<71."JX7ZGI6A5>ZL
MHKQX&EW$0N)%4'@D=,T <KI7B:6/19$DE%[>Q7"P*Y.!(7(VD^W)'X5/_P )
M)JGV[[ ;.U%S]J^SY\QMF/++[NF>U:.K:#%?--<1*/M4B*GS2%%^4Y#9 )R/
M6JVC^&#:2_:KZ=IKO[09P0^0"4V8)(&>">PK2\7=O^MO^"96FM$11^)+N1+:
M>2UB6SO)7@A=')<,H;!(]#M-1:3K^H)IVGK>PQN]Q8F:.0R8+LH&=W89R#6I
M'X:L8KE9@\[(CO)'"SYCC9LY*C'7D_G4<7A+38[;[.S7$L8M_LZ"23/EIWV\
M=\"E>-G_ %W':5U_78S5\83J]U;M!;2W$9B$9AD)0ES@ DCMBI-0UC6+&]L7
MNHH(HPDSS1HY8.% ((JXOA'3P)MTMR[2JBEV<9&TY4C X(J9O#5FZ1"6:ZD:
M,L2[R9+[N"#QT^F*+QZ E/J8\/C262VGD%O [B'SHQ&[$#G&UCC@\]JE'B&]
MM]52WN8(R\K0H0DA*J'[C(ZUIKX;M!;R0/<7<D3H$"O+D(N<X''\\T^Z\.V5
MW(\CM,DC!,.CX*E.A''6G>-]@M.V^IG3>);UKL6UK:0-(;J2 &1R!A4W9XJ;
M2/$%W?W=K'<6D<4=U"\B%7R04.#GV]*LVOAJQM)$D1YW=)7EW.^269=ISQZ5
M/;:+:6DMK)'YFZV1T3+=F.3FE>(6E?\ KN9$_B344OYHHK*!H([Q;-6,A#%F
M4$'Z GFH)?&,T200O#;17;RSQN9'/ECRFP<$#/.1BMTZ'9F1Y/WF7NENS\W\
M8  _#@5"_ANS)#QRW$,PEDE$L3@,#(<L.G0^E)-=?ZT_SN-J73^M_P!+&'>>
M*;Z^T:[FTVW6(PVGFRO(Q#(3G[OKC&>:M1Z[=(;I4\DM'*B;[F;"C,8;. ,]
M^@J]=>%+&ZB,9FNT#1"&4I+S*HZ;B0<]:)O"MA-*9=\Z2[PX='&0=H7N/0"G
M>)-IZ&*OBN\F>ROPL2VGD3/+&K$[BIQQ_2IH/&DDBE#;PR3.$\KRF)7+'&&)
M'!%:D?A33HX88@TY2+> "^=P?J#QTIX\-6A@:&6XNY5( 0R2Y,>.FWBG>(6G
MW(]$O;Z6YU4:@5#02 !4.5 QGBJ;>*+V'2I-5FLH19MD0L)/FSNVC</?VK9T
MW1X--^T&.6:5KAMTC3-N).,>@JFOA6P"21F2Y:)L[8C+\L>3G*CZ^N:FZN5:
M5C*_X26XO5B1&1)$NXD=X"2CJV> 2/:MWP[<37?AZQN)Y#)+)$"S'J32+H%O
ML42W%U.RRK+OEDR<KT[8Q5VQLHM.L8;2#=Y42[5W')Q0VK-((J5[LL4445)8
M4444 %%%% !1110 4444 %%%% !1110 53N[82H1BKE!&:35Q-7.)U3100=J
MUR=WH\BL3@UZU-;K(.167<Z0D@/R]:Y:F'3>ASSHWV/+X;%_F&T@U:MM+D9Q
ME379OH'SC:,>]:5MI"I@E1FLEA=3-4##TO1?F5BN#776MN(D Q3H;98QP*L@
M8KLITU%'5""B%%%%:%A6-J_ARSU12^!%<=I%'7ZULT4U)Q=T*45)69P$=SJ_
MA6<13*9;4G@'E3]#VKKM,UJSU6/= ^''WHVZBKLT$5Q$T4T:NC=589KD-4\*
M36DGVO29&!7GRP?F'T]:VO&IOHS#EG3^'5'9T5R&D^+F1Q:ZJI1QQYF,?F*Z
MV.1)HP\;!D(R"#G-92@X[FL*D9K0=1114EA1110 4444 4-7_P"/(?[XKGM?
MDW!%Z\_G6QK,^98;8'D_,1^/']:Y[5Y-\FWKS^==-%;'G8J7Q+T*NH_-X;F'
M)RA%=GH1SH-B?^F*_P JY*1#)I#+WQBNC\*W*SZ# @.7AS&_U%%=:)E8-J[1
MM4445S'>%%%% !1110 4444 %%%% !1110 4444 %%%% %+5CC2K@D$_+V^M
M9TKXL-OUJ?79R%M[=<YD?+$=@*HW3;;8#VS6U-:'+7EK\BM8])/I6YH7_(-'
M_71OYUBV2,-Q*D!AP?6M/09@%GMB?F#[Q]#_ )_6JJZHRPSM)&S1117.=X44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %"Y.W4(C_L'^M85\V[4
M>N2/QK6N9@]^V#D(NT_Y_&L2Y8-=Y]QFNBFC@KO\PNR!JVF'MYW]*[&N,U$[
M+JSF_N2J<GIU'],UV8((!'0UG5W-\/\ "PHHHK,Z HHHH **** "BBB@ HHH
MH **** "J]E_J&_ZZR?^AM5BJ]E_J&_ZZR?^AM0 )_R$9O\ KDG\WJQ5=/\
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M5S0TW6?[0N;JV:RN+:>W"ETEV\[AD8()%85OXLU%[BW5]-=Q(UP#''MW$(P
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M] *TJHZ5IW]EV;6XE\S=-)+NVX^^Y;'X9Q5ZI>^AHK]0HHHI#"BBB@ HHHH
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M;E)_*M$@2PO$W0BNFA5O%QM8NG/1Q:L<_P"$KU]-UQ8WD;R+G]VZGH&_A/\
M3Z&O3:\GU&V-O.&0\-R#Z&O0/#&J#5M$AE9RTT7[F8GJ77N?J,'\:Z\/4<DX
MO='J9?6YH.#W1L5GWVB:=J4XFN[?S)%7:#O8<9)['W-:%%=2;6QZ#2>C,;_A
M%-$_Y\O_ "*_^-'_  BFB?\ /E_Y%?\ QK9HI\\NY/LX=D8W_"*:)_SY?^17
M_P :/^$4T3_GR_\ (K_XULT4<\NX>SAV1C?\(IHG_/E_Y%?_ !IK^%-&V-ML
MOFQQ^]?K^=;=%/GEW#V<.R.0TSP3&FV349-Y_P">49P/Q-=5!;PVL0B@B2-!
MT51@5+11*<I;A"G&&R"BBBH+$9@BEF("@9)/:N5G<7UTUR4*E_E0$\A1T^E:
M>OW>R&.QC)\ZZ..!G"CJ3_+\:JV,(:X7;]R,5S5Y-M074XL5)MJFNI)+$MO:
M;=QR!DDC/-83V^X[RY.>[*/\36YJC[82!@DFL=5+D 5R5ZBC+E2.#$32ERI%
M?[/M8'S<8YX3/]:V8H8YH6!9QQN'&.?UJL+,F-B'&5[>M6K5BL:$_2JH5'LU
M8FG)IV:,:*9K#65N<DX;!YZKWKO58.@93E2,@CO7%ZG:YWNHY!SC%:_AF],]
MJ]LY^:+[O^Z?\_K731G:3BSMP=2TG!F]11172>B(RAE*L 01@@]ZJ?V1IO\
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M8(V8,6D89SA=N>W;/X5E#PUJ<,5@+>..*YCMX(GN$G(P4ZAEZ./3I3Y/#.H
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M_P"AM0 )_P A&;_KDG\WJQ5=/^0C-_UR3^;U8H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ,FM:5#<F
MVEU.R2X!QY33J&SZ8SF@&[&7=:;<W?BF21+F\M8?LH7S(%7#'/3+*?TJA=>'
M%CU+RK6U+K%8OY,LB[L2E@<YZ;NM=<DT4K.L<B.R'#!6!*GW]*?3NTK?U_6I
M/*G_ %_78\NU:SV:9YEOIMU;0I;*EX'B:/S9-Z^OWCU^8>O6M7^R?M4Y$&F3
M1:7)>6Y%O) 4'&=[%".%Z9R.<5VTHM;HM;2B&8C#-$^&QZ$C\*FJ^?\ K\2/
M9?U\CSZ]TF[20 6A73TOYF:(V33I@HH0^4I!9>#TSBFIILUDL<LFEW%X[6#1
MH3;LC?ZPG:2I8KA3P"<D#'7BO0)9HX(FEFD2.->K.P 'XFF_:8"DK^?'LB)$
MC;QA,<G/I4J3M;^MK#=-7_KO<\]M],N+A[R(Z8\=I+<6S+$EH\49 ^]\K?KD
M#Z5K"Q$7BB/1[>)$L PO2L8 5.,;<#IDY-=9%<03LRQ31R%<%@C XR,C/X4D
M=K;PS2316\4<LIS(ZH SGW/>GSZ_U_707LU;^OZZDU%%%0:GE]_;K<>)-=RV
MUO.0 _@*P$T:>*Z)4H^<XP?\:W+V;R_%6N#/_+=?Y"JR71\P $=\\5X^,Y75
MU/ELRY'B$F=1\/X7A2^5Q@XB[^S5VE<?X%D\S[>?^N7_ +-785Z='^&CZ+"_
MP8^@4445J;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%(S!5+,< #)-9FC:]9ZXD[6HE7R7V,
M)%VD^A'/0T6N)M(U**KW5_9V(4W=W!;ACA3-($R?;--EU*P@GC@EO;:.:3F.
M-Y5#/]!GFBP71:I"H88(!^M8P\361U(6(CG\TW/V;.T;=VW=GKTQ4U]KMM87
MK6DB2&1;=KG(**NT$ C+, #SWX]Z=F',OZ^XOFVMR<F"(GUV"C[-!_SPC_[X
M%5SK&F"X6W;4+03LVT1&==^[TQG.:D.HV(O/L9O+<71&?(,J[_\ OG.:5A>Z
M2"W@!R(8P?\ =%2!%!R% ^@J*YNK>SA,UU/%!$.KRN%4?B:;'?V<OE>7=P/Y
MH)CVR [P.I'K0/1%BBJ#ZYI$?W]4LEYQS<(.>GK4DFJ:?#.D$M_:I,^-D;3*
M&;/3 SS3LPNBW156+4[">66.&^MI)(O]8J2J2GU /%-AU;3KB&2:'4+62*+_
M %CI,I5/J0>*5@NBY15 :S8R) ]O<PW$<TGE"2*9"H.">N[GIT&3[4^VU;3;
MR;R;74+2>7;NV13*S8]< ]*=F%T7**IQ:MIL]P;>'4+62<$KY:3*6R.HP#FK
ME(84444 %%%% !5>R_U#?]=9/_0VJQ5>R_U#?]=9/_0VH $_Y",W_7)/YO5B
MJZ?\A&;_ *Y)_-ZL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7'PZ=>ZE<:U;1W-M%:R7)5PT!:3WPVX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH
MK_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6**
M *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5B
MB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU
M8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[
M-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]
M^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$_
M_?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA
M/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_Y
MX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/
M^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^U
MC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/
MM8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]F
MC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_
M9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\
MOV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_
M +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG
M_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \
M)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\
M/"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_
M #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q
M_P \)_\ OV:/M8_YX3_]^S5BB@"O]K'_ #PG_P"_9H^UC_GA/_W[-6** *_V
ML?\ /"?_ +]FC[6/^>$__?LU8HH K_:Q_P \)_\ OV:/M8_YX3_]^S5BB@"O
M]K'_ #PG_P"_9H^UC_GA/_W[-6** *_VL?\ /"?_ +]FC[6/^>$__?LU8HH
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MM7Q;;A/DLHO9/5J^M^AAZWXF.F6MC/:6WVH7AP@W%3VQV]ZI+XHUXL ?#%P
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M_P ^$?\ WRM'V6W_ .?"/_OE:S-2[15+[+;_ //A'_WRM'V6W_Y\(_\ OE:
M+M%4OLMO_P ^$?\ WRM'V6W_ .?"/_OE: +M%4OLMO\ \^$?_?*T?9;?_GPC
M_P"^5H NT52^RV__ #X1_P#?*T?9;?\ Y\(_^^5H NT52^RV_P#SX1_]\K1]
MEM_^?"/_ +Y6@"[15+[+;_\ /A'_ -\K1]EM_P#GPC_[Y6@"[15+[+;_ //A
M'_WRM'V6W_Y\(_\ OE: +M%4OLMO_P ^$?\ WRM'V6W_ .?"/_OE: +M%4OL
MMO\ \^$?_?*T?9;?_GPC_P"^5H NT52^RV__ #X1_P#?*T?9;?\ Y\(_^^5H
M NT52^RV_P#SX1_]\K1]EM_^?"/_ +Y6@"[15+[+;_\ /A'_ -\K1]EM_P#G
MPC_[Y6@"[15+[+;_ //A'_WRM'V6W_Y\(_\ OE: +M%4OLMO_P ^$?\ WRM'
MV6W_ .?"/_OE: +M%4OLMO\ \^$?_?*T?9;?_GPC_P"^5H NT52^RV__ #X1
M_P#?*T?9;?\ Y\(_^^5H NT52^RV_P#SX1_]\K1]EM_^?"/_ +Y6@"[15+[+
M;_\ /A'_ -\K1]EM_P#GPC_[Y6@"[15+[+;_ //A'_WRM'V6W_Y\(_\ OE:
M+M%4OLMO_P ^$?\ WRM'V6W_ .?"/_OE: +M%4OLMO\ \^$?_?*T?9;?_GPC
M_P"^5H NT52^RV__ #X1_P#?*T?9;?\ Y\(_^^5H NT52^RV_P#SX1_]\K1]
MEM_^?"/_ +Y6@"[15+[+;_\ /A'_ -\K1]EM_P#GPC_[Y6@"[15+[+;_ //A
M'_WRM'V6W_Y\(_\ OE: +M%4OLMO_P ^$?\ WRM'V6W_ .?"/_OE: +M%4OL
MMO\ \^$?_?*T?9;?_GPC_P"^5H NT52^RV__ #X1_P#?*T?9;?\ Y\(_^^5H
M NT52^RV_P#SX1_]\K1]EM_^?"/_ +Y6@"[15+[+;_\ /A'_ -\K1]EM_P#G
MPC_[Y6@"[15+[+;_ //A'_WRM'V6W_Y\(_\ OE: +M%4OLMO_P ^$?\ WRM'
MV6W_ .?"/_OE: +M%4OLMO\ \^$?_?*T?9;?_GPC_P"^5H NT52^RV__ #X1
M_P#?*T?9;?\ Y\(_^^5H NT52^RV_P#SX1_]\K1]EM_^?"/_ +Y6@"[15+[+
M;_\ /A'_ -\K1]EM_P#GPC_[Y6@"[15+[+;_ //A'_WRM'V6W_Y\(_\ OE:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"18VL4"L$)!(8\#WK,N;:[D>^U@PS)87=]"\D*@AVA1=I)'N<<>@H ] $J$
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MPEA]LF"W/VVUANUN"IWR.9" >$V],8IH%M+_ &/<RW#MJ3Z@!*K.<_>/!'8
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MB@ I!2GI2"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *X/Q[\3=/\%QVX417D\DA22%)@&C
M]R*Z[5)I(;4;&*EW5,KU&37D/Q*^#U[XCU.&^T3R_.<$W,D\F"YH ]9L-=T^
M_P!'34H[N#[.4#.XD!5..A-<9I/Q9TO4_&-UH;&WBABX2Z:<;9#Z"M/1/ -G
MIGA1=&+2)#)%B>%&&UFQSVKS+PY\#;VP\5/>:HD#:9&S/$J/EA@Y6@#W\'(X
MI:J:8[R:?"SL6;;R3WJW0 4444 %%%% !1110 49HJ"[)%I+MD$;;#AS_#QU
MH F# GBEKRW2?$EQI=O?_(EQ=Q%=UV+@RP,&;&YAD;2/3(J_-X\U.,0!H+&-
MG@,NUGSYI#[0$(;J1T'- 'H=13P^="\>XKN4KN'49[UP5[\0;FWU2]MH([66
M.&*1ERK*R.N.&R??M^M3:MXVO='73TN/L;W$ZH\L2HX^5F ^4YQP#0!;_P"$
M%))/]OZG_P!]C_"D_P"$%/\ T']3_P"^A_A639>+=6@LY6GN+%F:^EB#SY A
M4$XW8/Y=*UM(\3ZIJ^IVELD%K'&\ FE+!LD9Q\O/3ZU/)'L:^WJ=RM-\/FFG
M&[6;MXBA5O, 9A]/2L[6/#MEH.CI;17US<7 D#1%I/FB Y.,>U=SJ>I+9(D2
M /<R\11YQGW^@KF-;1-'L//5;>6Y9LRS3. 23UY)_#%-12V1,JDY*S9-%XR-
MW!''IT:/*I16-P=F21V'>IK/Q=)=-/&8K2.6!]DBM<CK['H:X^R58IX+B^LD
MGBEYF2/.-N<AACTXKNYQHD6EFYMK2TF&T,B(%R<D 9].:IHC3J'_  D$W_3A
M_P"!0J>SUF6YNTB;['AO^>=P&/Y5S4(O;#Q'%;ZE!IDUK<N$6.*#:T)8C')^
M]CI7:PZ;90NLD=I"CCHP0 BD]!Z%RBBB@04444 %%%% !114%Y=1V-G/=S$B
M*&-I'(&2 !D\4 3T5CP^([6:*.4P744<A 1I(2N[C.118^)M)U#[.(;Q0]PI
M>)'^5F .#P?I0!L457^WV9C\S[7!LSC=Y@QGTS5#4?$5EIES#!*)I'F0R(((
MR_RCJ>* ->BJ%GK%A?01S07<161=R@L V/H>:G^WV?DB7[7!Y9. _F#&?3-
M%BBHDN8))6B2:-I%Y958$CZBI: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** *NI_\@F\_ZX/_ .@FK$?^J3_=%5]3_P"03>?]<'_]!-6(
M_P#5)_NBGT)^T.HHHI%$-W!]JM)K?=M\Q"N[&<9%95OX=%O-ILGVHM]BMV@
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M,5SD>E=)J-@T7P^N+*WCNI&%HRHDH!E/' (7C/TKH([JWF8+%/%(2"P"N#D
MXS^=/DECA7=+(J+D#+' R>@IRDV$8I'&21?8[C5A>Z=<7'VVTB2WV0EPV$P4
M) ^7YCGG YJQX+TRYL9=1^W0L+C,"F1E^]MA4'![\YKKJ1W6-&=V"JHR6)P
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MR=#E6B!!]1BM.LSP^H30[-5&%$0  K3KVX_"CV0HHHJ@"BBB@ HHHH ****
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M;CQ]<^;,?,AM66<;<!@& &/J>:]F'2E'8[JGQ"T4451F%%%% !1110 5YO\
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M\<\8?\D?M/\ =M__ $(5Z]X?_P"1=T[_ *]D_P#012 TJ*** "BBB@ HHHH
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M7^K6B3NVQQ5HI#Z***DH**** "J]E_J&_P"NLG_H;58JO9?ZAO\ KK)_Z&U
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MT3#'_ 10!E^-,?\ "1Z?D?\ +LW_ *%7(I@:=??*,_:1V_VA76^-/^1CT_\
MZ]F_]"KDH_\ D'7O_7R/_0A4]2NAIPA3XHB&T?\ 'KZ>]10J/["<X'_'X>W^
MU4T/_(U1?]>G_LU10_\ (!?_ *_#_P"A5M$QD%\/^)EK' '[A.GTKJ( H\(@
M[5S]D]/:N7OO^0GK'_7!/Y5U,(_XI'_MT_\ 9:VI;R,ZFBB8_C0@?"*W/H(/
M_0A7KGAQQ)X:TUEZ&V3'_?(KR/QH,_"*W'^S!_Z$*];\-(8_#&F(3DBVCY_
M5RG0:E%%% !1110 4444 %%%% "&O"?C.!_HXR PO1_*O=C7@'QP?9>CG'^D
M(?\ QV@#UB-<ZUI#$=;6NHKE+&82:AH3!@P:R)!'3H*ZN@ HHJGJ)=;.22-R
MK*I(H MY%+7E?A?Q9JNKZGX@LKB8C[!'F%E'7GO7I.FLSZ? \A)=D!8GN<4
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M2KM=ATA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5%/;07*A9X8Y5!R ZAA^M2T4 5H=/L[>3S(;2"-_[R1@
M'\P*LT44 5?[.M/*FB\A-DQW2+C[Q]34GV:'RTCV81/N@'&*FHH 9%$D*!$&
M%':E>-9%*.H93P0PR#3J* *@TNP5@RV5LI!R"(E_PJV!@444 %%%% !1110
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MBR2^?XF6VI6Z,D;R-M9QP8V&T]/;.*]1^&VI7VH:#(-0N+>:2*4JGDJ0%7'
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M BN+:&[A,,\:R1GJK#(J10%4 =!Q2T4 %4[33(+*XN)HM^^X;<^6R,^U7**
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MG/\ >%6** *<UB)XS&[D*>H7O[5; P*6BB_0 J.'[I^M25'#]T_4T 24444
M%%%% !5>R_U#?]=9/_0VJQ5>R_U#?]=9/_0VH $_Y",W_7)/YO5BJZ?\A&;_
M *Y)_-ZL4 %%%% "'I0OW12T4 %-?=M^4C/O3J* (=LW]Y?RHVS?WE_*IJ*
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M@\?E2S:[K$=P+(/9_:#=K#YIC;:%89^[NZCZ\UIQZ/81020II,PCD #+YHY
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L^H;_ *ZR?^AM1]HE_P"?*?\ [Z3_ .*I;172WPZE&+NVTD<98D=/K0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20211231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20211231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'I [8# 2(  A$! Q$!_\0
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MLG!Y'/0TGHFP6K2-W3]9TS5BXT^_MKK9]_R9 VWZXJ]7F_PNF\/,=1.BV]]
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MNY\E73S0.[MZ_0?SI=4EU'T;?0]2GUO2[6RBO9]0MHK67_5S/* K?0]ZI_\
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MQUX:C\"ZWI]QI-Q.JR*71F;YE=2,\CMR*47HF^I36K2Z'OSNL:%W8*H&22<
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M $@>A'6A:[#>FYU=%%% !1110 4444 %%%% !1110 4444 %%%% !7/>.O\
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MNPH[:]R#X9>*(KG59-)GTJUM;K82)8(]I..H-<IX5_Y*W%_U^2_^S5ZGX1\
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MW*V.^,CFLBX^#%NVF006VI;+H.6EGDBW;AC@  C K-+W4GT+;]YM=3-\5_\
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MN 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*HO^?5_^^A1_PE47_/J__?0H Z"BN?\ ^$JB_P"?5_\ OH4?\)5%_P ^K_\
M?0H Z"BN?_X2J+_GU?\ [Z%6+'7X[V\CMU@92^>2W3 )_I0!L445S^J^*HM*
MOVM'M7D*@'<& ZBJC%R=D3*2BKLZ"BN2_P"$[@_Y\9/^^Q1_PG<'_/C)_P!]
MBJ]C/L1[>GW.MHKDO^$[@_Y\9/\ OL4?\)W!_P ^,G_?8H]C/L'MZ?<ZVBN2
M_P"$[@_Y\9/^^Q1_PG<'_/C)_P!]BCV,^P>WI]SK:*Y+_A.X/^?&3_OL4?\
M"=P?\^,G_?8H]C/L'MZ?<ZVBN2_X3N#_ )\9/^^Q1_PG<'_/C)_WV*/8S[![
M>GW.MHKDO^$[@_Y\9/\ OL4?\)W!_P ^,G_?8H]C/L'MZ?<ZVBN2_P"$[@_Y
M\9/^^Q1_PG<'_/C)_P!]BCV,^P>WI]SK:*Y+_A.X/^?&3_OL4?\ "=P?\^,G
M_?8H]C/L'MZ?<ZVBN2_X3N#_ )\9/^^Q1_PG<'_/C)_WV*/8S[![>GW.MHKD
MO^$[@_Y\9/\ OL4?\)W!_P ^,G_?8H]C/L'MZ?<ZVBN2_P"$[@_Y\9/^^Q1_
MPG<'_/C)_P!]BCV,^P>WI]SK:*Y+_A.X/^?&3_OL4?\ "=P?\^,G_?8H]C/L
M'MZ?<ZVBN2_X3N#_ )\9/^^Q1_PG<'_/C)_WV*/8S[![>GW.MHJGI6H+JFGQ
MW:1F,.2-I.<8.**AJSLS1--71<HHHI#"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_&_P#R)VH?1/\ T-:\
M6KVGQO\ \B=J'T3_ -#6O%JZ:/PGR.?_ .\Q_P /ZL****U/""BBB@ HHHH
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M$-OZVN5/^$5N!Y.Z[M4,R!HPS$%B>PXZTEII4::;JOVJ'_2+; 4Y/RFMK4;
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M_E7H]><>,/\ D8I?]Q/Y5OA_C.?%? 8-%%%=IYX4444 %%%% !1110 4444
M%%%% %[4M3DU,P&2-4\F,1C;W JC11222V&VWJPHHHIB"BBB@ HHHH ****
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MY4>>GJ?RH]K(/[$PG9_>>7_\*RU?_G[L?^^G_P#B:/\ A66K_P#/W8_]]/\
M_$UZAYZ>I_*CST]3^5'M9!_8F$[/[SR__A66K_\ /W8_]]/_ /$T?\*RU?\
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MF/\ A%[S_GM!^9_PJUIF@W-EJ$5Q))$53.0I.>01Z>];OGIZG\J5959L \T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*DA_UJU'4D/^M6@"U4$OWS4]02_?--"8RBBBJ)"BBB@ HHHH **** "BBB@
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MK4]7\1/NK6)8L+R_U>\-U X@L$;:JLF3+SS]/Z5NU6LIX)4EBMUVK;R&$KC
M!'I[59J7N7%:!1112&%%%% !1110 4444 %%%% $\7^K%%$7^K%%0RQ]%%%
M!1110 5!=6R75N\+_=88-3TE*45)68'(:KI=KI5F\\MP>!\JXY8^E>=7MO-?
MW&_<SNYPJ@=*[7QI;WLNJ1E4=X2H"!1D ]ZLZ=X>&FZ8+JX&;ER, _P#_&N:
M>&HT:;E&.IX]>%3$UO9VM%&+H&B-I\3!SB8X+&NPLK**ZC_UI#CJ,4VQM!=1
M2CHXQ@T6<,R7R*%((;YOI7GT:=I)R5TSTJ=-02BMC;M+5;6'8ISDY)KC[R67
MPKXPNM2FC9]+U%%\V51GRG7CGV-=N.E))&DJ%)$5U/4,,@U[,4DK(V.'\0>)
M+;7],DT?0W-U=78\LE!PBGJ2?I3;^RF\*ZQINK00O-9I:BUNM@R5 Z-BNTM[
M&TM"3;VT41/4H@&:G9592K $'J#3 XW5O'%E<:=)#HK->:A*I6*-%/RD]SZ8
MK"\(0.8O#"2HP_=W(?(]37H\.GV=NY>&UAC8]65 #4B6\2%=L2+MSMPO2@#A
MM"U5/!YN-&U@-!"LS/;7!'R.C'.,^M9OBCQ =>U/2(M-B>33X;Q&DN-OREL\
M 5Z5<6MO=)LN(8Y5]'4&D2SMHXEB2"-44Y"A1@&@#F?!*LMQKV5(SJ#$9'L*
M9XGC:3QGX6 !*[YP3CI\@KK4B2,G8BKN.3@8R:&BC=U=D4LOW21R/I0!PFA:
MFO@YKC1]7#16RRL]M<;?E96.<9]16JGBL:KJ]K9Z+#]JA+9NISD+&OMZFNCG
MMH+E-D\*2+Z.N11;VMO:H4MX8XE/9% H \]L(]-\+:A?6&N6,?V:2=IK:[:/
M<"&.=I/M5V.\L-6UJSM]!TRWDMU??<W1A^55'8'UKMI[:"YC\N>%)$]'7(H@
MMH+:/9!$D2>B+@4 2 8I:** "BBB@!DW^J:JE6YO]4U5* "BBB@ HHJ);B%K
MAX!(#*BAF3N >A_0T 2T5GOKNF1K$S7D8$HW(1DY'K["KZL&4,I!!&01WH 6
MBL?5-2O+?5K'3[**!GN4D<M,Q 79CT^M64NY[2W>757M8@#A3$6(/YCK0!?H
MK$U+Q';6NDKJ%J\<\?VB.%R20%W.%)/T!S5Q=:TUK66Y%W'Y,7^L8Y&WZB@"
M_16<VNZ8ENL[7:B-B0IVG)QUXQFGS:SI\$,,TEROES#,;*I8,/P% %ZBJ5EJ
M^GZBP%I=)*2"P ST!QW]ZCEU[2X2 ][&"02 ,DD [2>/>@#1HJC!K.G74Z0P
M7<<DCKN4*?O#V/2E&K6#79M5N4,XR-@]?3/3/M0!=HKAXO%M_+?YQ&(O+$OE
M8'W"H;[W7."/QKJK^[N8D@6SMQ++,V 7.%08SEJ +U%9FGZJ+BVNVNE2&2SE
M:*8@Y7( .0?3!%,T'66UN.ZF%N8HHYC''NZL !R?3K0!K451GUC3K:5XIKN-
M'1@C _PD],^E/BU2QG:98[F-C",R<XVCU^E %NBJ=KJMC>"0V]RCB,9?M@>O
M/:EL]3LM09UM;A9&3D@9!QZ\]J +=%%% !1110!)#_K14\O^J:H(?]:*GE_U
M34 5**** "BBB@ HHHH **** "BBB@ HHHH *SK[3I+S5-/N-Z"&U9G9#U)(
MP,5HT4 95W87::K_ &E8^2\K1"%XYW*K@$D$$ \\^E3Z1IW]EZ>MMOWL7>1V
M[;G8L<>V35ZB@ HHHH **** "BBB@ HHHH **** "BBB@ J2'_6K4=20_P"M
M6@"U4$OWS4]02_?--"8RBBBJ)"BBB@ HHHH **** "BBB@#)\1I(VC2-& 6C
M97P?8YJ_9W"W=G%.C AU!R*F8!E*D9!&"*Y\6]]H,CM:Q_:;%B6,0^\GKBJ6
MJL2]'<N:EH%MJ5PD[,T3])"G_+1?0_XU>8P:?9$A1'#"G0=@*R!XJM/+ -O<
M"?&?)V<U$T=_XA*B6,VE@&R5/WI!3L_M;$\T?L[EGPR)6T^6YE.3<SM*./H/
MZ5M4U$6-%1 %51@ =A3JEN[N7%65@HHHI#"BBB@ HHHH **** "BBB@">+_5
MBBB+_5BBH98^BBB@ HHHH **** &,JG&0#]:@O+;[5;F,'!SD5:HJ914E9A8
MHZ?9-:(VY@6;TJYM&<]Z=11&"BK( HHHJ@"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 9-_JFJI5N;_ %354H **** "N:\3I>V]Q!=:?&[RW"-
M9/L7.W=]QS[*<_G72T4 <EJ5I#IDP^Q/=6]PMLD2A;<RQ3*N<*>#C].M=%97
M#/!!'/'Y=R8@[H%.U?;/3\*MT47 YS6K&2]\4:/AKB.-8I]TL+%=IPN 2.F:
M-9MWLX;%%DN'B6?=)<,IFDCXXP,$^W2NCHH \[EMYC9ZJQM;R>-M4MI0LD9+
M2("F3CTX-7=;CDU1=0N[2WF-N;>.+!B93(V\'[I&>!_.NWHH_K\+!_7ZG,:D
M7BUF N)H(?LP598(2[.V?N9 .WMZ5E:?>7%AX5T_37BN[>2>2999#"[&%!(V
M>@/)!&/SKO** .0U5XK+3+34M'C;_1\VX5HV0L&X'# '[V#4UGIK6?B2R01,
M8XM*=#(5R-V]>_J>:Z"YL(+N:&28.WE'<J[R%SZD=#^-6:/Z_#_@@<3:V4T>
MF^'42WD1DN7+X0C9G=R?2H+2QN_(M-.FGO#/%=K(T2VZJHP^=WF8Z8]\GI7>
MT4+<#)_X1S3OM EV/M#[Q#O/E[O7;4/B#59K)H+2W61&GSNN%A:01*.^%!Y]
M*W** .9ETMIM)M5TN5/LJ.TLRW,3[IV]6'!Z\^_%6O"EO=P:*K7BHLDSM-M5
M2I&XYP0:W** .,N;*:\TF[5H'\S5-15'^0Y6(..3Z#:OZTNHV,]QJ.H7"6[_
M &>$P0;%0_/&IW/@=^HZ>E=E10M .3N_].N[F^BLIY+(6OV8J%,;2!C\Q //
M JQI$RI<R2LDDMK;6Z1Q74D#+(<DY3&,D#"\XKI**$ =11110 4444 20_ZT
M5/+_ *IJ@A_UHJ>7_5-0!4HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "I(?]:M1U)#_ *U: +502_?-
M3U!+]\TT)C****HD**** "BBB@ HHHH **** "BBB@!OEIOW[%W_ -['-.HH
MH **** "BBB@ HHHH **** "BBB@ HHHH GB_P!6**(O]6**AECZ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!DW^J:JE6YO]4U5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH DA_UHJ>7_5-4$/^M%3R_P"J
M:@"I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %20_ZU:CJ2'_6K0!:J"7[YJ>H)?OFFA,91115$A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ5)10!'Y8]*3RQZ5+10!'Y8]*-@J2B@"/8*-@J2B@!FP4;13Z* &[11MIU%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 3Q?ZL441?ZL45#+'T444
M%%%% !1110 4F:4]*YV76YUNFPJ^6K8QCDCZUC6KPI6YNII3I2J7Y3<GN4MT
MW/\ @!207*7";DSQU![5G7LZ7-K#)&<@D_A3M,<1I,S' &/ZUR?6W]9]G]FW
MZ7+]DO9\W4U<T9K/^VOOX VYZ5?4Y /K772K1JWY>AE*#CN.HK"UW69M+U/1
M[:*.-UOKGR7+9RHQG(]ZW:V)"BBJ.L7<MCI-U=0QB26*,LJ$$[B/I0!>HJCH
M]W+?Z1:W<T8CEEB5W0 _*2.G-7J "BL/2]:FOO$.JZ<\2+'9%0K#.6R.];E
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MFQAMI]LU)]F@\Y)O)C\U%V*^T9 ] ?2G_7Y@9'A.1Y-# =V;RYI(U+')"AB
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M0 4444 20_ZT5/+_ *IJ@A_UHJ>7_5-0!4HHHH **** "BBB@ HHHH ****
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MM%3R_P"J:H(?]:*GE_U34 5**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2'_6K4=20_P"M6@"U4$OW
MS4]02_?--"8RBBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.OJ:/LZ^IH KT58^SKZFC[.OJ: *]%6/LZ^IH^SKZF@"O15C[.OJ:/LZ^IH
MKT58^SKZFC[.OJ: *]%6/LZ^IH^SKZF@"O15C[.OJ:/LZ^IH KT58^SKZFC[
M.OJ: *]%6/LZ^IH^SKZF@"O15C[.OJ:/LZ^IH KT58^SKZFC[.OJ: *]%6/L
MZ^IH^SKZF@"O15C[.OJ:/LZ^IH KT58^SKZFC[.OJ: *]20_ZU:D^SKZFG+"
M$8,">* )*@E^^:GIC1ACG)IH3(**F\D>IH\D>IIW%8AHJ;R1ZFCR1ZFBX6(:
M*F\D>IH\D>IHN%B&BIO)'J:/)'J:+A8AHJ;R1ZFCR1ZFBX6(:*F\D>IH\D>I
MHN%B&BIO)'J:/)'J:+A8AHJ;R1ZFCR1ZFBX6(:*F\D>IH\D>IHN%B&BIO)'J
M:/)'J:+A8AHJ;R1ZFCR1ZFBX6(:*F\D>IH\D>IHN%B&BIO)'J:/)'J:+A86+
M_5BBG*NT8HJ2@I"*=10 PK32E2XI,4 0&.F&+VJSBC;0!3,/M49M_:K^VDV4
M 9S6WM3#:^U:?EBD\L4 9)M?:FFT]JU_*%'E"@#%-I[4AL_:MKR12>2* ,7[
M'[4?8_:MKR1Z4>2/2@#%^Q^U'V/VK:\D>E'DCTH Q_L?M2BS]JU_)'I2^4*
M,D6GM3Q:>U:GE#TI?+% &:+7VJ06WM5_RQ2[* *8@]J>L/M5K92[: (!'3PE
M28I<4 1/\B$CJ*B$[>@J>4?NFJK0!)Y[>@I?M#>@J*B@";[0WH*/M#>@J&B@
M";[0WH*/M#>@J&B@";[0WH*/M#>@J&B@";[0WH*/M#>@J&B@";[0WH*/M#>@
MJ&B@";[0WH*/M#>@J&B@";[0WH*/M#>@J&B@";[0WH*/M#>@J&B@";[0WH*/
MM#>@J&B@";[0WH*/M#>@J&B@";[0WH*/M#>@J&B@";[0WH*/M#>@J&B@";[0
MWH*/M#>@J&B@"Q',SN 0*FJK#_K15J@"-IE1L$'-)]H3T-13?ZTU'0!9^T)Z
M&C[0GH:K44 6?M">AH^T)Z&JU% %G[0GH:/M">AJM10!9^T)Z&C[0GH:K44
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M,LJ1C!.68#@=33P01D'(- !112.ZQH7=@J@9))P!0 M%(K!E#*001D$=Z6@
MHHHH **:TL:.J,ZJSG"@G!;Z4Z@ HHJ"6]M895BEN88Y&^ZCR $_04 3T444
M %%%% !1110 4444 20_ZT5:JK#_ *T5:H JS?ZTU'4DW^M-1T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX/'O@FM-/#]FALR&E)M9'D!+9\QF!#%LCG.3Z4U-!%O L5IJ-[;*C,R^6RD
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MVLIYU2XN<^4AZMCKB@"YFC-%5KZ_M=-M6N;R9885(!=NF3P* +.:6D!S2T(
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MSIZH--UC[5(T,[?OL\,?XJZJ-BZ)DY. *\K1F5PRDA@>,5Z1IQ9K:)I#^]V
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M*5@$Q2T44P"BBB@ HHHH 9-_JFJI5N;_ %354H **** "BBB@ HHHH ****
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU6 _P2_D/\:4:G"?X9/R'^-5%J9: + OXC_"_P"0_P :<+R,_P +_E4:U,E
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>U,M%PL.&3V-+M;TIRT\47"PD8*MDCM13Z*06/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20211231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20211231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G )$# 2(  A$! Q$!_\0
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M_6HOAMJ/C^U\(/#X6TVWGM7E;]](.5;O67\9O$VG^*_$L$FE":6.VC,;N8R
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M/#+"H(_'%%% %S&#ZTZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plx-20211231xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20211231xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +J W(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **KWUY'86<EU*K%$QD(,GD@?UK'_X
M3#3_ /GC=?\ ?*__ !585<32I/EG*S-84*E17BKG045S_P#PF&G_ //&Z_[Y
M7_XJC_A,-/\ ^>-U_P!\K_\ %5G]>PW\Z+^J5OY3H**Y_P#X3#3_ /GC=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A>,O^14O?^ ?
M^AK7E%>K^,O^14O?^ ?^AK7E%?.YO_'7I^K/H\H_@/U_1!1117E'JA1110 4
M444 %%%% !1110 4444 =W1117KGAFKX?_X_W_ZY'^8KI*YOP_\ \?[_ /7(
M_P Q725ZV#_A'F8O^(%%%%=1S!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!SWCEF3P=?LIP1Y?\ Z,6O&_M4W]_]
M!7L7CO\ Y$S4/^V?_HQ:\7KYS-_XZ]/U9]/DJ7U=^OZ(F^U3?W_T%'VJ;^_^
M@J&BO*/8LB;[5-_?_04?:IO[_P"@J&B@+(F^U3?W_P!!1]JF_O\ Z"H:* LB
M;[5-_?\ T%'VJ;^_^@J&B@+(F^U3?W_T%'VJ;^_^@J&B@+(F^U3?W_T%'VJ;
M^_\ H*AHH"R.Q_M.\_Y[?^.C_"C^T[S_ )[?^.C_  JI16'MJG\S^\\_V<.Q
MM:1JU]'=L5GP=A'W%]1[5M?VYJ/_ #\?^.+_ (5S&E_\?+?[A_F*UJEXO$1T
MC-KYLY*U*FYZQ7W&C_;FH_\ /Q_XXO\ A1_;FH_\_'_CB_X5G44OKN)_Y^2^
M]F/L:?\ *ON-'^W-1_Y^/_'%_P */[<U'_GX_P#'%_PK.HH^NXG_ )^2^]A[
M&G_*ON-'^W-1_P"?C_QQ?\*Z72IY+G389IFW2-G)P!W([5Q-=EH?_('@_P"!
M?^A&O9R/$5JF(DJDVU;JV^J.3&TX1IIQ5M30HHHKZD\P**** "BBB@ HHHH
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M?YHXL?\ PUZ_YFA1117UYY(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <YX[_P"1,U#_ +9_^C%KQ>O:/'?_ ")FH?\ ;/\ ]&+7B]?.
M9O\ QUZ?JSZC)/\ =WZ_H@HHHKRCV HHHH **** "BBB@ HHHH **** .FHH
MHKC.$NZ7_P ?+?[A_F*UJR=+_P"/EO\ </\ ,5K5E/<Y*WQ!1114&84444 %
M=EH?_('@_P"!?^A&N-KLM#_Y \'_  +_ -"->[P__O,O\+_-'%C_ .&O7_,T
M****^O/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"&O7_,T****^O/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M &_QH_MG5/\ H)7G_?\ ;_&J5%?0V.3V<.R.P\%W]Y=:Q,EQ=SS(+=B%DD+
M'<O/)KNJ\]\"?\AR;_KV;_T):]"K.6Y\]F22KV79!1114G %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+7H5>>^!/^0Y-_U[-_Z$M>A5G+<^;S/_ 'A^B"BBBI//"BBB@ HHHH ****
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MA1_PBWB'_H ZI_X!R?X5]-44?V='^8/]8*G\B/G7_A&M=_Z FI?^ K_X4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_PBOAW_ * .E_\ @''_ (4?\(KX=_Z .E_^ <?^%:]%')'L'MJG\S^\R/\
MA%?#O_0!TO\ \ X_\*/^$5\._P#0!TO_ , X_P#"M>BCDCV#VU3^9_>9UKX?
MT:RN$N+32+"WG3.V6*V1&7(P<$#(X)%:-%%-)+8F4I2UD[A1113)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEN;B18X8D+R.QP%4#))_"I*\-_:!\=?8[&/PE82XGN0)+UE/*Q_PI_P(\GV
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M>F[IGFNB@^"_C^=<C0&3_KI<1+_[-7M?[/7_ "35_P#K_E_]!2O5Z /C2_\
MA-XZTY&>;P[=.J]3 5E_1237'SV\UK.T-Q#)#*APR2*593[@U]]USOBOP/H/
MC.Q:WU:R1Y,8CN4 66(^JM_0Y'M0!\145U7C[P+J'@/7S879\ZVD!>UN0,+*
MG]&'<?T(KE: "BBB@"UIVH76DZE;:A93-#=6T@DB=>H8&OM?P9XFM_%_A2QU
MJ !3.F)8Q_RSD'#+^?3VQ7P]7NW[.'B-HM0U/PW,_P"[F3[7 ">C+A7 ^H*G
M_@- '<_%?X77_P 0+O3[FQU"VMC:1.A2=6^;<0>H^GI7E-U^SSXR@)\F;2[@
M#ILG92?^^E%?4U% 'Q_=?!7Q]:_\P,RCUBN(V_\ 9JX.:&2WGDAE4I)&Q1U/
M4$'!%??E?"&N_P#(PZG_ -?<O_H9H SZ*** "ONCPI_R)^B?]>$'_HM:^%Z^
MZ/"G_(GZ)_UX0?\ HM: ->BBB@#%\6>);3PEX9O=9O#E($^2/.#(YX51]3_4
MU\3ZQJMWKFL7>J7\ADNKJ0R2-[GL/8= /05Z9\=/'7_"1^)?[#LI=VFZ8Y5B
MIXEGZ,?<+]T?\"]:\FH **** "O;/V;/^1IUG_KR7_T,5XG7MG[-G_(TZS_U
MY+_Z&* /I.BBB@#,\2?\BMJ__7E-_P"@&OA.ONSQ)_R*VK_]>4W_ * :^$Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\0O^2<^(_^P=/_
M .@&NDKF_B%_R3GQ'_V#I_\ T T ?$E%%% !1110!]4?L]?\DU?_ *_Y?_04
MKU>O*/V>O^2:O_U_R_\ H*5ZO0 4444 <5\5/"4?B_P->VRQAKZV4W-HV.0Z
MC.W_ ($,C\1Z5\:U]_U\/^-]+71?'.MZ<@Q'#>2",>B%LK^A% &!1110 5UW
MPOU4Z/\ $K0;K?M5KI8'/^S)\A_]"KD:LZ?<&TU*UN5.#%,D@/T(- 'WM12
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M %%%% 'U1^SU_P DU?\ Z_Y?_04KU>O*/V>O^2:O_P!?\O\ Z"E>KT %%%%
M!7Q_\:X1#\6=:VC ?RG_ #B3-?8%?'_QJF$WQ9UK!X0Q)^424 <!1110 4JC
M+J!ZTE:&@VC:AXBTRS49,]W%$!_O.!_6@#[KMU*VT2GJ$ /Y5)110 5\(:[_
M ,C#J?\ U]R_^AFON^OA#7?^1AU/_K[E_P#0S0!GT444 %?='A3_ )$_1/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YO
MXA?\DY\1_P#8.G_] -=)7#_$OQ'HEGX'UVQN-6LH[N>QECB@,R^8[%2  N<T
M ?'%%%% !1110!]4?L]?\DU?_K_E_P#04KU>O%/@)XET.Q\$/IEYJUE;WIO)
M'$$TRHQ4A<$ ]>AKVE'21 Z,K*>05.0: '4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5G:_=S6'AS5+RW8+/!:2RQL1G#*A(./J*T:HZU92:EH6H6$3*DES;2
M0JS= 64@$^W- 'QEK'Q \6:]N&HZ_?2(W6-)/+3_ +Y7 _2N;)).2<FO:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>plx-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2022 11:04:08 AM-->
<!--Modified on: 3/31/2022 11:04:08 AM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.protalix.com/20211231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails">
        <link:definition>40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" id="DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails">
        <link:definition>41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" id="DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails">
        <link:definition>41201 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" id="DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails">
        <link:definition>41301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>41302 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" id="DisclosureConvertibleNotesTables">
        <link:definition>31003 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" id="DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" id="DisclosureCommercializationAgreementsDetails">
        <link:definition>40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" id="DisclosureInventoriesAdditionalInformationDetails">
        <link:definition>40402 - Disclosure - INVENTORIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" id="DisclosureLiabilityForEmployeeRightsUponRetirementDetails">
        <link:definition>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>40601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>40801 - Disclosure - REVENUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" id="DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails">
        <link:definition>40901 - Disclosure - SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" id="DisclosureShareCapitalSummaryOfStockOptionActivityDetails">
        <link:definition>40902 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" id="DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails">
        <link:definition>40903 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" id="DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails">
        <link:definition>40904 - Disclosure - SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" id="DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails">
        <link:definition>40905 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" id="DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails">
        <link:definition>40906 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" id="DisclosureShareCapitalAdditionalInformationDetails">
        <link:definition>40907 - Disclosure - SHARE CAPITAL (Additional information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" id="DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails">
        <link:definition>41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" id="DisclosureConvertibleNotesAdditionalInformationDetails">
        <link:definition>41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" id="DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails">
        <link:definition>41202 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" id="DisclosureTaxesOnIncomeAdditionalInformationDetails">
        <link:definition>41203 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41501 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreements" id="DisclosureCommercializationAgreements">
        <link:definition>10201 - Disclosure - COMMERCIALIZATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10301 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10401 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" id="DisclosureLiabilityForEmployeeRightsUponRetirement">
        <link:definition>10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>10601 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>10701 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10801 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapital" id="DisclosureShareCapital">
        <link:definition>10901 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" id="DisclosureConvertibleNotes">
        <link:definition>11001 - Disclosure - CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>11101 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>11201 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>11301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11401 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11501 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30403 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>30703 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30803 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" id="DisclosureShareCapitalTables">
        <link:definition>30903 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>31203 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>31303 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31403 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="SevenPointFivePercentageConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <xsd:element name="DisclosureOfLeasesOperatingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_CommercializationAgreementsAbstract" name="CommercializationAgreementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfUsefulLifeTableTextBlock" name="ScheduleOfUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" name="ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfOpenTaxYearsTableTextBlock" name="ScheduleOfOpenTaxYearsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FiocruzMember" name="FiocruzMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" name="PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" name="TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_FurnitureAndComputerEquipmentMember" name="FurnitureAndComputerEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ContributionPlansMember" name="ContributionPlansMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeSeveranceObligationPayment" name="EmployeeSeveranceObligationPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_BenefitsPayableDuringNextFiveYears" name="BenefitsPayableDuringNextFiveYears" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_RoyaltiesOnSaleOfProducts" name="RoyaltiesOnSaleOfProducts" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_CommitmentAmount" name="CommitmentAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_PercentageOfRoyaltiesToGrantReceived" name="PercentageOfRoyaltiesToGrantReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesStockExpired" name="StockIssuedDuringPeriodSharesStockExpired" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ConvertibleNotesDueTwoThousandTwentyOneMember" name="ConvertibleNotesDueTwoThousandTwentyOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FourPointFivePercentageConvertibleNotesMember" name="FourPointFivePercentageConvertibleNotesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_DebtInstrumentConvertibleConversionShareNumber" name="DebtInstrumentConvertibleConversionShareNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" name="DebtInstrumentConvertibleBaseValueForConversionRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" name="MaximumDebtInstrumentConvertibleConversionShareNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UsIsraelMember" name="UsIsraelMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_TaxYearThereafterMember" name="TaxYearThereafterMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_OtherAssetsInstitutionsCurrent" name="OtherAssetsInstitutionsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_OtherAssetsSundryCurrent" name="OtherAssetsSundryCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_CollaborativeArrangementProfitSharePercentage" name="CollaborativeArrangementProfitSharePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_PaymentInConsiderationForDevelopmentServicesPerformed" name="PaymentInConsiderationForDevelopmentServicesPerformed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" name="PaymentsInConnectionWithPerformanceOfAdditionalStudies" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_DeferredTaxAssetsOtherTimingDifferences" name="DeferredTaxAssetsOtherTimingDifferences" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_AlfataligliceraseMember" name="AlfataligliceraseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" name="StockIssuedDuringPeriodIssuePricePerShareNewIssues" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" name="WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" name="SeniorVicePresidentAndChiefDevelopmentOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_VicePresidentResearchAndDevelopmentMember" name="VicePresidentResearchAndDevelopmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AtmEquityOfferingSalesAgreementMember" name="AtmEquityOfferingSalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PresidentAndChiefExecutiveOfficerMember" name="PresidentAndChiefExecutiveOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_DebtInstrumentRedemption" name="DebtInstrumentRedemption" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_PercentageOfOutstandingCapitalStock" name="PercentageOfOutstandingCapitalStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" name="DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice5.60Member" name="ExercisePrice5.60Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice5.10Member" name="ExercisePrice5.10Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfCommissionOnSaleOfShares" name="PercentageOfCommissionOnSaleOfShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice4.69Member" name="ExercisePrice4.69Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice2.00Member" name="ExercisePrice2.00Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.59Member" name="ExercisePrice3.59Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.66Member" name="ExercisePrice3.66Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.73Member" name="ExercisePrice3.73Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.59OneMember" name="ExercisePrice3.59OneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.59TwoMember" name="ExercisePrice3.59TwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" name="OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.55Member" name="ExercisePrice3.55Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice3.70Member" name="ExercisePrice3.70Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice17.20Member" name="ExercisePrice17.20Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_KirinHoldingsCompanyLimitedMember" name="KirinHoldingsCompanyLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" name="NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_OfficeOfIsraeliInnovationAuthorityMember" name="OfficeOfIsraeliInnovationAuthorityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_OutsideOfIsraelMember" name="OutsideOfIsraelMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" name="LesseeOperatingLeaseNumberOfRenewalTermExtensions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" name="SeniorVicePresidentAndChiefFinancialOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SeniorVicePresidentOperationsMember" name="SeniorVicePresidentOperationsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_NumberOfDirectors" name="NumberOfDirectors" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_CertainEmployeesMember" name="CertainEmployeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeMember" name="EmployeeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestExpenseDebtOther" name="InterestExpenseDebtOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_NonRefundableFutureServicePayment" name="NonRefundableFutureServicePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_CommonStockNumberOfVotingRights" name="CommonStockNumberOfVotingRights" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_NoExercisePriceMember" name="NoExercisePriceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" name="NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_CompensationToNonExecutiveDirectorsMember" name="CompensationToNonExecutiveDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfPremiumToClosingPriceOfStock" name="PercentageOfPremiumToClosingPriceOfStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" id="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" id="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromExpenseReimbursements" id="plx_ProceedsFromExpenseReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReacquisitionOfEquityComponentOfConvertibleNotes" id="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityComponentOfConvertibleNotesNetOfTransactionCosts" id="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ThresholdPercentageOfConversionPrice" id="plx_ThresholdPercentageOfConversionPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" id="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExercisePrice1.57Member" id="plx_ExercisePrice1.57Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>plx-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2022 11:04:08 AM-->
<!--Modified on: 3/31/2022 11:04:08 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637843214459766070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637843214459766070" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637843214459766070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637843214459766070" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637843214459766070" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637843214459766070" xlink:to="plx_ShortTermBankDeposits_637843214459776073" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637843214459766070" xlink:to="us-gaap_AccountsReceivableNetCurrent_637843214459776073" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637843214459766070" xlink:to="us-gaap_OtherAssetsCurrent_637843214459776073" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637843214459766070" xlink:to="us-gaap_InventoryNet_637843214459776073" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637843214459776073" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637843214459776073" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637843214459776073" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637843214459776073" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637843214459776073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637843214459776073" xlink:to="us-gaap_LiabilitiesNoncurrent_637843214459776073" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637843214459776073" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637843214459786069" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637843214459776073" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637843214459786069" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637843214459776073" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637843214459786069" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637843214459776073" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637843214459786069" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637843214459776073" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637843214459786069" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637843214459776073" xlink:to="us-gaap_LiabilitiesCurrent_637843214459786069" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637843214459786069" xlink:to="us-gaap_AccountsPayableTradeCurrent_637843214459786069" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637843214459786069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637843214459786069" xlink:to="us-gaap_AccountsPayableOtherCurrent_637843214459786069" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637843214459786069" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637843214459796070" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637843214459786069" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637843214459796070" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637843214459786069" xlink:to="us-gaap_ConvertibleDebtCurrent_637843214459796070" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637843214459786069" xlink:to="us-gaap_NotesPayableCurrent_637843214459796070" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637843214459796070" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637843214459796070" xlink:to="us-gaap_CommonStockValue_637843214459796070" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637843214459796070" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637843214459796070" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637843214459796070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637843214459796070" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637843214459796070" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_OperatingIncomeLoss_637843214459806070" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637843214459806070" xlink:to="us-gaap_Revenues_637843214459806070" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637843214459806070" xlink:to="us-gaap_CostOfRevenue_637843214459806070" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637843214459806070" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637843214459806070" order="3" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637843214459806070" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637843214459806070" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_NonoperatingIncomeExpense_637843214459806070" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637843214459806070" xlink:to="us-gaap_OtherNonoperatingExpense_637843214459806070" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637843214459806070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637843214459806070" xlink:to="us-gaap_OtherNonoperatingIncome_637843214459806070" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_NetIncomeLoss_637843214459816070" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_ShareBasedCompensation_637843214459816070" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_Depreciation_637843214459816070" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637843214459816070" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637843214459816070" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637843214459816070" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637843214459816070" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214459816070" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214459816070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214459816070" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637843214459826070" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637843214459826070" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637843214459826070" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_IncreaseDecreaseInInventories_637843214459826070" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637843214459826070" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214459816070" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637843214459826070" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637843214459826070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" xlink:to="plx_IncreaseDecreaseInBankDeposits_637843214459826070" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637843214459836069" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637843214459836069" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637843214459836069" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" xlink:to="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637843214459836069" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214459826070" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637843214459836069" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" xlink:to="us-gaap_RepaymentsOfNotesPayable_637843214459836069" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637843214459836069" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637843214459836069" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_637843214459846071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_637843214459846071" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214459846071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214459846071" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637843214459846071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214459836069" xlink:to="us-gaap_ProceedsFromWarrantExercises_637843214459846071" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637843214459846071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637843214459846071" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637843214459846071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637843214459846071" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637843214459846071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637843214459846071" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637843214459856071" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637843214459856071" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637843214459856071" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637843214459856071" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637843214459856071" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637843214459856071" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637843214459856071" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637843214459856071" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637843214459856071" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637843214459856071" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_637843214459866070" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637843214459866070" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_InterestExpenseDebtOther" xlink:label="plx_InterestExpenseDebtOther_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="plx_InterestExpenseDebtOther_637843214459866070" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214459866070" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214459866070" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637843214459866070" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_637843214459866070" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637843214459866070" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637843214459866070" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637843214459876072" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent_637843214459876072" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637843214459876072" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_637843214459876072" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsSundryCurrent_637843214459876072" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="41302 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637843214459876072" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_InterestPayableCurrent_637843214459876072" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637843214459876072" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedVacationCurrent_637843214459876072" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637843214459886073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637843214459886073" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_637843214459886073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedRoyaltiesCurrent_637843214459886073" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_637843214459886073" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_637843214459886073" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>plx-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2022 11:04:08 AM-->
<!--Modified on: 3/31/2022 11:04:08 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureCommercializationAgreementsDetails" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirementDetails" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRevenueDetails" roleURI="http://www.protalix.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfStockOptionActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="31003 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_KirinHoldingsCompanyLimitedMember" xlink:label="plx_KirinHoldingsCompanyLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_KirinHoldingsCompanyLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_CollaborativeArrangementProfitSharePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentInConsiderationForDevelopmentServicesPerformed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NonRefundableFutureServicePayment" xlink:label="plx_NonRefundableFutureServicePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NonRefundableFutureServicePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="plx_ContributionPlansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EmployeeSeveranceObligationPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_BenefitsPayableDuringNextFiveYears" xlink:label="plx_BenefitsPayableDuringNextFiveYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_BenefitsPayableDuringNextFiveYears" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_RoyaltyAgreementTermsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OutsideOfIsraelMember" xlink:label="plx_OutsideOfIsraelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:to="plx_OutsideOfIsraelMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40801 - Disclosure - REVENUE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice4.69Member" xlink:label="plx_ExercisePrice4.69Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice4.69Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice2.00Member" xlink:label="plx_ExercisePrice2.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice2.00Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59OneMember" xlink:label="plx_ExercisePrice3.59OneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.59OneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.66Member" xlink:label="plx_ExercisePrice3.66Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.66Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.73Member" xlink:label="plx_ExercisePrice3.73Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.73Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NoExercisePriceMember" xlink:label="plx_NoExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_NoExercisePriceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59TwoMember" xlink:label="plx_ExercisePrice3.59TwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.59TwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice1.57Member" xlink:label="plx_ExercisePrice1.57Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice1.57Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesStockExpired" xlink:label="plx_StockIssuedDuringPeriodSharesStockExpired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="plx_StockIssuedDuringPeriodSharesStockExpired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice1.57Member" xlink:label="plx_ExercisePrice1.57Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice1.57Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice2.00Member" xlink:label="plx_ExercisePrice2.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice2.00Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.55Member" xlink:label="plx_ExercisePrice3.55Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.55Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59Member" xlink:label="plx_ExercisePrice3.59Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.59Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.66Member" xlink:label="plx_ExercisePrice3.66Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.66Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.70Member" xlink:label="plx_ExercisePrice3.70Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.70Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.73Member" xlink:label="plx_ExercisePrice3.73Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.73Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice4.69Member" xlink:label="plx_ExercisePrice4.69Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice4.69Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice5.10Member" xlink:label="plx_ExercisePrice5.10Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice5.10Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice5.60Member" xlink:label="plx_ExercisePrice5.60Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice5.60Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice17.20Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:type="extended" xlink:title="40907 - Disclosure - SHARE CAPITAL (Additional information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentOperationsMember" xlink:label="plx_SeniorVicePresidentOperationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentOperationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_VicePresidentResearchAndDevelopmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CertainEmployeesMember" xlink:label="plx_CertainEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_CertainEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_CommonStockNumberOfVotingRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfDirectors" xlink:label="plx_NumberOfDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_NumberOfDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_PercentageOfCommissionOnSaleOfShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_InterestExpenseDebtOther" xlink:label="plx_InterestExpenseDebtOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_InterestExpenseDebtOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestCostsIncurred" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="plx_FourPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_FourPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="plx_ConvertibleNotesDueTwoThousandTwentyOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDueTwoThousandTwentyOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ThresholdPercentageOfConversionPrice" xlink:label="plx_ThresholdPercentageOfConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ThresholdPercentageOfConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentRedemption" xlink:label="plx_DebtInstrumentRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfOutstandingCapitalStock" xlink:label="plx_PercentageOfOutstandingCapitalStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PercentageOfOutstandingCapitalStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_UsIsraelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="41203 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CompensationToNonExecutiveDirectorsMember" xlink:label="plx_CompensationToNonExecutiveDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="plx_CompensationToNonExecutiveDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromExpenseReimbursements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>plx-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2022 11:04:08 AM-->
<!--Modified on: 3/31/2022 11:04:08 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value: Authorized - as of December 31, 2020 and 2021, 120,000,000 shares; issued and outstanding - as of December 31, 2020 and 2021, 34,765,280 and 45,556,647 shares, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total capital deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES - NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity component of convertible notes, net of transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:to="us-gaap_IncreaseDecreaseOfRestrictedInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_lbl" xml:lang="en-US">Decrease (increase) in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption and transactions costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Net payment for convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Debt conversion converted instrument amount, cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommercializationAgreementsAbstract" xlink:to="plx_CommercializationAgreementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommercializationAgreementsAbstract_lbl" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUE</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">SHARE CAPITAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">CONVERTIBLE NOTES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment in value of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks and trade receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Useful Life Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:to="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of options and restricted stocks granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_lbl" xml:lang="en-US">Schedule Of Options And Restricted Stocks Granted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_lbl" xml:lang="en-US">Schedule of Options and Restricted Stocks Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Restricted Stock Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_lbl" xml:lang="en-US">Summary of Options Granted to Consultants, Directors, and Other Service Providers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Summary of Share Options Outstanding and Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense in Statement of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense Recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Open Tax Years Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Open Tax Years [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule of Open Tax Years</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental Information, Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="plx_LaboratoryEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful life</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="plx_FiocruzMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FiocruzMember_lbl" xml:lang="en-US">Fiocruz [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Per share price at which the new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Issue Price Per Share, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_lbl" xml:lang="en-US">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Warrants And Rights, Commencement Period For Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, commencement period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Noncreditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_lbl" xml:lang="en-US">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_lbl" xml:lang="en-US">Tax Rate Assumption Related To Deferred Tax Difference Reversal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_KirinHoldingsCompanyLimitedMember" xlink:label="plx_KirinHoldingsCompanyLimitedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_KirinHoldingsCompanyLimitedMember" xlink:to="plx_KirinHoldingsCompanyLimitedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_KirinHoldingsCompanyLimitedMember_lbl" xml:lang="en-US">Kirin Holdings Company, Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_KirinHoldingsCompanyLimitedMember_lbl" xml:lang="en-US">Kirin Holdings Company, Limited [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementProfitSharePercentage" xlink:to="plx_CollaborativeArrangementProfitSharePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementProfitSharePercentage_lbl" xml:lang="en-US">Collaborative arrangement profit sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementProfitSharePercentage_lbl" xml:lang="en-US">Collaborative Arrangement Profit Share Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment on notes payable</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:to="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" xml:lang="en-US">The cash inflow from consideration received for development services performed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" xml:lang="en-US">Payment in Consideration for Development Services Performed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_lbl" xml:lang="en-US">Payments in consideration for development services performed</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:to="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" xml:lang="en-US">The cash inflow in connection with performance of additional studies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" xml:lang="en-US">Payments in Connection with Performance of Additional Studies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_lbl" xml:lang="en-US">Payments in connection with performance of additional studies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Recognized revenues related to non-refundable payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Future milestone payment</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NonRefundableFutureServicePayment" xlink:label="plx_NonRefundableFutureServicePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NonRefundableFutureServicePayment" xlink:to="plx_NonRefundableFutureServicePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NonRefundableFutureServicePayment_lbl" xml:lang="en-US">Amount of non refundable payment received for future service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NonRefundableFutureServicePayment_lbl" xml:lang="en-US">Non-Refundable Future Service Payment</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:to="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_lbl" xml:lang="en-US">Represents the percentage of adult Gaucher patients treated with Uplyso.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_lbl" xml:lang="en-US">Percentage Of Adult Gaucher Patients Treated With alfataliglicerase</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="plx_FurnitureAndComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write-down</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US">Retirement Plan Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US">Retirement Plan Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" xml:lang="en-US">Contribution to Insurance Companies [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ContributionPlansMember" xlink:to="plx_ContributionPlansMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ContributionPlansMember_lbl" xml:lang="en-US">Contribution to Defined Contribution Plans [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="plx_EmployeeSeveranceObligationPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee severance obligation payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee Severance Obligation Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee severance obligation payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Postemployment Benefits, Period Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Severance expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" xml:lang="en-US">Gain for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number Of Employees To Receive Benefits During Next Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number Of Employees To Receive Benefits During Next Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number of benefit eligible employees</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_BenefitsPayableDuringNextFiveYears" xlink:label="plx_BenefitsPayableDuringNextFiveYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BenefitsPayableDuringNextFiveYears" xlink:to="plx_BenefitsPayableDuringNextFiveYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_BenefitsPayableDuringNextFiveYears_lbl" xml:lang="en-US">Amount of benefits payable during next five years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_BenefitsPayableDuringNextFiveYears_lbl" xml:lang="en-US">Benefits Payable During Next Five Years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementTermsMember" xlink:to="us-gaap_RoyaltyAgreementTermsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xml:lang="en-US">Royalty Agreement Terms [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OutsideOfIsraelMember" xlink:label="plx_OutsideOfIsraelMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutsideOfIsraelMember" xlink:to="plx_OutsideOfIsraelMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutsideOfIsraelMember_lbl" xml:lang="en-US">Outside of Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutsideOfIsraelMember_lbl" xml:lang="en-US">Outside of Israel [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xml:lang="en-US">Arrangement Other than Collaborative [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentsAndContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="plx_RoyaltiesOnSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Percentage of royalties based on sale of products developed from projects funded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Royalties On Sale Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Royalties based on sale of products developed from funded projects, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense included in cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued royalties</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="plx_CommitmentAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Commitment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Commitment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Subcontracting commitment amount</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfRoyaltiesToGrantReceived" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Required royalty payments represented as a percentage to grants received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Percentage of Royalties to Grant Received</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">2027 and thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease, term of agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Option to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice4.69Member" xlink:label="plx_ExercisePrice4.69Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice4.69Member" xlink:to="plx_ExercisePrice4.69Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice4.69Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 4.69.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice4.69Member_lbl" xml:lang="en-US">Exercise Price 4.69</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice2.00Member" xlink:label="plx_ExercisePrice2.00Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice2.00Member" xlink:to="plx_ExercisePrice2.00Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice2.00Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 2.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice2.00Member_lbl" xml:lang="en-US">Exercise Price 2.00</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59OneMember" xlink:label="plx_ExercisePrice3.59OneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.59OneMember" xlink:to="plx_ExercisePrice3.59OneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.59OneMember_lbl" xml:lang="en-US">Represents the information pertaining to exercise price one 3.59 .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.59OneMember_lbl" xml:lang="en-US">Exercise Price 3.59 One</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.66Member" xlink:label="plx_ExercisePrice3.66Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.66Member" xlink:to="plx_ExercisePrice3.66Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.66Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 3.66.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.66Member_lbl" xml:lang="en-US">Exercise Price 3.66</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.73Member" xlink:label="plx_ExercisePrice3.73Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.73Member" xlink:to="plx_ExercisePrice3.73Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.73Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 3.73</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.73Member_lbl" xml:lang="en-US">Exercise Price 3.73</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NoExercisePriceMember" xlink:label="plx_NoExercisePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NoExercisePriceMember" xlink:to="plx_NoExercisePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NoExercisePriceMember_lbl" xml:lang="en-US">No Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NoExercisePriceMember_lbl" xml:lang="en-US">No Exercise Price</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59TwoMember" xlink:label="plx_ExercisePrice3.59TwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.59TwoMember" xlink:to="plx_ExercisePrice3.59TwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.59TwoMember_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 3.59 two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.59TwoMember_lbl" xml:lang="en-US">Exercise Price 3.59 Two</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice1.57Member" xlink:label="plx_ExercisePrice1.57Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice1.57Member" xlink:to="plx_ExercisePrice1.57Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice1.57Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 1.57.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice1.57Member_lbl" xml:lang="en-US">Exercise Price 1.57</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Fair value at grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Fair value at grant</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award granted contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="plx_EmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeited and Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited and Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non vested at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_lbl" xml:lang="en-US">Represents information pertaining to options  granted to consultants directors and other service providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_lbl" xml:lang="en-US">Options granted to consultants, directors and other service providers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of options or restricted stock</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesStockExpired" xlink:label="plx_StockIssuedDuringPeriodSharesStockExpired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesStockExpired" xlink:to="plx_StockIssuedDuringPeriodSharesStockExpired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesStockExpired_lbl" xml:lang="en-US">Number of share options (or share units) expired during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesStockExpired_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesStockExpired_lbl" xml:lang="en-US">Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.55Member" xlink:label="plx_ExercisePrice3.55Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.55Member" xlink:to="plx_ExercisePrice3.55Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.55Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 3.55.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.55Member_lbl" xml:lang="en-US">Exercise Price 3.55</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59Member" xlink:label="plx_ExercisePrice3.59Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.59Member" xlink:to="plx_ExercisePrice3.59Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.59Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 3.59.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.59Member_lbl" xml:lang="en-US">Exercise Price 3.59</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.70Member" xlink:label="plx_ExercisePrice3.70Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.70Member" xlink:to="plx_ExercisePrice3.70Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.70Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price 3.70.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.70Member_lbl" xml:lang="en-US">Exercise Price 3.70</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice5.10Member" xlink:label="plx_ExercisePrice5.10Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice5.10Member" xlink:to="plx_ExercisePrice5.10Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice5.10Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price $5.10.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice5.10Member_lbl" xml:lang="en-US">Exercise Price 5.10</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice5.60Member" xlink:label="plx_ExercisePrice5.60Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice5.60Member" xlink:to="plx_ExercisePrice5.60Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice5.60Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price $5.60.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice5.60Member_lbl" xml:lang="en-US">Exercise Price 5.60</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice17.20Member" xlink:to="plx_ExercisePrice17.20Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price $17.20.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">Exercise Price 17.20</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of options outstanding at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PresidentAndChiefExecutiveOfficerMember" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">This member stands for President and Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">President and Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">This member stands for Senior Vice President and Chief Development Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US">Sr. Vice President And Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Sr. Vice President And Chief Financial Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Senior Vice President And Chief Financial Officer</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentOperationsMember" xlink:label="plx_SeniorVicePresidentOperationsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentOperationsMember" xlink:to="plx_SeniorVicePresidentOperationsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentOperationsMember_lbl" xml:lang="en-US">Senior Vice President, Operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentOperationsMember_lbl" xml:lang="en-US">Senior Vice President, Operations</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VicePresidentResearchAndDevelopmentMember" xlink:to="plx_VicePresidentResearchAndDevelopmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">This member stands for vice president research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President Research And Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CertainEmployeesMember" xlink:label="plx_CertainEmployeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CertainEmployeesMember" xlink:to="plx_CertainEmployeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CertainEmployeesMember_lbl" xml:lang="en-US">Certain Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CertainEmployeesMember_lbl" xml:lang="en-US">Certain Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Chairman, Board of Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtmEquityOfferingSalesAgreementMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to ATM Equity Offering Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Equity Offering Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">BofA Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockNumberOfVotingRights" xlink:to="plx_CommonStockNumberOfVotingRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Represents the number of votes for each share of common stock is entitled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Common Stock, Number Of Voting Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfDirectors" xlink:label="plx_NumberOfDirectors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfDirectors" xlink:to="plx_NumberOfDirectors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfDirectors_lbl" xml:lang="en-US">Number Of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfDirectors_lbl" xml:lang="en-US">Number Of Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares of Common Stock remain available for grant under the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of non-vested shares</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue_lbl" xml:lang="en-US">The aggregate value of non option equity instruments, that will be granted contingent upon certain conditions, on an annual basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non Option Equity Instruments, Grants, Contingent Upon Certain Conditions, Aggregate Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue_lbl" xml:lang="en-US">Aggregate value of Restricted Stock Units that will be granted, contingent upon certain conditions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized weighted average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted instrument, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of shares per warrant issued</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfCommissionOnSaleOfShares" xlink:to="plx_PercentageOfCommissionOnSaleOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Percentage of commission on sale of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Percentage of Commission on Sale of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Commission (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Contractual interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Debt discount amortization</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_InterestExpenseDebtOther" xlink:label="plx_InterestExpenseDebtOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestExpenseDebtOther" xlink:to="plx_InterestExpenseDebtOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestExpenseDebtOther_lbl" xml:lang="en-US">Interest Expense, Debt, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestExpenseDebtOther_lbl" xml:lang="en-US">Interest Expense, Debt, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_InterestExpenseDebtOther_lbl" xml:lang="en-US">Other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="plx_FourPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FourPointFivePercentageConvertibleNotesMember" xlink:to="plx_FourPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FourPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">4.5% Convertible Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="plx_ConvertibleNotesDueTwoThousandTwentyOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:to="plx_ConvertibleNotesDueTwoThousandTwentyOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDueTwoThousandTwentyOneMember_lbl" xml:lang="en-US">Convertible Notes Due Two Thousand Twenty One [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Amount of accrued and unpaid interest exchanged in cash in debt conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Exchange in Cash, Accrued and Unpaid Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Convertible notes exchange in cash, accrued and unpaid interest</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Base value for conversion rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Net proceeds from issuance of convertible notes</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Number of shares for basis conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfPremiumToClosingPriceOfStock" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of premium to closing price of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of Premium to Closing Price of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Mature term</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">The transaction costs in connection with exchange of convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Transactions costs in connection with the exchange of convertible notes</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:to="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">The maximum price per share of the conversion feature embedded in the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Maximum Debt Instrument Convertible Conversion Share Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Maximum price per share of the conversion feature</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US">Debt Instrument, Redemption, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US">Redemption, description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Threshold trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Threshold consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ThresholdPercentageOfConversionPrice" xlink:label="plx_ThresholdPercentageOfConversionPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ThresholdPercentageOfConversionPrice" xlink:to="plx_ThresholdPercentageOfConversionPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ThresholdPercentageOfConversionPrice_lbl" xml:lang="en-US">Threshold percentage of conversion price on sale price of the company's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ThresholdPercentageOfConversionPrice_lbl" xml:lang="en-US">Threshold Percentage Of Conversion Price</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:to="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" xml:lang="en-US">Aggregate percentage of principle amount of debt outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" xml:lang="en-US">Debt Instrument, Aggregate Percentage Of Principle Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_lbl" xml:lang="en-US">Aggregate percentage of principle amount</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentRedemption" xlink:label="plx_DebtInstrumentRedemption" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentRedemption" xlink:to="plx_DebtInstrumentRedemption_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentRedemption_lbl" xml:lang="en-US">The amount of redemption of debt as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentRedemption_lbl" xml:lang="en-US">Debt Instrument, Redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_DebtInstrumentRedemption_lbl" xml:lang="en-US">Amount of redemption of debt</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfOutstandingCapitalStock" xlink:label="plx_PercentageOfOutstandingCapitalStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfOutstandingCapitalStock" xlink:to="plx_PercentageOfOutstandingCapitalStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfOutstandingCapitalStock_lbl" xml:lang="en-US">Percentage of outstanding capital stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfOutstandingCapitalStock_lbl" xml:lang="en-US">Percentage of Outstanding Capital Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_PercentageOfOutstandingCapitalStock_lbl" xml:lang="en-US">Percentage of outstanding capital stock</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:to="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xml:lang="en-US">Represents the denomination of the principal amount of debt that is used in conversion calculations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xml:lang="en-US">Debt Instrument Principal Amount Denomination for Conversion Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_lbl" xml:lang="en-US">Denomination of the principal amount of debt</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:to="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" xml:lang="en-US">Number of calendar days after the date of applicable fundamental change purchase date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" xml:lang="en-US">Number Of Calendar Days After Date Of Applicable Fundamental Change</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_lbl" xml:lang="en-US">Number of calendar days after the date of applicable fundamental change purchase date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Redemption price, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net, Classification [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">In respect of:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsOtherTimingDifferences" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">The amount of deferred tax assets other timing differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">Deferred Tax Assets Other Timing Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">Other timing differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US">Income Tax Contingency [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UsIsraelMember" xlink:to="plx_UsIsraelMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UsIsraelMember_lbl" xml:lang="en-US">Israel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open tax year</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="plx_IncomeTaxDisclosureTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure Table</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Protalix Ltd</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="plx_TaxYearThereafterMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TaxYearThereafterMember_lbl" xml:lang="en-US">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure Line Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Other assets:</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Other Assets, Institutions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Institutions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="plx_OtherAssetsSundryCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Other Assets, Sundry, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Sundry</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CompensationToNonExecutiveDirectorsMember" xlink:label="plx_CompensationToNonExecutiveDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CompensationToNonExecutiveDirectorsMember" xlink:to="plx_CompensationToNonExecutiveDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CompensationToNonExecutiveDirectorsMember_lbl" xml:lang="en-US">Compensation To The Non-Executive Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CompensationToNonExecutiveDirectorsMember_lbl" xml:lang="en-US">Compensation to the non-executive directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Compensation (including share based compensation) to the non-executive directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseMember" xlink:to="plx_AlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromExpenseReimbursements" xlink:to="plx_ProceedsFromExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">The cash inflow from expense reimbursements in a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds from sales</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>plx-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2022 11:04:08 AM-->
<!--Modified on: 3/31/2022 11:04:08 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureCommercializationAgreements" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreements" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirement" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureCommitments" roleURI="http://www.protalix.com/role/DisclosureCommitments" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeases" roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRevenue" roleURI="http://www.protalix.com/role/DisclosureRevenue" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapital" roleURI="http://www.protalix.com/role/DisclosureShareCapital" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotes" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeasesTables" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRevenueTables" roleURI="http://www.protalix.com/role/DisclosureRevenueTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalTables" roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureCommercializationAgreementsDetails" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureInventoriesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirementDetails" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRevenueDetails" roleURI="http://www.protalix.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfStockOptionActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureShareCapitalAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637843214460826084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637843214460826084" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637843214460826084" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637843214460826084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637843214460826084" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637843214460826084" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637843214460826084" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637843214460826084" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637843214460826084" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637843214460826084" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637843214460826084" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637843214460826084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637843214460826084" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637843214460836084" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637843214460836084" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637843214460836084" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637843214460836084" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637843214460836084" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637843214460836084" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637843214460836084" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637843214460836084" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637843214460836084" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637843214460836084" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637843214460836084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637843214460836084" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637843214460846090" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637843214460846090" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637843214460846090" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637843214460846090" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637843214460846090" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637843214460846090" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637843214460846090" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637843214460846090" order="31" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637843214460846090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637843214460846090" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637843214460856087" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637843214460856087" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637843214460856087" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637843214460856087" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637843214460856087" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637843214460856087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637843214460856087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637843214460856087" xlink:to="us-gaap_AssetsCurrentAbstract_637843214460856087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637843214460856087" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637843214460866088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637843214460856087" xlink:to="plx_ShortTermBankDeposits_637843214460866088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637843214460856087" xlink:to="us-gaap_AccountsReceivableNetCurrent_637843214460866088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637843214460856087" xlink:to="us-gaap_OtherAssetsCurrent_637843214460866088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637843214460856087" xlink:to="us-gaap_InventoryNet_637843214460866088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637843214460856087" xlink:to="us-gaap_AssetsCurrent_637843214460866088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637843214460856087" xlink:to="us-gaap_AssetsNoncurrentAbstract_637843214460866088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637843214460866088" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637843214460866088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637843214460866088" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637843214460866088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637843214460866088" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637843214460866088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637843214460856087" xlink:to="us-gaap_Assets_637843214460866088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214460866088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214460866088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_AccountsPayableTradeCurrent_637843214460876086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_AccountsPayableOtherCurrent_637843214460876086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637843214460876086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637843214460876086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_ConvertibleDebtCurrent_637843214460876086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_NotesPayableCurrent_637843214460876086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637843214460866088" xlink:to="us-gaap_LiabilitiesCurrent_637843214460876086" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637843214460876086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637843214460876086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637843214460876086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637843214460886085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637843214460886085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637843214460876086" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637843214460886085" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_LiabilitiesNoncurrent_637843214460886085" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_Liabilities_637843214460886085" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_CommitmentsAndContingencies_637843214460886085" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_StockholdersEquityAbstract_637843214460886085" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637843214460886085" xlink:to="us-gaap_CommonStockValue_637843214460886085" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637843214460886085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637843214460886085" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637843214460886085" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637843214460886085" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637843214460896086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637843214460886085" xlink:to="us-gaap_StockholdersEquity_637843214460896086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637843214460866088" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637843214460896086" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637843214460896086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637843214460896086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637843214460896086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637843214460896086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637843214460896086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_637843214460906087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214460906087" xlink:to="srt_ProductOrServiceAxis_637843214460906087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637843214460906087" xlink:to="srt_ProductsAndServicesDomain_637843214460906087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637843214460906087" xlink:to="us-gaap_ProductMember_637843214460906087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637843214460906087" xlink:to="us-gaap_LicenseAndServiceMember_637843214460906087" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214460906087" xlink:to="us-gaap_StatementLineItems_637843214460906087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_Revenues_637843214460906087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_CostOfRevenue_637843214460906087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637843214460906087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637843214460906087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_OperatingIncomeLoss_637843214460906087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_OtherNonoperatingExpense_637843214460906087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_OtherNonoperatingIncome_637843214460906087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_NonoperatingIncomeExpense_637843214460906087" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637843214460906087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_NetIncomeLoss_637843214460906087" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_EarningsPerShareBasic_637843214460916087" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_EarningsPerShareDiluted_637843214460916087" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637843214460916087" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460906087" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637843214460916087" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637843214460916087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214460916087" xlink:to="us-gaap_StatementEquityComponentsAxis_637843214460916087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637843214460916087" xlink:to="us-gaap_CommonStockMember_637843214460916087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637843214460916087" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637843214460916087" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637843214460916087" xlink:to="us-gaap_RetainedEarningsMember_637843214460916087" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637843214460916087" xlink:to="us-gaap_EquityComponentDomain_637843214460916087" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214460916087" xlink:to="us-gaap_StatementLineItems_637843214460916087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637843214460916087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_StockholdersEquity_637843214460916087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637843214460926088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_SharesOutstanding_637843214460926088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637843214460926088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637843214460926088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637843214460966088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637843214460926088" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637843214460966088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637843214460966088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637843214460966088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637843214460966088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637843214460966088" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637843214460966088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637843214460966088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637843214460966088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637843214460966088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637843214460966088" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637843214460966088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637843214460966088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637843214460966088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637843214460976089" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637843214460976089" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637843214460976089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_637843214460976089" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_637843214460976089" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637843214460976089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637843214460976089" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637843214460976089" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_NetIncomeLoss_637843214460976089" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_StockholdersEquity_637843214460976089" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637843214460976089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214460916087" xlink:to="us-gaap_SharesOutstanding_637843214460976089" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_NetIncomeLoss_637843214460986088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_ShareBasedCompensation_637843214460986088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_Depreciation_637843214460986088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637843214460986088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637843214460986088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637843214460986088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637843214460986088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214460986088" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214460986088" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637843214460986088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637843214460986088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637843214460996089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637843214460996089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" xlink:to="us-gaap_IncreaseDecreaseInInventories_637843214460996089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637843214460996089" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637843214460986088" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637843214460996089" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637843214460986088" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637843214460996089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="plx_IncreaseDecreaseInBankDeposits_637843214460996089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637843214460996089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637843214460996089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637843214460996089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637843214461006105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637843214461006105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637843214461006105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637843214460996089" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637843214461006105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637843214461006105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" xlink:to="us-gaap_RepaymentsOfNotesPayable_637843214461006105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_637843214461006105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_637843214461006105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214461016094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" xlink:to="us-gaap_ProceedsFromWarrantExercises_637843214461016094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637843214461006105" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637843214461016094" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637843214461016094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637843214461016094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637843214461016094" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378432144610160941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378432144610160941" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637843214461016094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637843214461016094" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637843214461026089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637843214461016094" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637843214461026089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637843214461026089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637843214461016094" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637843214461026089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637843214461026089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637843214461026089" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637843214461026089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637843214461026089" xlink:to="us-gaap_InterestPaidNet_637843214461026089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_637843214461026089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637843214461026089" xlink:to="plx_InterestReceivedNet_637843214461026089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637843214461036090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637843214461036090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreements" xlink:type="extended" xlink:title="10201 - Disclosure - COMMERCIALIZATION AGREEMENTS">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637843214461036090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommercializationAgreementsAbstract_637041422967633303" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637843214461036090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10301 - Disclosure - PROPERTY AND EQUIPMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637843214461036090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967633303" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637843214461036090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10401 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637843214461036090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637843214461036090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" xlink:type="extended" xlink:title="10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637843214461036090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637843214461036090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10601 - Disclosure - COMMITMENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_637843214461046086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_637843214461046086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="10701 - Disclosure - OPERATING LEASES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637843214461046086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637843214461046086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10801 - Disclosure - REVENUE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637843214461046086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637843214461046086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapital" xlink:type="extended" xlink:title="10901 - Disclosure - SHARE CAPITAL">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637843214461046086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967633303" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637843214461046086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotes" xlink:type="extended" xlink:title="11001 - Disclosure - CONVERTIBLE NOTES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637843214461056092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967633303" xlink:to="us-gaap_DebtDisclosureTextBlock_637843214461056092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="11101 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637843214461056092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637843214461056092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="11201 - Disclosure - TAXES ON INCOME">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637843214461056092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637843214461056092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="11301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_637843214461056092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_637843214461056092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11401 - Disclosure - RELATED PARTY TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422967789587" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422967789587" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637843214461066087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11501 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637843214461066087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637843214461066087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637843214461066087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637843214461066087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637843214461066087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637843214461066087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_637843214461066087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_637843214461066087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_637843214461066087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637843214461076086" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637843214461076086" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637843214461076086" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637843214461076086" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637843214461076086" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637843214461076086" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637843214461076086" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637843214461076086" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_637843214461076086" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637843214461076086" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637843214461076086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637843214461076086" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967804651" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_637843214461086089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967804651" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock_637843214461086089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967809657" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637843214461086089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967809657" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637843214461086089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30403 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637843214461086089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637843214461086089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - OPERATING LEASES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637843214461086089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637843214461086089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637843214461086089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637843214461086089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30803 - Disclosure - REVENUE (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637843214461096087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalTables" xlink:type="extended" xlink:title="30903 - Disclosure - SHARE CAPITAL (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:label="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock_637843214461096087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637843214461096087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_637843214461096087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_637843214461096087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637843214461096087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637843214461096087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637843214461096087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="31003 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967819664" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967819664" xlink:to="us-gaap_StatementTable_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461106090" xlink:to="us-gaap_DebtInstrumentAxis_637843214461106090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461106090" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461106090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461106090" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461106090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461106090" xlink:to="us-gaap_StatementLineItems_637843214461106090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461106090" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461106090" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_637843214461106090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461106090" xlink:to="us-gaap_DebtInstrumentAxis_637843214461106090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461106090" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461106090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461106090" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461106090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637843214461106090" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461106090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461116088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461106090" xlink:to="us-gaap_StatementLineItems_637843214461116088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637843214461116088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461116088" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637843214461116088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="31203 - Disclosure - TAXES ON INCOME (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637843214461116088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637843214461116088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_637843214461116088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock_637843214461116088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="31303 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_637843214461116088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_637843214461116088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31403 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_637843214461116088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_637843214461116088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461126088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461126088" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461126088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461126088" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461126088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461126088" xlink:to="plx_LaboratoryEquipmentMember_637843214461126088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461126088" xlink:to="us-gaap_FurnitureAndFixturesMember_637843214461126088" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461126088" xlink:to="us-gaap_ComputerEquipmentMember_637843214461126088" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461126088" xlink:to="srt_RangeAxis_637843214461126088" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461126088" xlink:to="srt_RangeMember_637843214461126088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461126088" xlink:to="srt_MinimumMember_637843214461126088" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461126088" xlink:to="srt_MaximumMember_637843214461126088" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461126088" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461126088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637843214461126088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461126088" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637843214461126088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="plx_SignificantAccountingPoliciesTable_637843214461136090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637843214461136090" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637843214461136090" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461136090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461136090" xlink:to="plx_AtMarketEquityOfferingMember_637843214461136090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461136090" xlink:to="us-gaap_PrivatePlacementMember_637843214461136090" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="us-gaap_TypeOfArrangementAxis_637843214461136090" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637843214461136090" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461136090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461136090" xlink:to="plx_AmendedPfizerAgreementMember_637843214461136090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461136090" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461136090" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461136090" xlink:to="plx_ChiesiUSAgreementMember_637843214461136090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461136090" xlink:to="plx_ChiesiExUSAgreementMember_637843214461136090" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="dei_LegalEntityAxis_637843214461136090" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637843214461136090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637843214461136090" xlink:to="dei_EntityDomain_637843214461136090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637843214461136090" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637843214461146090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="srt_StatementGeographicalAxis_637843214461146090" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637843214461146090" xlink:to="srt_SegmentGeographicalDomain_637843214461146090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637843214461146090" xlink:to="country_BR_637843214461146090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="srt_RangeAxis_637843214461146090" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461146090" xlink:to="srt_RangeMember_637843214461146090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461146090" xlink:to="srt_MinimumMember_637843214461146090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461146090" xlink:to="srt_MaximumMember_637843214461146090" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="us-gaap_DebtInstrumentAxis_637843214461146090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461146090" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461146090" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637843214461146090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461146090" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637843214461146090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637843214461146090" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461156091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637843214461146090" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461156091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="srt_MajorCustomersAxis_637843214461156091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637843214461156091" xlink:to="srt_NameOfMajorCustomerDomain_637843214461156091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637843214461156091" xlink:to="plx_FiocruzMember_637843214461156091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637843214461156091" xlink:to="plx_ChiesiMember_637843214461156091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637843214461136090" xlink:to="plx_SignificantAccountingPoliciesLineItems_637843214461156091" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637843214461156091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637843214461156091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_SharesIssuedPricePerShare_637843214461156091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_SharePrice_637843214461166091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214461166091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637843214461166091" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637843214461166091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637843214461166091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637843214461166091" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637843214461166091" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants" xlink:label="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637843214461166091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants_637843214461166091" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637843214461176091" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637843214461176091" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637843214461176091" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637843214461176091" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_PaymentOnNetSalesPercentage_637843214461176091" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637843214461176091" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637843214461176091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637843214461176091" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt_637843214461186089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_ConvertibleDebt_637843214461186089" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:label="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_637843214461186089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal_637843214461186089" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637843214461186089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637843214461186089" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637843214461186089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637843214461186089" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637843214461186089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_OperatingLeaseLiability_637843214461186089" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_637843214461186089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="plx_RevenuePerformanceObligationNumber_637843214461186089" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637843214461156091" xlink:to="us-gaap_AccountsReceivableNetCurrent_637843214461196089" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommercializationAgreementsAbstract" xlink:to="us-gaap_StatementTable_637843214461196089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461196089" xlink:to="us-gaap_TypeOfArrangementAxis_637843214461196089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637843214461196089" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461196089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461196089" xlink:to="plx_PfizerMember_637843214461196089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461196089" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461196089" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461196089" xlink:to="plx_ChiesiUSAgreementMember_637843214461196089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637843214461196089" xlink:to="plx_ChiesiExUSAgreementMember_637843214461196089" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_KirinHoldingsCompanyLimitedMember" xlink:label="plx_KirinHoldingsCompanyLimitedMember_637843214461196089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461196089" xlink:to="plx_KirinHoldingsCompanyLimitedMember_637843214461196089" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461196089" xlink:to="srt_RangeAxis_637843214461206091" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461206091" xlink:to="srt_RangeMember_637843214461206091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461206091" xlink:to="srt_MaximumMember_637843214461206091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461206091" xlink:to="srt_MinimumMember_637843214461206091" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461196089" xlink:to="srt_StatementGeographicalAxis_637843214461206091" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637843214461206091" xlink:to="srt_SegmentGeographicalDomain_637843214461206091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637843214461206091" xlink:to="country_BR_637843214461206091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461196089" xlink:to="us-gaap_StatementLineItems_637843214461206091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:label="plx_CollaborativeArrangementProfitSharePercentage_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_CollaborativeArrangementProfitSharePercentage_637843214461206091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="us-gaap_DebtInstrumentFaceAmount_637843214461206091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="us-gaap_NotesPayableCurrent_637843214461206091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_637843214461206091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_637843214461206091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637843214461216090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637843214461216090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637843214461216090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_AgreementAmendmentPaymentReceivable_637843214461216090" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637843214461216090" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637843214461216090" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_PaymentOnNetSalesPercentage_637843214461216090" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentInConsiderationForDevelopmentServicesPerformed" xlink:label="plx_PaymentInConsiderationForDevelopmentServicesPerformed_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_PaymentInConsiderationForDevelopmentServicesPerformed_637843214461216090" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies" xlink:label="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies_637843214461216090" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637843214461216090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637843214461216090" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="us-gaap_ContractWithCustomerLiability_637843214461226092" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NonRefundableFutureServicePayment" xlink:label="plx_NonRefundableFutureServicePayment_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_NonRefundableFutureServicePayment_637843214461226092" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_637843214461226092" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461206091" xlink:to="us-gaap_RepaymentsOfNotesPayable_637843214461226092" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968011145" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968011145" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461226092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461226092" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461226092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461226092" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461226092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember_637843214461226092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461226092" xlink:to="plx_LaboratoryEquipmentMember_637843214461226092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461226092" xlink:to="plx_FurnitureAndComputerEquipmentMember_637843214461236092" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461226092" xlink:to="us-gaap_LeaseholdImprovementsMember_637843214461236092" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637843214461226092" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461236092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461236092" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637843214461236092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461236092" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637843214461236092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637843214461236092" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637843214461236092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968167243" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968167243" xlink:to="us-gaap_Depreciation_637843214461236092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637843214461236092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637843214461236092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637843214461236092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637843214461236092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637843214461236092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - INVENTORIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_353300" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_353300" xlink:to="us-gaap_InventoryWriteDown_637843214461246092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable_637843214461246092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461246092" xlink:to="us-gaap_RetirementPlanTypeAxis_637843214461246092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_637843214461246092" xlink:to="us-gaap_RetirementPlanTypeDomain_637843214461246092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637843214461246092" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_637843214461246092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_637843214461246092" xlink:to="plx_ContributionPlansMember_637843214461246092" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461246092" xlink:to="us-gaap_StatementLineItems_637843214461246092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="plx_EmployeeSeveranceObligationPayment_637843214461246092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_637843214461246092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_637843214461246092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_637843214461246092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_637843214461246092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_637843214461246092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_637843214461256091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_BenefitsPayableDuringNextFiveYears" xlink:label="plx_BenefitsPayableDuringNextFiveYears_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461246092" xlink:to="plx_BenefitsPayableDuringNextFiveYears_637843214461256091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" xlink:to="srt_RangeAxis_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461256091" xlink:to="srt_RangeMember_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461256091" xlink:to="srt_MinimumMember_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461256091" xlink:to="srt_MaximumMember_637843214461256091" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637843214461256091" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_637843214461256091" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_637843214461256091" xlink:to="us-gaap_RoyaltyAgreementTermsMember_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" xlink:to="srt_CounterpartyNameAxis_637843214461256091" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637843214461256091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637843214461256091" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637843214461256091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637843214461256091" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember_637843214461266097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OutsideOfIsraelMember" xlink:label="plx_OutsideOfIsraelMember_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_OfficeOfIsraeliInnovationAuthorityMember_637843214461266097" xlink:to="plx_OutsideOfIsraelMember_637843214461266097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" xlink:to="us-gaap_TypeOfArrangementAxis_637843214461266097" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637843214461266097" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461266097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461266097" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_637843214461266097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_637843214461256091" xlink:to="plx_CommitmentsAndContingenciesLineItems_637843214461266097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_637843214461266097" xlink:to="plx_RoyaltiesOnSaleOfProducts_637843214461266097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_637843214461266097" xlink:to="us-gaap_RoyaltyExpense_637843214461266097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_637843214461266097" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_637843214461266097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_637843214461266097" xlink:to="plx_CommitmentAmount_637843214461266097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_637843214461266097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_637843214461266097" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived_637843214461266097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_637843214461276095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_637843214461276095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637843214461276095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637843214461276095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637843214461276095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637843214461276095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637843214461276095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637843214461276095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637843214461276095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637843214461276095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637843214461276095" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637843214461276095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637843214461276095" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_637843214461286093" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637843214461286093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637843214461286093" xlink:to="srt_RangeAxis_637843214461286093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461286093" xlink:to="srt_RangeMember_637843214461286093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461286093" xlink:to="srt_MinimumMember_637843214461286093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461286093" xlink:to="srt_MaximumMember_637843214461286093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637843214461286093" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461286093" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637843214461286093" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461286093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637843214461286093" xlink:to="us-gaap_VehiclesMember_637843214461286093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637843214461286093" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_637843214461286093" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_637843214461286093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637843214461286093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637843214461286093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" xlink:to="us-gaap_SecurityDeposit_637843214461296093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637843214461286093" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_637843214461296093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40801 - Disclosure - REVENUE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637843214461296093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461296093" xlink:to="srt_ProductOrServiceAxis_637843214461296093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637843214461296093" xlink:to="srt_ProductsAndServicesDomain_637843214461296093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637843214461296093" xlink:to="us-gaap_ProductMember_637843214461296093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637843214461296093" xlink:to="us-gaap_LicenseAndServiceMember_637843214461296093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461296093" xlink:to="srt_StatementGeographicalAxis_637843214461296093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637843214461296093" xlink:to="srt_SegmentGeographicalDomain_637843214461296093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637843214461296093" xlink:to="plx_PfizerMember_637843214461296093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637843214461296093" xlink:to="country_BR_637843214461296093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637843214461296093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637843214461296093" xlink:to="plx_ChiesiMember_637843214461296093" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461296093" xlink:to="us-gaap_StatementLineItems_637843214461306093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461306093" xlink:to="us-gaap_Revenues_637843214461306093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461306093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461306093" xlink:to="us-gaap_AwardTypeAxis_637843214461306093" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461306093" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461306093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461306093" xlink:to="us-gaap_EmployeeStockOptionMember_637843214461306093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461306093" xlink:to="us-gaap_RestrictedStockMember_637843214461306093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461306093" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637843214461306093" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637843214461306093" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice4.69Member" xlink:label="plx_ExercisePrice4.69Member_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice4.69Member_637843214461306093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice2.00Member" xlink:label="plx_ExercisePrice2.00Member_637843214461306093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice2.00Member_637843214461306093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59OneMember" xlink:label="plx_ExercisePrice3.59OneMember_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice3.59OneMember_637843214461356092" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.66Member" xlink:label="plx_ExercisePrice3.66Member_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice3.66Member_637843214461356092" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.73Member" xlink:label="plx_ExercisePrice3.73Member_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice3.73Member_637843214461356092" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NoExercisePriceMember" xlink:label="plx_NoExercisePriceMember_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_NoExercisePriceMember_637843214461356092" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59TwoMember" xlink:label="plx_ExercisePrice3.59TwoMember_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice3.59TwoMember_637843214461356092" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice1.57Member" xlink:label="plx_ExercisePrice1.57Member_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461306093" xlink:to="plx_ExercisePrice1.57Member_637843214461356092" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461306093" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461356092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637843214461356092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637843214461356092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637843214461356092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637843214461356092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461356092" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm_637843214461366094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461366094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461366094" xlink:to="us-gaap_AwardTypeAxis_637843214461366094" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461366094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461366094" xlink:to="us-gaap_EmployeeStockOptionMember_637843214461366094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461366094" xlink:to="srt_TitleOfIndividualAxis_637843214461366094" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637843214461366094" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461366094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461366094" xlink:to="plx_EmployeeMember_637843214461366094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461366094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637843214461366094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637843214461366094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461376094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637843214461376094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637843214461376094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637843214461376094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461366094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637843214461376094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637843214461376094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637843214461376094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378432144613760941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378432144613760941" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637843214461376094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461376094" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637843214461376094" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461386097" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461386097" xlink:to="srt_TitleOfIndividualAxis_637843214461386097" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637843214461386097" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461386097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461386097" xlink:to="plx_EmployeeMember_637843214461386097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461386097" xlink:to="us-gaap_AwardTypeAxis_637843214461386097" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461386097" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461386097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461386097" xlink:to="us-gaap_RestrictedStockMember_637843214461386097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461386097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461386097" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461386097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637843214461386097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461386097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637843214461386097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637843214461386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461386097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637843214461386097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378432144613860971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461386097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378432144613860971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461396095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461396095" xlink:to="us-gaap_AwardTypeAxis_637843214461396095" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461396095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461396095" xlink:to="us-gaap_EmployeeStockOptionMember_637843214461396095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461396095" xlink:to="srt_TitleOfIndividualAxis_637843214461396095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637843214461396095" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461396095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:label="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461396095" xlink:to="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_637843214461396095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461396095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637843214461396095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461396095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodSharesStockExpired" xlink:label="plx_StockIssuedDuringPeriodSharesStockExpired_637843214461396095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" xlink:to="plx_StockIssuedDuringPeriodSharesStockExpired_637843214461396095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378432144613960951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378432144613960951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637843214461406098" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461396095" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637843214461406098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637843214461406098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637843214461406098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378432144614060981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378432144614060981" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637843214461406098" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637843214461406098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637843214461406098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637843214461406098" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice1.57Member" xlink:label="plx_ExercisePrice1.57Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice1.57Member_637843214461416092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice2.00Member" xlink:label="plx_ExercisePrice2.00Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice2.00Member_637843214461416092" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.55Member" xlink:label="plx_ExercisePrice3.55Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice3.55Member_637843214461416092" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.59Member" xlink:label="plx_ExercisePrice3.59Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice3.59Member_637843214461416092" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.66Member" xlink:label="plx_ExercisePrice3.66Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice3.66Member_637843214461416092" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.70Member" xlink:label="plx_ExercisePrice3.70Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice3.70Member_637843214461416092" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice3.73Member" xlink:label="plx_ExercisePrice3.73Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice3.73Member_637843214461416092" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice4.69Member" xlink:label="plx_ExercisePrice4.69Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice4.69Member_637843214461416092" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice5.10Member" xlink:label="plx_ExercisePrice5.10Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice5.10Member_637843214461416092" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice5.60Member" xlink:label="plx_ExercisePrice5.60Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice5.60Member_637843214461416092" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637843214461416092" xlink:to="plx_ExercisePrice17.20Member_637843214461416092" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637843214461406098" xlink:to="us-gaap_AwardTypeAxis_637843214461416092" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461416092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461416092" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461416092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461416092" xlink:to="us-gaap_EmployeeStockOptionMember_637843214461426093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_637843214461406098" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637843214461426093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637843214461426093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637843214461426093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637843214461426093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_637843214461426093" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_637843214461426093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637843214461426093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637843214461426093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637843214461426093" xlink:to="us-gaap_IncomeStatementLocationAxis_637843214461426093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637843214461426093" xlink:to="us-gaap_IncomeStatementLocationDomain_637843214461436119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637843214461436119" xlink:to="us-gaap_CostOfSalesMember_637843214461436119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637843214461436119" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637843214461436119" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637843214461436119" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637843214461436119" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637843214461426093" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637843214461436119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637843214461436119" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637843214461436119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:type="extended" xlink:title="40907 - Disclosure - SHARE CAPITAL (Additional information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" xlink:to="us-gaap_AwardTypeAxis_637843214461436119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461436119" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461436119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461436119" xlink:to="us-gaap_EmployeeStockOptionMember_637843214461436119" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461436119" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637843214461436119" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637843214461436119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461436119" xlink:to="us-gaap_RestrictedStockMember_637843214461436119" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" xlink:to="srt_TitleOfIndividualAxis_637843214461446094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637843214461446094" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember_637843214461446094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_637843214461446094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_637843214461446094" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentOperationsMember" xlink:label="plx_SeniorVicePresidentOperationsMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="plx_SeniorVicePresidentOperationsMember_637843214461446094" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_VicePresidentResearchAndDevelopmentMember" xlink:label="plx_VicePresidentResearchAndDevelopmentMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="plx_VicePresidentResearchAndDevelopmentMember_637843214461446094" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="srt_ChiefExecutiveOfficerMember_637843214461446094" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="srt_ChiefFinancialOfficerMember_637843214461446094" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CertainEmployeesMember" xlink:label="plx_CertainEmployeesMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="plx_CertainEmployeesMember_637843214461446094" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="srt_BoardOfDirectorsChairmanMember_637843214461446094" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461446094" xlink:to="srt_DirectorMember_637843214461446094" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637843214461446094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637843214461446094" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637843214461446094" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461456093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461456093" xlink:to="us-gaap_PrivatePlacementMember_637843214461456093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461456093" xlink:to="plx_AtMarketEquityOfferingMember_637843214461456093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461456093" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_637843214461456093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637843214461456093" xlink:to="us-gaap_OverAllotmentOptionMember_637843214461456093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" xlink:to="us-gaap_PlanNameAxis_637843214461456093" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637843214461456093" xlink:to="us-gaap_PlanNameDomain_637843214461456093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637843214461456093" xlink:to="plx_EmployeeStockIncentivePlan2006Member_637843214461456093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" xlink:to="srt_RangeAxis_637843214461456093" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461456093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461456093" xlink:to="srt_RangeMember_637843214461456093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461456093" xlink:to="srt_MaximumMember_637843214461466116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637843214461436119" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_CommonStockNumberOfVotingRights_637843214461466116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637843214461466116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfDirectors" xlink:label="plx_NumberOfDirectors_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_NumberOfDirectors_637843214461466116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637843214461466116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637843214461466116" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637843214461466116" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637843214461466116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637843214461466116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637843214461476098" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_637843214461476098" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637843214461476098" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637843214461476098" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637843214461476098" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637843214461476098" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637843214461476098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_637843214461476098" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637843214461486094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637843214461486094" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637843214461486094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637843214461486094" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637843214461486094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637843214461486094" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637843214461486094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637843214461486094" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue_637843214461486094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue_637843214461486094" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637843214461486094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637843214461486094" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637843214461496092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637843214461496092" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637843214461496092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637843214461496092" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637843214461496092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_DebtInstrumentFaceAmount_637843214461496092" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637843214461496092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637843214461496092" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637843214461496092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637843214461496092" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637843214461496092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637843214461496092" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637843214461506093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_SharePrice_637843214461506093" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues" xlink:label="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637843214461506093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues_637843214461506093" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637843214461506093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637843214461506093" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637843214461506093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637843214461506093" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637843214461506093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637843214461506093" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637843214461506093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ProceedsFromWarrantExercises_637843214461506093" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214461516093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637843214461516093" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637843214461516093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637843214461516093" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_637843214461516093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637843214461466116" xlink:to="plx_PercentageOfCommissionOnSaleOfShares_637843214461516093" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_637843214461526092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461526092" xlink:to="us-gaap_DebtInstrumentAxis_637843214461526092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461526092" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461526092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461526092" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461526092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461526092" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461526092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461526092" xlink:to="us-gaap_MeasurementInputTypeAxis_637843214461526092" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637843214461526092" xlink:to="us-gaap_MeasurementInputTypeDomain_637843214461526092" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461526092" xlink:to="us-gaap_MeasurementInputSharePriceMember_637843214461526092" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461526092" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637843214461526092" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461526092" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637843214461526092" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461526092" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637843214461526092" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461526092" xlink:to="plx_MeasurementInputYieldMember_637843214461526092" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461526092" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461526092" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461526092" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461526092" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461536094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461536094" xlink:to="us-gaap_FairValueInputsLevel3Member_637843214461536094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461526092" xlink:to="us-gaap_StatementLineItems_637843214461536094" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637843214461536094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637520135041292011" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637520135041292011" xlink:to="us-gaap_StatementTable_637843214461536094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461536094" xlink:to="us-gaap_DebtInstrumentAxis_637843214461536094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461536094" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461536094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461536094" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461536094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461536094" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461536094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461536094" xlink:to="us-gaap_StatementLineItems_637843214461536094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_637843214461536094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637843214461536094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637843214461536094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214461546095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637843214461546095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_InterestExpenseDebtOther" xlink:label="plx_InterestExpenseDebtOther_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="plx_InterestExpenseDebtOther_637843214461546095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461536094" xlink:to="us-gaap_InterestCostsIncurred_637843214461546095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="extended" xlink:title="41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_637843214461546095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461546095" xlink:to="us-gaap_DebtInstrumentAxis_637843214461546095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461546095" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461546095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461546095" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461546095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461546095" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461546095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_FourPointFivePercentageConvertibleNotesMember" xlink:label="plx_FourPointFivePercentageConvertibleNotesMember_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461546095" xlink:to="plx_FourPointFivePercentageConvertibleNotesMember_637843214461546095" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDueTwoThousandTwentyOneMember" xlink:label="plx_ConvertibleNotesDueTwoThousandTwentyOneMember_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461546095" xlink:to="plx_ConvertibleNotesDueTwoThousandTwentyOneMember_637843214461546095" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461546095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461546095" xlink:to="srt_RangeAxis_637843214461546095" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461546095" xlink:to="srt_RangeMember_637843214461556093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461556093" xlink:to="srt_MinimumMember_637843214461556093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461556093" xlink:to="srt_MaximumMember_637843214461556093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637843214461546095" xlink:to="us-gaap_StatementLineItems_637843214461556093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentFaceAmount_637843214461556093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637843214461556093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637843214461556093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_637843214461556093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637843214461556093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_ProceedsFromConvertibleDebt_637843214461556093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_637843214461556093" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637843214461556093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637843214461556093" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_637843214461566094" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637843214461566094" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentTerm_637843214461566094" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637843214461566094" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637843214461566094" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637843214461566094" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_637843214461566094" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_MaintainOfMinimumCashBalance_637843214461566094" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MaximumDebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_637843214461566094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_MaximumDebtInstrumentConvertibleConversionShareNumber_637843214461566094" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_ConvertibleDebt_637843214461576093" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_637843214461576093" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_637843214461576093" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_637843214461576093" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ThresholdPercentageOfConversionPrice" xlink:label="plx_ThresholdPercentageOfConversionPrice_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_ThresholdPercentageOfConversionPrice_637843214461576093" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding" xlink:label="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding_637843214461576093" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentRedemption" xlink:label="plx_DebtInstrumentRedemption_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtInstrumentRedemption_637843214461576093" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PercentageOfOutstandingCapitalStock" xlink:label="plx_PercentageOfOutstandingCapitalStock_637843214461576093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_PercentageOfOutstandingCapitalStock_637843214461576093" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock" xlink:label="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_637843214461586094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock_637843214461586094" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange" xlink:label="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_637843214461586094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange_637843214461586094" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_637843214461586094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_637843214461586094" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637843214461586094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461556093" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637843214461586094" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461586094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461586094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461586094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461586094" xlink:to="us-gaap_DebtInstrumentAxis_637843214461586094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461586094" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461596095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461596095" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637843214461596095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637843214461596095" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461596095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461586094" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461596095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461596095" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461596095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461596095" xlink:to="us-gaap_FairValueInputsLevel3Member_637843214461596095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461586094" xlink:to="us-gaap_MeasurementInputTypeAxis_637843214461596095" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637843214461596095" xlink:to="us-gaap_MeasurementInputTypeDomain_637843214461596095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461596095" xlink:to="us-gaap_MeasurementInputSharePriceMember_637843214461596095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461596095" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637843214461596095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461596095" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637843214461596095" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461596095" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637843214461596095" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637843214461596095" xlink:to="plx_MeasurementInputYieldMember_637843214461596095" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461596095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461586094" xlink:to="us-gaap_StatementLineItems_637843214461596095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461596095" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637843214461606093" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461606093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461606093" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461606093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637843214461606093" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461606093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637843214461606093" xlink:to="us-gaap_FairValueInputsLevel3Member_637843214461606093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461606093" xlink:to="us-gaap_DebtInstrumentAxis_637843214461606093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637843214461606093" xlink:to="us-gaap_DebtInstrumentNameDomain_637843214461606093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461606093" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637843214461606093" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637843214461606093" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637843214461606093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637843214461606093" xlink:to="us-gaap_StatementLineItems_637843214461606093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461606093" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637843214461606093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637843214461606093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637843214461606093" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637843214461606093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637843214461616095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_637843214461616095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637843214461616095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637843214461616095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_637843214461616095" xlink:to="us-gaap_DeferredTaxAssetsNet_637843214461616095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_IncomeTaxContingencyTable_637843214461616095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_637843214461616095" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637843214461616095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637843214461616095" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637843214461616095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637843214461616095" xlink:to="plx_UsIsraelMember_637843214461616095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_637843214461616095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637843214461616095" xlink:to="country_US_637843214461616095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_637843214461616095" xlink:to="srt_RangeAxis_637843214461626094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461626094" xlink:to="srt_RangeMember_637843214461626094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461626094" xlink:to="srt_MinimumMember_637843214461626094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461626094" xlink:to="srt_MaximumMember_637843214461626094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_637843214461616095" xlink:to="us-gaap_IncomeTaxContingencyLineItems_637843214461626094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems_637843214461626094" xlink:to="us-gaap_OpenTaxYear_637843214461626094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="41203 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="plx_IncomeTaxDisclosureTable_637843214461626094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_637843214461626094" xlink:to="srt_RangeAxis_637843214461626094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637843214461626094" xlink:to="srt_RangeMember_637843214461626094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637843214461626094" xlink:to="srt_MaximumMember_637843214461626094" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_637843214461626094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_637843214461626094" xlink:to="srt_ConsolidatedEntitiesAxis_637843214461626094" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis_637843214461626094" xlink:to="srt_ConsolidatedEntitiesDomain_637843214461636129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_637843214461636129" xlink:to="srt_ParentCompanyMember_637843214461636129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_637843214461636129" xlink:to="srt_SubsidiariesMember_637843214461636129" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_637843214461626094" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637843214461636129" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637843214461636129" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637843214461636129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637843214461636129" xlink:to="plx_TaxYearThereafterMember_637843214461636129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_637843214461626094" xlink:to="plx_IncomeTaxDisclosureLineItems_637843214461636129" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_637843214461636129" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637843214461636129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_637843214461636129" xlink:to="us-gaap_OperatingLossCarryforwards_637843214461636129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422968852328" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422968852328" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" xlink:to="plx_OtherAssetsInstitutionsCurrent_637843214461636129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637843214461636129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637843214461636129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" xlink:to="us-gaap_PrepaidExpenseCurrent_637843214461646097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" xlink:to="plx_OtherAssetsSundryCurrent_637843214461646097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637843214461636129" xlink:to="us-gaap_OtherAssetsCurrent_637843214461646097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="41302 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637843214461646097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="us-gaap_InterestPayableCurrent_637843214461646097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="us-gaap_AccruedVacationCurrent_637843214461646097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637843214461646097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="us-gaap_AccruedRoyaltiesCurrent_637843214461646097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_637843214461646097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637843214461646097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637843214461646097" xlink:to="us-gaap_AccountsPayableCurrent_637843214461646097" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422969008821" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637843214461656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637843214461656108" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637843214461656108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637843214461656108" xlink:to="us-gaap_RelatedPartyDomain_637843214461656108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_CompensationToNonExecutiveDirectorsMember" xlink:label="plx_CompensationToNonExecutiveDirectorsMember_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637843214461656108" xlink:to="plx_CompensationToNonExecutiveDirectorsMember_637843214461656108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637843214461656108" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637843214461656108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637843214461656108" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_637843214461656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637843214461656108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637843214461656108" xlink:to="us-gaap_SubsequentEventTypeAxis_637843214461656108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637843214461656108" xlink:to="us-gaap_SubsequentEventTypeDomain_637843214461656108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637843214461656108" xlink:to="us-gaap_SubsequentEventMember_637843214461656108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637843214461656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637843214461656108" xlink:to="us-gaap_TypeOfArrangementAxis_637843214461656108" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637843214461656108" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461666098" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461666098" xlink:to="plx_ChiesiAgreementsMember_637843214461666098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637843214461666098" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_637843214461666098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637843214461656108" xlink:to="srt_ProductOrServiceAxis_637843214461666098" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637843214461666098" xlink:to="srt_ProductsAndServicesDomain_637843214461666098" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637843214461666098" xlink:to="plx_AlfataligliceraseMember_637843214461666098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637843214461656108" xlink:to="us-gaap_AwardTypeAxis_637843214461666098" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637843214461666098" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461666098" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637843214461666098" xlink:to="us-gaap_RestrictedStockMember_637843214461666098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637843214461656108" xlink:to="srt_TitleOfIndividualAxis_637843214461666098" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637843214461666098" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461666098" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_PresidentAndChiefExecutiveOfficerMember" xlink:label="plx_PresidentAndChiefExecutiveOfficerMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461666098" xlink:to="plx_PresidentAndChiefExecutiveOfficerMember_637843214461666098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_637843214461666098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637843214461666098" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_637843214461666098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637843214461676097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637843214461656108" xlink:to="us-gaap_SubsequentEventLineItems_637843214461676097" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637843214461676097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637843214461676097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637843214461676097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements_637843214461676097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637843214461676097" xlink:to="plx_ProceedsFromExpenseReimbursements_637843214461676097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20211231.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_637843214461676097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637843214461676097" xlink:to="plx_ProceedsFromSaleOfProducts_637843214461676097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460194088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,316,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman & Kesselman C.P.A.s<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460336792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 38,985<span></span>
</td>
<td class="nump">$ 18,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">17,954<span></span>
</td>
<td class="nump">13,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">61,666<span></span>
</td>
<td class="nump">55,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">2,077<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,962<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4,960<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,665<span></span>
</td>
<td class="nump">67,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">6,986<span></span>
</td>
<td class="nump">7,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">16,433<span></span>
</td>
<td class="nump">13,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">8,550<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,176<span></span>
</td>
<td class="nump">86,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">27,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">11,790<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,376<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">46,525<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">79,701<span></span>
</td>
<td class="nump">94,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>CAPITAL DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2020 and 2021, 120,000,000 shares; issued and outstanding - as of December 31, 2020 and 2021, 34,765,280 and 45,556,647 shares, respectively</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">368,852<span></span>
</td>
<td class="nump">320,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(374,934)<span></span>
</td>
<td class="num">(347,352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(6,036)<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 73,665<span></span>
</td>
<td class="nump">$ 67,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985459078536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="nump">34,765,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="nump">34,765,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985453513880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 38,350<span></span>
</td>
<td class="nump">$ 62,898<span></span>
</td>
<td class="nump">$ 54,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(16,349)<span></span>
</td>
<td class="num">(10,873)<span></span>
</td>
<td class="num">(10,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="num">(29,734)<span></span>
</td>
<td class="num">(38,167)<span></span>
</td>
<td class="num">(44,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(12,729)<span></span>
</td>
<td class="num">(11,148)<span></span>
</td>
<td class="num">(9,899)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="num">(20,462)<span></span>
</td>
<td class="nump">2,710<span></span>
</td>
<td class="num">(10,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(7,521)<span></span>
</td>
<td class="num">(9,671)<span></span>
</td>
<td class="num">(7,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES - NET</a></td>
<td class="num">(7,120)<span></span>
</td>
<td class="num">(9,233)<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE YEAR</a></td>
<td class="num">$ (27,582)<span></span>
</td>
<td class="num">$ (6,523)<span></span>
</td>
<td class="num">$ (18,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</a></td>
<td class="nump">44,140,233<span></span>
</td>
<td class="nump">29,148,047<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</a></td>
<td class="nump">44,140,233<span></span>
</td>
<td class="nump">29,148,047<span></span>
</td>
<td class="nump">14,838,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 16,749<span></span>
</td>
<td class="nump">$ 16,236<span></span>
</td>
<td class="nump">$ 15,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 21,601<span></span>
</td>
<td class="nump">$ 46,662<span></span>
</td>
<td class="nump">$ 38,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985456484808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 269,657<span></span>
</td>
<td class="num">$ (322,553)<span></span>
</td>
<td class="num">$ (52,881)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">14,838,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,276)<span></span>
</td>
<td class="num">(18,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">270,492<span></span>
</td>
<td class="num">(340,829)<span></span>
</td>
<td class="num">(70,322)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">14,838,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">1,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="nump">694,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,523)<span></span>
</td>
<td class="num">(6,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">320,280<span></span>
</td>
<td class="num">(347,352)<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 368,852<span></span>
</td>
<td class="num">$ (374,934)<span></span>
</td>
<td class="num">$ (6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454576040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (27,582)<span></span>
</td>
<td class="num">$ (6,523)<span></span>
</td>
<td class="num">$ (18,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">133<span></span>
</td>
<td class="num">(494)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="nump">3,470<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="nump">13,230<span></span>
</td>
<td class="num">(26,205)<span></span>
</td>
<td class="num">(9,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
<td class="num">(1,032)<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(4,872)<span></span>
</td>
<td class="num">(4,927)<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,285)<span></span>
</td>
<td class="num">(26,106)<span></span>
</td>
<td class="num">(19,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(37,835)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">57,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,459)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseOfRestrictedInvestments', window );">Decrease (increase) in restricted deposit</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">18,921<span></span>
</td>
<td class="num">(19,952)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption and transactions costs</a></td>
<td class="num">(30,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="num">(4,086)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">37,625<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">8,575<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,078<span></span>
</td>
<td class="nump">46,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">20,720<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="num">(20,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">17,792<span></span>
</td>
<td class="nump">37,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
<td class="nump">38,985<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">17,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,410<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457283400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021. See also note 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme (agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#8217;s exclusive worldwide license agreement with SarcoMed USA Inc. with respect to PRX-110 for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its Common Stock having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;BofA Agreement&#8221;) it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company closed a public offering of its Common Stock, raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;18, 2020, the Company completed a private placement of its Common Stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of Common Stock at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants were exercisable commencing <span style="white-space:pre-wrap;">six months</span><span style="white-space:pre-wrap;"> following their issuance for a period of </span><span style="white-space:pre-wrap;">five years</span><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms. The net proceeds generated from the private placement were approximately $41.3&#160;million, after deducting advisory fees and other estimated offering expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company's clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that its cash and cash equivalents as of December&#160;31, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The severity, magnitude and duration, as well as the economic consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;">No write-off activity and recoveries for the periods presented were recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used statutory tax rates of 21% and 23%. See also Note 12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#8220;NATI&#8221;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December 31, 2021, the accounts receivables balance was composed of $2.2&#160;million from Fiocruz and $1.2&#160;million from Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock units, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for the </span>restricted stock units<span style="background:#ffffff;"> based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Options granted to consultants and other service providers are recognized over the related service period using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 7,838,120, 22,850,682 and 28,502,017 shares of Common Stock underlying outstanding options, warrants and convertible notes for the fiscal&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The 2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital. <span style="background:#ffffff;">The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2021, none of the 2021 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company adopted ASC&#160;842 on January 1, 2019, using a modified retrospective transition approach, with certain practical expedients, and as a result did not adjust prior periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the package of transition practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The lease standard also provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Additionally, following the adoption of ASC&#160;842 and in subsequent measurements, the Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;Recently issued accounting pronouncements, not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In March 2020, the FASB issued ASU 2020-04, &#8220;Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; In addition, in January 2021, the FASB issued ASU 2021-01, &#8220;Reference Rate Reform (Topic 848) - Scope.&#8221; The amendments in these ASUs apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Together, these ASUs provide optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December&#160;31, 2022, except for hedging relationships existing as of December&#160;31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. These ASUs were effective upon issuance and may be applied prospectively to contract modifications and hedging relationships entered into or evaluated through December&#160;31, 2022. <span style="background:#ffffff;">The adoption of this standard is not expected to have material impact on the Company's consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457314776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommercializationAgreementsAbstract', window );"><strong>COMMERCIALIZATION AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COMMERCIALIZATION AGREEMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><b style="font-weight:bold;">a.</b>&#160;&#160;&#160;&#160;On November&#160;30, 2009, Protalix&#160;Ltd. and Pfizer entered into the Pfizer Agreement (as amended in June&#160;2013) pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except for Israel and Brazil. Under the Pfizer Agreement Protalix was entitled to 40% of the results (profits or losses) earned on Pfizer&#8217;s sales of taliglucerase alfa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Protalix Ltd. also agreed to provide Pfizer with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Promissory note&#160;&#8211; as of the date of the amendment, the Company owed Pfizer $4.3&#160;million as a result of the accumulated losses incurred by the Collaboration Operation. Following the new agreements, the Company committed to pay Pfizer the principal sum of the debt at the earlier of (a)&#160;November&#160;12, 2020 and (b)&#160;the date upon which it becomes due pursuant to any event of default, as defined. In September 2020, the Company amended the outstanding $4.3&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a)&#160;January&#160;31, 2022 and (b)&#160;the date that the Company receives any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also provides that the Company shall make a payment of $430,000&#160;to Pfizer. The payment was creditable against the principal amount of the note, in whole or in part, if the Company satisfied the note in full on or prior to September&#160;30, 2021, depending on the date the note is satisfied. As of December&#160;31, 2020, the promissory note was classified to current liabilities. <span style="background:#ffffff;">On March&#160;29, 2021, the Company paid approximately </span><span style="background:#ffffff;">$4.0</span><span style="background:#ffffff;">&#160;million to Pfizer satisfying the promissory note in full.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><b style="font-weight:bold;">b.</b>&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#8211; the drug) for the treatment of Fabry disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the terms of the Chiesi Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Protalix&#160;Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$10.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$320.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix Ltd. will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Chiesi does not have sublicensing rights (except for certain territories).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In July 2018, Protalix Ltd. entered into the Chiesi U.S.&#160;Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi U.S.&#160;Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$20.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$760.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement, which has been reduced to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$735.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">40%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Chiesi does not have sublicensing rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">As of December&#160;31, 2021, the Company has received, or is entitled to receive, the following payments from Chiesi:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront payments equal to $50.0&#160;million, in the aggregate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to $45.0&#160;million in consideration for development services performed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments equal to approximately $33.6&#160;million in connection with the performance of extension studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">Payment equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$10.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;million in lieu of certain milestone payments.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">During 2019, 2020 and 2021, the Company recognized revenues of approximately $4.5&#160;million, $3.5&#160;million and $0.6&#160;million, respectively, related to the then $10.0&#160;million future milestone payment. The Company assessed the likelihood of achieving the milestone using the most likely amount method and evaluated for the constraint by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. <span style="background:#ffffff;">The&#160;</span><span style="background:#ffffff;">$10.0</span><span style="background:#ffffff;">&#160;million payment was received in June 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><b style="font-weight:bold;">c.</b>&#160;&#160;&#160;&#160;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil. Approximately 25% of adult Gaucher patients in Brazil are currently treated with BioManguinhos alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><b style="font-size:10pt;font-weight:bold;">d.</b><span style="font-size:10pt;">&#160;&#160;&#160;&#160;On March&#160;16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) to evaluate the production of a novel complex protein utilizing ProCellEx</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;">, the Company&#8217;s proprietary plant cell-based protein expression system. Under the agreement, Kirin was obligated to bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provided Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of </span><span style="font-size:10pt;">$1.0</span><span style="font-size:10pt;">&#160;million. </span><span style="font-size:10pt;background:#ffffff;">During the year ended December&#160;31, 2021, the Company</span><span style="color:#212529;font-size:10pt;"> completed its obligations under the agreement and the agreement expired, including the</span><span style="font-size:10pt;"> o</span><span style="color:#212529;font-size:10pt;background:#ffffff;">ption to provide additional services. Following the expiration of the option, the Company recognized as revenue the&#160;</span><span style="color:#212529;font-size:10pt;background:#ffffff;">$1.0</span><span style="color:#212529;font-size:10pt;background:#ffffff;">&#160;million received in March 2020</span><span style="font-size:10pt;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommercializationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommercializationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985474936216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;</b>Composition of property and equipment grouped by major classifications is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,237</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,718</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,759</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,714</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,752)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,962</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>Depreciation in respect of property and equipment totaled approximately $1.6&#160;million, $1.3&#160;million and $1.1&#160;million for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457307528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;- INVENTORIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2020 and 2021 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,166</p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,262</p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,526</p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,954</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>During the&#160;years ended December&#160;31, 2019, 2020 and 2021, the Company recorded approximately $0.5&#160;million, $0.3&#160;million and $0.4&#160;million, respectively, for write-down of inventory under cost of goods sold.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457741224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#8217;s salary for each&#160;year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2019, 2020 and 2021, the Company deposited approximately $143,000, $121,000 and $108,000, respectively, with insurance companies in connection with its severance payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The amounts of severance pay expenses were approximately $784,000, $885,000 and $990,000 for each of the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, of which approximately $642,000, $747,000 and $857,000 in the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, were in respect of the Contribution Plans. Gain on amounts funded in respect of employee rights upon retirement totaled approximately $58,000, $28,000 and $100,000 for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company expects to contribute approximately $984,000 in the&#160;year ending December&#160;31, 2022 to insurance companies in connection with its severance liabilities for its operations for that&#160;year, approximately $868,000 of which will be contributed to one or more Contribution Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the five-year period following December&#160;31, 2021, the Company expects to pay future benefits to four employees upon each such employee&#8217;s normal retirement age. The Company anticipates that the benefits payable will be approximately $72,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457433656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;6&#160;- COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Royalty Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is obligated to pay royalties to NATI on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of the applicable funding arrangements, royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, 100%<span style="white-space:pre-wrap;"> of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $1.4&#160;million, $911,000 and $1.2&#160;million during the years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">At December&#160;31, 2020 and 2021, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $39.8&#160;million and $38.6&#160;million, respectively (without interest, assuming 100% of the funds are payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Subcontracting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2021, total commitments under said agreements were approximately $0.9&#160;million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457448008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 7 - OPERATING LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the option to extend certain of such agreements on one additional occasion for an additional five-year period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by 7.5%-10% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2021, the Company provided bank guarantees of approximately $496,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2019, 2020 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,219</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,329</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.5</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,207</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 872</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 853</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 848</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,528</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,333</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,750</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Present value of  operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,583</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457745976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 8 - REVENUE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,160</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,400</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,749</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,601</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the year ended December&#160;31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457729784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;9&#160;- SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Rights of the Company&#8217;s Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s Common Stock is listed on the NYSE American and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Reverse stock split</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;9, 2019, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to, among other things, effect a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_bjDxAD1NEUOlk5FvFvWGtA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-ten</span></span>. The ratio was determined by the Company&#8217;s Board of Directors on December&#160;5, 2019 and the reverse stock split became effective at midnight December&#160;19, 2019. All share and per share amounts included in the consolidated financial statements have been adjusted retrospectively to reflect the effect of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Stock based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to 5,725,171 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;<span style="white-space:pre-wrap;">102 and 102A of the Israeli Income Tax Ordinance. Each option grant made to an Israeli citizen  is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Israeli Income Tax Ordinance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021, 1,786,256 shares of Common Stock remain available for grant under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For purposes of determining the fair value of the options and restricted stock unit granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the three years ended December&#160;31, 2021, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options and restricted stock units granted to employees:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;">a)&#160;&#160;&#160;&#160;Below is a table summarizing all of the options and restricted stock grants to employees during the three years ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">No. of options or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">restricted stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vesting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;grant (U.S.&#160;dollars</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year of grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">period</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">160,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">80,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">196,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">760,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">1,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">129,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">694,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">2,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">122,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">1.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December&#160;31, 2021 (a portion of such grants appear in the table above):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In June 2019, the Company granted to its Chief Executive Officer 10-year options to purchase, in the aggregate, 160,000 shares of Common Stock under the Plan. The options have an exercise price equal to $4.69 per share, vest over a four-year period in 16 equal quarterly increments. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $449,000 based on the following weighted average assumptions: share price equal to $4.69; dividend yield of 0%; expected volatility of 65.3%; risk-free interest rates of 1.8%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">In September 2019, the Company granted to its Chief Financial Officer 10-year options to purchase, in the aggregate, 80,000 shares of Common Stock under the Plan. The options have an exercise price equal to $2.00 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option pricing model to be approximately $97,000 based on the following weighted average assumptions: share price equal to $2.00; dividend yield of 0%; expected volatility of 66.48%; risk-free interest rates of 1.695%; and expected life of six years. In addition, contingent upon certain conditions, the chief financial officer is entitled to a grant of restricted stock units with an aggregate value of $100,000, on an annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On August&#160;11, 2020, the Company granted the following:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">447,927 shares of restricted Common Stock to its President and Chief Executive Officer under the Plan. The restricted shares vest over a four-year period in 16 equal quarterly increments and <span style="background:#ffffff;">are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control</span>, and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $1.6&#160;million.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">246,146 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. Of the shares, 27,855 shares vested on September&#160;22, 2020. The remaining 218,291 of the shares vest in 16&#160;equal, quarterly increments over a four-year period, commencing upon the date of grant and are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $900,000.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">III.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">10-year&#160;options to purchase&#160;122,656&#160;shares of Common Stock to the Company&#8217;s Sr. Vice President, Operations under the Plan. The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President, Operations are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President, Operations to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $300,000 based on the following weighted average assumptions: share price equal to $3.59; dividend yield of 0%; expected volatility of 80.51%; risk-free interest rate of&#160;0.365%; and expected life of six years.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On July&#160;5, 2020, the Company granted 10-year options to purchase 129,771 shares of Common Stock to the Company&#8217;s Vice President, Research and Development under the Plan. The options have an exercise price equal to $3.73 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the Vice President, Research and Development is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $329,000 based on the following weighted average assumptions: share price equal to $3.73; dividend yield of 0%; expected volatility of 80.60%; risk-free interest rate of 0.395%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On June 7, 2020, the Company granted the following:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">10-year options to purchase 196,995 shares of Common Stock to the Company&#8217;s Sr. Vice President and Chief Development Officer under the Plan. The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President and Chief Development Officer are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company&#8217;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#8217;s Sr. Vice President and Chief Development Officer to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $500,000 based on the following weighted average assumptions: share price equal to $3.59; dividend yield of 0%; expected volatility of 80.43%; risk-free interest rate of&#160;0.59%; and expected life of six years.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:90pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">II.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">10-year options to purchase 760,311 shares of Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Plan. The options granted have an exercise price equal to $3.66 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 108pt;">option-pricing model to be approximately $1.9&#160;million based on the following weighted average assumptions: share price equal to $3.66; dividend yield of 0%; expected volatility of 80.49%; risk-free interest rate of&#160;0.45%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On July&#160;25, 2021, the Company granted to a new employee, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 50,000 shares of Common Stock under the Plan. The options have an exercise price equal to $1.57 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $55,000 based on the following weighted average assumptions: share price equal to $1.57; dividend yield of 0%; expected volatility of 84.30%; risk-free interest rate of&#160;0.88%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b)&#160;&#160;&#160;&#160;The total unrecognized compensation cost of employee stock options at December&#160;31, 2021 is approximately $1.7&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.9&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">During the three years ended December 31, 2021, there were no exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options granted to directors:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On February&#160;3, 2020, the Company granted 10-year options to purchase 240,000 shares of Common Stock to the Chairman of the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to $3.70 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the Chairman of the Board is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $593,000 based on the following weighted average assumptions: share price equal to $3.70; dividend yield of 0%; expected volatility of 76.91%; risk-free interest rate of 1.4%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">On January&#160;20, 2020, the Company granted 10-year options to purchase a total of 200,000 shares of Common Stock to five of the Company&#8217;s independent directors under the Plan. The options have an exercise price equal to $3.55 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the directors is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $475,000 based on the following weighted average assumptions: share price equal to $3.55; dividend yield of 0%; expected volatility of 76.62%; risk-free interest rate of 1.685%; and expected life of six years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">3.&#160;&#160;&#160;&#160;A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the&#160;year ended December&#160;31, 2021, and the effect of share-based compensation on the statement of operations for the&#160;years ended December&#160;31, 2019, 2020 and 2021, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;">a)&#160;&#160;&#160;&#160;Options granted to employees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,087,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.66</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.57</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited and expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 318,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.00</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,819,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.61</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 961,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.47</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Restricted stock granted to employees:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Restricted Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">624,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">166,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">458,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;">c)&#160;&#160;&#160;&#160;Options granted to consultants, directors, and other service providers:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 464,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.74</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.60</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 440,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.63</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.63</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The following tables summarize information concerning outstanding and exercisable options as of December 31, 2021:</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.57 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.57</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$2.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.73</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.55 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.06</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.59 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 112,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.50</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.66 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 641,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.74</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.70 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.10</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.73 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.52</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$4.69 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.10 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 215,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.50</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.60 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.71</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$17.20 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.93</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,259,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,154,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*<span style="color:#231f20;"> As of December</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">31, 2021, all outstanding, exercisable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:0.05pt;"> had exercise prices that exceed the fair market value of the Common Stock as of such date</span><span style="color:#231f20;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">e)&#160;&#160;&#160;&#160;The following table illustrates the effect of share-based compensation on the statement of operations:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 269</p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 648</p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,458</p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,375</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Private and 144A Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;18, 2020, the Company completed a private placement to certain existing and new institutional and other accredited investors (the &#8220;Purchasers&#8221;) in reliance on the exemption from registration set forth in Section&#160;4(2) of the Securities Act. The Company sold approximately 17.6&#160;million unregistered shares of Common Stock to the Purchasers at a price per share of $2.485. The Company generated gross proceeds equal to approximately $43.7&#160;million in the Private Placement. Each share of Common Stock issued was accompanied by a warrant to purchase one share of Common Stock at an exercise price equal to $2.36. <span style="background:#ffffff;">During the year ended December&#160;31, 2020</span>, the Company issued 200,000 shares of Common Stock in connection with the cash exercise of a warrant issued in the transaction and generated proceeds equal to $472,000 from such exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June 7, 2021, the Company issued 173,816 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 2,816,901 shares of Common Stock issued in the transaction. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">On July&#160;2, 2021, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to </span><span style="background:#ffffff;">$20.0</span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to 3.0% of the aggregate gross proceeds from the ATM Shares sold. As of December&#160;31, 2021, the Company sold no ATM Shares under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December 31, 2021, but prior to the termination of the BofA Agreement, the Company sold 1,867,552 shares of Common Stock under the BofA Agreement. The Company generated gross proceeds equal to approximately $8.8&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of Common Stock in an underwritten public offering at a price to the public of $4.60 per share for gross proceeds of approximately $40.2&#160;million before deducting the underwriting discount and estimated expenses of the offering. The above included the exercise of the underwriters&#8217; over-allotment option to purchase 1,141,304 shares of Common Stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457299496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 10&#160;&#160;- CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;25, 2021, the Company completed the Exchanges of a substantial majority of the Company&#8217;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2021&#160;(&#8220;2021 Notes&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;1, 2016, the Company entered into a note purchase agreement with institutional investors, which held part of the 2018 Notes&#160;(the &#8220;2016 Purchasers&#8221;), relating to the sale by the Company of $22.5&#160;million aggregate principal amount of 7.50% Senior Secured Convertible Notes&#160;due 2021 in a private placement pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. Concurrently with the consummation of the private placement of the 2021 Notes, the Company entered into a privately negotiated exchange agreement (the &#8220;2016 Exchange Agreement&#8221;) with certain existing note holders identified therein to exchange $54.1&#160;million aggregate principal amount of the Company&#8217;s outstanding 2018 Notes&#160;for (i)&#160;$40.186&#160;million aggregate principal amount of 2021 Notes, (ii)&#160;2,384,673 shares of Common Stock and (iii)&#160;cash, equal to the accrued and unpaid interest on the 2018 Notes&#160;and any fractional shares. The closing date of the purchase agreement and the 2016 Exchange Agreement was December&#160;7, 2016. The issuance of the 2021 Notes&#160;and shares in the exchange and the private placement were made in reliance on the exemption from the registration requirements of the Securities Act pursuant to Section&#160;4(a)(2)&#160;thereof. The net proceeds from the private placement were $19.7&#160;million, after deducting the placement agent&#8217;s fees and the Company&#8217;s estimated offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In connection with the completion of the exchange and the private placement, the Company entered into the <a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of December&#160;7, 2016, with the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a> (the &#8220;2016 Indenture&#8221;). The 2021 Notes&#160;accrued interest at a rate of 7.50% per&#160;year. A portion of the interest payable was allowed to be made in shares of Common Stock at the Company&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;24, 2017, the Company entered into another note purchase agreement with certain institutional investors relating to the private issuance and sale by the Company of $10.0&#160;million in aggregate principal amount of its 2021 Notes. The 2021 Notes&#160;were issued pursuant to the 2016 Indenture. The net proceeds from this purchase agreement were $9.5&#160;million, after deducting the Company&#8217;s offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On November&#160;15, 2021, all the then outstanding 2021 Notes&#160;matured and were paid in full, and the 2016 Indenture expired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2021 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. Dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,855</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt discount amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,575</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 831</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,261</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2024&#160;(&#8220;2024 Notes&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#8220;2021 Indenture&#8221;). Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component and a reduction of stockholders&#8217; equity of $12.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature net of transaction costs of approximately $12.0&#160;million was recognized in the Company&#8217;s additional paid in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transaction costs in the amount of approximately $869,000 were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Holders may convert their 2024 Notes&#160;at any time. The initial conversion rate for the 2024 Notes&#160;is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes&#160;(equivalent to an initial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">conversion price of approximately $1.7755 per share of the Common Stock). Upon conversion, the Company may settle the 2024 Notes&#160;by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#8217;s election.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">To date, there has been no conversion of 2024&#160;Notes. As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to the maturity date, the Company may redeem in cash:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a)</span></span>any or all of the 2024 Notes&#160;if, on or after March&#160;31, 2023, the last reported sale price of the Common Stock for at least 20 trading&#160;days (whether or not consecutive) during the period of 30 consecutive trading&#160;days exceeds 130% of the conversion price on each applicable trading day, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b)</span></span>all of the 2024 Notes&#160;then outstanding if the aggregate principal amount of the 2024 Notes&#160;then outstanding is less than 15% of the aggregate principal amount of the notes issued on August&#160;25, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">To date, there has been no redemption of 2024&#160;Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes&#160;are guaranteed by the Restricted Subsidiaries (as defined in the 2024 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#8220;Collateral&#8221;), including, but not limited to, (i)&#160;100% of the capital stock of the Guarantors (as defined in the 2024 Indenture) and each Restricted Subsidiary of the Company that is held by the Company or any Restricted Subsidiary, (ii)&#160;intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii)&#160;all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv)&#160;all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2024 Indenture, and (v)&#160;all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both Wilmington Savings Fund Society, FSB, as collateral agent in the United States, and with Altshuler Shaham Trusts&#160;Ltd., as security trustee in Israel. The 2024 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#8217;s assets that constitute collateral securing the 2024 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Upon (i)&#160;the occurrence of a fundamental change (as defined in the 2024 Indenture) or (ii)&#160;if the Company calls the 2024 Notes&#160;for redemption as described below (either event, a &#8220;make-whole fundamental change&#8221;) and a holder elects to convert its 2024 Notes&#160;in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#8220;Additional Shares&#8221;). In no event will the conversion rate exceed the maximum conversion rate, which is 746.2686 shares per $1,000 principal amount of 2024 Notes, which amount is inclusive of repayment of the principal of the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2024 Notes, or any portion of the principal amount thereof, that is equal to $1,000 or an integral multiple of $1,000 in excess thereof, on a date of the Company&#8217;s choosing that is not less than 20 calendar&#160;days nor more than 35 calendar&#160;days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2024&#160;Note is equal to 100% of the principal amount of such 2024 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. Under the terms of the 2024 Indenture, the Company is required to <span style="color:#222222;background:#ffffff;">meet certain covenants including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to meet covenants can be considered an event of default and, accordingly, may </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2021, the Company was in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 767</p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457460440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;11&#160;- FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the outstanding $28.75&#160;million 2024 Notes as of December&#160;31, 2021 is approximately $33.3&#160;million based on a level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The Company prepared the valuation of the fair value of the 2024 Notes&#160;(a Level 3 valuation) as of December&#160;31, 2021. The value of these notes were estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 92.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457297928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;12&#160;- TAXES ON INCOME</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at the rate of up to 21%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was enacted into law. The new legislation represents fundamental and dramatic modifications to the U.S. tax system. The Act contained several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the Act included, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of net operating loss (&#8220;NOL&#8221;) deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The Act also repealed the corporate alternative minimum tax for tax&#160;years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the Act included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Modification of interest expense limitation rules under the Act provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 30% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">U.S.&#160;GAAP requires that the impact of tax legislation be recognized in the period in which the law was enacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that all future profits of its subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company as a &#8220;foreign-investment company&#8221; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tax rates</b></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The corporate tax rate was 23%<span style="white-space:pre-wrap;"> for 2019 and thereafter.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</b></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">a.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reduced tax rates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Accelerated depreciation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">c.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Conditions for entitlement to the benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">d.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021 and 2020, the Company had aggregate NOL carry-forwards equal to approximately $247.9&#160;million and $231.4&#160;million, respectively, that are available to reduce future taxable income as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company&#8217;s carry-forward NOLs, equal to approximately $36.1&#160;million and $30.9&#160;million as of December&#160;31, 2021 and 2020, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Protalix&#160;Ltd.</b></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">At December&#160;31, 2021 and 2020, the Israeli Subsidiary had approximately $211.8&#160;million and $200.5&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Deferred income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2020 and 2021 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,217</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,989)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,292</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (63,760)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,520)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Tax assessments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In accordance with the Income Tax Ordinance, as of December&#160;31, 2021, all of Protalix&#160;Ltd.&#8217;s tax assessments through tax&#160;year 2016 are considered final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2017-2021</p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2017-2021</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457387880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;13&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 54pt;">Balance sheets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 311</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 905</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,285</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,562</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 767</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,506</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,981</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 522</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,433</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457396488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;14&#160;- RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 475</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457410856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;15&#160;- SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On February&#160;25, 2022, the Company granted (i) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">637,531</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock to its President and Chief Executive Officer and (ii) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">121,951</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer, both under the Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January&#160;12, 2022 and February&#160;2, 2022, the Company collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On March 22, 2022, the Company collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales of alfataliglicerase to Fiocruz.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454579400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021. See also note 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme (agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#8217;s exclusive worldwide license agreement with SarcoMed USA Inc. with respect to PRX-110 for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its Common Stock having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;BofA Agreement&#8221;) it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company closed a public offering of its Common Stock, raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;18, 2020, the Company completed a private placement of its Common Stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of Common Stock at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants were exercisable commencing <span style="white-space:pre-wrap;">six months</span><span style="white-space:pre-wrap;"> following their issuance for a period of </span><span style="white-space:pre-wrap;">five years</span><span style="white-space:pre-wrap;"> from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#8217; terms. The net proceeds generated from the private placement were approximately $41.3&#160;million, after deducting advisory fees and other estimated offering expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company's clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that its cash and cash equivalents as of December&#160;31, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The severity, magnitude and duration, as well as the economic consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;">No write-off activity and recoveries for the periods presented were recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment in value of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used statutory tax rates of 21% and 23%. See also Note 12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#8220;NATI&#8221;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks and trade receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December 31, 2021, the accounts receivables balance was composed of $2.2&#160;million from Fiocruz and $1.2&#160;million from Chiesi.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock units, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for the </span>restricted stock units<span style="background:#ffffff;"> based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Options granted to consultants and other service providers are recognized over the related service period using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 7,838,120, 22,850,682 and 28,502,017 shares of Common Stock underlying outstanding options, warrants and convertible notes for the fiscal&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. The 2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital. <span style="background:#ffffff;">The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2021, none of the 2021 Notes&#160;were outstanding.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company adopted ASC&#160;842 on January 1, 2019, using a modified retrospective transition approach, with certain practical expedients, and as a result did not adjust prior periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the package of transition practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The lease standard also provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Additionally, following the adoption of ASC&#160;842 and in subsequent measurements, the Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;Recently issued accounting pronouncements, not yet adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In March 2020, the FASB issued ASU 2020-04, &#8220;Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; In addition, in January 2021, the FASB issued ASU 2021-01, &#8220;Reference Rate Reform (Topic 848) - Scope.&#8221; The amendments in these ASUs apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Together, these ASUs provide optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December&#160;31, 2022, except for hedging relationships existing as of December&#160;31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. These ASUs were effective upon issuance and may be applied prospectively to contract modifications and hedging relationships entered into or evaluated through December&#160;31, 2022. <span style="background:#ffffff;">The adoption of this standard is not expected to have material impact on the Company's consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457352008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfUsefulLifeTableTextBlock', window );">Schedule of Useful Life</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Useful Life Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457706600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18,237</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,718</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,759</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,768</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37,714</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,923)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,752)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,962</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457333352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,166</p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,262</p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,526</p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,954</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457583000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2019, 2020 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,219</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,329</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.5</p></td><td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,207</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 872</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 853</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 848</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,528</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,333</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,750</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Present value of  operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,583</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457406520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,160</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,400</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,749</p></td></tr><tr><td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,601</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460324136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock', window );">Schedule of Options and Restricted Stocks Granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">No. of options or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">restricted stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vesting</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;grant (U.S.&#160;dollars</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year of grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">period</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">160,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">80,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">196,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">760,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">1,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">129,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">694,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">2,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">122,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">3.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr><tr><td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">1.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;">10 years</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,087,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.66</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.57</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited and expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 318,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.00</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,819,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.61</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 961,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.47</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Restricted Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">624,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">166,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">458,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock', window );">Summary of Options Granted to Consultants, Directors, and Other Service Providers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 464,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.74</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.60</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 440,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.63</p></td></tr><tr><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.63</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Share Options Outstanding and Exercisable</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercisable*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.57 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.57</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$2.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.73</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.55 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.06</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.59 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 112,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.50</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.66 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 641,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.74</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.70 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 240,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.10</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$3.73 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.52</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$4.69 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.10 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 215,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.50</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$5.60 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.71</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$17.20 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.93</p></td></tr><tr><td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,259,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,154,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense in Statement of Operations</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 269</p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 648</p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,458</p></td></tr><tr><td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,375</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of options and restricted stocks granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of transaction in which grantor acquires product and service from nonemployee or provides consideration payable to customer in exchange for its equity security. Excludes transaction in which grantor acquires service from employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5444-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454481288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member', window );">Notes 2021 and 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">The following parameters were used:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2021 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. Dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,855</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt discount amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,575</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 831</p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,261</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 92.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 767</p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td></tr><tr><td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 864</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985459945848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member', window );">Notes 2021 and 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">The following parameters were used:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 92.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457399416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2020 and 2021 were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,217</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,989)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,292</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (63,760)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,520)</p></td></tr><tr><td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOpenTaxYearsTableTextBlock', window );">Schedule of Open Tax Years</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2017-2021</p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2017-2021</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOpenTaxYearsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Open Tax Years Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfOpenTaxYearsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457450760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 311</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 905</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,285</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,562</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 767</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,506</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,981</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 522</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,433</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457453256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 475</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460256264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985382690584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 07, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="nump">$ 4,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,502,017<span></span>
</td>
<td class="nump">22,850,682<span></span>
</td>
<td class="nump">7,838,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,960,000<span></span>
</td>
<td class="nump">$ 5,567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_ChiesiMember', window );">Chiesi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal', window );">Tax Rate Assumption Related To Deferred Tax Difference Reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal', window );">Tax Rate Assumption Related To Deferred Tax Difference Reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale Of Stock Maximum Offering Price</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants', window );">Exercise of warrants, commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share price at which the new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985455454472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2009</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,086,000<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase', window );">Percentage Of Adult Gaucher Patients Treated With alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Collaborative Arrangement Profit Share Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Payment on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentInConsiderationForDevelopmentServicesPerformed', window );">Payments in consideration for development services performed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies', window );">Payments in connection with performance of additional studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized revenues related to non-refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Future milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember', window );">Kirin Holdings Company, Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized revenues related to non-refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NonRefundableFutureServicePayment', window );">Non-Refundable Future Service Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement profit sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementProfitSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NonRefundableFutureServicePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non refundable payment received for future service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NonRefundableFutureServicePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentInConsiderationForDevelopmentServicesPerformed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from consideration received for development services performed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentInConsiderationForDevelopmentServicesPerformed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow in connection with performance of additional studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of adult Gaucher patients treated with Uplyso.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460285656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 37,714<span></span>
</td>
<td class="nump">$ 36,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation and amortization</a></td>
<td class="num">(32,752)<span></span>
</td>
<td class="num">(31,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net, Total</a></td>
<td class="nump">4,962<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">18,237<span></span>
</td>
<td class="nump">17,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember', window );">Furniture And Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 16,759<span></span>
</td>
<td class="nump">$ 16,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985459926952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985459053048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,166<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">11,526<span></span>
</td>
<td class="nump">6,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 17,954<span></span>
</td>
<td class="nump">$ 13,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985458756280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985384829096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EmployeeSeveranceObligationPayment', window );">Employee severance obligation payments</a></td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Severance expense</a></td>
<td class="nump">990,000<span></span>
</td>
<td class="nump">885,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
<td class="nump">857,000<span></span>
</td>
<td class="nump">747,000<span></span>
</td>
<td class="nump">642,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Gain for the period</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears', window );">Number of benefit eligible employees | employee</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_BenefitsPayableDuringNextFiveYears', window );">Benefits Payable During Next Five Years</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember', window );">Contribution to Insurance Companies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember', window );">Contribution to Defined Contribution Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</a></td>
<td class="nump">$ 868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_BenefitsPayableDuringNextFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits payable during next five years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_BenefitsPayableDuringNextFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EmployeeSeveranceObligationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee severance obligation payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EmployeeSeveranceObligationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees To Receive Benefits During Next Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454669752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Arrangement Other than Collaborative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms [Member] | Office of the Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 911,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Royalty Agreement Terms [Member] | Office of the Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Royalty Agreement Terms [Member] | Office of the Israeli Innovation Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="nump">$ 38,600,000<span></span>
</td>
<td class="nump">$ 39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfRoyaltiesToGrantReceived', window );">Percentage of Royalties to Grant Received</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Royalty Agreement Terms [Member] | Outside of Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfRoyaltiesToGrantReceived', window );">Percentage of Royalties to Grant Received</a></td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfRoyaltiesToGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required royalty payments represented as a percentage to grants received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfRoyaltiesToGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RoyaltiesOnSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties based on sale of products developed from projects funded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RoyaltiesOnSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=plx_OfficeOfIsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=plx_OfficeOfIsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=plx_OutsideOfIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=plx_OutsideOfIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985384818392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">$ 1,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="nump">$ 1,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454623384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2027 and thereafter</a></td>
<td class="nump">4,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">9,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 5,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460026824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions', window );">Lessee Operating Lease, Number Of Renewal Term Extensions | item</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit | $</a></td>
<td class="nump">$ 496,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of Change in Operating Lease Monthly Rental Payments</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of Change in Operating Lease Monthly Rental Payments</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Number Of Renewal Term Extensions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Change in Operating Lease Monthly Rental Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454529288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 38,350<span></span>
</td>
<td class="nump">$ 62,898<span></span>
</td>
<td class="nump">$ 54,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">16,749<span></span>
</td>
<td class="nump">16,236<span></span>
</td>
<td class="nump">15,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">8,105<span></span>
</td>
<td class="nump">6,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Chiesi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 21,601<span></span>
</td>
<td class="nump">$ 46,662<span></span>
</td>
<td class="nump">$ 38,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454207816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details) - Option to purchase shares of common stock - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 4.69</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 2.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 3.59 One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 3.66</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 3.73</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">No Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 3.59 Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Exercise Price 1.57</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award granted contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice2.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice2.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.66Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.66Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.73Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.73Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NoExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_NoExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.57Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.57Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985382607448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Stock Option Activity) (Details) - Option to purchase shares of common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,087,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,819,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460404248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Restricted Stock Activity) (Details) - Employee - Restricted Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">624,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="nump">166,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non vested at end of year</a></td>
<td class="nump">458,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454195688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details) - Option to purchase shares of common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options or restricted stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options granted to consultants, directors and other service providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options or restricted stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesStockExpired', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesStockExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) expired during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesStockExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985453826216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details) - Option to purchase shares of common stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">2,259,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">1,154,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.57Member', window );">Exercise Price 1.57</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice2.00Member', window );">Exercise Price 2.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55Member', window );">Exercise Price 3.55</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59Member', window );">Exercise Price 3.59</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">319,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">112,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.66Member', window );">Exercise Price 3.66</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">641,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">280,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.70Member', window );">Exercise Price 3.70</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.73Member', window );">Exercise Price 3.73</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">129,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">40,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69Member', window );">Exercise Price 4.69</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice5.10Member', window );">Exercise Price 5.10</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">215,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">181,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice5.60Member', window );">Exercise Price 5.60</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">105,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member', window );">Exercise Price 17.20</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 17.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">92,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">92,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.57Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.57Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice2.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice2.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.59Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.66Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.66Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.70Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.70Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.73Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.73Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice5.10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice5.10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice5.60Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice5.60Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985455316216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 2,375<span></span>
</td>
<td class="nump">$ 3,126<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 1,458<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985371691944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Additional information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 25, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 22, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 05, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 20, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 09, 2019</div></th>
<th class="th">
<div>Dec. 07, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommonStockNumberOfVotingRights', window );">Common Stock, Number Of Voting Rights | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of Common Stock remain available for grant under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Debt conversion converted instrument amount, cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="nump">$ 4,867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,725,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,725,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfCommissionOnSaleOfShares', window );">Commission (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">BofA Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="nump">84.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">0.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Sr. Vice President And Chief Development Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Senior Vice President, Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.365%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Vice President Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.395%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.695%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Certain Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Chairman, Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase shares of common stock | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfDirectors', window );">Number Of Directors | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.685%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue', window );">Aggregate value of Restricted Stock Units that will be granted, contingent upon certain conditions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Senior Vice President And Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of non-vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value at grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockNumberOfVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes for each share of common stock is entitled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockNumberOfVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfCommissionOnSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfCommissionOnSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of non option equity instruments, that will be granted contingent upon certain conditions, on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share price at which the new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_VicePresidentResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_VicePresidentResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_CertainEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_CertainEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985457526328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details) - Level 3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Aug. 25, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.83<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">2.67<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">92.79<span></span>
</td>
<td class="nump">91.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">10.31<span></span>
</td>
<td class="nump">7.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985458637672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="nump">$ 3,470<span></span>
</td>
<td class="nump">$ 2,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
<td class="nump">2,575<span></span>
</td>
<td class="nump">3,470<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_InterestExpenseDebtOther', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Total</a></td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">$ 9,114<span></span>
</td>
<td class="nump">$ 7,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Total</a></td>
<td class="nump">$ 864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestExpenseDebtOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Debt, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestExpenseDebtOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total interest costs incurred during the period and either capitalized or charged against earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985371495176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 07, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>D </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,036,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,019,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,027,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,384,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 54,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (831,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="nump">25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest', window );">Convertible notes exchange in cash, accrued and unpaid interest</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Base value for conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Number of shares for basis conversion | shares</a></td>
<td class="nump">563.2216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="nump">$ 1.7755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfPremiumToClosingPriceOfStock', window );">Percentage of Premium to Closing Price of Stock</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Mature term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Minimum cash balance required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumDebtInstrumentConvertibleConversionShareNumber', window );">Maximum price per share of the conversion feature | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746.2686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Redemption, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prior to the maturity date, the Company may redeem in cash<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ThresholdPercentageOfConversionPrice', window );">Threshold Percentage Of Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding', window );">Aggregate percentage of principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentRedemption', window );">Amount of redemption of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfOutstandingCapitalStock', window );">Percentage of outstanding capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock', window );">Denomination of the principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange', window );">Number of calendar days after the date of applicable fundamental change purchase date | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange', window );">Number of calendar days after the date of applicable fundamental change purchase date | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember', window );">4.5% Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember', window );">Convertible Notes Due Two Thousand Twenty One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued and unpaid interest exchanged in cash in debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction costs in connection with exchange of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate percentage of principle amount of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Base Value For Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Conversion Share Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the denomination of the principal amount of debt that is used in conversion calculations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of redemption of debt as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumDebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumDebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of calendar days after the date of applicable fundamental change purchase date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfOutstandingCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfOutstandingCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfPremiumToClosingPriceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium to closing price of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfPremiumToClosingPriceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ThresholdPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of conversion price on sale price of the company's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ThresholdPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDueTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985455314840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Aug. 25, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.83<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">2.67<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">92.79<span></span>
</td>
<td class="nump">91.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">10.31<span></span>
</td>
<td class="nump">7.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454433336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 28,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454501208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>In respect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">$ 7,217<span></span>
</td>
<td class="nump">$ 9,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DeferredTaxAssetsOtherTimingDifferences', window );">Other timing differences</a></td>
<td class="num">(1,989)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">56,292<span></span>
</td>
<td class="nump">54,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(61,520)<span></span>
</td>
<td class="num">(63,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsOtherTimingDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets other timing differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsOtherTimingDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985384825208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Open Tax Years) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">Israel | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">Israel | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">United States | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985460081656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 247.9<span></span>
</td>
<td class="nump">$ 231.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">36.1<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Protalix Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 211.8<span></span>
</td>
<td class="nump">$ 200.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Protalix Ltd | Law for Amending the Israel Income Tax Ordinance, Tax Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure Line Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985456422904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsInstitutionsCurrent', window );">Institutions</a></td>
<td class="nump">$ 311<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherAssetsSundryCurrent', window );">Sundry</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">$ 1,285<span></span>
</td>
<td class="nump">$ 2,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsInstitutionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsInstitutionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsSundryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsSundryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985455211944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,562<span></span>
</td>
<td class="nump">$ 1,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,981<span></span>
</td>
<td class="nump">9,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 16,433<span></span>
</td>
<td class="nump">$ 13,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454445960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToNonExecutiveDirectorsMember', window );">Compensation to the non-executive directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Compensation (including share based compensation) to the non-executive directors</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToNonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plx_CompensationToNonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139985454645896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 22, 2022</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Jan. 12, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Restricted Stock | President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Restricted Stock | Sr. Vice President And Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromExpenseReimbursements', window );">Proceeds from expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Brazil Agreement with Fiocruz | Alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds from sales</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from expense reimbursements in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>plx-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20211231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2019_To_12_31_2021_G69dnyWX7ESLQI7Zi6Aa7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GEPYGazCFU-lvckKnH9W0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_v_mup5ayK0SZBeWgSy-6vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bCxAc5Cnfkm0EGvQetJhcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_9_2019_To_12_9_2019_4z22q3wSv0-NR5YhbAeSLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-12-09</startDate>
            <endDate>2019-12-09</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_thD8r8M9pUScQANMOAi9Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kE8UTOIMfEGWg0hfCpFG2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ihvuMLoedUaKvUb3gZrBQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7sdZSqR5Akypy6gOZtXx-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EacWiMG0w0qlanSOpKQOQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MdPzxWvoIUiF79gdrm8reg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DMrVGdM36kS0syIA8uAVkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTJek5F4gEy9ScXTU5y5Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gHL5-QCaE0WNugpzgg9seQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSoqlLM0bEOf23D1EiiZ3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sleyo-TN7ECJ8-DDksi1cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_OHALbnwmZ0uHOEuQaP-GQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_3VKeoZyiuU-sD80UufftoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_cydItAIWhU2ynTqxcgAr8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_gNOcdY9dyE2xyodPldHVZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_mFoKIxmKnkitg7IY-C7heA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.70Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_lgDg9pDF2EWhgu2sSt2k9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_WDm67mnYvkO--UxyQkYsvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_wdkJLL3g1kqo4k9Y_B1iWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_JX7wlQ8FiU22etWN6WQRxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_mKYQ0uHMPk-JKlPiT881XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice5.10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.70Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_M8ski3P7vkqI4q67BPAWeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-22</startDate>
            <endDate>2020-09-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_JcT2p0tnbUqhmhTyDLIICw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_t32kanKUi0m7HxcXWb8NzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_c9-osb3oE0SkR9YTIYdxYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ssa4_sAGw0q1WnIXrqo2yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__onSW-uv_0Sf9fAA3WmGWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E0uJdNzPMUWVe1_NyQJfUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_H9sLbSYtM0qsnN-27mpO9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_xaWyKyysfE-N-Odg4q5ilQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_UATsTNG3GEyx6u5IsMGjaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GBgSGz6h9E-afGEP8417zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_VZS1TwgN7EWajbs4tfYp1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_3pw1DQ5CWkST8Aba5KMVVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_tr53Np7eY0-Ae6xS_WOJOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_T30NLjS9gUG6T5IRwHFs3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_M2UVRoW7sUyno7XdY9wpow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_OZABD-Gv0UisMJYQyGNklQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_ZsU_oN8S5kKt5laU31Nl6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_8B8k4Z958U29kvLCfB2P5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0sZc2uezPU2o1oMeQcRe9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_DKnjcKFjmUa1np2ibVNGnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_EbYkt392okObFSFj3u7OvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_HmzXf1hdDkK4__n1knviHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ePa1ql7mhEGcbcjaQMVPmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IDSvFh3OYUGGC0HZKS46ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_0yT3uJM1BkaHr4dUCEjvtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToNonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_DhX0f2VRfE65d2xBozNi3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToNonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_Pn1OJZqDxUCu6sqgk4Nceg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">plx:CompensationToNonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zzCp5Zo2W0mA_IzpPeDB8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_liu81wlz_0GnnLU4yo84rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lj6QlQZTj0urSG1zMHyXZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_NVfyMY4qKEy_rMZnOFmZmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DSmWGfJ_nUqGx4cINjjxwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_lOmaI6ivKUCWZWzYSmOiTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_sXO4gqAD5E6e4X8EJdE_Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vAaunvUCaUm5Awsb6iJhXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_3tCMe8rWHUGVmPE1Vg1qcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_Nn22_559OUKyhCIEmepH8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HY-SW4N2TkyfFq3zDY1uuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_XEZ5o0zCB0Gtu8ErPOcE8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2020_To_3_18_2020_KfspxYy3cU2Kf_nxZFH28w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-03-18</startDate>
            <endDate>2020-03-18</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_AUvvcJwK8kKDjzt8c3S49g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_D8rI_9bthkCH_hajh1im5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2017_To_7_24_2017_IHtLKtFOd0GdflSpPhFd5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-24</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2016_To_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rR_AcPv6HUeGQ6sr7l3x6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_4EDJzmaOZEiGDZsFWmKybw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_NaIif8seUUurDs8ggqZ2pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_DhHNkI_3EEiZeB01aqdpKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_Dv3dYp7Sn0usVBmj85F-iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_DVyyV14ssk6w6xsrUpAbPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_bOenO2dw9kqQgW48F-LuVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_JS88tOJOkUqlKtjBD7IPxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_k1N1AROJukiPb2LgQrs-Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_34oM70dfJ0WMj9Nuj8F7aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S4pb21hY0kuERZAIbjSSPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4zMtLtp0p0ed5O4m0g8GzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0E0KOb1OA0OHpvtP9-VXOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_KBRPKEthI0WlOxB3RgGCwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_NrgbIl6Vs0-zjQEgcvzrEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_5BNg8lS-ikul3R9lhuigJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_KCPpKqI-Okqwtns-9IWsAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_x038hBkxEEOMoMUfzZexDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_A2agnc-nXUWF5xH0NH47Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_QJLt9peuMUKwXJpzAoU8Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_W5Xtd1I87UWgu75FfSxL9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-h9AO0_j0Kk-RifcpTNhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xZes_pQ3jU-LW3EVr3FH_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_DCDOuQ7vOEmwiHAqrutTiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_oDSWqTAF3kmOozORnpamaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_we61rqymjEKVRph1U_HyOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wVjVKlFU-kmp2kWFh3RuVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_5QixDFM82UiwwWLbZe1sTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eHDaBvSg7EqtccoqK2mu0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_31zyHW8jdkSb7SBDmFiccg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_b7Ak3fDnlkmmGkfD-wjobA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Dql2hzl-NkS8Ek6wKzfhtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6zDHzo_aTEew3DryvNkYTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_bFAp9JROpkOcrhLPvQRlPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_GmiPA7ea602B3Bzo6qlgCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_7_24_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BD69mggkuU62grMnuucETQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-24</instant>
        </period>
    </context>
    <context id="As_Of_12_7_2016_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_-Ae00XL6BEyY4dAoZ4k0DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDueTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-07</instant>
        </period>
    </context>
    <context id="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cFbsJrjci0yg4ImOcaQUEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-01</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_wwXeRF1bvke94qCksDkYng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_FourPointFivePercentageConvertibleNotesMember_m95eebdJ1ECA3BKmoDsZlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-01</instant>
        </period>
    </context>
    <context id="Duration_12_1_2016_To_12_7_2016_MCerakGL40qMS2YHRbNFsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_CflCHQ20lEaDx_EcPWhJ-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:KirinHoldingsCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_8sWurxglp0KmGkrtptMYNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_sNb9nRVA7UyHg24tmVfidA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_pRbaNlihhk-Mb6yk0UeU_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_kaobUQfqT0ORdmCuBmiC7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lDW5LBY3rUuDb7f7KXNKnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-07</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_rKMXQYZpckOR3T6wCl0-lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_GvWEuJLKREuv90OClpZMKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_phM4VtIB9kyKjfXahRtTSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nz1R62d_CUWRP0hHMNoUuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cDyFN34pu0WU-HKDRkiujg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_avlksYPTbEKq7Od9FRAY9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jz0yWSUNLUeUy5fbrRm0BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qzxX_tCY20S2bKMHuz5WJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cm4dDuAzykmSlgO-pcMmBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_FiocruzMember_zNisG5sSw0exkK1iIkuF0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_ChiesiMember_9OarDvgYGEWjO_OZkl86jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-TK4_F-2eE-xNEY8Kn76Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_dXz0lHVvlkiQrMZ4_xG4Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Wn4pMZFBa0ulpQZlimXCwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_uVGroeg7jUGkxDgm63pXFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WwsBRNfRtkKswONdYE8A3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-18</startDate>
            <endDate>2020-03-18</endDate>
        </period>
    </context>
    <context id="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-25</startDate>
            <endDate>2021-07-25</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-11</startDate>
            <endDate>2020-08-11</endDate>
        </period>
    </context>
    <context id="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-05</startDate>
            <endDate>2020-07-05</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-07</startDate>
            <endDate>2020-06-07</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-07</startDate>
            <endDate>2020-06-07</endDate>
        </period>
    </context>
    <context id="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iKUFwyX_yU2n3k92ORA_uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.57Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NoExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.57Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_sXjLs1UWbk-sYqhuiYE3qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:NoExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_14Iut1EZ1UWck-v0gKCugw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_N12CUuFMQkiGURk7lpa5rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.66Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_7pabyZcaV0G2hX0lA_wo6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_z5fjaYB3Vk6_8J6_3XOy1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.59OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_mmHdbT-en0uuXTv2hCvVNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VF0OGmePw0eTywhYkjcUPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-11</instant>
        </period>
    </context>
    <context id="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:VicePresidentResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-05</instant>
        </period>
    </context>
    <context id="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-07</instant>
        </period>
    </context>
    <context id="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:CertainEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-07</instant>
        </period>
    </context>
    <context id="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-03</instant>
        </period>
    </context>
    <context id="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-20</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_RzJRTxQNVUyCZrS9EnncRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_Pgw8cC8LGkmkSDN1ikOZrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rSbtuiUSrEKogWgpJVQOAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_2cmmFTV-8k-KecBEkLzBtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_dh4fOPoiskqOmGCaGTu_CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2022_To_3_22_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_Ak-XTuYc0UeiX460wPg5iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-22</startDate>
            <endDate>2022-03-22</endDate>
        </period>
    </context>
    <context id="Duration_2_2_2022_To_2_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_TdEixVwmTkix-fdRgGxOWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="Duration_1_12_2022_To_1_12_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ph-iL0zoGk631_yyBbBhuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-01-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OutsideOfIsraelMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_eeNvck2ATEWfgpCZeTLqVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OutsideOfIsraelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__0_D2FCWxk2p5kjrroefXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_Wf6RC2H560WbAcJnDFtApw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_BNmP4P54wkaBDpMrzeAVfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_dm10EvNOd0iKnY1gsz2csw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_-QuyUNmrLkKtu3HAPB64rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_TGSo8Z2q4UakwLgn9fGO-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_BR_WFR8ra7qdUO5CmDbCylH2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MskvE4NE_0SV-ZzLosD1-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_b_41YkbhLEmgakzPAuDz4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_TMhvyqD6DkCvNMBhkKseug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HHTyRmsve0-CvhM6s-xekA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_OfZWjQmIWECye0yv_boCTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__EIHv6aGREKNgPGju82ldg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_9zcjXo47CkaRE7ICQLJ5lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Wv2Wn8JO-UidVlRirC-2eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-20</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kDIPT7eBJUiHYr1xa6GU6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ng8kcf3PY0-KI0QEryv2Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_16_2020_To_3_16_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_e7awM79XzUyuSOlCW0jrbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:KirinHoldingsCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-25</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_1SnkfDBBdEa_ScKv2fZZOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_gflWc2-vqEuhHmJU56LALg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2009_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_VnPnDdgZPUGYN2qTVnlGFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-11-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_TPIzg0z-10Sb7x1kinz4UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_-UYZW6POc02nrytjPuH6oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r5Iht_Jc2k2j2OA7nlHKlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_uD3PPat1MEmGE12PwGBQuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ASM4sF594k-MTqGZBVQyyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_15_2022_yzNKajpAX0W9kN1xa7645w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-03-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_MK3JtZwR6kijibu1mfvLvg">
        <measure>plx:Vote</measure>
    </unit>
    <unit id="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ">
        <measure>plx:D</measure>
    </unit>
    <unit id="Unit_Standard_director_yAcLdDF3PE-23pSbigEjyQ">
        <measure>plx:director</measure>
    </unit>
    <unit id="Unit_Standard_employee_BN18wiEo1UyImbahotyXDw">
        <measure>plx:employee</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      id="Hidden_LSkWDFyqpka1mNlo29Sx5A"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      id="Hidden_7f4UabzM3UKj1WoiR34YVA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="0"
      id="Hidden_J0D8mXPoJkuP-g2JgHsH8Q"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">14838213</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="0"
      id="Hidden_eu5z54v0BEi7IfWYizgaRQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">29148047</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="0"
      id="Hidden_ZUuOi-suMEe05uLU3Qjq7Q"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">44140233</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_3JVbmKYYYk6-829uppPjZg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_KDt1cM7Bk0uPZzDGwYlHww_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_ftSG9cLFR0KVJ03LttbkyQ_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_8lLMZqIe60CqzbGcCwJHTw_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_oLvPhaoiQkGOFbgFgauQXQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="INF"
      id="Hidden_HDYzV-AxhEO6ZtjFVfzV3A"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">45556647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="INF"
      id="Hidden_W9fROlZvR0eDAlWsPj0McQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">34765280</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="2"
      id="Hidden_chTUbKX-yU63liJhoI2MnA"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">-1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="2"
      id="Hidden_pwzKxLMzFUqTpVS-7SVM7w"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="2"
      id="Hidden_cL1EAZPir0ybRR3Iq6YGOw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_12_9_2019_To_12_9_2019_4z22q3wSv0-NR5YhbAeSLw"
      decimals="1"
      id="Hidden_bjDxAD1NEUOlk5FvFvWGtA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_Je-Ta-rqJEqh-LzV7yjAoQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_X6B0iZoMdk-wCAZ02qG92w_1_1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_ADwibvLoIUu55kjfWXUfCg">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_giS2bj23eECFiLBqnLpbIA_1_1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_Ifq7ZhM-BkyD00Pz6MaP-Q">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_-KeWy2rzQEafHi0aGachYg">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_K1Brb5_2-USIDwcS_411kQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_LjQGN-T8MUmF4Wss8L_bDA_1_1">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_Vi3EgQAiSkW9P1n-BqgYYw">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_ns7dkf5D7Ea7EwC76c6EaA">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_FNiHkg9nC0K87Fjq9s4xBQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_oH_I17b98ESJZBAY0ObukQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_aDt-PFM2l0m9JaYQ42PfMA_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_KtsP71zfl0a6kvmbETUOSQ">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_OXGqzrGDnEOUFy1sb8xUiw">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_urzUdxxcBEmIqxhanELQ4w_1_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_oFbQGFXp7EGDg3wOzGvw1Q_1_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_qT_rfT99Gki_xObOFtoMCQ_1_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_VQV7YfyptU2GOdHU1KZjGw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_0lsuwYUn_0KlbsR-ZfgmTQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_N5UiswvEWEOzze3pfxXu5A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_1Xb9YmkSsE2789SjXwLAYg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_1lYiD2_lHUibzfaubk4Fdg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_tEM5fq2i0kSkDwPSm4eM3Q_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tc_WIF5hDJWJkSZYvmLsQG_cw_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_XqmqycE_k0S2E4NFh6OgYg">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_xecEuZ9BDk65SgKESS7OLQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_ASM4sF594k-MTqGZBVQyyg"
      decimals="-5"
      id="Narr_3yEwLZ0FkEKQojoNx-UkZw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">85100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_15_2022_yzNKajpAX0W9kN1xa7645w"
      decimals="INF"
      id="Narr_TMb31ldOk0-4POSBNJchEg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">46316129</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_UmRgZISEUUKSFUnVf2bCdQ">Kesselman &amp; Kesselman C.P.A.s</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_wN2B3X94uEWZ2XSQUQOG8g">1309</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_vYtPTRjavkCoRgjginrkvw">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_lHTd_h0L9UuEQA2xlkTbzA_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_fs0Vr966xUm83PlEcDjs_w_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_FtyWNVK880qkvbwJKZgE9Q_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20280000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_2dc-NdMi2UGmBr6OORge6Q_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_QalFYplO50CLb9WvGxVTmw_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3442000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_bZ_RfM5hAkyEPeUNMM0kyA_9_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_H-GakV-9u0ut-tD8VEbIrw_9_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1285000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_q7VoK_ujo0SqHWbmIpvEEw_10_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">13082000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_W1Vd6LhIPk6MuCXQXfwk5Q_10_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">17954000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_vUCQ8CsIJEyarNJjGAIoDw_11_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">55723000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_TlQdTiQHDEy2AdX7S_k5_g_11_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">61666000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_kOYw7UfB0ECE0GNonrpozw_14_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1799000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_zPuqY_HiK0iowWipJ0C73g_14_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2077000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_NSJ78e3PlEem63K3ZAotjA_15_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4845000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_D5BGy3tiukKTi4h6QDuYGA_15_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_WFj4zHMYQUONMJry5mhG9A_16_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">5567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_eX-_bGZBEkymYI4lLo5FoQ_16_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4960000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_Fo6tlLiAZ0uVccqJmzPOTQ_17_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">67934000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_fapeKX1xM0CihGJDkT1hKw_17_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">73665000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_Zv5PgywO90GxrVmayvcmOQ_23_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7221000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_vE0wEdbrYkqNnEVvJ1sP6Q_23_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">6986000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_6KgfeaPBU02bTXhJsQQYKw_24_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">13926000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_WrTjfxZchkmSO6-9ztgrmQ_24_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16433000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_PLvqQRbxaE-utGuLiLMW_g_25_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc__V78BnOhLEqlY9wDFjd1Xg_25_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1207000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_ZrneXdG_TECZQRgxAds2Hw_26_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">5394000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_9NIIstHdyUSpcgzQhr0z9Q_26_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8550000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_hhPvrAms5k-6IjkTuCBLGw_27_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">54427000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_c66ni3HnTUSzR8jwPuBbiQ_28_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4086000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_TzK54gf8aEWLatevB-bocQ_29_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">86474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_h5HQCIqz0UCnh-luo1eVoA_29_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">33176000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_WPr1FgFSRk-E0qYPZTDTog_32_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">27887000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_MSMKVPbIxESyUqYMdgXgFQ_33_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1716000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_BeM3AHnVG0m9b_t9gYYEOg_33_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">11790000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_aFc3R9sRIUKqxxJnxTB3Pw_34_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2263000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_Q6eIVf8SbEWRozGgM_nHRA_34_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2472000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_aJMTyfbkK0isFze6KYeikQ_35_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4467000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_kWqUfAN7f0a3iYfwn72krw_35_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_XjP4DFX4gE-dHPGHwblnLw_36_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">51000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_S3pYcwGXQ06gyWr81RGvFg_37_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8497000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_rvVv4C-cS0yu7Q716_oYQA_37_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">46525000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_EdG_O9A59kSmhdUlEGgQqQ_38_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">94971000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_NkZRw9rM1EacjCNbYd7PcA_38_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">79701000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="INF"
      id="Narr_ih3d1Tzl8UuGokGhY7REpg"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="INF"
      id="Narr_iPbBLVQ-NUaNjvb6M_rG5A"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="INF"
      id="Narr_ls2WT_jFpEiSKWkaahuhUQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="INF"
      id="Narr_VvSfXW_EVkmzYGnIxp_8UA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="INF"
      id="Narr_GLsrN9afxk25hT8URHIPUA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">34765280</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="INF"
      id="Narr_arGEFsEIJUKNvskziM_1CQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">45556647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_q4EZs_8My0usxo6fhh4YUQ_43_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">35000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_h-CyuOAJa0y1uKnSBrXtNA_43_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">46000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_xkgT-VZTfUSafyFzrqf7DA_44_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">320280000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_vG3rGlQFxEWt4aKjMHog2w_44_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">368852000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_Bu04g0JhcUyM3rEhWYpdkg_45_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-347352000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_d8yrbXWubUqCAf8BdgH-WQ_45_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-374934000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_FlQrwd2lSUSaDFI13uaMew_46_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_Wn7C7bjIJ02TuUbJmP6tkQ_46_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_-gg0HC5h5kqLEZ4sJ-wY6Q_47_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">67934000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_mDeGQBX9yUi15NAtRF1wHg_47_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">73665000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_HmzXf1hdDkK4__n1knviHA"
      decimals="-3"
      id="Tc_CNLDTdsctkmqTIl6qX--KQ_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">15866000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_8B8k4Z958U29kvLCfB2P5g"
      decimals="-3"
      id="Tc_lPL_aKntz0-1SwvH75tRMw_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16236000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_tr53Np7eY0-Ae6xS_WOJOA"
      decimals="-3"
      id="Tc_DCZneEAkhECDYGlbiJos_A_3_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16749000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ePa1ql7mhEGcbcjaQMVPmw"
      decimals="-3"
      id="Tc_dS5MD4oJoEefdJgqYGgqEg_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38827000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0sZc2uezPU2o1oMeQcRe9g"
      decimals="-3"
      id="Tc_PK4OBbGfAk-teQEPO8bvDQ_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">46662000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_T30NLjS9gUG6T5IRwHFs3Q"
      decimals="-3"
      id="Tc_rEKeZvYSZEug2vHX3oXahg_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">21601000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_-8TMrpXMI0aRUmakd4By5A_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">54693000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_5EyVYd1qMUKnFiFAeefUIw_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">62898000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_crJB78x9_UmTuuBHJJR8QQ_5_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38350000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_O7rtbiCQwkO89oUJO7inmQ_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10895000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_QMYlEzCsIUWIfNrngkoa3Q_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10873000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_5Qrcbe3B6kaeN2PkRosmOg_6_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16349000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_uOJbe48u8EyGRtAMJMlmDg_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">44616000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_R5d-asVWgUuj55PQ7146rQ_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38167000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_Q87-43YILkmTA1nsbF8vDg_7_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">29734000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_MeHfLXFdA0SGN3GwfOE8Nw_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9899000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_YwTzi7TC6kqatRxHCyrDqQ_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">11148000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_7eIKLDCKJkSOyq2bVkHQIA_8_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12729000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_LOf3Jic1PEKR0SAOD3d1Yw_9_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-10717000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_H0kXZtNpVkS2Wn56TfcO0g_9_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2710000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_gW_wAE6khkW9W_mVri4aSA_9_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-20462000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_CsabvlmmwUCm6JH59NQh7A_10_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7966000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_4F2_KNYO9UW5yzAUZ0UhsA_10_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9671000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_2aqEdJE6MEiOyWZFASNlAQ_10_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7521000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_gYoFJcvsZ06AuJ6bZ1QcTg_11_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">407000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_7tlJzDFxXESbtqFg2FTz1A_11_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">438000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_Ae1ZuH6zBEOwS9Qms7pWIA_11_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">401000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_lve_VlgtEEWAbsl_QxKuLg_12_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-7559000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_ueSxQNdCOkOk6xc0PXhuqA_12_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-9233000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_MCzpGTZT60ay1MCgbh9NsA_12_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-7120000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_5nR1mx869UeGv8CYaUXxLg_13_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-18276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_zcwuPkx63E-zj8rKMU_1YA_13_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-6523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_ENRizmTiDUG9HaGtuJo7vA_13_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="2"
      id="Tc_nFpDznTQiU2PNzLrqaqRMw_14_3"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="2"
      id="Tc_CmxexE88_0Gn3ejAHf8Ttw_14_6"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="2"
      id="Tc_YxIOQJo6SkW79t8K3AHTig_14_9"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="0"
      id="Tc_KPz2Klsca0qLxApA7B9LxQ_16_3"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">14838213</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="0"
      id="Tc_w0Li3jkwSEuitwme7XoABQ_16_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">29148047</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="0"
      id="Tc_yTShvGNZLkOl6-33yFEWpg_16_9"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">44140233</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw"
      decimals="INF"
      id="Tc_E2XrxPIKmUK6tbEnjtWUmQ_6_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw"
      decimals="-3"
      id="Tc_NelsAh7rlE-pOOZZycwB9A_6_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uTJek5F4gEy9ScXTU5y5Nw"
      decimals="-3"
      id="Tc_UD2QWBqCSEu-oiqUkKIrgA_6_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">269657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DMrVGdM36kS0syIA8uAVkQ"
      decimals="-3"
      id="Tc_zA3z0GepAEe9Pvj1iXIE0w_6_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-322553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_rKMXQYZpckOR3T6wCl0-lw"
      decimals="-3"
      id="Tc_E2DFIoHBVEqdgW2wLxm9Qw_6_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-52881000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cm4dDuAzykmSlgO-pcMmBg"
      decimals="-3"
      id="Tc_4gWmiVDbtUCSKJRfhw0NYg_8_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">835000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_mABPGJs5hEmUFm-EW8mPEA_8_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">835000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0E0KOb1OA0OHpvtP9-VXOA"
      decimals="-3"
      id="Tc_WGTeup2xrkuKipZYbbpfqg_9_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-18276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_ccD1ReQ1hUST5HzYSbORug_9_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-18276000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sleyo-TN7ECJ8-DDksi1cA"
      decimals="INF"
      id="Tc_lYSEf-XPTUOf31pYlplRyA_10_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sleyo-TN7ECJ8-DDksi1cA"
      decimals="-3"
      id="Tc_8JURES_KTEmBJIgEe-P2dA_10_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MdPzxWvoIUiF79gdrm8reg"
      decimals="-3"
      id="Tc_w6KYX7DIpUefchAs0f7-CQ_10_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">270492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EacWiMG0w0qlanSOpKQOQw"
      decimals="-3"
      id="Tc_KYO5o90gvkms2mPTqPe9cQ_10_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-340829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA"
      decimals="-3"
      id="Tc_7zIYud7HukiWhxcpqLHvUw_10_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-70322000</us-gaap:StockholdersEquity>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="INF"
      id="Tc_1IduWJxxiEGzpEIEq84oQw_12_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="-3"
      id="Tc_kuFUk20cGEu-BrH4R-5U8g_12_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA"
      decimals="-3"
      id="Tc_gIPHOV7eZ0CMb9-liYupPA_12_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_w6b3KiE7A0e9rFcB3Tet5A_12_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="INF"
      id="Tc_e2pdLAcABkaUKV8NoONpUg_13_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1428571</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="-3"
      id="Tc_8t3ObCSbEkKTGhgurTDT4Q_13_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA"
      decimals="-3"
      id="Tc_CQP0XW9WoUiRceAY-k8CzQ_13_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4866000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_ckLgr_-6CkCu34mmoKyXfA_13_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4867000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA"
      decimals="-3"
      id="Tc_tXdcyieYSk2Hk_d4CwwtUg_14_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_Buc8LQQhNEiJSZ6bkh6lkA_14_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="INF"
      id="Tc_WLJ9Mlg7LUWCmRK3IoWp-Q_15_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">694073</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="-3"
      id="Tc_G_KZlwsNME-Ck0DssJp51g_15_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA"
      decimals="-3"
      id="Tc_GzfLE2WeRkm0aGNbEIDd8w_15_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">861000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_flzzBGEas06JAtFWZUruog_15_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">862000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BGlrXtJ5f0yGIWpmGv7fLw"
      decimals="INF"
      id="Tc_3yeeyoqgGk228uSlFR_4dQ_16_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">200000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8pXCvVz8Zka_hJQY1OnwDA"
      decimals="-3"
      id="Tc_AQC-48FkeUOufLZHtIEqdw_16_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">472000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_uuVKQZp8SUC7x3i4_jBuOQ_16_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">472000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4zMtLtp0p0ed5O4m0g8GzA"
      decimals="-3"
      id="Tc_4EO8y_fpN0aSfD3Koc9r_w_17_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-6523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_6uJjjeSxZUGhjmj2OJJ7KA_17_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-6523000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSoqlLM0bEOf23D1EiiZ3A"
      decimals="INF"
      id="Tc_lH-uwEL0rkKsDy5N_voD1A_18_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSoqlLM0bEOf23D1EiiZ3A"
      decimals="-3"
      id="Tc_K8XToHHy606fvYkKem0iJQ_18_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7sdZSqR5Akypy6gOZtXx-Q"
      decimals="-3"
      id="Tc_C7ILbroVj02DbtV-m4HVFA_18_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ihvuMLoedUaKvUb3gZrBQg"
      decimals="-3"
      id="Tc_E3FMllUL6kiDBCq7TAbGPA_18_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_kjA2PchGwk213tRNG5ENcA_18_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug"
      decimals="INF"
      id="Tc_pbMBetID7kK4sALv_oqwww_20_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug"
      decimals="-3"
      id="Tc_6bWhX8ymhEC8srJLbbzvgg_20_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"
      decimals="-3"
      id="Tc_r65ZZC9GBEKgV6PQg8bAzw_20_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_NPop2PCLqkuiqXCABA0TrA_20_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug"
      decimals="INF"
      id="Tc_e9-hivyNWUqS1E0_oQY-2w_21_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug"
      decimals="-3"
      id="Tc_RDJCJlw7bUuLvdD7PXR_cA_21_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"
      decimals="-3"
      id="Tc_FYRaW6PbsE6dd26SW693ew_21_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_b3eHF2ZkhEeZYjtyE4Vgow_21_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"
      decimals="-3"
      id="Tc_-8oD6dv_PUSy3v9b_mYdAA_22_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_U10t2AEIFkSQxSFSiwPQ4A_22_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"
      decimals="-3"
      id="Tc_WCHYUfFKUEGNdlclSu73pA_23_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">970000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_YR2wBFxOaU--frvnUMGXVg_23_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">970000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACetGLCFo0mQi490su78ug"
      decimals="INF"
      id="Tc_SbwgxAVjWEa4IPTxriKv2A_24_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"
      decimals="-3"
      id="Tc_G8hIU5gUOEOanVnSVgqOPg_25_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_u60gB_tcaEmJxXvLjsUYjA_25_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uPzNQb57LUGflUfTdHArmw"
      decimals="-3"
      id="Tc_KHAYE8QUt0-5YUqvz9iGzQ_26_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_NgwGpW-fQkubp_mOvSAElQ_26_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S4pb21hY0kuERZAIbjSSPg"
      decimals="-3"
      id="Tc_azpIEUfl00y3uZKWCmlm1A_27_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_CL8XmJkik0y3_CILuMyJNA_27_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gHL5-QCaE0WNugpzgg9seQ"
      decimals="INF"
      id="Tc_7lluMipghkqGX22fLeEaSw_28_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gHL5-QCaE0WNugpzgg9seQ"
      decimals="-3"
      id="Tc_M7nGZ0yzyE-8zbJ6LsRIJQ_28_5"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kE8UTOIMfEGWg0hfCpFG2w"
      decimals="-3"
      id="Tc_DSk0Ni9QKUS-LwyWJHXkXA_28_8"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_thD8r8M9pUScQANMOAi9Vw"
      decimals="-3"
      id="Tc_uGMsAS3Wh06HuwhnMPouXg_28_11"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_mT93EvVFQEq9vszypeBzfg_28_14"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_JoJMWJZzb0aF0z1EsOoaPQ_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-18276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_r3Ba0MQoU0CPcEQvTBr3UQ_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-6523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_GJbBMzlXf0WQnc6ZpcaXbg_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-27582000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_MQwj52IDd0GZerSYDBSFDw_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">835000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_YSWRmdUkzUaIHazYaFxI8w_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3126000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_FmZGYlmbMU6xFn2Ff_PfXg_6_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2375000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_z7r2wHgVwEWySeLuNTXRLg_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1617000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_zyfjHwfThkSuFT5tJx-SGg_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1302000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_UmzfDPyYr0WvYzZWyygDTA_7_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1118000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_egEh7xJ5zkKkXUdZgUzH4w_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-378000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_JMM9nuSfq02Jk7myAHrfsQ_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-171000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_L_DN_PSaRE-6xc42QBsLhQ_8_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-417000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_izEZFw0yyEGAxjPozKeF8g_9_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-10000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_HXvdRjjhTk6WZAyKhKnwtQ_9_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-494000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_kkpkD05jWk6v4pLRyazYCA_9_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">133000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_D2IzcZZjwkCaH3tP_wQK_Q_10_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">58000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_Y4YMSHVdS0CF9U0svDkg3Q_10_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_z7iNACRsekaK_qaMeIPgCA_10_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">100000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_NF3JhAIL6kSJYmLNldY4zw_11_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_3J-uzJtGPUWt4GnlL9y1TA_12_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-831000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_I9DoL8azGU2fd3tesc5BcA_13_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2991000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_vTIy3LWmRU6nLaR4AHVZ3w_13_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3470000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_4lEdN9xmvU6Kj5EV-CwmNw_13_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2673000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_gM77IFiUH0Gh9yE9KoIWAQ_15_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-9580000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_9sfVhnaP9k2IzVuZDQnrqw_15_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-26205000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_hP7lSV4Kc0ejIMmNdGZ1Aw_15_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">13230000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_nALmxKUjzUuW0YR9fanzVQ_16_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-188000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_Z21c-U-thE2V3OKyWeI9YQ_16_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-2091000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_OsAf5459jUqdJ9fdzmRCrw_16_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1032000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_P2MZUjd430-QwiEnHB9oMQ_17_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">110000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_Pvh2jFjJ9E6N9ggcQfpdNQ_17_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-95000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_flxwT9BDp0aiQ9Pj3-D7ZQ_17_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-241000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_lHCaBbuNUEKNi_p90y119g_18_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-414000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_DHJFNLNQQUSn1-8kHui28A_18_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4927000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_hlENV_esnUe8u1dZLsZswg_18_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4872000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_HzGR8LKBCEmMbI3mpQUNQw_19_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2735000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_hI8MZQY3kUKrhgbQRlndcQ_19_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2274000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_-c2iPopT6keQlPjFhd0aQw_19_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2385000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_Q03VDyitW0yD2KHEY_zH4A_20_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-482000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_VZatXFbv6UG2i6fsXR4j5g_20_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-458000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_4JlQsZLGYkWZDR4hzJXjGQ_20_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-51000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_pf2DiBrv6EydBbBsuTMTwg_21_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-19358000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_RWZAQtfyjU6038PIaYCaYw_21_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-26106000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_WMAL-5SdjUK55GLTcLXdXQ_21_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-10285000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_cHnfhsSpwEyyrNI3oXioKw_24_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_LLJdejhGMEGTUNhcbq5ejA_24_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_b5pZhNktpkuk3kFb0_wzqA_25_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">57835000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_bM8sE3u-s0iN_gdqeaGFmg_26_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">627000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_eD3c8unPfkGtbnt5XTf9lg_26_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">655000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_BiOFjBEfkkuYUej_x6RSSQ_26_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1459000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_mtcOejmI9EmBKCcrZI6YHQ_27_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:IncreaseDecreaseOfRestrictedInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_7mNmPHsl2E6CAVvTn8ZmxQ_28_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">259000</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
    <us-gaap:IncreaseDecreaseOfRestrictedInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_YgCEG3cc_kiyFG7U4njQ7w_28_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-384000</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
    <us-gaap:IncreaseDecreaseOfRestrictedInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_w-33H4bmukqiUlIRQldhUw_28_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-436000</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_0gW0gfJzpE6YkIHmUtyx6g_29_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-3000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_65RYeEMylUunXgyKGzZfcg_29_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-319000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_HEdF5fbwgE2pmCoD4jj-1g_29_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">109000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_uB6SNRaMHka-eD1Ygj-xnA_30_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-883000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_s121caE7EEuWD8n7PwHrpw_30_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-19952000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_8ys1DQa6l0utAKTIrD8xnw_30_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">18921000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_bC1GUatfN0SJEQlwa46bvg_33_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">30036000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_pWF97yOQJUC8RgmQU4-k2Q_34_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">215000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_XGJeSr4yY0KhXmYW76MCBw_34_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_4NLZA4wd60G0gqgUTmSkiQ_35_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">41343000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_8sDs6555cEW4u8LX9Ut3kg_35_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_Xby_shRC1kqhifmdDjbbSQ_36_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4867000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_3mKlZaAXI0uQIvfv64s2Nw_36_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_b2yiufwdQ0-r2ti0LEzpWA_37_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">472000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_MgZeRCip3E-IqVSt9oCqKg_38_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">46467000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_42upKbTNXkKqeRV7EILq2g_38_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12078000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_t9zH-jXG90K78ZJ_KDV22w_39_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">225000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_7vWgKsXCr0qIpXXXXUjIdA_39_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">64000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_5c_f2etqskCQmrogXeFbGg_39_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">6000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_bQ1RnnO_UUm8n-H1SWMhew_40_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-20016000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_ZK_GVb4Ew0C7b7_6CrfvrQ_40_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">473000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_MUDTd0magkOxyv4h7x_yXg_40_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_rKMXQYZpckOR3T6wCl0-lw"
      decimals="-3"
      id="Tc_W5otX0futkeI9bEA23QtKA_41_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">37808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA"
      decimals="-3"
      id="Tc_61sRQMPQF0WUhPtK40FU8w_41_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">17792000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_YqThTE3xTEOrbi6402GRPw_41_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">18265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA"
      decimals="-3"
      id="Tc_G_B6_vfWvk6lFtQMM7qGXg_42_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">17792000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc__CqDRAQ8-0aY6sqv9uL8Vg_42_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">18265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_nilYxhox9E2MOBn5CIvWow_42_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_CNtLcqeRcU6r-bW_7D6dPQ_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">98000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_19VFk6ExY0q21K6pevDd3g_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">317000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_xVSPpniMkE6vlx7CFBVslg_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">94000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_YhQ17pd_a0Kl2CqPY4vCcg_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">388000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_FR22VVYbbU-ZynPzKJwtJQ_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">632000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_HCoLDvNATECI-cypY9ac2w_5_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">309000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_9OkCNIJr7EKYhtLENcX40g_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4344000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_1bj560mrtUO_Gjdw01jFYg_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4344000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_nszHcCOmGEyEzF5ehUHxMA_8_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3410000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_820dPfYwEEOJ5dzVTaFJaw_9_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">407000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_m1ix4FGc20KwcE5YnZh87Q_9_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">438000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_xCWhL-5UQ0C7XNsr7J7EhA_9_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">379000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_1IC0GYRu10Ct3zHWo6lgfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On August&#160;25, 2021, the Company completed exchanges (the &#x201c;Exchanges&#x201d;) of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021. See also note 10.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#x201c;EMA&#x201d;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme (agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#x2019;s exclusive worldwide license agreement with SarcoMed USA Inc. with respect to PRX-110 for use in the treatment&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its Common Stock having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;BofA Agreement&#x201d;) it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company closed a public offering of its Common Stock, raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;18, 2020, the Company completed a private placement of its Common Stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of Common Stock at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants were exercisable commencing &lt;span style="white-space:pre-wrap;"&gt;six months&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; following their issuance for a period of &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms. The net proceeds generated from the private placement were approximately $41.3&#160;million, after deducting advisory fees and other estimated offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company's clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company believes that its cash and cash equivalents as of December&#160;31, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The severity, magnitude and duration, as well as the economic consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Functional currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#x2019;s revenues are derived in dollars. Most of the Company&#x2019;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#x2019;s financing has been provided in dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#x2013; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#x2013; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Accounts Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;"&gt;Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;"&gt;No write-off activity and recoveries for the periods presented were recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#x201c;moving average&#x201d; basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#x201c;moving average&#x201d; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;j.&#160;&#160;&#160;&#160;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Deferred income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used statutory tax rates of 21% and 23%. See also Note 12.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Uncertainty in income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Tax benefits recognized in the financial statements are those that the Company&#x2019;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#x2019;s management deems more likely than not to be sustained.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;k.&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;3.    Revenue from R&amp;amp;D services&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;l.&#160;&#160;&#160;&#160;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#x201c;NATI&#x201d;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company&#x2019;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;believe it is exposed to any significant credit risk on these instruments. The Company&#x2019;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December 31, 2021, the accounts receivables balance was composed of $2.2&#160;million from Fiocruz and $1.2&#160;million from Chiesi.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;n.&#160;&#160;&#160;&#160;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock units, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. &lt;span style="background:#ffffff;"&gt;This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company measures compensation expense for the &lt;/span&gt;restricted stock units&lt;span style="background:#ffffff;"&gt; based on the market value of the underlying stock at the date of grant&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Options granted to consultants and other service providers are recognized over the related service period using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elects to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;o.&#160;&#160;&#160;&#160;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 7,838,120, 22,850,682 and 28,502,017 shares of Common Stock underlying outstanding options, warrants and convertible notes for the fiscal&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;p.&#160;&#160;&#160;&#160;Convertible notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. The 2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital. &lt;span style="background:#ffffff;"&gt;The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2021, none of the 2021 Notes&#160;were outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;q.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company adopted ASC&#160;842 on January 1, 2019, using a modified retrospective transition approach, with certain practical expedients, and as a result did not adjust prior periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected the package of transition practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The lease standard also provides practical expedients for an entity&#x2019;s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Additionally, following the adoption of ASC&#160;842 and in subsequent measurements, the Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;r.&#160;&#160;&#160;&#160;Recently issued accounting pronouncements, not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In March 2020, the FASB issued ASU 2020-04, &#x201c;Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#x201d; In addition, in January 2021, the FASB issued ASU 2021-01, &#x201c;Reference Rate Reform (Topic 848) - Scope.&#x201d; The amendments in these ASUs apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Together, these ASUs provide optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December&#160;31, 2022, except for hedging relationships existing as of December&#160;31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. These ASUs were effective upon issuance and may be applied prospectively to contract modifications and hedging relationships entered into or evaluated through December&#160;31, 2022. &lt;span style="background:#ffffff;"&gt;The adoption of this standard is not expected to have material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_Rn_sD7qWH0uev5yzJTPhwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On August&#160;25, 2021, the Company completed exchanges (the &#x201c;Exchanges&#x201d;) of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021. See also note 10.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#x201c;EMA&#x201d;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme (agalsidase beta), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#x2019;s exclusive worldwide license agreement with SarcoMed USA Inc. with respect to PRX-110 for use in the treatment&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its Common Stock having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;BofA Agreement&#x201d;) it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company closed a public offering of its Common Stock, raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;18, 2020, the Company completed a private placement of its Common Stock and warrants. In connection with the offering, the Company issued 17,604,423 unregistered shares of Common Stock at a purchase price per share of $2.485 and warrants to purchase an additional 17,604,423 shares of Common Stock at an exercise price of $2.36 per share. The warrants were exercisable commencing &lt;span style="white-space:pre-wrap;"&gt;six months&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; following their issuance for a period of &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five years&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; from the date of issuance. For accounting purposes, the warrants are classified as equity considering the warrants&#x2019; terms. The net proceeds generated from the private placement were approximately $41.3&#160;million, after deducting advisory fees and other estimated offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&#160;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#x201c;Pfizer&#x201d;) in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company's clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company believes that its cash and cash equivalents as of December&#160;31, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw"
      decimals="4"
      id="Narr_tmadFwBwtEapw0Ht3eLdiQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw"
      decimals="-4"
      id="Narr_t99o9vD1Tk2cAZ4D3ibP2g"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">54650000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="-4"
      id="Narr_7pFGW1zRm02Xpop7-T3taw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="4"
      id="Narr_b6lNSxVe7Uu0M1ENL8VJLw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="-4"
      id="Narr_Q4UJshBSEE6g9XE3w8sk4Q"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25900000</us-gaap:RepaymentsOfConvertibleDebt>
    <plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="-5"
      id="Narr_Ho2tGzEmj0yu43Xp02uUZA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1100000</plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="INF"
      id="Narr_LhFxHVx56UuxHeT8hKCpzw"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="3"
      id="Narr_BWA4wyMFXkKaZLvGmQYa1Q"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="0"
      id="Narr_uJUo4ISfEkC5vROwdl--qQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="INF"
      id="Narr_SAjrT2E60kiZjhXqKg6dKw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <plx:PercentageOfPremiumToClosingPriceOfStock
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="3"
      id="Narr_cuAm7IfIT0GEMZTp8_-8KA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.325</plx:PercentageOfPremiumToClosingPriceOfStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rSbtuiUSrEKogWgpJVQOAA"
      decimals="-5"
      id="Narr_uvX0oKF5iEGgHAa9IDnTtw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_AUvvcJwK8kKDjzt8c3S49g"
      decimals="0"
      id="Narr_frBP5N8g60-tlTN5T-eZsA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_AUvvcJwK8kKDjzt8c3S49g"
      decimals="-5"
      id="Narr_INhXJHPTYkuk-TrWRxUKJw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ"
      decimals="-5"
      id="Narr_wcQqNw44XkOA2fgt_B00eA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">40200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q"
      decimals="2"
      id="Narr_2ccvQgTHhk6j-x6yQ8wwJA"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw"
      decimals="INF"
      id="Narr_rQ0pbYqhgUKp9mrOGNLfvw"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">17604423</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw"
      decimals="3"
      id="Narr_1LQGCM2Z5k22UwhTntll8g"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.485</plx:StockIssuedDuringPeriodIssuePricePerShareNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"
      decimals="INF"
      id="Narr_Cr5NjNn2-0GMpiZ-kkd_lw"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">17604423</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"
      decimals="2"
      id="Narr_eCfWiOSe20OnVfHEY1Fbww"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw"
      id="Narr_1mJ1kiFPU0eaRuyfv6k5Dg">P6M</plx:WarrantsAndRightsCommencementPeriodForExerciseOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"
      id="Narr_FoyqDHUUjEuDRGbv8RP3_A">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_18_2020_To_3_18_2020_KfspxYy3cU2Kf_nxZFH28w"
      decimals="-5"
      id="Narr_beiTChTrH0udTM0CM9Mu1Q"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">41300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_dXz0lHVvlkiQrMZ4_xG4Cw"
      decimals="-5"
      id="Narr_iPXwlF_w50-pxGiPcI-ORw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"
      decimals="-5"
      id="Narr_Pg2zKzLP10KlTzFhQk5fkQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"
      decimals="-5"
      id="Narr_DoZB7M6abkiuuNAAWTvB7w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"
      decimals="-5"
      id="Narr_LwkeyaHSLE-DJtMw52XZEg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"
      decimals="-5"
      id="Narr_RxG780a2CU2qDaCOJ6TPAA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_b_41YkbhLEmgakzPAuDz4Q"
      decimals="2"
      id="Narr_jShP7PkbckuM2MFSVHB8aQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_HHTyRmsve0-CvhM6s-xekA"
      decimals="2"
      id="Narr_pyP7dvqcmEuN8kkcV7p4yA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_MskvE4NE_0SV-ZzLosD1-w"
      decimals="2"
      id="Narr_L0zGCEKooUm2Q8pfzkyTvA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_TMhvyqD6DkCvNMBhkKseug"
      decimals="2"
      id="Narr_q9aMI6QT30-FSGljWqUUUQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_r5Iht_Jc2k2j2OA7nlHKlA"
      decimals="-5"
      id="Narr_mftACwTCf0-f-mIZ_7-YTQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_TPIzg0z-10Sb7x1kinz4UQ"
      decimals="-5"
      id="Narr_THWbxSo63E2z6lQK7K9Xng"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_gflWc2-vqEuhHmJU56LALg"
      decimals="2"
      id="Narr_hi0hWLqNfkG5pRm9jzxuww"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_h5yQ0uAy3kq3Tc6C6O2bkQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_F4YKuqgve0qILmWvY1p5cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The severity, magnitude and duration, as well as the economic consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_9o0IPY2-lkO_lHRcYhAfnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Functional currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#x2019;s revenues are derived in dollars. Most of the Company&#x2019;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#x2019;s financing has been provided in dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#x2013; exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#x2013; historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_eqfj0xPmUUi-idd_9R6bPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_1ry2Cmyx3U2l_W3sYA3iwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Accounts Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;"&gt;Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 60.5pt;"&gt;No write-off activity and recoveries for the periods presented were recognized.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_gwquuY0Q9USjnl5i1QW54w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#x201c;moving average&#x201d; basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#x201c;moving average&#x201d; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_3rK26UpnEkiLpAbqUXcZlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of (i) the expected lease term and (ii) the estimated useful life of the improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <plx:ScheduleOfUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_5msa4YZByEC8RgDXKHd2vQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_NVfyMY4qKEy_rMZnOFmZmQ"
      id="Tc_cZEKwEBiqEGMj7sG4lof7A_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_zzCp5Zo2W0mA_IzpPeDB8A"
      id="Narr_soSvnlepn0GxL8dTSvwwQA">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_liu81wlz_0GnnLU4yo84rw"
      id="Narr_lFd0QHXRSUODf1j0QKdRKw">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_lj6QlQZTj0urSG1zMHyXZg"
      id="Tc_8FvRFPr680-4yb2KEAwsEg_4_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_tDrCieaNqUeg1s9qN-seKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_IisAOFUj7ki8hADCU97iSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;j.&#160;&#160;&#160;&#160;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Deferred income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. The Company used statutory tax rates of 21% and 23%. See also Note 12.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Uncertainty in income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Tax benefits recognized in the financial statements are those that the Company&#x2019;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#x2019;s management deems more likely than not to be sustained.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_uVGroeg7jUGkxDgm63pXFQ"
      decimals="2"
      id="Narr_2h5pBFpXAkas0TShzXGw3w"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.21</plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal>
    <plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_Wn4pMZFBa0ulpQZlimXCwA"
      decimals="2"
      id="Narr_9QZmOQ0ALUCGQApHY1Sxiw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.23</plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_REzyQBWAnkGomdnSbViAkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;k.&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;3.    Revenue from R&amp;amp;D services&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg"
      decimals="INF"
      id="Narr_1Ng5w2e0IEKgemPuDzLHfQ"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_6lru2stIUki0EXrKbkR5EA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;l.&#160;&#160;&#160;&#160;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the National Authority for Technological Innovation (&#x201c;NATI&#x201d;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiaries will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_BYjWl7sIyUSmL_MoP89OVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company&#x2019;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;believe it is exposed to any significant credit risk on these instruments. The Company&#x2019;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December 31, 2021, the accounts receivables balance was composed of $2.2&#160;million from Fiocruz and $1.2&#160;million from Chiesi.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_FiocruzMember_zNisG5sSw0exkK1iIkuF0Q"
      decimals="-5"
      id="Narr_XF9WDLPIf0CVKcN6Qn1ePQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_srt_MajorCustomersAxis_plx_ChiesiMember_9OarDvgYGEWjO_OZkl86jg"
      decimals="-5"
      id="Narr_84-eo74moU6QKHsPvMd_rg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_XFF3K7wvhUG4OuHuqa-YKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;n.&#160;&#160;&#160;&#160;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock units, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. &lt;span style="background:#ffffff;"&gt;This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company measures compensation expense for the &lt;/span&gt;restricted stock units&lt;span style="background:#ffffff;"&gt; based on the market value of the underlying stock at the date of grant&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. Options granted to consultants and other service providers are recognized over the related service period using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elects to account for forfeitures as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_1FzmkDe4yU6DdQoxRqT-eA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;o.&#160;&#160;&#160;&#160;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 7,838,120, 22,850,682 and 28,502,017 shares of Common Stock underlying outstanding options, warrants and convertible notes for the fiscal&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="INF"
      id="Narr_GgDtdoH2q0uQV45A8KEwUg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">7838120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="INF"
      id="Narr_FiaNTOYHv0eZqDey9HVMHQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">22850682</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="INF"
      id="Narr_pQslM_rm90Scz-iX__Fm8g"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">28502017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_RslFju-R30aRwCU4UJAWSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;p.&#160;&#160;&#160;&#160;Convertible notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. The 2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital. &lt;span style="background:#ffffff;"&gt;The 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Issuance costs regarding the issuance of the 2021 Notes, as well as the debt discount and debt issuance costs from the issuance of the 2024 Notes, were deferred and amortized over the applicable convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding. In addition, as of December&#160;31, 2021, none of the 2021 Notes&#160;were outstanding.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="-4"
      id="Narr_2OC-Tsvu7ketqcqBETAjJw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28750000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg"
      decimals="0"
      id="Narr_owgQmdlGWEaLikIRz5XAkA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">0</us-gaap:ConvertibleDebt>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_qeKccOpY602TWq1n4ZYWHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;q.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company adopted ASC&#160;842 on January 1, 2019, using a modified retrospective transition approach, with certain practical expedients, and as a result did not adjust prior periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected the package of transition practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The lease standard also provides practical expedients for an entity&#x2019;s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Additionally, following the adoption of ASC&#160;842 and in subsequent measurements, the Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_tSxv5o0VIUOV6A3EDwU_Vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;r.&#160;&#160;&#160;&#160;Recently issued accounting pronouncements, not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In March 2020, the FASB issued ASU 2020-04, &#x201c;Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#x201d; In addition, in January 2021, the FASB issued ASU 2021-01, &#x201c;Reference Rate Reform (Topic 848) - Scope.&#x201d; The amendments in these ASUs apply to all entities that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. Together, these ASUs provide optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December&#160;31, 2022, except for hedging relationships existing as of December&#160;31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. These ASUs were effective upon issuance and may be applied prospectively to contract modifications and hedging relationships entered into or evaluated through December&#160;31, 2022. &lt;span style="background:#ffffff;"&gt;The adoption of this standard is not expected to have material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_18vJHMf3l0WVQrbOQ4OzqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&lt;/b&gt;&#160;&#160;&#160;&#160;On November&#160;30, 2009, Protalix&#160;Ltd. and Pfizer entered into the Pfizer Agreement (as amended in June&#160;2013) pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except for Israel and Brazil. Under the Pfizer Agreement Protalix was entitled to 40% of the results (profits or losses) earned on Pfizer&#x2019;s sales of taliglucerase alfa.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Protalix Ltd. also agreed to provide Pfizer with:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Promissory note&#160;&#x2013; as of the date of the amendment, the Company owed Pfizer $4.3&#160;million as a result of the accumulated losses incurred by the Collaboration Operation. Following the new agreements, the Company committed to pay Pfizer the principal sum of the debt at the earlier of (a)&#160;November&#160;12, 2020 and (b)&#160;the date upon which it becomes due pursuant to any event of default, as defined. In September 2020, the Company amended the outstanding $4.3&#160;million promissory note payable to Pfizer by November 2020 to extend the maturity date to the earlier of (a)&#160;January&#160;31, 2022 and (b)&#160;the date that the Company receives any milestone payment from Chiesi, if at all, subject to certain conditions and exceptions. The amendment also provides that the Company shall make a payment of $430,000&#160;to Pfizer. The payment was creditable against the principal amount of the note, in whole or in part, if the Company satisfied the note in full on or prior to September&#160;30, 2021, depending on the date the note is satisfied. As of December&#160;31, 2020, the promissory note was classified to current liabilities. &lt;span style="background:#ffffff;"&gt;On March&#160;29, 2021, the Company paid approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$4.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million to Pfizer satisfying the promissory note in full.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&lt;/b&gt;&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#x2013; the drug) for the treatment of Fabry disease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Under the terms of the Chiesi Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Protalix&#160;Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#x2019;s requests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The consideration consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront, non-refundable payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in development costs, capped at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million per&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments for additional studies, as may be approved from time to time by Chiesi.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Milestone payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$320.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments as consideration for the supply of the drug. The payment will vary from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;35%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Chiesi&#x2019;s average selling price of the drug, depending on the amount of annual sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Protalix Ltd. will be the sole manufacturer of the drug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Chiesi does not have sublicensing rights (except for certain territories).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;In July 2018, Protalix Ltd. entered into the Chiesi U.S.&#160;Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi U.S.&#160;Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. will be mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#x2019;s requests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The consideration consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront, non-refundable payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$20.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in development costs, capped at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million per&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments for additional studies, as may be approved from time to time by Chiesi.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Milestone payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$760.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Agreement, which has been reduced to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$735.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments as consideration for the supply of the drug. The payment will vary from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;40%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Chiesi&#x2019;s average selling price of the drug, depending on the amount of annual sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Protalix will be the sole manufacturer of the drug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Chiesi does not have sublicensing rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;As of December&#160;31, 2021, the Company has received, or is entitled to receive, the following payments from Chiesi:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront payments equal to $50.0&#160;million, in the aggregate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments equal to $45.0&#160;million in consideration for development services performed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments equal to approximately $33.6&#160;million in connection with the performance of extension studies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;Payment equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;&#160;million in lieu of certain milestone payments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;During 2019, 2020 and 2021, the Company recognized revenues of approximately $4.5&#160;million, $3.5&#160;million and $0.6&#160;million, respectively, related to the then $10.0&#160;million future milestone payment. The Company assessed the likelihood of achieving the milestone using the most likely amount method and evaluated for the constraint by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;span style="background:#ffffff;"&gt;The&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million payment was received in June 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;b style="font-weight:bold;"&gt;c.&lt;/b&gt;&#160;&#160;&#160;&#160;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil. Approximately 25% of adult Gaucher patients in Brazil are currently treated with BioManguinhos alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;d.&lt;/b&gt;&lt;span style="font-size:10pt;"&gt;&#160;&#160;&#160;&#160;On March&#160;16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (&#x201c;Kirin&#x201d;) to evaluate the production of a novel complex protein utilizing ProCellEx&lt;/span&gt;&lt;sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="font-size:10pt;"&gt;, the Company&#x2019;s proprietary plant cell-based protein expression system. Under the agreement, Kirin was obligated to bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provided Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$1.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million. &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;During the year ended December&#160;31, 2021, the Company&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt; completed its obligations under the agreement and the agreement expired, including the&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; o&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;background:#ffffff;"&gt;ption to provide additional services. Following the expiration of the option, the Company recognized as revenue the&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;background:#ffffff;"&gt;$1.0&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;background:#ffffff;"&gt;&#160;million received in March 2020&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <plx:CollaborativeArrangementProfitSharePercentage
      contextRef="As_Of_11_30_2009_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_VnPnDdgZPUGYN2qTVnlGFA"
      decimals="2"
      id="Narr_Gz5CCPn5BUmtBRKjH5Ea_w"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.40</plx:CollaborativeArrangementProfitSharePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_10_31_2015_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_wwXeRF1bvke94qCksDkYng"
      decimals="-5"
      id="Narr_rfWo0D5n_kiEh15QepY15A"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_34oM70dfJ0WMj9Nuj8F7aA"
      decimals="-5"
      id="Narr_k0khXKBF3k6SXljosHCe0w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4300000</us-gaap:NotesPayableCurrent>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_XEZ5o0zCB0Gtu8ErPOcE8g"
      decimals="0"
      id="Narr_gLVttn19YkWDYNmC_fJLUw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-430000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_TypeOfArrangementAxis_plx_PfizerMember_IDSvFh3OYUGGC0HZKS46ww"
      decimals="-5"
      id="Narr_CLYl5voQx06frWXwltT8GA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4000000.0</us-gaap:RepaymentsOfNotesPayable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"
      decimals="-5"
      id="Narr_t3cZ3DfePUO3n_BPuEH9dg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"
      decimals="-5"
      id="Narr_quAg_unXBEyOkFYOkGfgFw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"
      decimals="-5"
      id="Narr_dv86yCv72kKxSnHO7AoexA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E05oHFrfN0aqAVF3Jpiy0g"
      decimals="-5"
      id="Narr_wIVZDrjO_kG2uh3Kaugzlg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_9zcjXo47CkaRE7ICQLJ5lA"
      decimals="2"
      id="Narr_VZguZPhZFU6OlYIYiwcU2w"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Wv2Wn8JO-UidVlRirC-2eA"
      decimals="2"
      id="Narr_G5B4EUN0HECmSsG1ZE2IGA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-TK4_F-2eE-xNEY8Kn76Sw"
      decimals="-5"
      id="Narr_wnpRq0quZkKXmvm8FydKBA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"
      decimals="-5"
      id="Narr_gde-AQW6JEK6LG4oAXLXqg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"
      decimals="-5"
      id="Narr_Y_hjwT2CY0Grvbia1mdf0g"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"
      decimals="-5"
      id="Narr_wR-rDXqyJki6uoeU7PfLhw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_1u4yKLFcbkmgvu9h2ioVmg"
      decimals="-5"
      id="Narr_GPpkKY3Shk-nDZ0Ra23eyw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_uD3PPat1MEmGE12PwGBQuQ"
      decimals="-5"
      id="Narr_UZHGu5whJE6ooeaFJyIJcQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">735000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_OfZWjQmIWECye0yv_boCTg"
      decimals="2"
      id="Narr_HBkOJbTpAUeUqSPu8esU6A"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember__EIHv6aGREKNgPGju82ldg"
      decimals="2"
      id="Narr_I74NyBH5NkKv2aAIodNUBQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg"
      decimals="-5"
      id="Narr_VS-LUMsDV0yexHAxGQA2gQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">50000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:PaymentInConsiderationForDevelopmentServicesPerformed
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw"
      decimals="-5"
      id="Narr_-1ri4GLZ0EOnLpQp-kAycg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">45000000.0</plx:PaymentInConsiderationForDevelopmentServicesPerformed>
    <plx:PaymentsInConnectionWithPerformanceOfAdditionalStudies
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw"
      decimals="-5"
      id="Narr_j7v0Z0sdrUevGpb9M5hwVA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">33600000</plx:PaymentsInConnectionWithPerformanceOfAdditionalStudies>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_edkPo6kkCEKum8_zvzpgYg"
      decimals="-5"
      id="Narr_LNbEjlJnCU2reGz3EwLElw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_sNb9nRVA7UyHg24tmVfidA"
      decimals="-5"
      id="Narr_1YvRUG-YbkK_elVjz_Wv6Q"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_8sWurxglp0KmGkrtptMYNg"
      decimals="-5"
      id="Narr_WFlyjZlPrE2TNxY0S1UjJg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lXNPFUZKE0-ciSdXsE7Vgw"
      decimals="-5"
      id="Narr_NSZLBDmXjEe-fcGdxiHsSQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_kaobUQfqT0ORdmCuBmiC7A"
      decimals="-5"
      id="Narr_vSedQP0gMUSP_XE7zBoAcA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_pRbaNlihhk-Mb6yk0UeU_A"
      decimals="-5"
      id="Narr_j5OLIQp7jUiH2JcL0glYPg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</us-gaap:ContractWithCustomerLiability>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_-UYZW6POc02nrytjPuH6oQ"
      decimals="-5"
      id="Narr_wD_ZD5Rvk0SfJNKDF3TNzw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_BR_WFR8ra7qdUO5CmDbCylH2Q"
      decimals="2"
      id="Narr_XvUgQbDFz02B5vrRyyhrQw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.25</plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase>
    <plx:NonRefundableFutureServicePayment
      contextRef="Duration_3_16_2020_To_3_16_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_e7awM79XzUyuSOlCW0jrbw"
      decimals="-5"
      id="Narr_KuctlX-OGEabn557fCbMRA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000000.0</plx:NonRefundableFutureServicePayment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_CflCHQ20lEaDx_EcPWhJ-Q"
      decimals="-5"
      id="Narr_L9IKhETzU0uLUFnWCnlOlQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_tBY-3Twyd02Zc_VbP2JZjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&lt;/b&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 18,237&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,659&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,768&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,714&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less &#x2013; accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,923)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,752)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&lt;/b&gt;Depreciation in respect of property and equipment totaled approximately $1.6&#160;million, $1.3&#160;million and $1.1&#160;million for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_bMooHRtMCkWiN_nTYOcuaA">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 18,237&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,659&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,768&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37,714&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less &#x2013; accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,923)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,752)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_3tCMe8rWHUGVmPE1Vg1qcQ"
      decimals="-3"
      id="Tc_XQaCZR3-K0uLYmvCLCCuQg_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">17422000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_lOmaI6ivKUCWZWzYSmOiTg"
      decimals="-3"
      id="Tc_baxcm1TgxU2xUb9nmvWNlQ_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">18237000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_Nn22_559OUKyhCIEmepH8Q"
      decimals="-3"
      id="Tc_IjcdV8JJgkiQLDsXhsiJhw_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2687000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_sXO4gqAD5E6e4X8EJdE_Aw"
      decimals="-3"
      id="Tc_NxZ45d_B1EG1BbOnz1flHQ_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2718000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vAaunvUCaUm5Awsb6iJhXQ"
      decimals="-3"
      id="Tc_HFmSRIDI3EicmypgSGYnQw_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16659000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DSmWGfJ_nUqGx4cINjjxwg"
      decimals="-3"
      id="Tc_jU0Oy0NyjkOCEOaT6b2lRg_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16759000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_-2SMTRj-FUmekzZYLQzf9w_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">36768000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_jRnkxWrBSUaR3yKx41A87w_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">37714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_d-t99FbFp0GURax2hUEMiQ_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">31923000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc__xbpGtggIUCwkG6E-5J_QQ_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">32752000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_qyt3p5tfu0u4-wTYyLOGlw_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4845000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_a55jhC2QJ0SpkMbdfaSLFw_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-5"
      id="Narr_dL9J8pv0GUulqxECopDm0g"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-5"
      id="Narr_POwyAZVQRkafP8ZywDbzDA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-5"
      id="Narr_5hI8bCQCeEO0xLayLo3MAA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1100000</us-gaap:Depreciation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_7Jb8hyqBr0eFyCdIWDIePw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;4&#160;- INVENTORIES&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Inventories at December&#160;31, 2020 and 2021 consisted of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&lt;/b&gt;During the&#160;years ended December&#160;31, 2019, 2020 and 2021, the Company recorded approximately $0.5&#160;million, $0.3&#160;million and $0.4&#160;million, respectively, for write-down of inventory under cost of goods sold.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_bmur8O0Ra0Kei2uOTCZPvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_54by2RkZA0uBxqj_lhDNEA_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3347000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_1sa-HniJb0mqP8_FUr2tdQ_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_wbogQDui80GlmdSQARynMw_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2887000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_AvLT81pTJUa-YrDgaP0QGA_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3262000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_hrxI4U0xoEm01pU3BwbQDA_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">6848000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_NSy5I8WwEEiH7b3bNCaafA_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">11526000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_yKNa-xsPdE-XLM55hXb-Vg_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">13082000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_3sJ-zUmgkUigfc1v66FsGg_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">17954000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-5"
      id="Narr_6eSBb1jMnkCuAwdjumhp_w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-5"
      id="Narr_9OD9fRRZVkePOhyU8OfiEg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">300000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-5"
      id="Narr_Bh3L-zARp0S8ULe4revcnw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">400000</us-gaap:InventoryWriteDown>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_n8KYcBBBxEeGuygynznDUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#x2019;s salary for each&#160;year employed) is recorded on the Company&#x2019;s balance sheets under &#x201c;Liability for employee rights upon retirement.&#x201d; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#x2019;s balance sheets under &#x201c;Funds in respect of employee rights upon retirement.&#x201d; These policies are the Company&#x2019;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2019, 2020 and 2021, the Company deposited approximately $143,000, $121,000 and $108,000, respectively, with insurance companies in connection with its severance payment obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#x2019;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#x2019;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#x201c;Contribution Plans&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The amounts of severance pay expenses were approximately $784,000, $885,000 and $990,000 for each of the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, of which approximately $642,000, $747,000 and $857,000 in the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively, were in respect of the Contribution Plans. Gain on amounts funded in respect of employee rights upon retirement totaled approximately $58,000, $28,000 and $100,000 for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company expects to contribute approximately $984,000 in the&#160;year ending December&#160;31, 2022 to insurance companies in connection with its severance liabilities for its operations for that&#160;year, approximately $868,000 of which will be contributed to one or more Contribution Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;During the five-year period following December&#160;31, 2021, the Company expects to pay future benefits to four employees upon each such employee&#x2019;s normal retirement age. The Company anticipates that the benefits payable will be approximately $72,000.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="0"
      id="Narr_yWhh_4PNk0KT3li3Ei1RMA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">143000</plx:EmployeeSeveranceObligationPayment>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="0"
      id="Narr_kHnj3TK2TUeYY2kOa6WZ2A"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">121000</plx:EmployeeSeveranceObligationPayment>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="0"
      id="Narr_QKwsl7M1iUa2rqHgaasAYQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">108000</plx:EmployeeSeveranceObligationPayment>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="0"
      id="Narr_9DnJIaDuJEelfunB5mXQiw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">784000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="0"
      id="Narr_8NEJD6zr4UeCPvhp95PF7g"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">885000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="0"
      id="Narr_Zq8Xm0IRGU2FvN1aYbD5lw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">990000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="0"
      id="Narr_A3AqXrghlE2r528QiP8HyA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">642000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="0"
      id="Narr_0_XWbmV05UCW2MjiswGTRg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">747000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="0"
      id="Narr_MQUgiSV5Gk60KLTU1RxQKg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">857000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="0"
      id="Narr_J8LsaQh9yUSEDF-NI2c34w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">58000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="0"
      id="Narr_Y4rKmYikP0uJnypX2j7IuQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="0"
      id="Narr_gA2ESE-07E-MD6NaqnoCKg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">100000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_A2agnc-nXUWF5xH0NH47Bw"
      decimals="0"
      id="Narr_jxxpLr6xj0KU1shRbEMZPw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">984000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2021_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_QJLt9peuMUKwXJpzAoU8Lg"
      decimals="0"
      id="Narr_4lB-18Z2cE-nimWlGs4D3w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">868000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="INF"
      id="Narr_2Vqy6qcWpkGQbU31RIugwA"
      unitRef="Unit_Standard_employee_BN18wiEo1UyImbahotyXDw">4</plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears>
    <plx:BenefitsPayableDuringNextFiveYears
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="0"
      id="Narr_C5Tf_ouceUaKW0grcgvCNQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">72000</plx:BenefitsPayableDuringNextFiveYears>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_15GEU8Xgd0m79do9zZnfFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;6&#160;- COMMITMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;Royalty Commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is obligated to pay royalties to NATI on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of the applicable funding arrangements, royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, 100%&lt;span style="white-space:pre-wrap;"&gt; of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $1.4&#160;million, $911,000 and $1.2&#160;million during the years ended December&#160;31, 2019, 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;At December&#160;31, 2020 and 2021, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $39.8&#160;million and $38.6&#160;million, respectively (without interest, assuming 100% of the funds are payable).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Subcontracting Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2021, total commitments under said agreements were approximately $0.9&#160;million.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <plx:RoyaltiesOnSaleOfProducts
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_2cmmFTV-8k-KecBEkLzBtw"
      decimals="2"
      id="Narr_aLfY-gOkQ0SGYzK_mCYsRA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.03</plx:RoyaltiesOnSaleOfProducts>
    <plx:RoyaltiesOnSaleOfProducts
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_dh4fOPoiskqOmGCaGTu_CQ"
      decimals="2"
      id="Narr_sgAPOSpikk6lhY2dWUbRVg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.06</plx:RoyaltiesOnSaleOfProducts>
    <plx:PercentageOfRoyaltiesToGrantReceived
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_BNmP4P54wkaBDpMrzeAVfA"
      decimals="2"
      id="Narr_1J0b3rTFW0qMKy33eCKwdQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1</plx:PercentageOfRoyaltiesToGrantReceived>
    <plx:PercentageOfRoyaltiesToGrantReceived
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_Wf6RC2H560WbAcJnDFtApw"
      decimals="2"
      id="Narr_gaAonHM6NU6EkQ8KRMvLwA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1</plx:PercentageOfRoyaltiesToGrantReceived>
    <plx:PercentageOfRoyaltiesToGrantReceived
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__0_D2FCWxk2p5kjrroefXw"
      decimals="2"
      id="Narr_vQ0ew9sm1E6JA4WGQMXqcw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1</plx:PercentageOfRoyaltiesToGrantReceived>
    <plx:PercentageOfRoyaltiesToGrantReceived
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OutsideOfIsraelMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_eeNvck2ATEWfgpCZeTLqVw"
      decimals="2"
      id="Narr_4Ddyi4rsb0ai88QUGYkyGw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">3</plx:PercentageOfRoyaltiesToGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_UATsTNG3GEyx6u5IsMGjaw"
      decimals="-5"
      id="Narr_MBAjH5KvJEC8J3K0juvi3w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_xaWyKyysfE-N-Odg4q5ilQ"
      decimals="0"
      id="Narr_hapZyCqtSEuydII1JbxErQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">911000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_H9sLbSYtM0qsnN-27mpO9Q"
      decimals="-5"
      id="Narr_q_KYxXj350ymoGlRKtWUaA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1200000</us-gaap:RoyaltyExpense>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_Wf6RC2H560WbAcJnDFtApw"
      decimals="-5"
      id="Narr_zmC81LMeFkq-fAS8_tOr_w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">39800000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__0_D2FCWxk2p5kjrroefXw"
      decimals="-5"
      id="Narr_lUST-BAEbEWz-C6IkFyHhg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38600000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <plx:CommitmentAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_1SnkfDBBdEa_ScKv2fZZOg"
      decimals="-5"
      id="Narr_gWIfQnaE9kWBkm6kGI_ejQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">900000</plx:CommitmentAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb__LjrRUfmYkOnlB5nF45OEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 7 - OPERATING LEASES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the option to extend certain of such agreements on one additional occasion for an additional five-year period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by 7.5%-10% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2021, the Company provided bank guarantees of approximately $496,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the years ended December&#160;31, 2019, 2020 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 853&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 848&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Present value of  operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_GzPNcmTbskGHXrbj_NpWwg">true</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="INF"
      id="Narr_S4B1ooTj0EGMaWqIiK-9gg"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">1</plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      id="Narr_ZE_w1OGdIUOyZuZwzo3yBA">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_-QuyUNmrLkKtu3HAPB64rQ"
      decimals="3"
      id="Narr_eTOeRJDvvkuD06zWBUrj0A"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_TGSo8Z2q4UakwLgn9fGO-g"
      decimals="2"
      id="Narr_N8cEUsaMS0-y2TT1uH5OuA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.10</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="0"
      id="Narr_A0R9-9cxk0iW3IPJ1mvJsA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">496000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_KBRPKEthI0WlOxB3RgGCwg"
      id="Narr_IcNxbgG-hUGosTupk_Bn6g">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_bwXIokJoAEOmGjojuMMcdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the years ended December&#160;31, 2019, 2020 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_oFtQlIlgSEiSQLcw0ZJWdA_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1219000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_WkGKeXHpeEus-Aj4mus4Tg_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1382000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_z6G2GvZ_eE6EVZH9BXvUuA_3_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1632000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_EQviyuIYx0yFvngBaI6XCQ_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1329000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_RlJbNq6g7kCkdmWmFJPsLA_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1289000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_gkeLl2EDn0OU9hAKzUQa4w_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1391000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA"
      id="Tc_EVl31LdplUGbM6mbWPrW4A_5_3">P10Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      id="Tc_tw45Doct1Ea4IMVuK2IIyw_5_6">P9Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      id="Tc_8dP48qTZpk63j_PKQZqPcg_5_9">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2019_8_DQ8fTSjEOlEfZsfpS5RA"
      decimals="4"
      id="Tc_3V2-GXsHeEO98BecluLJmg_6_3"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.127</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="4"
      id="Tc_0H0UEcXUCEWmUT3_AVY91g_6_6"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.127</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="4"
      id="Tc_rEoXoD5gE0muXS6042Kyqw_6_9"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_O3O7zCCMP0SMN4LQpeQ7UA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 853&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 848&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Present value of  operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_ferQiJuzXUqMkLP05woaeQ_2_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1207000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_51aa7BdbvkSRi-AzadK4TQ_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1025000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_OVLyGq3pMEu4yJ6_dVznbw_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">872000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_JalRO_D44UaoFxc44pbw4g_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">853000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_w_bXYCEuEUGPjxF06N5rHw_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">848000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_mZZBgw74XUW2ieMGMwWJqw_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4528000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_vvN30INWzUaT6k5rom_3XA_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9333000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_qH8FRIUrNk-xm03Mv-W6xQ_9_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3750000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_-NaYWczdkUmuXgSRbQetWg_10_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">5583000</us-gaap:OperatingLeaseLiability>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_bB-DZX1nSUu-RPn0DF9iTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 8 - REVENUE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;During the year ended December&#160;31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_6XHq4pb4E06pNsyHNjj6MQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 38,827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_DKnjcKFjmUa1np2ibVNGnw"
      decimals="-3"
      id="Tc_WAxozEyon02rZe-cauE7Ww_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">6722000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_M2UVRoW7sUyno7XdY9wpow"
      decimals="-3"
      id="Tc_ONtFQUYm00GzEEcrsRMwhw_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8105000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GBgSGz6h9E-afGEP8417zg"
      decimals="-3"
      id="Tc_zUHPMnyzeEeVlmrSq5unIA_3_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10160000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_EbYkt392okObFSFj3u7OvA"
      decimals="-3"
      id="Tc_Irw2YwlLDkeMCtZXaieivA_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9144000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_ZsU_oN8S5kKt5laU31Nl6g"
      decimals="-3"
      id="Tc_3gHIBQ0DU0-zxSNH5lFLNQ_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_3pw1DQ5CWkST8Aba5KMVVA"
      decimals="-3"
      id="Tc_Jfs4NeFlhEWAStIQ0BKNhg_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_OZABD-Gv0UisMJYQyGNklQ"
      decimals="-3"
      id="Tc_6Cwo294NsU6SXCjhPCtcKA_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">131000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_VZS1TwgN7EWajbs4tfYp1A"
      decimals="-3"
      id="Tc_vilV6cFHgEaWa_sAqfUS6A_5_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">189000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_HmzXf1hdDkK4__n1knviHA"
      decimals="-3"
      id="Tc_bmKY_X0AdkujCP-ACiU03A_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">15866000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_8B8k4Z958U29kvLCfB2P5g"
      decimals="-3"
      id="Tc_a4molZDSAECVkQciiPIDAA_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16236000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_tr53Np7eY0-Ae6xS_WOJOA"
      decimals="-3"
      id="Tc__nWjiPYzCkSTdnSv0woQYw_6_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16749000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_ePa1ql7mhEGcbcjaQMVPmw"
      decimals="-3"
      id="Tc_e64DcXCuDEG5VfEiB_ryFQ_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">38827000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_0sZc2uezPU2o1oMeQcRe9g"
      decimals="-3"
      id="Tc_UnpBeEMpEkajAEEulotLrg_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">46662000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_T30NLjS9gUG6T5IRwHFs3Q"
      decimals="-3"
      id="Tc_9rxtUsVsKEWaYM6xbU3uMg_7_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">21601000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_KyuNtueviUGlU8z74VbRMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;9&#160;- SHARE CAPITAL&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;Rights of the Company&#x2019;s Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s Common Stock is listed on the NYSE American and on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Reverse stock split&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On December&#160;9, 2019, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Certificate of Incorporation, as amended, to, among other things, effect a reverse stock split at a ratio of &lt;span style="-sec-ix-hidden:Hidden_bjDxAD1NEUOlk5FvFvWGtA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-for-ten&lt;/span&gt;&lt;/span&gt;. The ratio was determined by the Company&#x2019;s Board of Directors on December&#160;5, 2019 and the reverse stock split became effective at midnight December&#160;19, 2019. All share and per share amounts included in the consolidated financial statements have been adjusted retrospectively to reflect the effect of the reverse stock split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Stock based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to 5,725,171 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;&lt;span style="white-space:pre-wrap;"&gt;102 and 102A of the Israeli Income Tax Ordinance. Each option grant made to an Israeli citizen  is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#x2019;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Israeli Income Tax Ordinance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2021, 1,786,256 shares of Common Stock remain available for grant under the Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;For purposes of determining the fair value of the options and restricted stock unit granted to employees and non-employees, the Company&#x2019;s management uses the fair value of the Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the three years ended December&#160;31, 2021, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Options and restricted stock units granted to employees:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;a)&#160;&#160;&#160;&#160;Below is a table summarizing all of the options and restricted stock grants to employees during the three years ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;No. of options or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;restricted stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vesting&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;grant (U.S.&#160;dollars&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year of grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;160,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;80,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;196,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;760,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;1,893&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;129,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;694,073&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;122,656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;1.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December&#160;31, 2021 (a portion of such grants appear in the table above):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;In June 2019, the Company granted to its Chief Executive Officer 10-year options to purchase, in the aggregate, 160,000 shares of Common Stock under the Plan. The options have an exercise price equal to $4.69 per share, vest over a four-year period in 16 equal quarterly increments. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $449,000 based on the following weighted average assumptions: share price equal to $4.69; dividend yield of 0%; expected volatility of 65.3%; risk-free interest rates of 1.8%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;In September 2019, the Company granted to its Chief Financial Officer 10-year options to purchase, in the aggregate, 80,000 shares of Common Stock under the Plan. The options have an exercise price equal to $2.00 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option pricing model to be approximately $97,000 based on the following weighted average assumptions: share price equal to $2.00; dividend yield of 0%; expected volatility of 66.48%; risk-free interest rates of 1.695%; and expected life of six years. In addition, contingent upon certain conditions, the chief financial officer is entitled to a grant of restricted stock units with an aggregate value of $100,000, on an annual basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;On August&#160;11, 2020, the Company granted the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:90pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;I.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;447,927 shares of restricted Common Stock to its President and Chief Executive Officer under the Plan. The restricted shares vest over a four-year period in 16 equal quarterly increments and &lt;span style="background:#ffffff;"&gt;are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control&lt;/span&gt;, and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $1.6&#160;million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:90pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;II.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;246,146 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. Of the shares, 27,855 shares vested on September&#160;22, 2020. The remaining 218,291 of the shares vest in 16&#160;equal, quarterly increments over a four-year period, commencing upon the date of grant and are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $900,000.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:90pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;III.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;10-year&#160;options to purchase&#160;122,656&#160;shares of Common Stock to the Company&#x2019;s Sr. Vice President, Operations under the Plan. The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President, Operations are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, and are subject to certain other terms and conditions. The Company&#x2019;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#x2019;s Sr. Vice President, Operations to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $300,000 based on the following weighted average assumptions: share price equal to $3.59; dividend yield of 0%; expected volatility of 80.51%; risk-free interest rate of&#160;0.365%; and expected life of six years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;On July&#160;5, 2020, the Company granted 10-year options to purchase 129,771 shares of Common Stock to the Company&#x2019;s Vice President, Research and Development under the Plan. The options have an exercise price equal to $3.73 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the Vice President, Research and Development is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $329,000 based on the following weighted average assumptions: share price equal to $3.73; dividend yield of 0%; expected volatility of 80.60%; risk-free interest rate of 0.395%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;On June 7, 2020, the Company granted the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:90pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;I.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;10-year options to purchase 196,995 shares of Common Stock to the Company&#x2019;s Sr. Vice President and Chief Development Officer under the Plan. The options have an exercise price equal to $3.59 per share and vest over a four-year period in 16&#160;equal quarterly increments. Vesting of the options granted to the Sr. Vice President and Chief Development Officer are subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company&#x2019;s President and Chief Executive Officer may, in his discretion, grant options to the Company&#x2019;s Sr. Vice President and Chief Development Officer to purchase additional shares if the Company effects certain transactions in which it issues additional shares of Common Stock. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $500,000 based on the following weighted average assumptions: share price equal to $3.59; dividend yield of 0%; expected volatility of 80.43%; risk-free interest rate of&#160;0.59%; and expected life of six years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:90pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;II.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;10-year options to purchase 760,311 shares of Common Stock, in the aggregate, to certain of the Company&#x2019;s employees under the Plan. The options granted have an exercise price equal to $3.66 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 108pt;"&gt;option-pricing model to be approximately $1.9&#160;million based on the following weighted average assumptions: share price equal to $3.66; dividend yield of 0%; expected volatility of 80.49%; risk-free interest rate of&#160;0.45%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;On July&#160;25, 2021, the Company granted to a new employee, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 50,000 shares of Common Stock under the Plan. The options have an exercise price equal to $1.57 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $55,000 based on the following weighted average assumptions: share price equal to $1.57; dividend yield of 0%; expected volatility of 84.30%; risk-free interest rate of&#160;0.88%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;b)&#160;&#160;&#160;&#160;The total unrecognized compensation cost of employee stock options at December&#160;31, 2021 is approximately $1.7&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.9&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;During the three years ended December 31, 2021, there were no exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Options granted to directors:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;On February&#160;3, 2020, the Company granted 10-year options to purchase 240,000 shares of Common Stock to the Chairman of the Company&#x2019;s Board of Directors under the Plan. The options have an exercise price equal to $3.70 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the Chairman of the Board is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $593,000 based on the following weighted average assumptions: share price equal to $3.70; dividend yield of 0%; expected volatility of 76.91%; risk-free interest rate of 1.4%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;On January&#160;20, 2020, the Company granted 10-year options to purchase a total of 200,000 shares of Common Stock to five of the Company&#x2019;s independent directors under the Plan. The options have an exercise price equal to $3.55 per share and vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the directors is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $475,000 based on the following weighted average assumptions: share price equal to $3.55; dividend yield of 0%; expected volatility of 76.62%; risk-free interest rate of 1.685%; and expected life of six years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;3.&#160;&#160;&#160;&#160;A summary of share option plans, and related information, under all of the Company&#x2019;s equity incentive plans for the&#160;year ended December&#160;31, 2021, and the effect of share-based compensation on the statement of operations for the&#160;years ended December&#160;31, 2019, 2020 and 2021, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;a)&#160;&#160;&#160;&#160;Options granted to employees:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,087,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited and expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 318,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,819,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 961,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;b)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Restricted stock granted to employees:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Restricted Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;624,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;166,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non vested at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;458,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;c)&#160;&#160;&#160;&#160;Options granted to consultants, directors, and other service providers:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 464,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 192,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;d)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The following tables summarize information concerning outstanding and exercisable options as of December 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:58.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;end&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.57 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.55 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.06&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.59 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319,651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 112,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.66 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 641,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.70 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.73 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$4.69 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.10 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 215,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.60 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$17.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,259,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,154,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;*&lt;span style="color:#231f20;"&gt; As of December&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#231f20;"&gt;31, 2021, all outstanding, exercisable&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231f20;"&gt;options&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt; had exercise prices that exceed the fair market value of the Common Stock as of such date&lt;/span&gt;&lt;span style="color:#231f20;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;e)&#160;&#160;&#160;&#160;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 269&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,036&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Private and 144A Offerings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;18, 2020, the Company completed a private placement to certain existing and new institutional and other accredited investors (the &#x201c;Purchasers&#x201d;) in reliance on the exemption from registration set forth in Section&#160;4(2) of the Securities Act. The Company sold approximately 17.6&#160;million unregistered shares of Common Stock to the Purchasers at a price per share of $2.485. The Company generated gross proceeds equal to approximately $43.7&#160;million in the Private Placement. Each share of Common Stock issued was accompanied by a warrant to purchase one share of Common Stock at an exercise price equal to $2.36. &lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2020&lt;/span&gt;, the Company issued 200,000 shares of Common Stock in connection with the cash exercise of a warrant issued in the transaction and generated proceeds equal to $472,000 from such exercises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On June 7, 2021, the Company issued 173,816 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 2,816,901 shares of Common Stock issued in the transaction. The Company did not generate any proceeds from the cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;On July&#160;2, 2021, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to 3.0% of the aggregate gross proceeds from the ATM Shares sold. As of December&#160;31, 2021, the Company sold no ATM Shares under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December 31, 2021, but prior to the termination of the BofA Agreement, the Company sold 1,867,552 shares of Common Stock under the BofA Agreement. The Company generated gross proceeds equal to approximately $8.8&#160;million in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Public Offering&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of Common Stock in an underwritten public offering at a price to the public of $4.60 per share for gross proceeds of approximately $40.2&#160;million before deducting the underwriting discount and estimated expenses of the offering. The above included the exercise of the underwriters&#x2019; over-allotment option to purchase 1,141,304 shares of Common Stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <plx:CommonStockNumberOfVotingRights
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="INF"
      id="Narr_rXKj9Qi8Rk-kLcblA-c0uA"
      unitRef="Unit_Standard_Vote_MK3JtZwR6kijibu1mfvLvg">1</plx:CommonStockNumberOfVotingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_JcT2p0tnbUqhmhTyDLIICw"
      decimals="0"
      id="Narr_I42gjmTyt0-IkW9RhaBcSQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">5725171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="0"
      id="Narr_3wIocETWo0W_f9BIySjLlQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1786256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_bWfhJoDwEU2hRstj_AZZqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;No. of options or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;restricted stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vesting&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;grant (U.S.&#160;dollars&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year of grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;160,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;80,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;196,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;760,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;1,893&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;129,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;694,073&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;122,656&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3.59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;1.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0.05pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw"
      decimals="INF"
      id="Tc_6rHcn90F30ei0Nk7bjxL-w_4_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw"
      decimals="2"
      id="Tc_mWdh69YR_ES6XctO5KXbog_4_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw"
      id="Tc_oUVEL-s7KU6DDyXUy3EVpg_4_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_RzJRTxQNVUyCZrS9EnncRA"
      decimals="-3"
      id="Tc_kwGkMV8h-0qB1Jj4TxnZhw_4_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">449000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw"
      id="Tc_H3yxy9l5OU6z_PZpby0xpg_4_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA"
      decimals="INF"
      id="Tc_D4D0sIib-EKSWhmr1U863w_5_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA"
      decimals="2"
      id="Tc_y8ac_YRWHkCOWAHvdOZDiA_5_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA"
      id="Tc_7jHujwWrUkS0AYlWf9I6cQ_5_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_Pgw8cC8LGkmkSDN1ikOZrg"
      decimals="-3"
      id="Tc_2CZb-Tz7w0K3S6SgAsSN5A_5_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">97000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_nZzzA7uHGkWy5NhQi0iXaA"
      id="Tc_kHOOnSEzqkeKFKkgm48dew_5_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA"
      decimals="INF"
      id="Tc_KmdDdkF6ZU2RDeeEmnsaGg_6_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">196995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA"
      decimals="2"
      id="Tc_-6P3alzTbEC-_BbJo7Oo2Q_6_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA"
      id="Tc_cQoPWedz70-zSoHfraK6fw_6_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_z5fjaYB3Vk6_8J6_3XOy1w"
      decimals="-3"
      id="Tc_5Fb9Faai00iGrbgb8-VxEw_6_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">482000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59OneMember_PcoJmz80IkOGJJbU2P_6QA"
      id="Tc_J_-BcGr3qk-IxcqDBc4v8g_6_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ"
      decimals="INF"
      id="Tc_PND5IfSzS06QeHne_fjBMQ_7_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">760311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ"
      decimals="2"
      id="Tc_aZ8Ie5gjn0GeeoxJLXw6NQ_7_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ"
      id="Tc_OD_nkzjFiEmz4agncRg2Rg_7_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_N12CUuFMQkiGURk7lpa5rA"
      decimals="-3"
      id="Tc_TotbdKmqTUyacupCXVU7RA_7_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1893000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_qbdulJhEl06Q96DC8WmkUQ"
      id="Tc_eJzd8g6keEWDZLfEovuDfg_7_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw"
      decimals="INF"
      id="Tc_nCAXi_iTN0uIN73fmF6GUw_8_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">129771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw"
      decimals="2"
      id="Tc_AtTd458vXEmvZPYIFw_9Kw_8_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw"
      id="Tc_mwGfFpO_j0mqDoR4lt4cUg_8_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_14Iut1EZ1UWck-v0gKCugw"
      decimals="-3"
      id="Tc_Zlt02sIlBUqLg5FVLsGGdA_8_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">329000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_PvT28sUKpkG4ZCV6zXVRbw"
      id="Tc_sYcYK8GcTkuGQDS9Kevk8w_8_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q"
      decimals="INF"
      id="Tc_4AtJzRR5aUivny6jFmZmKg_9_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">694073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q"
      id="Tc_gCX34f_tF06J_ZP_GWGldA_9_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_sXjLs1UWbk-sYqhuiYE3qg"
      decimals="-3"
      id="Tc_H-xFCB3qjUWkR89sRTUjfw_9_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2492000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_NoExercisePriceMember_tfFiQJxjN0meXBrWKZEI0Q"
      id="Tc_sxgadNSvTUeRGfClRwAWJw_9_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A"
      decimals="INF"
      id="Tc_AkmHGE8H90Ge-cyGOifbpA_10_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">122656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A"
      decimals="2"
      id="Tc_OfBL_9s1cUynUV3EiHNWrw_10_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A"
      id="Tc_g95KoZpfWUa9MgSnetZL6A_10_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_7pabyZcaV0G2hX0lA_wo6Q"
      decimals="-3"
      id="Tc_Jla91kOhL0is1QQ5ruEMFw_10_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">299000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59TwoMember_K0X2cZjHBUatpCuVFUjM5A"
      id="Tc_sq4YVOqJYUWqp6AJJGzwSQ_10_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      decimals="INF"
      id="Tc_KHN4zj8-hkuyHLNxI57BRA_11_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      decimals="2"
      id="Tc_mrsjbvfKOk2a_bWHWM41lg_11_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      id="Tc_y4w4nuheIUSVZjJ8h2qVIQ_11_7">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ"
      decimals="-3"
      id="Tc_58r6NNh2HUerBGb-Ns-7ug_11_10"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">55000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      id="Tc__CTXWMkvakeJyUc39efNqA_11_12">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      id="Narr_UiloDaQIwUGsUD3bPKB88A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      decimals="INF"
      id="Narr_XjE9FP5VCkSEsbzdiNsZ3w"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg"
      decimals="2"
      id="Narr_f5S2EclrhESlhwpzU7z_JQ"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      id="Narr_oskFULVPKEmtgNuZNA3qOw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      decimals="INF"
      id="Narr_074Ux0ChHk-ViFEcoUiZ5w"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg"
      decimals="0"
      id="Narr_usqDohRTvEGNiiLQo4s6FQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">449000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_zgnC2ukE-P9IrVGqyCcg"
      decimals="2"
      id="Narr_H3iws1NHT0CVxlREm745_A"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      decimals="2"
      id="Narr_Si8fEi_w20-kY0guW7LdNA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      decimals="3"
      id="Narr_F86Wmy0GFUWs7z2VfJN-4A"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      decimals="3"
      id="Narr_TM3qH91fykaoduLnbSOU8Q"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_1_2019_To_6_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xWQx34CfG0qIkDuLW8rH7A"
      id="Narr_FmDRiYLVtU6IFSRlnOI9UA">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      id="Narr_SZfzdpkQ5U6MlNpdP2Y4kA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      decimals="0"
      id="Narr_O5X5Tq-hwE2yzWa8ooDWoA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g"
      decimals="2"
      id="Narr_5qVCbuO9AEWYJ1672Ytvlw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      id="Narr_shp8G6Y4wUChh0G12mubog">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      decimals="INF"
      id="Narr_sgonKGGfHUaxR3pmYGWoAg"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g"
      decimals="0"
      id="Narr_5Stm_GCkDEm7f81TdoYqUw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">97000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ICGY4c3M0E6nTB_6j9FM5g"
      decimals="2"
      id="Narr_K3D4OPcc-E2XByylhFX79A"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      decimals="2"
      id="Narr_DzPpMWwCKEiZa_rlQ0V0yw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      decimals="4"
      id="Narr_DUECFB-l3kmFrR0DicVkEA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.6648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      decimals="5"
      id="Narr_WMZlRZEIyE-IFhiadnkFnA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.01695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M_CR5rz4JkatTUpjXIO6gg"
      id="Narr_TpXeZOvhVUuV84AwV5Rtzw">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue
      contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iKUFwyX_yU2n3k92ORA_uw"
      decimals="0"
      id="Narr_bnZpCFo9OUqAcPiib2Edyw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">100000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg"
      decimals="0"
      id="Narr_S3_j-9Z9DE6wK3rshPVF8g"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">447927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg"
      id="Narr_haFVA-Ua9E-Qe6lbf8IIaA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_wQ9hH4j35kedUyaGLYzeQg"
      decimals="INF"
      id="Narr_a75hRMCGBkeJx1cTubxLxw"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_VF0OGmePw0eTywhYkjcUPg"
      decimals="-5"
      id="Narr_K6UilgE8nk6qfpUGggL0fA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1600000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA"
      decimals="0"
      id="Narr_H2ruHNJkEUWXFyEcwEgTJg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">246146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_9_22_2020_To_9_22_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_M8ski3P7vkqI4q67BPAWeQ"
      decimals="0"
      id="Narr_W9skiDb76EyMaTHZk0a6-g"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">27855</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_mmHdbT-en0uuXTv2hCvVNg"
      decimals="0"
      id="Narr_6bbH23qJX0-GYUqW3H6j6A"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">218291</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA"
      decimals="INF"
      id="Narr_qI4Ltgwg6Eaqs8giG6of8A"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_rLPogd8CG0yyutYBXaV2SA"
      id="Narr_Lowr2D3vrkieYm8_o99tJg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_mmHdbT-en0uuXTv2hCvVNg"
      decimals="0"
      id="Narr_22elLf9MEUWGNXUJa2Cw0A"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      id="Narr_0FaEZyviJkiWt93G_aqDzw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      decimals="INF"
      id="Narr_EGZrrW2_IE62pmcdTi0kUw"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">122656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg"
      decimals="2"
      id="Narr_ZeAZOugfak63oI2bZEDzlw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      id="Narr_ptrLFeber0KAw-499JHMXg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      decimals="INF"
      id="Narr_LSFDZX0CxUWqDHgEriV94w"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg"
      decimals="0"
      id="Narr_OwEwPCiTUUihphonbnPW2Q"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">300000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_64QZw4CWakaTN5ATJNXaRg"
      decimals="2"
      id="Narr_LTPEK7_BSEi6GamhWJmUKA"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      decimals="2"
      id="Narr_o8g1T8bhekWO0iQz05zn0g"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      decimals="4"
      id="Narr_zerdtOs7d0irjnsrkkE1Kg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.8051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      decimals="5"
      id="Narr_mQB1c5YsbkqupgVT9cVwnw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.00365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_8_11_2020_To_8_11_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentOperationsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bovIYkC-E0S5U74xI44qZw"
      id="Narr_uRfvxtxI30-d4f2drIQ5Eg">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      id="Narr_zgNrTlj1L0Ckr6vSVBFaLQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      decimals="INF"
      id="Narr_MDEQVquA-0SfnX2hL8qPbQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">129771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA"
      decimals="2"
      id="Narr_XBvUE1X8pk-qKuRM_IdTyw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      id="Narr_sXd7WFJdTkyMBh1g2HCR3g">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      decimals="INF"
      id="Narr_cO8YK6-AWEm9CdBXbtuIyA"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA"
      decimals="0"
      id="Narr_-xC1CQGDH06ZkFThryPnbQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">329000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JJCter15QkSVganF6T_rmA"
      decimals="2"
      id="Narr_ipQ6xw8uuUqeXeYQz__Mig"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      decimals="2"
      id="Narr_H06_XTPshUq3fF2bl1kwMw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      decimals="4"
      id="Narr_JA9-UqnyQUiw4xbvLIyhsw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.8060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      decimals="5"
      id="Narr_hB_5Zd3g4U6VOl8PJjWPNA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.00395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_5_2020_To_7_5_2020_srt_TitleOfIndividualAxis_plx_VicePresidentResearchAndDevelopmentMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SxlSsOJapEmUpQWP48L3Rw"
      id="Narr_-X3BHHJVw0S5NvjIKWWvug">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      id="Narr_qvoaDj-PyEiN4Lziey2_jg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      decimals="INF"
      id="Narr_0wpAH6pzwE6Ncn6JC7dW1w"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">196995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ"
      decimals="2"
      id="Narr_tuBYbPdbkECWNKPFieIrRw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      id="Narr_gBWbgjSsnU-nLjY-_wzT5A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      decimals="INF"
      id="Narr_WfpGw9e2bEeyNt8u0o3kGA"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ"
      decimals="0"
      id="Narr_wAaeelLeoUadU-c0CVfdnA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">500000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFUCye3KbUuEd43SW8p1SQ"
      decimals="2"
      id="Narr_vzn-CF3R3kqbxhim-7a-pA"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      decimals="2"
      id="Narr_aESJSA7kzE2yJoyCCUISSw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      decimals="4"
      id="Narr_coHONNTkkkalY7D8Yt3rSw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.8043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      decimals="4"
      id="Narr_wsCpLEQOSEutS45T8G1tSg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_078iypH_9k29SiVgCve_JQ"
      id="Narr_gDuAofSa-E2yHq5bAChkQQ">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      id="Narr_0LstWmKk7EWQ5k4UeceZnw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      decimals="INF"
      id="Narr_KA9_TTHARECtZf-jHUSoCg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">760311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw"
      decimals="2"
      id="Narr_Mwi7Ak2WuE2oobRzpvpbPg"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      id="Narr_XiukU4qhIEqj5F0OPbsGhQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      decimals="INF"
      id="Narr_dop5At0R5UeoAmRhdBC16A"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw"
      decimals="-5"
      id="Narr_mXHhvVuyXEClu4l6lNKgtA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZSXjUCZnhE-YCE9oJpGrcw"
      decimals="2"
      id="Narr_c4DyGKhd3kOgatIZlrty_A"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      decimals="2"
      id="Narr_vynQRq_z4EGlHYwaF1BcJw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      decimals="4"
      id="Narr_DBPl3KjFpEqBTA3lijcP_Q"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.8049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      decimals="4"
      id="Narr_GDRhWk_Fu0yw68n9Tdzxzg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_TitleOfIndividualAxis_plx_CertainEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hy7z9_KsSk2h_gaxenjDMA"
      id="Narr_ggtrmyVrCU6PnxyMvyn4Ww">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      id="Narr_9l3sMQOxukmqvT_u04Og8g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      decimals="INF"
      id="Narr_YJE75F9iuUOghE5DUFtL4A"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ"
      decimals="2"
      id="Narr_DZ2uCbwFBEOFF6DXhvS3lg"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      id="Narr_kR7R8EpuBEKuSuP4MfnJXA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      decimals="INF"
      id="Narr_1FzjC4ANa0ir9Xr3FGaGAw"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ"
      decimals="0"
      id="Narr_eZizp4cm6UWC__X503NjsQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">55000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a8vh99Tvy0SxsEhG4TX4DQ"
      decimals="2"
      id="Narr_ovLelHT60UyCXd-pArrR3A"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      decimals="2"
      id="Narr_EezNP9eiiUmtVwIfA0fOmw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      decimals="4"
      id="Narr_PSVtKQKQik-LlFEKKwRa0Q"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.8430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      decimals="4"
      id="Narr_uRAIuGZpMkqMtv81jU77Ug"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg"
      id="Narr_8R7zH43jyEuQM0R8gr6szw">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-5"
      id="Narr_sg4luUzTw061uzoDzAKSrQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Narr_t7ogRQCo-EaZfrjUBfVQ3Q">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2021_G69dnyWX7ESLQI7Zi6Aa7Q"
      decimals="INF"
      id="Narr_e37CWWL2BEy1wZ0_f0SgVg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      id="Narr_vdNjIkTywUK9dlRSNNVA8Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      decimals="INF"
      id="Narr_lJQqQZmGSEW2j-a_E_hPjA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw"
      decimals="2"
      id="Narr_1AIaMeXtREaoAhMO5RYtEw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      id="Narr_wtCs4p3w40-ap-2rmOwNxw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      decimals="INF"
      id="Narr_MQRrXr9L0ESXagwMGVfRuw"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw"
      decimals="0"
      id="Narr_ozOeNu766km-9VgmWNJdmQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">593000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kyZjFGnN20OKptyvdinkQw"
      decimals="2"
      id="Narr_n2_gNNuj6UuoNcRfi2mkeg"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      decimals="2"
      id="Narr_MWEojIkBE0asaHcvZGbLjQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      decimals="4"
      id="Narr_X5e6ZYrk4E6xiJkII1mmBg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.7691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      decimals="3"
      id="Narr_2oeOWO1GiE-w6Wa3TQkacA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_2_3_2020_To_2_3_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JX4BjEQ4pECpSxLgJI-0kQ"
      id="Narr_l4L5WleICkeAw5HC5K0uag">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      id="Narr_Ic111ZbgVUuvnA5Z43Q14g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      decimals="INF"
      id="Narr_6aRdO3voVkek1sE17bV95g"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <plx:NumberOfDirectors
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      decimals="INF"
      id="Narr_B-0Yv-guiUqrraUxj2ikUQ"
      unitRef="Unit_Standard_director_yAcLdDF3PE-23pSbigEjyQ">5</plx:NumberOfDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g"
      decimals="2"
      id="Narr_m_1tQ8fNOUiXb44bQLEeCA"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      id="Narr_VUvUmuXfzkmt0-cfqHmgmg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      decimals="INF"
      id="Narr_NKVSuZI8N0esQgkAqVXgpw"
      unitRef="Unit_Standard_item_rx5NSxabyUCcVBIIgEufjg">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g"
      decimals="0"
      id="Narr_CTD3nhvfL0qQEv83Fm2tYg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">475000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_yH2AjgB230uSk578pe8v0g"
      decimals="2"
      id="Narr_S7zEiHpJb0a_ZvRX4uwvIw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      decimals="2"
      id="Narr_pMYxLEc5Xka8wZ4FoR03Fg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      decimals="4"
      id="Narr_fCmcXUBpAUC64xS52IKUkw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.7662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      decimals="5"
      id="Narr_EQ1IyjuSo0yrgZoRxAnUsg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.01685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_20_2020_To_1_20_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AQ8eqWQ4CU6hcxarmXtlPw"
      id="Narr__0kI80O5_kCoeyFG6IWToQ">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_iqAsZEGu-kah8XJEHVfbaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,087,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited and expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 318,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,819,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 961,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw"
      decimals="INF"
      id="Tc_jjzSYAqs50yz-gvCo7Kh8w_6_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">2087275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw"
      decimals="2"
      id="Tc_bEQ2b36DBkadQmra7vTKuA_6_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">5.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw"
      decimals="INF"
      id="Tc_75Y_qY4n9Uaiplk0PJs_ow_8_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw"
      decimals="2"
      id="Tc_PIKXNP7_xkmszQWHUf4uWQ_8_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw"
      decimals="INF"
      id="Tc_ITo57doiK0ODe97SEsxipw_9_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">318255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uhh1S1ScZka9M3fTnqRfUw"
      decimals="2"
      id="Tc_ClmAfvCkI0ycnQerojkMPQ_9_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">11.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA"
      decimals="INF"
      id="Tc_gSLMx8M3yk-2L3ZhchgvuQ_10_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1819020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA"
      decimals="2"
      id="Tc_YSXc0x6y90CNAyvRWEFfRA_10_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA"
      decimals="INF"
      id="Tc_aLRwKoBuK0y8KONhonjc7Q_11_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">961940</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6d5Z7wMnuUqkZTlYAd5RmA"
      decimals="2"
      id="Tc_cEsLgyZMeEi9f_BMAKbhkA_11_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">5.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb__jN6omTbcESElxyTFnuXzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Restricted Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;624,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;166,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non vested at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:44.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;458,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ssa4_sAGw0q1WnIXrqo2yw"
      decimals="INF"
      id="Tc_up1WZGns-0u-dGGoKQAfTg_3_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">624580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_t32kanKUi0m7HxcXWb8NzA"
      decimals="INF"
      id="Tc_e3amVD7uBEy2XHOoPftVfw_5_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">166553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_c9-osb3oE0SkR9YTIYdxYQ"
      decimals="INF"
      id="Tc_TVLO_SZ9Z0ytoKQwKaeVAg_6_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">458027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_ys89yMcK1Eexu2lpm6lbrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 464,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 192,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ"
      decimals="0"
      id="Tc_pOElBCAhPkyrVCdfrhdzdA_6_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">464375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ"
      decimals="2"
      id="Tc_umddOfbkQUeauZn0n9KL8Q_6_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <plx:StockIssuedDuringPeriodSharesStockExpired
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WwsBRNfRtkKswONdYE8A3A"
      decimals="0"
      id="Tc_ZKFuLiaSr0mRbWcKXe6AWg_8_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">24375</plx:StockIssuedDuringPeriodSharesStockExpired>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WwsBRNfRtkKswONdYE8A3A"
      decimals="2"
      id="Tc_2uX5dcmTX02_78NJgBYhnQ_8_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">5.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg"
      decimals="0"
      id="Tc_893YOA7NtUK0y5fcj3yMmw_9_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg"
      decimals="2"
      id="Tc_v2BMMTcWo0GsN_sOsYw_IQ_9_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg"
      decimals="0"
      id="Tc_3hYbDgy-cUaYCqTzhOCYWQ_10_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">192500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_32RLt9N1O0K6YQl4lLp2dg"
      decimals="2"
      id="Tc_9ccWoUx8fUWfswxv1HjoHw_10_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_qAQCmSzXEESyw__cLUqSIg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:58.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;end&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.57 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$2.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.55 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.06&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.59 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319,651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 112,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.66 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 641,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.70 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 240,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$3.73 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$4.69 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.10 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 215,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$5.60 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$17.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,259,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,154,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      decimals="2"
      id="Tc_k5WMhl97TUSfz8rrM7OTRw_8_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.57</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ"
      decimals="0"
      id="Tc_LBAMnE6--EKPrnn3iJRzbA_8_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      id="Tc_vgln8Qm_cUy86I_Caw65HA_8_4">P9Y6M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_F5qPBMBoE063ww_GCqwQeQ"
      decimals="0"
      id="Tc_gcNj7KT-fEOQ-oodpDGQjw_8_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">3125</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1.57Member_faYFEdC0VUOLBd1iI_uGQQ"
      id="Tc_JDkHV8vRI0mKVdV87-T6lw_8_8">P9Y6M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w"
      decimals="2"
      id="Tc_-pokF3EU2ESp7wDxrQqsow_9_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_JX7wlQ8FiU22etWN6WQRxg"
      decimals="0"
      id="Tc_h-k4cljLUEucgFwxJihGFg_9_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">80000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w"
      id="Tc_ooVYtTigTkuAdFLBKRisGg_9_4">P7Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_JX7wlQ8FiU22etWN6WQRxg"
      decimals="0"
      id="Tc_K6WcJwefaUWrwOulTEmuXA_9_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">45000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice2.00Member_OLiXVp66Y06RX4Ts3j1d0w"
      id="Tc_j0lfuiLLC0OiKEbtEr4-pw_9_8">P7Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw"
      decimals="2"
      id="Tc_FGFTsiqq_kyGOAZX8Juyew_10_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_wdkJLL3g1kqo4k9Y_B1iWg"
      decimals="0"
      id="Tc_GCWMkO9q4UmLe8RPFattbA_10_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw"
      id="Tc_zUOfpnl19UC73vZxzS28vw_10_4">P8Y21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_wdkJLL3g1kqo4k9Y_B1iWg"
      decimals="0"
      id="Tc_bfUvYa_JSUytf9IXbrE3Qw_10_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">87500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.55Member_bwv_CcwYEE6ezrBA3q55Nw"
      id="Tc__rzsa_Jjvk2CJLf1Ql630A_10_8">P8Y21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w"
      decimals="2"
      id="Tc_DOCjWHZc3kC6HCBtmAVF2g_11_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.59</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_WDm67mnYvkO--UxyQkYsvg"
      decimals="0"
      id="Tc_uH08YvZ7V0irQzp-AKow0Q_11_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">319651</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w"
      id="Tc_SPUnYiheyUWvWy_8D8oNyw_11_4">P8Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_WDm67mnYvkO--UxyQkYsvg"
      decimals="0"
      id="Tc_kvahYLI0tkmLuj6hzdgCNQ_11_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">112203</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.59Member_k1BLRns7W0-kYcWEm-9d6w"
      id="Tc_R_B2nm6x9ESSV10Lql3fyA_11_8">P8Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag"
      decimals="2"
      id="Tc_4_bsr4PaUk2keWYLF8I5ug_12_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_lgDg9pDF2EWhgu2sSt2k9w"
      decimals="0"
      id="Tc_McXvn1aRk0Gvg0Nq83qIGQ_12_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">641718</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag"
      id="Tc_OKzjn1ViRUOJTUGUlB6LMw_12_4">P7Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_lgDg9pDF2EWhgu2sSt2k9w"
      decimals="0"
      id="Tc_IRG3bsMP8kq85X2ilcUeLg_12_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">280835</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.66Member_gJzOKQhEWEiUCZClr4Rgag"
      id="Tc_u8CBuvG0a06ViD6J_GMxbw_12_8">P6Y8M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A"
      decimals="2"
      id="Tc_tn419ZeIsk2e9bKLTgptqw_13_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_mFoKIxmKnkitg7IY-C7heA"
      decimals="0"
      id="Tc_QRExSVbi6Eepjeg1PajV9w_13_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">240000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A"
      id="Tc__5CjuVIMzEyWfvUv5YFCCw_13_4">P8Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_mFoKIxmKnkitg7IY-C7heA"
      decimals="0"
      id="Tc_znynEJUJKEmuvBk7T0kgXA_13_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">105000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.70Member_sVxFhHhoRUuxPxOhQwhl_A"
      id="Tc_B4lA5vgi-UuPKtTgz6Q_lg_13_8">P8Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ"
      decimals="2"
      id="Tc_QU4Ae7ocu06-ckMOh8y8mw_14_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">3.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_gNOcdY9dyE2xyodPldHVZw"
      decimals="0"
      id="Tc_5AZ2paNlpkygE8dG5FetUg_14_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">129771</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ"
      id="Tc_x736wCHlEU-wfHpZVeXjnA_14_4">P8Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_gNOcdY9dyE2xyodPldHVZw"
      decimals="0"
      id="Tc_cPOsmFdNKUKduKQmyi72mw_14_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">40553</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice3.73Member_97jCGzngK02snlM7zMtbZQ"
      id="Tc_HVwMVqxeh0WxN69JPsp0QA_14_8">P8Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q"
      decimals="2"
      id="Tc_rXxEBBikYUqU9I3n128Kqw_15_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.69</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_cydItAIWhU2ynTqxcgAr8A"
      decimals="0"
      id="Tc_emoBOut1UUqbpMU8EL9l-A_15_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q"
      id="Tc_V7a0mAiOp0OviupVMk2C1w_15_4">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_cydItAIWhU2ynTqxcgAr8A"
      decimals="0"
      id="Tc_aLVXX6q7X0u85UOSjfAjOg_15_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_BgDRoo00_0uD-RCvQy873Q"
      id="Tc_Y05QHdkTpEiz3PUXgd72CQ_15_8">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA"
      decimals="2"
      id="Tc_Qp38axCs40y_yKuA-hNHiQ_16_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">5.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_3VKeoZyiuU-sD80UufftoQ"
      decimals="0"
      id="Tc_38WSzBjOREKOjYiCvLSFsw_16_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">215030</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA"
      id="Tc_TbBgiD_5fUKneSqJ6YaHCg_16_4">P5Y8M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_3VKeoZyiuU-sD80UufftoQ"
      decimals="0"
      id="Tc_vz-apX5qAUu1IssHkA4AFg_16_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">181749</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.10Member_w1l7ijEpDkSYARo3bSwMAA"
      id="Tc_mDSwN69hDkKtF-S4ni01iQ_16_8">P5Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw"
      decimals="2"
      id="Tc_Yh8qP0zgSEy5KVFIT02wag_17_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">5.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_OHALbnwmZ0uHOEuQaP-GQA"
      decimals="0"
      id="Tc_I3OByk-OgkCSA4NcW3r0Ig_17_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">130000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw"
      id="Tc_fGyMySPaIEGB-m2RQwLMGw_17_4">P6Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_OHALbnwmZ0uHOEuQaP-GQA"
      decimals="0"
      id="Tc_aD6PhrdSM06pM3cvKfsi3Q_17_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">105625</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice5.60Member_vVBS1TobiUS11R9YdLvMUw"
      id="Tc_weW2vbGezEiLafxHYuqyFQ_17_8">P6Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg"
      decimals="2"
      id="Tc_tcDLHYlbskWe11VE0rb0cA_18_0"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">17.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_mKYQ0uHMPk-JKlPiT881XA"
      decimals="0"
      id="Tc_bphH7ZUdA0yDYAcRqgA07w_18_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">92850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg"
      id="Tc_SDZjRmGJnEGmL5vSvP3uUw_18_4">P2Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_mKYQ0uHMPk-JKlPiT881XA"
      decimals="0"
      id="Tc_jbiu7ioaX0K6ITxKgE4Dhw_18_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">92850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice17.20Member_QwJYQiRF4kmAZJsF8tD6wg"
      id="Tc_WYfdXxieJ0SWNAd_I0zyug_18_8">P2Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg"
      decimals="0"
      id="Tc_5dEa9Rhwl0KQ-pkDJXb49Q_19_2"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">2259020</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg"
      decimals="0"
      id="Tc_68qHB9ifLkW0pqqLDatKQw_19_6"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1154440</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_Jghlsk7m_kWWsAGdQosSPQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 269&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 513&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,036&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nz1R62d_CUWRP0hHMNoUuA"
      decimals="-3"
      id="Tc_HGttPDZwekKgHWlDCB2Dow_3_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qzxX_tCY20S2bKMHuz5WJA"
      decimals="-3"
      id="Tc_fKLSPvJK2Uu0M41zEXMiQA_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">513000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_avlksYPTbEKq7Od9FRAY9g"
      decimals="-3"
      id="Tc_JtjvYxRnMky_O5yUtK75aA_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_phM4VtIB9kyKjfXahRtTSQ"
      decimals="-3"
      id="Tc_Ikl3SVjyakCQ-QE3Soa7sQ_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Jz0yWSUNLUeUy5fbrRm0BA"
      decimals="-3"
      id="Tc_inWC__1wKUq_1BYQ3BoS_w_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">322000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cDyFN34pu0WU-HKDRkiujg"
      decimals="-3"
      id="Tc_3DZoxIsKGUCrb3AaGzAsXg_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_GvWEuJLKREuv90OClpZMKA"
      decimals="-3"
      id="Tc_809i0R1EeUC839ZivGjoFA_5_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_KDBva7Rkak21uDlkh3pj3A"
      decimals="-3"
      id="Tc_a-vpf8_rLU2lZcHEq_R4nA_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">835000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_sbh8Xyzi-Ua5o9pPzEfF4w"
      decimals="-3"
      id="Tc_4idwpjpMQkefJncoFQuRfw_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      decimals="-3"
      id="Tc_wCm_BtoaEkOil7x38u_-og_6_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw"
      decimals="-5"
      id="Narr_wEGqAMTqckmlktDDR_5caQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">17600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"
      decimals="3"
      id="Narr_XiCcAP8uxkGyCsytx4PQPA"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.485</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_18_2020_To_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zE-3_2p6106vkPIImFhvtw"
      decimals="-5"
      id="Narr_G3h8otX0l0Wz2b80oNeSBw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">43700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"
      decimals="INF"
      id="Narr_H13Et8U1X0eYW0gE2I3pqA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oxE_B5i49U6BnUZDYgLLiw"
      decimals="2"
      id="Narr_ifo_e8zga0ex-aiQJjoGSw"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">2.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HY-SW4N2TkyfFq3zDY1uuA"
      decimals="INF"
      id="Narr_jdyhJB0TCk6G1dplksVY4A"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HY-SW4N2TkyfFq3zDY1uuA"
      decimals="0"
      id="Narr_V4zrSBXHkkOZD6tgymAL2g"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">472000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GEPYGazCFU-lvckKnH9W0w"
      decimals="0"
      id="Narr_youvm_f-Akawv7gCtIEegA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">173816</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_lDW5LBY3rUuDb7f7KXNKnw"
      decimals="0"
      id="Narr_ajSZhVLJc0uVfS3IAoTATg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">2816901</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_rSbtuiUSrEKogWgpJVQOAA"
      decimals="-5"
      id="Narr__rvf9tOvt06KhDUUNtHqYw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:PercentageOfCommissionOnSaleOfShares
      contextRef="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_dm10EvNOd0iKnY1gsz2csw"
      decimals="3"
      id="Narr_ICJixSsZMUS7FpkcdQ_ZSA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.030</plx:PercentageOfCommissionOnSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bCxAc5Cnfkm0EGvQetJhcA"
      decimals="INF"
      id="Narr_mOyfq4fRaEWIJE2hOsu4HA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_D8rI_9bthkCH_hajh1im5Q"
      decimals="INF"
      id="Narr_gd_VCq_g0UmouueKXXx4_w"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1867552</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_D8rI_9bthkCH_hajh1im5Q"
      decimals="-5"
      id="Narr_JdhD97OAsU29J5yBSpR0bQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">8800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ"
      decimals="INF"
      id="Narr_mnMMnw1MBkCAOsBsUJSzcg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q"
      decimals="2"
      id="Narr_4FCUUv8AMkiNo-WOe5ng6g"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">4.60</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_17_2021_To_2_17_2021_cfhKv1dOEkG9pb-LTiA8EQ"
      decimals="-5"
      id="Narr_jZj9p2ws3Ey9JsaRS-BfDA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">40200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_v_mup5ayK0SZBeWgSy-6vQ"
      decimals="INF"
      id="Narr_wSp7K3FF90mcyNYfvT9KuQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">1141304</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_k4imgXBc-EuQmN5vT0V28g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 10&#160;&#160;- CONVERTIBLE NOTES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On August&#160;25, 2021, the Company completed the Exchanges of a substantial majority of the Company&#x2019;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2021&#160;(&#x201c;2021 Notes&#x201d;)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On December&#160;1, 2016, the Company entered into a note purchase agreement with institutional investors, which held part of the 2018 Notes&#160;(the &#x201c;2016 Purchasers&#x201d;), relating to the sale by the Company of $22.5&#160;million aggregate principal amount of 7.50% Senior Secured Convertible Notes&#160;due 2021 in a private placement pursuant to Section&#160;4(a)(2)&#160;under the Securities Act. Concurrently with the consummation of the private placement of the 2021 Notes, the Company entered into a privately negotiated exchange agreement (the &#x201c;2016 Exchange Agreement&#x201d;) with certain existing note holders identified therein to exchange $54.1&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2018 Notes&#160;for (i)&#160;$40.186&#160;million aggregate principal amount of 2021 Notes, (ii)&#160;2,384,673 shares of Common Stock and (iii)&#160;cash, equal to the accrued and unpaid interest on the 2018 Notes&#160;and any fractional shares. The closing date of the purchase agreement and the 2016 Exchange Agreement was December&#160;7, 2016. The issuance of the 2021 Notes&#160;and shares in the exchange and the private placement were made in reliance on the exemption from the registration requirements of the Securities Act pursuant to Section&#160;4(a)(2)&#160;thereof. The net proceeds from the private placement were $19.7&#160;million, after deducting the placement agent&#x2019;s fees and the Company&#x2019;s estimated offering expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In connection with the completion of the exchange and the private placement, the Company entered into the &lt;a href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" style="-sec-extract:exhibit;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"&gt;Indenture, dated as of December&#160;7, 2016, with the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent&lt;/span&gt;&lt;/a&gt; (the &#x201c;2016 Indenture&#x201d;). The 2021 Notes&#160;accrued interest at a rate of 7.50% per&#160;year. A portion of the interest payable was allowed to be made in shares of Common Stock at the Company&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;24, 2017, the Company entered into another note purchase agreement with certain institutional investors relating to the private issuance and sale by the Company of $10.0&#160;million in aggregate principal amount of its 2021 Notes. The 2021 Notes&#160;were issued pursuant to the 2016 Indenture. The net proceeds from this purchase agreement were $9.5&#160;million, after deducting the Company&#x2019;s offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On November&#160;15, 2021, all the then outstanding 2021 Notes&#160;matured and were paid in full, and the 2016 Indenture expired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2021 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. Dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Debt discount amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9,114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,261&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;7.5% Convertible Notes Due 2024&#160;(&#x201c;2024 Notes&#x201d;)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#x201c;2021 Indenture&#x201d;). Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#x2019;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges were considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component and a reduction of stockholders&#x2019; equity of $12.2&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature net of transaction costs of approximately $12.0&#160;million was recognized in the Company&#x2019;s additional paid in capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Transaction costs in the amount of approximately $869,000 were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Holders may convert their 2024 Notes&#160;at any time. The initial conversion rate for the 2024 Notes&#160;is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes&#160;(equivalent to an initial &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;conversion price of approximately $1.7755 per share of the Common Stock). Upon conversion, the Company may settle the 2024 Notes&#160;by paying or delivering, as the case may be, cash, shares of Common Stock or a combination thereof, at the Company&#x2019;s election.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;To date, there has been no conversion of 2024&#160;Notes. As of December&#160;31, 2021, a total of $28.75&#160;million aggregate principal amount of the 2024 Notes&#160;were outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to the maturity date, the Company may redeem in cash:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a)&lt;/span&gt;&lt;/span&gt;any or all of the 2024 Notes&#160;if, on or after March&#160;31, 2023, the last reported sale price of the Common Stock for at least 20 trading&#160;days (whether or not consecutive) during the period of 30 consecutive trading&#160;days exceeds 130% of the conversion price on each applicable trading day, or&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;b)&lt;/span&gt;&lt;/span&gt;all of the 2024 Notes&#160;then outstanding if the aggregate principal amount of the 2024 Notes&#160;then outstanding is less than 15% of the aggregate principal amount of the notes issued on August&#160;25, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;To date, there has been no redemption of 2024&#160;Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The 2024 Notes&#160;are guaranteed by the Restricted Subsidiaries (as defined in the 2024 Indenture) and are secured by a first-priority security interest in all of the present and after-acquired assets of the Company and each of the Restricted Subsidiaries (the &#x201c;Collateral&#x201d;), including, but not limited to, (i)&#160;100% of the capital stock of the Guarantors (as defined in the 2024 Indenture) and each Restricted Subsidiary of the Company that is held by the Company or any Restricted Subsidiary, (ii)&#160;intellectual property, including all copyrights, copyright licenses, patents, patent licenses, software, trademarks, trademark licenses and trade secrets and other proprietary information, including, but not limited to, domain names, (iii)&#160;all cash, deposit accounts, securities accounts, commodities accounts and contract rights, (iv)&#160;all real property and leased property, subject to applicable minimum thresholds, as set forth in the 2024 Indenture, and (v)&#160;all other tangible and intangibles of the Company and the Guarantors. In connection with the grant of such liens, the Company entered into certain agreements with both Wilmington Savings Fund Society, FSB, as collateral agent in the United States, and with Altshuler Shaham Trusts&#160;Ltd., as security trustee in Israel. The 2024 Indenture restricts the ability of the Company, the Subsidiaries and any future subsidiaries to make certain investments, including transfers of the Company&#x2019;s assets that constitute collateral securing the 2024 Notes, in its existing and future foreign subsidiaries, subject to certain exceptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Upon (i)&#160;the occurrence of a fundamental change (as defined in the 2024 Indenture) or (ii)&#160;if the Company calls the 2024 Notes&#160;for redemption as described below (either event, a &#x201c;make-whole fundamental change&#x201d;) and a holder elects to convert its 2024 Notes&#160;in connection with such make-whole fundamental change, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares (the &#x201c;Additional Shares&#x201d;). In no event will the conversion rate exceed the maximum conversion rate, which is 746.2686 shares per $1,000 principal amount of 2024 Notes, which amount is inclusive of repayment of the principal of the 2024 Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;If a fundamental change occurs at any time, holders will have the right, at their option, to require the Company to purchase for cash any or all of the 2024 Notes, or any portion of the principal amount thereof, that is equal to $1,000 or an integral multiple of $1,000 in excess thereof, on a date of the Company&#x2019;s choosing that is not less than 20 calendar&#160;days nor more than 35 calendar&#160;days after the date of the applicable fundamental change company notice. The price the Company is required to pay for a 2024&#160;Note is equal to 100% of the principal amount of such 2024 Note plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. Under the terms of the 2024 Indenture, the Company is required to &lt;span style="color:#222222;background:#ffffff;"&gt;meet certain covenants including the requirement to &lt;/span&gt;maintain a minimum cash balance of at least $7.5&#160;million. Failure to meet covenants can be considered an event of default and, accordingly, may &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;result in the acceleration of the payment of the notes or in additional interest payments. As of December&#160;31, 2021, the Company was in compliance with all covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.45pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2024 Notes: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt issuance costs and debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw"
      decimals="-4"
      id="Narr_OohPHfrxTEGi5zhqBBzPVw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">54650000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="-4"
      id="Narr_KdXh27-UA0Wvm4J41NiNBw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="-4"
      id="Narr_FMHnCm5WPkaPYvj65xmTuA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">25900000</us-gaap:RepaymentsOfConvertibleDebt>
    <plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="-5"
      id="Narr_QDLGRFppdUGt5-XkzpQmaw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1100000</plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="INF"
      id="Narr_uPo6j2cTVUqLekCiMI_CFQ"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="0"
      id="Narr_XxNKP-d0xEOLE2rB6REFTw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="INF"
      id="Narr_JkjAFx1On0S5Ovm9LlR8Fg"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <plx:PercentageOfPremiumToClosingPriceOfStock
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="3"
      id="Narr_dzsQqfDc20qdLHv_K5uCcQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.325</plx:PercentageOfPremiumToClosingPriceOfStock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg"
      decimals="3"
      id="Narr_A-q8OJeB_E21kiVdxn1QyA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cFbsJrjci0yg4ImOcaQUEg"
      decimals="-5"
      id="Narr_vaJF5A0Jc020JcTocqlYVA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cFbsJrjci0yg4ImOcaQUEg"
      decimals="4"
      id="Narr_YB1lezT85k6OPGcyivXbxA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_1_2016_us-gaap_DebtInstrumentAxis_plx_FourPointFivePercentageConvertibleNotesMember_m95eebdJ1ECA3BKmoDsZlw"
      decimals="-5"
      id="Narr_tpFUzgSTN0mdUIRmchM2FQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">54100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_7_2016_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDueTwoThousandTwentyOneMember_-Ae00XL6BEyY4dAoZ4k0DA"
      decimals="-3"
      id="Narr_bh_oWmp3MEmVugwpwjx-Bg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">40186000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_12_1_2016_To_12_7_2016_MCerakGL40qMS2YHRbNFsA"
      decimals="0"
      id="Narr_p47NjPAUqEGUAbnrYefatw"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">2384673</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_12_1_2016_To_12_1_2016_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_rR_AcPv6HUeGQ6sr7l3x6g"
      decimals="-5"
      id="Narr_JqQgLJtAKkSB8IeL0efcrw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">19700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_JBy9gzN7ukuvvAF86iP2wg"
      decimals="4"
      id="Narr_Lll7ybmUtEagcyuAnAYIQA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_24_2017_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BD69mggkuU62grMnuucETQ"
      decimals="-5"
      id="Narr_oihLqo-XCECRRR3Fc8gbag"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_7_1_2017_To_7_24_2017_IHtLKtFOd0GdflSpPhFd5g"
      decimals="-5"
      id="Narr__OhhNbaTdEactbHeN_HzXQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      id="Tb_zJZ3ltB1mUmBuIBZE78vag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2021 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. Dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Debt discount amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9,114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,261&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ"
      decimals="-3"
      id="Tc_B0jzXSlicUy5MgU0kNCepg_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4344000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ"
      decimals="-3"
      id="Tc_J1PIzuGTH0isBVLgLgPG9Q_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">4344000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      decimals="-3"
      id="Tc_WwPSrBpdi0emnNZ-7woXFg_3_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2855000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ"
      decimals="-3"
      id="Tc_l34giQQYaEOLlWSmCU2cxg_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2991000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ"
      decimals="-3"
      id="Tc_IKD7Ia8AFk-Y4sXizJ3C0A_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">3470000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      decimals="-3"
      id="Tc_cQg4CM2wG0maObmmd7pqsA_4_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2575000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      decimals="-3"
      id="Tc_civzKhzdtk24CTJ-XLhA3A_5_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-831000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <plx:InterestExpenseDebtOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ"
      decimals="-3"
      id="Tc_GwmpInnpVUC4heDrWBUYow_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1300000</plx:InterestExpenseDebtOther>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_Xyquun8tuUiIJ4LJNzFoCQ"
      decimals="-3"
      id="Tc_dT9mloroNUmfDXBpuMaX2g_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7335000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_WqQEDR8JqEWEd2kEmy0VZQ"
      decimals="-3"
      id="Tc_Wl7IVhpUVE69ptOjbz6RDw_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9114000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      decimals="-3"
      id="Tc_rx6KeUbDBkqbmkIHs26D4g_7_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">6261000</us-gaap:InterestCostsIncurred>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="3"
      id="Narr_9DguQz6KHkaBgxBaj_Zg6Q"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="4"
      id="Narr_bNJTLn6Mkk21sNeI_5o5Jg"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      id="Narr_0yrJo5MtlUqjI2rFYVFcqQ">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      decimals="-5"
      id="Narr_BF3PX0Az50iEvKVPidQfVA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w"
      decimals="-5"
      id="Narr_4qEIZsDvOkWDqUBvMQZpkw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12200000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="-5"
      id="Narr_4zV0zdO0J0mvLJud8kwQyQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">12000000.0</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="-3"
      id="Narr_1tfwp77x4U-_JpRqLVGRCA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">869000</plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="INF"
      id="Narr_gec6krHFQUO4U6Bx5qU5NA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_5KmZq8B2b0O-U8s7vIJOcg"
      decimals="0"
      id="Narr_D0gDbWN210616U7ZsZ7KcA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wJi4kKdbdEODC2_vc82ktA"
      decimals="4"
      id="Narr_jQCcGMpgfk2Po61czS296Q"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="-4"
      id="Narr_4GUGZZL79UaNiPUAR0cQXA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28750000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentRedemptionDescription
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      id="Narr_3Cu074K_OECbw85HGVK1sQ">Prior to the maturity date, the Company may redeem in cash</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="INF"
      id="Narr_UxAma4MqH0-5nZszDwG12Q"
      unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="INF"
      id="Narr_flJDMJ6ZCUyFIn8laPd-yg"
      unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <plx:ThresholdPercentageOfConversionPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="2"
      id="Narr_M-L_N90EdEO9NzXIePwZIw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1.30</plx:ThresholdPercentageOfConversionPrice>
    <plx:DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="2"
      id="Narr_XXBcOq0qV0GGZ4Mcri6c9w"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.15</plx:DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding>
    <plx:DebtInstrumentRedemption
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="-3"
      id="Narr_WSkqyHWJ_Eq8gJsOIon6vA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">0</plx:DebtInstrumentRedemption>
    <plx:PercentageOfOutstandingCapitalStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="2"
      id="Narr_SljyX0gRPkyTacm8-Dod8w"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1</plx:PercentageOfOutstandingCapitalStock>
    <plx:MaximumDebtInstrumentConvertibleConversionShareNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="INF"
      id="Narr_YDvyJFHijE-zVIsvyF6DLg"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">746.2686</plx:MaximumDebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="-3"
      id="Narr_kr9JF9rzE0Cn0A7bEreJkA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="-3"
      id="Narr_vJbNB4P6LEW4i62-5ANqKA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="-3"
      id="Narr_HJ-IzcDlK0mBt0yFbjaE7w"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1000</plx:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock>
    <plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kDIPT7eBJUiHYr1xa6GU6A"
      decimals="INF"
      id="Narr_ZnJzUG6JsUqdckJcQzgbew"
      unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ">20</plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange>
    <plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ng8kcf3PY0-KI0QEryv2Yw"
      decimals="INF"
      id="Narr_4nrLx8mhB0-nYXFBi0X72g"
      unitRef="Unit_Standard_D_5PZijFhHx0GYLzISjZqtuQ">35</plx:NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="2"
      id="Narr_QMKgka-eIEa9goSx3Iy-WQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_D1P9hN9SgE6TdythZ_2bFw"
      decimals="-5"
      id="Narr_vZg9ZqjxjU2Yq_6jx15n-A"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_NrgbIl6Vs0-zjQEgcvzrEg"
      id="Group_Jl9SNnnh-kGZ9CMWO7pTbw">The following parameters were used:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.45pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_b7Ak3fDnlkmmGkfD-wjobA"
      decimals="2"
      id="Tc_WfgHdROk10aJbXXh80Zv_A_2_2"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_we61rqymjEKVRph1U_HyOQ"
      decimals="2"
      id="Tc_AN1k3pVqmUeHx1ce6iOtfw_2_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">1.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_bFAp9JROpkOcrhLPvQRlPw"
      decimals="2"
      id="Tc_5WElPmDEEUyJyPVrjAM5BQ_3_2"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_eHDaBvSg7EqtccoqK2mu0g"
      decimals="2"
      id="Tc_z3PgCsyOD0um4Tv4KWREBg_3_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">3.03</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Dql2hzl-NkS8Ek6wKzfhtw"
      decimals="2"
      id="Tc_ktjn6yy6NEWEU5NDo7gITA_4_2"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.05</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wVjVKlFU-kmp2kWFh3RuVg"
      decimals="2"
      id="Tc_eF2iGW8e70mmR1EO-x7cEQ_4_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.44</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6zDHzo_aTEew3DryvNkYTQ"
      decimals="2"
      id="Tc_soNWH8oGMUChAfQGdj0l5g_5_2"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">78.95</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_5QixDFM82UiwwWLbZe1sTQ"
      decimals="2"
      id="Tc_0rYoj7Hn1Eax17lfvG9QGg_5_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">91.35</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_GmiPA7ea602B3Bzo6qlgCQ"
      decimals="2"
      id="Tc_Giv82oIPqkGjS7O0C_JMBw_6_2"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">7.87</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_31zyHW8jdkSb7SBDmFiccg"
      decimals="2"
      id="Tc_em1eq9xg3keQCVSxj1vdaw_6_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">7.66</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      id="Tb_fA253TZhg0GisGMyPR7uIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2024 Notes: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt issuance costs and debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="-3"
      id="Tc_zbx593BAukK1vfiEZkvwEQ_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">767000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="-3"
      id="Tc_msEPorMooUGUTdY0kjuDmA_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">97000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      decimals="-3"
      id="Tc_GwCvXvwieUeFJ9cJ3PpysA_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">864000</us-gaap:InterestCostsIncurred>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_UkLNvfeftUOXKegDAnOPfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;11&#160;- FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The fair value of the outstanding $28.75&#160;million 2024 Notes as of December&#160;31, 2021 is approximately $33.3&#160;million based on a level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The Company prepared the valuation of the fair value of the 2024 Notes&#160;(a Level 3 valuation) as of December&#160;31, 2021. The value of these notes were estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 92.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg"
      decimals="-4"
      id="Narr_cFYxNH_tvk6sCgkIjrS83Q"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">28750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg"
      decimals="-5"
      id="Narr_XwKfsbmeH0y77kwwIqU5Mg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">33300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Tq-hhZ6bYEq_C41omGuBEg"
      id="Tb_Lp3UKmDNekywkAJWOLUvVw">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 92.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_W5Xtd1I87UWgu75FfSxL9w"
      decimals="2"
      id="Tc_uxuACzHuQEy4Y587g8a3yA_2_5"
      unitRef="Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ">0.83</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_DCDOuQ7vOEmwiHAqrutTiA"
      decimals="2"
      id="Tc_tMkEfG3a8kKmDNB2QoRMtg_3_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">2.67</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-h9AO0_j0Kk-RifcpTNhg"
      decimals="2"
      id="Tc_knt5QKDAGkS2ftcXP9tEfA_4_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_xZes_pQ3jU-LW3EVr3FH_g"
      decimals="2"
      id="Tc_EdWeavVuO0a6_anr76muYw_5_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">92.79</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_oDSWqTAF3kmOozORnpamaQ"
      decimals="2"
      id="Tc_uReVaoxuBEWY4JQlUepg3A_6_5"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">10.31</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_GWmf273WPEa2zQlRY98b5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;12&#160;- TAXES ON INCOME&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Company&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#x2019;s income is taxed in the United States at the rate of up to 21%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On December&#160;22, 2017, the Tax Cuts and Jobs Act (the &#x201c;Act&#x201d;) was enacted into law. The new legislation represents fundamental and dramatic modifications to the U.S. tax system. The Act contained several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the Act included, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of net operating loss (&#x201c;NOL&#x201d;) deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The Act also repealed the corporate alternative minimum tax for tax&#160;years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the Act included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Modification of interest expense limitation rules under the Act provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 30% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;U.S.&#160;GAAP requires that the impact of tax legislation be recognized in the period in which the law was enacted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company believes that all future profits of its subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company as a &#x201c;foreign-investment company&#x201d; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Tax rates&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The income of the Israeli Subsidiary, other than income from &#x201c;Approved Enterprises,&#x201d; is taxed in Israel at the regular corporate tax rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The corporate tax rate was 23%&lt;span style="white-space:pre-wrap;"&gt; for 2019 and thereafter.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Encouragement of Capital Investments Law&#x201d;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#x201c;Approved Enterprise&#x201d; or &#x201c;Benefited Enterprise&#x201d; status the Israeli Subsidiary is entitled to various tax benefits as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;a.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Reduced tax rates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary has an &#x201c;Approved Enterprise&#x201d; plan since 2004 and &#x201c;Benefited Enterprise&#x201d; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#x201c;Approved Enterprise&#x201d; or &#x201c;Benefited Enterprise&#x201d; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;b.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Accelerated depreciation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;c.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Conditions for entitlement to the benefits&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary&#x2019;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#x201c;Approved Enterprise&#x201d; from the Investment Center.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;d.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#x201c;Preferred Technological Enterprise&#x201d; and &#x201c;Special Preferred Technological Enterprise&#x201d; (the &#x201c;Capital Investments Law Amendment&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2021 and 2020, the Company had aggregate NOL carry-forwards equal to approximately $247.9&#160;million and $231.4&#160;million, respectively, that are available to reduce future taxable income as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Company&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company&#x2019;s carry-forward NOLs, equal to approximately $36.1&#160;million and $30.9&#160;million as of December&#160;31, 2021 and 2020, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#x201c;IRC&#x201d;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Protalix&#160;Ltd.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;At December&#160;31, 2021 and 2020, the Israeli Subsidiary had approximately $211.8&#160;million and $200.5&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Deferred income taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The components of the Company&#x2019;s net deferred tax assets at December&#160;31, 2020 and 2021 were as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other timing differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,989)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (63,760)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61,520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Tax assessments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In accordance with the Income Tax Ordinance, as of December&#160;31, 2021, all of Protalix&#160;Ltd.&#x2019;s tax assessments through tax&#160;year 2016 are considered final.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A summary of open tax&#160;years by major jurisdiction is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Jurisdiction:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2017-2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United States (*)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2017-2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_TGSo8Z2q4UakwLgn9fGO-g"
      decimals="2"
      id="Narr_8xlD3qfaCkWA3GyzhNd7gQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_x038hBkxEEOMoMUfzZexDA"
      decimals="2"
      id="Narr_k6oOWb32oEG68fkHOo-STw"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_KCPpKqI-Okqwtns-9IWsAA"
      decimals="2"
      id="Narr_ZJROFITExEqM9CgXhMJgvA"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_5BNg8lS-ikul3R9lhuigJA"
      decimals="2"
      id="Narr_ZMnZNw-B2UyTD1F2kTIfxQ"
      unitRef="Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-5"
      id="Narr_04kQF6uaakmkdWi9KI-VZQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">247900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-5"
      id="Narr_UwNewVS5DUKeuv6DRYEQvQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">231400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_NaIif8seUUurDs8ggqZ2pg"
      decimals="-5"
      id="Narr_AmM4mDn8S0uKj5CE3EQWaQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">36100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_Dv3dYp7Sn0usVBmj85F-iw"
      decimals="-5"
      id="Narr_oSZHO0gTi064ghHn7TlobQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">30900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_4EDJzmaOZEiGDZsFWmKybw"
      decimals="-5"
      id="Narr_YYjFEI8BPUu3aWQxL7Qnqw"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">211800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_DhHNkI_3EEiZeB01aqdpKA"
      decimals="-5"
      id="Narr_bziS4guqYE-9VH9J2IeScg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">200500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_OGmwp4CvJUWku6-N44_7eQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The components of the Company&#x2019;s net deferred tax assets at December&#160;31, 2020 and 2021 were as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other timing differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,989)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (63,760)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61,520)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_2XvJ3hTJ506dkKV9_0mYGw_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9598000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_BNFSd2UpK0OTI0DYGya1Zg_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">7217000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <plx:DeferredTaxAssetsOtherTimingDifferences
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_EdCdTATy6kyHHl0e__SPdw_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">40000</plx:DeferredTaxAssetsOtherTimingDifferences>
    <plx:DeferredTaxAssetsOtherTimingDifferences
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_jCpGVLKUZk-9GTRGBDfXvA_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">-1989000</plx:DeferredTaxAssetsOtherTimingDifferences>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_O2tY3YDxj02GqDkeHi1tXw_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">54122000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_dmY2hxunw0WalA39Puz_sw_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">56292000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_3N8AExcgP0yrGiFy1umxyQ_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">63760000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_9ODJtQzYNEW-Bl2_d0zoqw_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">61520000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_5soDWZH7JkSTLCe0fgOEjA_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_mgzRWnr8M0K4jIe8i4UbMw_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">0</us-gaap:DeferredTaxAssetsNet>
    <plx:ScheduleOfOpenTaxYearsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_XWcft6K9SU6BZCm3DNtqjQ">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Jurisdiction:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2017-2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United States (*)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2017-2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfOpenTaxYearsTableTextBlock>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_DVyyV14ssk6w6xsrUpAbPw"
      id="Narr_HAY5pAfAeEGVCP6sy68nxg">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_JS88tOJOkUqlKtjBD7IPxQ"
      id="Narr_rPSAomW_4023SMnXUaTfgg">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_bOenO2dw9kqQgW48F-LuVQ"
      id="Narr_aS7cwun5yUOpMXd8uaS12g">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_k1N1AROJukiPb2LgQrs-Bg"
      id="Narr_y60Fa1xY3US03Atq_gH4yg">2021</us-gaap:OpenTaxYear>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_qYP1J938B0C5kD9EQZTl7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;13&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 54pt;"&gt;Balance sheets:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&#160;Other assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sundry&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,096&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 317&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_rLdk9RBG9EqQYKEoEWzxMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&#160;Other assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sundry&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,096&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,285&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 9,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 317&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 16,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <plx:OtherAssetsInstitutionsCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_KTe69hs9XkuCeLve-EFBMQ_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">771000</plx:OtherAssetsInstitutionsCurrent>
    <plx:OtherAssetsInstitutionsCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_5tyXvrCqQEWvsxrVqYikHA_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">311000</plx:OtherAssetsInstitutionsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_7TJusOWogEStun4t5gnwoA_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">436000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_AFsQmauf_EmdcesnCxiiBA_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">841000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_TaFd6prfpEeD01JWszX7zQ_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">905000</us-gaap:PrepaidExpenseCurrent>
    <plx:OtherAssetsSundryCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_6vJ4J0ECcE-07_zBVOdstA_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">48000</plx:OtherAssetsSundryCurrent>
    <plx:OtherAssetsSundryCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_X9rNsjDNn0i3EMGN1jkCMQ_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">69000</plx:OtherAssetsSundryCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_-KA7XQ5f2U214gWSHH_cCA_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_4002VRRT5kWH2W_z9ZyOKA_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1285000</us-gaap:OtherAssetsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_GzcnRQD4ZkGH_R-usx5IQg_4_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1460000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_DBqed8rkK0ux9CMiwxDg6g_4_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1562000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_Lv_mqZY2ZUapDI09lZqQjQ_5_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">555000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_ok4US0y9e0eMS4RV_I1flQ_5_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">767000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_AgVU-ZVGdUWGxRgqKR_a-w_6_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1526000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_BZmMKjUrfEemdp8UMyM-ow_6_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1506000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_iYYaJVuFQE29AI2OxsT_5w_7_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">9586000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_NxtxQiFJgk2ygGC8vv_SgA_7_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">11981000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_hwqxjrGZMkC-pXPrfIO-ww_8_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">482000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_YqoKDhhq2E6fJWzFnhCHOQ_8_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">522000</us-gaap:AccruedRoyaltiesCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_l_AmYt60qE69Fcn3J5sRig_9_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">317000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_Sx8vCFDFhk6cEdMP9wxQow_9_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">95000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg"
      decimals="-3"
      id="Tc_o9TetTO6-E2a0IA2ducRKg_10_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">13926000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g"
      decimals="-3"
      id="Tc_xVnuoCfqGUmgryBKfghnMQ_10_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">16433000</us-gaap:AccountsPayableCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_-iSse8eS6kK-pcTWxqZQyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;14&#160;- RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation (including share-based compensation) to the non-executive directors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_c-zb-R98IEiBXeXlC1Jo0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation (including share-based compensation) to the non-executive directors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_Pn1OJZqDxUCu6sqgk4Nceg"
      decimals="-3"
      id="Tc_w8jX-zlzjkG8uqtVKes-cQ_3_3"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">444000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_DhX0f2VRfE65d2xBozNi3Q"
      decimals="-3"
      id="Tc_YmBJWnXe2Ea9-kbqZjIjgQ_3_6"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">814000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_0yT3uJM1BkaHr4dUCEjvtg"
      decimals="-3"
      id="Tc_9vhnTXrDgkaBnLPNx3mwIw_3_9"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">475000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg"
      id="Tb_krEMap1cdkS-2w4puawLiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;15&#160;- SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On February&#160;25, 2022, the Company granted (i) &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;637,531&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock to its President and Chief Executive Officer and (ii) &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;121,951&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer, both under the Plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On January&#160;12, 2022 and February&#160;2, 2022, the Company collected approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On March 22, 2022, the Company collected approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales of alfataliglicerase to Fiocruz.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E0uJdNzPMUWVe1_NyQJfUg"
      decimals="INF"
      id="Narr_rFQETHemEEuuhxSw9Jjr0w"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">637531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__onSW-uv_0Sf9fAA3WmGWA"
      decimals="INF"
      id="Narr_2fFped45Nk2zUVIGD78kZA"
      unitRef="Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ">121951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_1_12_2022_To_1_12_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_ph-iL0zoGk631_yyBbBhuQ"
      decimals="-5"
      id="Narr_l42cHFod3US2Zk2M6j24KA"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1200000</plx:ProceedsFromExpenseReimbursements>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_2_2_2022_To_2_2_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_TdEixVwmTkix-fdRgGxOWw"
      decimals="-5"
      id="Narr_pGAdCyKyD0-nFRUMPloNsg"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">1200000</plx:ProceedsFromExpenseReimbursements>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_3_22_2022_To_3_22_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_Ak-XTuYc0UeiX460wPg5iA"
      decimals="-5"
      id="Narr_SPrtF6YMLUG_SvCxJL1VZQ"
      unitRef="Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA">2200000</plx:ProceedsFromSaleOfProducts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)_70\[3S9Z!^.NQ*\(;Z\? SC%O@MT3E=LZE,8J3O8T/:T/#T7'X25,@B+U
M +EF25ER\5:O;5J:Z+3N.F%'&I&&UHF=UC]6Y4^2B.AT32D.VB?1(!;Z;M"Q
M1>2H+;?WY?/[N]_1<OIXB^:S\?5L/EO.IM8*31KV)9\TZ"?L_C71N94$8=BU
M^PVW$GO7?>+Q('K'C:&RM\^'22S 78G2L#.QL_/\'1I:<_%?NA=BZ,/=H-T1
MF*2(W]'7D8;%R2<L_N_8DNBD[5(]SPU2;E<G0!IF)Y\P>SU;I!S UI.8'>N$
MZ)SM=50]TC V.:59/Q7#-=$YV?4]TFY.#&*A.^P*6$/=Q$[=>["?0-2I.Q@&
M#FY#U,6& +$CH+1A>&IG^,G][>UL>0N3Q<(X\UNUU67=15E$,;OJ%3!#,+%E
MO1$R9</_8.BCATTEH=A^:S)^F"W'<W0S_3J;S*9WD[]L9AO2I_9>?L*S#+AE
M(7G\TD=?G'/'P="$"K2-THI=H'$E-S#N_LU6Z S:9]7EW["894]PAM[OA.IF
M5=TM]1$T/7V8_M4/*C<1Q. W!)6W G4EQ"M92GA03'&*.>KV ]_KDW#WH>OU
M81;H0[';&^^_CWS)EJ5&5J>&H:--- 89VC$DT:,K*7O)&Z]6B;HJA:-31,GJ
M#,;3."H2.$I&F'KMHWX8>FW^-LE9[H5H4R2IO4C" %)E51I)V*D56R=Q8JPR
M5*]^9S1PCR>@/5"3H!M0K^.:@S:5DGXRQ^Q:JETL]UA9'IMW7R]W9[Y#M00P
MB)' H1W429NZ2.UU4:-.-<^KI#\1OJ_=0IJ&4H.8:2@='-U3JW\2W$;B.<FA
M*V)KT'/. _!?[.[==R^2%_75]1.7DF?UXX;!$"F4 'R_YM#*[5_4;?CAOQ^C
M?P!02P,$%     @ A#E_5'"'4$QP @  H08  !@   !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6R55>]OVC 0_5>L:!]:J2,AOZ@JB$2!J96Z%I6N^^PF!['J
MQ)GME&Y__<Y.&D&!#?A ?)=[[]X[PF6X%O)5Y0":O!>\5",GU[JZ<EV5YE!0
MU1,5E'AG*61!-89RY:I* LTLJ."N[WFQ6U!6.LG0YN8R&8I:<U;"7!)5%P65
MOZ^!B_7(Z3L?B4>VRK5)N,FPHBM8@/Y1S25&;L>2L0)*Q41))"Q'SKA_-8E-
MO2UX9K!6&V=BG+P(\6J"VVSD>$80<$BU8:!X>8,)<&Z(4,:OEM/I6AK@YOF#
M_9OUCEY>J(*)X#]9IO.1<^F0#):TYOI1K&^@]1,9OE1P9;_)NJF-!PY):Z5%
MT8)10<'*YDK?VSEL /KA 8#? OQC 4$+"*S11IFU-:6:)D,IUD2::F0S!SL;
MBT8WK#2_XD)+O,L0IY/)P_WBX>YV.GZ:3<GU^&Y\/YF1Q<UL]K0@9W,JH=0Y
M:)92?DZ^DB_$)2K'K!JZ&KL;#C=M.UTWG?P#G::0]DC0OR"^Y_?WP"?'P[UM
MN(N>.^-^9]RW?,'IQO_!'G3L@64/#[&+HL"'=*%%^GI!<(Y$2(RHAHP\4UX#
MF0,FS"C)&2M))CBG4I$*LW; Y_L&W/2\M#W-W_,M\7J>A\-\VYSC_ZJV#(6=
MH? $0U:X(N-:YT*R/Y#M4]L01ALZ^KA;[.>3XF,JMU1'G>KH!-5,J7J_U&A'
M0!A%41R'@T]*=PN#<!!'_N4!H7$G-#Y!*&Y;I6F9L7*U3VU\K-K=P@-JW8T%
M8I;W=RI7K%2$PQ*A7F^ '+)9B$V@165WRHO0N*'L,<=W"$A3@/>70NB/P*RI
M[JV4_ 502P,$%     @ A#E_5$41R1W<!   #1(  !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6RUF%UOHS@4AO^*%8U6,]*T8/,]FT8B0%.T"42!=':U
MV@N:N V: %D@S>R_7QLH28VAV8N]">"\Y]C/\=>QQZ<L_U'L,"[!SV2?%G>C
M75D>O@E"L=GA)"INLP-.R3_/69Y$)?G,7X3BD.-H6QDE>P&)HBHD49R.)N.J
M;)E/QMFQW,<I7N:@."9)E/\SQ?OL=#>"H[>"5?RR*VF!,!D?HA<<X')]6.;D
M2VB];.,$IT6<I2#'SW<C$WZSH4$-*L5CC$_%Q3N@*$]9]H-^N-N[D4A;A/=X
M4U(7$7F\8@OO]]03:<??C=-16R<UO'Q_\WY?P1.8IZC 5K;_'F_+W=U('X$M
M?HZ.^W*5G1YP Z10?YML7U2_X-1HQ1'8'(LR2QICTH(D3NMG]+,)Q(4!5'L,
M4&. 6 .YQT!J#*1K#>3&0*XB4Z-4<;"C,IJ,\^P$<JHFWNA+%<S*FN#'*>WW
MH,S)OS&Q*R>6[P7^W+7-T+%!$)+'PO'" /CWP%\Z*S-TB0#<@'5@@\^?OH!/
M($Y!N,N.191NB[%0DC903\*FJ6]:UX=ZZH,(++*TW!7 2;=X^]Z!0!K?$J W
M@BD:]&CCS2V0X%> 1 0Y#;*N-Q<YYO;5YM 8H)':_I J?W*/O] /S3E8.8^.
MMW9XX:W-M<J<3NK7B:1+"FGYZR5S5Z4BW=#?J^RN2I%50VI5[PCDED >)+#\
M(*3#9^;[=@#(X+)Y&+4/Y:+J&ZA*LL%P\&2BKDD,"%]F*'P2I251!DE63N"8
M*^L!F)X-;-(E<W])9P=P?E\Z7N $7X'GA#PZI=L>9&B2S-!Q9)(.58VAX\AD
M684JGTYMZ=1!NL"9SUUO]A7,'(],]'E%:=H+UW.#D$[\1Z<%Y3&JG)@C#;$]
MR)-!*+-#D2,S=,/@(VHMHC:(V*Q@W@RXGN4O'/!Y[@?!%QZ-QNDQ45810].5
M(0TRD\_F^(*B!C4^C-["Z(,P]ZYG>I9+.FJH5_1NW9I"U\5W&!R5H6J,RN;Y
M,M2>86>T&,:5&'6?\"",3L6RR")P-!([J'A^>GH!BN<-4_R/_4"VQYYUH''U
M/H00L:LU3V8@B5WEN-X4I6>2P(L4  X2D<8#.C' O;\"X8,#_B#+'A<'=C:,
M&Z0I.CM+>#I501T>C@SJ2.L981"=@= @4 5#YCX('LR50S<C,M(6OD<2'-_Z
MC737U Q<BTM8.S8NFR3>=I8!O@PA%I C@[>H9X.%YQP!#B<)'_+9[GQ-$CHN
MH70=(5?6)>3(!@C/.00<3B*^.^[L@::DYB-9PF<.\-:+*0$FJ!5ST(%>!T3M
M>K1PN:[6?"9*0[W>S1]D&<IB9PI:'"4RR&XFRNRFS5$2G:0CV!><<UH"A_.2
M_R4X0T.FFX#TA:>K[ M/5_E!>,YY#1Q.;&99MBW GPN</.'\KX&<')[S"#B<
M2'R8E3?VETL9R>,ZZ2Q7AB25#0Y'INA].R\\9Q!P.(68QQMR8L> '-W ZI<H
M.?Q*SGPX?R7%UP7LO,G#X5W^XX 9'40$U<XNSY')JLJN5C9')NED)V$")ER<
MDQ.<OU3W#0789,>TK ^<;6E[IV%6)WFF?$KO.JKS]]E-?5&RB/*7."W 'C\3
ME^*M1D9X7M\]U!]E=JA.XT]92<[VU>L.1UN<4P'Y_SG+RK</6D%[ S3Y%U!+
M P04    " "$.7]4%>!SA>H%   T&P  &    'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;+U9:V_;-A3]*X0Q8"U0UR*IEPO'@"N[J[$VR6)W0S'L R/3L5!)
M="4Z;O_]*%F1+)*BTBQ=/L26?>[5N0_R7%J3(\N^Y#M*.?B6Q&E^,=AQOG\S
M&N7ACB8D?\WV-!7?;%F6$"XNL[M1OL\HV91&23Q"EN6.$A*E@^FD_.PZFT[8
M@<=12J\SD!^2A&3?W]*8'2\&</#PP4UTM^/%!Z/I9$_NZ(KR3_OK3%R-:B^;
M**%I'K$49'1[,9C!-PM<&I2(/R-ZS,_>@R*46\:^%!?+S<7 *AC1F(:\<$'$
MRST-:!P7G@2/KY7307W/PO#\_8/W=V7P(IA;DM. Q7]%&[Z[&/@#L*%;<HCY
M#3N^IU5 3N$O9'%>_@?'"FL-0'C(.4LJ8\$@B=+3*_E6)>+, *$. U09(,D
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MY>56!%!O2@#\ODFA"3A^D#>H7^VZ^#]02P,$%     @ A#E_5#U J6D!+
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M0"=#,Y&+=-0.CLU+YGV2?,V0^.ZIM'QNTJ!SH[X#%PU9\EB4IF<_XM<G\(<
M._3I%"J,)!0FD"WBY'<8 M2.:G<84]SGAD8,/AE2A(C>1>*6_,:#:OEO+>IT
M\K]9U'#2]%&+^<Q56M=VTPNJ./^AL@47 CE&X\;LV&GN0X9XE$C:U ;S%<6P
M2B0U%DF\)P/1E!5 RF.B(U=; S(Y]H-+_ER8K2!PBXU<Y,SB0:-JIN8J @6@
M&B4Y@\BJ08C'+5W3C/6(VP$9\*:^I6$HR%Y&99@TPN4@M9%!V[-@H<S@ZD&B
M,/](%&:<S=$H2!+S\?91JEM@*R3UGF9P$@OI*#((M2HM59*D((,]68'7E5[5
MK4'D[*Q!6J-VJ3# O\ ', M7!L,%E'2?_XJ+*VAE5F4'@WD#A&9\H74E6)*K
M,5^6@!,;Z1L6A,.?>8R&>Y!C^9$"E B4]+$J=Q01*@PYAP1,+G1[BQ0,M _3
MG%$#5]Q"!3N%[6*241*2YPD$<M@?\.S98'LRO]2'MDZ3'K>81Y$WER'[9(X>
MT&]*O2!$Y/>H8YMB6U\)C//<.:9X$\?5G\]G#0;Q]$6IL7]NKW*'EC"U7D%&
M6PA9[%)HHZ0?>7D9"NGDIHEH%;!,B(%7DK.E0FEXT9!^O&W4'Z:,_<%A#CK>
M]%!K\/$-P)"JTZ&1H.$F(NK9189,)^PB?&IF5=8+RJ/CM[*4$<L#V6HF#Q:B
MF]2,#@R.A/B!D8!&HRI;^L*1)O$7& 7.Q:#/.)RQ=6$6CG8=2AG7;BN&8U,A
M^D"\]1Z$1OWEOV8GTU?PW]F+5W7VV=ZJLH!0M.G^\';@O:ES^'?<NI6ID%WD
M20RV!W+7%77Q_,8='_O4T(/U;VD'\+Z9&F?1M%R1$%A%COZMJ3^"\>U,M:XM
MO<!#&!FB90B+V5O-U@Z]K\'Z'=4@%WA6R=M8D>T.$[(>O7G+3WLX$N,'LN "
M0=^I*!K/^6]4$)>EC?@3VZE/=8L;X'M4',XUW%;% _639:.,"MG8TVHVH)MI
MU4Q,U"/8(FR-+$:?0%8:W[86M_8LI.((S.(D\@/S17KMNEN<\<0^BD+GI6I"
M/\#?L4[J1.=SLU*5,U4\MQ(U!>* ^@TF@WU"<^H2FK@=:U5D50?F#FMUJL".
M;(WE6T#:UJ$_&0JA2;W915%/Q/?_MJ']MVW =%J6**S1D%3)V*B9-#JO):P5
M5T*U!B=J6ZS% 7OLG@BIHMY**X8A-+NDQZCEB/MF#(-33! ME]A^P,AN@QW=
MMB:X4AAJ2T>I($*Q:Z"444&^:@Q*2[7S(%?ZELBE4\=BZ)R\B<M+?:3?;XKN
ME[%$9LB^ _68)Q<.M#ORD P;"XU"1VLLND:%.@@V%L%0 *VIM0>-Q*UJ>E"K
MJ+6EK?B.738X7JFKE82)7.B1Y@\O+VR-?3FQZ3B(2YO86 1D?AAKA=%\A:I!
M#3<K*5!:ZEP$,7?9\?@K4SFWX#O @*U$GB8G6&./+R#K2DH9,9G4H!#Q![Y&
M$M!]^*HXE@8U[AR%VOZH#04I*/D@GUBZJJ51#\MAH$&YHNXFT3<W7\I6L(T&
MG)25;4 3@(=/"!CC7\(1#(M;"<2] \Q+C4#N#!_EF&V'(FPD2K# &+O<#18#
M)?:@*%P.[K09-FNTV73F<^5)WMMMK>7NE2KG1@'X2KJ%$#%1A6&<+<;96V4-
MD2J',5C4K@=H&1PMN!%X?ZL:Z9CJP>'0KNV;:N-LO.M-&HXPO;NEAN9?Y_,O
MH5((&_3-DABXW'=0X(:/'XCF#%)__<CG6'K0'F U@);DB7'AMY5JE O^*#@,
M5-%!)F#[1O2*>W')- HPHP;W0F)O+LQ9JZ6_"]#!0BP=*R%6U,K:=ES;806E
MBFWT9!8ZO+Q]&I8)2?0.$>%@&9?N''A+FF.I 1\WDJHR8VRB[*0#KVPM:5AA
ML"+A1+6V$6L(8DM+N;3FLOBBPM;NR,40W<P).JH3@9B(Z6S0.'U(JZ#VC%5E
M0I.VA2^PBWL$9.(779%:W5'2D8MA';E%L)A('K4WY[@G+@$G#BZR6*APWLAC
M'79K"FRD0LO$!?2"V&-R;(HGST6-#<P7X2(O-5*:PY*%['9'"3'92@:_9W4=
MF>,,M@O@;BXI5>Y%RW?$F@(#JL8=%O)?.9/<&#S*'OBAJQO3U)4+ZT, 5V\E
M,^3KO''*!LUH?.;5=3YAAJ.70O"F*,@DE9T;2BO G$PQ2-1'E(D#O>U) .(,
M+'U8&$R)BHFL:,'QL.& "AWQ!&0!B%@?FD8$EO"&=28RI%\\J12I*&[$I@D
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MQ6$Y>I[:]_)SDSU7QH,]!DVAUJO&:Q;93,JZ@9&@P[7PO_,^0NK!8DH@<R;
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MR=AXG(*W"!I#D0U%WCD\CY\.[KO^:>]'Z0:$+BREF*-5TGS\7C.:UQ'U?]&
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M?0=$LVT:0_':3OB:*[TO[+'0"QJ%"=#W&\[5P3 )VI4__0U02P,$%     @
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M(Z1-+BRP5<=UZ\KH;T*! =>-HE6F/#>3Z^*<57"XPB9=B0@]8BK<'&S5N@3
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MFH#C<V-\_4(.FG^'G/X#4$L#!!0    ( (0Y?U3T+F(5@04  *$,   9
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MAFT'#3^9B+LF23%26'Z!(+%"6Z ?W\1",JJLGW,.5K@F>3N4DWNY4',.N;7
M*$6S0'?47)P/8*B-V8:HPQ@7BA$<ZIC*?GZM%/?MP.+V,EF/:5<8'%N( FS+
M988MZ*G:<3.8C0^AXG&W:P<'CU1XLIU#LD,W?IIO3G-(;3J8#6("G539093/
M\'4V.>N2-'EN^ID.QL:2["8,QRY&%"?(?K>?OU=Q[-Q?C\/[M;0;A0K3E$-T
M-OGEW4C8.!#'A3=U&$(3XS'2AL\"_T.0Y0LXSXWQW8(-]/^57/X#4$L#!!0
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MH%%9 ]K/I31'P1XPC/SUOU!+ P04    " "$.7]4SPLVY482   ^4   &0
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M<ZBE;S6'UF!/-W= 3OH0 ]=ZW(0X'0\!#-HA_C1VIM/(&C)RHYTX3H(](,=
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MTPI#6=",3&7>F$JN3:6W>\G;+9DMF0FEU;A!9^RG%>:Q[Y$E.<AFVEC-D&7
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M"OSQ"SH8.L7/S%3**-?&Y-M"4<>'Q&KDA=MJXH8^2W9F?=-M)8H%?;D.BV&
M+/5YM^9M\W&\<_5-N+:[^K(>>.L%A$$L%7,8ZKGCZ(@5ZFMUZJ'*U_2%N)N\
MJO(5_5P*#J1B!VB?YWEE'G""YI.!K_\74$L#!!0    ( (0Y?U0OT[_[40\
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M,4NFL]F!WY/D' SZM;IN1*YMQHX)_P07^L-A<S=TDEQ<C,.O:3);C*)W9RB
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M7HV;EV"K>!W-;*#+;7PLZ+\)=&Q WY>6MJ=]X0#]_R>G_P)02P,$%     @
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M3\<_X3M_FOST2*RE$ZI%9#(+H Z. \,MXKE6"^UJZ4/\ W.<:D%YWK65!"Y
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MT0(7 F25YT0<I\CX8>3XSEFQI+N],@IW/"S)#E>HGLJ%T)+;H&0TQT)27H#
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M4VBG?=B+P#0ZUVR<KH*VT/<CI0K+@JX&--Z![+G6;KWQ"3:7S? W4$L#!!0
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M^[88TP,!IO$_>R DF]U$Z[@=1YEJ=+8P]7:M@+%R.@V<,R? X(?9L@;2!RB
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M^5RQTESKLH#MZY5&DF']=+4&_)H1_X$_O@8NJIM6=PV=XZH^C3X1?@'8,M0
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M*1G%Y@\\L ;Q?7!/L@"\P;'@2(CC;#DXY9;%47072TD6I.%6HU5Y5_7$6;T
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M#F([8L6$?GU) ZS.<^]V;K8U,8'1/B-W&PK8<4:(R I^W3I<"[X9,WY19Y(
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M#[!0<$E\L4];;^B?.#U&-_@#^'Y9UZW[ S>XJYMO!-YO_P=02P,$%     @
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M#$H;8,YS(?3!L +=JS7Y U!+ P04    " "$.7]46$3<6;H"   G!@  &0
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MF71=O ]X8%CKO3VX3!92/CEC6HR"V E"CKEQ#-0NSWB&G#LB*^//EC-HKW3
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M"2KG8.V%E.8@N 3=\S3_ U!+ P04    " "$.7]47$[RM$4&   W%P  &0
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M==;0U\EB[&6AWW$G3 9B,;:Q&)\:B_V[=C >AU'_5?S=G!A_O7 [Y,%.Y&C
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M&85QT/:8ZV,Y"B9 />(GOP!02P,$%     @ A#E_5,0CK<I0 P  H0<  !D
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MO]W2&XK:&=#_7"E[$%R YE5>_ M02P,$%     @ A#E_5/BSM]M! P  #0@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULK59M;^(X$/XK5FYUVI,0
M>0_0!23HMEJD+45 [W0?33(0:YTX:SNE_/L;.Q"H:/OE^@5[G)GGF1=[AN%>
MR%\J!]#DI>"E&CFYUM6-ZZHTAX*JKJB@Q"];(0NJ490[5U42:&:-"NX&GI>X
M!66E,Q[:LX4<#T6M.2MA(8FJBX+*PQ2XV(\<WSD=+-DNU^; '0\KNH,5Z*=J
M(5%R6Y2,%5 J)DHB83MR)O[--#+Z5N%O!GMUL2<FDHT0OXPPRT:.9QP"#JDV
M"!279[@%S@T0NO'[B.FTE,;P<G]"O[>Q8RP;JN!6\']8IO.1TW=(!EM:<[T4
M^Q]PC"<V>*G@ROZ2?:,;QPY):Z5%<31&#PI6-BM].>;APJ#OO6,0' T"ZW=#
M9+W\3C4=#Z78$VFT$<UL;*C6&IUCI2G*2DO\RM!.CU=/B\7/NX>[^7JR_)?<
MS^:3^>UL\I.LUI.U/2:S^?WC\F&RGCW.R=<UW7!0?PU=C=P&P4V//-.&)WB'
MQP_(@RAUKLA=F4'V&L!%IUO/@Y/GT^!#Q.^0=DGH=TC@!?X'>&&;B=#BA9^1
MB0_XHI8OLGS1>WQU57' ^ZTI)[.R>5]X43MD2CDM4R K4U7U5JX_1O[SCW[@
MA=_(9ZV8:2@V(&VVOY*G[JI+,L$YE8JPDNA<U(J6F3*5\&PY".V21YVC"54*
M8[BYPIR52C-=FX!5>_B%]'K^A13Z/EF"TI*E&C)\;)503)_UHS"Y EY(J"C+
M"+Q@WU)P5NY'9^B!%Y-576;R<,;JM]MD<(7ZA00=;Y!<R'XGZ,>?EN+_D>I-
METS25-0E)J:B!_- ":I@OTME37F3 -__1H0IR'4E%O0@D<':2.#49/HJ>2;>
M*/%>R7$28!DU2*Q0RWQ2B.-S<GI)#\LBGIGMY'C1R3--[5UO51 M2"XE+S%1
MR?HM9P:=N'^A['<&?;PGXD"Y9J"N7(GZP=FM(#"N5"#UP48,OVM6F4>(8PG?
M(P-YY@G]WIGSNM:8@[ S"%Y=BJ03A>%;S<&]:-$%R)T=1(K8NC7=NCUM9]VD
M:?%G]690/E"Y8_AJ.&S1U.OV<+3(9O@T@A:5;?@;H7%\V&V.\QJD4<#O6R'T
M23 $[3^ \7]02P,$%     @ A#E_5!#Y"11Q @  B@4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&ULM51M;]HP$/XKIVR:6FDE+Z0K[0 ):*M56CL$
M=%,_FO@@5OW";&?0?S_;@2R36J1]V)?89]\]]YPOS_6W2C^;$M'"3G!I!E%I
M[>8JCDU1HB"FHS8HW<U*:4&L,_4Z-AN-A(8@P>,L23[%@C 9#?OA;*J'?559
MSB1.-9A*"*)?QLC5=A"ET>%@QM:E]0?QL+\A:YRC?=Q,M;/B!H4R@=(P)4'C
M:A"-TJMQ[OV#PW>&6]/:@Z]DJ=2S-^[H($H\(>186(] W/(+)\BY!W(T?NXQ
MHR:E#VSO#^BWH797RY(8G"C^@U%;#J)>!!17I.)VIK9?<%_/N<<K%#?A"]O:
MMWL905$9J\0^V#$03-8KV>W?H1702]X(R/8!6>!=)PHLKXDEP[Y66]#>VZ'Y
M32@U1#MR3/JFS*UVM\S%V>'LYNMH<7,-T]%L\02+V>AA/IHL[KX]S.%D098<
MS6D_MBZ1=X^+/>BX!LW> $TSN%?2E@9N)$7Z-T#L&#8TLP/-<784\1J+#G33
MCY E67H$K]N4W0UXW7\N^PAXWH#G 3Q_ WSNE$,KCJ!6,$-.+%*8$FU?8*&)
M-"3\C^:U9SV.^^%=+TNZG^%_KT](=-TY<.^.8HDZO/T)/';F':"*<Z(-, FV
M5)4ADAK7E_32-R<)'8*)$FYL&!*4=\)DP2O*Y!I,232>>1E1*%H^IV"50T.0
M2I[A#HO*BQ4HTTZ]RB4[<'L/>9ZWK%[:MO*+\]?Z%[?T(5"OPQ0PCD E;2V5
MYK09-*-:7W_<ZREU3_2:20,<5RXTZ5R<1Z!KY=>&59N@MJ6R3KMA6[IAB=H[
MN/N54O9@^ 3-^!W^!E!+ P04    " "$.7]4^.^%/[H"  !("0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6R]EEMOVC 4Q[^*E:=5JIHX7'H1( &]
M+%*AJ+3;P[0'0T[ JB^I[8PB[<//=B P:01M$GLAMG/.[YSS=_!Q9R75FUX"
M&/3!F=#=8&E,?A.&>KX$3O2%S$'8-YE4G!@[58M0YPI(ZITX"^,H:H><4!'T
M.GYMHGH=61A&!4P4T@7G1*T'P.2J&^!@N_!,%TOC%L)>)R<+F()YS2?*SL**
MDE(.0E,ID(*L&_3QS0 WG8.W^$)AI??&R)4RD_+-39*T&T0N(V P-PY![.,'
M#($Q1[)YO&^@0173.>Z/M_1[7[PM9D8T#"7[2E.S[ 97 4HA(P4SSW+U&38%
MM1QO+IGVOVA5VK:M\;S01O*-L\V 4U$^R<=&B#T'W#[@$&\<8I]W&<AG>4L,
MZ7647"'EK"W-#7RIWMLF1X7;E:E1]BVU?J8W31[&R7TR[(]?4'\X?'H=OR3C
M!S1Y>DR&R=T4?9K:[R M&""9H5<-6<'0(\W@#'VZ!4,HTV>=T-A$'"Z<;X(.
MRJ#Q@: X1B,IS%*C.Y%"^CL@M!549<3;,@9Q+?$6YA>H@<]1',6XAM>H9&EX
M7O, [Y',I")&JC6Z>R]H;K]#@[Z-@,] ?:_A-RM^T_,;!_@39?]7RJS/T801
MBR8BW0_T:,U18H#KNF"M*EBKMIAM,!\%ME'.45%N)[/;^:<]K(>VT!J(TC7I
MM:OTVK6D^T():@H%E<#H)QI107G!:_"7%?[R]%)?5<&N3B%U/11'1[6^KO*[
M_@>MR<<1K7&T.TZBTZN-]TXO? J]CU#Q\8\;Q[L4XUK84/*\,*#^[B#!NY,*
M-_Z#XKN#"S=/HG@]M7%8\'"ON7%0"]_"-9K+0IBRSU6KU36A7S;'G7EYQQ@1
MM:!"(P:9=8TN+NT1I\JV74Z,S'VKG$EC&Z\?+NU5!Y0SL.\S*<UVX@)4EZ?>
M+U!+ P04    " "$.7]4V5>)+2P)  !",0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6R]FVUOVS80@/\*86Q "J2QWBC)0Q+ =9S4;5Z,O&P?AGU@
M9-HF*HD>)25IL1\_DI)-*98HV>N<#ZWE\(['N]-S1THY?:7L6[+$. 5O41@G
M9[UEFJY^Z_>38(DCE)S0%8[Y;^:412CEEVS13U8,HYD4BL*^91AN/T(D[IV?
MRN^F[/R49FE(8CQE(,FB"+'OGW!(7\]Z9F_]Q3U9+%/Q1?_\=(46^ &G3ZLI
MXU?]C989B7"<$!H#AN=GO:'YVXWG" $YXG>"7Y/29R"6\DSI-W$QF9WU#&$1
M#G&0"A6(__>"1S@,A29NQ]^%TMYF3B%8_KS6?BD7SQ?SC!(\HN$?9)8NSWI^
M#\SP'&5A>D]?/^-B05#H"VB8R'_!:S'6Z($@2U(:%<+<@HC$^?_HK7!$2< R
M&P2L0L!Z+] T@UT(V.\$;*]!P"D$G*X"L!" 7=?@%@)N5P&O$/#>"9A.@X!?
M"/CO!)RF&0:%P*#KHDUC'3FC:R3,3;"WHMVT#G,=;O-]O!N7;JX#;LJ(]_-<
ME(E\@5)T?LKH*V!B/-<G/LB[0<KS_"6QN'$?4L9_2[A<>OXPN;J=7$Y&P]M'
M,!R-[IYN'R>W5V!Z=ST93<8/X&@XFQ%QBZ$03.(<%/SJ SBZP"DB8?+AM)]R
M.X2V?E#,^2F?TVJ8\TL6G@##.@:689E/#Q?@Z)<Z+:,V+3'7XN5:DB5B.*E1
M<J%7<HF?3X#I54SY!?1!KJ]1ZUBO]08QKM676HWN6B\[N,VRA5;3;W;;E5[+
M79!RVP92B]>LY7,'+;8IM< :\8E>_ (':_&-VTF*HPY.^M)=\PZN_]I9JSEH
M5'*M5S+,%CQ^,%^TLJE&T4T':XS<&K<JWN>W_X8!UH8!EM1G-S& +&(R)P&*
M4S , IK%*8D78$I#$A"<@#^ON0"8\/@D?VFFLS?3V7(ZIV&Z$8TB7K(?4AI\
M.P93Q !E_ JE> 9^1V&&P13S+X1SP!&)P8R&(6()6/%OI<L^@'^ UG^3W !?
M&B!:EY=SX\0PS-/^2SF3VD955N=L5N=H5R?M3L D23(\X\MC)"@OJ,7RBUSY
MH&23<^+66P0W%L%VB\!*&M(V/>P^O;N9WM5.?\5HPH/':(#QK';27-XK3\IO
M7O%3#=AD>Z //;@U[DN-0M_URN,J*_$V*_&T*[G-HF<>2#HO' B(#+),TOP;
MD9G-SLVUP[+YGC/@/_5F^1NS?*U9T\*U8,YH).+\PF\EL I1@'F'G=:5+W_;
M0:9=]7C%E,'&E('6E"$GQXR$F6C&P0,.,L9[!^ZH\5L09C/N*FDB!\ J2V4?
M(9PY1BSFO$G477(,AI&@D,Z;D\&6-RT?&J*JO<N&FH%BI.M;U8%?MP=ZONV;
M5H-33$/U6(;6+7<<74@R]1KS3<8QD/NCCW3^\2G!8)@DN"Y*DT)K)4P#=_N^
M^%(S$$)-PINE[M#<S?)K@IY)2-+OM0:;6QZ$T+>;[5 5RK3TB967I83O%0/,
M$_PYQ. C>&1HAFL-L;8,L1W'JO&<M>6YG#Q-%JLB9^JKW"6A <M^@#]OL*"&
MKG":JK:8SB$JM:E*AZFO';OZ'=;<:SIWJB)BZJO(:,G71SIY4^'<] [B305J
M4T_J7;VYC6E3ZTV%:5//:=&!@EN:OB=KM7U4?+.,0SC24EBR]%B:Q"GF92$%
M3)2Z(Y0 )-K#@)>[NLW,I$6==P*-7^L:^CWE;G:7JSJBU+FW<'&Q8'@AZSTC
M<4!6?)N.9.VL=<,V[1I2R5*<L_2<XZGDM*>2(IQU$,)9BG"6GG#__V[DNK"@
MXT;#4DRT]$S<^2[0JVN^"W:6JRY( =G2-]@[9K.W7;M]N1UH2FH%:DL/ZAL2
MDRB+=(M2K+4&!]E=*QK;^F[S$;V!>^%$WEAFT4JVV?<XE!G]2,$%GF/&Q&<^
M[H+,^16.^=;P'K]@EJ"P=C^MG]&R>3KK4L!69+?U:+Q!;RV>MQ4<[<.<:Y0.
M-O0L_#\\WT)?L\WSBKRV_N!BR#>+8HLVG9,?G&U#?BO*_2/'&]]AIB@D;^ 3
MH>!QR;<$*\SW>$$")G% V8JR?#.W[LZXR">&?I"P2[]F*U3;\"#Q5("U6YI.
MP?IGN3J^GQTRAN)%[A,1LCB3.]L5CA/^050(:4T.8+2H:^D^MTQH&D9;/!5,
M;3U,BX[YZ:$42A3/0/']^*WZJRZ14ORT_8-$2D'6UC>TMS3^R/ \BV>RJ9ZB
M[T68UGUVW4%YH;-20*!1=_!4,[(8V%!J'$5K1\_.(I..1>+(QRN""'?/(5G(
M>^H8%*=._P!Q0%Z'B&*"RJ:KP2J%84>/X;KDZ9 ACF*S<Q V.XK-CIZ4^V3(
M9:&S/4.NBI%0-[)J>>E N07,Z@E<?BR6".OE*GA1&5%>/'AI><$A7<DEC6B2
MUCY>*N:I.>QHLE&AV6GIHC7YPE.WO9]R%)0=]R"9HT#JZ$&Z3I6[&-SB%#R@
M$"=ZS%^V:#3A-N6+>WEWP>JJ%*(=?8O;%K'6/LQ1<'8.T@%#Q52H9^H>$6O1
MZ-34Y3QB>PA65Z68##LQ>8_"#166X4&P#!66X<_'\A7<%;90P18>!K97L :V
M>AM+S_,ZP;8I$3KQ%BK>PH/P%BK>PI_-VZL6C<V\W4.PNBK%6]B)M[J@M2(7
M*N3"@R#75<AU?S9RKUHTVHU!VT.PNBJ%7%>/W.'C37[TISO<=!5=W8/0U55T
M=?5T%6$ =_/\='.=8/R+.<[WJN*=@+KWM]R:OE?;*;H*L*X>L/_Q(?JD4%]F
M?Y--"JBN'JC3XIGYM/Z9>55KZ;V'@X#35>!T];3:X46/<:&J?"9MG3@^;'"E
MPIRKQ]Q_#.^H4%\.K^G9ONE6]UOCVG&NX3B6_?YED.V1NH=HKF*LJS]SF&8L
M6*)D[?']'@Z,BTDZ!L)30/;T%%2!>$7BX"K=-11C;_M<8<O%5>,45ST]5\=O
MO#*0C>O*1N[IQF+"0<6-=L.K2YXBMJ=_OK8QM&3B,0AH%(F36UGQN)&$SFIM
MTNMV043C=*DK+9XBO==R](Q95#:RUAZ]"@B^8^YUG3F*\IZ>\GN\D^1M-\R.
M[=7=J?W2Z\[BKPMN$%N0. $AGG-1X\3C*<OR%_;SBY2NY!O0SS1-:20_+C&:
M828&\-_/*4W7%^*EZLV?39S_"U!+ P04    " "$.7]4QM)KK<$&  #%(
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M=(#4.NR\HC@/*BR2G<7Y#<!MKXSDD(KG8]4QK!0X8J2 N*7@+3%T6]PM<&\
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M8Z#?SSE7#PLSP303Z^@W4$L#!!0    ( (0Y?U2.Q!A@3 (  *L%   9
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MY-H_8=/6A@$4:VUDW8*M@IJ)YDU?VG/8 407!P!Q"XC? _H' $D+2(X%]%N
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MA1[J((R#/E]SKCX,,S>ZOXGL'U!+ P04    " "$.7]42M<STD("  "9!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R-5-M.XS 0_14KXJ&5ECHW
M8!>ED2AAM7V 172!9Y-,&PO'[MIN W^/+VFVH+;;E]@SGG/&9R:>K!7R5=4
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M)E>*(].QK)X9$YH8HT%^MN"C <MD1!-<<!!9'!/^,<:('8:&;1P/EG2WE_K
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M>2<BB)X#N&A=;:*_-_'*[T2<0WA! OJ&^)Y/6PRZ/E_<:Q&?GRU.1QW>!'7
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MB9231N1,9[(1"#G)J"Y)8;*W\V,<[ID8QO&!K0Z#/Y$2'+5Q!UI?$5;5C77
MC \%&CO#(-@S$*=)<,# 3J:%1PW,#0\$DE?*&Y=CLHTL;B.+<$:7C#-DT)U1
MX=Y'G"2#?_?%WTE=>X+=4[5B0AM$863!96K:4IM#83-!6;L@7DHTL>Z&I3E(
M0=D'S/U"2OR8V&QOC^;);U!+ P04    " "$.7]4S#;OIC8#  "N"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R]5EUOVC 4_2M6M$FM-)$/"K03
M(-'"MDJE167K'JH]F.1"K#HVLYU2I/WX73LTL W<O;0OQ'9\SSD^-[[<[DJJ
M!YT#&/)4<*%[06[,\F,8ZC2'@NJ&7(+ -W.I"FIPJA:A7BJ@F0LJ>)A$43LL
M*!-!O^O6)JK?E:7A3,!$$5T6!57K<^!RU0OBX'GAEBUR8Q?"?G=)%S %\VTY
M43@+:Y2,%2 TDX(HF/>"0?SQ/&[; +?CCL%*[XR)/<I,R@<[N<QZ0605 8?4
M6 B*CT>X ,XM$NKXN0$-:DX;N#M^1O_D#H^'F5$-%Y)_9YG)>\%I0#*8TY*;
M6[GZ IL#M2Q>*KEVOV15[6VW I*6VLAB$XP*"B:J)WW:&+$3D!P*2#8!B=-=
M$3F50VIHOZODBBB[&]'LP!W51:,X)FQ6ID;A6X9QIG\S&=T.OEY>?R97H\%T
M-"5'@RQCUC#*R:6HTHZS8W(T!$,9U\?=T""Q#0_3#<EY19(<((D3,I;"Y)J,
M1 ;9GP A*JYE)\^RSQ,OXA#2!FG&'T@2)?&WZ9 <O3MF!@H/=+-VI.F@FX>@
MF4ZYU*4"(N?D"C#EFMPL0:$/8D'NKW _N40N_</#=E*SG3BVDP-L5Z UP(<=
M L=H%]Q7:R09/1D0V3[7_=!&E>!1V*H5MOY#X;\"K\MB!HK<S,DM"%CAY_(5
M5%&IM7=6DU_DWY14PBO&EF.T=>.Q'W?#QSTBV[7(ME?D5AVOU!FK!?-'%PH
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MU.B@ZZIJCJJ)D4O7D,RDP?;&#7-L*$'9#?A^+J5YGEB"ND7M_P902P,$%
M  @ A#E_5"W<>%,7 P  FPH  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULG59=;YLP%/TK%JJF5MH*-H20+HG4E.Y#6J>H6;N':0]NN E6 6>VDW35
M?OQLH#0!$J5Y";8YY_C<$S"WO^;B4<8 "CVE228'5JS4XL*VY32&E,ISOH!,
MWYEQD5*EIV)NRX4 &N6D-+&)X_AV2EEF#?OYVE@,^WRI$I;!6""Y3%,J_HX@
MX>N!A:V7A5LVCY59L(?]!9W#!-3=8BSTS*Y4(I9")AG/D(#9P+K$%R%V#2%'
MW#-8RXTQ,J4\</YH)E^C@>481Y# 5!D)JB\KN((D,4K:QY]2U*KV-,3-\8OZ
MI[QX7<P#E7#%DY\L4O' "BP4P8PN$W7+UU^@+*AC]*8\D?DO6A=8S[70="D5
M3TNR=I"RK+C2IS*(#0+V=Q!(22!U@K>#X)8$]U""5Q*\/)FBE#R'D"HZ[ N^
M1L*@M9H9Y&'F;%T^R\S_/E%"WV6:IX:WU_?7W^^NT6D(BK)$GJ$/Z&X2HM.3
M,W2"6(9^Q'PI:1;)OJWT?H9E3TOM4:%-=FAC@FYXIF*)KK,(HFT!6QNMW)(7
MMR.R5S&$Z3ER\7M$'();#%T=3G=:Z.'!=-S;4XU;9>_F>MZN[&$%V1):DRV8
MW9QIWMW5T W<CC:]VBRWB?))T NV46$3U?'\GENAMLQ[E7EOK_G/G$<2_;J!
M] '$[SUI="K!SM%I%,S.1@78[WJ]6AIM*.+ZM31:4)W ]]O3\"OS_AO20/_0
M>,:>01R23[?:HGMT/MUF30[VZT]+$Q5@IU.+IPGRNX2TIQ-4UH.WI3,2])DE
MAZ33J[;H'9U.KUF2Y]3#:8("IPX*FZ >]KSV<+#S>@0[;XOG*F8@V2'QX(US
M'A\=4$G=>GZ"^MO5!G+QCMK)JRVRU]8W-M5-!"#]A4&W[VBZ^!BB"8B57C[H
M=,&OART^_K3%S2.2Z/<'UR-HPCS?]TGM*6F!N4% NK6L[(VO=@IBGG<_$DWY
M,E/%)[%:K3JLR[ROJ*V/3.>5=P.O,D7;=D/%G&42)3#3DLYY5_][HNB$BHGB
MB[PW>.!*=QKY,-;=(P@#T/=GG*N7B=F@ZD>'_P%02P,$%     @ A#E_5-Y=
M&BJ;!0  9B(  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULS9K1<MHX
M%(9?1</L13*SQ98L&=PAS*1 M]GIMDS2=B]V]D(!!3RU$2N+D+S]2K:#G-J6
ME8$+<A%L\/DEZYS_\\%FM.?B9[9F3(*G--ED5[VUE-OWGI<MUBRE69]OV49]
M\L!%2J7:%2LOVPI&EWE0FGC(]T,OI?&F-Q[E[\W%>,1W,HDW;"Y MDM3*IX_
ML(3OKWJP]_+&;;Q:2_V&-QYMZ8K=,?E].Q=JSSNH+..4;;*8;X!@#U>]:_A^
M%OHZ(#_B1\SV664;Z%.YY_RGWKE97O5\/2.6L(74$E2]/+()2Q*MI.;Q7RG:
M.XRI ZO;+^H?\Y-7)W-/,S;AR=_Q4JZO>L,>6+('NDOD+=]_8N4)$:VWX$F6
M_P?[\EB_!Q:[3/*T#%8S2.--\4J?RH6H!$#<$H#* .0:$)0!@6L +@.P:P I
M _)3]XISSQ=N2B4=CP3? Z&/5FIZ(U_]/%JM5[S1A7(GA?HT5G%R?/?I^G8&
M)M?SFV_7G\'%G2K$Y2YA@#^ KUN=R@S0S1+<LDR*>"'9$MQ)OOB9@3\$W:C=
M2W Q99+&278)WI4A0'*PW8G%6B409&LJ6*;U%CQ-U8>9CE?'?K^;@HO?+D>>
M5*>A)^,MRBE_**:,6J;\YR[I T1^!\A'L"%\8@^?LD4?!+ U?.H>[C>$SYS#
M8?0ZW%.I.^0/'?*'<KV@+7]Z>=]IJRS!A*>*'QG-<W M5()63'E:@OMG4#UN
M3I_SMZ_W5"S!/Y^5)+B1+,W^M4PH.$PHR">$6R;T99?>,Z'SS<OZ6165TI3H
M0HKD4AIICV/BJ[^1]]@P WR8 ;;.X(>JU7BS ELF8MXXK#T>@V=&1699"W*8
M";$J?:2Q (\TV3% 9;$.3=,I1 ;552"MJQ >Q@ZM8\^>F%C$RH!SY5L&<#^T
ME=O@H#HXCW(;'B8T/%FYS8:U<H-A>[U%ARE$;BN]U2O=-&X1'U7&+=+1-"KT
M#;G]X^I\UB'07>BP<AF!)RCU6:E2K76,H]840(-!B#J2L(U%48J6];!K0+][
M00P&H9V#O_@/]7W?IFO@!O%Y.! :RD$[YM[DP5*K:L)ANP>AP1UTY%VK"TN!
M:NVAEE$-#N'@6 _:!1P\:% ([2QT]>"PM@[1H#T#!H.PBX,N%K1K.%@0&4 B
M.]]^L6#0)Q'XNF$V;<,[!,_#AJC2"=KQ]18;3DNM5]?"*(PBTEP%R' /.7*O
MS8?34J!Z.=2I:1G8@!$=V?9-.P2ZK8@,$M$I.K\IJK=^>(A:O8@,#5$7#;N]
M..W0</&B 26R<Z[FQ3"TZ1KFH>&9^-!P$-D9]C8?1C4?#D(_@+"Y @(#O\ 1
M?JT^+ 5>^U"GI7%@0\; W@EV^[!#H-N'@6%B8&>BHP]+E:H/X3 *6HT85+X-
M=^'0P8@=&@Y&# PF SOE:D8<!#9=0[R G(<1 P/!P ZP-QFQU'IU04318-!F
M1$.^P)%\[48<-!A1IZ5Q8(/&P-X..AC1+N!@1 /%P Y%5R-&-2,&J/W[(38X
MQ%TX=/!AAX:##['!)+93[@L'KZUH4S6\PV=R.Q ; N+3W1"<XOH=P3#"?IL9
M<.6>X+'=88= MQFP824^27>(Z]TAPE%[>X@-&?$)VL,.#1<W&$CB-[:'ZJO:
MMSVW:1L.XC-I$;&A(3YABXCK+2)$*"0MG1HQ3"3'MHBDJ45L^ZI&#/O(L2UB
MAX##+7J#3'*2%I'46T04M5^9B.$C.4&'V*'AX$5B4$G>U"'"/AG8="L/0\ZD
M0R2&@^1T'>*$U#M$R],J8MA'CFP0)Z3>(!99:1S8@)$<V2!..@0<;&B02$[1
M($Y(O4&T/2PS+ R/[P\G'1HV%WJ51_3Z%QA_4;&*5;TE[$%I^?V!*BM1_*BA
MV)%\FS^UO^=2\C3?7#.Z9$(?H#Y_X%R^[.@? AQ^6C+^'U!+ P04    " "$
M.7]4'\YB>ST#  !W"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RU
M5EUOFS 4_2L6VD,KK0&3D) JB932;NNTK5&SK<\.W"16 3/;^?KWLPTA: '4
M2ED> L8^Y]YS?'WET8[Q5[$&D&B?Q*D86VLILUO;%N$:$B(Z+(-4S2P93XA4
M0[ZR1<:!1 :4Q+;K.'T[(32U)B/S;<8G([:1,4UAQI'8) GAASN(V6YL8>OX
MX9FNUE)_L">CC*Q@#O)7-N-J9)<L$4T@%92EB,-R;$WQ;8!]#3 K?E/8B<H[
MTE(6C+WJP6,TMAR=$<002DU!U&,+ <2Q9E)Y_"E(K3*F!E;?C^R?C'@E9D$$
M!"Q^H9%<CRW?0A$LR2:6SVSW!0I!GN8+62S,/]H5:QT+A1LA65* 508)3?,G
MV1=&5 "XUP!P"X#[5D"W '2-T#PS(^N>2#(9<;9#7*]6;/K%>&/02@U-]3;.
M)5>S5.'D9/YE^OR @NGL\>?T&[J:Y[N)V!+-)0M?T5-FW)YJMZD\7*.K>Y"$
MQN(:W1PG)4/9AH=KY282:\)!:'S(DD1-"D-S@SX@NY@<V5(EKL/;89'D79ZD
MVY#DUTW<0:[W$;F.BVO@03O\'L(.ZN(ZN*WL*CUS2\]<P]=MX/NQ21; M49F
M#! MG-V2LVLX>PV<GSE))43HBJ:%3==U/N4DGB'1)W0[\1SU&]G;FMB],G:O
M5<^+J745G&R!J[.+8 \\I&HW,TY#:%'GE1&\5G4/.2%9Q("(1)!&VKT#$%XG
M,N<:5D3BCC>HU]@O,^BW9Y!D,3M FYA!236XV/;[):??FM[31@I)THBF*VW0
M E8T3?6@V:; /ZL%U_$'[L"K=VI8IC*\0"4&P_=4(G9.[<AIC:YZ\Q*H*495
M) _[C'*(:H^\<Y9 %_NNUZ >5QHB?L]6M-=J4)!5T\ ^'CINDQ.G)H/=RYV9
MH""KYC'LXV&O*8U37\+=_]0<\*G_X-[%J[^@K'8)K]/O-\@]-2K<WJF*ZJ^-
MF"-UX;VA,>%39\+MK>GM)=\_KS7<$/W4S/#@DN4^./>@U^DW97%J?[B]_[VS
MV/V:O>_]NQ%VY5:DKZ3?"5=U)5 ,2P5S.@-E),]O>?E LLQ<E!9,JFN7>5VK
MFS%PO4#-+QF3QX&^>Y5W[<E?4$L#!!0    ( (0Y?U1*^8\/@@(  +H%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;'U446_:,!#^*Z<\M=+:A$#2
MJ@*D0#NU4MLAV+J':0\F.1*KB9W9!RG_?K8#&6L++XG/OON^[WR^&S92O>H"
MD>"M*H4>>051?>/[.BVP8OI2UBC,R4JJBI$Q5>[K6B'+7%!5^F$0Q'[%N/#&
M0[<W4^.A7%/)!<X4Z'55,;6=8"F;D=?S]AMSGA=D-_SQL&8Y+I!^U#-E++]#
MR7B%0G,I0.%JY"6]FTEL_9W#"\=&'ZS!9K*4\M4:#]G("ZP@+#$EB\#,;X-3
M+$L+9&3\V6%Z':4-/%SOT;^ZW$TN2Z9Q*LN?/*-BY%U[D.&*K4N:R^8>=_E$
M%B^5I79?:':^@0?I6I.L=L%&0<5%^V=ONWLX" B/!82[@-#I;HF<REM&;#Q4
ML@%EO0V:7;A47;01QX4MRH*4.>4FCL:+^V1^!]-D]O ]>82S15L;D"N8HR;%
M4\(,%B335TCL!7+:GL/9+1+CI3Z'"[BKZE)N$<WR?<30)Z/0\OCI3LVD51,>
M4=,+X4D**C3<B0RS_P%\DUJ77[C/;Q*>1+S%]!+ZO2\0!F%/%TRA/H':[VZM
M[U#[QV[- EW8UY#!5%:F0S1SCRQ1BHD<S:LE6&[AT&_&MFX[:9C*X->C@80'
MPDK_/B%HT D:.$&#(X*^K4D3$QD7.3!#C3D7PAJFD%MDZK-2M(B10[2]NQG'
MX2"Z#H;^YA,E4:<D.JGDQ3R"]Y5K^:(/?+TXCJ+^YWQQQQ>?Y'LVM[YQG#9Q
M%-FIE.,/$FS"X=4["?Y!/U6H<C<U-*1R+:AMK6ZW&TQ)VX__W-NI]L24*86&
M$E<F-+B\,N2JG12M0;)VW;F49'K=+0LS7%%9!W.^DI+VAB7HQO7X+U!+ P04
M    " "$.7]4X8*-8E$#  #^"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6RU5MMNVS@0_15"Z$,*M-;=C@O;0*IT>\%N:\3;[3,MC2TBDJB2M)W^
M?8<4+:N(I&V"W3S$I,@Y,^=P9C"+$Q?W,@=0Y*$L*KET<J7J-ZXKTQQ**B>\
MA@I/=ER45.%6[%U9"Z"9,2H+-_"\J5M25CFKA?FV%JL%/ZB"5; 61![*DHH?
M;Z'@IZ7C.^</=VR?*_W!72UJNH<-J*_U6N#.;5$R5D(E&:^(@-W2N?'?)/Y4
M&Y@;_S XR<Z::"I;SN_UYF.V=#P=$120*@U!\><("12%1L(XOEM0I_6I#;OK
M,_H?ACR2V5()"2^^L4SE2^?:(1GLZ*%0=_ST 2RA6..EO)#F/SG9NYY#TH-4
MO+3&&$')JN:7/E@A.@9^-& 06(/@=PU":Q :HDUDAM8M572U$/Q$A+Z-:'IA
MM#'6R(95^ADW2N I0SNUVGRXN7M'DIOUQ[]O_B17F^8U"=^1+[7669+W@E8*
M,J(X27"/\N!>OB*W3.!3<(%+6F7DB\I!D V((TN!K 4_L@R$?$FN;D%15N#J
MM<744/5!I#G*3V1.!4CM,.5EB8=(.;W'NR^(:P\7KD*F.EXWM:S>-JR" 5:?
M#L6$!/$K$GB!WV.>C)O?0CHAH=]G[J*^K<A!*W)@\,(!O,^'<HOB($=N1>4"
M:T JP5(MK:$\XB=L_83&3S3@Y_Q45ZRRTKWLTZX!B0V(+O/C*O;P;^$>>WQ'
MK>]HE.,W4S#HG!Y!8 ,@\  B9?C"-;*$$79QZR$>9?>N :3; @A5!##I4-$?
M0$4?R09KWB'I3^)9/\=I&\%T-()S2>PO)9%V2R([EX2I"&XJ0MJ*J,\5,:+$
MK(UC]K_FTW7KYWJ<[T%)I):Q:J\5W\*>597>#.N>7#]*KF@:A;.X7_EY&\G\
M7]Z^1FVS/H?S1PZ#87^^=^F+WE.XCV=;8L%^H1T-%Y7?:<_^?Y?TB07KAN'/
M@W@PC$L#\\<[V/.KV[\T+W^\>STGVRQDM\S#R2P:H'OI97[TW'2SEOK!+^US
M,AWP>.EM_GAS>V*ZQ8^#""?3<""*2W_SQQO<$[-MVB/^HR#<SG"B)\._J,"'
ME:2 '9IYDQER$<VPU6P4K\V\LN4*IQ^SS'% !:$OX/F.<W7>Z!&H'7E7/P%0
M2P,$%     @ A#E_5,&XZT *!P  S3(  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&ULS9M=;]LV%(;_"F'LH@5:6Z3X(1=)@"3MT +M&B3;>C'L0K&9
M6*AD>9*<M,-^_*@/Z\B12$IQ!#@7\8?$5X>'1P^IU]+)8YQ\3U=29NA'%*[3
MT\DJRS;O9K-TL9*1GT[CC5RK+7=Q$OF9^IC<S])-(OUET2@*9\1Q^"SR@_7D
M[*3X[BHY.XFW61BLY56"TFT4^<G/"QG&CZ<3/-E]<1W<K[+\B]G9R<:_ES<R
M^V-SE:A/LUIE&41RG0;Q&B7R[G1RCM]=>"1O4.SQ9R ?T\9[E'?E-HZ_YQ\^
M+4\G3AZ1#.4BRR5\]?(@+V48YDHJCG\JT4E]S+QA\_U._=>B\ZHSMWXJ+^/P
M6[#,5J<3;X*6\L[?AMEU_/A15AUBN=XB#M/B/WJL]G4F:+%-LSBJ&JL(HF!=
MOOH_JD0T&KBZ!J1J4"1B5AZHB/*]G_EG)TG\B))\;Z66ORFZ6K16P07K?%1N
MLD1M#52[[.SFX_GU!W1Y?O7I]_//Z-5-.3@HOD,W*S^1Z.LF3UZ*OFZS-//7
MRV!]C]0+^O!#)HL@]6]#^1J]>B\S/PC3U^AMU0!E,=ILD\5*)0REN5*::R[B
M*%(;5:\6WT]FF8H_CV*VJ&*]*&,EFE@Q05_B=;9*T8?U4B[W!6:JXW7OR:[W
M%\2H^%XNILC%;Q!Q"/X%S:I0R_\&?;?.KEOHN[KLYD)O\ZI9HLLX4J=2ZN?I
M>5-F-T7GVVP5)\&_:OM6]2E!-WEJ=DF\"OUU^F:7:XFNDF AT;6_OI?HK\_J
M6.A3)J/T;T.DM(Z4%I%23:2_;:-;=7@U1G$UXG%SQ#,DU:"KK3^EGW2-7*G.
M"O6<! ]GA+"Y0YR3V4-'6*P.BPT,2T+A=<7!6G%@S"BEFCAX'0<WQO%D"/"4
M"4/21:TJCKP\O#I2KU__-\4Q_D-PLG2-0BDV;XY"D;&N(9C7(<Q'K=!YJS*8
MH_ZZ@\(.\-,QAO6MX+X:(/]!)FH>4U-5/AGF,2T4K!(U[6S]$(7!76>]6M3G
M17=2Q%%4DH\PM/1_FMB$&^C'+WMR57K-'+J8,$T*"<1!1DVA6?TY*02^8W<(
M%\@T+RB]+M 8TR,G P9$8S.C![*A4A/-J4)304!G;,;SH6RHY)N%[1G@ 'S'
M8M3*-JN+JK*]NK)=:V4#\+&9^,/AX+5R2)D^AX!];.;^H3DTJS\CAP3F!F*F
M]Y/SSYTR9M(%<!-\Y'0@ '=BQN] .E1JS:5#F;:N(B+ :6+F]*& J.3WUK>.
MGA $0$_,Z^X#J]NB[E753;"UJ 'WY(67Y*2])O<$TZ8.H$_,T#\T=6;U :F#
MZ8"8@=WFP=RD"ZPFWK'S '!.S, =RH-Y%P_FW;7C IE=,YD/Y4$EO[\2GG.&
M-8$!VEWSFOS HK:H>T_7PM;)S@70NV;0#^9"I;=_K4Z(XVIRV#!=S+ _-(=F
M]:<Y-"4/I@'7#.H6&3@WZ0*L77;D9'"!YVY/CZ4?&2JU?3+D:>LL'F"T:V;T
MP600K:KF% OL:0(#R+OF!?FA56U6;ZV#L?4JV07FNT.M&QL:VF8-\1S/U:P#
M*7"?CNK66-1YZV*"VY)(86:@9G:W$"%,5@,%;E-RY(B@0';:TV[IAXA*;1\1
M&AN2-ISRD:WR#J^<ZJ\E*,">FE?FAQ:W67TW[^&RN)&]M('\=*A]8^$#;?LU
MV-&;#13H3T<U;"SJPU,(LP/M:=#7='!-NH!N.C]R.C" .^MIM_2C0Z7VA Z:
MU2<#3K.AKOHP/+"VR8[)7 C-I04#T+-1;7:+>NO20MB*FP'VV5#WQO8K8-NN
MH0YCNK$%]+-1W1J+^C-2V/@=M:=)7YZ!=,I-U@,#=#-^['P N+.>]DM//H@6
M'\JT==80D)H--=8'\J'MLV.N7SXP0#T;U6BWJ(O^E\T<B,^'VC@6,/"V;X,-
M/BX'ZO-1?1N+^I#DP7S >SKSY4G'IMAT0<&!UOS8;WKA '3>TW?IAX1*K8D$
ME39-[0";^5!'?1@1>-M@)Y@YKJZH&S>]C.JP6]39TZMESS;=<4 ]'^KBV,#0
MMFVPAP75X)X#[OFHMHU%G0T  TP$O*=%OP,#-X%! *V%<^1@$,!ST=-MZ0>&
M2FT?#!HO4@"AQ5!+?1@81(?#[NIG.P&(%Z,Z[!;UEHUF]R(%$%\,=6\L9!!M
MNP8[C.MN>Q* ?3&J76-1?TX286(0PVZ'%%-B1$3CALACOR-2 -G%B]X3*3IN
MBE1YTU01P%J,>UND:%OM<^(Q#2(\@+TWJM-N42<[)PWORIO:JML#]GLO?%^D
MU[9L3#D$_GNC.C86]2$YG#6>,(AD<E\\1Y&J*+;KK'S8H/ZV?E;CO'Q" 78O
M'_3XXB?W@<II*.]44V>:<RPIGYTH/V3QIGA>X3;.LC@JWJZDK\[U? >U_2Z.
ML]V'_ #U$RQG_P-02P,$%     @ A#E_5,\7JYY, P  I L  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3(N>&ULS5;+;MLZ$/T50N@B!9)(E/PL; -^Y*(!
M6M2(VWL711>T-):$4*0O2=O)WW=(*;+B%[()D(U-4G,.S_!0FAGLI'K4&8 A
M3P47>NAEQJR_^+Z.,RB8OI5K$/AD)57!#$Y5ZNNU I8X4,'], @Z?L%RX8T&
M;FVN1@.Y,3P7,%=$;XJ"J><)<+D;>M1[67C(T\S8!7\T6+,4%F!^K><*9W[-
MDN0%")U+012LAMZ8?IG1R )<Q+\Y['1C3&PJ2RD?[>0^&7J!500<8F,I&/YM
M80J<6R;4\7]%ZM5[6F!S_,+^CTL>DUDR#5/)_\L3DPV]GD<26+$--P]R]Q6J
MA-J6+Y9<NU^RJV(#C\0;;611@5%!D8ORGSU5!]$ T,X90%@!PD- ZPP@J@#1
M6P&M"M!R)U.FXLYAQ@P;#93<$66CD<T.W&$Z-*:?"^O[PBA\FB/.C!9?QP]W
M9#J>W_\<?R-7"[Q7R88#D2NR,#)^O)G@H29D*@N\:9HYK^Z>[!A(+C"&&<!K
M8"S@QQJ4B]"?R=4,#,LYCF[(K\6,7'WZ3#Y9Q,],;C03B1[X!O5;%7Y<:9V4
M6L,S6FE(ODMA,DWN1 +):P(?$Z^S#U^RGX07&6<0WY*(7I,P".D)0=.WPX,3
M\-F;X;1_(9NH]C)R?-$Y+S.FX&9Y;-A8*2;2TJ?E,VG&S=FS6Q[OF$JN7\.F
M4AOR^QON0N[19?WG@L96K;'E-+;.:!QS+F.\,PDYJ[:Z7J?N1\G===SVB[8=
MA5&W/?"W3<^.@R(:=EX'S8Z#>M&>Z%5J[3JU]L74W''A:Y!*F6BB);]T0SLU
M:>?#>MJM-7;?T=.2N]WTM-,_[42O%M2[*.@!-# 59P2_,U@$MEC=UNY$H)2A
M+R3=K_?H?UAC:+#_N@?O:$U%WO2FT^H=O&XG@F@0';YO)Z+:-#IM,VT4+WHQ
MO07V"[E(KTD* FL/=X:S!.MDKHVM15MXB^<TW&\8?ES7]W6 1N_I>G3T;:2M
M]I'MQU%AT \.;3^.BL+PP':_T;X4H%+7!FH2RXTP92VO5^M6<^P:K(/UB6U!
M75NTIRG[U^],I;G0A,,**8/;+EY$5;:$Y<3(M6N2EM)@R^6&&;;1H&P /E])
M:5XF=H.Z,1_]!5!+ P04    " "$.7]4?F2N;&P0  !4=   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6S-76MOVS@6_2M$, NT0,?1U5N#MD >;>(F
M';O)M(/%8C\H-I,(8UL>24Z:Q?SXI5XF;8OWTDG:N!_:Q!4/K_@XYY+BD=_>
MI]E?^2WG!?L^G<SR=WNW13'_;7\_']WR:9SWTCF?B?^Y3K-I7(A?LYO]?)[Q
M>%P5FD[V;<OR]Z=Q,MM[_[;Z;)B]?YLNBDDRX\.,Y8OI-,X>#ODDO7^W!WOM
M!Q?)S6U1?K#__NT\ON&7O/@Z'V;BM_TERCB9\EF>I#.6\>MW>P?PVR4$?EFB
MNN1;PN]SY6=6WLM5FOY5_M(?O]NSRI#XA(^*$B,6_]SQ(SZ9E% BD+\;U+UE
MI65!]><6_6-U]^)NKN*<'Z63/Y-Q<?MN+]QC8WX=+R;%17I_RIL[\DJ\43K)
MJ[_9?7.MM<=&B[Q(ITUA$<$TF=7_QM^;EE *N* I8#<%[+4"=J IX#0%G/4"
MNI#<IH"[5L#1U> U!3S3&ORF@&]ZTT%3(# M$#8%0M,"45,@,KUIL-J>LTSK
M@&5G;_1VI"O2=C>L]S>XNB)MAX-QCT/;Y;#>Y_I[:3L=UGM=7Z3M=ECO=T=;
MI.UX6.]Y[7"'MNMAO>_UM;2=#U7O[]>SMYKZQW$1OW^;I?<L*Z\7>.4/%7]4
MY<6,3V8EUUT6F?C?1)0KWE^>'EQ\8$<'P_X?!^?LU<%XG)04%$]8,JN95/SV
MFKTZYD6<3/+7;_<+46M9=G_4U'!8UV!K:OBTF/28[;UAMF7#U\MC]NJ7UTG!
MI[^P?9;?QAG/Z[\[D(\,D"U[!5F+=4QAS0164&-I03[@(!_Y58]!L!*0P6U^
MQ%$O^5PT8'V;EA;D! <Y6-R(T* &V:X73DUZP7L,<M^\3[9$_H0C?XXST1KA
M"K(!ZIE!]UO.8^(])UHB%BUA6QO(XR03*4.:&=3P&:_AF(]$[%%9 T0=Q7\W
M*5YU%?C:& 8& ]VQZABV:[^AP4AZ'/(7@QMW8&7*?TL+KL6[,,>S*$Z[?+[8
M]H5N+,7#7HJ'757@Z#JL!/JUS#3'["B=BOP[K_2"'619/+OA(B<NV-4#4Z\;
MQ@_5QP?W<39F_SD7D*PONB+_+Q*0LPS(J0)R-0&)(*:B^LLB'?WUAOV^F%[Q
MC VNF;CK9';#JDP^9_^4O_.NOJ[1O0J]7"7<O8>W^W=JBV-7K(3L+D-VT9 O
M^!W/<L[R,F:6SR=)P;*R%;OF< T%H%1O]30!>,L /#2 JG-REEXSM?7$.J9<
M*;'X3LA^?#7A3&0#[$9T:\$6L[%HUN*6L_DDGG6UH[?92D'HVYZ_UIKT=2NW
MY"]OR4=OZ>M,T&)Z,TO^)P;<2!V8HS0O1/__TA5TC1FL!&.5?]:"IJ];"3I8
M!AV8!WU?+='$#[$8'6+-R>8\2])Q5]@X*EA,]&EQFS/;9>/X 9OVX3+2$,7\
M\)UGHT1,YBY*"C>Z5-,NT;*VB)C3,]$&95LDL[S(%B5[O&E8FR5YONB,X_=H
M(P[;"5T_<+JC 4LFS!8:SS&_*L0X*H/*ZR&U&1^+I^FB#',4Y[>Z\=;4HPXD
MQ[(<7SN20$GJ 8VQ83XQIU?:B;T2,[K^I"N1_]"@JHT6!FXD_F@"DD(!-DTR
M;)@E(UXVQU)V.Z.HH2(E"K>G8020R@"X- RS=,3Y.&?763IE\RRYBXN*P$:U
M3'5WTJ<&5>TD%QQDNH,D?L"9?S6B/^.L(M=V<N6:B"X:U)6( EL?C]0!P(7@
M)$OS7+1,$U5W]1\:D)7J+;N#)[]T7!EZ@;=QX4479.@'^EN2.@"X$)0[?NS#
M=#Y)'SAOA*T_&XG^3N[$<-Q0K]5J)'-#L!MY$$B*!IRC-Q@@7A2W:5:)2ZGD
M)2'$HB4:,<^5R.9-9+$,OI.^-IG>"VP/@O64R>#"U9N4R@"X- R;63QL9S&6
MTTJ"MZW=Z$U;\KG](_C\V-[D<PB<$-;2L$^=U_F6Z]K.VE3MN-)&R-!65A+/
M)A"?&JA0#:+GAIXF!BD1-B$1BVQT*[JS5 <11MFXXW0RB;.\3+_J@%[3T3E;
M12?EPMY&+HP%S.Z0"P?+5VTI&#8N&!NCLFRE^T;'M)G9L;V9]=MB3$86K _+
MCN6!)F:I"#:N"*V\-GTL8F\"SA_=W_Y&NF+W'$V^8DM-L?'$_9'908-JFAW8
M4E!L7% ._OA<,QZZ<2"IVXYV@V0=R?L.GM@_CF2_-*@&*QY'\KV#\_UE/*G&
M9EYO9$SC[\ET,16?7(MEX.RF&;S=0^"HP0XV.%HW"!S)T@[.TG(0B,H_UU%A
M;:_LVS@[,APDWSHXWY:[(6($E$&\BD7^5')"F3EV#8(C LOI6=:_L*@DYSHX
MYQZFUP?LDH\665(DZ%QT)"<Z_HXTOF0_!V>_Q\W%HP95G8N.'?FPGL=\Z;@0
MQ)+#\VS-%)$\Z> \:;2*.FI 5C:1G+!K%=5Q91ABDUE2L(-GSX,[GOUZ,)FD
M1=63@WG9YTCON9))W1W)H%W)J.X/V1%Q.S)C*#< 7,VNKZ12%Z?2NKE9D;)Y
MFW;FRYW84;T36]$_=ON27]T=X5=7V??&.?')(;T1V= \R>I"0]W^Z"$1!ECL
M@8N4#[LGR<XNSL[+['+XA!7$85.)FE%"SPLT(T[2O(NGOL_0X/6@S=^PDSIE
M3MJ&+S\1O-=Y-_[F\E]/7ZZ4"!>7B&\\KQ[J:'?&#PD E^YXR?JNZ78+_WL1
M3YCX*RMX-GD0333*JJ8MM:!\YM@9Z>86"6A6$*[D=Q?G]X]QDK&[>++@+"Z:
M1S?=<G38(*DBXWG:/O*D$'AX2EVOZN<FJ_K#!LILU'N2^#V<^(^3NV3,9V/V
M[X1/.H<) 6 1N9LG*=_#*5_0%1^5#PJ^I1,Q\R9)\< NXLXGD8<$5.CV'#PJ
M*0T>ONMQD>1_L8\9%^0^$T-6S"I]4#B2U0M#-":I#1Y.RLN6^H-GG1.&*.^3
M4]M3'H_BG&XLU&*$7V8]]JT<[$/Q_^6P$\PIAM[1;<*OV3&_XY-T7B=;U]?B
ML@P+4/*ZMR/INR>YV<.I]2=I>Y\(PT#;/4GQGME3SR=I>[^I1&4YI^=IGJ]Y
MDNL]G.M?1MO[WN935HC\*-)L=OI2.'Q<.$AQ[Q, M+C[4D)\T[7#8\2][W>L
M(70''*26^+@ F(M[OT$*UA,PC;K[4CE\G.^W4/=^ V4V[GTI%#Y.]*2Z]PD
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MLOZE2.?5%]Q=I4613JL?;WD\YEEY@?C_ZS0MVE_*[\Q;?I'H^_\#4$L#!!0
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M(5YNCOF;CA9I?E*>"FW.W7ES93Z-0-H)YOY"F$(5'7OX+C^V!O\ 4$L#!!0
M   ( (0Y?U2\=:R)>P,  *<+   9    >&PO=V]R:W-H965T<R]S:&5E=#4U
M+GAM;+56VV[;.!#]%4+H0P)LHZLEN[ -Q)>B =HDB-/N,RV-+:(2Z9)4G/;K
MEZ046;$NR4/WQ9:HF3/G#&?(F1X9_RE2 (F>\XR*F95*>?ADVR).(<?BBAV
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MG7='3L\M2,W^W ]=NZ=MWI\:4Y/EV4&KROHDN%4);C4*GKYF>M]A# I%TF!
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MF@!Z'@NAMQLS(=L/XN0_4$L#!!0    ( (0Y?U2)S,@LC0(  )<(   9
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MR,2Z[P7>9F%"%X6V"WX2+\D"IZ@?EF-I9G[+DM,2N:*"@\1YWQL$5VG/QKN
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M=5^(:N]T.W.9P58R9XDB'")$U6MM//TROQ_D"RV660.<"8WM-)LN\$X%TFS
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M2X(@BMP(8&X%08 A<#?B"*8 -&!($%3OP9WWD;]^3_GM[YSCWU!+ P04
M" "$.7]4EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M" #J"*!^-4!V$R0 TD @C0M"1K'ZF3N> O0?F1\X(8 T$4CS:I"3&?< I(5
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MO9U ;T>]G4!O1[V=0&]'O9U ;T>]G4#O0+V#0.] O8- [T"]@T#O0+V#0.]
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M#?__FKT!4$L! A0#%     @ A#E_5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "$.7]4J,Z5S>X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ A#E_5'"'4$QP @
MH08  !@              ("!&A4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( (0Y?U1%$<D=W 0   T2   8              " @< 7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "$.7]4%>!S
MA>H%   T&P  &               @('2'   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ A#E_5.&X(=<["0  YB4  !@
M ("!\B(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (0Y
M?U0]0*EI 2P  $B'   8              " @6,L  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " "$.7]40O^#3E8*  !+'@  &
M        @(&:6   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( (0Y?U1"+Q6LS00  "H,   9              "
M@3EU  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ A#E_
M5$+2"^YX P  _@<  !D              ("!/7H  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " "$.7]4SPLVY482   ^4   &0
M        @('L?0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( (0Y?U0OT[_[40\  ,8N   9              " @6F0  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ A#E_5)'U3B W!0  JPP
M !D              ("!\9\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " "$.7]4!BUW>2(/  #O*0  &0              @(%?I0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( (0Y?U0@KL;#
M-@,  %D(   9              " @;BT  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ A#E_5!=L'(]; @  H@4  !D
M ("!);@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "$
M.7]4P))4Q.0"  !X!@  &0              @(&WN@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (0Y?U3I9:*RIBT  )R2   9
M          " @=*]  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ A#E_5-MM,N@L @  P00  !D              ("!K^L  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "$.7]46$3<6;H"   G
M!@  &0              @($2[@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( (0Y?U153YK);0(  )(%   9              " @0/Q
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ A#E_5%]W
M4FBA P  Z D  !D              ("!I_,  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    " "$.7]43@5Y%-<"  "J!@  &0
M    @(%_]P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M (0Y?U1<3O*T108  #<7   9              " @8WZ  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ A#E_5$!%RLD !   ]PP  !D
M             ("!"0$! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " "$.7]4X6Q-[\T"  #N!P  &0              @(% !0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (0Y?U3$(ZW*4 ,
M *$'   9              " @40( 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ A#E_5/BSM]M! P  #0@  !D              ("!
MRPL! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "$.7]4
M$/D)%'$"  "*!0  &0              @(%##P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( (0Y?U3X[X4_N@(  $@)   9
M      " @>L1 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ A#E_5-E7B2TL"0  0C$  !D              ("!W!0! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "$.7]4QM)KK<$&  #%(
M&0              @($_'@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( (0Y?U1?:;2F+ ,  +T*   9              " @3<E 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ A#E_5([$&&!,
M @  JP4  !D              ("!FB@! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " "$.7]4?QJ%RF,"   R!@  &0
M@($=*P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (0Y
M?U1*US/20@(  )D%   9              " @;<M 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ A#E_5!<(\(65 P  30L  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( (0Y?U0MW'A3%P,  )L*   9
M  " @:=! 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MA#E_5-Y=&BJ;!0  9B(  !D              ("!]40! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " "$.7]4'\YB>ST#  !W"P  &0
M            @(''2@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( (0Y?U1*^8\/@@(  +H%   9              " @3M. 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ A#E_5.&"C6)1 P
M_@H  !D              ("!]% ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " "$.7]4P;CK0 H'  #-,@  &0              @(%\
M5 $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( (0Y?U3/
M%ZN>3 ,  *0+   9              " @;U; 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ A#E_5'YDKFQL$   5'0  !D
M     ("!0%\! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (0Y?U0R;RX\30(  +8%   9              "
M@8B! 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ A#E_
M5("/)"N\ @  ' <  !D              ("!#(0! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " "$.7]4B<S(+(T"  "7"   &0
M        @('_A@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( (0Y?U3&]OCQ50,  +X+   9              " @<.) 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ A#E_5 2&]RR) @  L 8
M !D              ("!3XT! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " "$.7]4L/##.O4"  "-"   &0              @($/D $
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( (0Y?U2/JWEN
MBP(  %4&   9              " @3N3 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ A#E_5%UTFS81 P  L0D  !D
M ("!_94! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " "$
M.7]4D@O.)40#  #T%   #0              @ %%F0$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( (0Y?U27BKL<P    !,"   +              "  ;2<
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (0Y?U0^;H,?&04  / J   /
M          "  9V= 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "$.7]4
MM7%@?!8"  "J)@  &@              @ 'CH@$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "$.7]4TC1D%.P!   ')@  $P
M        @ $QI0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     20!) /83
(  !.IP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>251</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>89</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - COMMERCIALIZATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommercializationAgreements</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenue</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30403 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30703 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30803 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenueTables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapital</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesTables</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31203 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31303 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31403 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommercializationAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40402 - Disclosure - INVENTORIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails</Role>
      <ShortName>INVENTORIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommitments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>OPERATING LEASES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40801 - Disclosure - REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenueDetails</Role>
      <ShortName>REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenueTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40902 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40903 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40904 - Disclosure - SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40905 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40906 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40907 - Disclosure - SHARE CAPITAL (Additional information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails</Role>
      <ShortName>SHARE CAPITAL (Additional information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41201 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41202 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Open Tax Years) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41203 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41302 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="plx-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41501 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="plx-20211231x10k.htm">plx-20211231x10k.htm</File>
    <File>plx-20211231.xsd</File>
    <File>plx-20211231_cal.xml</File>
    <File>plx-20211231_def.xml</File>
    <File>plx-20211231_lab.xml</File>
    <File>plx-20211231_pre.xml</File>
    <File>plx-20211231xex23d1.htm</File>
    <File>plx-20211231xex31d1.htm</File>
    <File>plx-20211231xex31d2.htm</File>
    <File>plx-20211231xex32d1.htm</File>
    <File>plx-20211231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20211231x10k001.jpg</File>
    <File>plx-20211231x10k002.jpg</File>
    <File>plx-20211231x10k003.jpg</File>
    <File>plx-20211231x10k005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="705">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 251,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 544,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 11,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 16
   },
   "keyCustom": 77,
   "keyStandard": 267,
   "memberCustom": 51,
   "memberStandard": 36,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
     "role": "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement",
     "shortName": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - COMMITMENTS",
     "role": "http://www.protalix.com/role/DisclosureCommitments",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - OPERATING LEASES",
     "role": "http://www.protalix.com/role/DisclosureOperatingLeases",
     "shortName": "OPERATING LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - REVENUE",
     "role": "http://www.protalix.com/role/DisclosureRevenue",
     "shortName": "REVENUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - SHARE CAPITAL",
     "role": "http://www.protalix.com/role/DisclosureShareCapital",
     "shortName": "SHARE CAPITAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - CONVERTIBLE NOTES",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotes",
     "shortName": "CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - TAXES ON INCOME",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "shortName": "TAXES ON INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:ScheduleOfUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:ScheduleOfUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - OPERATING LEASES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesTables",
     "shortName": "OPERATING LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - REVENUE (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenueTables",
     "shortName": "REVENUE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - SHARE CAPITAL (Tables)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalTables",
     "shortName": "SHARE CAPITAL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_NrgbIl6Vs0-zjQEgcvzrEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - CONVERTIBLE NOTES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
     "shortName": "CONVERTIBLE NOTES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_NrgbIl6Vs0-zjQEgcvzrEg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - TAXES ON INCOME (Tables)",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "shortName": "TAXES ON INCOME (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_NVfyMY4qKEy_rMZnOFmZmQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_NVfyMY4qKEy_rMZnOFmZmQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_2_17_2021_DVOA92GZ7U6MwsQtXt2j3Q",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_QRTirqjZmECEWnNG6G_xCg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
     "shortName": "COMMERCIALIZATION AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_BR_WFR8ra7qdUO5CmDbCylH2Q",
      "decimals": "2",
      "lang": null,
      "name": "plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)",
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - INVENTORIES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails",
     "shortName": "INVENTORIES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "plx:EmployeeSeveranceObligationPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)",
     "role": "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
     "shortName": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "plx:EmployeeSeveranceObligationPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_1SnkfDBBdEa_ScKv2fZZOg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "plx:CommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - COMMITMENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureCommitmentsDetails",
     "shortName": "COMMITMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_1SnkfDBBdEa_ScKv2fZZOg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "plx:CommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails",
     "shortName": "OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails",
     "shortName": "OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - OPERATING LEASES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "shortName": "OPERATING LEASES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - REVENUE (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenueDetails",
     "shortName": "REVENUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_GBgSGz6h9E-afGEP8417zg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
     "shortName": "SHARE CAPITAL (Schedule of Options and Restricted Stocks Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice4.69Member_brtBp7TBlkmrQbMsd4e2Vw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
     "shortName": "SHARE CAPITAL (Summary of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_sVz6kKARx0yLCtQB_HJuXw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ssa4_sAGw0q1WnIXrqo2yw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
     "shortName": "SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ssa4_sAGw0q1WnIXrqo2yw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RClXrD-nT0i4fdW-XC8UWw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_7_25_2021_To_7_25_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hPM6hUloe0uGCWps24NVTg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
     "shortName": "SHARE CAPITAL (Summary of Options Granted to Consultants, Directors, and Other Service Providers) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_srt_TitleOfIndividualAxis_plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cLhX8qB38kKkXv-Vc_vQPQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
     "shortName": "SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VQcCKNxkBki38IfXuZSABg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40906 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails",
     "shortName": "SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "plx:CommonStockNumberOfVotingRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_Vote_MK3JtZwR6kijibu1mfvLvg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40907 - Disclosure - SHARE CAPITAL (Additional information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
     "shortName": "SHARE CAPITAL (Additional information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_b7Ak3fDnlkmmGkfD-wjobA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
     "shortName": "CONVERTIBLE NOTES (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_b7Ak3fDnlkmmGkfD-wjobA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_9UaZHg1TOUCUxjp1RfI3xQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
     "shortName": "CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_yx82626jc0CePf0ZYlRM5w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
     "shortName": "CONVERTIBLE NOTES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_7_1_2017_To_7_24_2017_IHtLKtFOd0GdflSpPhFd5g",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_W5Xtd1I87UWgu75FfSxL9w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_lEOXiGqieUGUdzM41V7KzQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_isVv8OTKJkWScJpHl4LYQw",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_yjvPXIcAlU-gX6S2dUOMWg",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails",
     "shortName": "TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOpenTaxYearsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_DVyyV14ssk6w6xsrUpAbPw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails",
     "shortName": "TAXES ON INCOME (Schedule of Open Tax Years) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOpenTaxYearsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_DVyyV14ssk6w6xsrUpAbPw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - TAXES ON INCOME (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
     "shortName": "TAXES ON INCOME (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "plx:OtherAssetsInstitutionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "plx:OtherAssetsInstitutionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_WcoWVPzi80-nFDFiy4-V8g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_0yT3uJM1BkaHr4dUCEjvtg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_plx_CompensationToNonExecutiveDirectorsMember_0yT3uJM1BkaHr4dUCEjvtg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_WmGvHZywwkuV8-YzD0DRsA",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E0uJdNzPMUWVe1_NyQJfUg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_plx_PresidentAndChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E0uJdNzPMUWVe1_NyQJfUg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_GJGdc_13o020E-eJ4ZCwGQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - COMMERCIALIZATION AGREEMENTS",
     "role": "http://www.protalix.com/role/DisclosureCommercializationAgreements",
     "shortName": "COMMERCIALIZATION AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_WR3L3fcRwEaAwtn12rhbbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 89,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AlfataligliceraseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the product, alfataliglicerase.",
        "label": "Alfataliglicerase"
       }
      }
     },
     "localname": "AlfataligliceraseMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtmEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ATM Equity Offering Sales Agreement.",
        "label": "ATM Equity Offering Sales Agreement [Member]",
        "terseLabel": "BofA Securities"
       }
      }
     },
     "localname": "AtmEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_BenefitsPayableDuringNextFiveYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefits payable during next five years.",
        "label": "Benefits Payable During Next Five Years"
       }
      }
     },
     "localname": "BenefitsPayableDuringNextFiveYears",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_CertainEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Employees [Member]",
        "label": "Certain Employees"
       }
      }
     },
     "localname": "CertainEmployeesMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi [Member]"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementProfitSharePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement profit sharing percentage.",
        "label": "Collaborative Arrangement Profit Share Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharePercentage",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_CommercializationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMERCIALIZATION AGREEMENTS"
       }
      }
     },
     "localname": "CommercializationAgreementsAbstract",
     "nsuri": "http://www.protalix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "plx_CommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment amount.",
        "label": "Commitment Amount",
        "terseLabel": "Subcontracting commitment amount"
       }
      }
     },
     "localname": "CommitmentAmount",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_CommonStockNumberOfVotingRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes for each share of common stock is entitled.",
        "label": "Common Stock, Number Of Voting Rights"
       }
      }
     },
     "localname": "CommonStockNumberOfVotingRights",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_CompensationToNonExecutiveDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation To The Non-Executive Directors [Member]",
        "label": "Compensation to the non-executive directors"
       }
      }
     },
     "localname": "CompensationToNonExecutiveDirectorsMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ContributionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution to Defined Contribution Plans [Member]"
       }
      }
     },
     "localname": "ContributionPlansMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ConvertibleNotesDueTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Due Two Thousand Twenty One [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesDueTwoThousandTwentyOneMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued and unpaid interest exchanged in cash in debt conversion.",
        "label": "Debt Conversion, Converted Instrument, Exchange in Cash, Accrued and Unpaid Interest",
        "terseLabel": "Convertible notes exchange in cash, accrued and unpaid interest"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction costs in connection with exchange of convertible notes.",
        "label": "Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt",
        "terseLabel": "Transactions costs in connection with the exchange of convertible notes"
       }
      }
     },
     "localname": "DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate percentage of principle amount of debt outstanding.",
        "label": "Debt Instrument, Aggregate Percentage Of Principle Amount Outstanding",
        "terseLabel": "Aggregate percentage of principle amount"
       }
      }
     },
     "localname": "DebtInstrumentAggregatePercentageOfPrincipleAmountOutstanding",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_DebtInstrumentConvertibleBaseValueForConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Base Value For Conversion Rate",
        "label": "Debt Instrument Convertible Base Value For Conversion Rate",
        "terseLabel": "Base value for conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBaseValueForConversionRate",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentConvertibleConversionShareNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Conversion Share Number",
        "label": "Debt Instrument Convertible Conversion Share Number",
        "terseLabel": "Number of shares for basis conversion"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionShareNumber",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the denomination of the principal amount of debt that is used in conversion calculations.",
        "label": "Debt Instrument Principal Amount Denomination for Conversion Into Common Stock",
        "verboseLabel": "Denomination of the principal amount of debt"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentRedemption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of redemption of debt as at the end of the reporting period.",
        "label": "Debt Instrument, Redemption",
        "verboseLabel": "Amount of redemption of debt"
       }
      }
     },
     "localname": "DebtInstrumentRedemption",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DeferredTaxAssetsOtherTimingDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax assets other timing differences.",
        "label": "Deferred Tax Assets Other Timing Differences",
        "terseLabel": "Other timing differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherTimingDifferences",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DisclosureOfLeasesOperatingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases Operating",
        "label": "Disclosure of Leases Operating [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfLeasesOperatingLineItems",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EmployeeSeveranceObligationPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee severance obligation payment.",
        "label": "Employee Severance Obligation Payment",
        "terseLabel": "Employee severance obligation payments"
       }
      }
     },
     "localname": "EmployeeSeveranceObligationPayment",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "localname": "EmployeeStockIncentivePlan2006Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "label": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "terseLabel": "Equity component of convertible notes, net of transaction costs"
       }
      }
     },
     "localname": "EquityComponentOfConvertibleNotesNetOfTransactionCosts",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ExercisePrice1.57Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 1.57.",
        "label": "Exercise Price 1.57"
       }
      }
     },
     "localname": "ExercisePrice1.57Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice17.20Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price $17.20.",
        "label": "Exercise Price 17.20"
       }
      }
     },
     "localname": "ExercisePrice17.20Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice2.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 2.00.",
        "label": "Exercise Price 2.00"
       }
      }
     },
     "localname": "ExercisePrice2.00Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.55Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.55.",
        "label": "Exercise Price 3.55"
       }
      }
     },
     "localname": "ExercisePrice3.55Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.59Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.59.",
        "label": "Exercise Price 3.59"
       }
      }
     },
     "localname": "ExercisePrice3.59Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.59OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price one 3.59 .",
        "label": "Exercise Price 3.59 One"
       }
      }
     },
     "localname": "ExercisePrice3.59OneMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.59TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.59 two.",
        "label": "Exercise Price 3.59 Two"
       }
      }
     },
     "localname": "ExercisePrice3.59TwoMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.66Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.66.",
        "label": "Exercise Price 3.66"
       }
      }
     },
     "localname": "ExercisePrice3.66Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.70Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.70.",
        "label": "Exercise Price 3.70"
       }
      }
     },
     "localname": "ExercisePrice3.70Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice3.73Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 3.73",
        "label": "Exercise Price 3.73"
       }
      }
     },
     "localname": "ExercisePrice3.73Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice4.69Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price 4.69.",
        "label": "Exercise Price 4.69"
       }
      }
     },
     "localname": "ExercisePrice4.69Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice5.10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price $5.10.",
        "label": "Exercise Price 5.10"
       }
      }
     },
     "localname": "ExercisePrice5.10Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ExercisePrice5.60Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price $5.60.",
        "label": "Exercise Price 5.60"
       }
      }
     },
     "localname": "ExercisePrice5.60Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_FiocruzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiocruz [Member]"
       }
      }
     },
     "localname": "FiocruzMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_FourPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.5% Convertible Notes [Member]"
       }
      }
     },
     "localname": "FourPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_FurnitureAndComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture And Computer Equipment Member",
        "label": "Furniture And Computer Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndComputerEquipmentMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Line Items",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Table",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestExpenseDebtOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Debt, Other",
        "label": "Interest Expense, Debt, Other",
        "verboseLabel": "Other expenses"
       }
      }
     },
     "localname": "InterestExpenseDebtOther",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, in shares.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, value.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_KirinHoldingsCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kirin Holdings Company, Limited [Member]",
        "label": "Kirin Holdings Company, Limited [Member]"
       }
      }
     },
     "localname": "KirinHoldingsCompanyLimitedMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "label": "Lessee Operating Lease, Number Of Renewal Term Extensions"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTermExtensions",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance",
        "terseLabel": "Minimum cash balance required"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumDebtInstrumentConvertibleConversionShareNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum price per share of the conversion feature embedded in the debt instrument.",
        "label": "Maximum Debt Instrument Convertible Conversion Share Number",
        "verboseLabel": "Maximum price per share of the conversion feature"
       }
      }
     },
     "localname": "MaximumDebtInstrumentConvertibleConversionShareNumber",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_NoExercisePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Exercise Price [Member]",
        "label": "No Exercise Price"
       }
      }
     },
     "localname": "NoExercisePriceMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NonRefundableFutureServicePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non refundable payment received for future service.",
        "label": "Non-Refundable Future Service Payment"
       }
      }
     },
     "localname": "NonRefundableFutureServicePayment",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of calendar days after the date of applicable fundamental change purchase date.",
        "label": "Number Of Calendar Days After Date Of Applicable Fundamental Change",
        "terseLabel": "Number of calendar days after the date of applicable fundamental change purchase date"
       }
      }
     },
     "localname": "NumberOfCalendarDaysAfterDateOfApplicableFundamentalChange",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_NumberOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Directors",
        "label": "Number Of Directors"
       }
      }
     },
     "localname": "NumberOfDirectors",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employees To Receive Benefits During Next Five Years",
        "label": "Number Of Employees To Receive Benefits During Next Five Years",
        "terseLabel": "Number of benefit eligible employees"
       }
      }
     },
     "localname": "NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_OfficeOfIsraeliInnovationAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office of the Israeli Innovation Authority [Member]",
        "label": "Office of the Israeli Innovation Authority [Member]"
       }
      }
     },
     "localname": "OfficeOfIsraeliInnovationAuthorityMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to options  granted to consultants directors and other service providers.",
        "label": "Options granted to consultants, directors and other service providers"
       }
      }
     },
     "localname": "OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_OtherAssetsInstitutionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).",
        "label": "Other Assets, Institutions, Current",
        "terseLabel": "Institutions"
       }
      }
     },
     "localname": "OtherAssetsInstitutionsCurrent",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_OtherAssetsSundryCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).",
        "label": "Other Assets, Sundry, Current",
        "terseLabel": "Sundry"
       }
      }
     },
     "localname": "OtherAssetsSundryCurrent",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_OutsideOfIsraelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside of Israel [Member]",
        "label": "Outside of Israel [Member]"
       }
      }
     },
     "localname": "OutsideOfIsraelMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PaymentInConsiderationForDevelopmentServicesPerformed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from consideration received for development services performed.",
        "label": "Payment in Consideration for Development Services Performed",
        "terseLabel": "Payments in consideration for development services performed"
       }
      }
     },
     "localname": "PaymentInConsiderationForDevelopmentServicesPerformed",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow in connection with performance of additional studies.",
        "label": "Payments in Connection with Performance of Additional Studies",
        "terseLabel": "Payments in connection with performance of additional studies"
       }
      }
     },
     "localname": "PaymentsInConnectionWithPerformanceOfAdditionalStudies",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of adult Gaucher patients treated with Uplyso.",
        "label": "Percentage Of Adult Gaucher Patients Treated With alfataliglicerase"
       }
      }
     },
     "localname": "PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Change in Operating Lease Monthly Rental Payments.",
        "label": "Percentage of Change in Operating Lease Monthly Rental Payments"
       }
      }
     },
     "localname": "PercentageOfChangeInOperatingLeaseMonthlyRentalPayments",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfCommissionOnSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on sale of shares.",
        "label": "Percentage of Commission on Sale of Shares",
        "terseLabel": "Commission (as a percent)"
       }
      }
     },
     "localname": "PercentageOfCommissionOnSaleOfShares",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfOutstandingCapitalStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding capital stock.",
        "label": "Percentage of Outstanding Capital Stock",
        "verboseLabel": "Percentage of outstanding capital stock"
       }
      }
     },
     "localname": "PercentageOfOutstandingCapitalStock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfPremiumToClosingPriceOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium to closing price of stock.",
        "label": "Percentage of Premium to Closing Price of Stock"
       }
      }
     },
     "localname": "PercentageOfPremiumToClosingPriceOfStock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfRoyaltiesToGrantReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required royalty payments represented as a percentage to grants received.",
        "label": "Percentage of Royalties to Grant Received"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesToGrantReceived",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PresidentAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for President and Chief Executive Officer.",
        "label": "President and Chief Executive Officer"
       }
      }
     },
     "localname": "PresidentAndChiefExecutiveOfficerMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from expense reimbursements in a collaboration agreement.",
        "label": "Proceeds from Expense Reimbursements",
        "terseLabel": "Proceeds from expense reimbursements"
       }
      }
     },
     "localname": "ProceedsFromExpenseReimbursements",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants, Net",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNet",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProducts",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReacquisitionOfEquityComponentOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reacquisition Of Equity Component Of Convertible Notes",
        "label": "Reacquisition Of Equity Component Of Convertible Notes",
        "negatedLabel": "Reacquisition of equity component of convertible notes",
        "terseLabel": "Reacquisition of equity component of convertible notes"
       }
      }
     },
     "localname": "ReacquisitionOfEquityComponentOfConvertibleNotes",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUE"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_RoyaltiesOnSaleOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties based on sale of products developed from projects funded.",
        "label": "Royalties On Sale Of Products",
        "terseLabel": "Royalties based on sale of products developed from funded projects, percentage"
       }
      }
     },
     "localname": "RoyaltiesOnSaleOfProducts",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ScheduleOfOpenTaxYearsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Open Tax Years Table Text Block",
        "label": "Schedule Of Open Tax Years [Table Text Block]",
        "terseLabel": "Schedule of Open Tax Years"
       }
      }
     },
     "localname": "ScheduleOfOpenTaxYearsTableTextBlock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of options and restricted stocks granted during the period.",
        "label": "Schedule Of Options And Restricted Stocks Granted [Table Text Block]",
        "terseLabel": "Schedule of Options and Restricted Stocks Granted"
       }
      }
     },
     "localname": "ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_ScheduleOfUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Useful Life Table Text Block",
        "label": "Schedule Of Useful Life [Table Text Block]",
        "terseLabel": "Schedule of Useful Life"
       }
      }
     },
     "localname": "ScheduleOfUsefulLifeTableTextBlock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_SeniorVicePresidentAndChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Senior Vice President and Chief Development Officer.",
        "label": "Sr. Vice President And Chief Development Officer"
       }
      }
     },
     "localname": "SeniorVicePresidentAndChiefDevelopmentOfficerMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SeniorVicePresidentAndChiefFinancialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sr. Vice President And Chief Financial Officer",
        "label": "Senior Vice President And Chief Financial Officer"
       }
      }
     },
     "localname": "SeniorVicePresidentAndChiefFinancialOfficerMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SeniorVicePresidentOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Vice President, Operations [Member]",
        "label": "Senior Vice President, Operations"
       }
      }
     },
     "localname": "SeniorVicePresidentOperationsMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Fair value at grant",
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "verboseLabel": "Fair value at grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award granted contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term",
        "verboseLabel": "Expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of non option equity instruments, that will be granted contingent upon certain conditions, on an annual basis.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non Option Equity Instruments, Grants, Contingent Upon Certain Conditions, Aggregate Value",
        "terseLabel": "Aggregate value of Restricted Stock Units that will be granted, contingent upon certain conditions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsContingentUponCertainConditionsAggregateValue",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodIssuePricePerShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share price at which the new stock issued during the period.",
        "label": "Stock Issued During Period, Issue Price Per Share, New Issues",
        "verboseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodIssuePricePerShareNewIssues",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesStockExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) expired during the current period.",
        "label": "Stock Issued During Period Shares Stock Expired",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockExpired",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SupplementalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "localname": "SupplementalInformationAbstract",
     "nsuri": "http://www.protalix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Supplemental Information, Balance Sheets"
       }
      }
     },
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz"
       }
      }
     },
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.",
        "label": "Tax Rate Assumption Related To Deferred Tax Difference Reversal"
       }
      }
     },
     "localname": "TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_TaxYearThereafterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Law for Amending the Israel Income Tax Ordinance, Tax Thereafter"
       }
      }
     },
     "localname": "TaxYearThereafterMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ThresholdPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage of conversion price on sale price of the company's common stock.",
        "label": "Threshold Percentage Of Conversion Price"
       }
      }
     },
     "localname": "ThresholdPercentageOfConversionPrice",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Noncreditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_UsIsraelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel"
       }
      }
     },
     "localname": "UsIsraelMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_VicePresidentResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for vice president research and development.",
        "label": "Vice President Research And Development"
       }
      }
     },
     "localname": "VicePresidentResearchAndDevelopmentMember",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_WarrantsAndRightsCommencementPeriodForExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period following the issuance date, the warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights, Commencement Period For Exercise Of Warrants",
        "verboseLabel": "Exercise of warrants, commencement period"
       }
      }
     },
     "localname": "WarrantsAndRightsCommencementPeriodForExerciseOfWarrants",
     "nsuri": "http://www.protalix.com/20211231",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman, Board of Directors"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r111",
      "r195",
      "r199",
      "r204",
      "r430",
      "r431",
      "r432",
      "r433",
      "r483",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r111",
      "r195",
      "r199",
      "r204",
      "r430",
      "r431",
      "r432",
      "r433",
      "r483",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r58",
      "r60",
      "r109",
      "r110",
      "r210",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r163",
      "r263",
      "r268",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r209",
      "r243",
      "r348",
      "r353",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r541",
      "r545",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r209",
      "r243",
      "r348",
      "r353",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r541",
      "r545",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r163",
      "r263",
      "r268",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r160",
      "r263",
      "r266",
      "r503",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r160",
      "r263",
      "r266",
      "r503",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r209",
      "r243",
      "r295",
      "r348",
      "r353",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r541",
      "r545",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r209",
      "r243",
      "r295",
      "r348",
      "r353",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r541",
      "r545",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r59",
      "r60",
      "r109",
      "r110",
      "r210",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r263",
      "r267",
      "r543",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r263",
      "r267",
      "r543",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r321",
      "r476",
      "r477",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Protalix Ltd"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r164",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts payable and accruals - other"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r10",
      "r43"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r10",
      "r43"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r521",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r9",
      "r46",
      "r269"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r186"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less - accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r389",
      "r390",
      "r391",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r355",
      "r357",
      "r395",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r357",
      "r385",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r77",
      "r92",
      "r229",
      "r454"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Debt discount amortization"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r92",
      "r229",
      "r237",
      "r238",
      "r456"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r149",
      "r152",
      "r158",
      "r174",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r430",
      "r432",
      "r441",
      "r484",
      "r486",
      "r517",
      "r531"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r57",
      "r107",
      "r174",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r430",
      "r432",
      "r441",
      "r484",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r358",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r39",
      "r94"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r94",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r444"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "verboseLabel": "Number of shares per warrant issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r426",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COMMERCIALIZATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r193",
      "r522",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.001 par value: Authorized - as of December 31, 2020 and 2021, 120,000,000 shares; issued and outstanding - as of December 31, 2020 and 2021, 34,765,280 and 45,556,647 shares, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net, Classification [Abstract]",
        "verboseLabel": "In respect of:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r141",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risks and trade receivable"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r261",
      "r262",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Future milestone payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r261",
      "r262",
      "r264"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r261",
      "r262",
      "r264"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Recognized revenues related to non-refundable payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r22",
      "r519",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r73",
      "r107",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r441"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Converted instrument, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r223",
      "r230",
      "r231",
      "r232",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r106",
      "r111",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r235",
      "r236",
      "r237",
      "r238",
      "r457",
      "r518",
      "r519",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r233",
      "r519",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r208",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r206",
      "r235",
      "r236",
      "r455",
      "r457",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r106",
      "r111",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r235",
      "r236",
      "r237",
      "r238",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Description",
        "verboseLabel": "Redemption, description"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "verboseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Mature term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r61",
      "r62",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "terseLabel": "Gain for the period"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r19",
      "r272",
      "r273",
      "r294",
      "r338",
      "r516",
      "r530"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r306",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPostretirementLifeInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide postretirement life insurance benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Contribution to Insurance Companies [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPostretirementLifeInsuranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r92",
      "r184"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r128",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r435",
      "r436",
      "r524",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r128",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r435",
      "r436",
      "r524",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r108",
      "r402",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Option to purchase shares of common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r66",
      "r67",
      "r68",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r138",
      "r175",
      "r256",
      "r258",
      "r389",
      "r390",
      "r391",
      "r418",
      "r419",
      "r434",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r546",
      "r547",
      "r548",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r235",
      "r236",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r338",
      "r437",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r221",
      "r235",
      "r236",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r338",
      "r437",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r235",
      "r236",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r338",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r93",
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r92",
      "r239",
      "r240"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": -1.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of convertible notes",
        "terseLabel": "Loss on extinguishment of convertible notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r183",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment in value of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r405",
      "r406",
      "r408",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r403",
      "r407",
      "r412",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r400",
      "r401",
      "r407",
      "r408",
      "r411",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r91",
      "r500"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseOfRestrictedInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for the increase (decrease) associated with investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Increase (Decrease) in Restricted Cash",
        "negatedLabel": "Decrease (increase) in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsIncurred": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings.",
        "label": "Interest Income (Expense), Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InterestCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r79",
      "r228",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense Recognized"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r89",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r46"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r179"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r53",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r54",
      "r101",
      "r137",
      "r176",
      "r178",
      "r180",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r179"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r34",
      "r179"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Maturity Analysis of Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted cash flows"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, term of agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES"
       }
      }
     },
     "localname": "LessorDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r107",
      "r153",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r431",
      "r432",
      "r433",
      "r441",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r107",
      "r174",
      "r441",
      "r486",
      "r520",
      "r534"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities net of capital deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r107",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r431",
      "r432",
      "r433",
      "r441",
      "r484",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r22",
      "r23",
      "r107",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r431",
      "r432",
      "r433",
      "r441",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price."
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r90",
      "r93"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r63",
      "r64",
      "r68",
      "r70",
      "r93",
      "r107",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r129",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r436",
      "r441",
      "r523",
      "r538"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS FOR THE YEAR",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncollaborativeArrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangement Other than Collaborative [Member]"
       }
      }
     },
     "localname": "NoncollaborativeArrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES - NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r465",
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r461",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r469",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r468",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r55",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r81",
      "r83"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24",
      "r272",
      "r273",
      "r294"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r295",
      "r297",
      "r303",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r338",
      "r340",
      "r341",
      "r342",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r358",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsPeriodExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period expense related to postemployment benefits.",
        "label": "Postemployment Benefits, Period Expense",
        "terseLabel": "Severance expense"
       }
      }
     },
     "localname": "PostemploymentBenefitsPeriodExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Net proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "negatedLabel": "Payment on notes payable"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r190",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r185"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r187",
      "r486",
      "r526",
      "r535"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r187",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r321",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r476",
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "verboseLabel": "Compensation (including share based compensation) to the non-executive directors"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r321",
      "r476",
      "r480",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r474",
      "r475",
      "r477",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption and transactions costs",
        "terseLabel": "Net payment for convertible notes",
        "verboseLabel": "Debt conversion converted instrument amount, cash"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment for promissory note",
        "verboseLabel": "Payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r397",
      "r502",
      "r567"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES, NET"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r16",
      "r94",
      "r100"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r258",
      "r392",
      "r486",
      "r533",
      "r549",
      "r550"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r175",
      "r389",
      "r390",
      "r391",
      "r418",
      "r419",
      "r434",
      "r546",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r69",
      "r107",
      "r147",
      "r148",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r163",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r441",
      "r525"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r467",
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense included in cost of revenue"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r357",
      "r384",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r357",
      "r384",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense in Statement of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r358",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Share Options Outstanding and Exercisable"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r364",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of transaction in which grantor acquires product and service from nonemployee or provides consideration payable to customer in exchange for its equity security. Excludes transaction in which grantor acquires service from employee.",
        "label": "Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]",
        "terseLabel": "Summary of Options Granted to Consultants, Directors, and Other Service Providers"
       }
      }
     },
     "localname": "ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non vested at end of year",
        "periodStartLabel": "Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under share-based payment arrangement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of Common Stock remain available for grant under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price (in dollars per share)",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "terseLabel": "Forfeited and Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r366",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options or restricted stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r356",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r358",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfOptionsAndRestrictedStocksGrantedDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Number of options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "terseLabel": "Number of options outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r379",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Number of non-vested shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r52",
      "r66",
      "r67",
      "r68",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r138",
      "r175",
      "r256",
      "r258",
      "r389",
      "r390",
      "r391",
      "r418",
      "r419",
      "r434",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r546",
      "r547",
      "r548",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r138",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureRevenueDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r26",
      "r256",
      "r258",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r256",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r30",
      "r31",
      "r107",
      "r172",
      "r174",
      "r441",
      "r486"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total capital deficiency"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r242",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHARE CAPITAL"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r451",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r451",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r451",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r451",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r487",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivables"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates in the preparation of financial statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Term of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5444-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r568": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r569": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r571": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r572": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r573": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r574": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r575": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r576": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001558370-22-004823-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-004823-xbrl.zip
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M E=KDQ7H?EMBL/ATL3;?:/L:]7ICV[I?IC;EG"E5%UD$F7#.5.!.-UG9TR4
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MLA0US8 LV:$W:W,0@++#OA0X6C-O\UFZG#/7$ZX(E'4>1.&-Z#@R>P7F"WA
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M,MJ;ER&RWSP&3R<.<A,M_>L]_?-U^F<:(4+N']?HT?)&/B%SPYA]#(@#E>+
MZ$$_'9.YT90_,Q$O ]16<C&G O9HVG26B1W55!96IAS<NU/A%Q0\8FN]=&W+
MXWBYN;!,5[ 06C.1Z+&,"-??S85E$RF";N3OEF%V((&$5J>W .FMYUN(K*E9
M,*7[ T?K=]^8"E#X:@!IIN%2^LI'O 5#@\>B@#F,5FW,H;75OA(Z$ QRFC/G
M.JZ%-S-KE[TO\@3SX/E.&%$+@X3OD:''I,DB9YR)/5B5#?FLD&K:W%$L(:-
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MSJWGFXJ]3J8I_S:E9&.(G*G<#66:UN!,RSNDHOP"=12USU0YD@HW5"5),>6
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M&5RE#_[E+=5>C%_Q<U(E%%YM8X%67? [ &Y^&;NFA()JW/1?ME:C)3\O>31
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M&I:4]CK\JG9W[-WAW;&[Z>1N-)W_/AC>7@Y&_[P?W]%K8X,?ML,.@L5@._#
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M-8I&^H5G1N5>('A=JE2R>$M'D< NJM7[$78?XL30(0BS3_%"2 B' QFN"XF
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MZ!HO(P:T_AA5O<\1!G,VU*OR?4YQDV.%@76_(4Y';=. V@T:"N+%39;<<<;
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M1L]?>]0'U7W[S^_AGV_$/[GD[#__.(^8?2X?DC1VW#2GQF7XM[](?O^ZX =
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MQ>*D; TRN3P0,K/-Z;W5.5; 828W>^!DO(/1$[=,SA%2Y(\RSA%/Z?*$=TY
MD^5C3/F5LF2',P39_ %DN&CYB4,?$^6(,90]U5VNO]L[+K>?](F*: ?\1\A<
MA=A89GKG"9<"0")F^!54+@4'CZEF74.9@CHD 1:(D_-@]O!Q]-QH[%\X'5(0
M,G^R.%I(Y5'B$'K,\\"7;@C)7>W<7D>XQ[%N1XYMC=_I$J['\<A0;?(\:OY&
M[55,V-= _W&"$H[Q( /$'.E"+(E$++W_/"0I<)7<1XIT!3X9#TY"/4AZHF'"
MK>*6LL4S\5.:=6T5$W=+W>@QY%2Z'G.??UBL?!4STUE/>9EW3(2L&1,"21)O
MBF&AZKSK'6T^^AL^/*F.OR %!T7[<\$#J3"!]?(VRJQ6I\JM$"4Q%<DJ;*J%
MOXSV\/=1)=_RO556DML4)DECWX4*"AZ&_N3$GHA 7T;QEOKI07[E=!0UA+W7
M\<(7>['QI'#V9L?RV_8,N^@0\O-A+)3^3Z:WE)\=99K=.B:2;10SU)R!_+:"
MLV#X5#CYW(CW%L]:KI"41/-;*DXVOYZJ4$;8]<TS#3UN3J$!-C@\Y4W[!#1/
MROG);]Z/)GAJCK#S_G4"DY_S+GH&WW?*TS&7(^R?DW'NT'AT/T]#6+W0V/43
MN1L<AF]-K*U;0)TP?PO9IGA;%X<MG?R8Q_7KH?ILMU;9J=&,$,#FZ23V!.]U
MQ=6(W^>D2$'+F@#<(%%7D@]F)D1_A.]0$K#&>?2(J!6KM]I]=+*H?1M]0@YD
MF, Z 7R+7<@P864^9):MR"UU7!%/8[JZV39*CR%',GRF<>H_!/0Z2J4>93@)
M\SYEK)BY5QF*C^)7QC$I26VND(&C0:O&G&?\%K0()V;4H7Q&DO:WJ9]-8.9;
M1-B0'XJ$P/S:L!0XG.W3=OI0J\0=[5M[V>:'V'OFW!/'!18AVUSF8<<2,N]G
MCQ,Y][;CJ*#XW&-8[6_F(7,_><"F0I,759CUP)^[W)WN:0[ANWU2D5*;5J1W
M9=+C=#T[=Y*GRR#ZE.@W.Y.@H/<X4XJA:&W6@L?L:*9@9E CL^7=+^3R:O,K
MYI,VS'A E)LX>O8]ZIV]?DBHMPZ+9ZF63/N?V9).^Y1M#"&TAQ-&BMQX76$@
M%8PG&$:Q*&W)#Y1(3HH\O)(O@!KQPR])^:!:29'\GM-LM2 QD_,RF?"EF9++
MV\U[4K[#MCR_7W]<WZ]7=S_;DL8'F3FAZ[.5L?K2PGTTC8W/,Y0%Z7H33YLR
M16^B<7#3\B85HB\5KQB,M!^+83^?FE="FL@8SN)Q?O>:SVB8O;0"?X5_NS"9
M!S%_I'Q:RBE&Q'1S\NMJU49- 8S85TK)>JNY5 L2I\.4@HW.^_XJ.%*-Y5C6
MW0[6#:KY!;2Z</TNY:Z#X*BTC,VJ(E=_-ZZ^[<%;7[X*@E4?>R2;!I7R,HJI
M_QB>'^*8ANYK)=;RSO%#6+0^A#%U DB.50@[C 2.4H\1LZKT0_"-&\5PYMJO
M-0H2)*=1BPX"E6QCMB E*:QGAJ<0UP\=ME%R K8=@LU95KL%#9^#5T)?W"<&
M38GG;[<4!L&MYKIABQ>3;AEZ_.'9FXAM#FG*-GVP SRC(=WZ:?<[KH,HX%CH
M""&K!CH W;A]#N:MI:\9!=X*2;R%7"=",BH)C^23+VXI6Z02IM[1EO]EIC=C
M^W9LQPM^S@TQX97WKAM#RDK@.P]^ *%^GI2SVP?1*Z4DAF=5$G+8\W34?)#)
M[B!SU[()1=E(<@F%H.ST=DN3/773S7:5<7++&?FPAX3;G W)W<>Q!,W?24XS
M!?G=Y''44.XHIV"YI>%B<0UXU ,L7% F6TX:]#X6Q/FU>[>RFTU&FV\V@"K9
MA"2C2P1AZ'67D>8I)OE<".H$R)-;I>&;2"Z9;T:.5 S$O4LY)U NO]G>Q!!]
M2E]OF)#\&9>]Q#\.1<;9L0P3K;I9T<,TOD\9PI;"CUWE?NS"3_91F3"4DR*<
M%BF(89TACA<5&D(P5!!NZ[\PBW22A**F$0!;"0A%F5BK%PCP'OSD25QJ7]"'
M+BOKP<,S,"V!FK;5B81B5AH<]5E4'1/T#G Q#6B,4'QM9]+0EC3(Z9*(@IF\
M4=Y%C),_'9$/FH5!PD>>5\6.:<QKNWR;H;KCTD9'NOD=*%[M-E<3U_P-[2#&
M9&T."O3<:]3;2"<\KE#00;H^G59*#Z2L]<T44O*_>QDQ1$-<AVY,G81>4/&_
ME6O@K&M+3\+&$ (XQCA<Q*HYZF,;-\BAK+6;BV4$R!<YB2_A0%>F-11/@R'G
M-!PM:25^5\DZX#ME;HYY, \Y Z$MYWD4<KE^]=.G\T.21CL:7^611^W9ZJ%B
MBUUJ"=MMG)TD++!0#?YTS30G13XQ6B0GMB %.:Q;YZFE]JI2NQFII!* _\+G
M?7+!IL,H?./R&[F4[&$ICD+,*[/V5"Q=L7^XI2[UGQVV&=>>11FJ+::K%JO;
M7MMX%ABIBBE=R\SQ24D ZWQ\A' Y"C>O4C@G%RXN"/ E-.+W@>.C3]+K+K%N
M5Y;[*^"#AZTWVP\)7?+A)#%P743SUU?#1,JOJ?2P4*ZCAK#6T?R.5P"(?(?:
M'I13$[<K<-]R8/\A*)J]9CI*RD%R85P932 =WUSS>Q_XFB .>B2Z[?S6X3/3
MY"CVE2^R].#8LMY*!.E>:"L(%JRP+6YTE]8*HCU+:K\TBK745TMCQ2;UQGF%
M]7T9>DN1]7)5GI,';SBZB=EB6$-$U]O:=E&RP!3UV1R\_<U(\NUA1I14J-IS
M/IUB#JI;XWU%<)XOY@1V&3C/@[MF]B&.RF/,NHN$+<;<+V9/J%>);X'A]C&G
M'>[E![>2T.PF.B;<.U368L&%B"\7,(B@:S:-=]5@[TF4Q2MF:0@!V\O@9>:H
MCVUQV?MTY>[SF&*4.D&7*4XB:6_5IWUF"%OZ9(KN%)V$K#)+#9$US+.#BBUF
MVLOB4',M"-I4!SZ9\,WN%.OKCZN[*;I32".^[;7_S G_<4%Y%J<LTMN'8#["
MJR="'MGMAD:)Z.JPU!')]8M]9NWFSLOPR1,-/'%I^<#(&H[CCI)-L7,&3)*C
M8H1M1PH#'H!G!3(9X!,4GV8R*V9>QZ742RZ948C,YKNG*$[OV?:[PY2UL,S;
M\P!A<J/60$&Q;&V^.LR;[^;\<!M$GPA,4I%_G@"I-_R(E2N46=L>+UV.*02Z
MRP2Z*P6:Q\IUFA-.)53'5\*L*79>\T?C7-Y IE8!L0R]OMJ<(020*HH'BU@K
M*-;&-E]//)"UMH)F!/B#B()$4:&S$"4Z"QY#1:_3.5Y4QM23(QK [_,B)!"-
MJD0S:80M%S/8"H=00#+#X4+6[% ?W;PA#N5-<_TS:8O:M?P3RYHOB]8997-O
MO]F6#V>56WC=^QHEMAU7-3W"==W2*%#1+V@Z^=(]858>>8-@CBTI#\-D4R0_
M5%YHRS:B%NQ#+Z.XZF'XO9,D9-:S3="F@KLC'2BL;%NJ20)M;SJ(/_4&%5J\
M?%%;.+[,[DUEL5_L7>IQ0B^/Z/# &UB=Q&W.T5%S^V]OCKNUL?BV9KI;&JLN
M58=)RL-P^ZJDAUQ2OY#4YBO6HK;VV"O63D)6&:F&R!K&VD'%%J/M9;'WEO%R
M?;V\/K>G!_XMW6>K:^UYF(Y^)IT8.&JI(415_SK C2M:+R^2U\)R#-%^L.Q^
M@=FP9+@<V:Z.[T%;/3S8WLMC>[(T[\I8>4\HD3\H9"9,,UQ,6-/V7:)BI0L/
M%X6WMA#\)^)A)X[%5V?F!/D-7=9(;<'7<4O\&G_K*LN!UIB,.CB^1Y.QKW)G
M55A47]9FI,>1B<?3,@P;O)B&!%47QK:L.S])HOB5F[4-5CVM!),D3>2-<<#E
M['91R%\A7H9>_N P\Y8]=\5:%'"3*08(*4NLT$!'3[+0YK'GFJ)H(<0;>0$E
MDO 'M&'1SU^4YM$7O)2+"60%,F53*/YL))=5/!;.:!5/@B^@8!@W&\/\M[7D
MCE@JN,9]G0(/_SZX4R#5+; 4"?7NMX.C'A5<5U2P:G+X=[SC95*:%<2U8Y(^
M47[1G9#E8TS5T6M3&Y*Q0K^+H>/C/L.VQ$-D+G#U0F/73]3W99TH^'Y!)8;*
M)33A4;V!G)D>H\F02(&%[P$TY<A_!W//%\V3"'H?'5FU/\A]7'#;XJ#VN)NH
M@I"M-U'#)&W=1&T+^:RX?UIMM^+5@^P]I5LGI9L0Y&:;=?@?R!A[9EL!=3K5
M,!(XYCA&S*I!#L$W;I+#F6LO$)P$+ \Y$0)4H%DVMU4X;?%_5$CAK'Y3"'MY
MN3J_AS?@5_]Q_LOR^MV*W"[O5T3\^XYLKL7C\,OK"_&/U;]_6']<7L'+\8BF
M"L(U!"PSS;()J/^A GE#8S_RVC5166_(ZFR*&59,OVDF<-P%SE17'8Y9#HR[
M+ SQVM?JC.RBY=86S<12[OR:?ZLA"(:()$]U00JV&IY5<(:SL[%B]J]7]V1]
M?7Z[6MZMV(RMQ+^^9'_[_+SO'-_A)'WCY*[NM#S7O(YH%F>RY^:^"CNO/.>8
ME+/EU?+Z? 7;-*4_(,M[LF)_9S"_K9:W,T[ 7>K$J:U3<+9ZM[Z^AGPPQ408
M]I.70?0)&E*Q?Y9YFZ$G.3G#DR%!E!QBVI/>>#Q9/&\YQ70T'>8Q-%%\YO$,
M2]TF ;H+DE&NY#&#KY3%DDA)'KT-S4SS<O?AYN9J]9YYA^7M;VP_=;FY?;^\
M7[-C+?M_E0XUS)O(,DG)]09V9A\W5Q_AAS+Y%#/%-'O*A+]$[/DIFX1D+3K>
M>6>']#I*?Z/IC>-[RIG61<=R$\/$J[L#/5P$LQ_"F,2\Q0,[57R2$R /AQ32
MO<@K30D0P;J:/%)(JVO?&SW.-P^IXX<0 \\/>9=17.^*WO?\SE$4D;(HCY^$
M6J+E>'+F<S&/Y;6=K@D4WT3;-Q_REOXDIPK%=$6(!%()F\\!S/MV3W_6]CR3
M47\0@$25V:#5V0CIITI[R(#/B!W-6N\.^WW <T2<(-_1K$/&\XXG ?9L[+6Q
M<:Q_H'!52]=$-6[5@_AJ;RXKV*38@9,*@;FWU1J+\I$BUO;/%^N[\ZO-W8?;
M57$QQ'?#J.TOF+=B1P785[23G9506.TLI,S6VU;40!#:4TC&E[2A$%!\N[F
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MS3;6H1OMZ+WS,B [NP,#*\>V5XAZBJT2'"'#MH>7=A!R^1_B^8?U]?GF/68
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M<=O3XJ>E6#D686B$X]FW*(Z3[)JF)(B2!'I?DP3PD%LBZAF(%!*O%:*&(4C
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M9J+Z]DNC!\#V5U-PK^V@^#C<#U5&(OE0U=ZJY.&5Y*/9ZI3FF;K2"^4'M/Q
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M0IO/ >EAI9VXD2/8H#E0T7-@![)N3]D+C?7V<"?S]7>'I: (;PYW\"%YG$U
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MA0HJ)&L\9-_UYZ7C=L=]U. V7&VVV5=?9):PR->634;Z+RD!0Q$0P;B/[!6
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MKNO%M=]WT.D$>>2<4Y() 0R.-^I,7Q@;*P3XD&>PKPE_\NQZH>> QYKM.R)
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M[WZ':_'_^@IB@_Z?^%)_)?[ &[W?_@]02P,$%     @ A#E_5%XFN9198@
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M%(8;-)=#7J[0!_@[2VY%7"\'[CMLT?-+X9^I+*Y/3[;Q:CMP)#]Z?A_6]#8
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MS!8.O0B:931X"_'1\X']YO;6L-.NN4F9$+\9MHN4_.+Z ![,Z(\C\C1Q9IE
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M2*90AJCHP5O5KQQSZ)@PGHME$V0(<A0N.DA% Q<J9HU=HCYL6J*UPX+:P<V
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M:PM8R)80/7V'41_-^X;O0AB"Y!HQ.@Q0)B A;3>/D_+5DW@05K4NJW1.'JT
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MB+.5&J"? R#)?EY=?*G/#Z%P1OMUC6]]H8!DGZZ<DDT!C%=$O=SSA.7=U@#
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M+36G%ICK<&-2K"*I"=-..D6G#B0LQK^$2X\HQ>B5ADM.BLZK"RCKI8ZKCP1
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M.9OP=!']D#_ROKM0&3F<4/W2,9.O<)Y7DP9X%^J?#IG\[3+Y]96T7^C -:&
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M]1HG2H%;56 ]K/WM#7SD9I)Z>G!K,*=&#G W=+I\%J2KA)-5+Y1IG%2UQ7D
MK^%N/_AHF*"[]-;4."U:\=/E%Y=&$A;5/ATADGH7^1W]!)>#G2*B\16-.]J2
MSM?(:5.LHIX2XE6]8-5M29V 5?R(/7KP'BO&?G4 TAB%=#DU3I=AO$I)Z%3U
M0I)&)V6!#WF;A2'XB?]$=>AFJGRZ)*N@GX1O5>_V:'Q3ZG!=Z-MTZ#?SM:U!
M-L*C7@_0=9!P@W2Q)=AADTQ@_!O</_AOW%G:3%&ND=-#7J">$G94O>S1;:4:
M^YX)@!4\0F20^(9K@M%\_ST"RJS"5OGT>"= /PG?Y%R$W"EB6\\Q K@U_,U
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M1.,<F5!GI;2<(FO1F\74'\GP8T8X;O=%T@7+&D<:A%$&=;$!$E?(^J\VPD,
M@H/;2)<SPC-%?2P6L^,))Q"Z22J#=B6GWXWP;S;"P[ E<UD@[M@^[*"G.E2"
M--3J(-O,CBDW5IW=[&)1^&V?6P#?TV39E8F1E%&+-,_KA*K/E*>;Q=0?R?!C
MM@^H"<14BTU&;$X<B&.A7F[7)E<XHWVQ[?.](*!X,K%9AM[^6/,:Q4E4Y9V@
MBL/&3#[3G&5'5+7'Y7)I_*E?;-+,/'2L7S/XX*"^=K>=PLC$:2O.>T4OGXZN
M 338@%1#D3TM2"!;$/WS^2EO]\UV.6\GU5G+J!CZ)KQ[<WA_[1EY+<HME(F4
M*CQ9M,2EV?',"9UGM TN.I4,P;K<J73XH[8Q+@ZJS*B+RV2[(;-,5"(7*6-9
M4<*WYW6]H JC6WYQ4-5THEKH3S,++NTR]G2HTA41W#75;=@[K^RZ;_.@HE]E
M15<F[N19,#"T'&&CCH<R/* C3>S45?RXTP.AOEG7TA7'M9 EF546Z*\UQ);+
MM!GM&V0'GR3Y_-*L@4PJ'DHO:2<7*?JY1Y6/N]H[7M9;Y-S:Y<?I>=.3Z@E0
M%1:7@ZJFN'%BKBUY/*?K)8[VC#AMA<ZT/P357:K<H?J=.:[? T4T/[D.L#9E
MUC@<,W6MWF^-<==JYHAE^<GK]D,[*[\++4>&?(?*$:@@<ZXD# Q8HV%YSX%2
M:<M>N4=/BZS'6^6^7LU.^I/0^@0G 079;4<'?%,P.9Y>[!TJI 0$&XP,3<I/
M3,N8^4L\&X^Q.>GDY *O<]/<@A;SE?%X$=XL]N]2(Z\,^YP8^=JL<I]6!UIU
M(N0995;DTIU^9]EK3JI*Z[H9_F7J()2LWK6MCAD+=K=*#Z?)3)1E -V-LP6)
MY9.A,UK?S?03AGYE[,?/KN!G2<'59UQ:X";1Y-P>,$IAU+WNZ?_[%/SETLB?
M3\%33KH,XE;GB<NU)S66: ^)J7C=#/\.!1\>5I^BX"LZ2?+1:*+*%;U1.L].
M@/D4OWZF?Y^"OUA6_V-[0BA!DB(I@N4U!90\RD_/]"RP1)E!+P(2300[K'_J
M8<T.72%;JB=GI]0RTR-<-W1KI[MYH X.<S?4Y- X;W-/)[$#B@1/X?N8.#':
MH,OVHP:^3*?PG./&6:M6%=EX:$WZ[XXV\&\S.I7?L"B%GS6\A(AO&+[]491M
M<]'S*)$CBS*O+_K9)S)^<?O\ Y2C,")^(N5VBYZ!<C&>W*R3;?Y^6WDB84DZ
M$S1I.%Y5EF'#^A 5LC>930(I2G*SF5B8%^-J,3->.G&1:M+A"U4_08\B23II
MR)=<*8MA^$EWBSTK>I:LET1L@Y3M#U$>%6>$5&757,(<8*66DHRS%[>0/D Y
M$B-B)U)NM^CEEZ+/(629N)7G$P-GI*:?^)$P'A'*)!I:.S7L0O9]NQ:Q52Q*
M+-#&].I'_LDI%9UL5<)SDJPUS=HH*UW^H-=[XRUBOLHY*=["+TK2YY0Q<D4Y
M)A"RX,=:QC)@X.2AKV&Y>^9>$\R 7C,4W<FBZS2 A2[6$(8@;>@SZ$@I PU4
M#&>S1VTU^*18FS%/',C5&=N*:=0B?(<XUU+V<LSK7-7O&?2EY(Q@D/"<!I=G
M1<]\YP.Z"<K0% D%,;&H]PI4-NN8AXVJ4C8HH-E,83D1JGU6R67Z=K8S*7J#
MT"WZKM+G'1[9*G#AY="N;%'W!/;5! N@#'T34]#7"1<K0EZ1XS;@.-?*V/'A
M<-HGS=!)\=O\.S"V*V,@_B'YRXR>*FJ>IUA6Z8,43@A3R2R&;F$F1/)WV4M:
MWRU_F1DE]<Q84\==NYV:C./1+*9<H?[\.OG[TJM03PE/S>NB,0$M8;')MKHQ
MJ3A[E9)US>RVY[4)VK959LXL;(LSDX-:*)E]V0C4PQ1;&63[)+M-Q^8R@%L?
M,N::_* *]"HIS1/JM#[LT/$L5G+;H?. OP]HZV/%7/-/!]C!*.;3-5JA&8\[
MU4)5Y:9:T1FG,K%\;7$50#MOH/)=HUT"<#L:324J1+)1+;BJ4AN0I6'=LK%4
M*/V4[P':C6JTE9']X4U+BC;*,5R2"WBG/$Y4W'$\&Q-"YQU]XZ;EGEV]MP]Y
M.;MZL]2_3ONQ6M]&OH.APY_V_MT-P!$4';H<@J4K^G#M]S9I<T 2HQZNNFRC
MG\P/QLUF+73Z8+/&_]I0=^_-.C36FQ+HDR-5/@,.>EEV2HZ)FSB0HE5Z@@_C
MN?#=;1QN<(3Y%/*GP(&S>+$Z(*I)O/IDSIQ: FMWPY>M.]3@^);3Q&<YI=(&
M(T74-JNGQ52C5F2=41[O:-5%BFH,<^D;.9BR/]*PKX6?:C,<V;I\OEN7<0'Z
M#-((_H]>;W58PT%>8]HVCBW'=78HSI86&UIF']NP/&6H-VTQ'+[R\GV[)B<L
M=,"'/2!8K1&P@" [&Y<BFJH,XUH34U17HQH);>0JPT+HIH^S;KB<917D"#UO
M&JJ'+YC\,J@6TS6S.,UC574Z=W0;2^0[=O(.U=!!-8RF]A=#=8%3\5%*7;!L
MM6R4.7G9!XO,':IA@VJX#'_H]"B6[QPAB_B%K9\!,G*)4D"'?S@U ]I2FP]*
MB@R@=06%0-^DTDR2PE 7,;W+=;+1Q1->>:)CJ=#MSNYX? <&O[7_WSGZL#L(
M[P5!X!4XEC)PD9Y#+]=ZJEXH.0D3N&6N..\6S&72X.*ET#H"QQ@=. .'1GBU
MS'QG9&H3Z(IA-8'H6D Z[!C1S^:FK*!8;4%S0<K;_/D$^8,NM?5*Z$K;_1Q-
MZS)YW70=VR] /:NR# 0H2CZ'_%(O%-'S LV18(&:M4WBVXEV'8G(QV-<9^C&
MHEFYN2@E0JMYWAM*>SJ7/C]7GL;>G9Q1Q_G[^<X< \:V^;>0<1?D4 MR0['5
MK 5@G=#R K;3@ 9.4*>#C1+)*LZ/\:**-119-%N546CGF+M(7TRDCV/D+MRA
M%FY?#;<-#;K)&J3[VE'M SC:.C7FL%*'8ML6E7WB[W+]Y\GU07C<13K4(LTN
M3" Z0&H!:QV!EDEGJFX]-JNRD[GRE)Q:L!HE= M/=WF^N#R_Q,9=F$,AS*CK
MSU_V%*!)005&IMF9MI)92IU4C66UH9O"1 A="/)=@L\FP8A<KP#B.L0VSI/1
M6Y;:D]>^YH AK*DW&;/%=L,<$1S_Y%7OXGN[XOOM:U]X'".C=SF^V-+7O#UN
M%[4LAZD3DU0[V1'5<-MW%_G/D^AO6/JZR_;%5KZB=661R9;C)*?,YYW2H \(
MNW6?J/\\L?[:E:^[1%]FX0L\9834K#F,L5-'%(UID9RX^'V6_O/$^0L7ONZR
M?,9U+XI8>D^=^%A2FX-8,Y699!51O OP[0KP=ZU[A4MJCV0C#--L^V*-:Q!+
MJI2<T35U,LFI<@:;CXW!S6PRO3-5XJV)Y7T]Z]KD\Y6UJ\Q4(T=+#:NHS3BK
M,O/B4AXY-Q.)>9?4^SK5E<KLX34I9IEY6AJ\T&+!G,I8WJRB]FYG3>HNKO?U
MI^N3U -K38-LTDP4&E53K8K6J%2;U1M:^/)>WL7TOJYT8S+ZUAI2;J+4DC$@
M,#B9HE)+@YEJP_1]_KP-P;R)]:+MO1_GE<94ADE,AD/5Y1AR:)5UUQ79/]9R
M_!3'G]]?<H: UMA)]Y4<6!5NS8W6R'!M09=:<UC6J^IKSQY+ ASOEI@4Z_5H
M*6GT:14/7X:!MQC^KC%?B-^K"TAB9^3W1>ZG$;,#NV"-107WAG1^4A6%.G=]
MZ9Y"(>'/KISY-,?Q(,U(]+WY7.?S+FADB<%,!0EZFE;MC-K30\O3;\WG2D0Q
M @]3P/(1,57L]BQ>;14+:J<I%LPGC2[UZG^J;Q@JT^MDQ9PU7.MTAD\240 &
M4H%@TTDJ59P8&;NO71W#WS7FL*OEHQ?'!898.0V=&S57HO%IN4GVGAJ#2M:^
MN.UT C$^=X?:&:ZUO(TS6-YX5NOFQ:3&8<,NTR0EKEKNA'9:_=-#23X[283L
M^.&1::*0\A+#927FJNYLELS&&:5&AC<U;\CM@G-GZ:5V\EM2+W*W'S?FBXJE
MZ$\&'*(^M(/+PDK*1'' >D4R+6OIISJ):ZR06?"L6.N,"EAHUV5>L?#?'.HY
MF?WR!O63[YZGOC2M_W%HI$<*L!5N>[-Q4I=6S]@%]^**Y[C=<:W%4#/QXB2G
M6H[IE'N5T&J'5V#RKF%?$C*ART!Z;LC8E4%";[23,<Y[&I*T,VG+BA3:!<"P
M0R8,F4#/KU;,QD"H:,IHI&+E >.I. <X_HZ14-VT>@'5H K&@*O+TQ9>;4B3
MM)N:*.G8G>T?6Y5(G)?MC+\(L7MMU#K%LM<4-$B(IF.(ZIZK6[.4&50P-4T0
M=[FL93K14JI'69R;&<3D6+%;*>JA77@Z.LRM\WAXG)=;7&3.N.L#/8CXLQN?
M/LI78\'RJ:A")S@FI7/]3&]8*H7O"N6P\M5W 8CX!;1TG,_4XW*K.6:K&BOW
M;=EL1AMA6#6\G++:C#[.6\5RM][KFZ):;5 M9I[6<.SRR]SO&WW\0M?W'+7E
MS[,TU/6FKJO''9=3\@6Z5*@LL\8?&[5TC7;\J;<]K6X^V%R!5C)$_[.]2:$)
M-$W1ASF@ TO0H+V3E":*KD!ZP[(S@*(0=7L#G=RLP[J%4K'!NK,$7DUK9K]<
M#*VE]\KXM[/%NPAPL16$,%RW\QD8-8 -T"(]I%\&+<(;_L5J ?'6WN&H3+>=
M?"JA>L6QW!5&#:?5#*W>.0D\)PS[#IDCD$D;M@/M-V%[G6!E23084N+37*=1
MPT=/Y8K!N=>M75X,\J;A<&S9^OP3D9CQLA6*-EV\PV%/Q4Q#5=QQ:!>PKV@B
M"L%2]J=@=,I$),PTU>[56@.V.(U5I42VD>PEKAL\WSD1A0 R1SVF\VN>PA+W
M.DVN4N( YT7E@=68X*GKGJ1"H7G"X$E]"D:G:)[I<M'EG72/Q)ODH%A^<I?1
M3OAN/[T6S1-JR)QVR7I2DA14FZ#5!$7*ZVG!5!Q!6ULY$UK*N,FEITZ:VK"*
MF6)YD@KM1'7B7>NO#OFFH/(BQ M=_%D6QH:5=FT'BI9E;X. %4.TW&7 ^&5%
ML7-1NSG'P4(M$DI>=;-XZ%QE=&/GR^$$ ;Z[X[G8GLJE8O%>8=1J/S#@4Z(J
M6)G9L)=C.^,J7^VK6IP)GQOR&I]VAW,E;,)YJ&;WSC2^N9'=?+YEC;6*-)_%
M2,!BBPK;BQ?U&-,,[:;7VUO6SP=XH<WI&#H40R2^DY4GQB1(W26N/;6AIZ?4
MK7*?YA<Y.GW%#/[6F(1SLWU?T3;0H'TV^VH7>AX3=YWZHJ/39KF?30FXJYGU
MOJ9,NNEYZ QFI& WHUC=9+TWC"M1K*^R15CLL,5MYRP##&-C+J<N,L,)0YG=
M;"CMD^=LV1U&V-GRUFH[XDM+<5 81%Z7E)DBN8*VT9=5$WUKYZ!.06E$C#3\
MX6JH*W9&L8#H&- .T*6J,P)6$U@S100URX"50/O@V5F9Y%RPI!>9:]B)J1D>
M 'X(QJJUM=3.[52C(C<<M6C/JQ6IQ\:35"BE]B#Y5HKW\_0[BJ^3YX4]PF]=
MJ*.4O^G=A6.;3:=YVO#QQ-!]B@4H3::!DRNELP8^J2MT K?=6-P-G?'^3N_Z
MQ3!O$Q+;^#?_",W9@N&6+$;QI,D0.#-3:_G\)#N:A3>!92B"X5X>GMF&P[UY
M>&9;] R@B&W.V$-0Q%X<N'_O+#:JE9D1IQD =W/ICFF3=*7="JU^"--4$=LY
M1O^Z7M@K>@8(Q'EBNX6X_?&ZI;0ZX=KV)W#H5R%F5&';?HV?-84&QBS?4],8
MBS>C7(Q>Y&EZV@^=0GG#%#J!0#=DZ^ H#P1QZ@' W:(A G"P2B!G%5W01470
MJK(,WULGP;D!;,=24/;!77O)*M6,H11/YW#/<YU>JBNTR>:U6?7O)M7%@'V0
MR'=0;S,7/></NP"BBS:D/P_E>3TQ>J+'5%0%$N<)N5)O">JAF]K?@/*)!+H#
M^!R6972#W\W?K\-W3\4<WB3_I&G17&A-NUH03';"F?5.C8Z7J,:UF18GD^FV
M#(P8AI]D(3\K>@8H!P<"?2AO_OZP>;'#IO=HY>.@QF-QQ3.?^(1*)II*>YB>
M ;X0RI7ECQD9QPAV6_#>/>KX!KR9LR22^@R\T\!R!$5?$^JS'M_(BRT3?-%N
MJN2('PH+H(\SY6LSDP_3Y [2\X"4Y*D-2#=_'P<I>I,R(.&J\F;G(3T2%&LB
MZ)\$:Z%+I\9LG3;9M-E<E(:%/(:KUZ1NT:O7:7-;H"4QG#H1M+M%SP#:Q$Z\
M8X*G\-6/UU'[\26(XY M\^E&U%K2!55P6IPY[N:KS/":?#?TZCL6'+X<KRCH
M,G%RT"4L2N%GM02V>&7>@]</K3,<Q^NB4U]0=%K.X=.\FG%+G;CU%+[L**?@
M]8O7%[X%K\SI>&7.@M=5[,WE%>JSU1I.5QR[T>2";Y4BEYU[7=[C2)U2$V2U
MD>3=:UI+^"ZE^BI9+Q-@]%Q77B[ Z*,J;[,-C^[P3 DVRAL[00="_-;\IW;2
M=4:&I2R!Q.D2L'8JJ6F";J<\J&TL4;%7=X!N@]&0Q[;WBGB(QH)V9:&79:4T
MWN:JI91$*'G>S=5#9\V>7>V=W.(%^+%R%X\PY#9C3]XXI1HV8:D8>R^#5AVH
M*.N%Q;B"3T W976*?38?OA,F-R@J!]EQ28_QN\_F7HV@[+VB'F+K].ZU68N,
MVUS15'-T/]UFEMUV8Q ZV^@&1>4(0^["$CYA89B@W>E <K7"B-5PIIY@,NEX
M9Z)R]WGERX5ES9"[L(1/6**)UMP(FB[B75+LCY]2G."8:;>=Y<;E:.A6AVY?
M7G9X<A>9,(K,]BK*FF@4)LLXGE>KN4)AP)$UGJG?1>8;1.8B5V6&362.9O@(
MM<C0#TQB'8)N.2DSUDIIZL2J#\JV1 .R??=?OEA>M@RYY/9%:-/AA%I8R <<
M#]K5^\ME,N8^Y=2.%ZV,Z@JN=(7[Y/+%PK)ER$T)R]$[WT(M'3L;+-GHM)8J
MIPP69ZCYG,^EI_,ZN'OW-['!<KG$$I\_BBG$9Z-$HC7S\.;"9D<YNM6E,[>/
MN\]R<>]TY=G2@X37:3R\U65WQR6;X#H#%;-[TY&K]%AJ&KJ L1M46A??ZKK\
M;5DA!ONQ[2J"SKL.P?8AXD45F^'#8MH=WMV]F]BNN@/^P)93A2#3G)LMUU4E
MQS74F&8*4>ONLMW$EM,=\(>WC6*F,/#ZHM#&<^2HBVM)?FXPMV\0AP[S%]HV
MNL/^\-;/,BJ/A5Z*:JL,'R\P/-6M>L3=MKF5K9_+P3X,J8 8NMZ?T^F.H JM
M2C39*E2Z0B-T?NB?G@IH_V[/W3P2WXC!"V3SF4R>I$$+ SKNNMW6C!RE9^W*
M#:#Q5K/Y?#\N+YF0IYW%J[D)J,UQT/+FHYXZ%KG:M:'QYA/R7 Z#H4FJ4RBD
M'6 1T;K:; \%/<NT>&L2NL6$>U*=EW#<S9/S63B&,#&.E.72'J"* \YE)9IJ
M=N(F$;[;4^^)<5Z#Z&X:D2^"Z)F3V_2;W3&7[NLC%NNEV811,'.6&#H'_ ],
M;G,YH'UO@AK5ZX^S.;U"XM6BZ7@S2='5^C4![M83U.P#;S?GS*>7*B'L3D'>
MFJR?1)KW1";'PQ1)X6Y3C<;B)HC/\&MR0="K?5K<$K((C#Q#QH/]1?!KB4_=
M">9N+ N-UJ)>:7->NF\U$ZRNBXW0^2>WO@)^F6#NO10?%]GUN1; [P1DUX;S
MN)B.EW+J1&UF*H2B5OM6Z-3RK0/^,@'9EP/\=R:HRZ=S/5JDRCC+Z*T4SXP3
MV7(T=(@-82ZE+[8JSI=':>V1?U^2.8)?#O4TZ:HL5DODK79NZJ7%J\3<+2:9
MV\<<<][<73'HH>]<>O3L;K2C%V&A.3?IE 5+!<&58I#@L'5]&$#*:@X<5^&:
M%ELTAIVA66C7J\G06IJO7(6%)K/71GI.3K^\"0DG-_6\=1/2MNCE+LWS%9#A
MP@\L$W;'JPB3K0VV$CDHG+8E $W)Z[HQ\VL+# G'"[#QUK6M.YM]!_8>=NZY
M3<.N6X+HM(P:L&3#FF0-R[]1$1HG+[<.#4_0'&]SYVT+6)/U@B8I3B;95AN+
MJU@1B"E6+2U3X;NXS==R!Z@?W#AY(OD_K@P_?%'MR7)X%H[O;&D>9_DEQ?;;
MD\M]F=@*BV\56VE$R]6:H=CJM#K)I85<R^73H=S5"IO8"J=<9'P7VW!<49L!
M R</33W+]<FZW3^> 1VB7W>RT."%A!7A6V$((+%GP'*4@08JAK/9M/,6<9(A
MF;&(IT%-QOL]K5&.AFZ.6V/@Y9C7>\#O&?1MPH7B2=]0)U?7UZY_((U<LPS)
M%9WJ^D[IK;&NR8(C:,I00VZ18(-G2AM9P&#J0@*P,R1RS]7PL_?/OD;%J_*.
MP&]!ZIJFYD'%T +B2#<T8^BU8"D;FM ;^>XHSBBK&*+E+H-ZDRK6;;D]$>>
MTJ49?%X;1I70>0](DQXB>. T'*;X&=;L#K-JJS\/\NKS[1YD<B"5'^'RQ803
M;2-BY$F>T[.B9[F=92N;F[\O+65H[<-6-J1>J_R6Q"J+]GS24I4%)DN-86Y1
M[816Y8<0UX?I>DG@DB>Z_,^*GL<(V2)W^^.;H&N.,*6$+XV<RD!SR/-2@]3(
M#9UI?X?N#AZ1H7,B='>+GC$ASNM^KNN@F,&UIQ5:IQ: RDQ4R62+[<A#,]T'
MK=(T? G7WG!J#]'Z[L%>,,;ES$EW_H#%(Q[G,V0VW5FHI!E5QY9E +E[;7)V
M7SRZ7='#;U;T.C+32)-/40;O#))B0<]DG:1Y%[V[Z(4DO4$0A'&+HI>J3&IT
M+4K/52&5,<O6$B3;<BA7UNZB%V;1.U_(W>NA**=*T"="5:0)@;.S2E7"E:+>
M(X;VDA3M4,Y&EX7D/0CF]-WTU\)7L+KK<96)55*+CDL])6LIAK9"MW3UX6".
MJ]XZ.YVE>UJFE6L:\3XYI3E!G9>&>D+.5;%0!DA^2$7<*DN;#JP;#2D'C*$E
MF"-%#")I161<6!Z?:O"=;"-N";&IQ%6CZ4EFD/:T)S*4XGIT.#]^!^-Y3#7^
M.":?$DGXUO8#U]Q83L&795N=L72%Y?%F&^LO2X:=(;"K, K.&Y'WY@[#"]+=
M ?@! +*+EQ <\#314P>C$CL9"NJREG0S2SJ4BNF;(7B >'\Z" _Z2._7@JWR
M:.9-,TQ&3<\JY=1(+=K O1V[YZX%PP7 0UKPZ:GE-2;V#.!8>C8J,S:V &HH
M%ZR^&8)_C!:,K>Z*B@?K1-3JQ^5,P:K<[XSKDWR'37L ]V;\P$BWKD()WJHI
M2,3]M9Z3KE_RBY+4=^#O3),PS^:?9HR0:[#%RK"6&[MQ4I.N G^W.@E_+_X(
M? 7 F#\+PQ^)U:]+^B*)I3CN&G0LK0H--I9/UTN%J'85L_#M^B)$#"/P$U'H
M%R42WX/"L]F"G1G9T>.%*L8I4EMK*%8:(\%5H/!V;<%O1N'K)Z?>G&SM#96"
M3)(^[>SGP-.ZE5J6ZQ=9'!.5IM2UV5@[O+<BO3U1GC;LVW0?MHGA_#CW+\T2
MEZS'P;13I],<,Q(7@C7I.EHM=#CZ@[+$O;PN?)LG[O7KPO>*GCF&_10K[IV'
M0E>Y<YM ="V4ZVG_L&3&!;!M.FA!S>1KK1A(%3CEJ6<1"X')<<Q5S++GM?7>
M>P3U=!*?$\%?%@-^BE%W.5!6AG%5E*E:#\>*>;S.6MZ,[(52<U[6]/MS0;ES
M_)E@-A/X]L?;-E]1L13]R8!CU(<VRG<GZ%Y)F2@.D *4@9@P+\<2W27GN<VJ
MEN[@8VL0.I2=8.>].=1+3J(41C G3J*[1<_G#N![[L 6&IL BE4,&Z*+H<.?
M]I[YEI0D!=4F:#5!D?)Z6C 51U@?&(N;W?2LO8SW58$?%>H]HJK/,Z&;'3<Q
M?:^->&MKO3KDR]I;I[D!^*6VLCX'%?AX8NB[5]&D<IK5=0I1&?=R^8XYR<UB
M<BFT&N1$>+P8YA\)B?.D8>E,ZVRF$2],V0XKD2H[\?!V/W11'5>2AB4,<#FV
M]G2.R<:M+2OU0316XG*RQLDMZ2EI3:Y=FWS/9/,=:TXO_*C+^TD9HI8851+-
M(<NT),\9]7ERD TM8OY<;V9]>1X9_2IDS L*K1:E@<16,VF2GXEQ4G5":[A>
M(3+P.$:>X0ZQ"V6%>P=26E-L-.HS@QX[Y=,T84QR;HH-7<#!=2'EV^>B#:RV
M.@?BZBL54+0XZ4_C*7* 5S$N;L=F^4(U?%G&KQM6NRKHC<-RNT6_:R=V_;9B
MZ**A:<+ 0+7-P$XY/X^<(.Y>H4TT=57.I%(2*_!-L3@CY7Z_&EH@'5FE6[]^
MU]!O4R.M0TFB02@)%?R2@,*7P%#06'\8&UU4LPR46'&14HS6"%B""5Q'$>T\
M)*1E&JM* ZB<? KL[=7C)/PE :DF*\N=K(9!.T-9ZX@D-INR[NAI4N"B3"E9
M"ATD(4$?GQ%T???PJ13]^ [&YT^P?5;D_%/,KW#Q8B$RT=-#9/RB9_0]B=6U
M(GCB!(2OB!(@NJW7](PT[->X7*]"3EMM7<ME0^LNO,+QW5%=QO;'$QA!G/=:
MCB-+D?9@%.]Z2P7CA*B1,&M+5L[2%_?NKW!5CDCL4@[^*F92,R'64 65)-R,
MIHXH<TQ=',[O512)DRGW//_&&2@7Y0EJ8\)M?WPF8+-5RR^'^!+JM.8@MB!4
M15_27&@7N\,45HDL,C@74*<(T;.B%UBO/%<<)9#4FL&H:IHMNI,XOYPMS6$O
M=&92F.,H+[<6&5Q =@&N8UROWV%J51$G=<MSQC7WB3&N5PM\-]?/= 78BNOG
MT?-6-#]R^()(JN28K"9CNO94#-_QD+#H^7UN[JKN,X;L??R\F9NA:C7!(<KL
M),<29&V>2]7#FWK[>T^%74X=;T\6?IR3A$M[Q5)6'*B3X<Q-C$C%:$^N>+K]
M&DX^/[+W::'<'H[ZC(YE\:CQE+7D"BY,D^TL53 5+WPWS(=/QSX_=71&'=L1
MC4Z[ME3B.*9G,UG%H[%V_.(L^5:UM+,846^T%&LZ[D_8--O1*SDFQR_2(1O]
MF1/$;FWD9+-,V]EH@E:Q<FN:ZZ?:=<\+V>#/;"I2/!%=W0GB+2M%86PFNW@G
MH5:(A1!CZ,M?)?:^P?LW^Q!?L!_?:5 E2A8;<U9(SAV=(*W18! &)'S+!H^K
M*RNR<? /M/6B2X(E\;9_HSR?*^0D$7H<!I1,%@,%NI^>Y[:FY00(MFN!WT$?
M_6_6[:S?K7^CAMYHE&MF^,XD-WOJ>_.YZK;C6&^9P3,-._FB1<4V:)*(/<)/
M/M&@"<OS"4[H/PV)5I5+<XNQ233D/+4X-D;TQ2<:;!L.X,M%JN#TYPU&5<;*
MP"4F\JPT&[YH$$V]J/PGFE,<,.&M1;327 @#CTN+[50^/V1=>7RX.53^$\UE
M^&BMKXRSHZ<%GNN5EOGFN#]UW)>T1&U]AF]2<**1]Y)B2<IDJ1H+[3^S.5"&
M[-@[W-[ZFT\T"X(3CGRJ0L3G"FL0G)>?#(21X7C=S/Q@L^MOWM]L!AWD!+Y0
M!-*HL=6NDILJ@,MQTK),$^U8<;D=K7_R$^Q65G$G "I#P_J@^+SX'CW, -V8
M*/JA:D_5 WM5_-KO_1Y=?BF+1UB7X5HBL%<_1T"0?(4*/_C]#_Q/Q'8\#>KE
MB;# YHKDC!ZA&O[??YN"A [38!J0G4?Z@8YM'UG*<+1Y9MA^<"ML1O/W\__^
M\:Q6:ZCHF&.8CR3QP)C.WSMMP*+FNJ ,]2HF"Q-%\Q[_W8(&MAVI@'FD84P$
M_=\_5T_@_VVHC>5__^V7MI4E@!7!.E>M/,(_(^A?*O@#-2!$1A:0__OC7ZUJ
M&OZT34'?:]+_^U$WK(F@K:J= W]\P:,?OUO"0 ,10XZ@%.5P H*L0;5 $@KP
M7_, *44-"-;CP'!&?S^GZB%R?9X&<*AKYL!6'6.R]P@1'_U&\Q:&;FC4'U$0
M#[#^'A@6!,/VFT7$-C1%BOP+]_]9OT<54 ^(J/NOMV2'PQ@.6%1GUB?)>=CZ
MLL-[+1Y@)OJ4W@!B,S 2/IHIMC)0-&@^/(X4"9H6L(;_^5><Q*F_-PPU$5Z0
M!N$3LB"+<@SP\H"2>'H@#_@!+<=Y =!10 T$(1$%/U80^)JQ#EX.E$ CW87L
MP- D6):KY%ML)M)L)5ML\Y]?@]]?R))W=+/)IKE&OI5GFY%D)1-AN^FG9"7'
M1M+5<CG?;.:KE?/U/?9&UWVU06^UQOXP]OO=$>P1%"O'T']&,@_IAPB)1^G$
MF>E\0)S?+[ZG2 OS*6GY_&"I=X-JGQO9:J/\/_\B&/QOGP-PAM,-W9]X%3$2
M&.L-- %\T*^)Z +R6E H4<80_>!(M-;SPU<3%<&R^ + 6@)F30OL=(25ENV8
M-T[ZVSVO=9O L>(*,GL]ODH($=\,H8]/%=\,_K>TT@G8AZJSPB5+O@9M-9*5
M)E2HU4JDP=:JC58S4N,:32Y9:45:U0C4M^A=,T)0$?@A$?U+^D\X-6PU&VD]
ML9&="6(S.233K0A\320H^KQ]?]93YK2>_H7N"(E4=;"E9&! 2)0H#Q*"S#-X
M@N%I*2[R Q"C>(J)X6(\/I!(/!88$*LO6B*?YJKCC*6;(CNM+XN,D5B."M00
MJ:L7)8>"9L4UL<P*<K_($)J;58DANAP]*.GX1FO0\4#(_;A;TP:/ZS]VA0B)
MPF@U-F2SBBM;=]\-V-4J*R< WS7H'PC"M^D=:]UP4"&Q(J0CK9_[P>*BH 5@
M@?9E4 NL SH5.Q(0-+>6AATC>Z=N ]8G:\9\+:WKW]C<$LS'@04$%9M#&KSI
MK6S>"P.H!ET'_(U,W[U!^B-<6?S!?QWII*$Q#S1SHT-+4 ]4]!K']LNQ$%S/
M LUSX>#<'C&J<]\J0K=K"<Y_?RA06]M A+K,T :"IAG.P%C\N)#1E-1U5] :
MP#0LY\=:C769%*[TC;($&9U.]G%RFDN0<]38"[V[)D03# T0X?*1IC>!2OBY
M&C^@H__G7XD8S?Q]U-HZ&\K//8>.7=M19.\=!D%@#*QF_T.3_\I2WC$ 5@_>
M.>&>778N@?G#%M]VJO^(Q1=F&3\^WA= N3P!+B\KA];]=LS+KZ/&70[N<A >
M.3BR!G=D:LP:5L09@8BLV+#WJ[G  X(5\0\-10ZLJ.S8#H\2.MP$*QU)@H>^
M OJEC(>:OP?+KG9F=Y9>DIFY,IB5C#SG1J/J6.YT.=D/R3B=!!D@^E$WJ\%3
MQ,\(ZMOKQH(O\K]\%^LK,?RYA>UP>?B-Y_XRQ5 B/8B1?%Q,)'A:!C3\2R9X
M&<BQ@4 ),4D<//>"L^-6JFB(LJ 6%7PN+^S6M&\G#_G+DW(\FR2T)T\EF]0D
MAO,S,L$D[_YRB)W*N[\<OK'=_>4O\Y?]P_ ^EY[YS$.E20[&) 78=%8II:9Z
MR1SDDY?PF>D_PF=^L6I^]YOO_L(?XR\\W^RX^\UW.?@CY"#V@@"O[K0&CK*S
MF94CJ[C@B&P9DY6C?/Q[?WZ2@!AD%D&.A6$]KK?8G[_5%!T\NM !M]!?+UZO
M M;\77J?QF@>"L-_WZ#!NJL1Q_C#R?4FH2('#(8_;K7AI*B.2T;[L/Y1@ZRB
M 5C_ %@[RTYY>1KKC\I82O4R.%Y;,F6AAKV,^'G-P,9Q J,H*AJ[7!#09Z-+
M_D)IL!4;G7.+R) ,$=VGPQEC1OZL2#<Z%(!N@*%BHVG,J< W.Z#&BJ#CD=:R
MS@KRDX(+.4$<]5ZNI>YCI-:HMI*E?#>2RE>A)]1(UEBNE4\W?ZY47;Z2?@@Q
MP-F%(#H^A5!XM[6A3$2P([8)1'3V2(HH>D1Q[(@X$BSGCX5_L$HK,"))$W*,
M)X 8YVDB'N,%"A?Y^ !0"< 0 I"%YVNO(VMF,K,TGF.+*<.HF!)'",,Y3_+X
M\Y)+PIIXZ6XMQG8F,\H36T_Y3G\(2Q+/2PJ6( )%*%H<)D5K9F&24LKFG*=?
MUMEO3*D4J_=)EI2$=CW'6GT0'?+,RY+QA9=Q4HUABYO0XU&'RO8RA<(<EERW
M_N5KQ(GX0_332\11_"%&7^-BXPECHQ,/Y,TOI+[)P.^PM9ZOB=HHTZ%I&3.D
M3<^_$;B:N_;R,_JY%=.K+(II0P*;!=(BD;(&49[$N&8^,Q>;4$T1:AVVC+_#
M0KN@#Y*!6)H+Z!SD)Q=7WT3_K1CA+6&1#\X"BWZ%NQ8YY'AI7,]5L%:\S$VR
M=,>VXR5^D#F\)/XM'&>B&,[05"Q&G;"O'!JM\%GSRA?0B&%%#&<$K,C8M11;
M4OSTOE\7=OY6)Z'=I^QJ%;^_UE#0E:6PU]/P".6GS=[\0^.A^1 )+ARUPL.,
M?2&/5(R'_[QW[V0"9W0-?)F,;(WJH,KU$L^;B-GKZ.5!\V9'PZ5[0C+Q)"7)
M K8=_*\$-3VQXS&W%8H=UI-*4^TD:H2.I:;#GG]'Y^G+0&2$TZ%9:4$STHO4
M-&$I7/A06!AI2N[05+=CDBI',S%6B+'S=(P1&5C?NVC:=!4X[T#3^T\A91K^
M6;5:QES?(62VHCRIPX2>QHOQ6'8\3=CT(O6>-<H+VD-/@J@"E.I?/<BB$/3P
MYZ'8QPNRT+>5JE8-.E#0'-E=EC.>^#P1&R3B;+/03R5[>'7@JB'A8Z7P01]F
MM0#UI[DQ :]K!G26M;YB[GFM0L;!:MDRJ>&31$'HU6FR)I>3/!T6'P:/,?@I
M8;'A,2'>YOG)QMI7X_63=O3./F-(F?-I'R:0);1N;UI092JFH$7  H@N6J:#
MCZ$7 >S_W*+[!C5'!*F.0[[1?9OXQ*0D7ZT^_[JX/8&LP*0%A.VLXML/1<>N
MQ8BEK.$"H\XF [;%59LAL1_((S-*"+KVG\L;@"4#*J#:R-!?!AA4N[GITLIE
M=+;*93W"'L07G/(>S_*2BYD)!DM0=/3[]G7?DZ!AN]V-M \1^]N..$ #)B)[
M$-#P$ZT :BY2\A$!"A!DLP2^.#'&B:/QK]M3' 6VO=JM!A:0(J9KV2[:MG:,
M""R!>!;$*Y-_#8)(93A/HOBUI.@\/C]YPP!!(BD2\$0T3O(T+B7X08(4X4^9
M$:)1*1$5H\_W2JUY5VVEK(6BIN.U_-@:5M/5=)W'7^ZJL@(Y2)A4/,U-1U@A
M"^1^BJH/8<D79W0&W$@2);(GL@(_HNE)9I&PI20L27_C&9U@]_4DVX%,/$03
M__O4I&I^ZT??6L%FY2L9V5X- _@&JZ6E.*L\>4 01Q%1$VS[7:87^1 [$_'"
M2)WCT8#O(!'%/%#TR42Z1@Q9@J^'5P=5_D(&_#O(0SS$HW<(O:FDZ-.5U!5"
MJ!*$<_E:""S$$<K('S'TR'RDP"?;>?-COO$M*_EO7R<+[!N/( ?^;+)9'7.M
M)2<M%F**G>2G"\A2ME2GYT%,Q_&3"S]^HQA6 [TU1/5GY'_A#SA.1$S!BLP$
MS04;5_0341A7/&U](G/>UYR#N>[Y[MO%*9A-5Y/I1I:,[*">RW;-&)O+#*EY
M=9F;S8EZ<&K^-5FJE;KG$)AKGJ5#+S'7/;V?(1 1S?B7B4%<3TYL8%-LX^>A
M4$U;O"6W$HF<JO"+ZJ":=8QR&@D5_89057I--I+TQR+H;XK7G[G(^[U+*,-7
MEE"^?3>@8NAG7*NZQ(F$TTX8AR:'L**C(#1H>9@?.R;]XW=>EU $&X@,O(@X
M J(:F: DL<H*/CNG3!0[(D3F0-,P53?FL#X@V)"=$GQANVA=4K C$I 5?74(
MI>%J8(5$&H]& C3NP!D"\R'2 _:^:[@BTHO^!C1Z1J*_GX\%Y8$@J>/5[!5]
MV>SE]]0[D'Q%1+UF0+R\3[O=**UZ.]:3/=/AR%Q5>N*(8G^<F[^EE8UCJOB]
M)/@XY>.)1.(V4*X;#GPR=16D:J&&]4\36GY:$_L5U4NA8-S]1]O4&UMM_.>!
MOFUHKNX(EG\ZU;)WP(YKMCOO<3J/%[6!W<#Z\G#2JM_!?AFPST? #VU_AOB_
MB "C(ZC $=:EB*!I&\#O2L( ! 5@Q0? _Q+O._I^;8<B&4#3 4HU$Y'@6WWH
M%S4M( )_-94@5W7XR?KLR%^P9F@V1VQ7'$7LD8&.-:[3&3@CP7D^GKE@OQ1?
M_^-@2/^!4Y4N1?XB=\8]@!8X+#08PU&AC_SR\$O4GZ RE.;(]GOB=U>PG4@"
M7]4@"9[]$/DZB4J[E@5[LTJUA%QF1W#<7<&J1#G%GL_8#EM=+@%ERHNN&TV^
M 9L>L$,F6:<V6S$NJ%"O7+P1NB&P)XKC0'D &@2X9>C(&]>\"(">N1?)(QM9
M$/U0I(S@")'L:L;;$_QM';M3X LKKP&&KK8Z$-'$6I&_T,O8WR1%/FS,0,4_
MG6RBT\E?H@!6/=^(-+#_\Q#YZCEPA\2(PH$ [T@LT1TD>A.U:;-D+)YHCKOS
M4M(_SWZ7V.^1V-B[!/9],NF[4AJL"T0$480R"4$&L8K B?PH_>!3:)?JV,$7
M]@0*,VS%6L\'$,(32 GO)YJ5875P[D+]'D:&EC%W1NO7#W!^!BN?;94D"(KG
M_TQ=P_G[6-]6;X-";[P^WJN@&)J$5W\>Z5]0;L^9),@!1J[=R5V;XF$O2"0Q
M(.0!!7A9BL5X.D90?%R@!GR,Q!,Q^ \MT>LPC4U !YW(*B6FR$[PZ: [6WB3
M>J'F)8--F[V22MM+MEM0"^ "ULVFYF4J*C:&P0'.O9+YOJM,:KDRSDUXI^O0
M_6J[(,X/I7RE.EQO('FC*E?48BW6F3$\/D2M4\]+ZK-,E$GDT@XN=')Y,H:E
MJJ V/Y1V8&3-HFH<4#3>'%0HQJFRH%Y%"0I>M%Y2NTZCZE("A[52TX59RP/]
MVR]H^5@J@;W@9R+QC<?M@Y4AO^$7)^\_FDU@;WA4XB%QVR,DJ5L?X;=F1/[,
M\-X.0WB'*)X_05X)36&K.6-GHEH]\&>K]QZD>%/8+I#D[YA!]#)'[DX2W%.W
MX=XG:.<?7?(L;+EPJLW+\"1<LO/NE-*K>^U]=B&C=VA8WJ62J/AKANF@D<W^
M):'UE S):T^<,EC*@CM0Z:PT#)(TO;YX>,"&_GB8P/4I".:*%$1SY4&LE,/&
MC5C]#%R$D&F+<"5G7TF03\64:RLZL.V-!#EL.2I/2057FVIF7FM.:%"FZE""
MJ'>AZI GOHNQCQ^^_%;CX6-'+;]! 7RLH]\@R^QA%_\NOV_*[YIR.9]PZ17=
M-G+<R6>CHTRA4U";_=YL4K+K.5Z<0\_]#'),GRC'?VZ$SVEK@_(K:W#H.->)
M6]-H)=]?OX=V"]JC=HR(:P._%.S+Z@ZL QF_#<MO2_-0XW,%-@V;C>APG 9:
MG(,T\^T@7=!%1=#0HA_*4H<*VXZ@2X(EV1&4*D^17HT\HOX2]O?^]A;G(I\U
MFZ]\!R;85PT60U%\/UK]%!P'H%2$B%V0H"AO*QR%,/3W&C<G  7;AC,W>K1>
M]P2R#/R]!#TX5(Z^5- 6@PXYB)2096@1M"JPP]CM.JQ_=G+-O@B-TW\-_K.)
MT!&L@0"KQ:H+#7C^9NU?1#3"/30?T@^1&,F@0WK_00/?CC*(21MH4$'NP$=6
MK,EJ@\:$;0NH$$2<'RTD^3T67$EQ@GX=VS[]4H6;%V4KB3IE6,DM:[*:,-S9
MJ>E.)U-/9'D5;Y(L7<F.F.KP\$[-.;7M%>/?W^VP1T#3UDHO\M>Q6+&]Y7T(
MOO\\K)X?B9DY?ML?P@D0=%G0;' ANQJ-:&\Z]N&Q "+K]A.IC,I$F\,BVVS&
MJJ6#,2T?W-SZX$;?9?;=SA\(\[ZYM05A(@R'$&T(C@B%P%D=EEF#:&:L]YXV
M)VLBD'-^#(N_HR:C, _XM;W^HK&761L^++AZ $\*7UVXZ.\Q"R:<%A<*A!S0
MO,C_"L"8];=Y85.NKJP Q\$_^&8PE_)<,\-W)KG94]^;SU6W'<=ZRPR>:=C)
M'WL UMV)9#@2$&$#VH\(NO$24I79QW+2YJLRS_ 4OL)NLEFF[6PT0:M8N37-
M]5/MNN=![ ;5V/_]@45?(KGFJ^ZL9@B[.]*4Q\Y+?3RKLL6Z,38J"XQ3^_,?
MO^/1!V*-PO5@ Z1!9FOPU\_(0$!&!9K5(#U%S; 1"TR(5[#:R1_!V>  O3=3
MWAZW5A/$*NH(E=^+0=]&!J#[/1^^!(,0=U4]4A8L<;0.]/-A0?Y\AHD3(;$B
M!Y\KY"21)R@#)W$6 P6ZGY[GZJ>@ C^$"HHGH@@5).\M*T5A;":[>">A5HB%
M$&/HZ'P7%?E*]D"4D<^$)N)!T^]AU75\DQ R<P<GK?* (C2IJN(87:LV4Y6"
M.&+A?$@S/RF"^4F0B1=H>1\ ?FY/P&V.Q($ 1#\C<VA]1(QMS\X$@;>FR^-3
M)!42WV0O /XMC7KB1:B9:IHKLY56,Y*OI*N-6K61;+&92*H7:;!9ML%6TNP%
M#AN\TF_RL,$R'RD.P. 3$3Q"X]/?%X-E(C5D 1OZ!GG62^0A^?4B?H)PW^3V
M=\Y6@43(9D4"%4GJN@LM:E\T1I RP+*#[R-E /SY9C=:TG8'-IBZL#:H$R!H
M=W+XKK2:!62(8EU$;^"'-0&Z"/E\?A,N%;37V#@/6:@2(@2.%1^0FP5,?Z8"
M"Q,EF8)M'*W_YZFCAL(%S37D90Y0A A\N(X#,U'GUAT+;/<O==1"NRIP[#C*
M^M'J?-J!L>V?3J$>$+ _=L+M6@^L'.\X>9Z.2XIM:H*'9J$@3.7D4: D0UBP
M^?[A8>"?&L;.WOO__7_M[=\+HCJTH,,M/<N9)$+GQT)+IZ-U% [I(W$(L%5X
M@"##:>%1T.:"9Z_O[R ><&9]&/-Q@RO*GQ\>Z-C_CFS_W$8$[/0&!?KL! WL
MQ?H0N']%WGZXS_KA&U$* >$0^DGBP2<Y_!F,BR8>8E'S>=C012Z>I/#M;"-$
M1A:RM?[5JJ8/<AW]#>$&33=M+^%5\ BZ+GY(%=2DZ55LU#:44]CE^@X==ICZ
MG-2'*+B^!"<A4P1-$#S F3A/XV243PP&!"\2.,V(3#1*1M<Q9N>AV@N[X8T3
M@]EJHQS8T7!&VPGC6Y'V^SK62J9*++H6-UVMM)#5\X5) '<!=:*6.%>,7B!N
MOM@*KF.L'ZQDUG]R^3"^[1GQ^,.MWAD?CSW@-WO7T0-YE4-[3W*=-Y!Y@>VP
M#V10>A-DX>CF6WBYQ-[BJU<%0E/I>$IBJ$V1WOWO#^K'FR/SH;8UU![_)8H
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MLE/G+4X+M[<(F^?I*!4E8Y]9A=TNPUZEKHB6_1A>V;"V48'V*A*1G;J*XS6
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MWE*Y;N31M,UYIB[$$]/'R081%>,OCIKWL3^^V$3O6 &+E?Z?-B.'*O67C(M
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M7-" E0/O-RH3:6!>$,>L>G0LA(;FU671.S2!ECJ&L9GT+M*#74_+M0OA,/K
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MF[8V9IM')+3:M22&-_#'<GX<N4Y9=^+N"M?%4A'U>C\]WFVYY@8+02"9BVW
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M (X]ZBX;I^PM<2@KOPK0<6P&)DW@:WUM6;W]NZS>75;O\V;UKA;F["F<ZDE
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M]\B@!SOCKIO\+=D8U\/963DU&HFYO_?PV[<GO#OWS9D41HIUHGP7RR4CT53
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M65DH968;4^KTC[9(311U/!+,!&Z:6^<B791-QN R4_D31+[8VT]G)KS_F?+
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MZJ!G$LE+,^F*&(4OV=OQ')9Q!KA<S:0 EK#FD=H6?F-+<0:7Y(#[9'CC4J2
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MG"_N;MTK-SHP_CEQH\T5'][&T_VG1VIBTIOY" 7TIP-.@F?U1=DVBEJ9^UA
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M('P L<?A7,W\HP0' J;^5F&F7(<%=IL7Y1GY@(53WE@C".@20[&NR"GY54H
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M0WO@4I\\PWM8E>U&$-[IY^BMK5G-1*/3=&=P'R/_<"G*:&R]YWT!=;. PBR
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M /OL,K)BNDJ=T2CLIR*66T*1W& )-;*"WI_I&FHT[/>I>QP&QQ2#Q<^XH>T
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M_JW$W3-\D9.O#RUUO#\%RU#*)@#LZ-)TD\HBCUYD_N(CNC\!Q98E;[N^\K!
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ML,4YQBQBP#RA%6XXG4!)GG,B8>.$^MQ@]&[=(Q-W9$(I>633K0/E<A4%*/7
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M>5<W0C75"T43L$4_,CA!#$X"-1(@(1(K4561'AJJIWN>B3WU?8Q:EA]R-]=
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M-L=,)-J:[Y$9EFJH2CFT6H=RR?,BX:(D.U>2^#<$]P<C?24_G_^3K*"$.$U
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M_2((I!XNB)69GXHW,"DJS?C1049YG>B +_@:@#UY"JK& .@8^:0^%I+Z0!+
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MON'5-2+UA,;=>$O$][3AE%0I;LV;DD# MA"^ E$(Y;*C1AIA'AW"CW=,'VG
MI- \6?:[JP9[9QL2I5Q%BU."0@[:L*\R];M]K3F[7 '*NF /I?AIIMWO3(HE
M45\K/0OGWCR=[9]$W+G#!/,+K=AO6N_';ME^1"_6U"P%U_FR8W!W2H3.M)A'
M%U0-HYZTH47P\^FO+Q $7##LEP1 )=?UBDA--><5%92)&?I:1_E3>K&;_.:I
M,.SG:KTKQZ2^.8BH;9#5N;HLM#DT3B?2(TH>Y+@%!YU$%/=<52LF*\07'@R/
M2!4<NQ8XY[14Z@\$51%0?.4>H!-:E70]D(UBYW"9,O1CFSM.1)F;6E5?76U8
MD F5776>[)?=@\Q<&IK/\[SQ_H1S4?#H^':3Y^"BBD+/*O\./\]M*B3L#LG%
M4*>-W +C1YX""Z69?5NUN&4KI+'C?*VL1O*M4$YO) Y_N,>V'"7\\+7R*] <
M<!MXY?#=3(H!!4N?ZU;L@KROBFXE?D/>:+0??8+A+"RL5$LA$1E3?_\VY*BA
M79$'_:P1:^0(RNN^ML;74<5V;WS$UX(>*K5X"S9@Q#+.-G?5N*BE+$(,_%R4
MN[%MT(V>_1E"PR'*_P>V!7]JP7C-FX$N4)FE6:-*VE&EUD-K)"U=2(W-9>PU
MERH*8O-SH'QYU *JUR.TXMR@U8"6@00'F3P#J0/G2+,>?N;/JA7Q/H,4C,S_
M3Q]L3A(MO28?7>4M1X[&'07T. 5>XG+5$B83^UJ>WS F(A&>2]4EV6RFSH]X
MN1$$3HT=3)5K.4FSJ-9^)YIN33'.,'8NA="S3N\>F0YZ .H+K9%0'>:#<^'?
M!ZV!N5A^"%7;4 ]#J%SBNHF6VGC96,!/ J0'@HNI*(K'-OP)+:$WX6ISH^KW
M:9G@YE@X_Q&E$;FJ2<-#/D:'3KV4GJ0+HO&,*GT7:;% %D[7G^JY+Q_6U0"+
MW<@H^:3F-C ;1C970Y ?S;;;-/>1%8&6%)$2+AG226P++GI'AXY-KL6YBWQ-
M,*F@\+ V9/Y R:2/ILS:E%F[KV32@HKQ/F^TQL,@7C$Q;HBL\;'TAHFOH+&Z
MPNM$56"AA$2O$F.N_EPA:J94K@GHX0K+-[FBRUB5=(O0[2$ODYM,",<"P;%H
MF5NK>6IZ:[+=6O-=14:?*@%L?:DYU[<J^7Z,7DO3MY%2QM?D)@F?)*5*"G_=
M8;I)>B6"D\>7) 6,BG&S&O8PM8T*?*5=XLK;\.>( WB%<Z^#_Y-.OKV*"''+
MN%*>QWEQ#EOMOAX&90[J*KDWS=#CPN;DWB+L%%>S$L67P@)9M:"?-0(+358?
M;3L5_Q6YGH%8T6A.T/-R2^D=OI>)Q"4WU36:*HP+Z6LM" R)4:X+K6J.+L/9
MJLG=IM?T'R_@3R$W<3N%9Z.CI6!KX#0=FREW"07+RY9-IK8]0->C-;3#/AVL
M_S0]!ZI=:#]*<FC(HL.N@%!EI8QM'N8<K79:5QU5;SK1'O60;H/$,(1.R!E$
M X@D0(/RPX4;6:TQ>&U!ZS&UF;W9*EP8!<<8>MKPUK@S.J]=V:")Z[/N[/-$
MQXBXN_(V?CL+HPH=^X^C8DD6//,A)IH.QD7(VTZ,Y] -H9R$ :W+ [-???YN
M=/:BW8RV8-<'J@U>/ZINQ@P[IX)7GG<879J #B]\S<7H0H0A>(I[.X@@ W,I
M!@KN!WK)%+7!HT!6!#A5Z*3 GG8K8LNL?5FW#*Z'J>PDSI66\?RXYZ+I3VVF
M>:4>%+3^%F9$H\:1T6SQ@[R)\$6YND('LXR^MT0'@6D^S6]F>KNV6O$9'N=_
M34'9.9MY6EZ.MH5>;FQU<>?>#B$WK[3?4/ &Y.SO)L_D*N;R_<;KA0QC?<R1
M1[7=6D_/Q\>L 1DN7"4.$MG",.<YQ]FP%I8G&QHQLHRX ,3RU)>"+PCW]1RG
M,H>WW%*<O2?CON)?@2R#2JNQ:K4VBE4#N1X<C!IX^PH"@1/$CAAY5C@,H)6-
MX2(;0N8<A:,"#WE/;EDX0;J(;%8)/UA%>/41$<:*,PX#18W&(98)Z^XKA8#
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MS^_SZF5:GG5Y>5XUI$2Q3?4,.31J@5?_OD[_R(NGR3VZFR<ANFLABN"JP2\
M<2G98;^DA;WO:*D]>)_,ODFT[EJT**1F0PR@IDIX28]AF.PU5YZGZJIC(BYT
M9"A=.WBUDWA-XA7$BW)E@7RLJWWCD!$9 <X?[Y2<Y&F2IR!/#&5*PN12N@2)
ME8A8'AJ&WB.2MS(3J9MO;(0S+=-BT[234$U"M<V\DGS1/*],>WY>9EW3UE/!
M]20ZL>@(Q*2&$WI@P1SN\N'^T"HO'Q%7E4_$&41O!+0+')[W(L6X/9_RK%+
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M=[@ JS5>FD3Z)_<4WB)K)TO?NE43V>W^H7"'G%62F+OT(D37)"4/_MLT1 3
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M[_3=/.3WCW\5@^@3MI!>L%1P+'4#M3*+XD*$5G/1BK.5*MD^,'F@!C^9R3-
ML8ET=A@GHYB+7</[\#:MU*PW2K6:G@E"8ZJ1>=QRDIK5+5^.*JNJ2^"#N6GB
M] XN4Y0-VHJWQD$!/,U;/+*L9U/?YF?8LO&E\0G#^=1S[(2%> OKQRK^.[Z
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M\@\<E]L<6-1882U8)-Z [;^(A4<PSOQH58G'YXE4P-EE--V$9J=1W!B^9JJ
MB/,":9V^I>*!4O=>I>ZQN Y$-AP])RJ#"]&V[1T2C.US01.98\E=35NXFG +
M/V@JU4JJ5:I6:(BLR$\Y_OBD'MLL8/4*%LO?S"W#"-=X+!822C&BONGPS^HE
M7VJDU,AYC10^)/,NHA /!*!*9NH"8<YN>/&-A\BD2DF5FE>I^,RPB$NSW?3
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MW9WDO/()8^8<>(20+&/"D@]+;+WB,>;S6USL&/;;_<"O_%U2VLJ8BMK<8 9
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M+$-^'T_[:M6JKE:UFMI0:[7JNZNJ7J^K:A\9W_++9FKH7IM.%$#;E0,;IF5
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MV:Y'W.Z4QWM ZU]";^L/Q*J6%>\*,0S"A9UP>:M'C(UJRIMS/4EV!WC\A"O
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M+E+T=_:Z*:GL6QC^MQ>]'FJREQ <55.?:\#M(BTDO@^Y_%H$&RG+F4_5JZ[
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M]^LKS2U1L<''V**ZYN=\.L-5URT)9Z+H"Y5D239)X(<Q&,17(D! @/ 10/A
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MQ7%?V.\TXF%BN"\(Q]"^H'UYCSW&G+P&A/;E4_ORSL96?Z3WK[8([#L6X:)
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M37=.-+/5A16:BT&6S_!8U^/A.0I3,^!!2AS+6;_=K(S7"$:PWZKF)8*)ENB
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M"<@)<.[G8[G4^[29?=X<^0-L#T":M 1GJ@J \6\+I8FE?@">Y-<2$%]QS<?
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MXOT/1[?_9=Y_O.IU%H9V,:OFEOICOEP[N;)UX/TBN?:?Z]WWASO6F8W3!=(
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M)?0'$XZ[( 3I:L;4M/$+]!4:>X5#8X:!QF3@7]( ?!+Q4D>J;JX\DXN)1Q=
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MA9A-3QL[XZ;MG6@]*HJD U^Q(9-<2!;KTK#A2_5[$7K=@H+%2;P50G3XT%,
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M\]3N+"^4H36!-,17[2E=RV?YW'K$,E5/H"(!1 6Q_?"=;:QO*1E* ]5V(F(
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M2-Q,KY@YGK!!<4MRJQJGKVZJ>M@;FD! G--5X"$PBY)=CKKJW'PWM'S0^9#
M\,Q>BZKCH(H-9&MBPB<J\,<E,+V@!>NGJF(\LZ^*\;>TRWV?:#@-*6-V^FR:
MWY0F1,HU^F-5^7CG*13V1)1 *CCG0;XP@%T+V\AL.@$5.SNZGI04_&'9X8O)
M!TFK"D#OS[;"8$FCL[X3^<]/W.5+VT78@5WTEBY*[]L,QAEX]GJBS[&J4=1L
M=^[6'QH?[V!WALT8%/3-;*2W;([H-=8/6!?G9Q54^NFUS?!E*K93S[T?C>ZH
MELT;PQD'DF.YJ*S5DM.%PH&]9J+>18F**O1 -W?!;>P@..Q?AY\"\\+!O@N
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MB"0B_"6*##Q[YXY(13S_F%N=1'<Q#VL'_.__=5 C86>\)\-"E2$#[RTLK,U
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MU)N\P^GCU+<_M4^NR;X#R]:0GS>WK8D-G//9(S\1FK[)5>&7SY>^(_)<SK9
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M=$-<F%8. 1R.O6 8G;_/P==N@(7'#;! W #KO">X<0.L"S3 >O%H_I,"05%
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MO^FF#L9T)T>4*!H;2*Q<,?,%EYU_2%E\?%,G(FN9I3K=X&E.:S/53GU90Y&
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M..>=!UTV[A.L?PSX;&:5KZSDQX/\4"4YHJH<+/73_:<CXRP2<B3US?$>1!Q
M )(^%(N2+-O/R-T;UT,WN8.Y1J" =TUMG,]F%4X4NG)U28Q'H^;[*[FAH,)C
M,L23.UW[PC\9E,=M4^0RVB"K&;16+ M@UD8UW#(OR_XEZZ\]+QA?-!NH!AD?
M@&80*# G-13W<(ZS@83:S.[P8^-!:YIZEC(+*:K)L<=%U4Z/NZ6B:HET(IEH
MMK@.VRLWBHD:QW:Y<Z8-O3TE1_2S-#9![8P &'5$_GTLB?**QZ(<IAK?[14C
M>TQG15#LEV. .Q<X"5"L5!TA%WV8>C@-ZT5<@+/V95^R++@8T]_I-[!<<XY>
MV+,X?_I[*%#<MAJRT9,<K5@:VM),:,P'*V@"6/X7_*(?_E>>RONC?A@'"2Q[
M1(7?>R,>0Z5C"/:::G37HK3A<W(_6RY/.&\\FYS[WMD[4F!/$3!*B^T $ZQ$
M'5ES/BU1$8_369;=5!:WK-X,XXIU<; HJ]5D9H(H:X(3$8;P) %5Z9-E,:B$
MA@K&F/L?O<!3;\XR?4H"Z ,_(<%+?+2W_/VR IRPPIM%I<PW-R-OM-I:Y":+
M,GVC].HC[@G2K>\3>[G8.\D*A#08<7=XN']8'1#9M<C(B9(#_*.0*+B,W-MK
M)*"\E"J4;'L;OF'8-:WJ>F2);67IE'T0&WE+G>NGQP:Y*7IEV3S<J7I I(Y/
MH[ XU#-I'J#7!)U*?KG4O#Q&;P=9WIYA</O2)TH"_RMY T0]<-]ZQ:[%C(A%
MBA>U56UB9L;%9G+RIV<Q?TS4!B-SO"/6NUAR0_1ZN%>BFAZ*2ITZG0EODR8"
MU#U4*'N7#, :SE!U0'AWP4>+ *=5,[I]$,C-Z\;VWAM"+P&5E#2UQ,03T2$1
M"'+VOF1N?(1@750R"UJ ^:!(U^D:&U@GD\S(:PU3!V2Y5<&-905.\W<J0S]S
M7_TXX^BP.M?8T\<0B:)#(O_:TF/YL[V*44^MD>]R#YB([P'']X#C>\ W= ]8
M]/%.8#(I6A8)1DC)(BFD,!D(#&!H@:!I&L=(0J33F5_!5HI1NXQ:O29[R?ZF
MI='D=-4V1;M"]UFDJI^.%%-L@^Z6EBU-U>8;J_RP<;KUE4 (V-.1>KYO\;-2
M>\Q7:9#$>M5.7FFQ<.31,_-#NZPNF/*8$[D9EU%)@^U1;3B2>CK226G*E!E6
M%CSH8$G/[#SH6A&-9)Z.Q*;9=$JCO1%651=D:5.SR:',"N3Q/.D1V5KPS7P5
MHV6KGA$G*M>E)W#DT3PGJJ>;&;S2X+JC;;Z6Q5<-?(F:SA_-<YI.KK;%4:JJ
M=2O-9*[4K!AL%SWS:)Z=:267,>2TB>4:V:Y$NF!>PE$WZ:-Y-K!I/=/TZCP&
MJ'S&,MLS-CU#G=2.1KKEQ;!=%<:"-E!6Q'0]LYMDEQ7HXY$\]D#W2..APF\P
M)EE+UB:3BH':I*2>CARV1SE;]+@>WVVY'M&E!^M4&STS_70DJ^7H#LN0\)E:
MNVK43<P=-]MP)'[X>D&B&)%AL(Q TY@BI' &%Q@)'\-?19"F1((2*?#TX;.J
MTR;H7H'""*&9+M'"=H71*\BH1TL#_0;'C2VRR8/>DN=*=5;2RNU3+#WA2U)J
M9,VJ/#W#3& PI,-2DU,L32>3/,,T! S;Y+>9A2 6W'GI)$N+=4K(S3M9'LMA
MV8PW=7+)4?DD^RT6>5$OUPU-H_$1T2&[FW:SSYYB/Z)+CO!.86'QHOM -',+
MHK%-M4^Q"MDO:*5UL6YK58[H\>G^B$JE)W#DT3,U9M/0%WC?TXI6<]QT&QDF
M;4Y.,=6T9KIK62HR6'=JT,IFV*)+9!N./'JFH:VL=5V<4!P])-8=6ZC29;Q]
MBOWZ^6+>$(HCCEOTMBS5G#)33$-,=?1,22EH&;+?'6(+;#!6[;3F3%L3(7W\
MS.$JO<VELZ;'0]]]VR_FO$INAD8>/9/%:IY"E?665BW9BVE]KDTM*,[,"2@K
M$_FEJ@ZV'%$A!ZV4).7'O14<>3S/!48P^$)?\VJ^,>:]Y="JVA,A<T+T(&[;
MC&@QVD L;:;CAEQ.35DX\NB9V;K0G,\JZA"C1^5Q<=%W"BEK L7I^*%CK9JK
M4>EUDZ/;O32]IGL;E_2'1D]]IEC$BR''3X[J'9Z&A$&]]T1%HM!\RT:Y6^X&
M73M'!V7<PE/]PXH3)WE],%6AOHWB]-5LIU7EW&D9&^C-=9;L3(JYU84"*V6Y
ML98FQ>24+UI.SYMK0M:D)[]^N]",>R:RXCL506!S&4X\*K;HW\GSRQ;K*!D@
MB+:@NW9PFW9CT2C_&>&]N\L'R.&[<I;C^I;E<61<6@W+EE:Q6*YI%&?6S*O7
M965UH5CW*VSX6!W [P"60/7Z$:51KP+1%1%UH?<;!;2>%A:VH@W?WZ,/Y9[\
MX^],.(?0J0J:ROGG37,'_!/]L+]"Y(.$_@<R&N7 @C\X.1$]UXK^$'@[_E\.
MG")LKT].,.;1[V0"1\:UHWF%[\,#_^-MS5IIU'[NI1:(>X;PWO-1ZO08[D]T
MWA/][F>/_Q-XD$@B7_7<0G?:?W$T5)0<2_=<\!D>V_/-&/>^]_8CKCU'_(W]
M"\.>C%0ZWH3K;<+SO3())MZ7V]N7]#W]8C?F>%\^ ;2(>S+>A!L4CABT;G-?
MTO>QCK_!;8EA[#;W)8:QV]R7]#V3B??E]O:%OJ?P>%\NMB]^-WK__Q_>H-="
M+=>CRWL(\X>@_G*@XTN10+9T],?_]XOY]4%RD/@]0T<I%;L4Z_D:]=Y6E424
MK'%!>NW:;K]THGY(0.G@G?M'\[]^/X0EBD]%5X,?_OMOZ1R,]!K:?1U&>CNP
M[*/(E5GF)<+\]5_U1**+ZL+%R*B\W7WW/A'4#0E[#%N>(YJ*\_=__ZV^AS5N
M&U"8/\ 3XJ-XPMQGWL ;X><H6^HK8PTZK'DGFNPY?-<BPE?C)^8'\1.!G4D[
M?5T6.Z++I_-<YA[_43R'QQ;1>2RB7:KS/_\CRP",QU<E1O,P \$O3^1\S+JY
ML94=;/,G>8TH%'B"#(<H04(@4"P/96K< LK^GS.L/#CHO,65[X&@GYBR3PKR
M*2G>>COL\_HY)M]R^RO*FSI,'T,)5+OK+>2O*.G/*KAMO:Q/NIS:;=?D%3:J
M#!2404K^^HW?$?CQ3>\/&JXQ&OQ<-#BM#:Z^\%L"@P_T(#T_& RT8A4,2W/
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M>_QP[:7>$J1<_'CB %+ZHR[>6TT::6X@SB0GY8X?YOA%'(VEJO=IN5":<.)
M%!QV,>:[-((4=#S!9+[VV410$3*Z@IL8VY:1<("NH_N\$\M2SE$5\MK'%G^:
MA/I'\'CM@C@7LZ^NO; ;@KX_/0DI&=OA&)\J>:V:$@03U\RE6KH(EDE&]4$8
M8JRB>;-<*\GF5!XCV: (.$[=,33]'6.A,0#$ '#3[A239;34*$,Q/)'1EK7<
M.$NTJ(N<A8@IP])'^2[+Y?I:6U;55CG/(@! _A%]1Y Q ,0 \$9WZ-H+NR4
M^$/GQ[4ILC%/@P<LR0)ZW14&S4KS(A: 8 YF:NMAF].Z/<7L+K&5U7Y I;,R
M/@"D4^=W:*X=&ND<>#<ZW G3 7XOD,[_%8WY?_+0X_$WZ'S.SK67?#OH=X-%
MDZ\6<O[9&/E^+ZD6B"IK*N&G(5J"EH@O]+0QY8JR),_$=KW?,BZ2KP[H5%X>
MYKP\5Z3Z8T[-"O:FT [:@Y#,'4.\U*'[.T648PR),>0&,.3]CM9S&((Y(YGP
MP+;%$Q9NU4%;[H#,15PNWIQG 5>?<YHX8SG.TRVW9J,BH-#E2M%W-/U3;L+%
M&'(CYU0_'$/>[:L]AR$]$FO49MW,A"_2/:K<694*#GF18^V,O79YI^]4N8'X
M4*?7$D]Z=80AT&LC\#L:>^ED^^;JN;^WYOFER]A"!O'KUTY!8H.J&8'3U8P2
MB%ON?,=QK^@MJG';J25L.%I=PJ_Y3B;Z:R'/^F,MU'$2-5T#MH-8%W[+2:Q4
M=YH(#C3O]NOD)N2I:$Y0 R/720#'A7SBHAJ[=L+U3^IDRT$?K.= 1FV.7"LA
M@81JRIYMPU\]TU7UA .YW1EOHMG-@>VSH"F#A"5!$11#H8(3"E[M3R/!3FS@
M'[XZ]XG>5'7@DAQ/#YHIP9^A>, ?=R>%<+W6Q(3$#3]VT(Q0.5\7??69=\*1
MB(;WNY+\E^3$9YCO Y5__ZVHR]__A?^)'B7KD$T0'$__<_A4$KTW!&,LJ,U[
M=OP\+!U"I/;X.5AU(4F0>_/V__N__]?^_!\U!*I@;-G_1&I@;V%A)6'"UP@3
MD)1L(&I)OW'J/Z*^$C=.N-!TYK&TRC\[38(HD<"Q>Y+Z5V+O9T21(W*BZLA[
M1#NH?AQ^[;  <O1'RU$17_UC QTRV!*@IQ\\U]\;UYK_ YD.R;H!?PT7EH+*
MDKK0;CV!&O)Q;_XK)J8V4DK_TVOF3I9.0C]#N8#"HQ^43PK_].NW7Q(<25K.
M\@M*/S;H$<\)ET?6VBO5:UJ=9H^ME8>);+G9*W$=ML7QO7*N&Q:!*S=R]]>:
M75#@G3@H\-X-IM5K)G+-1K=9*^?9'I=/%,H-MI$KL[5$MP?_4.<:O>X;,."0
M?T^QY:7KQW==2]:FD!)0RW +#T):PW)?++]?W7@-UP-+E2_J/+--I_I2ISX)
M3"<58KS"NB^,$] P_#:*]0=;F0G^22:Z);;#)7)LJPP9\I(\=VI6H4DAWC]7
MW*J#ON\$FO*X/#[\W8"*TM_-R]D^^)Z!UGME%@FHSG7507: 9?IS;CQTN03K
M,S($+]_$"3[H 3W!+J&(!%_DUH$Q<Y_@1'F:<*:B'>+6X=.AN*JN'E@S;S3]
M^Y"WA7J5K+BC58?6U)DJ>;@Q7M:6DS]NR51N% Z,]J0#9&2XKZ"&<X"YW^0B
M6(F_$"C9T%9LCN',H)X*-GEGR&.!T#5$VQ;L8766::M,1TMJ-5G2V:2,>>RO
MWY8)CFSXQ!*N$UEC(!&*-J*?3TCGB)*(NG !U@$]0[,T 8%+A?:- BW/*3"A
M$6<GQA[Z%7U+!Q-1US<)<2FJ.M(N=_XH?VO5,2*-+B+S4MKXVYRUX!:@U^=5
M^'C7LJ'!V%61J8>,5O3#',W^T*Z=BD["M-S'AZ$_[F9U4=7P@IA*SXLIHI&#
M^CT@VCIS:"1^CCPVS2>>1P8Y'GCF[B1>.'NPGQ#G<]M:^K1-0!XU%63-(RXX
MB30HMC"&(NSZ0EDV9<N>6X$J@DZ.$SP!*/"]%OP=\MDD=&6@A0]=F+L$&(^1
MS2_Z3L$36B5$_P/T-/3T SL'"51272<#D_N?DO^/(,WR:S:/-SB^J6M485E8
M#HHN>S*&]$><\;J!!24Q">4_"8VKG6GE_Q-(8K"H%:20 J"= 4W*1]%X2N1C
M44%8>;B_5+"_OK2A9YRBI@1DN!TAQ9$\0_(:JF*BB3]Y'![RRWV"U?40=-&C
MH4L6_>8WRO0E5?>4P(%#+X:XZ6<OBPCKQZH)O3<5NIQ.E)3K0"&&KY8 @@9E
MYODZP0:N;?G.'YP6Q! ?<\8Z8@STS)!'0FUW8FG7DGSY6<D/T%02'=0='>XG
M,!U?**XD_G@*[2=&WSV#O7 KK+D?"X ?MVP4)5#7B:QJ05ZUH6GFN:KL1$:X
M*=_[#PM5!OP=*0NXJ2U=/)#ZQ%_H<8B/">P_Z$/_1_P_?P<R@/[B0[KCXW[
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M0K9FLW#DT3R'MC4G1NEL1P."FN8757ZT&$X$'#N>:*8Q[QC3ZB:-%0>K\69
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M7ZHIZQX2SH0-= BI2F(N0FD'SM\)R!WH[^B[[M0&((GV)S'WC<$$@,RJ)/)
M]CGN__X/3F/_(?&[!)*7Q%]B8@XGA/2E-4XXGCR-)B3.Y^@AJAD\%NUE0I2L
M)?C[G\\A5ME,5#P3P'GBF;L#NDP"[D7T4>%,<U,5C!-0PF3/59<@T1R/H9#9
MB;? ".W#")Y!,$(+)!;\XMBNT%-='33'95-!D0HH(;XLHT_\]^U>%[[M"8Z\
M%W_6@_::3.7&16Q1UO)>;<#8I?3IDQ6TMR>=!^EU()"> @&WGJL!*0+7(8"
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M15ZF=9:FNM,UDLL*73>UP3JC8C5) %I3Y.-I<SI ;D=WC>3(4:$S CP'&%Y
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M,LR_PO&@NZ5M'XF&+_KB)- P[-S>AZ!A(':P15><N/G$\(\(^13=G(8SP??
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M?KW_]E9]PGVTM7TSFQ\]G7.1%K5WK77N8U0 6)52&PV-AJ!*_L!"+*94IAM
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MV;7K@4JQV-Y:;&.3?)<F^5UP4:&9PX=NI4X;<YKL8;HI"VHY<+:I7_]@-/)
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ME3,;5XB.5T@SQKHT&?6D<=-KMQI?KW(*AHFW.I.U9'"-9(/'6[:4<AM Y8!
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M._A6#A_S))_/Z;\[ZUKMM_@$&V E,*CQ]M\.O^5(0?AC'T?@*'X8@>^CVL"
MWRCC(;V8\;@TBX9JZ$PR[#*1=3&]9K1-->4;_F+!9FE*KV/+#_/?>8VS\_V@
M!0FZPBE/RSG/A6QR3M>*:EKD,=30.\K*0AMKX."GSC+AP2MMC0B0K8!30E+\
M>WL,^RF:WAW#_K(\U'&%1I!N1ZE7:NRD$-W9X[_2<:7=,1"T/W2^4Y9CU502
M,\G98PS@:?3NS8,=.3B<#E>2.#VA_I ("S$A-AX*-TPMPL.2AXN^&@@!&#UH
M8T5=F,_E[- M.A-91]8:49C69*DA\!^/B#X%."RD8I9DD:(,8H"BW+;EN=GO
MP+#UG&X]CG.>8)]S[M/5=,V-2/!YR.?CJJ:?1DUUTZ9)@ZK5<_):7_2&JU#5
MG"O5"DUZ8FO33U5/2#9EJW^").B9+A.S@_+89]T<I/_\&_M/^,M!U="SQ@[@
ML> #!]P*>+U/9W1LR_6GTZ-BG=-G[U7"3AF^JH:VWP>/L53-!GYXF 3;FMXG
MM72B479PP%.MR;[WQ1&FO>^R<0AG _+ 6'ZDAPBVH^I!.FS_W!OKG*SM.^_G
M]RE#JNI0*:(\Q^+ITM3.N /S\P?N/PQ:>[.LL-%:[2HR581"<RJ/*U@051-O
MPBNOJYVWT>MCJP.C\G_K6^:^&@E3[R+A&6^\O;3;8]MWP8/;2W#MNF;MAHXD
M615!>F4JS:_[A,+: \) ,I]OI?@AJS$<BW9W.L,K_+3C:\O9<K)*IK4@RXW2
M;[4:>9V ASK@W_J.,M<LW]M+6)@"W=*JPJF.9.3*!#*OM+!^OCFL9MU/GZ%]
M$ZD,\\5A'OE\S#LC4M5)G17F?$Y@AY;35T>2MPQ:2-'$ Y4Z'4KW$A(%,4BP
MM;N]#:'G?3E=4/7["EJYC9:>"U( 70-=/=H^'=PL?'R(8^ZB,&6;)@H+:TX\
M27B7[=W/J>N@3\:QWYH*_=8M6KJMTS@U*$^+W&Z*;AU';+LGGQJG)7COQ%12
MU'<T2((?'35)<B!TY 0W>CIK<F0YWVEX Y-CC\+WM%3O3"7V"TN_7D7D,\FY
MBF?F-$56KB^HO*#F&I3KI$Q\17W>.3ZLZGE/6J<X;VCEHL>6C%::+JAE1!W)
M#@02F;?ZP3PD@B.6S^IYGF@C:5O_([!1(Q5PPXX'GQNPIU*??9G:KN;G,;&O
M_3AL#7=W!UUQ)#[H&A]TC0^Z1NB@JQ1H01%#)6I(D*A(2A0I$I1*BPPS&HHR
MIH+E*%A*4H:_0E)*NY:7U<*RO^9MMH50*U.NB [7W-!+:"">7^FI=-V6!J,1
M[_,N6A<9=U' -!$3D>=7#G/H@%HT,AND.Y'[R8R>T7)+%I[A>G[E)CE)%HK]
MVH"?FI6Q*)3[Q62K :XDGU]9MKCI0/*1B5'2>FG3\^OSE0NOI)]?.5[FD]U\
MUEOSZ_9F2'8[J-^>:2)^NDYZBJWP34%=(6N4*Q&",IDU'!9<>;+.0;97L)KD
ME!-*Q:E73FXT@L'@/4_6Z:1U0JUURV/$G^C-#IIU*FT'3G _66=ZO<XER>1@
M(6!51)@45N.5IL&IHR?K3"KNBF5QP4!J;=4K(_2,K*SAW(B3*_.KM$FO6WT#
MH>I$HRAN_+Q-P :F)U=F4&90[?J3H3!MS[):R>&6_:8&7.J3*SMC931N)NL8
MWZ73FM$9X-,-#J\\V25A-#<+59]K"KI67%?%GEDV^@UPY<DNI<=)CJ@.517A
M<CX[Y)F\,QFSX,K=+KUP=/OU\L,/%"MBUU+'A\AMX85F*&'1WP',\K9K^\:!
M:K"SVW>!A]>20%U!1^>WNAKK0WVKT+8O^'_GONW]_>9KAI?]_6MK4<:>-W-_
M__77<KE\!$]XU.S%7RR("8 "<O]2%4UR_@+Q@O07T%$41J-_ 7N/H@2!(01*
MH2#JP?"_%@1)D#0JJBLBB3Z.O>DY"_5!*KQISPH6A()\1WT(XAD0^)PY\IC:
M >I[$FF^!#NLP$ZL$ A?AS"29S\$/GU:L@QX%[B\ONT8B?^_O3?M39U9UH:_
M'^G\![3.V=*Z7P6V!\9U]K,D X8PSY#D"S*V 0=C@P>&_/JWJ]L& \[,E,1;
MVO<*QMC=U575U35=%5E5T6JV#1N=NIQ%N@E5(USD!EYHP769K&Y/49&=,++@
MB(=KSLU0#IE*H98N*K*%?I5KI?&/D.V$%#S!RP3[T[,1'[K+-M-TO63D\'%P
MJ'(.BYL3(BZA,)R#WK>+.9W3$5Q6U<1Z,.U8O# 2US:G<?>%QO..X)G+>U!0
M&0EQH9EN>#7"9H5FPAJ;9+CM).*R)2G&'FS/N<^Y#BS_ XI*U-$YNW9MFD-$
ML: E7G(9:Z0I\HOQ*_^$YFWSY/W0DZM--SX'P2FC/UL\"FV643AR)XXL ^EL
M/#4=C29V)\Z,C(IFVR+?_G@AS;L\B[HR+L_U\%V&SS2;338G)D<# 3([_+HU
M'.3=O>Q:A'X$6^7EK\RPQ\3)EYWM-0S958K/>V(4TY?)3NJ+21#O2\)I;.#P
M1>'6*I>L7$VB\M)0;<WJXYP4.Y_SI%\;CZL#H2WQ:+:#6[G:OWVZ:_SZFWHM
MMNCO.SGPZQ\X0\ZF?JKZPAL[WY1A(&5*2M3'LO9,UKPS4<'"P3I0&I@S'"=K
M:&BKZLVN'W3#<C!1!?V*S//CU3W'51?K59*),_%'D<K(]2'U<*\V*['E/N^X
MFQ\!XN.T3?:M YS@J2."K>FPF.BI^,"J5IJ>=J9INY!^X!/)!=(,IRD/>J7]
MRE"'31/S)=Y'3=DRG5[XEF[A;</9:1W61+N'J(\T]'R);"1DP]WU4?_!R^H\
MT7%[$8P/;+;-3/F/^X=WO. E<CQ$<*P7B8_%=?-AEY1@6[I[@?BC\)4=MY4'
M)L2Y9^L93!)7DV6XXW+>1Q,/T1O1 V,1FGX)C]3CJO \'PH1AXC:+N"$^SD,
M&"E_B(\/FFJ\ZEMS')[XQ>ZMPL#45=N2S^%3>QY!Q_.[MV-L>%REGX<82@;K
M<GWK0D?80%ZN<%V2$9H-UN7ZUB708]>Y+G0D&@O6Y?K6)=!CU[DN@1Z[SG4)
M]-AUK@O28TRP+B=;%XQ!B?]_G&/^Q8B0=+,P2(1/L=#HQ3>3Y:0J_?(T\6:F
MO),DHJ["Q?_W*_GK@^1AF4CR7WN MO1L!;WO%.D<>+;)EQ+6_.DYV'FGEWR_
M_MY#0U/>'V#*26C^]V ?YO7=(G9A>KU('<4G1<P1N%]_?W<BK4@H"[Y,P\G$
M)3GNYC__^;?R)>3M50*\Q![/UF?N,(57LIB/2E8*VRS?1[(8BDX=D"G@D4_R
M2"SUO7@$$/P"'CDRCWRK'1JB;D?9@SW@$*(HR\/A1:T\2+"&B+KM$X,\FCA<
MV9QW+-NS6/,D,'-E9/C?(TR,> 0O,#&/9./8LW>F;"2V/]>W9A5^L,D[G?(F
M3*!/QTV8N%O/;5M+6G9'*12CY6+U*:=G&A^NW-Q/I$!CY%?0[9>4X*+W/^')
M;5)TV%^;C&GJ\>FNA8SRSCI6&76H234CXZQV]M??Z T;/>Q &RB1XRD1;)E?
M%QD")7)Z6-_C*)'>O,%GF\GBG._Q$C/AIVNJ^W 1)5*DZX4G.]^^I10SW2V/
MRJ-Z/M5 2B0>*)% B7S*IQ\HD<ND;IY?B?26]9:1GDD*)4^UZD,XL=3O<F")
MI#"\L$]3O\^>W"XI(4 9#YJ#AS1?P6=QE7KPY52YT\_9];P<R7SZ66KN:QVX
MO*JL-G1!,$"4G=Z6/OI-9:,CI=&X%_A:6>VUIID.(ZY&_2B<M)B;5.JPZU&@
M"4Z2I!%H@JO6!%_KU/0135 H91,%(<GE)N'[J'FG/!79# 45^NBXQ-Y$$WZ@
MQ($F^/&:X,4,IV^I";[4T><CFD!LC**9"K/,4U.A-IA.I<1L;H(FP&>>F _@
MRS>+5I4!0! 7S2(>0&^V%7,\Q5T) O_0-XY4'=E NC(GT16L>L#\U^L<#9@_
M8/Z ^8/PP ^TD?."HIE@\\EF3>-W+#YB,B,;&1$6/=7/6%863Z7QDV1-F&BF
M70S?E<<<"^WJD+&<9%]RGWV]\$ -=RMRNYH$Q__/F+Z7RU@\NREPX:E^";O@
MI\G A;/_ QD(G.EO 8CSR1S FZ"/(9!?3F<%39MU.YGH6,X:O73G7E_VX^ _
MIV]8'WC'0'D$RN--QXDK5A['XX=OX3EN0Y>UP%EP<C?QKDBP2"0DW8;^=-<@
M_B=-5K[XS*_+E/A:&3JN.9'13<LL$%PZR<>6D-JIJ:H;>K4S'6;OTC.[(MPQ
MT(6>_?4W<<.R+T7@ IUS(@?EQ24OT#G7H7.^QO'EO3JGIR8*W?&LT^7CJ9E5
M>QP\Q9O9)=(YZ/R2NJ'IH%PBT#EGK*>X^,RO3.=\J8C*6W6.L8J7Y,X@FY[,
M!]-)X=9DXMDHV#FI7W_C-TS\U?#)OW%7ZK\'.'/'9OY]K4"^V1S) =KMC8KB
M1*!=>W**&X.S<3SP0>39?@Q7BH%"@*,=W&@?]%GT[*C#N%FZGAI74ZT1'V]+
M:VO\T&<&N1W&_3C8[/MQ45+9D=UXBI=N)T)ZM$H+C_V'4;R!<5%\8%$. +%#
M68*%'760YS>@-TS4[=%/ &_.@R?@X% X[PX]!T$A ,3%!@G BV\RD*VE+&M>
MD(2;:T4<VH,98F@_F"&7(UR458<PBJH"1@V&2C#EJ1(6-,T65'7]-2"'CBIN
MYX0A&E2+[;(6KTPF#&U6Y4(_IL>*HY=@B$*P,E,"D>)9/()Z$3H_=,4[2-^>
MA\?CA_C@GI_W,U%:G^;M-#_:H3; H?V1; /:0YJR]C*YV[(Q]="26AM%/5:Q
MU,[\L< 8N?MN3IPCU66-#21: -QD[N^R#AB*Y04X=N" ;Q!SJ[)IAM#O5 7=
MY +/2#= 5H(R?;.!@I-"NA%"% !(&H(](A@;+2&C2[O011ND%=,>F(JD"(;B
MP<UQ]14\PB24A=^CU1_*(@!<H %I)H@PH*(X$%2"B;$R=I':\4@ G6?G/>=1
MOCE$$4'$F=J YX'H-]-- !\'A0=(+FCYS$,\:0]"RRXAT R0@K$4K)8D!2!J
M-DA[+J"UH^/1 J'9R@0&9B\%&MXH(3XBU-[0">EGD8"'  J)H!BAA:#:&[QK
M]XD$WM!"JVJB]QM;L!'8!13 1<*3Q7A88V36R&B#\&XBA_-$;P(D:[2% -"@
MKL$0!\!GKHH^'(RJ",1.\_Y$1F(D._"$WOEN(6\,>2K /F=LT,E$+US*_B@B
M(<X$W2^;MKH':.C!7!%"ZC.YYBX0N F:T*6\/G-H:&YQT4\'HWTE!X_W($%]
M()7+"PR5SK'U.XI[BE$*ORAUZXK4&':Y7W^I2/(5D"\)\1=:#) :O+A>>#L_
MAL,Z#E2>+;JWFH!DYW"]H^%<KCH!5-N77&8(R3=E0414(0V-:T,>4RCC$K8V
MW!^![T)'YWSAP<PN:I->=MY)+RJ-A]D$X-.9"//R2I])_>]H5[(-('6!"'2@
MW$'+;#GL-RCG?S!['>C%WV3G-3&_S6!J_[B[B>@YBFCXN5-A#38MVA4M%;UY
MB1@3;1SH_:"JT5](/8F".;YQH1?) _<VT!OT.UG;[OADUS@8&,8Y1)IRAO9G
M5Y_"PT.> 0]E8J,!L!V\!/801Q)$\#+ 16$V,_05AJ1'(_PB$G,$$_!B4O34
MI9ZD&E6DIHMRT9:2DV5CW<!2]!HH(NRAGGU0T7SM._#K.8"7+@Z=*,R@7^^Y
MQ/" S9R1;M$; Z9[<S85##*S$6D/;1T_86:#']U#&L&U2G>8<0?3D?+P(FT-
ME[-$8A7MA/O%67->[N:;&;1U)^.I&\HG^8J8N@=FW%:3^JE0HK^DW2XIZ#Y\
M97,&(HP"@)^&Y&)$;K[<6NQ>\UR2'7L8VP6D9A-LV(5SOCK4S\@25'0I9)ON
M&^0A'&_0*F\;;(+CX82"XI&36\=8AUW#&:MCG7N=5QB5&2B&3G/H182:"AA+
M2, ]NAX[3 [W.O( Q7RK(X5@!??SQ;PD]FE6IQB*#\O%Z$-FF?=UI23[3.Q<
M8K4L*M%)21I(?"V;8?H+,<E,+,XK5H5J[AURM1VEY[U;86L!+=#!?>#)7?2*
MST@6XQ/C-M?HU**=>'H5FW=B520^L3@;81@Z?B@_SR QP[*AO65\.DVX726D
M"L^Y9+'2]&&>3#,#JA;N),W$HE"LB3N:D/KL@J71T;4+AU5T_-\N'GC$?%<M
M2XVR@UZ5H:DX'>\D'LR'1$GD(-_45^7Y@0_OB]=OT'GHO"Q[G+M$0$GH!3T3
M5D71;,$)R&!$#@_NB*C*@@&!O_'_[89)6- AIP >>;;_,A/UJ"H2QLF%H2AG
M%T_DO_]K!S=E$XP$?%/=^.-&'#T3<_!:&!Q\',EA LN"_6%_!'4IK$UGHHE4
M9)/^_6<3M&2)G1%A8_\*>?X&BAR0$[!3/43;P49U?K8+C^I>? 4>QED;2Y_]
M8>@(A(JFZ*,SL2@=2<1.M%I[NPB[79O_"*&Q ;+^/^U:QA<:!/Y&/(U$3-V)
M@3F7D,&&46JQ4L)PL^8F]B:<-/[V4@MP-*QZL];FRH6[4+I0:]_R3:[.=]J%
M3,M!W2A4,\?<I]\U.F+S,IM%J-;:?(L,JUT+96K55JU<R')M/AO*%:I<-5/@
MRJ%6&UVH\-5VRR-+S^F 7?[U8\L]I>)"*T^BRG1TEQ;#O-V85F.+-M5EDJ,^
MW,J0S0']0I8XZ[6[V5,QK_>LL,.NWH2'F2%C\"9TC\?(0<J8F(/O.D!DE84B
MR7C3=,P;E:_=*?FY(G?R'>FI$J6[B=+3%S!O/AXH\C5PZD!.VG>7?&QDQ'QE
M-AI.F+H>I\6G%I."J"S2<0F?!HXX3H2)Z_%F; R<?R*ASDS7/.;JKG,7+&#B
M-/&U7B$0(:S!9M<!1EY%] 6H^(U;7T0&@.-[N7$<+,\86A ?@)/)0-$<M[H;
M>G$\,ON':5DE9ZO(\=,17CI!ZR$)<?8-&5YH+(!'7];0*<9K\3N&"*$1)A?V
MGZ/+!SA%(0?1WD$T/X%K]"KCJN'WR,MS!^8=YTV^DW]X*"=2':&JU#M<DQ(;
M=\AV9)(1GPX_N]X;832"XRTZI?F9E'Y\CT_;NFU!$ ILE3/Y;[YD1/<EW=>4
M)7F*7:U9V10-94;ZUFY6E<W85"):ZM?XS&"9C-WFNR7:1+H.J4<X3Q,G!PYW
M@V-C(YD[ZHL$8ET/[W[4]\^95LZ[FTJ*.5.%]1]%4Q4-6=LJ4H#$J"&9)W\\
M)XODX<\_;TR];G@*_VS4*OX'B DJ>AMB/G!D(%4-JL]PXN@5P1#'.VJ.)6NC
M"N#+D6<ZN-!#)I+DK?&POSWA\S?: )#]A7[T1L68[<?J#\IC;GR[HO+WY:="
MZ_%A;MF-K^>*?)O/Y%6SHHV.(2:$XMJ& -HJBPYTOJ9%9\5-A6AE?DN%8]J#
M^91=YFFF 3 ^AV:%19Y%5EA"3PS]7HYEW%(!K9FF6SA,CN@ 5O$_(<DV7->>
MX^M[>PI1L*#/+6AF2V+/VOK;C4.UF*T4XP^9SCI7T)*J4)?"Z]&OOZS/XGJ6
MSF>AY94HR]*;'9=OS@#["BO(O-$GMEFB[3A<S__&OO=/ ZN$R_UJBN+162-5
M?;HKR/7E0P&"N3X+]2]/2LK>24PC?DMT'%,5$;L1G(5$V^0:J6HCV/C\-K[!
M_L;W_(YG03#88P2&%"?YZMWFY.&3S!#.-[/&:/:!F+W5]<RYE/<*79TL@BIS
M> UJ6S+[R]_=75JLS:EYE\KG'Z(59)7&Q13(GU_2L_[6)2=A+B??&"TB9X]L
MTR++S\3(,?!<4>!GSK!!K!=GG")>V\LX/62T[;EEOPP$LU"O-9FO;WO%/C]/
MCHIFK:!K\04ZC&KZX59K;![EYS:X1&J\$]GT35EMRH@$"LX[;7FR2$._$1-)
M\A!I]4WV W[@)NO\GTT>K">)50@-%<.TPC,XSL$)#G\'?VR"OLI.7NL,7=OD
MF\$Q(XSS/G"H^=F45[P/.M>?';\G73ZSR:5W4^5OT# <@)6;T,"VL'FK*E.%
MA-IO0K^5?TY3@_(5A.BMNMJKE#U:.$-28/!YSU\CM]3']1TU:M8GZ[8@3I/A
MK"XE02/[1 6W%A%Y+,E#="_FMY4:;^18S#Q^7+/>9S6T5T/61&@LJ_L9WOA4
MC/[Q?0YPC\L^P/8J.#8A&W9F0((L5'ELN _+@JC/UC@V9MYL_T;L*.(^=C>A
MF8!#1>X?GF],?6@MD0S>8%M01AIA8GK^WMQ)LH3A,DBD 7(%5W1\NH-A(9FQ
M@ 2*1E8>^XU?D1%)AXQCS \FGK,[:3PG[!N69!Q/<5,$8<1$(8"(;B^*X"&0
M=J_B 8+D ".$7/+\5A:>EQBRAZKX!^!7@/J?#:5->_#HI.UY+.>IHBE3>QJR
M7*.>)*XCA0.<;XW]&8@D6__VCH!0$#'^".>^X(1\S?WHJ[QVN19J=F"63EX1
M237$)4AP TZ[M1&_XI* 74_83B63B"8+:R$@JP5G8YOD21#A^D3-D4,%4'7
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MQKVE1<O>O7J>%6J[&*J&.V*T*$A?31']K:4L$U@WTT6ZWX*N[P&MNBAN9+T
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MAZ!WCDJ>%Z"+?OU]1C]>:C@%C(N%GCJ4)4 YN\$N8AF[@54=_-N_=2-D*F@
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M67#/)=!W>,^ 08158:W;UI^ALI(EK[)S%3:9^FZ(CMS&QLEW>XZ!3XUZSZN
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MR&O4T*<AN57IV1V7=& Z >73YN=KQG-A PJQVL7/GO%M,/(5RTZ2LS[6"3O
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M645BV4XQ@<S <@ZI 5\5A-?:C;7O4-%@-L#;"*T"=R5E__E1U!K4C9< _/)
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M7\>?W\8X77'T]4<E;7;=YTX&KT?LU6ZJ6JDX:(B7Y A].LYUZ_3=,J;]?00
MRV5CBW<;A(_6?4NBG]CD$(!V?3[,]BA8FG0L*;\=CS4P.%6"%;[ :%3!PQ1_
MO2Q>]+WU^:!I8/]!G-VG1!63,6/?8X%4ICXGZ&\'2="&;4]5T&QK[^S2JPM>
M6P:*FLY!X+"V8&YN23/WD@!,PONQ%\#LDVK/F#GJ*-6A<"[&^O!+2=1%SC6)
MD$.CE[_(KZ6$F EP-<7XYL_)W0$SX*],4KXQ"=K6T1O%KA?^$#'EA<]Y">?V
M%^I;TBK,UOZBS?N@\Q33W;9[<-K+0Y,3F\NT:/=D?P765^>7DA+85B#A8#Y:
M6]F'_,$O#$\_58S#0+_;39,YQ6A?&)98D;>M,]2!OZCV=9P-RX6SQFPBOCH_
M]_[6!7SK!]!;)?8].NI@+GVP&#?_ _&T7OM6#G1Y',SJ'>K+X.9?0-6'Q7RY
MP+SB,:WN1O$OUU!G[PR!-=X[8M'1?FH,%P/Z!'%G*CTW#'_(PZ*O_UO4@#7)
M7OE\ J"*W%HA *N"[E>V:!9&C+ 8"S$Y1Z.5Q_.0]7D" *?YCGJ3B#KZ5U1)
M.5L^[V(7\H<V;UEPQHL$@(18TXO<6 >S=N0S8@DSI #J:D+4]3Q[SO*V;#%<
MV1:S#2?6G#2].![D\A@Q3#9#EB"#+Y'HS18&+A?\(9Q1US >#R%.BNP&?&D8
M_LV81981:.$%.&KQI9;V,O8, W*+6 ,0&<"@8X=["4"E[7>-%8J"[ C =[DS
M.>W;EX5 -M^=T@5.%',6 7#^+@,&^BCJJX]J$TOA8X>(C&Q^,/HFYI>:? LM
MH.'F]/3$TOII'F[X7[2&D\O]=VM^FB^9[/YLTYP/[U%(X3OZN\^(U2U4YPCY
MAY(K;*!3@S8]9G;[)P$$"_S")CJ<ZZ\._Q8<<UQ@+?6839< I!E]%:K^.< "
M'P??I649R+/-WG<6.D;1I^9N]#76^+"GHQN7K4$/,!(9QDN^PX@<(P!2@ZWJ
MAE!B'.:D?8WP%_<I]: ?8'_':^XT5 ,#&US\]-\PX\!M9DL/C_O6"[S_(WPX
MY)P0*WE"><N#X-00]PL8?,S0&H[J:O\6HPH2H)/N$IT4FEBQO*TCOGN!_F7]
M_N+*+.=$ %9R-I#H>8OORH%.>F*[>Q]:_6&[E.^\V;93CAQM0]?@HARW'8LC
M9(4!_OLF-AUT[_NZM%O7,09M&=ZU91IM:U?LVIIVK;CQ]-QZ/'TN6/%*WD%^
M7;CPVN*OVU;D7S0^*><,7<EQ A4V^^'-WPE_K7C1.2YP)3ZQWF4,Y"^DOR:B
M7MTP",ME^/M^;/U'/XC[+L!_NZLH_$ZXRP<].J9_N6U ?Z?\.6N!B960O[CG
M+Y1BX^"2M@.7=*P3?7_CRK1>H+!S1/L^*M$0$.CR'Z[" !A4NZ<HZ/_$Y!I2
M>N=(=><F/W[PF@->GX!W2OJ+!K,20F/4K0Q455L/4\.?L;\/2$JS== 4R[)L
MRSZH;S3\H<=;T<KZ:0:99EW<O8MI4[ OM78?H>)34OGGS@N),MS/?^FBUA;+
M/7FR'Y60=2&A^V$:M:Z'#BJ-&B:I@TIP-I5):;VXL#P'%5<GV_&E-)?''<.M
M$X".)X:9H?(-F:I2._"92SE=9F>\"("N",Y1<,Z[U8Z[1H89-S9!3P 87&()
M &J1;PHY+MUHF5XU#5H/@PN! (E?32#"UZ\-CMZ,1!FM)OUH)%#]+SH#4&B&
MSR  \Z^RA"YUP<AM_6!J;6Z@6[]DUB/8L#LJZ#1PEY2F[;SFN@9O3QZ-AJ]J
M_6J12!Y/ET!#I[ML6Z';F;]: (+N9?J#/P%B+).'./FDU-#K,2@U/&?0SY;7
MV0$.X7U![6%XCW/8;@+@F_2KF4 ED3^K.$FC9/%+)85=VAU<4TAA"ZU^$?\
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M]Q@[U'WA)FRM<$MB8?\X=B.GT8SAA<O1G ,3^^(,PV[9S=#8*4C/W<1<EE)
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MVM0-%39908TTD?EGP+SOC)>8'E<6 RL4''GJ0X-=U0,FTG.K+(/A[?1I!XZ
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MF<X9H::MP>F !T!^([ XO=,JT)6>)T0 G@1EP-OC\O"2>$%X;7T/<KJMGP"
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M #LQ1)N9XIVC,:P@SDUYL.9I?>[7C+ %IAZ.EZ[_.Q7TP:2( RB?#'AGO;T
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M+@R5#DYT/U5MO3@G)61[P]W+"3 XGTOGFO:!<R8]:C7M-$?A=W^BXS.)X=-
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M!/3X5/$QMRWEM<5K<B(9%0;LB>!]JU'-D=#-]M)\EGASV(_;N+%#&^7U;,7
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M;P2!ZYI]F"7<J\:348.QG11A,?E\*OXW!&LV4"?6Z:KJ"B<W-4TXP\VLZF4
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MXI]"$/(;V*E!9'QQ66!8ZQ*L_460N$O&1-+@0VSTGM894)- D\V(NWMU;^:
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M9OWR=J+\0/=[N6-JMH 4FGG'"^R(6K+O/!=8>>.+YW-LA+MIPU90F7X7*K+
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M[S_FM21V#C0+D@(_$!+Y8MT26"H^-@O9)?@>**-?VKXA3":D_FAN5L\<O!7
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MJ;<,Z'7NI=$U4=,I^9PK;EUZ"-3M@WW;!>D.XKFMXT.@CB^CDWT7.:GQ>OB
MW+[O+$GF75WB/8!+WJE7E6*=CVY$2I8D9XI5OV[7?6/5=')+*AW7=:SNR*Z
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MKAX4KGW/T37;@TGM6U]=O6U79[1K.]#/SO$B?&TRL]\_+W#:-;PK]&L$P+#
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MP"Z^#.".5A%72<R%>RN9:/(&OX*\?]4O6/24M>18,2?@[@LFP-MYD1U;BA[
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M/;D1S&ZOX'Q/.Y-Z9UL'XB.H5 "3RW#(ILV=BJ!&L:ZX.ZYZP0&QVMGRP8E
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M-+*E[/7(COJ>.OY1+VQ3CNJU=S'#2MR!5;HP\7=YA;53V6<+4OW&H7RJ(N$
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M'WCR"3W13NF^&BC0'"U%R1#*'>XH[EV-=-\=<5%?/Z@;GW_WD:.+Z+/:0@C
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M6'Z13]!<-R%):"2I6 X /<[]+U!+ P04    " "$.7]48%]6\R6!  #GGP
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MRZJZ.,Y-GA)$(X9W*L&>9F 0_[2_V^/$E^&TZ*9=4[YR<KUI%@;@[<KOCWC
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M0UOK4WH!V\U>':W8)=[B!35%+AYT5^E.P5H?F4251!4EU\L"^0Q>3)*I5#<
M66JW^O0'>F?(G227.$L2!>R>N8MW>89/VN6W^ .Y2A%[N22CCEEFFX2QAFN#
M>';9-^48(I8(E\CLC5#?>\T\R?6F#!3>K)NZU.:(>BJF]2:C.9@68I#\K:(G
M/X20X"/"&#I0=E:W\:<!9S.XV)O?@;X2-W&\//?EU.A'EB%GW;C&B9/LTY6
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M@*=MQ>!K51\,NV4;%VYO31B %O0&!O  E1C<J*\I,M]+".4<92H[7<5L58(
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M!NL&IH^Y#Q'</89G<MZ<,   !AC#DLJZ,99/6Y.Z*F$K]UJKCU/UT,,%-_H
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M#/Y>L$$],, 9@Q756WA&FF[2:<[[ZW6#Q0-#'WP]GL#) \X^?(02Y:>,F2&
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M:?_E"-+//S5D07&]1F^/4+=!'0V@_XQI.K;Q?WT?^:>!]Q[^<XI]!2/_>XL
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M<Y^#!R(7BT#;;(6 PM@H1R!=$&?W1\*JL$RD79JS<6:_L$E2Z2!)$ZL1,P>
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MS8CA&#9&#M%'I)O^+RW*@G@&,5X]+)>$7>?=3"M$HR2.SX^V6.Y"O30R#ML
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M.9]GQ$]TJ9S@]7/FW$[]"&WNB2LOA9OS&Z=1W-&*D52T;WB&:+^*Z+%"DV3
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M^,&:Q.\Z];RL3/_*!5CKP?Z?!#QON W3^K9S>T7,24%6;+KKS8)7"CC2$53
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MDNUR1(R71^^\8KQ=$3ZE#O^UQ,RS!>1UBTWO-#1N+U/+:+6^W]Y\;O2IS@Y
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M^@0%\*3BB=?]<N=\)OCXYPC<NO+=#C17MSL[R^V[T,SGJBN?,.UP29> Q*3
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M_EBU@JU2X!DAS8"%QW2A!&NB>7 PV'NS3L:^;>CXGO\(UGU5._D?4$L#!!0
M   ( (0Y?U1)Y^))=0@  -<J   7    <&QX+3(P,C$Q,C,Q>&5X,S%D,BYH
M=&WM6FUOVS@2_BL\%[=- -NRXF0O)Z<&\E:L<=L79-V]NX^42%E$*%%+4G9\
MO_YF2,F6DSA)F[1(@P2(;5%#<CCS<.892D=_Z_7.BXP6"6?DM^F'WPE3297S
MPI)$<VJA=2%L1J:J+&E!/G"MA93D1 LVXX3\LQ^&_4'_\*#7&Q_!4*=U'U5$
M9!@,PV!OL+='PC :'$3A/CG^0':^3$]WG?39I]/I?S^?^UD_?SGY?7)*.KT@
M^/?P- C.IF?^QGY_$)*IIH415JB"RB X_]@AG<S:,@J"Q6+17PS[2L^"Z460
MV5SN!U(IP_O,LL[X"%O@DU,V/LJYI23)J#;<ONM\F;[O'8*$%5;R\5'0?'O9
M6+'E^(B).3%V*?F[3D[U3!0]J\IH."CM"'H&</N:S%5O(9C-HG P^/NHI(R)
M8M:3/+710?_P<-VDQ2Q;M2F_M$AS2:V8<QR[-6HB.=51K&PVNC[!;3W+IE^J
M"MM+:2[D,GH[%3DWY"-?D N5T^)MU[? M^%:I&]'3MJ(_W$8&I9G^97M42EF
M,#CJ.O+KC^JEQQN3++A;3JPD@YOG__EM<C*9DF'8WSL*8K!3^8.T0NFMBLV%
M$;&0PBZC3##&"^CQRYO#O<%P=!2@]'=2-(&]Q/57V._T_&(Z>3\Y/9Y./GU\
M8@-NM]</-<^&&I,N.5]222ZJ6!1=DG!M1;HD-J,V>GE+WP@*X6&#%5' O#;J
MN98-5</^+V_"7P>C;9\3DM$Y)YK/!5] Z+69,.2X*"HT*2^5MA"-R7NE<Q(.
M>O\B*B6?M;( SBMR(M0TXYJ6O+(B,5TR*9+^Z-7HX[U[C'Y"C<MR)%^2RT(M
M)(=TV/6VU][H3(&*A8(\"KI041!:+$E56%UQ6!-D29=DP1N4Y'"E!?@KI0DT
M::)R88E57NZ&0,$3;@S52Q3)Z26'>5MC&FACH Q,*3&NX!PHD @-F1W$(-<;
MT(1Q31:92#)B*OQ8]U]PS>M!< &Y,)""T(">"VAN2IXX!7'<$E13#)8YAVZ,
MQ,NV&5[!U!D/MX)I*XPX244!CD*?KQW3!0R!.-S6K?NB2&%S4R0"\#N1%8,Q
MP?DM+W0!.$++)2G!=P@[A"/0N!6N:I>::U,#=)EC&%V4J"0( )@4>-Q-9YP^
M"3492:5:F 9IFL^$L<#9+*'8Z/4&+;LMP)A&F1O:OF*F,]Z_)P!--\R,>H?_
M&)D:&W4*Q0VKTE3 I7/ A%#-G:O!=2*6'%U".. KEL)D*(YB.00K#%AXS81)
MI#(5],,PII7T/B^U@H(!F@W9 1<S#ICQ?CR_ H9=0&UP#!'BHI(@$0YI+SS8
MX;NN:WC _)6_%,B."H\U')]@&&E!T$,"=7GP1.G&1.GNG6QKER#%0D-<1RX,
M@9GUI7.0X:_7T>A:UJJ2YM^U=\8[=/=N;-[]><8-T&+PH<LZ]P.LBPDQH95Y
M>!?,3#$'L-0S^5RG*@T#0/!!6V-( RE>N'&0:ZZ#83N@^LH*T%<GNS5 NG6P
MQ9L" B/H8I04S-6_IHJ-8()J@0L0/B6[$%_@2)7!-.DVJW$YU05 J%I!(:A#
M7:>2 NR32E*,V[ LI\0ZW4(/G[S;G -^Q1P%(;1"?\Z>,I0^#C4;:*^+:3<2
M#OTSH3]^0O0_./C=V 0/#YL/W@NP?^:"(<2I407%_$ -; _DBXA[JEF#0=@5
M@GJ'8<Z_;5K<D0ZN#HE^,VV(MOBF2T-7]8+*2I>P$XSC*$FB-',*..8YXP50
M#PD; N[P$G<:B@"K]J"''2E*R 2OL']RV">/@OWYG,K*14;$!$]3()MB#MXT
MMY#&%9MY0*3WE[?S2(=RZ A1VGBV&JO*;M?@(;F(KJ0Y4O'T_@J(Q W)=QN7
M>TN /B,<_-DX^,4 E3TN/GL,W,025N\UX71W;@7L5T1E9!PJ22J-B&FE]UM&
MS96QT(X'B3"626"@ORI@!S#TSI8N*4 ?XN4UZ5IQ*-BX.WC ,PEW3N3UVO5:
M9=2LN!!&6K=5.',IR-FC3@]+(L4EE_4IQ#7Y[J--]-3;XSER[X=4@@=;*\%O
MJP'=:2%K8-Y=AR>,EFVHK2,5@N4KJ,H-JKQ2C0)=MDJ;%3MP#3!DG@MK.;\C
M%\0*^ ?>9P+T<X/L " A]!H,[?"-I+W91?RO2H#Z;L=41>(.*W9?>B5W+YI6
ML=*U=\;;"[EC"00-"*, Y& QC'5W(CBXNLZYJV)IP>DE)E%/V%P:=533'6,V
M!T5?!:"ZKO%G%;?$&LJ@H^&K4+,5;#5!A2Z &."179_)#:1Q4^5@%C"C6TP=
MXF\]4GL-0[< 9WL-= QI,M6PK;O@1NXB$0#!G2+7B.GZ+".*N9)SCJFFH+/Z
M,%S7P8OGI51+#G<7F?(1BV[@$?#S)'FX_YP\ZQXG6U=XU1UC0"W7O41)24O#
MH^9'>VJD/9D_TL+'P[ABL.6H3>%H9573X)\\NY8-#+1!X66PI?6PN4/<\\QW
M'?] $Y^<ZT;/>O[0+]VRU<(Q"0$#J1^%QLI:E=>#'L"8+9/5<S?F:SW_;@V.
M;L23YL:,S75OH6D9Q1 N+GL+L-F]S]2])G[B1I3&1LG*\HU%-T_YZT_+7OSR
M JO1M4^SSN^PL\ZPC(S(!ZJ3S,><8=@E^)Z)VT1/YJ+OH+I7=ZWF<S?U=7U_
M$C6_P:QUH*WW3=C'7.=.<\F;@?O[L2L*3-!Z)^);'+!]09@I#1X.%_:G<],/
MU?=Q#G@U[1WZ_J'[Y$^H2<EG#<4"4LXN.<T$3\G[%4?[Y*O6+IEB%5!I(' _
M<SP*'+%K,NTS89SMY)^MV%Q,D\N95E7!D'DJ'34QL/4FXN:-FL/L@2)2%+Q7
M7P\V6*A_VW&#AFXTK5ZM+*$>Z'FV0U.@FA&=*\%J;QX>]O?V5_'-MPT<D?&O
M;+IW0,?_!U!+ P04    " "$.7]4Q^Y$8FH%  !^%0  %P   '!L>"TR,#(Q
M,3(S,7AE>#,R9#$N:'1MY5A[;]LV$/\J-Q=K4\!Z.@Y<V0V0."YJK'D@5;#N
M3TJD+*(4J5)T'._3[ZA'(ALK5A1)UFX!'%M'\NY^]Q9GOSC.0N9$IHS"^_C\
M U"5K@LF#:2:$8/4#3<YQ*HLB81SIC47 DXUIRL&\,8- M=W)V/'.9XAJWE[
M1LD(1MXH\$(_#"$((G\<!4=P<@X'-_'\=;W[['(>_W&U:*1>W9Q^6,YAX'C>
M[Z.YYYW%9\W"H>L'$&LB*VZXDD1XWN)B (/<F#+RO,UFXVY&KM(K+[[V<E.(
M0T\H53&7&CHXGED*_F>$'L\*9@BD.=$5,V\'-_$[9X([##>"'<^\[KO9FRBZ
M/9Y1?@N5V0KV=E 0O>+2,:J,1GYIIGC2P^6]/7?.AE.31X'O_SHM":5<KAS!
M,A.-W<GD@:3Y*K^GJ09:I)D@AM\RR[O'-16,Z"A1)I_N"_B[DV5W+E/2.!DI
MN-A&KV)>L HNV :N54'DJV%#P>^*:9Z]FM:[*_XG0]8(S[ [XQ#!5\C<ZCIM
M\$>X!O83A,T/*S'9D;AA-;9$"8J+BT_OEZ?+&$:A&\R\!(U6/H&**<8KT]^K
MX]7U97SR8?D)3I>7\?O%]<G5XB9>SC\.87DQ=_]-K=>=R/H49:G2I';X6E*F
M!9=LNK?BI$HH';WPZS_D,5]<Q\MWR_E)O+R\F'GKQ\3R=<V7$E(E)4NM3DT%
M,3F#$RG71, U*Y4VH#*XTLJ@,>[@E*LX9YJ4;&UX6J'I9>K"@3WT\L4D#/WI
M7!58@;;U4S!]C24&WBE=0. [OT&F="V@1#T5!8;FH7#&4E8D3+]\$1SYTU$P
M!*Q& 9 *,BZZPF9/?63I6F,F(7@B*2SNL$A(+&\HLN!592'T-6G4[Q1!58=P
MIE&!4U+AN2&"8A6GMH1:;O.<LPQYH@R;HG"993QEVJ*W/%M80T#T+-D"+AF>
M;:V6[0Z*%;5>5=D0*B68V-9XR[7& L#J?;$M7A!,ABB.E!A5<#0:6ES6_@W^
M8#3V.Y8WDMLJ_=$@ZPI5H&R(=&+ *"BV\%FJ#1IHQ:(G#I;PT#T<UP%S$+RN
M-6M#(UL+1)FB;83URKVG-/NRYIK9_E3CWD-X0# N- 3C XI^01.2$AFD)!$(
ML,7><_:]HT_2.AJ#-Z/#J77:\\$.&]A<HD>+.H-MXAB"J4V1NF,3PC4:I<3H
MLO"'=IE@+\9C*!G3"A=*M$<UK$]E7&)7MW1D2.L^4<<C[EJ+QGH*TZ666>U%
M(]A0:$.OR8G=!*M0-D6[8A"YCVBKG889A&XX[@HFBD/,D=,1]ZQJ/X[O^HU1
MXYQC4-=Y5.L(^)@P9(QAI26O<C0M!OHW9KZ-(@GL+N<)-]VYQB6/B?T!D2W\
M=G&';;,1@V=ZRRO41'"SC7).T2RXW]8B?S2=>79O4^'M %&WF;<#:TX[Z-@T
MZ)@F2F,'L=U"D+)B4?>CK]812LN;3FD'#QN7Z(1=+_7=U@PUEM*;4:Q@W4EM
MN04-2$,[^JUU5DI$VQAQUC&J:+F,D4G/.*VPSE"].:G'7"'#3*A-9Z'NV=E@
MAXD2'%(_.QNTP#_.7HTFC>!N*TFP"*\-VT/93(/M?T/_\_ \HZUK'P?G$^30
MF:U.$9P3G>8[$T#X+%G[C6GZ:)'R!'@:JSVH^:-[?%_?GT3-[S!K6[W;],4W
M<.Q_F+6<0C?X/RLBK_+Z$_#W>.#KB(Q]]R^)MJWG9_/3\Q:\!P_ _R<5GE7?
M;WNS^YF-[]538M?H?Y0FV9L]\OMA,B'IYY56:TGW+CUZ%V:["^T(9:=H>W?B
MM,]=M>Q?U+64_CW=_@U@25;,:88MDN$K6$1N%:>M-R<3-SR\+VL-S:_GJ.9F
ML;ZJ//X+4$L#!!0    ( (0Y?U1G3\T_?04  "$5   7    <&QX+3(P,C$Q
M,C,Q>&5X,S)D,BYH=&WM6'MOVS80_RJW%&M3P'K9<>'*;H#$<1!CS0.)LG5_
M4B)E$95)C:+B>)]^1U)*;&/=NB[IUF$&_-#Q>(_?'>_.G'SG>3-1$)$Q"F?)
M^7N@,FN63&C(%",:J2NN"TAD51$!YTPI7I9PK#A=,("W?A3YH3\:>M[A!$5-
MVSU2Q# (!E'0#_M]B*(X',;16S@ZA_W;9/K:<I]<3I.?KV9.Z]7M\?OY%/:\
M(/AI, V"D^3$+1SX802)(J+FFDM!RB"87>S!7J%U%0?!:K7R5P-?JD607 >%
M7I8'02EES7RJZ=[AQ%#PDQ%Z.%DR32 KB*J9?K=WFYQZ(^307)?L<!)TWXXW
ME71].*'\#FJ]+MF[O251"RX\+:MX$%9ZC#L#7-[AN?=6G.HBCL+P^W%%*.5B
MX94LU_'0'XT>28HOB@>:=*[%BI5$\SMF9&](S4I&5)Q*78QW%?S>SJK;ETNA
MO9PL>;F.7R5\R6JX8"NXEDLB7O4<!;]KIGC^:FRY:_XK0]'HGF;WVB,E7Z!P
M8^O8^1_C&IAWU'<_C,9T2^.*6=]265)<G'TXFQ_/$QCT_?XD2!&TZAE,S#!?
MF?I2&Z^N+Y.C]_,/<#R_3,YFUT=7L]MD/KWIP?QBZO^35C>=2KN+LDPJ8@/>
M",I4R04;[ZQXF2REBE^$]H4RIK/K9'XZGQXE\\N+2= \I2^?MGPN()-"L,S8
MY"J(+A@<"=&0$JY9)94&F<.5DAK!N(=C+I."*5*Q1O.L1NA%YL.^V?3RQ:C?
M#\=3N<0*M+9/T?@UEA@XE6H)4>C] +E45D&%=DH*#.&A<,(RMDR9>ODB>A..
M!U$/L!I%0&K(>=D5-K/KAF6-PI.$SA-!87:/14)@>4.52U[7QH5-2YSYG2%H
M:@]F:^-6DW+1@QOEPX\\8^@<JSDUI=1(G1:<Y7#*!=9:CMR7>8Y,RJ!@9+?N
M]0!18.D:<$GS?&VL;3DH5E:[*O,>U+)DY?K1[T9A,6"6-S&%#*)1#U62"C,,
MW@QZQD<3"X=%-!B&G=A;P4W%OM$HOD8S*.LAG6C0$I9K^"CD"L%:L/B9$Z=_
MX!\,;?+L1Z^M96V:Y$V)GF:(3VDB]! UQ7YIN&*F5UF_=SS<)Y@C"J+A/L48
M(8RD0@$924MTL/5](_ /03_*;&9&;P<'8Q.XK^=VW[G-!49U:4^S.42:X#&G
M2-W"A'"%H%288<;]GEDFV)=Q&VK&[,*%"O&H>W97_I!U*)#:GF%S$KF:TJ$G
M\>A8G?5.1H))A3;]W/G8/FPUZJ:(*R:1_X18;37/"+O'L"N>J Y]CKV.N(.J
M>7NA'SI0DX)C4MNS9&T$?$P9"L:T4H+7!4*+B?Z95<!DD0!V7_"4ZVZ?"\E3
M^O[HD6D"9G%+K&/$Y!G?\1HM*;E>QP6G" ORF[H4#L:3P/"Z:F_G%&TROY.3
M2H4-Q#2+DE0UB[L?FY:\006%:Y1F[C"IB+BWQKFXD$;+CN!&&DO9BMUF,!V/
MH6Q,,7M@VR$..K8?FI%,=7:V^B.'A*8=_<Y$-"-EVTEQ.-)RV0H=HLP-!%O=
M'9H;@]6&<(D"\U*N.AB[9V^%+2E.<:K]Z*T0LS\=UIPE3G''2E*LUHUF6TYW
MXV/[J>E_WKU *Q/:I_'S&0[:B2EA,9P3E15;(T/?'J(G"]$SF.[,?33SWP[U
MKKW?B)E? &M;:-MS@_^5L3OA<>$4NA']JWH4U,'&K/HE ?BT0]K\2:^(>FP2
MWTZ8OJJ]?R\ _T/[!_;^M?]>WR;\@9WDNM;ZW!/G9XZ8F]V^>!C?4I)]7"C9
M"+IS+[%QI[6]T XM9K@UUQM>^QQNC9WNWFQK[MPB/5S2563!/#?>D!QGRYC<
M24[;:(Y&?O_@H: Y6F@G%W?Y9V\3#W\#4$L! A0#%     @ A#E_5%VD='B;
M&   X 4! !               ( !     '!L>"TR,#(Q,3(S,2YX<V102P$"
M% ,4    " "$.7]46"6N^ <0  #=V0  %               @ ')&   <&QX
M+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "$.7]4=7RZT!)!  !F8P0
M%               @ $"*0  <&QX+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4
M    " "$.7]4#,M<1'>   "@Z@8 %               @ %&:@  <&QX+3(P
M,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "$.7]47B:YE%EB  #A_@8 %
M            @ 'OZ@  <&QX+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4
M" "$.7]4#W[&,<K1 P#&QB, %               @ %Z30$ <&QX+3(P,C$Q
M,C,Q>#$P:RYH=&U02P$"% ,4    " "$.7]4&RQ\?$E3  #5?0  %P
M        @ %V'P4 <&QX+3(P,C$Q,C,Q>#$P:S P,2YJ<&=02P$"% ,4
M" "$.7]4'5G5H*^R  #0TP  %P              @ 'T<@4 <&QX+3(P,C$Q
M,C,Q>#$P:S P,BYJ<&=02P$"% ,4    " "$.7]48%]6\R6!  #GGP  %P
M            @ '8)08 <&QX+3(P,C$Q,C,Q>#$P:S P,RYJ<&=02P$"% ,4
M    " "$.7]4?6GNNN8(  "M"0  %P              @ $RIP8 <&QX+3(P
M,C$Q,C,Q>#$P:S P-2YJ<&=02P$"% ,4    " "$.7]43@7;B'D%   M'0
M%P              @ %-L 8 <&QX+3(P,C$Q,C,Q>&5X,C-D,2YH=&U02P$"
M% ,4    " "$.7]4!?CFJGT(   I+   %P              @ '[M08 <&QX
M+3(P,C$Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    " "$.7]42>?B274(  #7
M*@  %P              @ &MO@8 <&QX+3(P,C$Q,C,Q>&5X,S%D,BYH=&U0
M2P$"% ,4    " "$.7]4Q^Y$8FH%  !^%0  %P              @ %7QP8
M<&QX+3(P,C$Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4    " "$.7]49T_-/WT%
M   A%0  %P              @ 'VS 8 <&QX+3(P,C$Q,C,Q>&5X,S)D,BYH
8=&U02P4&      \ #P#U P  J-(&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
